NP ID	NP Name	PubChem CID	Synonymous	Molecule Type	InChI	InChIKey	Canonical SMILES	Formula	CAS Number	CHEBI	HERB ID	SymMap ID	TCMSP ID	TTD ID	DrugBank ID	ETMC ID	GDSC
NP0016	Silibinin	CID: 31553	Silybin; 22888-70-6; Flavobin; Silymarin I; Silybin A; Silybine; Silibinine; Silliver; Silibinin A; Silibininum; Silibinina; Flavobin Spofa; Silymarine I; Silibinin [INN]; Silymarine; Silibininum [INN-Latin]; Silibinine [INN-French]; Silibinina [INN-Spanish]; 7C3MT; UNII-33X338MNE4; EINECS 245-302-5; NSC 651520; Silimarin; Silibin; CHEBI:9144; 33X338MNE4; Silibinin (INN); NSC651520; C25H22O10; NCGC00091057-01; DSSTox_CID_6018; DSSTox_RID_77985; DSSTox_GSID_26018; (2R,3R)-3,5,7-trihydroxy-2-((2R,3R)-3-(4-hydroxy-	.	1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1	SEBFKMXJBCUCAI-HKTJVKLFSA-N	COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O	C25H22O10	CAS 22888-70-6	 CHEBI:9144	HBIN044028	.	.	D02ADM	.	.	.
NP0031	Hesperetin	CID: 72281	Hesperin; TNP00238; YSO2; Cyanidanon 4'-methyl ether 1626; Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN); Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN) (8CI); (-)-hesperetin; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavanone; 3',5,7-Trihydroxy-4-methoxyflavanone; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-(9CI); 5,7,3'-Trihydroxy-4'-methoxyflavanone	.	1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1	AIONOLUJZLIMTK-AWEZNQCLSA-N	COC1=C(C=C(C=C1)C2CC(=O)C3=C(C=C(C=C3O2)O)O)O	C16H14O6	CAS 520-33-2	CHEBI:28230	HBIN029190	SMIT04602	MOL002341	D07MGA	.	3405	.
NP0050	Phenethyl isothiocyanate	CID: 16741	2-Phenylethyl isothiocyanate; Phenethyl isothiocyanate; 2257-09-2; Phenylethyl isothiocyanate; (2-Isothiocyanatoethyl)benzene; Phenethyl mustard oil; Benzene, (2-isothiocyanatoethyl)-; Phenylaethylsenfoel; 2-isothiocyanatoethylbenzene; PEITC; Phenylethyl mustard oil; PHENETHYLISOTHIOCYANATE; phenethyl-isothiocyanate; 2-phenethyl isothiocyanate; 2-phenylethylisothiocyanate; ISOTHIOCYANIC ACID, PHENETHYL ESTER; beta-Phenethyl isothiocyanate; MFCD00004821; beta-Phenylethyl isothiocyanate; CHEBI:351346; NSC 87868; UNII-6U7TFK75KV; 6U7TFK75KV; CHEMBL151649; .beta.-Phenethyl isothiocyanate; 1-Isothiocyanato-2-phenylethane; .beta.-Phenylethyl isothiocyanate; 1-(2-isothiocyanatoethyl)benzene; (2-Isothiocyanato-ethyl)-benzene; Isothiocyanic Acid 2-Phenylethyl Ester; 2-phenylethanisothiocyanate; Phenylaethylsenfoel [German]; 1-ISOTHIOCYANATO-2-PHENYLETHANE (1,1,2,2-D4); CCRIS 3146; EINECS 218-855-5; BRN 2084162; ACMC-1CLKQ; DSSTox_CID_1120; WLN: SCN2R; beta-phenethylisothiocyanate; ss-Phenethyl isothiocyanate; Epitope ID:138724; b-phenylethyl isothiocyanate; DSSTox_RID_75951; DSSTox_GSID_21120; 2-phenyl ethyl isothiocyanate; SCHEMBL156960; Phenethyl isothiocyanate, 99%; DTXSID5021120; IZJDOKYDEWTZSO-UHFFFAOYSA-; (2-Isothiocyanatoethyl)benzene #; 2-Phenylethyl isothiocyanate, FG; HMS1783C17; HMS3870G13; NSC87868; ZINC2022074; Tox21_200100; (2-Isothiocyanatoethyl)benzene, 9CI; ANW-13714; BBL009999; BDBM50240850; NSC-87868; SBB002732; STK397325; AKOS000119469; DB12695; JC-5411; MCULE-7681211375; NE22461; Isothiocyanic acid beta-phenylethyl ester; NCGC00248526-01; NCGC00257654-01; AC-12769; AS-17373; BP-12941; NCI60_041942; U800; CAS-2257-09-2; DB-045947; Isothiocyanic acid .beta.-phenylethyl ester; FT-0604634; P0986; Phenethyl isothiocyanate, analytical standard; ST50330661; 4-12-00-02476 (Beilstein Handbook Reference); A816267; J-802164; Q7181339; W-107466; BRD-K56700933-001-02-1; F0001-0795	Small molecule	1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2	IZJDOKYDEWTZSO-UHFFFAOYSA-N	C1=CC=C(C=C1)CCN=C=S	C9H9NS	CAS 2257-09-2	CHEBI:351346	.	.	.	D07AOL	.	.	.
NP0060	Norcantharidin	CID: 93004	Norcantharidin; 5442-12-6; 29745-04-8; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; Endothall anhydride; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-; NCTD; 3,6-Endoxohexahydrophthalic anhydride; (+/-)-NCTD; 7-Oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride; Norcantharadine; (+/-)-Norcantharidin; Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; 4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione; 4,10-dioxatricyclo[5.2.1.0<2,6>]decane-3,5-dione; exo-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; DEMETHYL-CANTHARIDIN; Isocantharidin; MFCD00213361; 3, hexahydro-; NSC 14003; Norcantharidin, solid; Spectrum_001667; 3,6-Endooxyphthalic anhydride, hexahydro-; SpecPlus_000904; Phthalic anhydride, hexahydro-3,6-endoxo-; 4,3-dione, hexahydro-; Spectrum2_001683; Spectrum3_001634; Spectrum4_000601; Spectrum5_001514; CHEMBL8327; Lopac0_000830; BSPBio_003327; KBioGR_001122; KBioSS_002147; Phthalic anhydride,6-endoxo-; MLS002153470; DivK1c_007000; SCHEMBL177729; SPECTRUM1504153; SPBio_001606; KBio1_001944; KBio2_002147; KBio2_004715; KBio2_007283; KBio3_002547; DTXSID30884158; HMS3262F21; HMS3370H07; 4,7-Epoxyisobenzofuran-1,3-dione; BCP09826; BCP25426; HY-N0585; NSC14003; NSC59023; Tox21_500830; WLN: T C555 A AO DVOVTJ; CCG-39454; NSC-14003; NSC-59023; NSC148536; s3759; SBB005955; STK424286; Hexahydro-3,6-epoxyphthalic anhydride; AKOS003267901; FS-4623; LP00830; MCULE-7561066553; NSC-148536; SDCCGSBI-0050807.P003; NCGC00015756-03; NCGC00015756-04; NCGC00015756-05; NCGC00015756-06; NCGC00015756-07; NCGC00015756-08; NCGC00015756-09; NCGC00015756-14; NCGC00094161-01; NCGC00094161-02; NCGC00094161-03; NCGC00094161-04; NCGC00094161-05; NCGC00094161-06; NCGC00261515-01; NCI60_001019; SMR000326693; ST057264; DB-050518; CS-0009119; EU-0100830; FT-0614776; FT-0621477; FT-0626378; N1662; hexahydro-4,7-epoxy-2-benzofuran-1,3-dione; N 8784; 3,6-Endoxohexahydrophthalic anhydride, exo isomer; SR-01000076037; SR-01000076037-1; 4,10-dioxatricyclo[5.2.1.0?,?]decane-3,5-dione; BRD-A66914119-001-04-0; Q15425762; 4,10-Dioxa-tricyclo[5.2.1.02,6]decane-3,5-dione; 3-(5'-(4-(diphenylamino)phenyl)-[2,2'-bithiophen]-5-yl)cyclohex-2-enone; EXO-7-OXA-BICYCLO(2.2.1)-HEPTANE-2,3-DICARBOXYLIC ANHYDRIDE; Exo-cis-Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; Endothall anhydride; 51154-98-4; TIMTEC-BB SBB005955;4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-;4,10-Dioxatricyclo[5.2.1.0(2,6)]decane-3,5-dione	Small molecule	1S/C8H8O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h3-6H,1-2H2	JAABVEXCGCXWRR-UHFFFAOYSA-N	C1CC2C3C(C1O2)C(=O)OC3=O	C8H8O4	CAS 5442-12-6	.	.	.	.	D0W4IL	.	.	.
NP0067	L-arginine	CID: 6322	L-arginine; arginine; 74-79-3; L-(+)-Arginine; L(+)-Arginine; L-Arg; H-Arg-OH; (S)-2-Amino-5-guanidinopentanoic acid; (L)-Arginine; Arginina; ARGININE, L-; Arginine (VAN); L-Arginin; Argininum [INN-Latin]; Arginina [INN-Spanish]; L-Ornithine, N5-(aminoiminomethyl)-; Argamine; Argivene; Detoxargin; Levargin; L-alpha-Amino-delta-guanidinovaleric acid; Minophagen A; 1-Amino-4-guanidovaleric acid; CCRIS 3609; NSC 206269; arg; HSDB 1429; AI3-24165; UNII-94ZLA3W45F; MFCD00002635; (S)-2-Amino-5-guanidinovaleric acid; BRN 1725413; CHEBI:16467; (S)-2-Amino-5-((aminoiminomethyl)amino)pentanoic acid; L-Norvaline, 5-((aminoiminomethyl)amino)-; (S)-(+)-arginine; L-Arginine, monohydrochloride; 2-amino-5-guanidinovaleric acid; CHEMBL1485; (2S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; 94ZLA3W45F; Pentanoic acid, 2-amino-5-((aminoiminomethyl)amino)-, (S)-; (2S)-2-amino-5-(carbamimidamido)pentanoic acid; L-2-Amino-5-guanidinopentanoic acid; Arginine (L-Arginine); R-Gene; L-Norvaline, 5-[(aminoiminomethyl)amino]-; (2S)-2-amino-5-carbamimidamidopentanoic acid; DSSTox_CID_21056; DSSTox_RID_79618; Poly(L-arginine); DSSTox_GSID_41056; L(+)-Arginine, 98+%; C6H14N4O2; Argininum; Pentanoic acid, 2-amino-5-[(aminoiminomethyl)amino]-, (S)-; L-Arginine, homopolymer; Arginine [USAN:INN]; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid; CAS-74-79-3; Arginine [USP:INN]; EINECS 200-811-1; 2-AMINO-5-GUANIDINO-PENTANOIC ACID; (2S)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid; NSC203450; 3h-l-arginine; L-Arginine, labeled with tritium; 1laf; NSC-206269; L-a-Amino-d-guanidinovaleric acid; NCGC00015064-02; (S)-Arginine; L(+) arginine; L-Aryginine,(S); cyclohexyl-l-alanine; H-Arg; L-(+) arginine; L(+)-Arginine;; PubChem7933; L-Arginine (9CI); Arginine (USP/INN); Tocris-0663; (2S)-2-amino-5-guanidino-pentanoic acid; L-Arginine (JP17); GND; Lopac-A-5006; Arginine, L- (8CI); bmse000029; bmse000899; bmse000919; Epitope ID:140084; L-Arginine (H-Arg-OH); EC 200-811-1; SCHEMBL1791; 2-amino-5-guanidinovalerate; Lopac0_000077; Arginine hydrochloride(USAN); GTPL721; 4-04-00-02648 (Beilstein Handbook Reference); L-a-Amino-d-guanidinovalerate; L-Amino-4-guanidovaleric acid; US9138393, L-Arginine; US9144538, L-Arginine; 1-Amino-4-guanidovalerlic acid; DTXSID6041056; BDBM21959; L-Arginine, 99%, FCC, FG; BDBM181132; HMS3260O15; N5-(aminoiminomethyl)-L-Ornithine; HY-N0455; ZINC1532525; L-Arginine, Vetec(TM), 98.5%; Tox21_113046; Tox21_500077; AC-083; ANW-36527; L-alpha-Amino-delta-guanidinovalerate; L-Arginine, reagent grade, >=98%; s5634; AKOS006239069; AKOS015854096; Tox21_113046_1; AM81500; CCG-204172; DB00125; LP00077; MCULE-5108123240; SDCCGSBI-0050065.P002; L-Arginine, 99%, natural, FCC, FG; (s)-2-amino-5-guanidino-pentanoic acid; 5-[(aminoiminomethyl)amino]-L-Norvaline; NCGC00015064-01; NCGC00024715-01; NCGC00024715-02; NCGC00024715-03; NCGC00024715-04; NCGC00024715-05; NCGC00024715-10; NCGC00260762-01; 25212-18-4; 4455-52-1; AK-81231; AS-14190; K277; L-Arginine, BioUltra, >=99.5% (NT); SBI-0207062.P001; AB0014136; A0526; A7079; EU-0100077; L-Arginine, SAJ special grade, >=98.0%; A 5006; C00062; D02982; L-Arginine, Vetec(TM) reagent grade, >=98%; M02981; Y-8965; 14932-EP2316830A2; AB00374192_03; Norvaline, 5-[(aminoiminomethyl)amino]-, (L)-; 002A635; A837397; Q173670; SR-01000075479; SR-01000597671; (S)-2-amino-5-[(aminoiminomethyl)amino]-Pentanoate; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate; SR-01000075479-1; SR-01000597671-1; W-104410; (S)-2-amino-5-[(aminoiminomethyl)amino]-Pentanoic acid; Arginine, European Pharmacopoeia (EP) Reference Standard; (2S)-2-amino-5-[(diaminomethylidene)amino]pentanoic acid; 7F15B0C7-356D-45D7-AC33-03AEE4394A0E; S-(+)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; UNII-0O72R8RF8A component ODKSFYDXXFIFQN-BYPYZUCNSA-N; UNII-FL26NTK3EP component ODKSFYDXXFIFQN-BYPYZUCNSA-N; L-Arginine, United States Pharmacopeia (USP) Reference Standard; L-Arginine, Pharmaceutical Secondary Standard; Certified Reference Material; L-; L-Arginine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%; L-Arginine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture	Small molecule	1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1	ODKSFYDXXFIFQN-BYPYZUCNSA-N	C(CC(C(=O)O)N)CN=C(N)N	C6H14N4O2	CAS 74-79-3	CHEBI:16467	.	.	.	D0F5DO	.	.	.
NP0074	Acteoside	CID: 5281800	Acteoside; Verbascoside; 61276-17-3; Kusaginin; acetoside; Verbacoside; TJC 160; UNII-3TGX09BD5B; NSC 603831; 3TGX09BD5B; [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]; Verbacoside;; Acteoside;; MFCD00221751; MLS002473233; SCHEMBL657970; CHEBI:9953; CHEMBL231853; CHEMBL444478; cid_5281800; Verbascoside, >=99% (HPLC); CHEBI:132853; cid_24978601; HMS2205K11; 22323-52-0; HY-N0021; ZINC8234351; BDBM50241867; s5458; AKOS015897165; CCG-270269; DB12996; AS-75167; Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), (E)-beta-D-; SMR001397320; N1341; V1534; C10501; 276A173; B864379; Q411426; Q-100706; Verbascoside, primary pharmaceutical reference standard; UNII-3TGX09BD5B component FBSKJMQYURKNSU-ZLSOWSIRSA-N; Verbascoside, United States Pharmacopeia (USP) Reference Standard; ((2R,3R,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-3-yl) 3-(3,4-dihydroxyphenyl)acrylate; ((2R,3R,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-3-yl)3-(3,4-dihydroxyphenyl)acrylate; (2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; (3,4-Dihydroxyphenyl)ethyl O-.alpha.-rhamnopyranosyl(1->3)-4-O-caffeoyl-.beta.-D glucopyranoside; .beta.-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-.alpha.-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]; .beta.-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl3-O-(6-deoxy-.alpha.-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]; 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranoside; 2-(3,4-dihydroxyphenyl)ethyl 3-O-(alpha-L-rhamnopyranosyl)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranoside; 3,4-Dihydroxyphenethyl 3-O-alpha-L-rhamnopyranosyl-4-O-[3-(3,4-dihydroxyphenyl)acryloyl]-beta-D-glucopyranoside	Small molecule	1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1	FBSKJMQYURKNSU-ZLSOWSIRSA-N	CC1C(C(C(C(O1)OC2C(C(OC(C2OC(=O)C=CC3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O	C29H36O15	CAS 61276-17-3	CHEBI:9953	.	.	.	D08OTG	.	.	.
NP0075	Xylitol	CID: 6912	xylitol; ribitol; adonitol; 87-99-0; Xylite; 488-81-3; D-Xylitol; Adonite; Adonit; D-ribitol; Eutrit; Klinit; Xyliton; Xylit; Xylite (sugar); Kannit; Newtol; 1,2,3,4,5-pentanepentol; Xylisorb; L-ribitol; (2R,3R,4S)-Pentane-1,2,3,4,5-pentaol; (2R,3S,4S)-Pentane-1,2,3,4,5-pentaol; meso-ribitol; meso-xylitol; L-xylitol; D-Adonitol; UNII-353ZQ9TVDA; UNII-VCQ006KQ1E; NSC 25283; BRN 1720523; CHEBI:15963; CHEBI:17151; (2S,4R)-pentane-1,2,3,4,5-pentol; 1,2,3,4,5-Pentahydroxypentane; (2R,3s,4S)-pentane-1,2,3,4,5-pentol; MFCD00064291; MFCD00064292; 353ZQ9TVDA; VCQ006KQ1E; Xylooligosaccharide; Adonitol, 99+%; Xylitol, 99+%; (2R,3r,4S)-pentane-1,2,3,4,5-pentol; 4-01-00-02832 (Beilstein Handbook Reference); C5H12O5; EINECS 201-788-0; Adonito; Fluorette; Kylit; xylo-Pentitol; Xylitol [INN:BAN:JAN:NF]; NSC-25283; DL-Arabinit; Xylitol C; HSDB 7967; Xylitab DC; Wood sugar alcohol; RB0; Xylitol,(S); EINECS 207-685-7; Ribitol (Adonitol); Adonitol (7CI); Xylisorb 300; Xylisorb 700; NSC 16868; Xylitab 100; Xylitab 300; BRN 1720524; D-ribitol (incorrect); L-ribitol (incorrect); Adonitol, >=99%; (2R,4S)-pentane-1,2,3,4,5-pentol; Xylitol, >=99%; bmse000062; bmse000129; bmse000886; Epitope ID:114702; Epitope ID:114703; EC 201-788-0; SCHEMBL4250; Xylitol, analytical standard; DSSTox_CID_22514; DSSTox_RID_80046; DSSTox_GSID_42514; SCHEMBL15318; MLS002695898; CHEMBL96783; Ribitol (6CI,8CI,9CI); INS NO.967; QSPL 191; SCHEMBL1924966; CHEMBL1865120; CHEMBL3137744; DTXSID7042514; INS-967; HY-N0538; Tox21_201056; s2612; s4546; ZINC18068098; AKOS015903403; AKOS015915193; ZINC100014205; ZINC100018612; CCG-214167; CCG-266218; CS-6043; DB01904; DB11195; DB14704; CAS-87-99-0; (2S,4R)pentane-1,2,3,4,5-pentaol; NCGC00165982-01; NCGC00165982-02; NCGC00258609-01; NCGC00390798-01; Adonitol, BioXtra, >=99.0% (HPLC); AS-55964; DS-11416; E967; K573; SMR001562099; HY-100582; Xylitol, Vetec(TM) reagent grade, >=99%; A0171; E-967; N1725; ST50411707; SW220290-1; Xylite 1000 microg/mL in Acetonitrile:Water; 2088-EP2272822A1; 2088-EP2275417A2; 2088-EP2284162A2; 2088-EP2284163A2; 2088-EP2292234A1; 2088-EP2292612A2; 2088-EP2301938A1; 2088-EP2305254A1; 2088-EP2311842A2; 2088-EP2314584A1; 2088-EP2371811A2; 2088-EP2377849A2; Adonitol, BioReagent, suitable for cell culture; C00379; C00474; K-9195; X-7000; WURCS=2.0/1,1,0/[h212h]/1/; WURCS=2.0/1,1,0/[h222h]/1/; 127873-EP2275398A1; 127873-EP2295402A2; 127873-EP2374783A1; 127873-EP2377841A1; Q212093; Q416534; (S)-1-BOC-2-METHYLSULFONYLETHYL-PIPERAZINE; Xylitol, European Pharmacopoeia (EP) Reference Standard; UNII-YFV05Y57M9 component HEBKCHPVOIAQTA-SCDXWVJYSA-N; UNII-YFV05Y57M9 component HEBKCHPVOIAQTA-ZXFHETKHSA-N; 5DCF4F57-E023-469A-B4F3-91E8349A6705; Xylitol, United States Pharmacopeia (USP) Reference Standard; 6684F574-C267-40CB-8828-12F2550E58D0; Xylitol, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C5H12O5/c6-1-3(8)5(10)4(9)2-7/h3-10H,1-2H2/t3-,4+,5?	HEBKCHPVOIAQTA-NGQZWQHPSA-N	C(C(C(C(CO)O)O)O)O	C5H12O5	CAS 87-99-0	CHEBI:15963	.	.	.	.	.	.	.
NP0082	Tretinoin	CID: 444795	Retinoic acid; tretinoin; 302-79-4; all-trans-Retinoic acid; Vitamin A acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; All-trans Retinoic Acid; all-trans-Vitamin A acid; Dermairol; Aknoten; Aberel; Eudyna; Aknefug; Cordes vas; Epi-aberel; TRETINON; Tretin M; Atralin; all-trans-Vitamin A1 acid; all-trans-Tretinoin; Retionic acid; All Trans Retinoic Acid; Vitamin A1 acid, all-trans-; Retin-A Micro; beta-Retinoic acid; all-(E)-Retinoic acid; Vitamin A acid, all-trans-; Retinoate; Retinoic acid, all-trans-; Alltrans-retinoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; Retacnyl; Vesnaroid; NSC-122758; Ro 1-5488; Tretinoin, all-trans-; all trans-Retinoic acid; Retin A; Stieva-A; Tretinoine; Solage; all-trans-beta-Retinoic acid; Effederm; .beta.-Retinoic acid; Tretinoin/All-Trans Retinoic Acid; Aberela [Norway]; Avitoin [Norway]; Effederm [France]; MFCD00001551; UNII-5688UTC01R; A-Acido (Argentina); 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; MLS000028588; b-Retinoic acid; RETINOIC ACID, ALL TRANS; Tretinoine [INN-French]; Tretinoinum [INN-Latin]; AT-RA; Tretinoina [INN-Spanish]; Tretinoino [INN-Spanish]; CHEMBL38; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; NSC122758; Atragen; Retinova; SMR000058245; CHEBI:15367; 15-Apo-beta-caroten-15-oic acid; 5688UTC01R; Tretinoin (TN); beta-Ra; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; Acnavit [Denmark]; AGN 100335; REA; 9-cis-RA; Retin A (TN); NCGC00017280-10; Tretinoinum; Aberela; Acnavit; Avitoin; Betarretin; Tretinoina; Tretinoino; A-Vitaminsyre; all-trans-b-Retinoic acid; DSSTox_CID_1239; Cordes VAS [Germany]; A-Vitaminsyre [Denmark]; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL); DSSTox_RID_76031; DSSTox_GSID_21239; trans-Retinoate; beta-Retinoate; all-trans-Retinoic acid, 97%; tretinoine (French) (EINECS); cis-Retinoic acid; Acide retinoique (French) (DSL); Refissa; Nexret; Vitamin a acid, trans-; Retisol-A; Acid A Vit (Belgium, Netherlands); 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid; 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2E,4E,6E,8E-tetraenoic acid; (11Z)-retinoic acid; (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; [3H]Retinoic acid; Renova (TN); CCRIS 3294; Avita (TN); HSDB 2169; SR-01000000239; EINECS 206-129-0; NSC 122758; BRN 2057223; Tretinoin (JAN/USP/INN); Retinoic acid, cis-9,trans-13-; TNP00194; BML2-E05; 1cbr; [3H]tretinoin; [All-E]-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; Tretinoin [USAN:USP:INN:BAN]; retinoic acid group; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetr aenoic acid; CAS-302-79-4; Prestwick_424; all-(E)-Retinoate; Tretinoine (French); Retinoic acid, cis-; (5E)-Retinoic acid; [3H]Vitamin A acid; PubChem16466; 1n4h; CPD000058245; Retinoic acid all trans; 6-s-trans-retinoic acid; Vitamin-A-sA currencyure; Opera_ID_1055; Prestwick2_000257; Prestwick3_000257; Spectrum5_001746; Spectrum5_001933; acide retinoique (French); Vesanoid (TN) (Roche); Tretinoin - Retinoic Acid; bmse000562; UPCMLD-DP097; R 2625; Renova (0.02% cream); SCHEMBL3145; (9Z,13Z)-Retinoic acid; 3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoic acid; Altreno (0.05% lotion); BIDD:PXR0081; Lopac0_001061; Avita (0.025% gel); BSPBio_000074; BSPBio_001500; MLS001076515; MLS002207234; MLS002222211; MLS002548861; MLS006010222; ARONIS25153; BIDD:GT0483; SPECTRUM1502016; 9-cis-retinoic acid (9cRA); [3H]RA; BPBio1_000082; cid_444795; GTPL2644; .beta.-all-trans-Retinoic acid; all-trans-retinoic acid (ATRA); DTXSID7021239; SCHEMBL19091395; BDBM31883; HMS502N05; QCR-120; BCPP000036; BDBM323588; HMS1361K22; HMS1568D16; HMS1791K22; HMS1921D14; HMS1989K22; HMS2089D20; HMS2092N11; HMS2095D16; HMS2236N03; HMS3259E11; HMS3263E04; HMS3402K22; HMS3411B09; HMS3675B09; HMS3712D16; Pharmakon1600-01502016; Retinoic acid, all-trans- (8CI); 124510-04-9; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-; ACT00012; BCP01405; US10188615, at-RA; Tox21_110812; Tox21_202330; Tox21_300305; Tox21_501061; All-trans Retinoic Acid (Tretinoin); CCG-39912; LMPR01090019; NSC759631; s1653; SBB065722; ZINC12358651; AKOS000280845; Tox21_110812_1; AB03039; AC-6824; CS-1269; DB00755; GS-3578; LP01061; NC00481; NSC-759631; SDCCGSBI-0051031.P004; IDI1_000903; IDI1_033970; NCGC00017280-05; NCGC00017280-06; NCGC00017280-07; NCGC00017280-08; NCGC00017280-09; NCGC00017280-12; NCGC00017280-15; NCGC00017280-16; NCGC00017280-17; NCGC00017280-18; NCGC00017280-19; NCGC00017280-20; NCGC00017280-23; NCGC00017280-38; NCGC00021808-04; NCGC00021808-05; NCGC00021808-06; NCGC00021808-07; NCGC00021808-09; NCGC00021808-11; NCGC00021808-14; NCGC00021808-15; NCGC00254179-01; NCGC00259879-01; NCGC00261746-01; trans-Retinoic acid; ; ; Retinoid analogues; BP-20401; HY-14649; Retinoic acid, >=98% (HPLC), powder; ST057075; SBI-0051031.P003; EU-0101061; R0064; SW203749-4; 02T794; 5914-EP2275412A1; 5914-EP2292576A2; A10944; C00777; D00094; J10054; Q29417; S-1635; 33998-EP2275420A1; 33998-EP2295055A2; 33998-EP2295416A2; 33998-EP2295426A1; 33998-EP2295427A1; 33998-EP2298748A2; 33998-EP2298764A1; 33998-EP2298765A1; 33998-EP2298768A1; 33998-EP2301928A1; 33998-EP2305642A2; 33998-EP2308833A2; 33998-EP2308861A1; 33998-EP2311453A1; 33998-EP2311808A1; 33998-EP2311829A1; 33998-EP2311840A1; AB00052318-15; AB00052318-16; AB00052318-17; AB00052318_18; AB00052318_19; L000833; Q-200610; SR-01000000239-3; SR-01000000239-4; SR-01000000239-6; SR-01000000239-7; BRD-K06926592-001-01-7; BRD-K71879491-001-15-0; BRD-K71879491-001-22-6; SR-01000000239-12; SR-01000000239-13; SR-01000000239-14; SR-01000000239-15; WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1; Tretinoin, European Pharmacopoeia (EP) Reference Standard; WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1; Tretinoin, United States Pharmacopeia (USP) Reference Standard; 3,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; Tretinoin, Pharmaceutical Secondary Standard; Certified Reference Material; (2E,4E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraenoic acid; (4E,6E,8E)-9-(2,6,6-Trimethyl-1-cyclohexenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate; 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-; 2,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6E,8E,-nonatetraenoic acid; all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid; 2,4, 6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6, 6-trimethyl-1-cyclohexen-1-yl)-, (2E, 4E, 6E, 8E)-; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)--, (all trans)-; 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all trans)-; 2,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid-, (all trans)-; 97950-17-9	Small molecule	1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C	C20H28O2	CAS 302-79-4	CHEBI:15367	.	.	.	D02DGU	.	.	.
NP0090	Sesquiterpene lactone	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP0109	Menadione	CID: 4055	menadione; 58-27-5; Vitamin K3; 2-Methyl-1,4-naphthoquinone; 2-methylnaphthalene-1,4-dione; Menaphthone; Kayquinone; 2-Methylnaphthoquinone; 2-Methyl-1,4-naphthalenedione; Thyloquinone; Kappaxin; Klottone; Panosine; Kayklot; Kolklot; Menaphthon; Menadion; Kanone; Kipca; Aquinone; Kaergona; Kativ-G; Mitenone; Prokayvit; Aquakay; Hemodal; Karcon; Kareon; Kaykot; Koaxin; Mitenon; Synkay; K-Thrombyl; K-Vitan; Kipca-Oil Soluble; Juva-K; Vitamin K2(0); Vitamin K0; Vitamin K 3; 2-Methyl-1,4-naphthochinon; Menaquinone 0; Menaphtone; Usaf ek-5185; 1,4-Naphthalenedione, 2-methyl-; 3-Methyl-1,4-naphthoquinone; Menaphthene; Kaynone; 2-Methyl-1,4-naftochinon; 1,4-Naphthoquinone, 2-methyl-; MFCD00001681; Menaquinone O; Menadione (Vitamin K3); Methyl-1,4-naphthoquinone; NSC 4170; 2-methyl-1,4-dihydronaphthalene-1,4-dione; UNII-723JX6CXY5; NSC4170; MNQ; CHEMBL590; 2-Methyl-1,4-naphthalendione; MLS000069420; 723JX6CXY5; 1,4-Dihydro-2-methylnaphthalene-1,4-dione; Menadionum; Memodol; CHEBI:28869; NSC-4170; Methylnaphthoquinone; Kappaxan (VAN); VK3; CAS-58-27-5; Menadione semiquinone; NCGC00016258-02; SMR000059102; DSSTox_CID_1715; DSSTox_RID_76289; DSSTox_GSID_21715; 2-Methyl-1,4-naphthoquinone, 98%; 2-Methyl-1,4-naftochinon [Czech]; 2-(Methyl-d3)-1,4-naphthoquinone; Menadione (USP); Kappaxin (TN); Kipca, oil soluble; 2-Methyl-1,4-naphthochinon [German]; NAPHTHOQUINONE, METHYL-; CCRIS 6672; HSDB 3354; Menadione [USP:BAN]; SR-01000712386; EINECS 200-372-6; 2-Methyl-1,4-naphthodione; Methyl-1,4-naphthalenedione; Mendione; AI3-14700; 2-methyl-1,4-naphthoquinone, 5; Menadione, 9; Menadione,(S); Prestwick_313; Menadione, 98%; 5172-16-7; Menadione, crystalline; PubChem14596; Spectrum_001228; ACMC-1BCKI; SpecPlus_000191; Opera_ID_1802; Prestwick0_000459; Prestwick1_000459; Prestwick2_000459; Prestwick3_000459; Spectrum2_001194; Spectrum4_000722; Spectrum5_001764; M0373; NCIMech_000105; cid_4055; 2-methyl-1,4-napthoquinone; SCHEMBL25970; BSPBio_000538; KBioGR_000984; KBioGR_002527; KBioSS_001708; KBioSS_002535; 2-methyl-1,4 naphthoquinone; 34524-96-4; MLS001148443; ARONIS24154; BIDD:ER0556; DivK1c_000080; DivK1c_006287; SPECTRUM1502254; SPBio_001267; SPBio_002477; 3-methyl-1,4-naphthalenedione; BPBio1_000592; ZINC1677; DTXSID4021715; 2-Methyl-[1,4]-naphthoquinone; BDBM24778; HMS500D22; KBio1_000080; KBio1_001231; KBio2_001708; KBio2_002527; KBio2_004276; KBio2_005095; KBio2_006844; KBio2_007663; KBio3_003005; WLN: L66 BV EVJ C1; cMAP_000077; NINDS_000080; Bio1_000471; Bio1_000960; Bio1_001449; HMS1569K20; HMS1921P06; HMS2092F12; HMS2096K20; HMS2232A09; HMS2234J16; HMS3371M08; HMS3373A12; HMS3655P03; HMS3869N03; Pharmakon1600-01502254; AMY31055; BCP25699; HY-B0332; STR01143; Tox21_110334; Tox21_301367; ANW-32906; BBL027351; CCG-35354; Menadione (K3), analytical standard; NSC758200; s1949; SBB012369; STL377874; AKOS004910447; AKOS025244105; Tox21_110334_1; DB00170; FS-2556; MCULE-2487773379; NSC-758200; SB17255; IDI1_000080; QTL1_000056; NCGC00016258-01; NCGC00016258-03; NCGC00016258-04; NCGC00016258-06; NCGC00016258-07; NCGC00016258-08; NCGC00094978-01; NCGC00094978-02; NCGC00255225-01; 72060-21-0; H500; NCI60_003945; SMR000653532; ST066885; SY018303; SBI-0051776.P002; Menadione, meets USP testing specifications; FT-0612893; FT-0675843; SW219798-1; C05377; D02335; Z-3172; 001M681; A831816; Q192471; 1,4-Naphthalenedione, 2-methyl-, radical ion(1-); Q-201350; SR-01000712386-2; SR-01000712386-5; SR-01000712386-6; VITAMIN K3; 2-METHYL-1,4-NAPHTHALENEDIONE; BRD-K78126613-001-16-0; Menadione (Vitamin K3) 10 microg/mL in Acetonitrile; Vitamin K3; 2-Methyl-1,4-naphthoquinone; Menaphthone; Vitamin K3: 1,4-Dihydro-1,4-dioxo-2-methylnaphthalene; Menadione, European Pharmacopoeia (EP) Reference Standard; 03AAE1E9-B215-45AF-976C-91E61894A467; Menadione, United States Pharmacopeia (USP) Reference Standard; Menadione, Pharmaceutical Secondary Standard; Certified Reference Material; 47817-80-1	Small molecule	1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3	MJVAVZPDRWSRRC-UHFFFAOYSA-N	CC1=CC(=O)C2=CC=CC=C2C1=O	C11H8O2	CAS 58-27-5	CHEBI:28869	.	.	.	D03GET	.	.	.
NP0140	Vitamin E	CID: 14985	alpha-Tocopherol; VITAMIN E; D-alpha-Tocopherol; 59-02-9; 5,7,8-Trimethyltocol; (+)-alpha-Tocopherol; alpha-Vitamin E; Aquasol E; (R,R,R)-alpha-Tocopherol; Phytogermine; Eprolin; (2R,4'R,8'R)-alpha-Tocopherol; dl-a-Tocopherol; Denamone; Viteolin; Esorb; a-Tocopherol; Tocopherol alpha; alpha Tocopherol; 2074-53-5; (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; Vitamin Ea; Mixed tocopherols; D-alpha tocopherol; Syntopherol; (R)-2,5,7,8-Tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-ol; Tocopherol (R,S); UNII-N9PR3490H9; CHEBI:18145; (+/-)-alpha-Tocopherol; 2,5,7,8-Tetramethyl-2-(4',8',12'-trimethyltridecyl)-6-chromanol; Evitaminum; Profecundin; Waynecomycin; Almefrol; Emipherol; Epsilan; Etamican; Tokopharm; Vascuals; Vitayonon; Etavit; Ilitia; Evion; 1406-18-4; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; BPBio1_000362; Vitaplex E; Eprolin S; Spavit E; ido-E; Endo E; N9PR3490H9; Vita E; Lan-E; Med-E; Antisterility vitamin; MFCD00072045; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-, (2R)-; Vi-E; E307; DSSTox_CID_6339; DSSTox_RID_78103; DSSTox_GSID_26339; alpha-Tocopherol, D-; Viprimol; alpha-Tokoferol; Vitamin E alpha; Viterra E; E Prolin; (2R)-2-((4R,8R)-4,8,12-trimethyltridecyl)-2,5,7,8-tetramethylchroman-6-ol; CAS-59-02-9; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, (2R-(2R*(4R*,8R*)))-; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, [2R-[2R*(4R*,8R*)]]-; SMR000471844; VIV; (+/-)-alpha-Tocopherol, 95%, synthetic; alpha-Tocopherol acid; Tenox GT 1; Rhenogran Ronotec 50; Covitol F 1000; 3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-benzopyran-6-ol; E 307 (tocopherol); (all-R)-alpha-Tocopherol; Phytogermin; Palmvtee; alpha-Tocoferol; (+-)-Med-E; E-Oil 1000; Vitamin Ealpha; CCRIS 3588; MFCD00072051; a-D-Tocopherol; HSDB 2556; Pheryl-E; Vita plus E; d-..-Tocopherol; NCGC00016688-02; Vitamin E, liquid; (+)--tocopherol; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-, (2R)-; Prestwick_653; EINECS 200-412-2; EINECS 215-798-8; EINECS 218-197-9; .alpha.-Vitamin E; (+)-a-Tocopherol; NSC 20812; NSC 82623; RRR-alpha-tocopherol; RRR-alpha-tocopheryl; Vitamin E (liquid); Vitamin E [USP]; ()-alpha-Tocopherol; delta-alpha-tocopherol; alpha-delta-Tocopherol; Vitamin E (D-form); CHEMBL47; (R,R,R)-a-Tocopherol; Prestwick3_000404; E 307; (+)-.alpha.-Tocopherol; all-rac-alpha-Tocopherolum; bmse000600; EC 200-412-2; SCHEMBL3097; DL-all-rac-alpha-Tocopherol; UNII-H4N855PNZ1; BIDD:PXR0174; D-alpha-Tocopherol, 97+%; BSPBio_000328; MLS001066396; MLS001335981; MLS001335982; BIDD:ER0562; T1539_SIGMA; H4N855PNZ1; DTXSID0026339; (2R,4'R,8'R)-a-Tocopherol; HMS2096A10; HMS2231G08; C29H50O2 (D-alpha-tocopherol); HY-N0683; ZINC4095858; Tox21_110563; Tox21_113208; Tox21_202081; BDBM50458513; LMPR02020001; MFCD00006848; AKOS004910417; CS-8161; DB00163; MCULE-3684036705; NCGC00142625-01; NCGC00142625-04; NCGC00142625-05; NCGC00142625-06; NCGC00142625-07; NCGC00142625-10; NCGC00259630-01; (2R*(4R*,8R*))-(1)-3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-benzopyran-6-ol; 18920-62-2; AS-13990; M349; P500; ST073358; (+/-)-alpha-Tocopherol (Vitamin E) solution; C02477; d-alpha, d-beta, d-gamma & d-delta tocopherols; Q158348; Q-201932; W-107596; W-109164; 07AA93F0-3339-4EEC-B50B-ADB70F657087; UNII-7QWA1RIO01 component GVJHHUAWPYXKBD-IEOSBIPESA-N; UNII-N53I4V2IA6 component GVJHHUAWPYXKBD-IEOSBIPESA-N; UNII-R0ZB2556P8 component GVJHHUAWPYXKBD-IEOSBIPESA-N; (+)-alpha-Tocopherol, from vegetable oil, Type V, ~1000 IU/g; (2R,4'R,8'R)-2,5,7,8-Tetramethyl-2-(4',8',12'-trimethyltridecyl)-6-chromanol; 3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1- -benzopyran-6-ol; (+)-alpha-Tocopherol, Type VI, from vegetable oil, neat (liquid, >=0.88M based on potency, density and molecular wt.), BioReagent, suitable for insect cell culture, >=1000 IU/g; (2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol; (R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-3,4-dihydro-2H-chromen-6-ol; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-,  2R- 2R*(4R*,8R*)  -; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, (2R*(4R*,8R*))-(+-)- (9CI)	Small molecule	1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1	GVJHHUAWPYXKBD-IEOSBIPESA-N	CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C	C29H50O2	CAS 59-02-9	CHEBI:18145	.	.	.	D02TQO	.	.	.
NP0165	Voglibose	CID: 444020	voglibose; 83480-29-9; Glustat; Basen; AO-128; UNII-S77P977AG8; A-71100; Voglibosa; CHEMBL476960; (1S,2S,3R,4S,5S)-5-((1,3-dihydroxypropan-2-yl)amino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol; S77P977AG8; AO 128; DSSTox_CID_1442; DSSTox_RID_76161; DSSTox_GSID_21442; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol; (1S,2S,3R,4S,5S)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; Voglibosum; 3,4-Dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-C-(hydroxymethyl)-D-epi-inositol; Basen OD; 3,4-DIDEOXY-4-[[2-HYDROXY-1-(HYDROXYMETHYL)ETHYL]AMINO]-2-C-(HYDROXYMETHYL)-D-EPINOSITOL; CAS-83480-29-9; Basen (TN); Voglibose [USAN:INN]; Voglibosum [INN-Latin]; Voglibosa [INN-Spanish]; CCRIS 4540; Voglibose/; NCGC00164595-01; 3,4-Dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epi-inositol; VOG; SCHEMBL5882; A 71100; MLS003882582; Voglibose (JP17/USAN/INN); DTXSID2021442; CHEBI:32300; AOB5593; BCPP000020; HMS3414A17; HMS3678A17; Voglibose, >=97.0% (TLC); HY-B0025; ZINC3788703; Tox21_112220; ABP000769; BDBM50263044; s4101; AKOS015950839; Tox21_112220_1; CCG-267119; DB04878; NCGC00164595-02; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; SMR002530327; D01665; AB01566929_01; 480V299; SR-01000883931; Q-101310; Q7939403; SR-01000883931-1; BRD-K66850609-001-01-7; BRD-K66850609-001-07-4	Small molecule	1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1	FZNCGRZWXLXZSZ-CIQUZCHMSA-N	C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO	C10H21NO7	CAS 83480-29-9	CHEBI:32300	.	.	.	D04ZTY	.	.	.
NP0166	Coumarins	CID: 54678486	warfarin; Coumadin; 81-81-2; Coumafene; Prothromadin; Coumafen; Zoocoumarin; Vampirinip II; Coumarins; Coumefene; Panwarfin; Warfarine; Brumolin; Dethmor; Dethnel; Kumader; Kypfarin; Maveran; Solfarin; Kumadu; Rosex; Athrombine-K; Frass-Ratron; Mar-Frin; Rattentraenke; Rattunal; Rodafarin; Temus W; Warfarat; Kumatox; Ratorex; Ratron; Vampirinip iii; D-Con; Rats-no-more; Tox-hid; Ratten-Koederrohr; Rat-Gard; Rat-Kill; Rat-Trol; Rat-Mix; Rat-Ola; Ro-Deth; Coumaphene; Rat-a-way; Rat & mice bait; Ratoxin; Martin's mar-frin; Rat-B-gon; Maag Rattentod Cum; Warfarin plus; Rodex blox; CO-Rax; Fasco fascrat powder; Liqua-tox; Mouse pak; Place-pax; Twin light rat away; Warfarin Q; Dicusat E; Ratron G; Eastern states duocide; Compound 42; Ratox; Cov-R-Tox; rac-Warfarin; Rodafarin C; Rough & ready mouse mix; WARF compound 42; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; Rat-o-cide #2; Latka 42; Arab Rat Death; Spray-trol brand roden-trol; Warf 42; 200 coumarin; Rattenstreupulver Neu Schacht; Coumaphen; Warficide; Sorexa plus; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-; Arab rat deth; Rodex; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one; Rattenstreupulver new schacht; Athrombin-K; W.A.R.F. 42; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin; Rcra waste number P001; Sakarat; Sewarin; Waran; 3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine; 4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin; 4OH-Coumarin deriv.; RAX; 1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone; Rat-o-cide No. 2; 2-hydroxy-3-(3-oxo-1-phenylbutyl)-4h-chromen-4-one; 3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin; (R)-(+)-Warfarin; 4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine; DL-3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin; (Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine; 3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin; CHEMBL1464; 5543-58-8; 3-(.alpha.-Acetonylbenzyl)-4-hydroxycoumarin; CHEBI:87732; C19H16O4; 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one; NSC59813; Rcr grey squirrel killer concentrate; 3-(Acetonylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin; NSC-59813; Coumafene [French]; NCGC00094810-01; Warfarina; Warfarinum; Zoocoumarin [Russian]; Latka 42 [Czech]; Warfarin [INN:BAN]; DSSTox_CID_3742; 4-Idrossi-3-(3-oxo-)-fenil-butil)-cumarine; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; DSSTox_RID_77177; (Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarin; Coumarin, 3-(.alpha.-acetonylbenzyl)-4-hydroxy-; DSSTox_GSID_23742; Warfarina [INN-Spanish]; Warfarin, analytical standard; 951658-59-6; Warfarin plus [discontinued]; 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one; Caswell No. 903; 3-(.alpha.-Phenyl-.beta.-acetylethyl)-4-hydroxycoumarin; Warfarin [BSI:ISO]; Warfarin (and salts of); (R)-Warfarin-d5; Zoocoumarin [Netherlands and USSR]; CAS-81-81-2; Warfarin (INN); Choice (TN); HSDB 1786; SR-01000195154; NCGC00094810-04; EINECS 201-377-6; NSC 59813; RCRA waste no. P001; CBKinase1_000192; CBKinase1_012592; EPA Pesticide Chemical Code 086002; BRN 1293536; wafarin; delta-con; Athrombine K; Rat-alpha-way; Rat-beta-gon; Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy-; Killgerm sewarin p; Rat and mice bait; (RS)-Warfarin; 4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine [Dutch]; 4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin [German]; 4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine [Italian]; 2-HYDROXY-3-(3-OXO-1-PHENYL-BUTYL)CHROMEN-4-ONE; Rattentraenke (German); Spectrum_000194; (Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine [French]; 3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin [German]; (.+/-.)-Warfarin; Spectrum2_000935; Spectrum3_000583; Spectrum4_000381; Spectrum5_001751; Rough and ready mouse mix; EC 201-377-6; Ratten-Koederrohr (German); SCHEMBL3689; CHEMBL7252; BSPBio_002026; CBDivE_002127; CBDivE_013236; KBioGR_000901; KBioSS_000674; 5-18-04-00162 (Beilstein Handbook Reference); MLS001304042; DivK1c_000444; SCHEMBL136434; SPECTRUM1500613; SPBio_000870; BEN360; GTPL6853; DTXSID5023742; HMS501G06; KBio1_000444; KBio2_000674; KBio2_003242; KBio2_005810; KBio3_001526; NINDS_000444; HMS1921K07; HMS2092C20; HMS2233L10; HMS3372L19; HMS3648B15; HMS3714G21; Pharmakon1600-01500613; 773005-79-1; 791013-22-4; EBD16262; HY-B0687; Tox21_113185; Tox21_202182; Tox21_300531; Warfarin 1.0 mg/ml in Acetonitrile; BBL027615; BDBM50343352; CCG-39672; MFCD00272376; NSC757385; s4545; SBB058124; STK364490; Warfarin and salts, when present at concentration greater than 0.3%; WLN: T66 BOVJ DYR&1V1 EQ; AKOS005430103; AKOS026749956; DB00682; MCULE-1618253893; NSC-757385; Rattenstreupulver Neu Schacht (German); VC30411; 3-(a-acetonylbenzyl)-4-hydroxycoumarin; IDI1_000444; SMP1_000316; Warfarin 100 microg/mL in Acetonitrile; NCGC00094810-02; NCGC00094810-03; NCGC00094810-05; NCGC00094810-06; NCGC00159398-03; NCGC00178855-01; NCGC00188986-01; NCGC00188986-02; NCGC00254457-01; NCGC00259731-01; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, & salts, when present at concentrations greater than 0.3%; AC-15978; SMR000718754; SBI-0051556.P002; AB0015503; DB-052729; DB-052730; DL-3-(a-Acetonylbenzyl)-4-hydroxycoumarin; R-(+)-3-Acetonybenzyl)-4-hydroxycoumarin; FT-0635767; FT-0635768; ST50308693; Warfarin, PESTANAL(R), analytical standard; 4-Hydroxy-3- (3-oxo-1-fenyl-butyl) cumarine; 4-Hydroxy-3- (3-oxo-1-phenyl-butyl)-cumarin; 4-Idrossi-3- (3-oxo-)-fenil-butil)-cumarine; C01541; D08682; AB00052125_02; AB00876255-06; 006W854; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, 97%; A830639; Q407431; 4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-chromen-2-one; 4-hydroxy-3-(3-oxo-1-phenyl-butyl)chromen-2-one; SR-01000195154-3; SR-01000195154-4; BRD-A24514565-001-02-2; BRD-A24514565-236-01-6; SR-01000195154-10; 2-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-4-one; 3-(.alpha.-Phenyl-.beta.-acetylaethyl)-4-hydroxycumarin; Warfarin, British Pharmacopoeia (BP) Reference Standard; Z1692482575; 4-(4-hydroxy-2-oxo-2H-3-chromenyl)-4-phenyl-2-butanone; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one #; Warfarin4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-chromen-2-one; 2-oxidanyl-3-(3-oxidanylidene-1-phenyl-butyl)chromen-4-one; Warfarin, United States Pharmacopeia (USP) Reference Standard; 2-Hydroxy-3-(alpha-(2-oxopropyl)benzyl)-4H-1-benzopyran-4-one; 2H-1-Benzopyran-2-one,4-hydroxy-3-[(1S)-3-oxo-1-phenylbutyl]-; R-(+)-4-Hydroxy-3-(3-oxo-1-phenybutyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin; 3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin	Small molecule	1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3	PJVWKTKQMONHTI-UHFFFAOYSA-N	CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O	C19H16O4	CAS 81-81-2	CHEBI:87732	.	.	.	D0E3OF	.	.	.
NP0195	Testosterone	CID: 6013	testosterone; 58-22-0; Testosteron; Androderm; Testim; Testoderm; Mertestate; Virosterone; Androlin; Oreton; AndroGel; Synandrol F; Testostosterone; Andropatch; Malerone; Testogel; Testoviron; trans-Testosterone; Relibra; Cristerone T; LibiGel; 17beta-Hydroxyandrost-4-en-3-one; Oreton-F; Testoject-50; Testosterona; Testosteronum; Striant; Andro 100; Testex; Testosterone hydrate; Sustason 250; beta testosterone; Sustanon; Malestrone (amps); Testosteroid; Andronaq; Andrusol; Homosteron; Homosterone; Intrinsa; Orquisteron; Perandren; Primotest; Primoteston; Sustanone; Testandrone; Testobase; Testopropon; Testrone; Virormone; Teslen; Testryl; Testiculosterone; Malogen, aquaspension injection; Cristerona T; Testoviron T; Testosteronum [INN-Latin]; Testosterona [INN-Spanish]; Neotestis; Testoviron Schering; Geno-cristaux gremy; Neo-Hombreol F; Androst-4-en-17beta-ol-3-one; Testolin; Percutacrine androgenique; 17beta-Hydroxy-4-androsten-3-one; 7-beta-Hydroxyandrost-4-en-3-one; COL 1621; delta4-Androsten-17beta-ol-3-one; Androst-4-en-3-one, 17-hydroxy-, (17beta)-; 17beta-Hydroxyandrost-4-ene-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 4-Androsten-17beta-ol-3-one; Testro AQ; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; delta(sup 4)-Androsten-17(beta)-ol-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; UNII-3XMK78S47O; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; Androst-4-en-3-one, 17beta-hydroxy-; Androst-4-en-3-one, 17-beta-hydroxy-; CHEBI:17347; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Neo-testis; Testoderm Tts; 3XMK78S47O; Androst-4-en-3-one, 17-hydroxy-, (17b)-; Testopel Pellets; CDB 111C; Testosterone and its esters; Halotensin; Fortesta; Nasobol; Natesto; Vogelxo; (+)-testosterone; Axiron; Tefina; CompleoTRT; CP 601B; (8alpha,10alpha,13alpha,14beta,17alpha)-17-hydroxyandrost-4-en-3-one; Androderm (TN); Androgel 1%; 17.beta.-Testosterone; Androgel (TN); SMR000058344; CCRIS 574; Striant (TN); Bio-T-Gel; AA 2500; Testim (TN); Androgel 1.62%; HSDB 3398; NSC 9700; Androst-4-en-3-one, 17-hydroxy-, (17.beta.)-; EINECS 200-370-5; Testosterone (JAN/USP); Androst-4-en-3-on-17B-ol; CHEMBL386630; component of Duogen (Salt/Mix); component of Tostrex (Salt/Mix); component of Di-Met (Salt/Mix); component of Intrinsa (Salt/Mix); 4-Androsten-17.beta.-ol-3-one; 4-Androsten-3-one-17.beta.-ol; Tlando; component of Di-Genik (Salt/Mix); 4-Androsten-3-one, 17b-hydroxy-; NSC-9700; Testosterone [USP:INN:BAN]; component of Mal-O-Fem (Salt/Mix); Testosterone [Androgenic steroids, anabolic]; 4-androstene-17beta-ol-3-one; Testosterone ciii; 17b-hydroxy-4-androsten-3-one; delta4-androsten-17b-ol-3-one; LPCN 1021; testosterone group; Testosterone, 1; 3kdm; 17-.beta.-Hydroxyandrost-4-en-3-one; NCGC00091018-01; Androst-4-en-3-one, 17-hydroxy-, (17-beta)-; Axiron (TN); CMC_13449; mpp10; 17.beta.-Hydroxy-.DELTA.4-androsten-3-one; 17-Hydroxyandrost-4-en-3-one, (17.beta.)-; Testosterone, >=98%; DSSTox_CID_2371; Epitope ID:135865; EC 200-370-5; Testosterone EP Impurity C; SCHEMBL8452; DSSTox_RID_76563; DSSTox_GSID_22371; MLS000563091; MLS001032098; MLS001306401; MLS001424262; MLS002174283; BIDD:ER0555; BDBM8885; GTPL2858; DTXSID8022371; 17beta-hydroxy-4-androsten-3one; Testosterone, cell culture tested; 1i37; HMS2052N11; HMS2272B03; HMS2272P03; (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; Tox21_200689; HY-15554A; LMST02020002; RB3046; AKOS015894897; ZINC118912393; CCG-101189; CS-1415; DB00624; MCULE-1294118086; NC00439; CAS-58-22-0; Testosterone 1.0 mg/ml in Acetonitrile; (17?)-17-Hydroxyandrost-4-en-3-one; NCGC00258243-01; AC-14899; CPD000058344; SMR001261453; Testosterone, purum, >=99.0% (HPLC); Testosterone 100 microg/mL in Acetonitrile; BIM-0061761.0001; C00535; D00075; S00309; W-5033; AB00973630-03; Testosterone, VETRANAL(TM), analytical standard; 003T654; Androst-4-en-3-one, 17-hydroxy, (17.beta.)-; Q-101251; Q1318776; B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E; Testosterone, European Pharmacopoeia (EP) Reference Standard; Testosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, drug standard; Testosterone;  4-Androsten-17?-ol-3-one;  17?-Hydroxy-4-androsten-3-one; Testosterone for impurity D identification, European Pharmacopoeia (EP) Reference Standard; Testosterone for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one; 1050678-68-6; 17?-hydroxyandrost-4-en-3-one; epitestosterone; 17-epi-Testosterone; 17?-cis-Testosterone; 4-Androstene-17?-ol-3-one; Isotestosterone; Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material	Small molecule	1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	MUMGGOZAMZWBJJ-DYKIIFRCSA-N	CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C	C19H28O2	CAS 58-22-0	CHEBI:17347	.	.	.	D06XMU	.	.	.
NP0204	Menthol	CID: 1254	MENTHOL; dl-Menthol; 1490-04-6; 2-Isopropyl-5-methylcyclohexanol; p-Menthan-3-ol; Cyclohexanol, 5-methyl-2-(1-methylethyl)-; 15356-70-4; 89-78-1; Racementhol; (+/-)-Menthol; 5-methyl-2-propan-2-ylcyclohexan-1-ol; Menthol [USP]; Neomenthol; rac-Menthol; 5-methyl-2-(propan-2-yl)cyclohexan-1-ol; CHEBI:25187; Menthyl alcohol; (1R,2S,5R)-Menthol; Menthol, dl-; Menthol (USP); (1S, 2S, 5R)-(+)-Neomenthol; 5-methyl-2-(propan-2-yl)cyclohexanol; DSSTox_CID_805; DSSTox_RID_78794; DSSTox_GSID_29650; Racemic menthol; FEMA No. 2665; Caswell No. 540; 3-p-Menthanol; Mentholum; Mineral ice; MFCD00001484; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1S-(1.alpha.,2.alpha.,5.beta.)]-; Therapeutic mineral ice; 3-p-Menthol; CAS-1490-04-6; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel-; CCRIS 9231; 1217765-02-0; 3-Hydroxy-p-menthane; Fisherman's friend lozenges; Robitussin Cough Drops; EINECS 216-074-4; EPA Pesticide Chemical Code 051601; (+/-)-p-Menthan-3-ol; Menthol, cis-1,3,trans-1,4-; 5-Methyl-2-(1-methylethyl)-cyclohexanol; AI3-08161; HSDB 593; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.beta.,5.alpha.)-; (-)menthol; NCGC00159382-02; 3623-51-6; 3623-52-7; (-) menthol; 2-Isopropyl-5-methylcyclohexan-1-ol; 4-Isopropyl-1-methylcyclohexan-3-ol; Menthol, 99%; p-menthan-3-ol group; (+/-)-Neoisomenthol; dl-Menthol (JP17); 1-methyl-4-isopropyl-3-hydroxycyclohexane; ACMC-1BQW4; EC 216-074-4; SCHEMBL4612; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1S,2S,5R)-; Menthol, (.+/-.)-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2R,5S)-rel-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5S)-rel-; Menthol, puriss., 99.0%; CHEMBL256087; DL-Menthol, analytical standard; DTXSID8029650; AMY3077; Fisherman's friend lozenges (TN); BDBM248162; HMS3744K19; (1S,2R,5R)-(+)-Isomenthol; 2-Isopropyl-5-methylcyclohexanol #; BCP27552; BCP31841; CS-M3737; HY-N1369; menthol crystals; 15356-70-4; Tox21_200010; Tox21_303464; ANW-21459; BBL009325; DL-Menthol, >=95%, FCC, FG; STK802468; AKOS000119740; AKOS016843634; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.alpha.,5.beta.)-; Menthol-d4 (mixture of diastereomers); AM81446; MCULE-3070949324; 5-methyl-2-propan-2-yl-1-cyclohexanol; Menthol 1000 microg/mL in Acetonitrile; Menthol, SAJ special grade, >=98.0%; NCGC00159382-03; NCGC00159382-04; NCGC00159382-05; NCGC00159382-06; NCGC00257403-01; NCGC00257564-01; 5-methyl-2-propan-2-yl-cyclohexan-1-ol; AK110724; AK158890; HY-75161; K601; SY004225; SY010603; VS-02042; DB-063989; Levomenthol; D-(-)-Menthol; (-)-Menthol; CS-0016777; FT-0600039; FT-0604399; FT-0604426; FT-0604430; FT-0620596; FT-0625488; FT-0695077; FT-0695078; FT-0695079; H2461; M0321; (+/-)-Menthol, racemic, >=98.0% (GC); 2-Isopropy-5-methylcyclohexanol-1,2,6,6-d4; D04849; D04918; (1S,2R,5R)-2-isopropyl-5-methyl-cyclohexanol; A808833; J-500418; 2-$l^{1}-oxidanyl-4-methyl-1-propan-2-ylcyclohexane; Q27109870; Z1258992394; Menthol-plus it inverted exclamation markas 3 isomers-1,2,6,6-d4; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.beta.,5.alpha.)-(.+/-.)-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1R-(1.alpha.,2.alpha.,5.beta.)]-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1S-(1.alpha.,2.beta.,5.beta.)]-; L-Menthol; (-)-Menthol; Levomenthol; Menthomenthol;2-isopropyl-5-methyl-cyclohexanol;Menthol; Menthol solution, NMR reference standard, 30 wt. % in chloroform-d (99.8 atom % D), NMR tube size 5 mm x 8 in.; Menthol solution, NMR reference standard, 50% in chloroform-d (99.8 atom % D), chromium(III) acetylacetonate 0.5 %, NMR tube size 5 mm x 8 in.	Small molecule	1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3	NOOLISFMXDJSKH-UHFFFAOYSA-N	CC1CCC(C(C1)O)C(C)C	C10H20O	CAS 89-78-1	CHEBI:25187	.	.	.	D04CSZ	.	.	.
NP0239	Schisandrin A	CID: 155256	Schizandrin A; schisandrin A; 61281-38-7; Deoxyschizandrin; Deoxyschisandrin; (-)-Deoxyschizandrin; UNII-74XQL5DO3S; 74XQL5DO3S; 69176-53-0; Dimethylgomisin J; Wuweizisu A; (6R,7S)-1,2,3,10,11,12-Hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulene; hexamethoxy(dimethyl)[?]; Di-O-methylgomisin J; (-)-Deoxyschisandrin; (-)-Dimethylgomisin J; (+)-Deoxyschizandrin; MLS000728483; CHEMBL253908; GTPL2769; SCHEMBL2404905; DTXSID10219222; HMS2227F15; Schisandrin A, analytical standard; HY-N0693; Schisandrin A, >=98% (HPLC); BDBM50485611; MFCD09026934; s3822; ZINC18269545; AKOS015960456; CCG-268845; CS-3658; AC-11192; BS-17208; Dibenzo(a,c)cyclooctene, 5,6,7,8-tetrahydro-1,2,3,10,11,12-hexamethoxy-6,7-dimethyl-, (6R,7S,12aS)-; Dibenzo(a,c)cyclooctene, 5,6,7,8-tetrahydro-1,2,3,10,11,12-hexamethoxy-6,7-dimethyl-, stereoisomer; SMR000445690; NCGC00385070-01!; V0367; A14531; SR-01000777559; SR-01000777559-3; Q15410931; Dibenzo(a,c)cyclooctene, 5,6,7,8-tetrahydro-6,7-dimethyl-1,2,3,10,11,12-hexamethoxy-; (9S,10R)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.0^{2,7}]hexadeca-1(16),2,4,6,12,14-hexaene	Small molecule	1S/C24H32O6/c1-13-9-15-11-17(25-3)21(27-5)23(29-7)19(15)20-16(10-14(13)2)12-18(26-4)22(28-6)24(20)30-8/h11-14H,9-10H2,1-8H3/t13-,14+	JEJFTTRHGBKKEI-OKILXGFUSA-N	CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3CC1C)OC)OC)OC)OC)OC)OC	C24H32O6	CAS 61281-38-7	.	.	.	.	D0Y4YV	.	.	.
NP0258	Wogonoside	CID: 3084961	Wogonoside; Oroxindin; 51059-44-0; Wogonin 7-O-glucuronide; UNII-ETX4944Z3R; CHEBI:61282; 5,7-dihydroxy-8-methoxyflavone 7-O-beta-D-glucuronide; CHEMBL464732; ETX4944Z3R; wogonin 7-O-beta-D-glucuronide; MFCD08704808; 5-hydroxy-8-methoxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(5-hydroxy-8-methoxy-4-oxo-2-phenylchromen-7-yl)oxyoxane-2-carboxylic acid; wogonin 7-O-beta-glucuronine methyl ester; MEGxp0_000537; ACon1_000851; DTXSID80199062; HY-N0399; BDBM50478452; s9115; ZINC28537647; AKOS015897144; CCG-269333; MCULE-2705236589; Wogonoside, >=95% (LC/MS-ELSD); NCGC00169296-01; CS-0008934; Q3356626; W-202920; BRD-K72010518-001-01-0; (2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((5-hydroxy-8-methoxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid; NCGC00169296-02!(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(5-hydroxy-8-methoxy-4-oxo-2-phenylchromen-7-yl)oxyoxane-2-carboxylic acid	Small molecule	1S/C22H20O11/c1-30-18-13(32-22-17(27)15(25)16(26)20(33-22)21(28)29)8-11(24)14-10(23)7-12(31-19(14)18)9-5-3-2-4-6-9/h2-8,15-17,20,22,24-27H,1H3,(H,28,29)/t15-,16-,17+,20-,22+/m0/s1	LNOHXHDWGCMVCO-NTKSAMNMSA-N	COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)OC4C(C(C(C(O4)C(=O)O)O)O)O	C22H20O11	CAS 51059-44-0	CHEBI:61282	.	.	.	.	.	.	.
NP0310	Succinic acids	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP0318	Kynurenine	CID: 846	kynurenine; 343-65-7; dl-Kynurenine; 2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid; 3-Anthraniloylalanine; 3-Anthraniloyl-DL-alanine; Kynurenin; alpha-2-Diamino-gamma-oxobenzenebutyric acid; Alanine, 3-anthraniloyl-; CHEBI:28683; Benzenebutanoic acid, alpha,2-diamino-gamma-oxo-; Quinurenine; Benzenebutanoic acid, .alpha.,2-diamino-.gamma.-oxo-; 3039-10-9; rac-Kynurenine; Alanine, 3-anthraniloyl-, DL-; (+-)-Kynurenine; EINECS 206-445-9; (+/-)-Kynurenine; Spectrum_001162; SpecPlus_000330; 2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid #; D-2-Amino-4-[2-aminophenyl]-4-oxobutanoic acid; Spectrum2_001380; Spectrum3_000781; Spectrum4_001916; Spectrum5_000632; DL-Kynurenine, free base; SCHEMBL20874; BSPBio_002482; KBioGR_002539; KBioSS_001642; DivK1c_006426; SPECTRUM1500879; SPBio_001340; CHEMBL1377927; BDBM31880; KBio1_001370; KBio2_001642; KBio2_004210; KBio2_006778; KBio3_001702; DTXSID90861884; Alanine, 3-anthraniloyl- (8CI); ANW-58102; CCG-38856; DL-Kynurenine, >=95.0% (NT); MFCD00025194; SBB005347; STL453545; AKOS015894416; CS-W015220; HY-W014504; MCULE-6365994952; SDCCGMLS-0066734.P001; DL-Kynurenine sulfate (salt) monohydrate; NCGC00017339-02; NCGC00017339-03; NCGC00095648-01; NCGC00095648-02; AS-12298; ST057185; 2-Amino-3-(2-aminobenzoyl)propionic acid; DB-006353; DB-050656; FT-0600276; FT-0600475; FT-0627925; 2-Amino-4-(2-aminophenyl)-4-oxobutyric acid; C01718; .alpha.-2-diamino-.gamma.-oxobenzenebutyric acid; SR-05000002450; SR-05000002450-1; Q32908783; Benzenebutanoic acid, alpha,2-diamino-gamma-oxo- (9CI); AD0899CA-9379-461E-BD7D-45908947C589	Small molecule	1S/C10H12N2O3/c11-7-4-2-1-3-6(7)9(13)5-8(12)10(14)15/h1-4,8H,5,11-12H2,(H,14,15)	YGPSJZOEDVAXAB-UHFFFAOYSA-N	C1=CC=C(C(=C1)C(=O)CC(C(=O)O)N)N	C10H12N2O3	CAS 343-65-7	CHEBI:28683	.	.	.	.	.	.	.
NP0393	Caffeine citrate	CID: 6241	Caffeine citrate; 69-22-7; Caffeine, Citrated; Caffeine citrated; UNII-U26EO4675Q; U26EO4675Q; NCGC00015208-09; Caffeina citrate; Citrated caffein; 2-hydroxypropane-1,2,3-tricarboxylic acid;1,3,7-trimethylpurine-2,6-dione; DSSTox_CID_26938; DSSTox_RID_82023; DSSTox_GSID_46938; Caffeine citrate (1:1); CAS-69-22-7; CAFFEINECITRATED; C8H10N4O2.C6H8O7; Caffeine, citrated [NF]; Citric acid, compd. with caffeine (1:1); Cafcit (TN); 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; Caffeine citrate (USP); caffeine-citric acid 1/1; SCHEMBL452067; CHEMBL1200569; DTXSID5046938; Caffeine mixture with citric acid; NSC63248; Tox21_110099; 7902AF; NSC-63248; AKOS030254796; Tox21_110099_1; NCGC00015208-19; DB-055239; FT-0623368; D07603; Q2974480; 1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione 2-hydroxypropane-1,2,3-tricarboxylate	Small molecule	1S/C8H10N4O2.C6H8O7/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2;7-3(8)1-6(13,5(11)12)2-4(9)10/h4H,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)	RCQXSQPPHJPGOF-UHFFFAOYSA-N	CN1C=NC2=C1C(=O)N(C(=O)N2C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O	C14H18N4O9	CAS 69-22-7	.	.	.	.	.	.	.	.
NP0395	Nobiletin	CID: 72344	Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; UNII-D65ILJ7WLY; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; D65ILJ7WLY; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; CHEMBL76447; Nobiletin (Hexamethoxyflavone); CHEBI:7602; NSC76751; MFCD03273560; Flavone, 5,6,7,8,3',4'-hexamethoxy; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; SMR000156231; CCRIS 9012; NSC 76751; CPD000156231; Nobiletin, >=97%; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; KBio3_001922; DTXSID30197275; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HY-N0155; ZINC1531669; 3'4'5,6,7,8-Hexamethoxyflavone; 3,4,5,6,7,8-Hexamethoxyflavone; ANW-42631; BDBM50338976; CCG-38781; CN0043; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; MCULE-1015144950; NC00186; NSC-618903; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AK168175; AS-17452; NCI60_041691; DB-050181; FT-0686667; N0871; N1311; S2333; SW197566-2; V0181; C10112; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI; 3 inverted exclamation mark ,4 inverted exclamation mark ,5,6,7,8-HEXAMETHOXYFLAVONE; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (9CI)	.	1S/C21H22O8/c1-23-13-8-7-11(9-15(13)24-2)14-10-12(22)16-17(25-3)19(26-4)21(28-6)20(27-5)18(16)29-14/h7-10H,1-6H3	MRIAQLRQZPPODS-UHFFFAOYSA-N	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC	C21H22O8	CAS 478-01-3	.	HBIN037171	SMIT00234	MOL005828	.	.	1348	.
NP0404	D-cycloserine	CID: 6234	D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclo-D-serine; Cyclorin; D-4-amino-3-isoxazolidinone; Cicloserina; Farmiserina; Miroseryn; Tisomycin; Wasserina; Closina; D-4-amino-3-isoxazolidone; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Cycloserinum; Miroserina; Tebemicina; Novoserin; (R)-4-AMINOISOXAZOLIDIN-3-ONE; (+)-Cycloserine; Oxamicina; (4R)-4-amino-1,2-oxazolidin-3-one; D-(+)-Cycloserine; (4R)-4-aminoisoxazolidin-3-one; PA 94; Cycloserin; Micoserina; 3-Isoxazolidinone, 4-amino-, (4R)-; PA-94; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; D-Oxamycin; RO-1-9213; D-CS; E-733-A; D-4-Amino-3-isossazolidone; 3-Isoxazolidinone, 4-amino-, (R)-; (R)-4-Amino-3-isoxazolidinone; HSDB 3218; D-Oxamicina; 3-Isoxazolidinone, 4-amino-, d-; K-300; UNII-95IK5KI84Z; (R)-(+)-4-Amino-3-isoxazolidinone; I-1431; 3-Isoxazolidinone, 4-amino-, (+)-; NSC 154851; CHEBI:40009; AI3-50153; D-Cycloserine, synthetic; MFCD00005353; DCS; CHEMBL771; SC-49088; 95IK5KI84Z; CAS-68-41-7; NCGC00016306-01; D-Cycloserine, 98%; Oxamicina [Italian]; Cicloserina [Italian]; DSSTox_CID_2870; 3-Isoxazolidinone, 4-amino-, (+)- (8CI); DSSTox_RID_76766; DSSTox_GSID_22870; Cycloserinum [INN-Latin]; Cicloserina [INN-Spanish]; Cycloserine, D-; Closerin; .alpha.-Cycloserine; (R)-Cycloserine; Seromycin (TN); SMR000058313; D-4-Amino-3-isossazolidone [Italian]; R-(+)-Cycloserine; (4R)-4-Amino-3-isoxazolidinone; CYCLOSERINE (D); SR-01000075432; DRG-0195; (R)-(+)-Cycloserine; EINECS 200-688-4; D-amino-3-isoxazolidinone; BRN 0080798; (R)-4-Amino-3-isoxazolidone; NSC-76029; cycloserine-(d); Serine, cyclo-; NSC-154851; 3-Isoxazolidinone, 4-amino-, D; R(+)-4-Amino-3-isoxazolidinone; Cycloserine [USP:INN:BAN:JAN]; 4AX; 3-Isoxazolidinone, 4-amino-, (R); Cycloserine, D(+); PubChem5763; D-Cycloserine, powder; Spectrum_000860; 1pb9; Prestwick0_001089; Prestwick1_001089; Prestwick2_001089; Prestwick3_001089; Spectrum2_000084; Spectrum3_000371; Spectrum4_000305; Spectrum5_000797; Lopac-C-1159; Lopac-C-3909; Lopac-C-7005; 3-Isoxazolidinone, 4-amino-, (4R)- (9CI); C 3909; C-9390; C-9400; Lopac0_000252; SCHEMBL34322; BSPBio_001138; BSPBio_002121; KBioGR_000890; KBioSS_001340; 4-27-00-05549 (Beilstein Handbook Reference); MLS000758215; MLS001423962; MLS002548887; BIDD:GT0707; D-Cycloserine synth. BP 88; DivK1c_000098; SPECTRUM1500215; SPBio_000008; SPBio_003029; BPBio1_001252; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; GTPL9489; Cycloserine (JP17/USP/INN); 4-Amino-3-isoxazolidinone, D-; DTXSID8022870; HMS500E20; KBio1_000098; KBio2_001340; KBio2_003908; KBio2_006476; KBio3_001341; NINDS_000098; HMS1571I20; HMS1920C06; HMS2051C15; HMS2091I14; HMS2098I20; HMS2232F03; HMS3259L19; HMS3260D06; HMS3715I14; NJ-21; Pharmakon1600-01500215; (R)-3-Isoxazolidinone, 4-amino-; 4-Amino-3-isoxazolidinone, (R)-; ACT04767; HY-B0030; Tox21_110361; Tox21_500252; BDBM50038178; BDBM50103516; CCG-39705; D-Cycloserine, >=96.0% (NT); LMPK14000007; NSC756712; s1998; ZINC34676245; 4-Isoxazolidinamine, 3-oxo-, (D)-; AKOS015994626; Tox21_110361_1; AC-4721; DB00260; HS-0079; LP00252; MCULE-4212827696; NC00050; NC00676; NSC-756712; SDCCGSBI-0050240.P005; IDI1_000098; SMP1_000167; NCGC00015213-01; NCGC00015213-02; NCGC00015213-03; NCGC00016306-02; NCGC00016306-03; NCGC00016306-04; NCGC00016306-05; NCGC00016306-07; NCGC00016306-08; NCGC00016306-17; NCGC00093713-01; NCGC00093713-02; NCGC00260937-01; CAS-339-72-0; K138; ST075697; SBI-0050240.P004; AB0007232; AB00443920; EU-0100252; (4R)-4-amino-2,4,5-trihydroisoxazol-3-one; C08057; D00877; AB00443920_09; AB00443920_10; 005C353; 101039-EP2295402A2; 101039-EP2301544A1; Q418508; SR-01000759389; SR-01000075432-1; SR-01000075432-2; SR-01000075432-5; SR-01000075432-9; SR-01000759389-4; SR-01000075432-10; F2173-1228; Z1522567171; Cycloserine, United States Pharmacopeia (USP) Reference Standard; Cycloserine, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1	DYDCUQKUCUHJBH-UWTATZPHSA-N	C1C(C(=O)NO1)N	C3H6N2O2	CAS 68-41-7	CHEBI:40009	.	.	.	D02WFK	.	.	.
NP0419	Triamcinolone	CID: 31307	triamcinolone; 124-94-7; Fluoxyprednisolone; Aristocort; Rodinolone; Triamcinolon; Kenacort; Volon; Adcortyl; Delphicort; Ledercort; Triamcet; Tricortale; Celeste; Triam-Tablinen; Cinolone-T; SK-Triamcinolone; Triamcinlon; Fluoxiprednisolone; Triamcinolonum [INN]; Triamcinalone; Triamcinolona; Triamcinolonum; Tiamcinolonum [INN-Latin]; Triamcinolona [INN-Spanish]; Kenacort-AG; 9alpha-Fluoro-16alpha-hydroxyprednisolone; CL 19823; Mycolog; UNII-1ZK20VI6TY; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Omcilon; 1ZK20VI6TY; Aristocort Tablets; MLS000028542; MLS001066543; CHEBI:9667; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; 124-94-7 (free); 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; NSC13397; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; NSC-13397; Tiamcinolonum; SMR000058333; Prednisolone, 9-fluoro-16.alpha.-hydroxy-; NSC 13397; DSSTox_CID_20742; DSSTox_RID_79584; DSSTox_GSID_40742; 11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione; Kenacort (TN); 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Triamcinolone (Aristocort); HSDB 3194; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; EINECS 204-718-7; BRN 2341955; Prednisolone, 9-fluoro-16alpha-hydroxy-; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)-; NCGC00094799-01; CAS-124-94-7; Triamcinolone [USP:INN:BAN:JAN]; Prestwick_438; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; Triamcinolone, topical; Prestwick0_000120; Prestwick1_000120; Prestwick2_000120; Prestwick3_000120; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-; SCHEMBL4447; CHEMBL1451; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11-beta,16-alpha)-; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)-; Lopac0_001179; BSPBio_000140; 4-08-00-03629 (Beilstein Handbook Reference); cid_31307; MLS002695935; SPBio_002079; BPBio1_000154; GTPL2870; DTXSID1040742; BDBM41132; Triamcinolone (JP17/USP/INN); HMS1568G22; HMS2090D12; HMS2095G22; HMS2231E20; HMS3263L19; HMS3712G22; BCP11941; EX-A4109; HY-B0328; ZINC3882036; Tox21_111332; Tox21_300178; Tox21_501179; MFCD00010477; s1933; AKOS015895436; Tox21_111332_1; AC-2072; CCG-205253; DB00620; LP01179; SDCCGSBI-0051146.P002; (11beta,16alpha)-9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 11.beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; BRN-2341955; SMP1_000300; NCGC00021580-03; NCGC00021580-04; NCGC00021580-05; NCGC00021580-06; NCGC00021580-07; NCGC00021580-08; NCGC00021580-16; NCGC00178404-03; NCGC00254049-01; NCGC00261864-01; 51855-44-8; AS-13657; NCI60_000750; EU-0101179; D00385; J10062; 124T947; SR-01000000079; Q1074056; SR-01000000079-3; BRD-K77554836-001-03-3; BRD-K77554836-001-14-0; Triamcinolone, British Pharmacopoeia (BP) Reference Standard; Triamcinolone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ; Triamcinolone, United States Pharmacopeia (USP) Reference Standard; 3-[2[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]ETHYL]-PIPERIDINE; 9.alpha.-Fluoro-11.beta.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Pregna-1,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; Pregna-1,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)-; Pregna-1,4-diene-3, 20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI); (1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)-, tetrahydro deriv.	Small molecule	1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1	GFNANZIMVAIWHM-OBYCQNJPSA-N	CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O	C21H27FO6	CAS 124-94-7	CHEBI:9667	.	.	.	D03BLF	.	.	.
NP0439	Tetrandrine	CID: 73078	Tetrandrine, Millenia Hope; Tetrandrine, West Virginia University; Tranex-18	.	1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30-/m0/s1	WVTKBKWTSCPRNU-KYJUHHDHSA-N	CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC	C38H42N2O6	CAS 518-34-3	.	HBIN046110	SMIT00150	MOL002343	D0G4ES	DB14066	7201	.
NP0445	Cardamonin	CID: 641785	CARDAMOMIN; Alpinetin chalcone; Dihydroxymethoxychalcone; 18956-16-6; 2',4'-dihydroxy-6'-methoxychalcone; UNII-H8KP1OJ8JX; 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; 2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-, (2E)-; H8KP1OJ8JX; (E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one; CHEMBL378104; 2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-; (2E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one; (E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; (E)-1-(2,4-Dihydroxy-6-methoxy-phenyl)-3-phenyl-propenone; Cardamoni; Cardamonin ,(S); 2'4'-Dihydroxy-6'-methoxy-chalcone; MLS000876992; SCHEMBL449220; MEGxp0_000534; Cardamonin, >=98% (HPLC); ACon1_000221; CHEBI:125601; HMS2271N04; HY-N0279; ZINC4716487; BDBM50185446; LMPK12120245; MFCD00238554; s3867; AKOS015896716; CCG-208127; DB14122; MCULE-6098713539; NCGC00180767-01; DS-15713; SMR000440601; B7085; CS-0008777; W1234; 309C149; A813330; J-012229; Q-100234; Q5038242; BRD-K61559475-001-01-0; 1-(2\\',4\\'-Dihydroxy-6\\'-methoxy-phenyl)-3-phenyl-propenone; (2E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; (E)-1-(2,4-dihydroxy-6-methoxy-phenyl)-3-phenyl-prop-2-en-1-one; (E)-1-[2-methoxy-4,6-bis(oxidanyl)phenyl]-3-phenyl-prop-2-en-1-one; NCGC00180767-02!(E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one	.	1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+	NYSZJNUIVUBQMM-BQYQJAHWSA-N	COC1=CC(=CC(=C1C(=O)C=CC2=CC=CC=C2)O)O	C16H14O4	CAS 19309-14-9	.	HBIN019723	.	.	.	.	1085	.
NP0477	Perindopril	CID: 107807	PERINDOPRIL; 82834-16-0; Coversyl; Perindoprilum; S-9490; McN-A-2833; UNII-Y5GMK36KGY; CHEBI:8024; Y5GMK36KGY; 107133-36-8; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid; DSSTox_CID_3440; DSSTox_RID_77030; DSSTox_GSID_23440; Prestarium; Coverex; Coversum; Coverene Cor; CAS-82834-16-0; Perindoprilum [Latin]; Perindopril (USAN/INN); Perindopril [USAN:INN:BAN]; McN-A 2833; S 9490; NCGC00159509-02; SED-9490; DW-7950; BRN 4300272; PubChem21085; Spectrum_001948; Spectrum2_001108; Spectrum3_001683; Spectrum4_000775; Spectrum5_001689; CHEMBL1581; SCHEMBL16205; BSPBio_003206; KBioGR_001190; KBioSS_002502; Perindopril Erbumine(Aceon)/; MLS002154153; BIDD:GT0786; SPBio_001216; GTPL6367; IND041; DTXSID6023440; KBio2_002494; KBio2_005062; KBio2_007630; KBio3_002426; HMS2098M04; HMS2232M24; HMS3715M04; 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-; HY-B0130; ZINC3812867; Tox21_113087; ABP000467; BDBM50493988; AKOS025311315; Tox21_113087_1; CCG-221101; CS-1903; DB00790; NCGC00274070-01; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-((S)-N-((S)-1-Carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid; ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; I553; SMR001233453; SBI-0206736.P001; C07706; D03753; AB00918721_06; 834P160; Q277785; S-90652; SR-01000841817; J-523913; SR-01000841817-2; BRD-K92731339-227-02-3; BRD-K92731339-227-03-1; UNII-7327NJ3271 component IPVQLZZIHOAWMC-QMHWVQJVSA-N; UNII-7327NJ3271 component IPVQLZZIHOAWMC-QXKUPLGCSA-N; (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-2-pent-yl]amino]propanoyl]-octahydro-1h-indole-2-carboxylic acid; (2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}octahydro-1H-indole-2-carboxylic acid; 11H-Indole-2-carboxylic acid, octahydro-1-(2-((1-ethoxycarbonyl)butyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-beta,7a-beta))-; 1H-Indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,7abeta))-	Small molecule	1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1	IPVQLZZIHOAWMC-QXKUPLGCSA-N	CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O	C19H32N2O5	CAS 82834-16-0	CHEBI:8024	.	.	.	D03KYG	.	.	.
NP0478	Xanthohumol	CID: 639665	Xanthohumol; 6754-58-1; 1-(2,4-Dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 569-83-5; UNII-T4467YT1NT; T4467YT1NT; CHEBI:66331; 2',4,4'-trihydroxy-6'-methoxy-3'-prenylchalcone; 1-(2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; (2E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-(2,4-Dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one; (E)-1-(2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; XANTHOHUMO; 2',4,4'-Trihydroxy-3'-prenyl-6'-methoxychalcone; SCHEMBL143683; CHEMBL253896; MEGxp0_000104; ACon1_001634; CHEBI:94745; DTXSID00893171; Xanthohumol(Random Configuration); HMS3886H19; BCP18498; ZINC5158937; 0397AC; BDBM50384998; LMPK12120294; MFCD00210576; s7889; AKOS016010098; CCG-268086; DB15359; MCULE-7307777782; (E)-1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-hydroxyphenyl)propenone; SMP2_000278; NCGC00180304-01; AC-31276; BS-17392; W2672; C16417; Q408088; BRD-K77390737-001-01-6; Q27166535; Xanthohumol, primary pharmaceutical reference standard; Xanthohumol from hop (Humulus lupulus), >=96% (HPLC); (2E)-1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one; 1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-but-2-enyl)-phenyl]-3-(4-hydroxy-phenyl)-propenone; 2-Propen-1-one, 1-(2,4-hydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-, (E)-	Small molecule	1S/C21H22O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7+	ORXQGKIUCDPEAJ-YRNVUSSQSA-N	CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C	C21H22O5	CAS 6754-58-1	CHEBI:66331	.	.	.	.	.	.	.
NP0484	Rebamipide	CID: 5042	rebamipide; 90098-04-7; Proamipide; Mucosta; 111911-87-6; OPC-12759; Rebamipide hydrate; Pramipide; 2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid; 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid; 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid; MFCD00866895; 139344-42-6; NCGC00095161-01; 2-(4-Chlorobenzamido)-3-[2(1H)-quinolinon-4-yl]propionic Acid; DSSTox_CID_25937; DSSTox_RID_81235; DSSTox_GSID_45937; Rebamipida; Rebamipidum; Rebamipide [INN:JAN]; Rebamipidum [INN-Latin]; 2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid; OPC 12759; CAS-90098-04-7; CCRIS 3585; SR-05000001520; Mucosta hydrate; N-[(4-chlorophenyl)carbonyl]-3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine; DisperseRed72; Proamipide hydrate; 2-[(4-chlorophenyl)carbonylamino]-3-(2-oxidanylidene-1H-quinolin-4-yl)propanoic acid; Rebamipide-[d4]; Mucosta (TN); OPC 12759 hydrate; Spectrum2_000039; Spectrum3_001959; Rebamipide (JP17/INN); (+-)-2-(4-Chlorobenzoylamino)-3-(2(1H)-quinolinon-4-yl)propionic acid; (+-)-1,2-Dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoic acid; BSPBio_003559; GTPL871; MLS006011883; SCHEMBL221527; SPECTRUM1505310; SPBio_000137; QUI103; rebamipide 111911-87-6; CHEMBL1697771; DTXSID8045937; CHEBI:93814; KBio3_002880; AOB5606; OPC-759; HMS1922B20; HMS2090L13; HMS3655L11; HMS3714A15; Pharmakon1600-01505310; BCP07230; HY-B0360; Tox21_111460; ANW-42341; BBL011328; CCG-39619; CR0013; MFCD11114396; NSC758955; s2032; STK577121; STL146407; AKOS005501649; AKOS005721106; Tox21_111460_1; 111911-87-6 (anhyd.); AC-6841; AC-7588; DB11656; MCULE-3675104222; NSC 758955; NSC-758955; 2-(4-chloro-benzoylamino)-3-(2-oxo-1,2-dihydro-quinolin-4-yl)-propionic acid; 4-Quinolinepropanoic acid, 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-, (+-)-; NCGC00095161-02; NCGC00095161-03; NCGC00095161-04; NCGC00095161-05; AK316145; SMR003309276; SY057250; VS-02924; SBI-0207054.P001; AB0073108; FT-0630971; FT-0655225; R0085; SW199113-2; D01121; AB01275518-01; AB01275518_02; AB01275518_03; 911R876; A802443; A843443; Q-201660; Q7301602; SR-05000001520-1; SR-05000001520-2; SR-05000001520-3; BRD-A15909516-001-02-5; BRD-A15909516-001-03-3; 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid; 2-(4-chlorobenzoylamino)-3-[2(1h)-quinolinon-4-yl] propionic acid; 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid; N-[(4-chlorophenyl)carbonyl]-3-(2-hydroxyquinolin-4-yl)alanine; 2-(4-chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionic acid; 4-Quinolinepropanoic acid, ; A-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo-; 4-Quinolinepropanoicacid,a-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo-; (+/-)-2-(4-CHLOROBENZOYLAMINO)-3-(2(1H)-QUINOLINON-4-YL)-PROPIONIC ACID; (R)-2-[(4-CHLOROBENZOYL)AMINO]-3-(1,2-DIHYDRO-2-OXO-4-QUINOLYL)PROPANOIC ACID; 2-[(4-chlorophenyl)formamido]-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid; alpha-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic acid hydrate	Small molecule	1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)	ALLWOAVDORUJLA-UHFFFAOYSA-N	C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl	C19H15ClN2O4	CAS 90098-04-7	CHEBI:93814	.	.	.	D03BQP	.	.	.
NP0515	Iloprost	CID: 5311181	ILOPROST; Ciloprost; Ventavis; Iloprostum; 78919-13-8; ZK 36374; ZK-36374; CHEMBL494; CHEBI:63916; [3H]-Iloprost; Endoprost; Ilomedin; Ventavis (TN); ZK 00036374; (16R,S)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2; 73873-87-7; (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; Iloprostum [Latin]; SR-05000001498; Iloprost [USAN:INN:BAN]; Ilomedine; BAY Q6256; Iloprost (USAN/INN); SCHEMBL6083382; Iloprost, >=98% (HPLC); BAY-q-6256; DTXSID2041046; BDBM23954; HMS2090A19; HY-A0096; SH-401; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); AKOS024456922; CS-5586; DB01088; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure; K395; Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-; ZK-00036374; D02721; ACETICACID2-TERT-BUTYL-4-METHYLPHENYLESTER; J-502615; SR-05000001498-1; SR-05000001498-2; BRD-A45664787-001-01-4; BRD-A45664787-001-02-2; Q20817139; (1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane; (5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (Z)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid; 5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid	Small molecule	1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1	HIFJCPQKFCZDDL-ACWOEMLNSA-N	CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O	C22H32O4	CAS 78919-13-8	CHEBI:63916	.	.	.	D05ZTH	.	.	.
NP0551	Oridonin	CID: 5321010	Oridonin; 28957-04-2; ISODONOL; Oridonine; UNII-0APJ98UCLQ; Rubescensin A; 0APJ98UCLQ; Rubescensin; Oridonin A; Kaur-16-en-15-one, 7,20-epoxy-1,6,7,14-tetrahydroxy-, (1alpha,6beta,7alpha,14R)-; NSC 250682; Curator_000006; CHEMBL1164920; SCHEMBL19217133; CHEBI:138236; HY-N0004; ZINC12661785; (14R)-7-alpha,20-Epoxy-1-alpha,6-beta,7,14-tetrahydroxykaur-16-en-15-one; AKOS025310967; CCG-208386; (1-alpha,6-beta,7-alpha,14R)-7,20-Epoxy-1,6,7,14-tetrahydroxykaur-16-en-15-one; AS-15421; P269; AB0016908; CS-0007086; 957O042; Q27236543; 7?,20-Epoxy-1?,6?,7,14-tetrahydroxykaur-16-en-15-one; (1alpha,6beta,7alpha,14R)-7,20-epoxy-1,6,7,14-tetrahydroxykaur-16-en-15-one; Kaur-16-en-15-one, 7,20-epoxy-1,6,7,14-tetrahydroxy-, (1a,6b,7a,14R)-; KAUR-16-EN-15-ONE, 7-alpha,20-EPOXY-1-alpha,6-beta,7,14-TETRAHYDROXY-, (14R)-; (1alpha,5beta,6beta,7alpha,8alpha,9beta,10alpha,13alpha,14R)-1,6,7,14-tetrahydroxy-7,20-epoxykaur-16-en-15-one; (1S,2S,5S,8R,9S,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one	Small molecule	1S/C20H28O6/c1-9-10-4-5-11-18-8-26-20(25,19(11,14(9)22)15(10)23)16(24)13(18)17(2,3)7-6-12(18)21/h10-13,15-16,21,23-25H,1,4-8H2,2-3H3/t10-,11-,12-,13+,15+,16-,18+,19-,20+/m0/s1	SDHTXBWLVGWJFT-XKCURVIJSA-N	CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C	C20H28O6	CAS 28957-04-2	CHEBI:138236	.	.	.	.	.	.	.
NP0580	17-beta-Estradiol	CID: 5757	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP0587	Glatiramer acetate	CID: 3081884	Glatiramer acetate; 147245-92-9; Copaxone; Copolymer 1; Copolymer-1; Protiramer; Glatopa; COP-1; TV 5010; UNII-5M691HL4BO; Glatirameracetat; Glatiramer acetate [USAN:BAN]; 5M691HL4BO; DTXSID30163637; C9H11NO3.C6H14N2O2.; AM84438; L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt); L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt); AC-28732; L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1); AB0110033; Y0429; Q418274; acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid	Small molecule	1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1	FHEAIOHRHQGZPC-KIWGSFCNSA-N	CC(C(=O)O)N.CC(=O)O.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N	C25H45N5O13	CAS 147245-92-9	.	.	.	.	D04CRL	.	.	.
NP0601	Piperlongumine	CID: 637858	Piperlongumine; Piplartine; 20069-09-4; Piperlongumin; UNII-SGD66V4SVJ; (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one; CHEBI:8241; SGD66V4SVJ; MFCD00075706; ST079382; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-1,2,5,6-tetrahydropyridin-2-one; 2(1H)-Pyridinone, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-; 5,6-Dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-2(1H)-pyridinone; BRD2293; Piplartin; BRD-2293; PPLGM; (E)-1-[3-(3,4,5-Trimethoxyphenyl)acryloyl]-5,6-dihydropyridin-2(1H)-one; 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one; 5,6-Dihydro-1-(1-oxo-3-[3,4,5-trimethoxyphenyl]-trans-2-propenyl)-2[1H]-pyridinone; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-trans-2-propenyl]-2(1H)-pyridinone; Piplartine;PPLGM; Prestwick_399; FERROUSFLUOBORATE; Prestwick2_000604; Prestwick3_000604; Piperlongumine; Piplartine; BSPBio_000508; MLS002153903; SCHEMBL173092; SPECTRUM1505135; BPBio1_000560; CHEMBL465843; SCHEMBL2465593; 1-[3-(3,4,5-Trimethoxy-phenyl)-acryloyl]-5,6-dihydro-1H-pyridin-2-one; ACon1_001541; CHEBI:92424; HMS1569J10; HMS2096J10; HMS2234K24; Piperlongumine, >=97% (HPLC); ZINC899053; BCP13030; EX-A2925; HY-N2329; 2659AH; BDBM50462013; NSC794671; s7551; AKOS024284776; CCG-214375; NSC-794671; 2(1H)-Pyridinone, 5,6-dihydro-1-(1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-, (E)-; NCGC00096028-01; NCGC00096028-02; NCGC00096028-03; NCGC00096028-04; NCGC00096028-14; AC-32683; AS-74140; BP-25401; LS-14579; SMR001233252; CS-0021113; P2361; A14124; C10166; SR-01000841248; A1-00162; J-012992; N-(3,4,5-Trimethoxycinnamoyl)-D3-piperidin-2-one; Q7197361; SR-01000841248-2; BRD-K24132293-001-05-3; BRD-K24132293-001-09-5; BRD-K24132293-001-16-0; 5,6-Dihydro-1-(3,4,5-trimethoxycinnamoyl)-2(1H)-pyridinone; 1-[(2E)-3-(3,4,5-Trimethoxyphenyl)-2-propenoyl]-5,6-dihydro-2(1H)-pyridinone #; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-1,5,6-trihydropyridin-2-one; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-5,6-dihydropyridin-2(1H)-one; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone, 9CI; Prop-2-en-1-one, 3-(3,4,5-trimethoxyphenyl)-1-(2,3-dihydropyridin-6(1H)-one-1-yl)-; (2E)-1-(1,2,5,6-Tetrahydro-2-oxopyridine-1-yl)-3-(3,4,5-trimethoxyphenyl)-2-propene-1-one	Small molecule	1S/C17H19NO5/c1-21-13-10-12(11-14(22-2)17(13)23-3)7-8-16(20)18-9-5-4-6-15(18)19/h4,6-8,10-11H,5,9H2,1-3H3/b8-7+	VABYUUZNAVQNPG-BQYQJAHWSA-N	COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCC=CC2=O	C17H19NO5	CAS 20069-09-4	CHEBI:8241	.	.	.	D5R7AE	.	.	.
NP0624	Meloxicam	CID: 54677470	meloxicam; 71125-38-7; Mobic; Metacam; Movalis; Mobicox; Meloxicam (Mobic); Mobec; Movatec; Parocin; Meloxicamum [Latin]; UH-AC 62XX; 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Meloxicamum; UNII-VG2QF83CGL; UHAC-62XX; C14H13N3O4S2; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; VG2QF83CGL; CHEMBL599; MLS000028587; CHEBI:6741; MFCD00868752; NCGC00018248-04; SMR000058994; DSSTox_CID_803; Meloxicam, 99-101%; N-1539; DSSTox_RID_75796; DSSTox_GSID_20803; Revmoksikam; Coxflam; Coxicam; Melonex; Meloxivet; Tenaron; Vivlodex; Melfax; (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide; CAS-71125-38-7; CCRIS 9139; Ilacox; HSDB 7741; Meloxicam [USAN:USP:INN:BAN]; Meloxicam,(S); 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1?^{6},2-benzothiazine-3-carboxamide; Mobic (TN); Opera_ID_2; Spectrum_001633; Spectrum2_000941; Spectrum3_000649; Spectrum4_000787; Spectrum5_001813; SCHEMBL3576; Meloxicam (JAN/USP/INN); Lopac0_000766; SCHEMBL33369; BSPBio_002257; KBioGR_001234; KBioSS_002113; MLS001304725; MLS001306413; MLS006011422; BIDD:GT0726; SCHEMBL713100; SPECTRUM1504150; UH-AC-62 XX; SPBio_000902; GTPL7220; CHEMBL1741042; DTXSID1020803; KBio2_002113; KBio2_004681; KBio2_007249; KBio3_001477; ETI-511; HMS1922D19; HMS2089B18; HMS2096I19; HMS2234P07; HMS2236C09; HMS3259H06; HMS3372C13; HMS3372P18; HMS3655K06; HMS3713I19; HMS3744K09; HMS3884G08; ALBB-027268; AMY40407; BCP11928; HY-B0261; Tox21_111734; Tox21_113192; Tox21_201689; Tox21_302756; ANW-57553; BBL029076; BDBM50056998; CCG-39098; HSCI1_000045; s1734; STK620505; ZINC13129998; Meloxicam - CAS 71125-38-7; AKOS000279442; AKOS026749959; Tox21_111734_1; ZINC103620661; AC-1325; DB00814; KS-1084; MCULE-4138373089; NC00698; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; SMP2_000133; Meloxicam 100 microg/mL in Acetonitrile; NCGC00018248-01; NCGC00018248-02; NCGC00018248-03; NCGC00018248-05; NCGC00018248-06; NCGC00018248-07; NCGC00018248-08; NCGC00018248-10; NCGC00018248-23; NCGC00018248-26; NCGC00022924-03; NCGC00022924-04; NCGC00256316-01; NCGC00259238-01; NCGC00263878-02; (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; AK-77454; SMR000718800; AB0007297; DB-055490; Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide; FT-0628193; M1959; R3928; SW219562-1; EN300-52507; C08169; D00969; J10218; AB00383033-17; AB00383033-18; AB00383033_20; 125M387; A837087; AN-668/13244001; Q414028; SR-01000003132-10; F2173-0387; Z1695493323; O=C1C2=CC=CC=C2S(=O)(=O)N(C)\\C1=C(\\O)NC1=NC=C(C)S1; 4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide; (3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one; (3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one; 133687-22-6; 4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide	Small molecule	1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)	ZRVUJXDFFKFLMG-UHFFFAOYSA-N	CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O	C14H13N3O4S2	CAS 71125-38-7	CHEBI:6741	.	.	.	D0G7FJ	.	.	.
NP0649	Ellagic acid	CID: 5281855	Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728	.	1S/C14H6O8/c15-5-1-3-7-8-4(14(20)22-11(7)9(5)17)2-6(16)10(18)12(8)21-13(3)19/h1-2,15-18H	AFSDNFLWKVMVRB-UHFFFAOYSA-N	C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O	C14H6O8	CAS 476-66-4	.	HBIN025006	SMIT00090	MOL001002	D0A1CM	.	2721	.
NP0703	Cucurbitacin E	CID: 5281319	Cucurbitacin E; 18444-66-1; alpha-Elaterin; alpha-Elaterine; ELATERIN, ALPHA; UNII-V8A45XYI21; CHEBI:3944; V8A45XYI21; [(E,6R)-6-[(8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate; 19-Norlanosta-1,5,23-triene-3,11,22-trione,25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9b,10a,16a,23E)-; Cucurbitacine E; .alpha.-Elaterin; .alpha.-Elaterine; Cucurbitacine-E; CUE; NSC 106399; Cucurbitacin-E; NSC106399; 19-Nor-9.beta.,5,23-triene-3,11,22-trione, 2,16.alpha.,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-1,23-triene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9.beta.,10.alpha.,16.alpha.,23E)-; C32H44O8; EINECS 242-325-2; NSC-106399; BRN 2343323; cucurbitacin E derivatives; SCHEMBL140616; (R,E)-6-((8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-4,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; HY-N0417; ZINC4097800; LMST01010107; MFCD00135936; NSC521775; AKOS015896851; CS-3817; NSC-521775; 19-Norlanosta-1,5,23-triene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9beta,10alpha,16alpha,23E)-; 2,16alpha,20,25-Tetrahydroxy-9beta-methyl-10alpha,-19-norlanosta-1,5,23(E)-triene-3,11,22-trione 25-acetate; 25-(Acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione (9beta,10alpha,16alpha,23E)-; N2791; Y0059; C08797; 444C661; Q5192451; UNII-W3RWP6CB48 component NDYMQXYDSVBNLL-MUYMLXPFSA-N; (23E)-25-acetyloxy-2,16alpha,20-trihydroxy-9beta-methyl-19-nor-10alpha-lanosta-1,5,23-triene-3,11,22-trione; (4R,23E)-2,16alpha,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-2,5,23-trien-25-yl acetate; 19-Nor-9-beta,10-alpha-lanosta-1,5,23-triene-3,11,22-trione, 2,16-alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Nor-9beta,10alpha-lanosta-1,5,23-triene-3,11,22-trione, 2,16alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate (8CI); 2,16alpha,20,25-tetrahydroxy-9-methyl-19-nor-9beta,10alpha-lanosta-1,5,23-triene-3,11,22-trione 25-acetate	Small molecule	1S/C32H44O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,12-14,19,21-22,25,34-35,39H,11,15-16H2,1-9H3/b13-12+/t19-,21-,22+,25+,29+,30-,31+,32+/m1/s1	NDYMQXYDSVBNLL-MUYMLXPFSA-N	CC(=O)OC(C)(C)C=CC(=O)C(C)(C1C(CC2(C1(CC(=O)C3(C2CC=C4C3C=C(C(=O)C4(C)C)O)C)C)C)O)O	C32H44O8	CAS 18444-66-1	CHEBI:3944	.	.	.	.	.	.	.
NP0706	Theophylline	CID: 2153	theophylline; 58-55-9; 1,3-Dimethylxanthine; Elixophyllin; Theophyllin; Theolair; Nuelin; Theophylline anhydrous; Respbid; Theocin; Theo-dur; Elixophylline; Pseudotheophylline; Lanophyllin; Theovent; Uniphyl; Slo-phyllin; Accurbron; Armophylline; Bronkodyl; Doraphyllin; Liquophylline; Maphylline; Medaphyllin; Optiphyllin; Parkophyllin; Synophylate; Teofyllamin; Theacitin; Theocontin; Uniphyllin; Xantivent; Aerolate; Elixicon; Solosin; Teolair; Theobid; Theofol; Theograd; Theolix; Elixex; Acet-theocin; Slo-bid; Theophyl-225; Aerolate III; Duraphyl; Euphylong; Sustaire; Xanthium; Austyn; Somophyllin-t; Constant-T; Teofilina; Theochron; Asmax; Quibron T/SR; Theal tablets; Somophyllin-DF; Bronkodyl SR; Theoclair-SR; Theoclear LA; Spophyllin retard; Choledyl SA; Quibron-T; 1,3-dimethyl-7H-purine-2,6-dione; Theoclear 80; Theophyline; Theo-11; Theostat 80; 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione; Synophylate-L.A. Cenules; Theophylline, anhydrous; Theo-Dur-Sprinkle; Aquaphyllin; Tefamin; Theo-24; Theodel; Unifyl; Theona P; 1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; LaBID; Euphylline; Elixomin; Theolixir; Theophyl; Bronkotabs; Elixophyllin SR; Theophylline-SR; Somophyllin-CRT; Aerolate SR; Theo-Organidin; Theolair-SR; Theophyl-SR; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-; GS 2591A; Uni-Dur; Theoclear-80; Quibron-T/SR; T-Phyl; Theoclear-200; Xanthine, 1,3-dimethyl-; Dimethylxanthine; NSC 2066; X 115; Quadrinal; Theobid Jr.; Theoclear L.A.-130; Theal tabl.; 1,3-dimethyl-1H-purine-2,6(3H,7H)-dione; 1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; UNII-0I55128JYK; 2,6-Dihydroxy-1,3-dimethylpurine; Purine-2,6(1H,3H)-dione, 1,3-dimethyl-; Aerobin; Theodur; Theopek; Theospan; CHEMBL190; Theophylline [USP]; 1H-Purine-2,6-dione, 3,9-dihydro-1,3-dimethyl-; MLS000069390; 1,3-Dimethylxanthine;Theo-24; Diffumal; 1,3-dimethyl-1H-purine-2,6(3H,9H)-dione; CHEBI:28177; LASMA; 0I55128JYK; Pro-vent; Theophylline melting point standard; NSC-2066; 58-55-9 (ANHYDROUS); 1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurine; MFCD00079619; Teofilina [Polish]; NCGC00018117-07; NCGC00018117-17; Mudrane; Pulmidur; SMR000058537; Teonova; Theokin; Hylate; DSSTox_CID_1336; Nuelin SA; Bronchodid Duracap; 1,3-dimethyl-1,3,7-trihydropurine-2,6-dione; DSSTox_RID_76090; Uniphyllin continus; DSSTox_GSID_21336; Theophylline, 99+%, anhydrous; Teocen 200; Elixophyllin(e); CAS-58-55-9; Theolair (TN); Elixophyllin (TN); Uniphyl (TN); Quibron-t (TN); Theodur G (TN); CCRIS 4729; HSDB 3399; 1,3-dimethyl-3,9-dihydro-1H-purine-2,6-dione; SR-01000075195; EINECS 200-385-7; Theo-24 (TN); Telbans; Physpa; AI3-50216; Unicontin CR; 4eoh; Aescin-IIA; Theophylline form II; PubChem9695; theophylline solu-tion; component of Primatene; Xanthine,3-dimethyl-; Opera_ID_76; Spectrum_001038; Theophylline (JP17); 2a3a; Prestwick0_000820; Prestwick0_000873; Prestwick1_000820; Prestwick1_000873; Prestwick2_000820; Prestwick2_000873; Prestwick3_000820; Prestwick3_000873; Spectrum2_000842; Spectrum3_000672; Spectrum4_000353; Spectrum5_001232; 8-(2-Furyl)theophylline; UPCMLD-DP123; component of Theo-Organidin; EC 200-385-7; SCHEMBL4915; Theophylline Anhydrous,(S); Theophylline Anhydrous, USP; Lopac0_000014; BSPBio_000719; BSPBio_000945; BSPBio_002363; component of Dicurin Procaine; GTPL413; KBioGR_000785; KBioSS_001518; MLS002152943; MLS002153487; MLS004491910; MLS006011970; ARONIS25346; BIDD:ER0557; BIDD:GT0151; DivK1c_000203; SPECTRUM1500568; Theophylline-d6(dimethyl-d6); SPBio_000823; SPBio_002640; SPBio_002866; BPBio1_000791; BPBio1_001041; SCHEMBL8312163; component of Tedral (Salt/Mix); DTXSID5021336; THEOPHYLLINE, [8-3H]; UPCMLD-DP123:001; BCBcMAP01_000071; BDBM10847; BDBM82053; component of Quibron (Salt/Mix); HMS500K05; KBio1_000203; KBio2_001518; KBio2_004086; KBio2_006654; KBio3_001583; NSC2066; component of Hecadrol (Salt/Mix); NINDS_000203; HMS1921E03; HMS2089A06; HMS2092M05; HMS2233E16; HMS3259O06; HMS3369N14; Pharmakon1600-01500568; component of Primatene (Salt/Mix); BCP30664; component of Bronkotabs (Salt/Mix); HY-B0809; Theophylline 1.0 mg/ml in Methanol; Theophylline, >=99.0% (HPLC); Tox21_110827; Tox21_202375; Tox21_300028; BBL023514; CCG-20301; NSC757346; PDSP1_001018; PDSP1_001234; PDSP2_001002; PDSP2_001218; STK397040; Theophylline (1,3-dimethylxanthine); ZINC18043251; AKOS000120961; AKOS005434016; component of Quibron Plus (Salt/Mix); Tox21_110827_1; component of Quibron-T/SR (Salt/Mix); component of Theo-organdin (Salt/Mix); component of Theolair plus (Salt/Mix); CS-4158; DB00277; MCULE-8236489917; NC00542; NE11194; NSC-757346; Purine-2,3H)-dione, 1,3-dimethyl-; SDCCGMLS-0066620.P001; SDCCGSBI-0050003.P005; component of Theo-Organidin (Salt/Mix); IDI1_000203; SMP1_000291; component of Slo-phyllin GG (Salt/Mix); NCGC00018117-01; NCGC00018117-02; NCGC00018117-03; NCGC00018117-04; NCGC00018117-05; NCGC00018117-06; NCGC00018117-08; NCGC00018117-09; NCGC00018117-10; NCGC00018117-11; NCGC00018117-12; NCGC00018117-13; NCGC00018117-14; NCGC00018117-15; NCGC00018117-16; NCGC00018117-18; NCGC00018117-19; NCGC00018117-20; NCGC00018117-23; NCGC00018117-37; NCGC00022112-03; NCGC00022112-04; NCGC00022112-05; NCGC00022112-07; NCGC00022112-08; NCGC00022112-09; NCGC00022112-10; NCGC00022112-11; NCGC00022112-12; NCGC00254040-01; NCGC00259924-01; WLN: T56 BM DN FNVNVJ F1 H1; AC-20328; component of Dicurin Procaine (Salt/Mix); NCI60_001736; SMR003435989; ST024762; Theophylline, anhydrous, >=99%, powder; component of Primatene tablets (Salt/Mix); Purine,6(1H,3H)-dione, 1,3-dimethyl-; SBI-0050003.P004; component of Mudrane GG elixir (Salt/Mix); DB-053224; 1H-Purine-2, 3,7-dihydro-1,3-dimethyl-; AB00052106; FT-0631259; FT-0675140; N1442; 6461-EP1441224A2; 6461-EP2272835A1; 6461-EP2272841A1; 6461-EP2272844A1; 6461-EP2280006A1; 6461-EP2281813A1; 6461-EP2281815A1; 6461-EP2286811A1; 6461-EP2295434A2; 6461-EP2298305A1; 6461-EP2301933A1; 6461-EP2301936A1; 6461-EP2301937A1; 6461-EP2305219A1; 6461-EP2305640A2; 6461-EP2308562A2; 6461-EP2311827A1; 6461-EP2314590A1; C07130; D00371; 83377-EP2371823A1; AB00052106-20; AB00052106-22; AB00052106-23; AB00052106_24; AB00052106_25; AB00052106_26; L000595; Q407308; 1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione #; Q-201819; SR-01000075195-1; SR-01000075195-3; SR-01000075195-5; 1,3-Dimethyl-6-hydroxy-1,3-dihydro-2H-purin-2-one; BRD-K97799481-001-02-0; BRD-K97799481-001-12-9; BRD-K97799481-002-03-6; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, mo; F2173-0145; Z271004650; A3133D49-AAB6-49A1-B60B-B5198F327D3F; Theophylline, British Pharmacopoeia (BP) Reference Standard; Theophylline, European Pharmacopoeia (EP) Reference Standard; (8alpha, 9S)-10,11-Dihydro-6'-methoxycinchonan-9-amine trihydrochloride, min. 90%; Theophylline melting point standard, United States Pharmacopeia (USP) Reference Standard; Theophylline solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Theophylline, Pharmaceutical Secondary Standard; Certified Reference Material; 134459-03-3; 75448-53-2; Theo-24;1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione ;1,3-Dimethylxanthine;1,3-dimethyl-xanthin; Theophylline melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material; Theophylline, certified reference material, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	CN1C2=C(C(=O)N(C1=O)C)NC=N2	C7H8N4O2	CAS 58-55-9	CHEBI:28177	.	.	.	D0F8RA	.	.	.
NP0708	Semaglutide	CID: 56843331	Semaglutide; NN9535; Ozempic; 910463-68-2; Unknown (acetate); NN 9535; NNC 0113-0217; NN-9535; Semaglutide [USAN:INN]; Sermaglutide; Rybelsus; Rybelsus (oral semaglutide); GTPL9724; Ozempic (injectable semaglutide); CHEBI:167574; EX-A2424; AC-32580; NNC-0113-0217; Rybelsus;Ozempic;NN9535;OG217SC;NNC 0113-0217	Small molecule	1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1	DLSWIYLPEUIQAV-CCUURXOWSA-N	CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N	C187H291N45O59	CAS 910463-68-2	CHEBI:167574	.	.	.	D02ULU	.	.	.
NP0709	Tadalafil	CID: 110635	Tadalafil; Cialis; 171596-29-5; Ic351; Tadanafil; ADCIRCA; IC 351; ICOS 351; Tadalafil(Cialis); GF 196960; UNII-742SXX0ICT; (6R,12aR)-6-(Benzo[d][1,3]dioxol-5-yl)-2-methyl-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6H,7H)-dione; CHEMBL779; IC-351; 742SXX0ICT; GF-196960; Tadalafil, (6R ,12aS)-; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-6-(benzo[d][1,3]dioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; CHEBI:71940; LY-450190; DSSTox_CID_26786; DSSTox_RID_81904; DSSTox_GSID_46786; 6-BENZO[1,3]DIOXOL-5-YL-2-METHYL-2,3,6,7,12,12A-HEXAHYDRO-PYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE; Tadalafil Lilly; (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione; Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-; SMR000466321; Cialis (TN); TILDENAFIL; CAS-171596-29-5; HSDB 7303; Tadalafila; Tadalafilo; Taldalafil; Tadalafil [USAN:INN:BAN]; Tadalafil solution; 1xoz; Cialis, Tadalafil; NCGC00168781-01; (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.0^{3,8}.0^{11,16}]heptadeca-1(10),11,13,15-tetraene-4,7-dione; (6R,12aS)-6-(1,3-Benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; Pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-; Adcirca (TN); Tadalafil (Cialis); Tadalafil(Cialis)/; Zalutia (TN); Tardenafil; ; ; Cialis; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; KS-1117; TADALAFIL; CIALIS; (-)-Tadalafil (6R); Tadalafil (JAN/USP/INN); SCHEMBL33333; MLS000759426; MLS001165782; MLS001195644; MLS001424132; MLS006010126; GTPL7299; PYR280; DTXSID9046786; BDBM14777; HMS2051N17; HMS2235L21; HMS3884G19; Pharmakon1600-01505639; AMY10321; EX-A2644; ZINC3993855; Tox21_112642; ABP000527; ANW-54093; CC0257; HY-90009A; MFCD10465563; NSC750236; NSC759172; s1512; Tadalafil 1.0 mg/ml in Acetonitrile; AKOS015892559; Tox21_112642_1; AB42193; CCG-100973; CS-1414; DB00820; NC00223; NSC 750236; NSC 759172; NSC-750236; NSC-759172; SB17348; 1,3-benzodioxol-5-yl(methyl)[?]dione; NCGC00263909-02; Tadalafil 100 microg/mL in Acetonitrile; (6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione; GF196960; LY450190; Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans)-; AB0008473; SW197603-2; A23556; D02008; J90025; W-5349; X-3024; AB00639969-08; AB00639969_09; AB00639969_10; 596T295; AR-270/43507798; Q424156; SR-05000001940; SR-05000001940-1; BRD-K93645900-001-04-8; Tadalafil solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione; (2R,8R)-2-(2H-1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.0^{3,8}.0^{11,16}]heptadeca-1(10),11(16),12,14-tetraene-4,7-dione; (2R,8R)-2-(2H-1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.0^{3,8}.0^{11,16}]heptadeca-1(10),11,13,15-tetraene-4,7-dione; (6R,12 aR)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione; (6R,12aR) 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino [1',2':1,6] pyrido[3,4-b]indole-1,4-dione; (6R,12aR) 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione; (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1,2,1,6]pyrido[3,4-b]indole-1,4-dione; (6R,3,6,7,12,12a-Hexahydro-2-methyl-6-[3,4-(methylenedioxy)phenyl]pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione; 1242099-07-5; 171488-03-2; 6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione; Pyrazino[1',6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12ahexahydro-2-methyl-, (6R,12aR)-; rel-(6R,12aR)-6-(Benzo[d][1,3]dioxol-5-yl)-2-methyl-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6H,7H)-dione	Small molecule	1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1	WOXKDUGGOYFFRN-IIBYNOLFSA-N	CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36	C22H19N3O4	CAS 171596-29-5	CHEBI:71940	.	.	.	D05MQK	.	.	.
NP0718	Delta-9-tetrahydrocannabinol	CID: 16078	Dronabinol; TETRAHYDROCANNABINOL; Marinol; delta9-Tetrahydrocannabinol; delta9-THC; delta-9-tetrahydrocannabinol; Deltanyne; 1972-08-3; Abbott 40566; delta-9-THC; delta(9)-THC; delta1-THC; Dronabinolum; THC; delta(1)-Tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; 1-trans-delta-9-Tetrahydrocannabinol; delta(sup 1)-Thc; delta(sup 9)-Thc; Namisol; (-)-delta9-trans-Tetrahydrocannabinol; 9-tetrahydrocannabinol; QCD 84924; SP 104; delta1-Tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; QCD-84924; Syndros; delta(sup 1)-Tetrahydrocannabinol; delta(sup 9)-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; Cannabinol, delta1-tetrahydro-; CCRIS 4726; (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; CHEBI:66964; 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol; CHEMBL465; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol; UNII-7J8897W37S; Cannabinol, 1-trans-delta(sup 9)-tetrahydro-; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; 7J8897W37S; NSC-134454; Dronabinolum [Latin]; Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; 6,6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenzo(b,d)pyran-1-ol; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; .DELTA.9-Tetrahydrocannabinol; (-)-.DELTA.9-THC; Compassia; Relivar; (L)-.delta.1-Tetrahydrocannabinol; (-)-.DELTA.1-Tetrahydrocannabinol; (-)-.DELTA.9-Tetrahydrocannabinol; L-.delta.1-trans-Tetrahydrocannabinol; L-trans-.delta.9-Tetrahydrocannabinol; (6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; (6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR,10aR)-; 6H-dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR,10aR)-; (-)-.DELTA.9-trans-Tetrahydrocannabinol; (-)-trans-.DELTA.9-Tetrahydrocannabinol; Marinol (TN); DEA No. 7369; .DELTA.1-THC; .DELTA.9-THC; delta1-Tetrahydrocannabinol (VAN); delta9-Tetrahydrocannabinol (VAN); Dronabinol (USP/INN); .DELTA.1-Tetrahydrocannabinol; Tetrahydrocannabinol delta9; (-)-trans-Delta9-THC; (l)-delta(sup 1)-Tetrahydrocannabinol; Cannabinol, .DELTA.1-tetrahydro-; 1-trans-delta(sup 9)-Tetrahydrocannabinol; .DELTA.9-trans-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; L-.delta.1-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; delta9-trans-Tetrahydrocannabinol; HSDB 6471; trans-delta9-Tetrahydrocannabinol; (6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; (6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; CAT-310; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-; L-trans-delta9-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; DRG-0138; 14C-.DELTA.1-Tetrahydrocannabinol; trans-.DELTA.9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-delta9-Tetrahydrocannabinol; NSC 134454; .delta.-9-THC; 1-trans-delta(sup9)-tetrahydrocannabinol; .delta.(sup9)-THC; 3ls4; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; 1-trans-.delta.(sup9)-tetrahydrocannabinol; DSSTox_CID_1327; (-)-.delta.(sup9)-trans-Tetrahydrocannabinol; Epitope ID:224552; SCHEMBL4609; delta 9-Tetrahydrocannabinol; delta-9 Tetrahydrocannabinol; DSSTox_RID_76083; trans-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; DSSTox_GSID_21327; BIDD:GT0427; Dronabinol [USAN:USP:INN]; ABBOTT-40566; GTPL2424; Cannabinol, tetrahydro- (6CI); DTXSID6021327; BDBM60994; J882F; US9416103, Delta9-THC; INT-0010; ZINC1530625; Tox21_112616; BDBM50007391; NSC134454; PDSP2_000714; SP-104; Cannabinol, Delta1-tetrahydro- (7CI); DB00470; INT-0010/06; (-)-Delta9-Tetrahydrocannabinol solution; 6465-30-1; CAS-1972-08-3; Synthetic THC in sesame oil / soft gelatin; C06972; Cannabinol, 1-trans-.delta.(sup9)-tetrahydro-; D00306; Tetrahydrocannabinols (-)-trans-.delta.9-form; 23623-EP2269989A1; 23623-EP2275420A1; 23623-EP2298764A1; 23623-EP2298765A1; 23623-EP2298772A1; 23623-EP2308839A1; 23623-EP2314298A1; 23623-EP2314580A1; Dronabinol in sesame oil in soft gelatin capsule; 124699-EP2272825A2; 124699-EP2289509A2; 124699-EP2295426A1; 124699-EP2295427A1; 148820-EP2289509A2; Q190067; (-)-Delta9-THC (Dronabinol) 0.1 mg/ml in Methanol; (-)-Delta9-THC (Dronabinol) 1.0 mg/ml in Methanol; (-)-Delta9-THC (Dronabinol) 5.0 mg/ml in Methanol; Delta9-Tetrahydrocannabinol solution, ethanol solution; UNII-K4H93P747O component CYQFCXCEBYINGO-IAGOWNOFSA-N; 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-; (-)-Delta9-Tetrahydrocannabinol (Delta9-THC) 100 microg/mL in Methanol; (-)-Delta9-Tetrahydrocannabinol (Delta9-THC) 1000 microg/mL in Methanol; 6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol; 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-; (-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol(l)-delta(sup 1)-Tetrahydrocannabinol; (10R,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; (6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6H,6AH,7H,8H,10AH-BENZO[C]ISOCHROMEN-1-OL; (S)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol(DeltaE-9-THC); 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; Delta-9-Tetrahydrocannabinol, United States Pharmacopeia (USP) Reference Standard; (-)-Delta9-Tetrahydrocannabinol solution, ~1 mg/mL in ethanol, analytical standard, for drug analysis; (-)-trans-Delta9-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol(delta9-THC(delta9-tetrahydrocannabinol)); 8,8-Dimethyl-11-methylene-5-pentyl-3,4,8a,9,10,11,12,12a-octahydro-2H,8H-1,7-dioxa-benzo[c]phenanthrene; Delta9-Tetrahydrocannabinol solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis	Small molecule	1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1	CYQFCXCEBYINGO-IAGOWNOFSA-N	CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O	C21H30O2	CAS 1972-08-3	CHEBI:66964	.	.	.	D0P1FO	.	.	.
NP0754	Cordycepin	CID: 6303	3'-deoxyadenosine	.	1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1	OFEZSBMBBKLLBJ-BAJZRUMYSA-N	C1C(OC(C1O)N2C=NC3=C(N=CN=C32)N)CO	C10H13N5O3	CAS 73-03-0	.	HBIN021460	SMIT01351	.	D0Q9MA	.	.	.
NP0768	Irbesartan	CID: 3749	irbesartan; 138402-11-6; Avapro; Aprovel; Karvea; SR-47436; BMS-186295; BMS 186295; SR 47436; Irbesartan free base; UNII-J0E2756Z7N; CHEMBL1513; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one; CHEBI:5959; 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; J0E2756Z7N; 138402-11-6 (free base); MFCD00864464; 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; NCGC00095122-01; DSSTox_CID_3169; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one; DSSTox_RID_76900; DSSTox_GSID_23169; Irbetan; Irbesartan Krka; Irbesartan BMS; [3H]irbesartan; 3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; Irbesartan Winthrop; 2-BUTYL-3-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE; SMR000466306; Avapro (TN); CAS-138402-11-6; HSDB 8215; Irbesartan [USAN:USP:INN:BAN]; Irbesartan ,(S); 2-butyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; Irbesartan (Avapro); Irbesartan(Avapro)/; 1216883-23-6; PubChem21382; Spectrum_001751; Spectrum2_001675; Spectrum3_000994; Spectrum4_001122; Spectrum5_001288; SCHEMBL4246; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one; BSPBio_002687; GTPL589; KBioGR_001603; KBioSS_002231; 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; MLS000759408; MLS001424099; BIDD:GT0347; SPECTRUM1504259; SPBio_001889; GTPL6908; Irbesartan (JP17/USP/INN); DTXSID0023169; KBio2_002231; KBio2_004799; KBio2_007367; KBio3_001907; EBD8758; BCPP000202; HMS1922J05; HMS2051L08; HMS2093E16; HMS2232F23; HMS3370B06; HMS3393L08; HMS3715L04; Pharmakon1600-01504259; BCP02004; HY-B0202; ZINC3872931; Tox21_111433; ABP000523; AC-537; BDBM50042235; CCG-39091; NSC758696; STK645362; AKOS005576396; AKOS015895353; Irbesartan, >=98% (HPLC), powder; Tox21_111433_1; AB07472; AM90289; BCP9000792; CCG-101012; DB01029; KS-1151; MCULE-9617953373; NC00262; NSC 758696; NSC-758696; NCGC00095122-02; NCGC00095122-03; NCGC00095122-04; NCGC00095122-05; AK-57149; H931; SBI-0206769.P001; AB0013366; FT-0601598; FT-0670413; I0859; S1507; SR-47436;BMS-186295; C07469; D00523; J10394; S-1797; 54246-EP2270011A1; 54246-EP2295406A1; 54246-EP2295422A2; 54246-EP2298772A1; 54246-EP2298776A1; 54246-EP2298779A1; 54246-EP2301923A1; 54246-EP2301931A1; 54246-EP2305219A1; 54246-EP2308562A2; 54246-EP2308839A1; AB00639954-06; AB00639954_07; AB00639954_08; 402I116; A807387; L000319; Q947266; SR-05000001997; Q-201249; SR-05000001997-1; BRD-K60038276-001-02-5; BRD-K60038276-001-03-3; Irbesartan, European Pharmacopoeia (EP) Reference Standard; Irbesartan, United States Pharmacopeia (USP) Reference Standard; Irbesartan, Pharmaceutical Secondary Standard; Certified Reference Material; 2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one; 2-butyl-3-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 2-n-butyl-3-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>-1,3-diazaspiro<4.4>non-1-en-4-one;; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one	Small molecule	1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)	YOSHYTLCDANDAN-UHFFFAOYSA-N	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5	C25H28N6O	CAS 138402-11-6	CHEBI:5959	.	.	.	D00JAU	.	.	.
NP0790	Saikosaponin D	CID: 107793	Saikosaponin D; UNII-UR635J3F00; UR635J3F00; Saikosaponins; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-[[(1S,2R,4S,5R,8R,9R,10S,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; Saikosaponin D from Bupleurum falcatnum; SCHEMBL929710; CHEMBL3613719; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-[hydroxy-(hydroxymethyl)-hexamethyl-[?]yl]oxy-6-methyl-tetrahydropyran-4-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; HY-N0250; MFCD09028095; s5454; AKOS016034270; ZINC247647500; CCG-270465; CS-0008281; N1887; Q-100262; Q27291219; beta-D-Galactopyranoside, (3beta,4alpha,16alpha)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-O-beta-D-glucopyranosyl	Small molecule	1S/C42H68O13/c1-21-28(46)33(55-34-31(49)30(48)29(47)22(18-43)53-34)32(50)35(52-21)54-27-10-11-37(4)23(38(27,5)19-44)8-12-39(6)24(37)9-13-42-25-16-36(2,3)14-15-41(25,20-51-42)26(45)17-40(39,42)7/h9,13,21-35,43-50H,8,10-12,14-20H2,1-7H3/t21-,22-,23-,24-,25-,26-,27+,28+,29-,30+,31-,32-,33+,34+,35+,37+,38+,39-,40+,41-,42+/m1/s1	KYWSCMDFVARMPN-LCSVLAELSA-N	CC1C(C(C(C(O1)OC2CCC3(C(C2(C)CO)CCC4(C3C=CC56C4(CC(C7(C5CC(CC7)(C)C)CO6)O)C)C)C)O)OC8C(C(C(C(O8)CO)O)O)O)O	C42H68O13	CAS 20874-52-6	.	.	.	.	.	.	.	.
NP0798	Polydatin	CID: 5281718	Polydatin; Piceid; 65914-17-2; Trans-Piceid; 27208-80-6; 3,4,5-Trihydroxystilbene-3-beta-monoglucoside; 3,4,5-Tsg; (2S,3R,4S,5S,6R)-2-(3-Hydroxy-5-(4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Polydatin (E)-isomer; Resveratrol 3-beta-mono-D-glucoside; Resveratrol 3-O-beta-glucopyranoside; UNII-XM261C37CQ; MLS001424114; CHEBI:8198; XM261C37CQ; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol; Polydotin Peceid; trans-resveratrol 3-beta-glucoside; (E/Z)-Polydatin; trans-resveratrol 3-beta-D-glucoside; 3,4'-5-Trihydroxystilbene-3-beta-D-glucopyranoside; trans-resveratrol 3-O-beta-D-glucoside; 3,5,4'-Trihydroxystilbene 3-glucoside; SMR000466371; b-D-Glucopyranoside, 3-hydroxy-5-[2-(4-hydroxyphenyl)ethenyl]phenyl; 3,4',5-trihydroxystilbene-3-beta-D-glucoside; C20H22O8; (2S,3R,4S,5S,6R)-2-(3-hydroxy-5-((E)-4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Polydatin(Piceid); Resveratrol 3-Glucoside; 5-Tsg; resveratrol 3-O-beta-D-glucoside; trans-Polydatin; MFCD00210592; (E)-Polydatin; Polydatin,(S); Polydatin - Piceid; Polydatin(Piceid)/; (E)-Piceid; 5-Trihydroxystilbene-3-beta-monoglucoside; 3-Hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl-beta-D-glucoside; Resveratrol 3-O-glucoside; Resveratrol 5-O-glucoside; SCHEMBL41411; trans-Resveratrol C-glucoside; MLS000759499; trans-Resveratrol 3-glucoside; CHEMBL142652; Resveratrol 3-beta-D-glucoside; trans-Resveratrol 3-O-glucoside; BDBM60919; CHEBI:94610; cid_5281718; DTXSID20897454; HMS2051A20; 148766-36-3; HY-N0120; ZINC4098633; resveratrol-3-O-b-mono-D-glucoside; ABP000698; CP0092; LMPK13090012; s2390; AKOS015961013; CCG-100895; DB11263; KS-5384; NC00145; Resveratrol 3-.beta.-mono-d-glucoside; NCGC00246971-01; NCGC00246971-04; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl]phenoxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; AS-13910; O911; trans-resveratrol 3-beta-d-glucopyranoside; AB0016722; CS-0007830; C10275; AB00639953-07; 3,4',5-Trihydroxystilbene-3-b-D-glucopyranoside; 914P172; 5,4'-dihydroxystilbene-3-O-beta-D-glucopyranoside; Q-100342; Q3902665; W-203441; 3,4',5-TRIHYDROXYSTILBENE-3-BETA-MONOGLUCOSIDE; 3,4'-5-Trihydroxystilbene-3-beta-D-glucopyranoside, 97%; 3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenyl beta-D-glucopyranoside; beta-D-Glucopyranoside, 3-hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl; beta-D-Glucopyranoside, 3-hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl-, (E)-; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-oxidanyl-phenoxy]oxane-3,4,5-triol; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl]phenoxy]-6-methylol-tetrahydropyran-3,4,5-triol; .beta.-D-Glucopyranoside, 3-hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenyl3,5,4'-Trihydroxystilbene 3-glucoside	Small molecule	1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1	HSTZMXCBWJGKHG-CUYWLFDKSA-N	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O	C20H22O8	CAS 27208-80-6	CHEBI:8198	.	.	.	.	.	.	.
NP0812	Oleanolic acid	CID: 10494	OLEANOLIC ACID; 508-02-1; Oleanic acid; Caryophyllin; Astrantiagenin C; Giganteumgenin C; Virgaureagenin B; 3beta-Hydroxyolean-12-en-28-oic acid; 3-beta-Hydroxyolean-12-en-28-oic acid; UNII-6SMK8R7TGJ; (3-beta)-3-Hydroxyolean-12-en-28-oic acid; MFCD00064914; NSC114945; 6SMK8R7TGJ; (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid; NSC-114945; CHEBI:37659; oleonolic acid; Oleanolic acid, 97%; NSC 114945; Olean-12-en-28-oic acid, 3-hydroxy-, (3beta)-; (2S,5S,10S,18S,1R,14R,15R,20R)-18-hydroxy-1,2,8,8,15,19,19-heptamethylpentacyc lo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-5-carboxylic acid; (4aS,5S,6aS,6bR,8R,8aR,10S,12aR,12bR,14bS)-10-Hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydro-2H-picene-4a-carboxylic acid; 3-Beta-Hydroxy-Olean-12-En-28-Oicaci; SMR000445561; CCRIS 6493; OLEANOLIC_ACID; CHEMBL168; EINECS 208-081-6; oleanolic acids; oleanolic-acid; OleanolsA currencyure; Oleanoic Acid Hydrate; Olean-12-en-28-oic acid, 3.beta.-hydroxy-; Oleanolic acid anhydrous; Oleanolic acid, >=97%; SCHEMBL71070; MLS000697656; MLS002207133; Olean-12-en-28-oic acid, 3-hydroxy-, (3-beta)-; GTPL3306; AOB5588; DTXSID50858790; HMS2232D15; Oleanolic acid (OA)(Compound 1); Oleanolic acid, analytical standard; EX-A1991; HY-N0156; ZINC3785416; BDBM50346601; 3-beta-Hydroxyolean-12-en-28-oate; 3beta-hydroxy-Olean-12-en-28-oate; AKOS015951416; AC-8026; CCG-208530; CS-3800; LMPR0106150004; VA11435; 3.beta.-hydroxy-Olean-12-en-28-oate; 3  -hydroxy-Olean-12-en-28-oic acid; 3beta-hydroxy-Olean-12-en-28-oic acid; (4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2H)-carboxylic acid; AS-35338; BP-25410; ST057162; (3-beta)-3-Hydroxyolean-12-en-28-oate; (3?)-3-Hydroxyolean-12-en-28-oic acid; 3.beta.-hydroxy-Olean-12-en-28-oic acid; N1826; (3.beta.)-3-hydroxy-Olean-12-en-28-oate; C17148; (3.beta.)-3-hydroxy-Olean-12-en-28-oic acid; (3.beta.)-3-beta-hydroxy-Olean-12-en-28-oate; 508O021; Q418628; Olean-12-en-28-oic acid, 3-beta-hydroxy- (8CI); Olean-12-en-28-oic acid, 3beta-hydroxy- (8CI); Q-100572; (3.beta.)-3-beta-hydroxy-Olean-12-en-28-oic acid; Oleanolic acid, primary pharmaceutical reference standard; C7EE6ACC-7175-4947-B524-FF8479525DA1; Oleanolic acid, European Pharmacopoeia (EP) Reference Standard; Oleanolic acid, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C30H48O3/c1-25(2)14-16-30(24(32)33)17-15-28(6)19(20(30)18-25)8-9-22-27(5)12-11-23(31)26(3,4)21(27)10-13-29(22,28)7/h8,20-23,31H,9-18H2,1-7H3,(H,32,33)/t20-,21-,22+,23-,27-,28+,29+,30-/m0/s1	MIJYXULNPSFWEK-GTOFXWBISA-N	CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)O)C	C30H48O3	CAS 508-02-1	CHEBI:37659	.	.	.	D0SJ2Q	.	.	.
NP0815	Bosentan	CID: 104865	Bosentan; 147536-97-8; Tracleer; Ro 47-0203; Ro-47-0203; C27H29N5O6S; Bosentan [USAN:INN:BAN]; UNII-XUL93R30K2; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide; p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; CHEMBL957; XUL93R30K2; Actelion; CHEBI:51450; 147536-97-8 (free); 4-(tert-butyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide; NCGC00167440-01; bosentan anhydrous; DSSTox_CID_26627; DSSTox_RID_81776; DSSTox_GSID_46627; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-tert-butyl-N-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide; Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-; bosentanum; Bosentan (INN); 1174918-31-0; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-; CAS-147536-97-8; Ro 47-0203/039; SR-05000001532; Ro 47-0203/029; 4-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; KS-5062; PubChem19119; Ro-47-0203/029; Ro-47-0203/039; SCHEMBL4218; N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide; GTPL3494; DTXSID7046627; HMS2090N14; HMS3652F15; HMS3715N05; HMS3750A13; BCP05202; HY-A0013; ZINC1538857; Tox21_112444; ABP001094; AC-148; BDBM50061101; PDSP1_001731; PDSP2_001714; s4220; AKOS015852063; Tox21_112444_1; ACN-048487; AM84442; BCP9000445; CCG-221182; CS-0381; DB00559; MCULE-3074160312; SB17356; VA10428; NCGC00167440-02; 174227-18-0; AB0018010; Ro-470203029; B5118; FT-0658809; SW199648-3; Ro-47-0203-029; D07538; W-5165; AB01275536-01; 144096-EP2287165A2; 144096-EP2287166A2; 144096-EP2292620A2; 212B550; A808658; L001086; Q419769; J-008366; SR-05000001532-1; SR-05000001532-2; SR-05000001532-4; Z1541632805; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2''-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide; 4-(tert-Butyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide; 4-tert butyl-N-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]benzenesulphonamide; 4-tert-Butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-4-yl]benzene-1-sulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2''-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide; 4-tert-Butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide; K86	Small molecule	1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)	GJPICJJJRGTNOD-UHFFFAOYSA-N	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC	C27H29N5O6S	CAS 147536-97-8	CHEBI:51450	.	.	.	D0U4CE	.	.	.
NP0822	Cinnamaldehyde	CID: 637511	cinnamic aldehyde	.	1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4+	KJPRLNWUNMBNBZ-QPJJXVBHSA-N	C1=CC=C(C=C1)C=CC=O	C9H8O	CAS 104-55-2	.	HBIN020653	SMIT00089	MOL000991	D0PJ3M	.	1081	.
NP0871	Isotretinoin	CID: 5282379	Isotretinoin; 13-cis-Retinoic acid; 4759-48-2; Accutane; Roaccutane; Neovitamin A acid; 13-cis-Vitamin A acid; 13-cis retinoic acid; Claravis; Amnesteem; Isotrex; Teriosal; Sotret; ISOTRETINON; isotretinoino; Isotretinoine; Isotretinoinum; Roaccutan; 13-RA; Absorica; Roacutan; Isotretinoine [INN-French]; Isotretinoinum [INN-Latin]; Isotretinoino [INN-Spanish]; CIP-Isotretinoin; Accutane (TN); Isotretinoin (USP); Ro-4-3780; UNII-EH28UP18IF; cis-RA; (7E,9E,11E,13Z)-retinoic acid; Ro 4-3780; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; (13cis)-retinoic acid; 13-cis RA; Ro-43780; CHEMBL547; EH28UP18IF; RETINOIC ACID, 13-cis-; CHEBI:6067; 13-cis-retinoic acid,Isotretinoin; Isotane; (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; cis-Retinoic acid; Myorisan; Zenatane; Isosuprea Lidose; Sotret (TN); CCRIS 4286; HSDB 3929; 13 Cis-Retinoic Acid; SR-01000076103; EINECS 225-296-0; BRN 1885770; isotretinoina; cis-Retinoate; BML2-E07; Isotretinoin [USAN:BAN:INN]; MFCD00079542; cis retinoic acid; Trans-Retinoicacid; Absorica (TN); Prestwick_642; CAS-4759-48-2; Isotretinoin [USAN:USP:INN:BAN]; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid; (13-cis)-Retinoate; CPD000471891; 13cRA; Prestwick2_000256; Prestwick3_000256; Spectrum5_001795; Spectrum5_001937; (13-cis)-Retinoic acid; DSSTox_CID_3177; R 3255; Retinoic acid 13-cis-form; Retinoic acid, (13cis)-; DSSTox_RID_76906; DSSTox_GSID_23177; Lopac0_001081; SCHEMBL38299; BSPBio_000072; BSPBio_001331; BSPBio_003345; 4-09-00-02388 (Beilstein Handbook Reference); MLS001074662; SPECTRUM1502013; BPBio1_000080; GTPL7600; DTXSID4023177; PAT-001; HMS1361C13; HMS1568D14; HMS1791C13; HMS1921D08; HMS1989C13; HMS2092N07; HMS2095D14; HMS2233A07; HMS3259J09; HMS3263I04; HMS3402C13; HMS3712D14; HMS3884A13; Pharmakon1600-01502013; BCP18950; ZINC3792789; Tox21_200093; Tox21_501081; BDBM50031459; LMPR01090021; NSC758156; 13-Cis- Retionic acid(Isotretinoin); AKOS015841158; CCG-205158; CS-1864; DB00982; DS-3367; LP01081; NC00635; NSC 758156; NSC-758156; SDCCGSBI-0051051.P004; IDI1_033801; NCGC00094358-01; NCGC00094358-02; NCGC00094358-03; NCGC00094358-04; NCGC00094358-05; NCGC00094358-06; NCGC00094358-07; NCGC00094358-08; NCGC00094358-09; NCGC00094358-10; NCGC00094358-11; NCGC00094358-12; NCGC00094358-13; NCGC00094358-14; NCGC00094358-15; NCGC00094358-26; NCGC00257647-01; NCGC00261766-01; HY-15127; SMR000471891; 13-cis-Retinoic acid, >=98% (HPLC); 13-cis-Retinoic acid; ; ; Retinoid analogues; SBI-0051051.P003; EU-0101081; R0088; 5952-EP0930075A1; 5952-EP2295426A1; 5952-EP2311840A1; 59I482; C07058; D00348; 24210-EP2311808A1; 24210-EP2311829A1; 24210-EP2314590A1; Q287029; SR-01000076103-2; SR-01000076103-5; SR-01000076103-6; SR-01000076103-9; BRD-K76723084-001-05-9; SR-01000076103-10; Isotretinoin, European Pharmacopoeia (EP) Reference Standard; Isotretinoin, United States Pharmacopeia (USP) Reference Standard; (2Z,4E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraenoic acid; Isotretinoin for peak identification, European Pharmacopoeia (EP) Reference Standard; Isotretinoin, Pharmaceutical Secondary Standard; Certified Reference Material; (2Z,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid	Small molecule	1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-	SHGAZHPCJJPHSC-XFYACQKRSA-N	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C	C20H28O2	CAS 4759-48-2	CHEBI:6067	.	.	.	D00DKK	.	.	.
NP0873	Gentiopicroside	CID: 88708	Gentiopicroside; Gentiopicrin; 20831-76-9; UNII-0WE09Z21RC; 0WE09Z21RC; CHEBI:5321; Gentiopicroside, >=98% (HPLC); (5R,6S)-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-5-vinyl-5,6-dihydro-1H,3H-pyrano[3,4-c]pyran-1-one; 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(beta-D-glucopyranosyloxy)-5,6-dihydro-, (5R,6S)-; Gentiopicrin,(S); (3S,4R)-4-ethenyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,6-dihydro-3H-pyrano[3,4-c]pyran-8-one; (5R,6S)-6-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-5-vinyl-5,6-dihydropyrano[3,4-c]pyran-1(3H)-one; MLS002473254; SCHEMBL154304; CHEMBL508320; MEGxp0_000872; POLYPROPYLENEGLYCOL4000; ACon1_001284; DTXSID40878043; HMS2198G10; HY-N0494; ZINC4098340; EINECS 244-070-2; MFCD00075700; s3777; ZB1867; AKOS015896721; CCG-268110; LMPR0102070009; NSC 606402; NCGC00180669-01; 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-D-glucopyranosyloxy)-5,6-dihydro-, (5R-trans)-; AC-20248; AS-74360; O673; SMR001397341; CS-0009015; N1898; C09782; 831G769; BRD-K33131085-001-01-5; Q27106718; (5R,6S)-5-ethenyl-6-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1H,3H,5H,6H-pyrano[3,4-c]pyran-1-one; (5R,6S)-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-5-vinyl-5,6-dihydropyrano[3,4-c]pyran-1(3H)-one; (5R-trans)-6-(??-D-glucopyranosyloxy)-5,6-dihydro-5-vinyl-1H,3H-pyrano[3,4-c]pyran-1-one; (5R-trans)-6-(beta-D-Glucopyranosyloxy)-5,6-dihydro-5-vinyl-1H,3H-pyrano(3,4-c)pyran-1-one	Small molecule	1S/C16H20O9/c1-2-7-8-3-4-22-14(21)9(8)6-23-15(7)25-16-13(20)12(19)11(18)10(5-17)24-16/h2-3,6-7,10-13,15-20H,1,4-5H2/t7-,10-,11-,12+,13-,15+,16+/m1/s1	DUAGQYUORDTXOR-GPQRQXLASA-N	C=CC1C(OC=C2C1=CCOC2=O)OC3C(C(C(C(O3)CO)O)O)O	C16H20O9	CAS 20831-76-9	CHEBI:5321	.	.	.	.	.	.	.
NP0904	Ginsenoside	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP0944	Ferulic acid	CID: 445858	ferulic acid; trans-Ferulic Acid; 1135-24-6; 537-98-4; 4-Hydroxy-3-methoxycinnamic acid; trans-4-Hydroxy-3-methoxycinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; ferulate; (E)-Ferulic acid; Coniferic acid; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; Ferulic acid, trans-; Fumalic acid; (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; Cinnamic acid, 4-hydroxy-3-methoxy-; 3-methoxy-4-hydroxycinnamic acid; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; MFCD00004400; UNII-AVM951ZWST; Cinnamic acid, 4-hydroxy-3-methoxy-, (E)-; (E)-4-Hydroxy-3-methoxycinnamic acid; (E)-4'-Hydroxy-3'-methoxycinnamic acid; (2E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; 4-Hydroxy-3-methoxy cinnamic acid; Cinnamic acid, 4-hydroxy-3-methoxy-, trans-; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (2E)-; AVM951ZWST; (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid; (2E)-3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; Ferulic acid dehydrogenation homopolymer; (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; Fumalic acid (Ferulic acid); 4-Hydroxy-3-methoxycinnamate; CHEMBL32749; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (E)-; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid homopolymer; CHEBI:17620; NSC2821; 3-Methoxy-4-hydroxy-trans-cinnamate; 4-Hydroxy-3-Methoxycinnamic Acid, 99%; (E)-Ferulate; 3-(4-Hydroxy-3-methoxyphenyl)propenoic acid; 97274-61-8; CINNAMIC ACID,4-HYDROXY,3-METHOXY   FERULIC ACID; caffeic acid 3-methyl ether; 3-methoxy-4-hydroxy-trans-cinnamic acid; SMR000112202; 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; EINECS 208-679-7; ferulic acid (trans-4-hydroxy-3-methoxycinnamic acid); ferulasaure; trans-Ferulate; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoate; CCRIS 3256; CCRIS 7127; CCRIS 7575; HSDB 7663; NSC 2821; Ferulic acid, E-; EINECS 214-490-0; NSC 51986; trans-4-Hydroxy-3-methoxycinnamicacid; Ferulic acid (M5); NSC 674320; PubChem8183; 3-(4-Hydroxy-3-methoxy-phenyl)-acrylic acid; Ferulic Acid ,(S); FERULIC-ACID; Ferulic Acid, Synthetic; Spectrum5_000554; bmse000459; bmse000587; bmse010211; trans-Ferulic acid, 99%; SCHEMBL15673; BSPBio_003168; MLS001066385; MLS001332483; MLS001332484; MLS002207079; MLS006011435; SPECTRUM1501017; trans-Ferulic acid, >=99%; (E)-3-(4-hydroxy-3-methoxy-phenyl)prop-2-enoic acid; ZINC58258; DTXSID70892035; HMS1921D05; HMS2269P04; (E)-4-Hydroxy-3-methoxycinnamate; trans-4-Hydroxy-3-methoxycinnamate; ALBB-013505; BCP21231; BCP21789; HY-N0060; NSC-2821; NSC51986; STR00961; (E)-4-hydroxy-3-methoxy-Cinnamate; (E)4-hydroxy-3-methoxycinnamic acid; BBL010345; BDBM50214744; CCG-38860; CF0041; NSC-51986; s2300; SBB000326; STK801551; AKOS000263735; AC-7965; ACN-035275; BCP9000163; DB07767; PS-3435; SDCCGMLS-0066667.P001; trans-3-methoxy-4-hydroxycinnamic acid; (E)-4-hydroxy-3-methoxy-Cinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)propenoate; 4-Hydroxy-3-methoxycinnamic acid, trans; NCGC00094889-01; NCGC00094889-02; NCGC00094889-03; NCGC00094889-04; AC-10321; BS-17543; SMR004703246; ST097625; AM20060784; CS-0007108; N1878; SW219616-1; trans-Ferulic Acid (purified by sublimation); C01494; J10038; J10187; W-2799; ferulic acid (4-hydroxy-3-methoxycinnamic acid); A829775; Q417362; SR-01000765539; (2E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoate; J-002980; SR-01000765539-3; (E)-3-(3-methoxy-4-oxidanyl-phenyl)prop-2-enoic acid; 3-(4-HYDROXY-3-METHOXYPHENYL)PROP-2-ENOICACID; 055E203F-B305-4B7F-8CE7-F9C0C03AB609; 3986A1BE-A670-4B06-833B-E17253079FD8; Ferulic acid, European Pharmacopoeia (EP) Reference Standard; trans-Ferulic acid, certified reference material, TraceCERT(R); 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (E)- (9CI); Diethyl2-(acetamido)-2-(2-(bromomethyl)-5-nitrobenzyl)malonate; Ferulic acid, United States Pharmacopeia (USP) Reference Standard; trans-Ferulic acid, matrix substance for MALDI-MS, >=99.0% (HPLC); 4-Hydroxy-3-methoxycinnamic acid, mixture of isomers, analytical reference material; Ferulic Acid, Pharmaceutical Secondary Standard; Certified Reference Material; 831-85-6	Small molecule	1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+	KSEBMYQBYZTDHS-HWKANZROSA-N	COC1=C(C=CC(=C1)C=CC(=O)O)O	C10H10O4	CAS 537-98-4	CHEBI:17620	.	.	.	D03SLR	.	.	.
NP0953	Plasmin	.	.	.	.	.	.	.	.	.	.	.	.	D0L9XS	.	.	.
NP0956	Bisdemethoxycurcumin	CID: 5315472	Bisdemethoxycurcumin; 33171-05-0; Curcumin III; Didemethoxycurcumin; (1E,6E)-1,7-bis(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; Bis(4-hydroxycinnamoyl)methane; 24939-16-0; Bis-demethoxycurcumin; Bis(p-hydroxycinnamoyl)methane; UNII-2EFO1BP34R; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxyphenyl)-; NSC687839; 2EFO1BP34R; 1,7-Bis(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; CHEMBL105350; CHEBI:71045; bisdesmethoxycurcumin; (1E,6E)-1,7-Bis(4-hydroxyphenyl)-hepta-1,6-diene-3,5-dione; BHCMT; 1,7-bis(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; Curcumin Lll; Curcuminoid A; Curcumin III,; Bisdemethoxy Curcumin; di-p-coumaroylmethane; Dide Methoxycurcu Min; SCHEMBL428638; SCHEMBL13521971; cid_5324473; DTXSID00872663; ZINC1651126; 1,3-Di(4-hydroxystyryl)propanedial; BDBM50059989; MFCD03419284; AKOS015902102; CCG-207959; CCG-208635; NSC-687839; Bisdemethoxycurcumin, analytical standard; AC-24239; ADAMANTAN-1-YL-ACETICACIDHYDRAZIDE; AS-57295; AS-68737; B3347; Bisdemethoxycurcumin, >=98% (HPLC), solid; N1712; S3938; V2229; A14544; Q-100322; Q4917168; BRD-K37445107-001-01-9; 1,7-bis(4-hydroxyphenyl)-1,6-Heptadiene-3,5-dione(E,E); 1,7-bis(4-hydroxyphenyl)-3-hydroxy-1,3,6-heptatrien-5-one; (1E,6E)-1,7-Bis-(4-hydroxy-phenyl)-hepta-1,6-diene-3,5-dione; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxyphenyl)-, (1E,6E)-; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxyphenyl)-, (E,E)-; 5-Hydroxy-1,7-bis-(4-hydroxy-phenyl)-hepta-1,4,6-trien-3-one; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-phenyl)-hepta-1,4,6-trien-3-one; 22608-12-4	Small molecule	1S/C19H16O4/c20-16-7-1-14(2-8-16)5-11-18(22)13-19(23)12-6-15-3-9-17(21)10-4-15/h1-12,20-21H,13H2/b11-5+,12-6+	PREBVFJICNPEKM-YDWXAUTNSA-N	C1=CC(=CC=C1C=CC(=O)CC(=O)C=CC2=CC=C(C=C2)O)O	C19H16O4	CAS 33171-05-0	CHEBI:71045	.	.	.	.	.	.	.
NP0982	Idebenone	CID: 3686	idebenone; 58186-27-9; Idebenona; Idebenonum; CV 2619; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; CV-2619; UNII-HB6PN45W4J; BRN 2001459; CHEBI:31687; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone; 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone; HB6PN45W4J; Raxone; 5,6-DIMETHOXY-2-(10-HYDROXYDECYL)-3-METHYL-1,4-BENZOQUINONE; 2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-; MFCD00274552; NCGC00160514-01; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylbenzo-1,4-quinone; 2,5-Cyclohexadiene-1,4-dione, 5,6-dimethoxy-2-(10-hydroxydecyl)-3-methyl-; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione; 2-(10-hydroxydecyl)-6-methoxy-3-methyl-5-(trideuteriomethoxy)cyclohexa-2,5-diene-1,4-dione; DSSTox_CID_20678; DSSTox_RID_79536; DSSTox_GSID_40678; Idebenonum [Latin]; Idebenona [Spanish]; Idebenone [INN:JAN]; 2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4-benzoquinone; SMR000466364; CAS-58186-27-9; SR-01000759378; Cerestabon; Sovrima; Catena; Mnesis; Avan; Raxone (TN); PubChem13642; SNT-MC17; SCHEMBL28320; Idebenone (JAN/USAN/INN); MLS000759487; MLS001032035; MLS001424002; MLS006011882; Idebenone, analytical standard; CHEMBL252556; QSA-10; DTXSID0040678; Idebenone, >=98% (HPLC); FR114; HMS2051O06; HMS2089D08; HMS3393O06; HMS3656K22; HMS3713A10; HMS3884B12; Pharmakon1600-01505755; ALBB-027258; BCP09116; HY-N0303; STR09227; ZINC1542890; Tox21_111864; BBL025842; BDBM50505498; NSC759228; s2605; STK801942; AKOS005622577; Tox21_111864_1; AC-4337; CCG-100846; KS-5193; MCULE-6391829243; NC00096; NSC 759228; NSC-759228; SB19130; NCGC00160514-02; NCGC00160514-03; AK161748; SY051193; SBI-0207024.P001; AB0010667; DB-053168; FT-0617205; I0848; SW219495-1; A11707; D01750; J10031; M-1155; AB00639997-04; AB00639997-06; AB00639997_07; AB00639997_08; 186I279; A-68500; A831776; Q4197874; SR-01000759378-4; SR-01000759378-5; SR-01000759378-6; BRD-K37516142-001-01-4; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methylbenzoquinone; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4benzoquinone; 2,3-dimethoxy-5-methyl-6-(10-oxidanyldecyl)cyclohexa-2,5-diene-1,4-dione	Small molecule	1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3	JGPMMRGNQUBGND-UHFFFAOYSA-N	CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO	C19H30O5	CAS 58186-27-9	CHEBI:31687	.	.	.	D0MM8N	.	.	.
NP0996	Bucillamine	CID: 656604	bucillamine; 65002-17-7; Tiobutarit; Rimatil; N-(2-Mercapto-2-methylpropionyl)-L-cysteine; UNII-R80LRA5WTF; De-019; N-(2-Mercapto-2-methylpropanoyl)-L-cysteine; R80LRA5WTF; N-(2-Mercapto-2-methyl-1-oxopropyl)-L-cysteine; (R)-3-mercapto-2-(2-mercapto-2-methylpropanamido)propanoic acid; CHEMBL80830; L-CYSTEINE, N-(2-MERCAPTO-2-METHYL-1-OXOPROPYL)-; Thiobutarit; DSSTox_CID_28513; DSSTox_RID_82785; DSSTox_GSID_48587; Bucilamina; Bucillaminum; (R)-3-Mercapto-2-(2-mercapto-2-methylpropanamido)-propanoic acid; CAS-65002-17-7; Bucilamina [Spanish]; Bucillaminum [Latin]; (2R)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid; Bucillamine [INN:JAN]; C7H13NO3S2; CCRIS 5260; SA96; N-(2-Mercaptoisobutyryl)cysteine; SA-96; NCGC00182062-02; NCGC00183271-01; Bucilant (TN); N-(2-Mercaptoisobutyryl)-L-cysteine; Bucillamine (JP17/INN); MLS006010100; SCHEMBL121965; DTXSID2048587; CHEBI:31312; ZINC20222; QCR-239; BCP12127; Tox21_112916; Tox21_113147; BDBM50406934; MFCD00867570; RB3025; AKOS015841445; AKOS015895462; AM62722; DB12160; KS-1449; AC-32465; K055; SMR004701240; AB0007152; D01809; 002B177; A834941; SR-01000883966; Q-101254; Q4982752; SR-01000883966-1; (2R)-2-[(2-methyl-2-sulfanyl-propanoyl)amino]-3-sulfanyl-propanoic acid; (2R)-3-mercapto-2-[(2-mercapto-2-methyl-1-oxopropyl)amino]propanoic acid	Small molecule	1S/C7H13NO3S2/c1-7(2,13)6(11)8-4(3-12)5(9)10/h4,12-13H,3H2,1-2H3,(H,8,11)(H,9,10)/t4-/m0/s1	VUAFHZCUKUDDBC-BYPYZUCNSA-N	CC(C)(C(=O)NC(CS)C(=O)O)S	C7H13NO3S2	CAS 65002-17-7	CHEBI:31312	.	.	.	D01FJT	.	.	.
NP1003	Apalcillin	CID: 6602341	Apalcillin; apalcilina; 63469-19-2; Apalcilline; Apalcillinum; UNII-3373RT9U7A; C25H23N5O6S; CHEBI:51691; 3373RT9U7A; PC-904; (2S,5R,6R)-6-{[(2R)-2-{[(4-hydroxy-1,5-naphthyridin-3-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[(4-hydroxy-1,5-naphthyridin-3-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; Apalcillin [INN]; Apalcilina [INN-Spanish]; Apalcilline [INN-French]; Apalcillinum [INN-Latin]; BRN 6030446; SCHEMBL33854; CHEMBL3306902; GTPL10759; DTXSID601016509; PC904; ZINC59817121; (6R)-6-((R)-2-(4-Hydroxy-1,5-naphthyridin-3-carboxamido)-2-phenylacetamido)penicillansaeure; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(4-oxo-1H-1,5-naphthyridine-3-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-((R)-2-(4-Hydroxy-1,5-naphthyridin-3-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-5-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (2S,5R,6R)-6-((R)-2-(4-Hydroxy-1,5-naphthyridin-3-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-5-thia-1-azabicyclo(3.2.0)heptan-2-carboxylic acid; U326; WY-44417; WY-44,417; Q15633259; DIETHYL5,5-METHYLENEBIS(4-ETHYL-3-METHYL-2-PYRROLECARBOXYLATE); (2S,5R,6R)-6-(2-(4-hydroxy-1,5-naphthyridine-3-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2R)-(((4-hydroxy-1,5-naphthyridin-3-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S,5R,6R)-	Small molecule	1S/C25H23N5O6S/c1-25(2)19(24(35)36)30-22(34)17(23(30)37-25)29-21(33)15(12-7-4-3-5-8-12)28-20(32)13-11-27-14-9-6-10-26-16(14)18(13)31/h3-11,15,17,19,23H,1-2H3,(H,27,31)(H,28,32)(H,29,33)(H,35,36)/t15-,17-,19+,23-/m1/s1	XMQVYNAURODYCQ-SLFBBCNNSA-N	CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)C4=CNC5=C(C4=O)N=CC=C5)C(=O)O)C	C25H23N5O6S	CAS 63469-19-2	CHEBI:51691	.	.	.	.	.	.	.
NP1023	Morin	CID: 5281670	Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]	.	1S/C15H10O7/c16-6-1-2-8(9(18)3-6)15-14(21)13(20)12-10(19)4-7(17)5-11(12)22-15/h1-5,16-19,21H	YXOLAZRVSSWPPT-UHFFFAOYSA-N	C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O	C15H10O7	CAS 480-16-0	.	HBIN035746	SMIT00073	MOL000737	D0NJ4H	.	4885	.
NP1047	Zerumbone	CID: 5470187	Zerumbone; 471-05-6; (2E,6E,10E)-2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; (E,E,E)-2,6,9,9-Tetramethyl-2,6,10-cycloundecatrien-1-one; CHEMBL245412; 2E,6E,9E-humulatrien-8-one; CHEBI:63892; C15H22O; Zerumbone (6CI,7CI); 2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; SCHEMBL12831266; Zerumbone, >=98% (HPLC); HY-N7015; BDBM50241296; MFCD03700769; NSC698299; s5928; ZINC28878195; CCG-208558; NSC-698299; CS-0003365; C20262; Q27132897	Small molecule	1S/C15H22O/c1-12-6-5-7-13(2)14(16)9-11-15(3,4)10-8-12/h7-9,11H,5-6,10H2,1-4H3/b11-9+,12-8+,13-7+	GIHNTRQPEMKFKO-SKTNYSRSSA-N	CC1=CCC(C=CC(=O)C(=CCC1)C)(C)C	C15H22O	CAS 471-05-6	CHEBI:63892	.	.	.	.	.	.	.
NP1083	Vitexin	CID: 5280441	Vitexin; 3681-93-4; Apigenin 8-C-glucoside; Vitxein; UNII-9VP70K75OK; 9VP70K75OK; CHEBI:16954; MFCD00017456; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-beta-D-glucopyranosyl-2-(4-hydroxyphenyl)-; 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; Flavone, 8-D-glucosyl-4',5,7-trihydroxy-; (1S)-1,5-anhydro-1-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-D-glucitol; 8-beta-D-Glucopyranosyl-apigenin; EINECS 222-963-8; Vitexin,(S); Vitexin, analytical standard; 8-beta-D-Glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; SCHEMBL25277; CHEMBL487417; DTXSID90190287; 4H-1-Benzopyran-4-one, 8-.beta.-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-; Apigenin 8-C-.beta.-D-glucoside; ACT02625; HY-N0013; ZINC4245684; BDBM50362886; s9192; AKOS025311479; AC-6086; CCG-208516; 4H-1-Benzopyran-4-one, 8-beta-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-; NCGC00163642-01; 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; AS-55909; (hydroxymethyl)tetrahydro-2H-pyran-2-yl)-; CS-0007090; N1319; V0191; A12135; C01460; 681V934; Q259075; Vitexin, primary pharmaceutical reference standard; Q-100437; 8-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-; 5,7,4'-Trihydroxyflavone 8-C-.beta.-D-glucopyranoside; Vitexin, United States Pharmacopeia (USP) Reference Standard; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-.beta.-D-glucopyranosyl-2-(4-hydroxyphenyl)-; 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one	Small molecule	1S/C21H20O10/c22-7-14-17(27)18(28)19(29)21(31-14)16-11(25)5-10(24)15-12(26)6-13(30-20(15)16)8-1-3-9(23)4-2-8/h1-6,14,17-19,21-25,27-29H,7H2/t14-,17-,18+,19-,21+/m1/s1	SGEWCQFRYRRZDC-VPRICQMDSA-N	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4C(C(C(C(O4)CO)O)O)O)O	C21H20O10	CAS 3681-93-4	CHEBI:16954	.	.	.	.	.	.	.
NP1128	Rottlerin	CID: 5281847	rottlerin; Mallotoxin; 82-08-6; Kamalin; UNII-E29LP3ZMUH; E29LP3ZMUH; CHEMBL34241; CHEBI:8899; (E)-1-(6-((3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl)-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-phenyl-2-propen-1-one; NSC56346; NSC94525; MFCD00017361; 1-[6-(3-Acetyl-2,4,6-trihydroxy-5-methyl-benzyl)-5,7-dihydroxy-2,2-dimethyl-2H-chromen-8-yl]-3-phenyl-propenone; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one; (E)-1-(6-(3-acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5,7-dihydroxy-2,2-dimethyl-2H-chromen-8-yl)-3-phenylprop-2-en-1-one; SR-01000076106; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one; EINECS 201-395-4; NSC 56346; NSC 94525; BRN 0070757; BMK1-F10; Rottlerin, 98%; R5648 (Rottlerin); BiomolKI_000058; BiomolKI2_000064; R 5648; Lopac0_001052; BSPBio_001080; (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one; 5-18-05-00695 (Beilstein Handbook Reference); MLS003370622; SCHEMBL148175; GTPL2611; SCHEMBL1537089; BCBcMAP01_000019; CHEBI:92065; Rottlerin - CAS 82-08-6; DTXSID30231502; HMS1362F21; HMS1792F21; HMS1990F21; HMS3263C06; HMS3403F21; ZINC3874886; Tox21_501052; BDBM50126829; CCG-36482; LMPK12120428; NSC-56346; NSC-94525; AKOS024282482; LP01052; SDCCGSBI-0051022.P002; IDI1_002135; NCGC00025228-02; NCGC00025228-03; NCGC00025228-04; NCGC00025228-05; NCGC00025228-06; NCGC00025228-07; NCGC00025228-08; NCGC00025228-09; NCGC00025228-10; NCGC00025228-11; NCGC00025228-12; NCGC00025228-19; NCGC00261737-01; (2E)-1-[6-(3-acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5,7-dihydroxy-2,2-dimethyl-2H-chromen-8-yl]-3-phenylprop-2-en-1-one; Acetophenone, 3'-((8-cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-6-yl)methyl)-2',4',6'-trihydroxy-5'-methyl-; HY-18980; SMR000058242; ST056358; CS-0014823; EU-0101052; S7862; C10721; Q7370686; SR-01000076106-2; SR-01000076106-3; SR-01000076106-6; BRD-K03816923-001-03-9; BRD-K39256324-001-01-5; (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methyl-phenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-chromen-8-yl]-3-phenyl-prop-2-en-1-one; (E)-1-[6-[(3-Acetyl-2,4,6-trihydroxy-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one; 1-(6-(3-acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5,7-dihydroxy-2,2-dimethyl-2H-chromen-8-yl)-3-phenylprop-2-en-1-one; 3'-((8-cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-6-yl)methyl)-2',4',6'-trihydroxy-5'-methyl-acetophenone; 3'-[(8-Cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-6-yl)methyl]-2',4',6'-trihydroxy-5'-methylacetophenone; 3-{[8-((2E)-3-phenylprop-2-enoyl)-5,7-dihydroxy-2,2-dimethyl(2H-chromen-6-yl)] methyl}-1-acetyl-2,4,6-trihydroxy-5-methylbenzene; 6-(3-Acetyl-2,4,6-trihydroxy-5-methylbenzyl)-2,2-dimethyl-8-(3-phenylpropenoyl)-2H-1-benzopyran-5,7-diol	Small molecule	1S/C30H28O8/c1-15-24(33)19(27(36)22(16(2)31)25(15)34)14-20-26(35)18-12-13-30(3,4)38-29(18)23(28(20)37)21(32)11-10-17-8-6-5-7-9-17/h5-13,33-37H,14H2,1-4H3/b11-10+	DEZFNHCVIZBHBI-ZHACJKMWSA-N	CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)C=CC4=CC=CC=C4)O)O	C30H28O8	CAS 82-08-6	CHEBI:8899	.	.	.	D0R1JI	.	.	.
NP1168	Quercetin	CID: 5280343	Kvercetin; Meletin; QUE; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; Xanthaurine; Flavin meletin; Kvercetin [Czech]; Quercetin content; Quercetin dihydrate; CI Natural Yellow 10; Cyanidelonon 1522; KUC104418N; KUC107684N; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; TNP00070; TNP00089; LIM-5662; LNS-5662; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; CU-01000012502-3; KSC-10-126; KSC-23-76; T-Gelb bzw. grun 1; C.I. Natural yellow 10 & 13; 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one	.	1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H	REFJWTPEDVJJIY-UHFFFAOYSA-N	C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O	C15H10O7	CAS 117-39-5	CHEBI:16243	HBIN041495	SMIT00013	MOL000098	D0K8KX	.	1697	.
NP1197	12-O-tetradecanoyl phorbol-13-acetate	CID: 27924	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	Small molecule	1S/C36H56O8/c1-7-8-9-10-11-12-13-14-15-16-17-18-29(39)43-32-24(3)35(42)27(30-33(5,6)36(30,32)44-25(4)38)20-26(22-37)21-34(41)28(35)19-23(2)31(34)40/h19-20,24,27-28,30,32,37,41-42H,7-18,21-22H2,1-6H3/t24-,27+,28-,30-,32-,34-,35-,36-/m1/s1	PHEDXBVPIONUQT-RGYGYFBISA-N	CCCCCCCCCCCCCC(=O)OC1C(C2(C(C=C(CC3(C2C=C(C3=O)C)O)CO)C4C1(C4(C)C)OC(=O)C)O)C	C36H56O8	CAS 16561-29-8	.	.	.	.	D09DHT	.	.	.
NP1214	Wedelolactone	CID: 5281813	7-Methoxy-5,11,12-trihydroxycoumestan; 7-Methoxy-5,11,12-trihydroxy-coumestan; 1,8,9-Trihydroxy-3-methoxycoumestan; Wedelolactone, Eclipta alba; CHEMBL97453; 0K6L725GNS; CHEBI:10037; IKK Inhibitor II, Wedelolactone; 1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c][1]benzopyran-6-one; 1,8,9-trihydroxy-3-methoxy-benzofuro[3,2-c]chromen-6-one; 1,8,9-Trihydroxy-3-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one; AC1NQZ4Z; SCHEMBL601220; GTPL5551; CTK8G3781; DTXSID60200408; Wedelolactone, analyti; 524-12-9; UNII-0K6L725GNS	.	1S/C16H10O7/c1-21-6-2-10(19)14-12(3-6)23-16(20)13-7-4-8(17)9(18)5-11(7)22-15(13)14/h2-5,17-19H,1H3	XQDCKJKKMFWXGB-UHFFFAOYSA-N	COC1=CC(=C2C(=C1)OC(=O)C3=C2OC4=CC(=C(C=C43)O)O)O	C16H10O7	CAS 524-12-9	.	HBIN048224	SMIT00178	MOL003404	D0F8QJ	.	7339	.
NP1217	Polysaccharide	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP1309	Cinchonine	CID: 90454	cinchonine; (+)-Cinchonine; 118-10-5; D-Cinchonine; Cinchonan-9-ol, (9S)-; (9S)-Cinchonan-9-ol; (8R,9S)-Cinchonine; (+)-Cinconine; TCMDC-123933; cinchonin; UNII-V43X79NZCD; (+)-cinchonin; GNF-Pf-3189; MFCD00064372; V43X79NZCD; CHEBI:27509; (S)-quinolin-4-yl((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (1S)-Quinolin-4-yl((2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; NSC6176; .alpha.-Quinidine; (S)-Quinolin-4-yl-(5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; 2-Quinuclidinemethanol, alpha-4-quinolyl-5-vinyl-; NSC-6176; NSC 6176; EINECS 204-234-6; CINCHORINE; PubChem7961; AI3-09058; Prestwick3_000608; 2-Quinuclidinemethanol, .alpha.-4-quinolyl-5-vinyl-; (+)-Cinchonine, 85%; (+)-Cinchonine; >99%; BSPBio_000516; MLS002153907; SCHEMBL158394; 2-Quinuclidinemethanol, alpha-(5-vinyl-2-quinolyl)-; BPBio1_000568; CHEMBL588619; MEGxp0_001905; (S)-Quinolin-4-yl((1S,2R,4S,5S)-5-vinylquinuclidin-2-yl)methanol; DTXSID6045082; ACon0_001352; ACon1_000336; HMS2096J18; HMS2235N18; HY-Y0152; ZINC3881680; (+)-Cinchonine, analytical standard; BDBM50370411; AKOS015895982; EBD2201796; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol; NCGC00169174-01; NCGC00169174-02; NCGC00262542-03; DS-15267; NCI60_005298; SMR001233256; Cinchonine, crystallized, >=98.0% (NT); AB00374715; CS-0008420; WLN: T66 BNJ EYQ-DT66 A B CNTJ A1U1; Q2972710; BRD-K90268819-001-03-4; 2-Quinuclidinemethanol, .alpha.-(5-vinyl-2-quinolyl)-; NCGC00262542-03_C19H22N2O_(9S)-Cinchonan-9-ol; (S)-4-quinolyl-[(2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol; (S)-quinolin-4-yl((2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol	Small molecule	1S/C19H22N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h2-7,9,13-14,18-19,22H,1,8,10-12H2/t13-,14-,18+,19-/m0/s1	KMPWYEUPVWOPIM-QAMTZSDWSA-N	C=CC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O	C19H22N2O	CAS 118-10-5	CHEBI:27509	.	.	.	.	.	.	.
NP1313	Beta caryophyllene	CID: 5281515	BETA-CARYOPHYLLENE; Caryophyllene; (-)-trans-Caryophyllene; 87-44-5; L-Caryophyllene; (-)-beta-caryophyllene; trans-Caryophyllene; (E)-Caryophyllene; (E)-beta-caryophyllene; b-caryophyllene; trans-beta-caryophyllene; Beta-Caryophylene; (-)-Caryophyllene; .beta.-Caryophyllen; .beta.-Caryophyllene; CHEBI:10357; (E)-beta-caryophylene; .beta.-(E)-Caryophyllene; beta-Caryophyllen; (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene; MFCD00075925; UNII-BHW853AU9H; g-Caryophyllene; (1R,9S,E)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; (1S,9R)-6,10,10-trimethyl-2-methylenebicyclo[7.2.0]undec-5-ene; NSC 11906; E-.beta.-caryophyllene; BHW853AU9H; .beta.-Caryophyllene, (-); Tincturoid; NSC11906; Caryophyllene B; beta-cariofillene; (1R,4E,9S)-4,11,11-trimethyl-8-methylene-bicyclo[7.2.0]undec-4-ene; beta-caryophillene; Bicyclo(7.2.0)undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R-(1R*,4E,9S*)]-; E-beta-caryophyllene; Caryophyllene, (E); beta-(e)-caryophyllene; beta-trans-caryophyllene; (-)-  -caryophyllene; (-)-(E)-Caryophyllene; DSSTox_CID_4739; .beta.-trans-Caryophyllene; trans-.beta.-Caryophyllene; (-)-I(2)-caryophyllene; DSSTox_RID_77517; DSSTox_GSID_24739; 8-Methylene-4,11,11-(trimethyl)bicyclo[7.2.0]undec-4-ene; CHEMBL445740; DTXSID8024739; HY-N1415; ZINC8234282; Tox21_301497; BDBM50529607; s6058; (1R,4E,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; AKOS024283988; trans-(1R,9S)-8-Methylene-4,11,11-trimethylbicyclo[7.2.0]undec-4-ene; LMPR0103120001; beta-Caryophyllene, >=80%, FCC, FG; CAS-87-44-5; NCGC00142620-01; NCGC00255159-01; ST072181; (-)-trans-Caryophyllene, analytical standard; CS-0016839; V0915; C09629; Q421614; W-109317; UNII-K4H93P747O component NPNUFJAVOOONJE-GFUGXAQUSA-N; (-)-trans-Caryophyllene, >=98.5% (sum of enantiomers, GC); trans-(1R,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; 8-Methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene, (1R,4E,9S)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R- (1R*,4E,9S*)]-	Small molecule	1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3/b11-6+/t13-,14-/m1/s1	NPNUFJAVOOONJE-GFUGXAQUSA-N	CC1=CCCC(=C)C2CC(C2CC1)(C)C	C15H24	CAS 87-44-5	CHEBI:10357	.	.	.	D53QMP	.	.	.
NP1339	Vitamin C	CID: 54670067	ascorbic acid; vitamin C; l-ascorbic acid; 50-81-7; L(+)-Ascorbic acid; ascorbate; Cevitamic acid; Ascoltin; Ascorbicap; Cenolate; Natrascorb; Hybrin; Allercorb; Ascorbajen; Ascorbutina; Ascorteal; Cescorbat; Cetemican; Cevitamin; Citriscorb; Laroscorbine; Lemascorb; Proscorbin; Roscorbic; Secorbate; Testascorbic; Vitacimin; Vitamisin; Vitascorbol; Ascorin; Ascorvit; Cantaxin; Cebicure; Cebione; Cegiolan; Ceglion; Celaskon; Cemagyl; Cenetone; Cergona; Cetamid; Cevalin; Cevatine; Cevimin; Cevital; Cevitan; Cevitex; Colascor; Concemin; Redoxon; Vicelat; Viforcit; Viscorin; Vitacee; Vitacin; Adenex; Ascorb; Cantan; Cebid; Cebion; Cecon; Cemill; Cereon; Cevex; Ciamin; Cipca; Hicee; Ribena; Vitace; Xitix; L-ascorbate; Davitamon C; Arco-cee; Planavit C; Catavin C; Ce lent; Liqui-Cee; Vicomin C; Cee-Vite; Cevi-Bid; Scorbu-C; C-Level; C-Vimin; Cetane-Caps TD; Duoscorb; Scorbacid; Cewin; Antiscorbic vitamin; C-Long; C-Quin; C-Span; Meri-C; Cee-Caps TD; L-Lyxoascorbic acid; L-Xyloascorbic acid; Antiscorbutic vitamin; Cetane-Caps TC; 3-Oxo-L-gulofuranolactone; Ce-Mi-Lin; IDO-C; Natrascorb injectable; L-(+)-Ascorbic Acid; CE-VI-Sol; Ferrous ascorbate; Acidum ascorbinicum; Ascor-B.I.D.; Acidum ascorbicum; Celin; Dora-C-500; Kyselina askorbova; 3-Keto-L-gulofuranolactone; Cortalex; Ferancee; Stuartinic; Tolfrinic; (R)-5-((S)-1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one; Acido ascorbico; Acide ascorbique; Antiscorbutic factor; L-3-Ketothreohexuronic acid lactone; L-Threoascorbic acid; Chromagen; Kyselina askorbova [Czech]; Caswell No. 061B; Vicin; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; Sodascorbate; Ascorbicin; NCI-C54808; L-threo-Hex-2-enonic acid, gamma-lactone; L-threo-Ascorbic acid; FEMA No. 2109; 3-Oxo-L-gulofuranolactone (enol form); UNII-PQ6CK8PD0R; monodehydro-L-ascorbic acid; MFCD00064328; Cetebe; Ascorbin; (+)-Ascorbic acid; Hex-2-enonic acid gamma-lactone, L-threo-; Iron(II) ascorbate; PQ6CK8PD0R; component of E and C-Level; component of Endoglobin Forte; Vasc; Ascorbicab; CHEBI:29073; CCRIS 57; component of Cortalex; component of Ferancee; HSDB 818; NCGC00164357-01; E300; DSSTox_CID_106; E-300; hex-1-enofuranos-3-ulose; Iron-ascorbic acid complexes; DSSTox_RID_75370; DSSTox_GSID_20106; Kangbingfeng; Chewcee; Citrovit; Juvamine; 6730-29-6; Ceklin; L(+)-Ascorbic acid, 99%; (+)-Sodium L-ascorbate; Rovimix C; Scorbu C; Ascorbinsaeure; Parentrovite; Cell C; L(+)-Ascorbic acid, ACS reagent; Viscorin 100M; (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one; Ronotec 100; Suncoat VC 40; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one; Rontex 100; Ascorbicap (TN); Xyloascorbic acid, L-; Ascoltin (TN); [14C]ascorbic acid; Ascorbic acid [BAN:INN:JAN]; Vitamin C (Ascorbic acid); [14C]-ascorbic acid; ascorbic acid (vit C); L-Ascorbic acid, meets USP testing specifications; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; 299-36-5; EINECS 200-066-2; NSC 33832; Cevitamate; Ascor; L-lyxoascorbate; L-xyloascorbate; .Ascorbinsaure; NSC-33832; Vitamin B mixture with vitamin C; 3eka; NSC-218455; Ester C; Ester-C; (+)-ascorbate; L(+)-ascorbate; L-threo-hex-2-enono-1,4-lactone; L-Ascorbic acid, free radical form; L-(+)-ascorbate; Ascorbic acid [USP:INN:BAN:JAN]; Ascorbic acid mixture with Vitamin B; Vitamin C,(S); E 300; 178101-88-7; PubChem18445; Ascorbic Acid DC97SF; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; Prestwick3_000325; L-Ascorbic acid, 99%; Ascorbic Acid mixture with Vitamin B Complex; ASCOR (TN); SCHEMBL785; bmse000182; SCHEMBL4430; L-Ascorbic acid, FCC, FG; BSPBio_000329; (r)-5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5h-furan-2-one; MLS002153776; CHEMBL40274; BPBio1_000363; GTPL4532; GTPL4781; INS NO.300; L-Ascorbic acid, reagent grade; DTXSID5020106; L-Ascorbic acid, >=99.0%; DTXSID50986567; INS-300; Ascorbic acid (JP17/USP/INN); HMS2096A11; HMS2231N16; HMS3713A11; L-Ascorbic acid ACS reagent grade; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; BCP27915; HY-B0166; Tox21_110315; Tox21_112104; Tox21_202127; Tox21_302958; ANW-73969; gamma-lactone L-threo-Hex-2-enonate; L-Ascorbic acid, analytical standard; L-Ascorbic acid, AR, >=99.5%; s3114; AKOS016843589; Tox21_112104_1; ZINC100006770; ZINC100019304; CCG-207946; DB00126; L-Ascorbic acid, mixt. with vitamin B; NSC 218455; gamma-lactone L-threo-Hex-2-enonic acid; L-Ascorbic acid, ACS reagent, >=99%; NCGC00091517-01; NCGC00091517-02; NCGC00091517-03; NCGC00091517-06; NCGC00188972-01; NCGC00256504-01; NCGC00259676-01; 53262-66-1; BP-12831; SMR001233160; L-Ascorbic acid, plant cell culture tested; AB0010512; L-Ascorbic acid, reagent grade, crystalline; A0537; A8158; AB00376923; Ascorbic Acid (L-Ascorbic Acid; Vitamin C); SW198791-2; L-Ascorbic acid, BioUltra, >=99.5% (RT); L-Ascorbic acid, tested according to Ph.Eur.; 3466-EP2269610A2; 3466-EP2269978A2; 3466-EP2269985A2; 3466-EP2269988A2; 3466-EP2269991A2; 3466-EP2270000A1; 3466-EP2270002A1; 3466-EP2270008A1; 3466-EP2270011A1; 3466-EP2270505A1; 3466-EP2272516A2; 3466-EP2272537A2; 3466-EP2272822A1; 3466-EP2272834A1; 3466-EP2272835A1; 3466-EP2272844A1; 3466-EP2275413A1; 3466-EP2277848A1; 3466-EP2277865A1; 3466-EP2281823A2; 3466-EP2284149A1; 3466-EP2284150A2; 3466-EP2284151A2; 3466-EP2284152A2; 3466-EP2284153A2; 3466-EP2284155A2; 3466-EP2284156A2; 3466-EP2284164A2; 3466-EP2284171A1; 3466-EP2284178A2; 3466-EP2284179A2; 3466-EP2287140A2; 3466-EP2287148A2; 3466-EP2287150A2; 3466-EP2287153A1; 3466-EP2287156A1; 3466-EP2289510A1; 3466-EP2289883A1; 3466-EP2289890A1; 3466-EP2289892A1; 3466-EP2292227A2; 3466-EP2292228A1; 3466-EP2292592A1; 3466-EP2292612A2; 3466-EP2292617A1; 3466-EP2295055A2; 3466-EP2295401A2; 3466-EP2295409A1; 3466-EP2295416A2; 3466-EP2295419A2; 3466-EP2295426A1; 3466-EP2295427A1; 3466-EP2295435A1; 3466-EP2298735A1; 3466-EP2298742A1; 3466-EP2298748A2; 3466-EP2298768A1; 3466-EP2298770A1; 3466-EP2298776A1; 3466-EP2301536A1; 3466-EP2301538A1; 3466-EP2301929A1; 3466-EP2301931A1; 3466-EP2301935A1; 3466-EP2301940A1; 3466-EP2305219A1; 3466-EP2305257A1; 3466-EP2305636A1; 3466-EP2305637A2; 3466-EP2305648A1; 3466-EP2305651A1; 3466-EP2305668A1; 3466-EP2305674A1; 3466-EP2305679A1; 3466-EP2305683A1; 3466-EP2308854A1; 3466-EP2308857A1; 3466-EP2308861A1; 3466-EP2308867A2; 3466-EP2308870A2; 3466-EP2311453A1; 3466-EP2311455A1; 3466-EP2311805A1; 3466-EP2311807A1; 3466-EP2311809A1; 3466-EP2311824A1; 3466-EP2311839A1; 3466-EP2311842A2; 3466-EP2314295A1; 3466-EP2314584A1; 3466-EP2314585A1; 3466-EP2314588A1; 3466-EP2314589A1; 3466-EP2314590A1; 3466-EP2314593A1; 3466-EP2316452A1; 3466-EP2316457A1; 3466-EP2316458A1; 3466-EP2316470A2; 3466-EP2316825A1; 3466-EP2316826A1; 3466-EP2316827A1; 3466-EP2316828A1; 3466-EP2316832A1; 3466-EP2316833A1; 3466-EP2316837A1; 3466-EP2374792A1; 3466-EP2377510A1; 3466-EP2380568A1; C 1000; C00072; D00018; L-Ascorbic acid, p.a., ACS reagent, 99.0%; 93398-EP2380568A1; AB00376923_04; AB00376923_05; L-Ascorbic acid 1000 microg/mL in Acetonitrile; L-Ascorbic acid, JIS special grade, >=99.0%; L-Ascorbic acid, Vetec(TM) reagent grade, 99%; L-Ascorbic acid, BioXtra, >=99.0%, crystalline; Q199678; L-Ascorbic acid, puriss. p.a., >=99.0% (RT); Q27101942; 47A605F0-4187-47A8-B0CE-F9E7DA1B0076; L-Ascorbic acid, p.a., ACS reagent, reag. ISO, 99.7%; Ascorbic acid, British Pharmacopoeia (BP) Reference Standard; Ascorbic acid, European Pharmacopoeia (EP) Reference Standard; L-Ascorbic acid, certified reference material, TraceCERT(R); L-Ascorbic acid, powder, cell culture tested, gamma-irradiated; 3,4-Dihydroxy-5beta-[(S)-1,2-dihydroxyethyl]furan-2(5H)-one; Ascorbic acid, United States Pharmacopeia (USP) Reference Standard; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxy-2,3-dihydrofuran-3-one; 4-((E)-2-[(2-HYDROXYETHYL)SULFANYL]DIAZENYL)BENZENECARBOXYLICACID; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one (non-preferred name); L-Ascorbic acid solution, 1.0 mg/mL in acetonitrile: water, certified reference material; L-Ascorbic acid, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; L-Ascorbic acid, suitable for cell culture, suitable for plant cell culture, >=98%; L-Ascorbic Acid (Vitamin C)-13C6 solution, 500 mug/mL in acetonitrile: water, certified reference material, ampule of 1 mL; L-Ascorbic acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.7-100.5% (oxidimetric); Valeryl fentanyl hydrochloride solution, 100 mug/mL in methanol (as a free base), certified reference material, ampule of 0.5 mL	Small molecule	1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1	CIWBSHSKHKDKBQ-JLAZNSOCSA-N	C(C(C1C(=C(C(=O)O1)O)O)O)O	C6H8O6	CAS 50-81-7	CHEBI:29073	.	.	.	D07AHW	.	.	.
NP1351	Mupirocin	CID: 446596	Mupirocin; 12650-69-0; Pseudomonic acid; Bactroban; Mupirocine; Centany; Pseudomonic acid A; Mupirocina; Mupirocinum; BRL 4910A; BRL-4910A; UNII-D0GX863OA5; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid; Bactroban (TN); CHEMBL719; CHEBI:7025; D0GX863OA5; MRC; Bactoderm; 6-Chloro-2,4-dimethoxy pyrimidine; MFCD01711620; NCGC00164554-03; Plasimine; mupirocin calcium salt; 9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid; L-talo-Non-2-enonic acid, 5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]-3-methyl-, 8-carboxyoctyl ester, (2E)-; Mupirocine [French]; Mupirocinum [Latin]; Mupirocina [Spanish]; C26H44O9; Bactroban Ointment; BRL-4910F; 80558-54-9; Centany (TN); trans-Pseudomonic acid; Mupirocin Neo-Sensitabs; Mupirocin (USP/INN); SR-05000001947; 115074-43-6; 73346-79-9; 1jzs; Mupirocin [USAN:USP:INN:BAN]; Mupirocin,(S); 9-((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid; mupirocin lithium salt; CPD000471888; SCHEMBL3291; DSSTox_CID_26438; DSSTox_RID_81614; DSSTox_GSID_46438; 8-Carboxyoctyl (E)-4-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2H-pyran-2-yl)-3-methylcrotonat; MLS001074711; BIDD:GT0320; Mupirocin, Pseudomonic Acid A; cid_446596; SCHEMBL1027618; Pseudomonic acid A lithium salt; DTXSID0046438; CHEBI:94519; GTPL10916; AOB6353; HMS2234E20; HMS3259L05; HMS3712K03; Pharmakon1600-01505706; HY-B0958; ZINC4102194; Tox21_112183; BDBM50290686; MFCD11977847; NSC759182; NSC815348; AKOS015994756; Mupirocin, >=92% (HPLC), powder; CCG-213522; DB00410; KS-5137; NC00620; NSC 759182; NSC-759182; NSC-815348; NCGC00164554-05; NCGC00164554-06; (E)-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl)tetrahydro-3,4-dihydroxy-beta-methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid; AS-11580; SMR000471888; SBI-0206892.P001; AB0010371; CAS-12650-69-0; M2955; S4297; C11758; D01076; M-8680; AB01563109_01; Mupirocin, Antibiotic for Culture Media Use Only; Q413578; SR-05000001947-1; SR-05000001947-2; BRD-K15262564-001-06-9; Mupirocin, United States Pharmacopeia (USP) Reference Standard; 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-enonic acid 8-carboxyoctyl ester; 9-((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid; 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic acid; 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid calcium salt; 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid lithium salt; 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl}oxy)nonanoic acid; 9-(4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid; 9-(4-{3,4-Dihydroxy-5-[3-(2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic acid (Mupirocin); 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methyl-propyl]oxiran-2-yl]methyl]tetrahydropyran-2-yl]-3-methyl-but-2-enoyl]oxynonanoic acid; 9-{[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-{[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl}oxan-2-yl]-3-methylbut-2-enoyl]oxy}nonanoic acid; Nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2H-pyran-2-yl)-2-butenyl)oxy)-, (2S-(2alpha(E),3beta,4beta,5alpha(2R*,3R*(1R*,2R*))))-; rel-9-(((E)-4-((2S,3R,4R,5S)-3,4-Dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid	Small molecule	1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1	MINDHVHHQZYEEK-HBBNESRFSA-N	CC(C1C(O1)CC2COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)O)C)C(C)O	C26H44O9	CAS 12650-69-0	CHEBI:7025	.	.	.	D03JSJ	.	.	.
NP1359	Olmesartan	CID: 158781	Olmesartan; 144689-24-7; Olmesartan Acid; RNH-6270; RNH 6270; UNII-8W1IQP3U10; CS-088; 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; CHEMBL1516; 8W1IQP3U10; CHEBI:48416; MFCD00914967; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; Olmesartan-d6 Acid; Votum; 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; omesartan; Olme sartan; 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; SMR000466337; 1420880-41-6; Olmesartan [USAN:INN:BAN]; Benicar;Olmetec; HSDB 8214; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; Olmesartan medoximil; Diclofenacdiethylamine; Olmesartan (USAN/INN); EC 646-413-5; SCHEMBL94037; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; cc-480; MLS000759446; MLS001424016; MLS006011945; DTXSID2040571; Olmesartan, >=98% (HPLC); HMS2051K12; HMS2235O24; HMS3369I09; HMS3393K12; HMS3604J06; Pharmakon1600-01505206; ZINC538621; BCP12007; 3949AH; BDBM50241364; DE-092; NSC759810; s5581; AKOS015900241; AKOS024458255; Olmesartan (RNH6270, CS 088); AC-9385; CCG-100868; CCG-269198; CS-0576; DB00275; MCULE-9101392328; NC00118; NSC 759810; NSC-759810; NCGC00246968-01; NCGC00246968-02; NCGC00246968-04; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-; 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid; AK546552; AS-10242; HY-17004; Olmesartan medoxomil impurity, olmesartan-; SMR004703526; AB0109206; DB-042742; FT-0631169; O-125; O0507; C21543; D05246; W-5216; 54247-EP2295422A2; 54247-EP2308562A2; 689O247; L001097; Q421156; W-201270; Z1583819783; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate; 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole -5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (Olmesartan); 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)-1,1''-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[2,3,5,6-tetradeuterio-4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid.; OLM	Small molecule	1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)	VTRAEEWXHOVJFV-UHFFFAOYSA-N	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O	C24H26N6O3	CAS 144689-24-7	CHEBI:48416	.	.	.	.	.	.	.
NP1406	Cryptotanshinone	CID: 160254	Cryptotanshinone; 35825-57-1; Tanshinone c; (R)-1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl-phenanthro(1,2-b)furan-10,11-dione; Cryptotanshinon; UNII-5E9SXT166N; C19H20O3; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione; MLS001049002; 5E9SXT166N; MFCD07636810; SMR000387041; (R)-1,6,6-trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione; Phenanthro[1,2-b]furan-10,11-dione,1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (R)-; 1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl[1,2-b]furan-10,11-dione; (-)-Cryptotanshinone; SR-01000758222; NSC686518; SPECTRUM1505812; CHEMBL187460; cid_160254; SCHEMBL5940386; BDBM57938; CHEBI:149838; Phenanthro(1,2-b)furan-10,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (R)-; HMS2269A22; BCP02909; Cryptotanshinone, >=90% (HPLC); Cryptotanshinone, >=98% (HPLC); HY-N0174; ZINC2109876; Cryptotanshinone, analytical standard; ANW-46875; s2285; AKOS015895392; BCP9000554; CCG-208561; CS-3276; DB15579; MCULE-9919031730; NSC-686518; NCGC00163650-01; NCGC00163650-02; 4733-35-1; BS-17094; NCI60_031208; BCP0726000307; N1843; W2147; 825C571; Q-100429; SR-01000758222-3; SR-01000758222-4; BRD-K33336844-001-05-3; Q27261913; Phenanthro[1,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (1R)-; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g]benzofuran-10,11-dione; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g]benzofuran-10,11-quinone; (R)-(-)-1,6,6-Trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione; (R)-1,2,6,7,8,9-Hexahydro-1,6,6-trimethylphenanthro[1,2-b]furan-10,11-dione; 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl- (R)-phenanthro(1,2-b)furan-10,11-dione	Small molecule	1S/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,10H,4-5,8-9H2,1-3H3/t10-/m0/s1	GVKKJJOMQCNPGB-JTQLQIEISA-N	CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C	C19H20O3	CAS 35825-57-1	CHEBI:149838	.	.	.	.	.	.	.
NP1411	Theanine	CID: 439378	L-Theanine; Theanine; 3081-61-6; Theanin; N-Ethyl-L-glutamine; Suntheanine; (S)-2-Amino-5-(ethylamino)-5-oxopentanoic acid; N5-Ethyl-L-glutamine; L-gamma-Glutamylethylamide; N(5)-ethyl-L-glutamine; N-gamma-Ethyl-L-glutamine; UNII-8021PR16QO; (2S)-2-amino-5-(ethylamino)-5-oxopentanoic acid; CHEBI:17394; L-Glutamic acid ?-(ethylamide); 8021PR16QO; L-Theanine, 98%; N(5)-ethyl-L-glutamine zwitterion; CCRIS 7326; EINECS 221-379-0; NSC 21308; n-ethylglutamine; L-Theamine; MFCD00059653; NSC-21308; HSDB 8166; (+)-Theanine; N?-Ethyl-L-glutamine; H-Glu(NHEt)-OH; PubChem13022; N-?-Ethyl-L-glutamine; Spectrum2_001693; Spectrum3_001137; Spectrum4_001984; Spectrum5_000897; Glutamine, N-gamma-ethyl-; Glutamine, N-ethyl-, L-; BSPBio_002633; KBioGR_002514; SCHEMBL190716; SPECTRUM1505254; SPBio_001646; EBD678; CHEMBL3039113; KBio3_002133; DTXSID80184817; L-glutamic acid -r-monoethylamide; L-Theanine, >=98% (HPLC); BCP28252; ZINC1532828; ANW-26983; CCG-38778; CT0238; s3852; AKOS016842508; AM82649; DB12444; L-Theanine (Ngamma-ethyl-L-glutamine); SDCCGMLS-0066811.P001; NCGC00178565-01; AC-23939; AS-12265; HY-15121; AB0006097; CS-0003777; N2085; C01047; 081T616; A820634; Q909931; SR-05000002409; Q-201330; SR-05000002409-1; (2S)-2-azanyl-5-(ethylamino)-5-oxidanylidene-pentanoic acid; C6B5A580-D410-4464-ADB8-543860137D4C; L-Theanine, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C7H14N2O3/c1-2-9-6(10)4-3-5(8)7(11)12/h5H,2-4,8H2,1H3,(H,9,10)(H,11,12)/t5-/m0/s1	DATAGRPVKZEWHA-YFKPBYRVSA-N	CCNC(=O)CCC(C(=O)O)N	C7H14N2O3	CAS 3081-61-6	CHEBI:17394	.	.	.	.	.	.	.
NP1427	Estramustine	CID: 259331	estramustine; 2998-57-4; Estramustina; Estramustinum; Emcyt; Estramustinum [INN-Latin]; Estramustina [INN-Spanish]; UNII-35LT29625A; Estradiol 3-(N,N-bis(2-chloroethyl)carbamate); 17beta-Estradiol 3-(bis(2-chloroethyl)carbamate); CHEMBL1575; Estradiol 3-[bis(2-chloroethyl)carbamate]; CHEBI:4868; NSC-89201; 35LT29625A; [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate; LEO 275; NCGC00164581-01; Estradiol 3-(bis(2-chloroethyl)carbamate); Estradiol, 3-[bis(2-chloroethyl)carbamate]; Ro 22-2296/000; DSSTox_CID_26458; DSSTox_RID_81632; DSSTox_GSID_46458; (8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl bis(2-chloroethyl)carbamate; RO 21-8837; NSC 89201; estra-1,3,5(10)-triene-3,17beta-diol, 3-[bis(2-chloroethyl)carbamate]; C23H31Cl2NO3; CAS-2998-57-4; Estradiol, 3-(bis(2-chloroethyl)carbamate); Estradiol 3-[N,N-Bis(2-chloroethyl)carbamate]; MLS002701936; 17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate]; Estramustine (USAN/INN); estramustin; NSC89201; Estramustine [USAN:INN:BAN]; EINECS 221-076-3; SCHEMBL4252; Estramustin Sodium Phosphate; BIDD:GT0482; GTPL9076; DTXSID8046458; HMS3715D22; ZINC4099032; Tox21_112207; BDBM50333646; LMST02010038; (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate; AKOS025402444; Tox21_112207_1; AC-9163; CCG-221220; DB01196; NCGC00164581-02; AS-12259; NCI60_041982; Ro-222296000; Ro-22-2296000; Ro-22-2296-000; C11228; D04066; 15163-EP2272827A1; 15163-EP2275420A1; 15163-EP2295055A2; 15163-EP2295416A2; 15163-EP2298748A2; 15163-EP2298764A1; 15163-EP2298765A1; 15163-EP2305642A2; 15163-EP2308833A2; 15163-EP2308861A1; 15163-EP2311453A1; 15163-EP2311840A1; 15163-EP2316832A1; 15163-EP2316833A1; 998E574; Q412939; W-106963; Carbamic acid, bis(2-chloroethyl)-, 17beta-hydroxyestra-1,3,5(10)-trien-3-yl ester; Estra-1,3,5(10)-triene-3,17-diol (17beta)-, 3-(bis(2-chloroethyl)carbamate) (9CI); Estra-1,3,5(10)-triene-3,17-diol, 3-(bis(2-chloroethyl)carbamate), (17beta)-; Estra-1,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]; Estra-1,5(10)-triene-3,17-diol, 3-[bis(2-chloroethyl)carbamate], (17.beta.)-; Bis-(2-chloro-ethyl)-carbamic acid 17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl ester	Small molecule	1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1	FRPJXPJMRWBBIH-RBRWEJTLSA-N	CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl	C23H31Cl2NO3	CAS 2998-57-4	CHEBI:4868	.	.	.	D03SRY	.	.	.
NP1431	Orientin	CID: 5281675	Orientin; 28608-75-5; Lutexin; Luteolin-8-glucoside; Luteolin 8-C-glucoside; UNII-IAX93XCW6C; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-8-beta-D-glucopyranosyl-5,7-dihydroxy-; 8-beta-D-glucosylluteolin; IAX93XCW6C; CHEBI:7781; MFCD00017432; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; Orientin (Flavone); 8-glucosylluteolin; Orientine; Luteolin-8-C-glucoside; Luteolin 8-C-beta-D-glucopyranoside; 2-(3,4-dihydroxyphenyl)-8-beta-D-glucopyranosyl-5,7-dihydroxy-4H-chromen-4-one; NSC-133101; 8-beta-D-Glucopyranosyl-3',4',5,7-tetrahydroxyflavone; 2-(3,4-Dihydroxyphenyl)-8-beta-D-glucopyranosyl-5,7-dihydroxy-4H-1-benzopyran-4-one; SCHEMBL25942; Orientin, analytical standard; CHEMBL520866; Orientin, >=97% (HPLC); BDBM84982; DTXSID60182790; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-8-.beta.-D-glucopyranosyl-5,7-dihydroxy-; HMS3886J16; HY-N0405; ZINC4098560; s9099; AKOS015896746; CCG-269214; AS-73888; CS-0008937; Y0149; A12096; C10114; 608O755; A819507; Orientin, primary pharmaceutical reference standard; Q421676; Q-100362; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; 2-[3,4-bis(oxidanyl)phenyl]-8-[(2S,3R,4R,5S,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-5,7-bis(oxidanyl)chromen-4-one	Small molecule	1S/C21H20O11/c22-6-14-17(28)18(29)19(30)21(32-14)16-11(26)4-10(25)15-12(27)5-13(31-20(15)16)7-1-2-8(23)9(24)3-7/h1-5,14,17-19,21-26,28-30H,6H2/t14-,17-,18+,19-,21+/m1/s1	PLAPMLGJVGLZOV-VPRICQMDSA-N	C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4C(C(C(C(O4)CO)O)O)O)O)O	C21H20O11	CAS 28608-75-5	CHEBI:7781	.	.	.	.	.	.	.
NP1489	Tropisetron	CID: 656665	tropisetron; 89565-68-4; Tropisetronum; Tropisteron; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; UNII-6I819NIK1W; Novaban; ICS 205930; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate; Navoban (TN); ICF 205-930; CHEMBL56564; beta-Tropisetron; 6I819NIK1W; CHEBI:32269; Tropisetron (INN); DSSTox_CID_24137; DSSTox_RID_80108; DSSTox_GSID_44137; 1alphaH,5alphaH-Tropan-3alpha-yl indole-3-carboxylate; 1H-indole-3-carboxylic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester; TKT; Lopac-T-104; CAS-89565-68-4; Tropisetron [INN:BAN]; ICS-205930; Tropisetronum [INN-Latin]; NCGC00015984-03; ICS-205-930; SCHEMBL18297; SCHEMBL18298; SCHEMBL18299; GTPL260; ics205-930; SCHEMBL3953452; CHEMBL1289230; DTXSID2044137; SCHEMBL13287285; CHEBI:94647; HMS2090D16; HMS3886M10; HY-B0072; Tox21_110272; BDBM50108392; PDSP1_000776; PDSP2_000764; s5538; ZINC18130447; AKOS015969677; Tox21_110272_1; ZINC100019233; ZINC100023360; CCG-267308; CS-1146; DB11699; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-; NCGC00015984-01; NCGC00015984-04; NCGC00161414-01; NCGC00161414-03; NCGC00390718-01; H833; C13666; D02130; Q29428; W-5128; AB00698553-07; AB00698553-09; 565T684; BRD-K50866992-003-09-5; BRD-K50866992-003-10-3; Q27166461; 1H-Indole-3-carboxylic acid (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octane-3-yl ester	Small molecule	1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?	ZNRGQMMCGHDTEI-FUNVUKJBSA-N	CN1C2CCC1CC(C2)OC(=O)C3=CNC4=CC=CC=C43	C17H20N2O2	CAS 89565-68-4	CHEBI:32269	.	.	.	D0K0KH	.	.	.
NP1541	6-shogaol	CID: 5281794	Shogaol; 555-66-8; [6]-Shogaol; (6)-Shogaol; enexasogaol; Trans-6-Shogaol; 23513-13-5; (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one; UNII-83DNB5FIRF; 1-(4-Hydroxy-3-methoxyphenyl)-4-decen-3-one; CHEBI:10138; Shogaol (6-Shogaol); 1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one; 83DNB5FIRF; CHEMBL25948; (4E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one; 4-DECEN-3-ONE, 1-(4-HYDROXY-3-METHOXYPHENYL)-; CCRIS 2038; 6-Shogaol (constituent of ginger) [DSC]; SCHEMBL49054; (E)-1-(4-Hydroxy-3- methoxyphenyl)dec-4-en-3-one; GTPL9773; MEGxp0_001217; Shogaol, >=90% (HPLC); 4-Decen-3-one, 1-(4-hydroxy-3-methoxyphenyl)-, (E); ACon1_001190; 4-Decen-3-one, 1-(4-hydroxy-3-methoxyphenyl)-, (4E)-; [6]-Shogaol, analytical standard; ZINC1531865; BDBM50237536; BDBM50240419; MFCD01736094; NSC752389; AKOS015888385; CCG-267210; CS-6175; MCULE-3275039845; NSC-752389; NCGC00169591-01; AS-55975; HY-14616; N2449; S9043; X1222; Y8376; A14648; C10494; 4-Decen-3-one, 1-(4-hydroxy-3-methoxyphenyl); 555S668; Q-100639; Q2746448; W-206831; BRD-K23331196-001-01-9; (E)-1-(4-Hydroxy-3-methoxy-phenyl)-dec-4-en-3-one; [(E)-1-(4-hydroxy-3-methoxyphenyl)-dec-4-en-3-one]; 1-(4-Hydroxy-3-methoxyphenyl)-4-dodecen-3-one, 9CI	.	1S/C17H24O3/c1-3-4-5-6-7-8-15(18)11-9-14-10-12-16(19)17(13-14)20-2/h7-8,10,12-13,19H,3-6,9,11H2,1-2H3/b8-7+	OQWKEEOHDMUXEO-BQYQJAHWSA-N	CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC	C17H24O3	CAS 555-66-8	.	HBIN012818	SMIT00160	MOL002495	.	.	2551	.
NP1549	Naringenin	CID: 932	5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone	.	1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2	FTVWIRXFELQLPI-UHFFFAOYSA-N	C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O	C15H12O5	CAS 67604-48-2	.	HBIN036366	SMIT00202	MOL004328	D02ABO	.	139	.
NP1552	Furanodiene	CID: 636458	Isofuranodiene; Furanodiene; 57566-47-9; 19912-61-9; Furanoelemene (furanodiene); CHEMBL324514; SCHEMBL22491603; CHEBI:80824; ZINC6072098; W2263; C16959; (5E)-3,6,10-trimethyl-4,7,8,11-tetrahydrocyclodeca[b]furan	Small molecule	1S/C15H20O/c1-11-5-4-6-12(2)9-15-14(8-7-11)13(3)10-16-15/h6-7,10H,4-5,8-9H2,1-3H3/b11-7+,12-6+	VMDXHYHOJPKFEK-IAVOFVOCSA-N	CC1=CCC2=C(CC(=CCC1)C)OC=C2C	C15H20O	CAS 57566-47-9	CHEBI:80824	.	.	.	.	.	.	.
NP1559	Luteolin	CID: 5280445	Luteolol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Luteoline; Digitoflavone; Flacitran; Weld Lake; Cyanidenon 1470; Salifazide; Yama kariyasu; 5,7,3',4'-Tetrahydroxyflavone; UNII-KUX1ZNC9J2; CI Natural Yellow 2; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 7-Tetrahydroxyflavone; CCRIS 3790; EINECS 207-741-0; KUX1ZNC9J2; CHEMBL151; BRN 0292084; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one	.	1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H	IQPNAANSBPBGFQ-UHFFFAOYSA-N	C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O	C15H10O6	CAS 491-70-3	.	HBIN033803	SMIT00002	MOL000006	D04AIT	.	841	.
NP1591	Reserpine	CID: 5770	reserpine; 50-55-5; Serpalan; Serpasil; Serpivite; Apoplon; Hypersil; Alserin; Elserpine; Hiserpia; Raunervil; Raupasil; Rausedil; Rausedyl; Rauwasedin; Reserpin; Serpanray; Resine; Rivasin; Sandril; Serpate; (-)-Reserpine; Rau-Sed; Ascoserpina; Austrapine; Bioserpine; Enipresser; Eskaserpine; Helfoserpin; Hiposerpil; Maviserpin; Mayserpine; Mephaserpin; Purserpine; Rauserpine; Reserpamed; Reserpanca; Alkarau; Apsical; Banasil; Benazyl; Carditivo; Carrserp; Escaspere; Eserpine; Eskaserp; Hypersine; Idsoserp; Interpina; Lemiserp; Loweserp; Neoserfin; Neoserp; Quiescin; Raudiford; Raudixoid; Rauloydin; Raumorine; Raunorine; Raupoid; Raurine; Rausedan; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwilid; Rauwipur; Rauwoleaf; Rawilid; Resedrex; Reserbal; Resercaps; Resercen; Reserjen; Reserlor; Reserpal; Reserpene; Reserpex; Reserpil; Reserpina; Reserpoid; Respital; Restran; Riserpa; Roxinoid; Kitine; Raucap; Raugal; Raulen; Rausan; Reserp; Key-serpine; 3P Reserp; Crystoserpine; Neo-antitensol; Rauserpin-Alk; Deserpine; Ryser; Reserfia; 3,4,5-Trimethoxybenzoyl methyl reserpate; V-Serp; Carpacil; Gilucard; Klimanosid; Resaltex; Resedril; Reserpidefe; Recipin; Serpine; ENT 50146; Raunova; Residin; Serpivate; Rese-lar; Reser-ar; NCI-C50157; H 520; UNII-8B1QWR724A; Sedaraupina; Temposerpine; Eberpine; Raudixin; Reserpur; Residine; Resocalm; Resperine; Rezerpin; Sandron; Sedaraupin; Sedserp; Serfolia; Serolfia; Serpaloid; Serpasol; Serpazol; Serpena; Serpentil; Serpentina; Serpicon; Serpiloid; Serpogen; Serpoid; Serpone; Sertabs; Sertens; Sertina; Triserpin; Unilord; Serfin; Serpen; Roxel; Vio-Serpine; SK-Reserpine; Renese R; T-Serp; C33H40N2O9; MFCD00005091; CHEMBL772; Broserpine; R-e-s; Reserpinum; Sederaupin; Serpaneurona; Tefaserpina; Tenserpinie; Tepserpine; Eberspine; Reserpka; Resiatric; Resperin; Rivased; Rolserp; Roxynoid; Serpazil; Serpedin; Serpentin; Serpipur; Serpyrit; Sertensin; Serpil; Tempo-Reserpina; 8B1QWR724A; 50-55-5 (free); Mallopress; Rcra waste number U200; Hydropine; Hydroserp; Rauwita; .gamma.-Serpine; CHEBI:28487; Hydromox-R; Diurese-R; NSC59272; Metatensin #2; Metatensin #4; NSC-59272; component of Naquival; component of Regroton; Hydropres 25; Hydropres 50; Hydrosine 25; NSC-237659; (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; methyl (1S,2R,3R,4aS,13bR,14aS)-2,11-dimethoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate; methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Usaf cb-27; component of Renese R; component of Metatensin; NCGC00091250-04; Hydroserpalan; Diupres 250; Diupres 500; l-Carpserp; component of Butiserpazide; DSSTox_CID_1237; Hydroserpine Plus; Hydroserpine #1; DSSTox_RID_76029; DSSTox_GSID_21237; Chloroserp-250; Chloroserp-500; Chloroserpin-250; Serpasil premix; Chloroserpine-500; Hydro-Reserpine-25; Hydro-Reserpine-50; Hydro-Fluserpine #1; l -Carpserp; Caswell No. 722A; Serp-AFD; Reserpina [INN-Spanish]; 3,5-Trimethoxybenzoyl methyl reserpate; (1S,2R,3R,4aS,13bR,14aS)-methyl 2,11-dimethoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate; methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate; methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-bis(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; SMR000059122; Yohimban-16-carboxylic acid,11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester,(3b,16b,17a,18b,20a)-; Apoplon (TN); CCRIS 550; Serpine (pharmaceutical); HSDB 213; Methyl reserpate 3,5-trimethyloxybenzoic acid; 11,17-Dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohimban-16-carboxylic acid methyl ester; Methyl reserpate 3,5-trimethoxybenzoic acid ester; EINECS 200-047-9; RCRA waste no. U200; EPA Pesticide Chemical Code 123101; NSC 237659; BRN 0102014; AI3-50146; Reserpine/; WLN: T F6 D5 C666 EM ON&&TTTJ HO1 SOVR CO1 DO1 EO1& TO1 UVO1; Reserpine [USP:INN:BAN:JAN]; CAS-50-55-5; Reserpine,(S); Serpalan (TN); 3-.beta., 18-.beta.-hydroxy-11,17-.alpha.-dimethoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester); 3.beta., 18.beta.-hydroxy-11,17.alpha.-dimethoxy- methyl ester 3,4,5-trimethoxybenzoate (ester); Benz[g]indolo[2, 1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-3-hydroxy-2,11-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate; methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-{[(3,4,5-trimethoxyphenyl)carbonyl]oxy}yohimban-16-carboxylate; Yohimban-16-carboxylic acid,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester, (3.beta.,16.beta.,17.alpha.,18.beta.,20.alpha.)-; Prestwick_147; Methyl reserpate 3,4,5-trimethoxybenzoic acid ester; Reserpine, 99%; Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)-; Spectrum_000109; Reserpic acid methyl ester 3,4,5-trimethoxybenzoate (ester); 79 more names available; 1263-94-1; Prestwick0_000875; Prestwick1_000875; Prestwick2_000875; Prestwick3_000875; Spectrum3_000894; Spectrum4_000989; Spectrum5_001415; R 0875; SCHEMBL2589; Lopac0_000073; BSPBio_000949; KBioGR_001397; KBioSS_000549; 4-25-00-01319 (Beilstein Handbook Reference); Methyl 18beta-hydroxy-11,17alpha-dimethoxy-3beta,20alpha-yohimban-16beta-carboxylate 3,4,5-trimethoxybenzoate (ester); methyl dimethoxy-(3,4,5-trimethoxybenzoyl)oxy-[?]carboxylate; MLS002154046; MLS006011754; DivK1c_000012; SPECTRUM1500526; SPBio_002870; Reserpine (JP17/USP/INN); AMY591; BPBio1_001045; GTPL4823; MEGxp0_001904; DTXSID7021237; ACon1_000086; HMS500A14; KBio1_000012; KBio2_000549; KBio2_003117; KBio2_005685; KBio3_001808; AOB5791; NINDS_000012; HMS1570P11; HMS1920P04; HMS2092G05; HMS2097P11; HMS2234E24; HMS3260O07; HMS3413D20; HMS3677D20; HMS3714P11; HMS3884I21; Pharmakon1600-01500526; HY-N0480; Reserpine, Vetec(TM) reagent grade; RKL10049; ZINC3938746; Tox21_111107; Tox21_202395; Tox21_300537; Tox21_500073; ABP000583; BBL028800; BDBM50017712; ENT-50146; NSC237659; NSC757309; STK801975; AKOS000277559; Tox21_111107_1; CCG-204168; CS-1913; DB00206; KS-5106; LP00073; MCULE-9131256292; MCULE-9946449258; NSC-757309; SDCCGSBI-0050061.P005; IDI1_000012; NCGC00091250-01; NCGC00091250-02; NCGC00091250-03; NCGC00091250-05; NCGC00091250-06; NCGC00091250-07; NCGC00091250-08; NCGC00091250-09; NCGC00091250-10; NCGC00091250-12; NCGC00091250-14; NCGC00091250-25; NCGC00254489-01; NCGC00259944-01; NCGC00260758-01; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-11,17-alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); AC-13142; methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate; NCI60_004446; SBI-0050061.P004; EU-0100073; Reserpine, crystallized, >=99.0% (HPLC); SW196458-3; UNM000011053801; C06539; D00197; J10192; 91098-EP2275420A1; 91098-EP2305219A1; AB01562943_01; 005R091; 146088-EP2287158A1; 146088-EP2292597A1; Q407841; Q-100566; BRD-K95921201-001-07-0; Methyl reserpate; 3,4,5-Trimethoxybenzoic acid ester; Reserpine, certified reference material, TraceCERT(R); Reserpine solution, 1 pg/muL in methanol: water (1:1); Reserpine, European Pharmacopoeia (EP) Reference Standard; Reserpine Standard for LC-MS, analytical standard, for LC-MS; Reserpine, United States Pharmacopeia (USP) Reference Standard; Reserpine, Pharmaceutical Secondary Standard; Certified Reference Material; (3?,16?,17?,18?,20?)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; (3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18- [(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxyl ic acid methyl ester; 3beta,20alpha-Yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy- methyl ester 3,4,5-trimethoxybenzoate (ester) (8CI); methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(3,4,5-trimethoxyphenyl)carbonyloxy]-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate	Small molecule	1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1	QEVHRUUCFGRFIF-MDEJGZGSSA-N	COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC	C33H40N2O9	CAS 50-55-5	CHEBI:28487	.	.	.	D0J4JM	.	.	.
NP1596	Alpinumisoflavone	CID: 5490139	Alpinumisoflavone; 34086-50-5; Alpinum Isoflavone; UNII-6Q33HOF94Z; 5-hydroxy-7-(4-hydroxyphenyl)-2,2-dimethylpyrano[3,2-g]chromen-6-one; 6Q33HOF94Z; CHEMBL238628; CHEBI:69746; SCHEMBL571695; DTXSID00187683; BDBM50200542; LMPK12050202; NSC775898; ZINC14417338; AKOS032962128; NSC-775898; W1705; Q4735614; 2H,6H-Benzodipyran-6-one, 5-hydroxy-7-(4-hydroxyphenyl)-2,2-dimethyl-; 5-hydroxy-7-(4-hydroxyphenyl)-2,2-dimethyl-pyrano[3,2-g]chromen-6-one; 5-Hydroxy-7-(p-hydroxyphenyl)-2,2-dimethyl-2H,6H-benzodipyran-6-one; 5-hydroxy-3-(4-hydroxy-phenyl)-8,8-dimethyl-8H-pyrano[3,2-g]chromen-4-one; 5-hydroxy-7-(4-hydroxyphenyl)-2,2- dimethyl-2H,6H-benzo[1,2-b:5,4-b']dipyran-6-one; 5-hydroxy-7-(4-hydroxyphenyl)-2,2-dimethyl-2h,6h-benzo[1,2-b:5,4-b']dipyran-6-one; 5-Hydroxy-7-(4-hydroxyphenyl)-2,2-dimethyl-2H,6H-pyrano[3,2-g]chromen-6-one	Small molecule	1S/C20H16O5/c1-20(2)8-7-13-15(25-20)9-16-17(18(13)22)19(23)14(10-24-16)11-3-5-12(21)6-4-11/h3-10,21-22H,1-2H3	RQAMSFTXEFSBPK-UHFFFAOYSA-N	CC1(C=CC2=C(O1)C=C3C(=C2O)C(=O)C(=CO3)C4=CC=C(C=C4)O)C	C20H16O5	CAS 34086-50-5	CHEBI:69746	.	.	.	.	.	.	.
NP1614	Corticosteroid	.	.	.	.	.	.	.	.	.	.	.	.	D0J8II	.	.	.
NP1644	Vincristine	CID: 5978	LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine	.	1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1	OGWKCGZFUXNPDA-XQKSVPLYSA-N	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	C46H56N4O10	CAS 57-22-7	CHEBI:28445	HBIN047954	SMIT18173	.	D09QVV	DB00541	.	.
NP1667	Jerusalem artichoke	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP1687	Sanguinarine	CID: 5154	SANGUINARINE; 2447-54-3; Sanguinarin; Pseudochelerythrine; sangvinarin; Veadent; SANGUINARIUM; Viadent; Dimethylenedioxy benzphenanthridine; UNII-AV9VK043SS; Pseudochelerythrine;Sanguinarin; [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-; Benzophenanthridine alkaloid; AV9VK043SS; CHEBI:17183; NCGC00015959-03; Sanguiritrin; CAS-2447-54-3; DSSTox_CID_25204; DSSTox_RID_80748; DSSTox_GSID_45204; 24-methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene; 13-Methyl[1,3]benzodioxolo[5,6-C][1,3]dioxolo[4,5-I]phenanthridin-13-Ium; 13-Methyl-[1,3]dioxolo[4',5':4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-13-ium; C20H14NO4; EINECS 219-503-3; BRN 3915507; Sangrovit; y-Chelerythrine; SR-01000075650; sanguinarium-chloride; Spectrum_000259; Prestwick0_000987; Prestwick1_000987; Prestwick2_000987; Prestwick3_000987; Spectrum2_000724; Spectrum3_001148; Spectrum4_001838; Spectrum5_000635; Lopac-S-5890; cid_5154; C20H14NO4Cl; Lopac0_001108; BSPBio_001053; BSPBio_002675; KBioGR_002542; KBioSS_000739; ZINC706; MLS002154085; DivK1c_000495; SCHEMBL123241; SPBio_000648; SPBio_002954; BPBio1_001159; CHEMBL417799; DTXSID0045204; SCHEMBL17131945; BDBM25525; GTPL11563; KBio1_000495; KBio2_000739; KBio2_003307; KBio2_005875; KBio3_002175; NINDS_000495; HMS1571E15; HMS2098E15; BCP13614; EX-A5014; HY-N0052; Tox21_110268; 4022AH; NSC765394; s9032; AKOS025311557; Tox21_110268_1; CCG-205184; compound 1 [PMID: 28621943]; CS-3818; NSC-765394; SDCCGMLS-0066612.P001; IDI1_000495; NCGC00015959-01; NCGC00015959-02; NCGC00015959-04; NCGC00015959-05; NCGC00015959-09; NCGC00015959-16; NCGC00160289-01; NCGC00160289-02; M892; SMR001233394; SBI-0051077.P003; DB-046461; AB00053789; FT-0634289; N1338; C06162; AB00053789_04; 447S543; Q347392; Q-100313; SR-01000075650-7; BRD-K66898851-001-03-7; 5-Methyl-2,3:7,8-bis(methylenedioxy)benzo[c]phenanthridinium(1+); 13-methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium; (1,3)-Benzodioxolo(5,6-c)-1,3-dioxolo(4,5-i)phenanthridinium, 13-methyl- (9CI); 13-Methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium nitrate; 13-Methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium(1+), 9CI; 13-methyl-2H,10H-[1,3]dioxolo[4,5-i][1,3]dioxolo[4',5':4,5]benzo[1,2-c]phenanthridinium; 24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0^{2,10}.0^{4,8}.0^{14,22}.0^{17,21}]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21),23-nonaen-24-ium; 24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0^{2,10}.0^{4,8}.0^{14,22}.0^{17,21}]tetracosa-1(13),2,4(8),9,11,14,16,21,23-nonaen-24-ium; 24-methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.0^{2,10.0^{4,8.0^{14,22.0^{17,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene; UI5	Small molecule	1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1	INVGWHRKADIJHF-UHFFFAOYSA-N	C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6	C20H14NO4+	CAS 2447-54-3	CHEBI:17183	.	.	.	D0T3NB	.	.	.
NP1709	Salvianolic acid A	CID: 5281793	Salvianolic acid A; 96574-01-5; (R)-3-(3,4-Dihydroxyphenyl)-2-(((E)-3-(2-((E)-3,4-dihydroxystyryl)-3,4-dihydroxyphenyl)acryloyl)oxy)propanoic acid; Salvianolic-acid-A; SALVIANOLIC ACID; CHEMBL457077; UNII-51622542XO; CHEBI:9017; Salvianolic acid A hydrate; 51622542XO; Dan Phenolic Acid A; Salvianolicacid; MFCD20527310; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid; AC1NQZ3H; Dan phenolic acid A hydrate; SCHEMBL19235589; BCP15440; HY-N0318; ZINC4098737; BDBM50414250; MFCD08458447; s9055; AKOS016009674; CCG-269648; DB15246; Salvianolic acid A, analytical standard; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-3,4-dihydroxy-phenyl]prop-2-enoyl]oxy-propanoic acid; AS-75007; CS-0008816; N1803; X1224; C10492; 574S015; Q-100906; Q27108214; UNII-U5TCN455JO component YMGFTDKNIWPMGF-UCPJVGPRSA-N; (2R)-3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-{2-[(1E)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl}prop-2-enoyl]oxy}propanoic acid; Benzenepropanoic acid, alpha-((3-(2-(2-(3,4-dihydroxyphenyl)ethenyl)-3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3,4-dihydroxy-, (R-(E,E))-	Small molecule	1S/C26H22O10/c27-18-7-2-14(11-21(18)30)1-6-17-16(4-9-20(29)25(17)33)5-10-24(32)36-23(26(34)35)13-15-3-8-19(28)22(31)12-15/h1-12,23,27-31,33H,13H2,(H,34,35)/b6-1+,10-5+/t23-/m1/s1	YMGFTDKNIWPMGF-UCPJVGPRSA-N	C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=C(C(=C(C=C2)O)O)C=CC3=CC(=C(C=C3)O)O)O)O	C26H22O10	CAS 96574-01-5	CHEBI:9017	.	.	.	.	.	.	.
NP1734	Trandolapril	CID: 5484727	trandolapril; 87679-37-6; Mavik; Gopten; Odrik; Trandolaprilum [Latin]; RU-44570; RU 44570; UNII-1T0N3G9CRC; Indolapril; C24H34N2O5; 1T0N3G9CRC; RU44570; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; NCGC00182079-02; Trandolaprilum; Udrik; DSSTox_CID_3692; DSSTox_RID_77151; DSSTox_GSID_23692; Odric; Preran; CAS-87679-37-6; CCRIS 6594; Mavik (TN); Trandopril; Trandolapril [USP:INN:BAN]; NCGC00095153-01; CHEMBL1519; SCHEMBL16610; (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; BIDD:GT0804; Trandolapril (JAN/USP/INN); CHEBI:9649; GTPL6453; DTXSID2023692; HSDB 8392; HMS3262J10; HY-B0592; ZINC1853205; Tox21_111453; Tox21_113152; Tox21_500924; BDBM50369775; s6468; AKOS015843316; AKOS015896050; CCG-222228; DB00519; KS-1467; LP00924; NSC 758939; SDCCGSBI-0633768.P001; NCGC00182079-03; NCGC00261609-01; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; 1H-Indole-2-carboxylic acid, 1-((2S)-2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S,3aR,7aS)-; 1H-Indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-alpha,7a-beta))-; Trandolapril, >=98% (HPLC), white powder; D00383; 679T376; A842336; Q929420; SR-02000000917; SR-02000000917-2; BRD-K28550399-001-01-4; Trandolapril, European Pharmacopoeia (EP) Reference Standard; Trandolapril, United States Pharmacopeia (USP) Reference Standard; (2s,3ar,7as)-1-[(2s)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1h-indole-2-carboxylic acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxidanylidene-4-phenyl-butan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid; Trandolapril/(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid	Small molecule	1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1	VXFJYXUZANRPDJ-WTNASJBWSA-N	CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCCC3CC2C(=O)O	C24H34N2O5	CAS 87679-37-6	CHEBI:9649	.	.	.	D0M5OC	.	.	.
NP1829	Aloe emodin	CID: 10207	Aloe-emodin; Aloe emodin; 481-72-1; Aloeemodin; Aloe-emodine; Rhabarberone; 1,8-dihydroxy-3-(hydroxymethyl)anthracene-9,10-dione; 3-Hydroxymethylchrysazine; EMODINE; 3-Hydroxymethylchrysazin; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone; 1,8-Dihydroxy-3-hydroxymethylanthraquinone; 9,10-Anthracenedione, 1,8-dihydroxy-3-(hydroxymethyl)-; NSC 38628; 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-anthracenedione; UNII-C8IYT9CR7C; C8IYT9CR7C; 3-(Hydroxymethyl)chrysazin; CHEMBL40275; CHEBI:2607; 1,8-dihydroxy-3-hydroxymethyl-anthraquinone; NSC38628; 1,8-Dihydroxy-3-(hydroxymethyl)anthra-9,10-quinone; MFCD00017373; SMR000470920; CCRIS 3526; EINECS 207-571-7; BRN 2059062; Aloe-emodol; Rottlerin?; Aloe-Emodine,(S); Aloe-emodin-[d5]; 1286579-72-3; DSSTox_CID_10695; DSSTox_RID_78855; DSSTox_GSID_30695; 4-08-00-03578 (Beilstein Handbook Reference); cid_10207; MLS000697563; MLS006011799; SCHEMBL309756; ANTHRAQUINONE, 1,8-DIHYDROXY-3-HYDROXYMETHYL-; Aloe-emodin, analytical standard; DTXSID2030695; Aloe-emodin, >=95% (HPLC); HMS3655N16; BCP28272; HY-N0189; ZINC4098644; Tox21_302400; AC-020; BBL027838; BDBM50085551; CA0128; LMPK13040002; NSC-38628; s2259; STL146380; AKOS005720864; CCG-208456; CS-3709; MCULE-6965338444; 9, 1,8-dihydroxy-3-(hydroxymethyl)-; SMP2_000291; NCGC00163510-01; NCGC00163510-02; NCGC00163510-03; NCGC00255349-01; AK160272; AS-11638; CAS-481-72-1; NCI60_003685; AB0010470; FT-0622062; N1851; SW219916-1; Anthraquinone,8-dihydroxy-3-(hydroxymethyl)-; C10294; 481A721; Anthraquinone, 1,8-dihydroxy-3-(hydroxymethyl)-; SR-01000765772; Q-100526; Q3533249; SR-01000765772-3; 1,8-Dihydroxy-3-(hydroxymethyl)anthra-9,10-quinone #; 1,8-Dihydroxy-3-hydroxymethyl-9,10-anthracenedione, 9CI; 9,10-Anthracenedione, 1,8-dihydroxy-3-(hydroxymethyl)- (9CI); 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-hydroxymethyl-anthracene; Diacerein impurity B, European Pharmacopoeia (EP) Reference Standard; 1,8-Dihydroxy-3-(hydroxymethyl)-anthracene-9,10-dione (Aloe-Emodin)	Small molecule	1S/C15H10O5/c16-6-7-4-9-13(11(18)5-7)15(20)12-8(14(9)19)2-1-3-10(12)17/h1-5,16-18H,6H2	YDQWDHRMZQUTBA-UHFFFAOYSA-N	C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)CO	C15H10O5	CAS 481-72-1	CHEBI:2607	.	.	.	D09BUG	.	.	.
NP1844	Berberine	CID: 2353	Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE	.	1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1	YBHILYKTIRIUTE-UHFFFAOYSA-N	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC	C20H18NO4+	CAS 2086-83-1	CHEBI:16118	HBIN017893	SMIT00104	MOL001454	D0W8WB	DB04115	465	.
NP1886	Scutellarin	CID: 185617	Breviscapin; Scutellarein-7-glucuronide; Breviscapine; Scutellarein-7beta-D-glucuronide; Scutellarein-7beta-D-glucuronoside; Scutellarein-7-O-beta-D-glucuronide; UNII-16IGP0ML9A; SCUTELLAREIN 7-O-GLUCURONIDE; Scutellarein 7-O-beta-D-glucuronide; 16IGP0ML9A; CHEMBL487805; (2S,3S,4S,5R,6S)-6-((5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; CHEBI:61278; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl; 116122-36-2; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranosiduronic acid; dengzhanhua; Scutellarine; new-breviscapine; Scutellarin,(S); (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yloxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; MEGxp0_000554; SCHEMBL4211849; Scutellarin, analytical standard; DTXSID60921924; BCP11536; Flavone, 4',5,6,7-tetrahydroxy-, 7-beta-D-glucopyranuronoside; HY-N0751; BDBM50242284; MFCD01861503; s3810; ZINC21992916; AKOS016009652; AC-6073; CCG-269364; CCG-269365; CS-4273; BS-16838; O359; AB0016413; N1753; A12117; W-2538; 740S018; Q410712; Breviscapin;Scutellarein-7-glucuronide;Scutellarin B; Q-100351; 5,6-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl hexopyranosiduronic acid; 7-(beta-d-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7- yl]oxy-3,4,5-trihydroxy-oxane-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-; Glucopyranosiduronic acid, 5,6-dihydroxy-2-(p-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl, beta-D-	.	1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30)/t16-,17-,18+,19-,21+/m0/s1	DJSISFGPUUYILV-ZFORQUDYSA-N	C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O	C21H18O12	CAS 27740-01-8	.	HBIN043533	SMIT00173	MOL002931	.	.	795	.
NP1928	Carnosic acid	CID: 65126	Salvin; UNII-LI791SXT24; LI791SXT24; CHEBI:65585; 11,12-dihydroxyabieta-8,11,13-trien-20-oic acid; MFCD02259459; NSC694080; (4aR,10aS)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-4a-carboxylic Acid; Carnosic acid from Rosmarinus officinalis; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylic acid; 139236-75-2; RoseOx; 11,12-dihydroxy-13-isopropylpodocarpa-8,11,13-trien-17-oic acid; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2H)-carboxylic acid; Rosamox; Carnosic-acid; Carsonic acid; Carnosic  acid; Deoxypicrosalvinic acid; PubChem13039; UPCMLD-DP056; CHEMBL484853; SCHEMBL9923661; UPCMLD-DP056:001; DTXSID20904450; BCPP000299; Carnosic acid, analytical standard; HY-N0644; ZINC3984016; ANW-43614; BDBM50371232; s3838; AKOS015901362; AC-6030; BCP9000491; CCG-207954; NSC-694080; SMP2_000204; NCGC00161623-01; 4a(2H)-Phenanthrenecarboxylic acid, 1,3,4,9,10,10a-hexahydro-5,6-dihydroxy-1,1-dimethyl-7-(1-methylethyl)-, (4aR-trans)-; AS-31052; NCI60_033653; P527; BCP0726000155; C3477; CS-0009671; N2759; C21818; 650C097; Q412827; SR-05000002202; SR-05000002202-2; Carnosic acid, primary pharmaceutical reference standard; Carnosic acid from Rosmarinus officinalis, >=91%, powder; Carnosic acid, United States Pharmacopeia (USP) Reference Standard; Podocarpa-8,11,13-trien-17-oic acid, 11,12-dihydroxy-13-isopropyl-	.	1S/C20H28O4/c1-11(2)13-10-12-6-7-14-19(3,4)8-5-9-20(14,18(23)24)15(12)17(22)16(13)21/h10-11,14,21-22H,5-9H2,1-4H3,(H,23,24)/t14-,20+/m0/s1	QRYRORQUOLYVBU-VBKZILBWSA-N	CC(C)C1=C(C(=C2C(=C1)CCC3C2(CCCC3(C)C)C(=O)O)O)O	C20H28O4	CAS 3650-09-7	.	HBIN019753	.	.	.	.	.	.
NP1946	Dehydrocostus lactone	CID: 73174	Dehydrocostus lactone; dehydrocostuslactone; 477-43-0; (-)-dehydrocostus lactone; (-)-dehydrocostuslactone; CHEBI:244418; (3aS,6aR,9aR,9bS)-decahydro-3,6,9-tris(methylene)azuleno[4,5-b]furan-2(3H)-one; (3aR,6aS,9aS,9bR)-3,6,9-tris(methylidene)octahydroazuleno[4,5-b]furan-2,8(3H,4H)-dione; (3aS,6aR,9aR,9bS)-3,6,9-trimethylenedecahydroazuleno[4,5-b]furan-2(3H)-one; (3aS,6aR,9aR,9bS)-3,6,9-Trimethylenedecahydroazuleno[4,5-b]furan-2(9bH)-one; Dehydrocostus-Lactone; UNII-71TRF5K040; Epiligulyl oxide; CHEMBL88985; SCHEMBL699070; DTXSID80891554; 71TRF5K040; ZINC898477; Azuleno(4,5-b)furan-2(3H)-one, decahydro-3,6,9-tris(methylene)-, (3aS-(3a.alpha.,6a.alpha.,9a.alpha.,9b.beta.))-; Dehydro-costus lactone (6CI,7CI); EBD10311; HY-N0591; BDBM50370831; s3615; AKOS015896789; CCG-208469; CS-3636; MCULE-3657815830; Dehydrocostus lactone, >=98% (HPLC); NCGC00385838-01; (3aS,6aR,9aR,9bS)-3,6,9-trimethylene-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-2-one; AK168191; Dehydrocostus lactone, analytical standard; D5366; A14809; C09387; 299D482; Q27105152; (-)-Dehydrocostus lactone; Dehydrocostus lactone; Epiligulyl oxide; (3aR,6aS,9aS,9bR)-3,6,9-tris(methylene)octahydroazuleno[4,5-b]furan-2,8(3H,4H)-dione; (3aS,6aR,9aR,9bS)-Decahydro-3,6,9-tris(methylene)-azuleno[4,5-b]furan-2(3H)-one; Guaia-4(15),10(14),11(13)-trien-12-oic acid, 6alpha-hydroxy-, gamma-lactone; [3aS-(3aalpha,6aalpha,9aalpha,9bbeta)]-Decahydro-3,6,9-tris(methylene)-azuleno[4,5-b]furan-2(3H)-one; Azuleno(4,5-b)furan-2(3H)-one, decahydro-3,6,9-tris(methylene)-, (3aS-(3aalpha,6aalpha,9aalpha,9bbeta))-	Small molecule	1S/C15H18O2/c1-8-4-7-12-10(3)15(16)17-14(12)13-9(2)5-6-11(8)13/h11-14H,1-7H2/t11-,12-,13-,14-/m0/s1	NETSQGRTUNRXEO-XUXIUFHCSA-N	C=C1CCC2C(C3C1CCC3=C)OC(=O)C2=C	C15H18O2	CAS 477-43-0	CHEBI:244418	.	.	.	.	.	.	.
NP1965	Tanshinone IIA	CID: 164676	Tanshinone IIA; 568-72-9; Tanshinone II; Dan Shen Ketone; Tanshinone B; Tanshinon II; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione; UNII-4GPC9FQG6L; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione; Phenanthro[1,2-b]furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; C19H18O3; 4GPC9FQG6L; MLS001048863; MFCD00238692; NSC686519; SMR000387068; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione; Phenanthro(1,2-b)furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; tanshinone II A; SR-01000758926; NSC 686518; tanshinone-IIA; HSDB 8104; Tanshinone centoA; Tanshinone 2-A; Tanshinone Iia ,(S); BSPBio_001597; BSPBio_002426; KBioGR_000317; KBioSS_000317; MLS006011834; SPECTRUM1505824; CHEMBL187266; cid_164676; SCHEMBL2026738; Tanshinone IIA (Tanshinone B); BDBM83922; KBio2_000317; KBio2_002885; KBio2_005453; KBio3_000633; KBio3_000634; DTXSID60205352; CHEBI:108595; Bio2_000317; Bio2_000797; HMS1361P19; HMS1791P19; HMS1989P19; HMS2089H08; HMS2270D15; HMS3402P19; HMS3656C11; NP474; BCP28199; HY-N0135; Tanshinone IIA, analytical standard; ZINC1650576; BBL028449; CT0134; s2365; STK801917; Tanshinone IIA, >=97% (HPLC); AKOS004120032; AC-1440; ACN-035345; CCG-207955; CCG-208275; NSC-686519; IDI1_034067; NCGC00095709-01; NCGC00095709-02; NCGC00095709-03; NCGC00095709-04; NCGC00095709-05; NCGC00095709-06; NCGC00095709-08; AK168188; AS-16136; NCI60_031209; S594; AB0018692; NCGC00095709-02!TANSHINONE IIA; FT-0652880; N1846; SW220025-1; W-2832; 568T729; Q-100654; SR-01000758926-2; SR-01000758926-4; SR-01000758926-5; BRD-K00141480-001-03-0; Q27187517; Phenanthro[1,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; Tanshinone IIA, European Pharmacopoeia (EP) Reference Standard; Tanshinone IIA, United States Pharmacopeia (USP) Reference Standard; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione #; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-quinone; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione; 6,7,8,9-Tetrahydro-1,6,6-trimethylphenanthro[1,2-b]furan-10,11-dione	Small molecule	1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3	HYXITZLLTYIPOF-UHFFFAOYSA-N	CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C	C19H18O3	CAS 568-72-9	CHEBI:108595	.	.	.	.	.	.	.
NP2010	Delphinidin	CID: 68245	Delphinidin chloride; Delphinidin; 528-53-0; Delphinidine; Delphinidol; Ephdine; Delfinidol chloride; UNII-EM6MD4AEHE; 8012-95-1; 1-Benzopyrylium, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, chloride; EM6MD4AEHE; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol chloride; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)benzopyrylium chloride; IdB 1056; CHEBI:38701; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium chloride; MFCD00016663; Paraffin, liquid, pure; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol;chloride; 3,3',4',5,5',7-Hexahydroxyflavylium chloride; Delphinidine; Delphinidol; Ephdine; IdB 1056;Delfinidol chloride; Delphinidin; CHEMBL590878; Delphinidin chloride, analytical standard; 3,3',4',5,5',7-Hexahydroxy-2-phenylbenzopyrylium chloride; CCRIS 2518; EINECS 208-437-0; C15H11O7.Cl; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol; Delphinidinchloride; 2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium-3,5,7-triol; Paraffin, liquid, technical; SCHEMBL22369; IdB-1056; DTXSID701019982; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenium chloride; BCP15819; 6267AF; AKOS027326494; FT-0645153; FT-0665679; A11978; Q367258; Flavylium 3,3',4',5,5',7-hexahydroxy-, chloride (8CI); UNII-R911H793SU component FFNDMZIBVDSQFI-UHFFFAOYSA-N; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium chloride; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-1lambda-chromen-1-ylium	Small molecule	1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H	FFNDMZIBVDSQFI-UHFFFAOYSA-N	C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-]	C15H11ClO7	CAS 8012-95-1	CHEBI:38701	.	.	.	D0ZN1R	.	.	.
NP2036	Aprepitant	CID: 135413536	Aprepitant; 170729-80-3; Emend; MK-869; MK-0869; L-754030; UNII-1NF15YR6UY; C23H21F7N4O3; 1NF15YR6UY; CHEMBL1471; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; CHEBI:499361; L-754,030; 5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1H-1,2,4-triazol-3(2H)-one; MK0869; 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(Trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; MK 869; 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1H-1,2,4-triazol-5(4H)-one; 5-[(2R,3S)-2-[(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one; MK 0869; Emend (TN); Aprepitant (MK-0869); aprepitantum; L 754030; Cinvanti; eMende; Aprepitant [USAN:INN:JAN]; Cinvanti (TN); aprepitant, form I; ONO-7436; aprepitant, form II; Aprepitant(MK-0869); Aprepitant (JAN/USP/INN); Aprepitant Related Compound A; cc-310; MLS006011068; SCHEMBL264924; GTPL3490; DTXSID3049047; AOB6779; EX-A212; HMS2090N12; HMS3714E16; HMS3884G05; 1148113-53-4; 5-[2-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one; ONO 7436; ABP000600; BDBM50220136; NSC748825; s1189; ZINC27428713; AKOS015895498; AKOS015969344; ACN-037208; BCP9000312; CCG-220747; CCG-264854; CS-0487; DB00673; NSC 748825; NSC-748825; SB18892; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-2,4-dihydro-; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; AS-14638; HY-10052; L982; SMR002530053; Aprepitant (MK-0869, L-754030); Aprepitant,MK-0869, L-754030, Emend; C21555; D02968; W-5373; AB01274775-01; AB01274775_02; AB01275535-01; 729A803; SR-05000001531; Q-200647; SR-05000001531-1; BRD-K52827117-001-01-6; Aprepitant, United States Pharmacopeia (USP) Reference Standard; 3-[((2R,5-bis(trifluoromethyl)benzyl]oxy}morpholino)methyl]-.delta.2-1,2,4-triazolin-5-one; 3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one; 3-[2-{1-[3,5-di(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)-1,4-oxazinan-4-ylmethyl]-4,5-dihydro-1H-1,2,4-triazol-5-one; 3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-4,5-dihydro-1H-1,2,4-triazol-5-one; 321125-94-4; 3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-; 3H-1,2,4-Triazol-3-one, 5-((2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-, (2R-(2alpha(R*),3alpha))-; 3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, rel-; 3H-1,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-; 5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-2H-1,2,4-triazol-3(4H)-one	Small molecule	1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1	ATALOFNDEOCMKK-OITMNORJSA-N	CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F	C23H21F7N4O3	CAS 170729-80-3	CHEBI:499361	.	.	.	D0GU4K	.	.	.
NP2096	Andrographolide	CID: 5318517	Andrographis; UNII-410105JHGR; CHEBI:65408; 410105JHGR; (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2(3H)-one; AK-47364; 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one; EINECS 226-852-5; NSC 383468; 3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone; 5508-58-7	.	1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1	BOJKULTULYSRAS-OTESTREVSA-N	CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)CO)O	C20H30O5	CAS 5508-58-7	CHEBI:65408	HBIN016019	SMIT01269	.	D04VIS	DB05767	1512	.
NP2139	Vernodalol	CID: 442318	Vernodalol; CHEBI:9960; C09577; 65388-17-2; AC1L9CLB; CHEMBL1172876; DTXSID10331796; ZINC4098206; ZINC04098206; Vernodalol, >=95% (LC/MS-ELSD); Q27108534; [(4aR,5R,6S,7S,8aR)-5-hydroxy-6-(1-methoxycarbonylvinyl)-4-methylene-3-oxo-8a-vinyl-1,4a,5,6,7,8-hexahydroisochromen-7-yl] 2-(hydroxymethyl)prop-2-enoate	Small molecule	1S/C20H24O8/c1-6-20-7-13(28-17(23)10(2)8-21)14(11(3)18(24)26-5)16(22)15(20)12(4)19(25)27-9-20/h6,13-16,21-22H,1-4,7-9H2,5H3/t13-,14+,15+,16-,20+/m0/s1	FZALQGCQQJLGKE-BBNZOYGDSA-N	COC(=O)C(=C)C1C(CC2(COC(=O)C(=C)C2C1O)C=C)OC(=O)C(=C)CO	C20H24O8	CAS 65388-17-2	CHEBI:9960	.	.	.	.	.	.	.
NP2147	Verminoside	CID: 12000883	verminoside; 50932-19-9; CHEBI:69799; HY-N1094; ZINC67912123; MCULE-6297417833; NCGC00385664-01; CS-0016382; Q27138140; [(1S,2S,4S,5S,6R,10S)-2-(Hydroxymethyl)-10-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-5-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; NCGC00385664-01_C24H28O13_(1aS,1bS,2S,5aR,6S,6aS)-2-(beta-D-Glucopyranosyloxy)-1a-(hydroxymethyl)-1a,1b,2,5a,6,6a-hexahydrooxireno[4,5]cyclopenta[1,2-c]pyran-6-yl (2E)-3-(3,4-dihydroxyphenyl)acrylate	Small molecule	1S/C24H28O13/c25-8-14-17(30)18(31)19(32)23(34-14)36-22-16-11(5-6-33-22)20(21-24(16,9-26)37-21)35-15(29)4-2-10-1-3-12(27)13(28)7-10/h1-7,11,14,16-23,25-28,30-32H,8-9H2/b4-2+/t11-,14-,16-,17-,18+,19-,20+,21+,22+,23+,24-/m1/s1	MZQXNUBTVLKMLP-QOEJBJAYSA-N	C1=COC(C2C1C(C3C2(O3)CO)OC(=O)C=CC4=CC(=C(C=C4)O)O)OC5C(C(C(C(O5)CO)O)O)O	C24H28O13	CAS 50932-19-9	CHEBI:69799	.	.	.	.	.	.	.
NP2151	Echinocandin	.	.	.	.	.	.	.	.	.	.	.	.	D0FY4M	.	.	.
NP2169	Vitamin K	CID: 5280483	VITAMIN K; Kinadion; Konakion; Mephyton; Monodion; Kephton; Aqua mephyton; Synthex P; Mono-Kay; Combinal K1; Kativ N; K-Ject; 12001-79-5; Aquamephyton; Phythyl-menadion; 2',3'-trans-Vitamin K1; Aqua-Mephytin; Vitamin K1(20); .alpha.-Phylloquinone; trans-Phylloquinone; Phytomenadionum; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 2-Methyl-3-phythyl-1,4-naphthochinon; 81818-54-4; Fitomenadione; 2-methyl-3-[(2E)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-dihydronaphthalene-1,4-dione; 3-((2E)-3,7,11,15-tetramethylhexadec-2-enyl)-2-methylnaphthalene-1,4-dione; SMR000059144; Vitamin K semiquinone radical; a-Phylloquinone; NSC-270681; 2-methyl-3-[(2E)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-dione; NCGC00159423-02; Mephyton (TN); EINECS 234-408-7; EINECS 279-833-9; Vitamin K (generic); Phytomenadione (INN); Vitamin K1 (TN); 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; Vitamin K1 (Phytonadione); Phytonadione (JP17/USP); MLS001332659; MLS001332660; CHEMBL520156; 2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone #; CHEBI:94399; [r-[r*,R*-(E)]]-2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-napthalenedione; [r-[r*,R*-(E)]]-2-Methyl-3-(3-7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; HMS2232C17; 10485-69-5; BCP23822; BBL036678; NSC270681; STL559057; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2-Methyl-3-phytyl-1,4-napthoquinone; AKOS024284357; NCGC00186656-01; 27696-10-2; ST075162; VS-13623; P0642; C02059; D00148; 1, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-; 2-(3,7,11,15-Tetramethyl-2-hexadecenyl)-3-methyl-1,4-naphthoquinone; 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; 2-Methyl-3-(3,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; (E)-2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione1; 1, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, [R-[R*,R*-(E)]]-; 2-Methyl-3-[(2Z)-3,7,11,15-tetramethyl-2-hexadecenyl]-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-), (R-(R*,R*-(E)))-; 2581046-19-5	Small molecule	1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+	MBWXNTAXLNYFJB-LKUDQCMESA-N	CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C	C31H46O2	CAS 12001-79-5	CHEBI:94399	.	.	.	D07QPA	.	.	.
NP2206	Taxifolin	CID: 439533	TAXIFOLIN; 480-18-2; (+)-Taxifolin; dihydroquercetin; Distylin; Taxifoliol; (2R,3R)-Dihydroquercetin; (+)-Dihydroquercetin; TAXIFOLIN-(+); Lariksin; Lavitol; 24198-97-8; taxifolin (dihydroquercetin); (2R,3R)-3,3',4',5,7-Pentahydroxyflavanone; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychroman-4-one; UNII-9SOB9E3987; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-; (2R,3R)-Taxifolin; (2R,3R)-2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-2,3-DIHYDRO-4H-CHROMEN-4-ONE; (+/-)-Taxifolin hydrate; 3,5,7,3',4'-Pentahydroxyflavanone; (+/-)-Taxifolin; 2,3-Dihydroquercetin; (2R-trans)-2-(3,4-Dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-4-benzopyrone; (2R,3R)-(+)-Taxifolin; 17654-26-1; CHEBI:17948; 9SOB9E3987; MFCD00006845; Flavanone, 3,3',4',5,7-pentahydroxy-; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one; Diquertin; (?)-Taxifolin; 3,3',4',5,7-Pentahydroxyflavanone; Flamena D; (2R,3R)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one; DQH; SMR000466389; trans-Dihydroquercetin; (+)-trans-Taxifolin; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-; Dihydroquercetin hydrate; CCRIS 9292; (+)-(2R,3R)-dihydroquercetin; Taxifolin (Tax); EINECS 207-543-4; (+)-trans Taxifolin; (2R,3R)-TRANS-DIHYDROQUERCETIN; BRN 0093548; Taxifolin, (+/-)-; Dihydroquercetin, (+/-)-; SCHEMBL39786; 5-18-05-00451 (Beilstein Handbook Reference); MLS000759539; MLS001066341; MLS001074712; MLS001424044; MLS002153142; BIDD:ER0483; Taxifolin, analytical standard; Flavone, 2,3-dihydro-3,3',4',5,7-pentahydroxy-; MEGxp0_000741; DTXSID8022450; ACon1_000239; BDBM212435; DTXSID301017215; HMS2051M22; HMS2234L14; HY-N0136; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chroman-4-one; AC-935; MFCD11044454; s2366; AKOS015965399; ZINC100018343; CCG-100909; CS-3365; DB02224; KS-1312; MCULE-2394173874; MCULE-2692728789; NC00159; NCGC00016024-08; NCGC00180750-01; 20254-28-8; AS-17723; (+)-3,3',4',5,7-Pentahydroxyflavanone; 3,3',4',5,7-Pentahydroxyflavanone hydrate; SW197539-2; V1551; C01617; (2R,3R)-3,5,7,3',4'-Pentahydroxyflavanone; Q412191; SR-01000759385; Flavanone, 3,3',4',5,7-pentahydroxy-, (R,R)-; J-011205; SR-01000759385-6; Taxifolin, primary pharmaceutical reference standard; F40AB773-26FA-4112-A46D-DC970AF64BC1; Flavanone, 3,3',4',5,7-pentahydroxy-, (2R)-trans-; Flavanone, 3,3',4',5,7-pentahydroxy-, trans-(+)-; Flavanone, 3,3',4',5,7-pentahydroxy-, (2R,3R)-(+)-; UNII-EAS93SC1VS component CXQWRCVTCMQVQX-LSDHHAIUSA-N; rel-(2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychroman-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-chromen-4-one, (2R-trans)-; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R-trans)-; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, trans-(+/-)-	Small molecule	1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15+/m0/s1	CXQWRCVTCMQVQX-LSDHHAIUSA-N	C1=CC(=C(C=C1C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O	C15H12O7	CAS 480-18-2	CHEBI:17948	.	.	.	.	.	.	.
NP2215	Colistin	CID: 5311054	colistin; Polymyxin E; 1066-17-7; Colobreathe; Promixin; Colistin,(S); CHEMBL499783; SCHEMBL1979092; GTPL10794; Colistin  sulfate, >19000 IU/mg; N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide; AB01566924_01; 066C177; Q418946; SR-01000872582; SR-01000872582-1; N-[(1S)-3-amino-1-[[(1S,2R)-1-[[(1S)-3-amino-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-diisobutyl-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]propyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]propyl]-5-methyl-heptanamide; N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2-; N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2-hydroxypropyl]carbamoyl}propyl]-5-methylheptanamide	Small molecule	1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1	YKQOSKADJPQZHB-QNPLFGSASA-N	CCC(C)CCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)C(C)O	C52H98N16O13	CAS 1066-17-7	.	.	.	.	D0K7NQ	.	.	.
NP2230	Nicotinamide	CID: 936	nicotinamide; niacinamide; 98-92-0; 3-Pyridinecarboxamide; Nicotinic acid amide; pyridine-3-carboxamide; vitamin PP; Papulex; Aminicotin; Amixicotyn; Nicobion; Nicotylamide; Nikotinamid; Savacotyl; Benicot; Dipegyl; Endobion; Hansamid; Pelmine; Nicotinic amide; Delonin amide; Pelonin amide; Vi-Nicotyl; Austrovit PP; Inovitan PP; Vitamin B; Nicosylamide; Nicotilamide; Nicotililamido; Amnicotin; Niacevit; Nicamina; Nicamindon; Nicofort; Nicomidol; Nicotamide; Nicovitina; Nicovitol; Nicozymin; Niocinamide; Niozymin; Niamide; Nicasir; Nicogen; Nicota; Nicotol; Nicovit; Niko-tamin; 3-Carbamoylpyridine; Nicotine acid amide; Nandervit-N; Pyridine-3-carboxylic acid amide; Niavit PP; Nicosan 2; Nicotine amide; beta-Pyridinecarboxamide; Nikotinsaeureamid; Nicotylamidum; Mediatric; Nicotinsaureamid; Pyridine, 3-carbamoyl-; 3-Pyridinecarboxylic acid amide; Nicotinamidum; m-(Aminocarbonyl)pyridine; Acid amide; Factor pp; Nicotinamida; Nicovel; Vitamin B (VAN); Pelmin; Amid kyseliny nikotinove; Witamina PP; PP-Faktor; Amide PP; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Amid kyseliny nikotinove [Czech]; Nicotinamidum [INN-Latin]; Nicotinamida [INN-Spanish]; NAM; Nictoamide; CCRIS 1901; Dipigyl; HSDB 1237; Vi-noctyl; AI3-02906; Nicotinamide (Vitamin B3); NSC 13128; b-Pyridinecarboxamide; Niacinamide [USP]; UNII-25X51I8RD4; 3-(aminocarbonyl)pyridine; MFCD00006395; .beta.-Pyridinecarboxamide; CHEMBL1140; MLS000069714; CHEBI:17154; Nicotinamide-d4; 25X51I8RD4; NSC13128; Niacinamide (USP); NSC-13128; NSC-27452; Nicotinamide, 99%; NCGC00093354-03; NCGC00093354-05; SMR000058212; DSSTox_CID_929; Niacinamide;Nicotinic acid amide;Vitamin B3; WLN: T6NJ CVZ; DSSTox_RID_75873; DSSTox_GSID_20929; Niacinamide [USAN]; Enduramide; CAS-98-92-0; B3, Vitamin; Vitamin B 3; B 3, Vitamin; 3 Pyridinecarboxamide; SR-01000721872; Nicotinsaureamid Jenapharm; EINECS 202-713-4; Jenapharm, Nicotinsaureamid; Niacotinamide; Nicotinamid; nicotin-amide; Nicotinsaeureamid; 3-Amidopyridine; DEA No. 1405; Nicotinamide,(S); Vitamin B3 amide; 3-yridinecarboxamide; Nicotinamide [INN]; ACMC-20aizz; Mediatric (Salt/Mix); niacin - Vitamin B3; 1yc5; Opera_ID_775; Niacinamide(Vitamin B3); bmse000281; MolMap_000061; EC 202-713-4; SCHEMBL2926; Nicotinamide (JP17/INN); MLS001424246; Nicotinamide-(amide-[15N]); SCHEMBL6278767; SGCUT00176; ZINC5878; DTXSID2020929; SCHEMBL19978192; BDBM27507; Nicotinamide, niacin, vitamin B3; HMS2052M21; HMS2090B05; HMS2093H03; HMS2236J03; HMS3370F21; HMS3394M21; HMS3655M20; HMS3713B22; HMS3884A16; Pharmakon1600-01505397; [N]C(=O)C1=CC=CN=C1; BCP07322; HY-B0150; Nicotinamide (Vitamin B3) solution; NSC27452; to_000073; Nicotinamide 1.0 mg/ml in Methanol; Nicotinamide, >=98.5% (HPLC); Nicotinamide, >=99.5% (HPLC); Tox21_111202; Tox21_201716; Tox21_302776; ANW-75549; BBL013003; NSC759115; s1899; SBB004283; STL163867; AKOS005715850; Tox21_111202_1; CCG-101149; CS-1968; DB02701; MCULE-3532732201; NC00399; NSC-759115; Nicotinamide, >=98% (HPLC), powder; NCGC00093354-04; NCGC00093354-06; NCGC00093354-09; NCGC00256432-01; NCGC00259265-01; AS-13845; K774; Nicotinamide, puriss., 99.0-101.0%; Nicotinamide 10 microg/mL in Acetonitrile; Nicotinamide, tested according to Ph.Eur.; SBI-0206826.P001; DB-057754; FT-0631517; FT-0672696; FT-0773644; N0078; N1651; ST51037366; SW197779-3; EN300-15612; Niacinamide, meets USP testing specifications; 3418-EP2281816A1; 3418-EP2281818A1; 3418-EP2285778A1; 3418-EP2287165A2; 3418-EP2295424A1; 3418-EP2307377A1; 3418-EP2307378A1; 3418-EP2308858A1; 3418-EP2308874A1; 3418-EP2311808A1; 3418-EP2311829A1; C00153; D00036; J10422; Nicotinamide (Niacinamide), analytical standard; W-3583; 11783-EP2269610A2; 11783-EP2289510A1; 11783-EP2316457A1; 11783-EP2316458A1; 11783-EP2316825A1; 11783-EP2316826A1; 11783-EP2316827A1; 11783-EP2316828A1; AB00373895-13; AB00373895_15; AB00373895_16; Nicotinamide, Vetec(TM) reagent grade, >=98%; A845925; AC-907/25014114; Q192423; Q-201470; SR-01000721872-3; SR-01000721872-4; SR-01000721872-5; Z33546463; F2173-0513; Niacinamide;Nicotinic acid amide;Vitamin B3; Vitamin PP; Nicotinamide, British Pharmacopoeia (BP) Reference Standard; A186B02E-6C70-4E54-9739-79398D439AAA; Nicotinamide, European Pharmacopoeia (EP) Reference Standard; Niacinamide, United States Pharmacopeia (USP) Reference Standard; Niacinamide, Pharmaceutical Secondary Standard; Certified Reference Material; Nicotinamide, BioReagent, suitable for cell culture, suitable for insect cell culture; Nicotinamide (Vitamin B3) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material	Small molecule	1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)	DFPAKSUCGFBDDF-UHFFFAOYSA-N	C1=CC(=CN=C1)C(=O)N	C6H6N2O	CAS 98-92-0	CHEBI:17154	.	.	.	D06NVJ	.	.	.
NP2294	Geraniol	CID: 637566	GERANIOL; 106-24-1; Lemonol; Geranyl alcohol; trans-Geraniol; (E)-Geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol; (E)-Nerol; trans-3,7-Dimethyl-2,6-octadien-1-ol; (E)-3,7-Dimethylocta-2,6-dien-1-ol; Geraniol Extra; Geraniol alcohol; 3,7-Dimethyl-2,6-octadien-1-ol; (E)-3,7-Dimethyl-2,6-octadien-1-ol; beta-Geraniol; 3,7-Dimethyl-trans-2,6-octadien-1-ol; 2,6-Octadien-1-ol, 3,7-dimethyl-, (2E)-; Guaniol; t-geraniol; 2E-geraniol; Geraniol (natural); 2-trans-3,7-Dimethyl-2,6-octadien-1-ol; 2,6-Octadien-1-ol, 3,7-dimethyl-; CHEBI:17447	.	1S/C10H18O/c1-9(2)5-4-6-10(3)7-8-11/h5,7,11H,4,6,8H2,1-3H3/b10-7+	GLZPCOQZEFWAFX-JXMROGBWSA-N	CC(=CCCC(=CCO)C)C	C10H18O	CAS 106-24-1	.	HBIN027528	SMIT00017	MOL000123	D0Q4GB	.	850	.
NP2322	Periplocin	CID: 14463159	Periplocin; 13137-64-9; Periplocoside; UNII-199X940O3K; 199X940O3K; 3-[(3S,5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-4-methoxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one; Card-20(22)-enolide, 3-[(2,6-dideoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-, (3beta,5beta)-; Periplogenin + D-cymarose + D-glucose; BRN 0075742; Periplogenin + D-cymarose + D-glucose [German]; 4-18-00-02439 (Beilstein Handbook Reference); HY-N1381; 8208AH; s9181; ZINC79216652; AKOS030573522; CCG-270383; AS-75113; CS-0016801; 137P649; Q27252090; 15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one; 3-[(3S,5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-4-methoxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,; 3-[(3S,5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-4-methoxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]; Card-20(22)-enolide, 3-((2,6-dideoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-, (3-beta,5-beta)-	Small molecule	1S/C36H56O13/c1-18-31(49-32-30(41)29(40)28(39)25(16-37)48-32)24(44-4)14-27(46-18)47-20-5-9-33(2)22-6-10-34(3)21(19-13-26(38)45-17-19)8-12-36(34,43)23(22)7-11-35(33,42)15-20/h13,18,20-25,27-32,37,39-43H,5-12,14-17H2,1-4H3/t18-,20+,21-,22+,23-,24+,25-,27+,28-,29+,30-,31-,32+,33-,34-,35+,36+/m1/s1	KWBPKUMWVXUSCA-AXQDKOMKSA-N	CC1C(C(CC(O1)OC2CCC3(C4CCC5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)C)OC)OC7C(C(C(C(O7)CO)O)O)O	C36H56O13	CAS 13137-64-9	.	.	.	.	.	.	.	.
NP2434	Astragaloside IV	CID: 13943297	Astragaloside IV; Astragaloside A; 84687-43-4; Cyclosiversioside F; UNII-1J6XA9YCFV; Astramembrannin I; 1J6XA9YCFV; CHEBI:65457; 83207-58-3; 3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosylcycloastragenol; C41H68O14; MFCD16036240; Cyclosieversioside F; Astragaloside IV 95%; Astragaloside IV, >98.0%; CHEMBL3121562; SCHEMBL21888259; HMS3885E12; EBD11477; HY-N0431; s3901; AKOS025311424; ZINC238809356; CCG-270470; AS-19402; beta-D-Glucopyranoside, (3beta,6alpha,16beta,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl; K514; AB0033838; X7614; C17799; 846A434; n-benzyloxycarbonyl-1-aminocyclopropanecarboxylic acid; Q27133900; Astragaloside IV, European Pharmacopoeia (EP) Reference Standard; Astragaloside IV, United States Pharmacopeia (USP) Reference Standard; (2R,3R,4S,5S,6R)-2-(((2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol	Small molecule	1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39+,40-,41+/m0/s1	QMNWISYXSJWHRY-YLNUDOOFSA-N	CC1(C(CCC23C1C(CC4C2(C3)CCC5(C4(CC(C5C6(CCC(O6)C(C)(C)O)C)O)C)C)OC7C(C(C(C(O7)CO)O)O)O)OC8C(C(C(CO8)O)O)O)C	C41H68O14	CAS 84687-43-4	CHEBI:65457	.	.	.	.	.	.	.
NP2458	Methyl jasmonate	CID: 5281929	Methyl jasmonate; (-)-Methyl jasmonate; Methyl cis-jasmonate; 1211-29-6; methyl (-)-jasmonate; Methyl 2-((1R,2R)-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)acetate; Jasmonic acid methyl ester; Methyl jasmonic acid; (-)-Jasmonic acid methyl ester; UNII-900N171A0F; CHEBI:15929; methyl 2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetate; (3R,7R)-Methyl jasmonate; Methyl (2-pent-2-enyl-3-oxo-1-cyclopentyl)acetate; Z-Methyl jasmonoate; 900N171A0F; 3-oxo-2-(2-pentenyl)cyclopentaneacetic acid methyl ester; (-)-Jasmonic acid, methyl ester (trans); Cyclopentaneacetic acid, 3-oxo-2-(2Z)-2-pentenyl-, methyl ester, (1R,2R)-; Methyl 3-oxo-2-(2-pentenyl)cyclopentaneacetate, (1R-(1alpha,2beta(Z)))-; Methyljasmonate; methyl 2-((1R,2R)-3-oxo-2-pent-2Z-enyl)cyclopentyl)acetate; Methyl (1R-(1alpha,2beta(Z)))-3-oxo-2-(pent-2-enyl)cyclopentaneacetate; Cyclopentaneacetic acid, 3-oxo-2-(2-pentenyl)-, methyl ester, (1R-(1alpha,2beta(Z)))-; Cyclopentaneacetic acid, 3-oxo-2-(2-pentenyl)-, methyl ester, (1theta-(1alpha,2beta(Z)))-; Methyl dl-jasmonate; Cyclopentaneacetic acid, 3-oxo-trans-2-(cis-2-pentenyl), methyl ester; Methyl 3-oxo-2-(2-pentenyl)cyclopentaneacetate; HSDB 8131; Cyclopentaneacetic acid, 3-oxo-2-(2-pentenyl)-, methyl ester, [1R-[1alpha,2beta(Z)]]-; Cyclopentaneacetic acid, 3-oxo-2-(2Z)-2-penten-1-yl-, methyl ester, (1R,2R)-; Cyclopentaneacetic acid, 3-oxo-2-(2Z)-2-pentenyl-, methyl ester, (1R,2R)-rel-; 20073-13-6; 39924-52-2; EINECS 214-918-6; EINECS 243-497-1; 3-Oxo-2-(2-pentenyl)cyclopentaneacetic acid, methyl ester; SCHEMBL36186; CHEMBL2139332; FEMA 3410; Cyclopentaneacetic acid, 3-oxo-2-(2Z)-2-penten-1-yl-, methyl ester, (1R,2R)-rel-; (3R,7R)-(?)-Methyl jasmonate; Methyl 3-oxo-2-(2-pentenyl)cyclopentaneacetate, (Z)-trans-; CMC_7389; ZINC4654657; BDBM50509748; CMC_13964; LMFA02020010; (+-)-Cyclopentaneacetic acid, 3-oxo-trans-2-(cis-2-pentenyl), methyl ester; AKOS015950850; Cyclopentaneacetic acid, 3-oxo-2-(2-pentenyl)-, methyl ester, (Z)-trans-; C11512; Q26840883; 8171C3E0-B789-4211-B5C1-88C6B260AE3C; Methyl (1alpha,2beta(Z))-(1)-3-oxo-2-(pent-2-enyl)cyclopentaneacetate; methyl {(1R,2R)-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl}acetate; Cyclopentaneacetic acid, 3-oxo-2-(2-pentenyl)-, methyl ester, (Z)-trans- (8CI); Cyclopentaneacetic acid, 3-oxo-2-(2Z)-2-pentenyl-, methyl ester, (1R,2R)- (9CI); Cyclopentaneacetic acid, 3-oxo-2-[(2Z)-2-pentenyl]-, methyl ester, (1R,2R)-	Small molecule	1S/C13H20O3/c1-3-4-5-6-11-10(7-8-12(11)14)9-13(15)16-2/h4-5,10-11H,3,6-9H2,1-2H3/b5-4-/t10-,11-/m1/s1	GEWDNTWNSAZUDX-WQMVXFAESA-N	CCC=CCC1C(CCC1=O)CC(=O)OC	C13H20O3	CAS 1211-29-6	CHEBI:15929	.	.	.	.	.	.	.
NP2528	Alpha solanine	CID: 9549171	alpha-Solanine; 20562-02-1; alpha-Solanin; MLS000517299; MLS001074921; CHEBI:9188; MFCD00077873; SOLANINE; SMR000127418; 51938-42-2; Solanin; Prestwick3_000640; alpha-Solanine with HPLC; 1,4-butanedioldimethacrylate; BSPBio_000640; BPBio1_000704; CHEMBL1392894; BDBM89803; cid_9549171; HMS2096P22; HMS2268G17; HY-N6602; ZINC254003405; NCGC00179493-01; NCGC00179493-03; AS-74952; AB00513871; alpha-Solanine, from potato sprouts, >=95%; CS-0034333; SR-01000721955; J-013423; SR-01000721955-4; BRD-K70881766-001-02-3; (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-2-[[(1S,2S,7S,10R,11S,14S,15R,16S,17R,20S,23S)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracos-4-en-7-yl]oxy]-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol; beta-D-Galactopyranoside, (3beta)-solanid-5-en-3-yl O-6-deoxy-alpha-L-mannopyranosyl-(1-->2)-O-[beta-D-glucopyranosyl-(1-->3)]-; solanid-5-en-3beta-yl 6-deoxy-alpha-L-mannopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->3)]-beta-D-galactopyranoside	Small molecule	1S/C45H73NO15/c1-19-6-9-27-20(2)31-28(46(27)16-19)15-26-24-8-7-22-14-23(10-12-44(22,4)25(24)11-13-45(26,31)5)57-43-40(61-41-37(54)35(52)32(49)21(3)56-41)39(34(51)30(18-48)59-43)60-42-38(55)36(53)33(50)29(17-47)58-42/h7,19-21,23-43,47-55H,6,8-18H2,1-5H3/t19-,20+,21-,23-,24+,25-,26-,27+,28-,29+,30+,31-,32-,33+,34-,35+,36-,37+,38+,39-,40+,41-,42-,43+,44-,45-/m0/s1	ZGVSETXHNHBTRK-UDJLNJFBSA-N	CC1CCC2C(C3C(N2C1)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)OC8C(C(C(C(O8)CO)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C	C45H73NO15	CAS 20562-02-1	CHEBI:9188	.	.	.	.	.	.	.
NP2556	Anisodamine	CID: 6918612	anisodamine; UNII-01343Q8EL8; 01343Q8EL8; 6-Hydroxy hyoscyamine; 55869-99-3; 6-Hydroxyhyoscyamine; 654-II; (Z)-RACANISODAMINE; CHEMBL2165224; HY-N0584; ZINC3197739; AKOS015955736; CCG-221772; CS-4549; DB11785; MCULE-3459933530; Hyoscyamine, 6-hydroxy- (6CI, 7CI); NCGC00485098-01; NCGC00485098-02; UNII-QQZ59S1DUT component WTQYWNWRJNXDEG-RBZJEDDUSA-N; (S)-3-hydroxy-2-phenyl-propionic acid (1r,3s,5r,6S)-6-hydroxy-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester, AldrichCPR; [(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate; alpha-(Hydroxymethyl)benzeneacetic acid 6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (alphaS)-; Benzeneacetic acid, alpha-(hydroxymethyl)-, 6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (1R-(1-alpha,3-beta(S*),5-alpha,6-alpha))-	Small molecule	1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13-,14+,15+,16-/m0/s1	WTQYWNWRJNXDEG-RBZJEDDUSA-N	CN1C2CC(CC1C(C2)O)OC(=O)C(CO)C3=CC=CC=C3	C17H23NO4	CAS 55869-99-3	.	.	.	.	D06VFO	.	.	.
NP2616	Curdione	CID: 6441391	Curdione; 13657-68-6; Germacr-1(10)-ene-5,8-dione; Cyclodecene-1,4-dione, 6,10-dimethyl-3-(1-methylethyl)-, (3S-(3R*,6E,10R*))-; SCHEMBL3297349; CHEBI:81131; HY-N0353; MFCD28977990; s9164; ZINC12153222; CCG-266841; 6-Cyclodecene-1,4-dione, 6,10-dimethyl-3-(1-methylethyl)-, (3S-(3R*,6E,10R*))- (9CI); AS-72874; N1432; C17493; Q15410914; (3S,6E,10S)-6,10-dimethyl-3-(propan-2-yl)cyclodec-6-ene-1,4-dione	Small molecule	1S/C15H24O2/c1-10(2)13-9-14(16)12(4)7-5-6-11(3)8-15(13)17/h6,10,12-13H,5,7-9H2,1-4H3/b11-6+/t12-,13-/m0/s1	KDPFMRXIVDLQKX-NHFJXKHHSA-N	CC1CCC=C(CC(=O)C(CC1=O)C(C)C)C	C15H24O2	CAS 13657-68-6	CHEBI:81131	.	.	.	.	.	.	.
NP2632	Fucoidan	CID: 92023653	ZINC97974745	.	1S/C7H14O7S/c1-3-5(8)6(9)7(4(2)13-3)14-15(10,11)12/h3-9H,1-2H3,(H,10,11,12)/t3-,4+,5-,6+,7-/m1/s1	NLMDZXKCTWKRSQ-IBISWUOJSA-N	CC1C(C(C(C(O1)C)OS(=O)(=O)O)O)O	C7H14O7S	.	.	HBIN026803	.	.	.	.	7208	.
NP2665	Alpha lipoic acid	CID: 864	dl-Thioctic acid; thioctic acid; alpha-Lipoic acid; 1077-28-7; lipoic acid; 5-(1,2-Dithiolan-3-yl)pentanoic acid; DL-alpha-Lipoic acid; 1,2-dithiolane-3-pentanoic acid; alpha Lipoic Acid; Thioctacid; Biletan; 6,8-Thioctic acid; 6-Thioctic acid; Lipothion; dl-Lipoic acid; DL-6,8-Thioctic acid; Liposan; Thioctsan; Tioctacid; Rac-lipoate; 1,2-Dithiolane-3-valeric acid; 6,8-Dithiooctanoic acid; alpha-Liponsaeure; DL-6-Thioctic acid; Thioctic acid dl-form; 62-46-4; alpha-liponic acid; Thioktsaeure; Tioctidasi; (RS)-Lipoic acid; 5-(1,2-Dithiolan-3-yl)valeric acid; espa-lipon; 5-(Dithiolan-3-yl)valeric acid; Acetate-replacing factor; 5-(dithiolan-3-yl)pentanoic acid; 6,8-Thiotic acid; Thioctansaeure; 6-Thiotic acid; DL-1,2-Dithiolane 3-valeric acid; (+-)-Lipoic acid; MFCD00005474; Thioctsaeure; liponic acid; Thiooctic acid; DL-.alpha.-Lipoic acid; (+/-)-1,2-Dithiolane-3-pentanoic acid; DL-1,2-Dithiolane-3-valeric acid; lipoate; NSC 90788; Lipoic acid, alpha; NSC 628502; (RS)-thioctic acid; (+-)-1,2-Dithiolane-3-pentanoic acid; .alpha.-Liponic acid; CHEBI:16494; Lip(S2); DL-1,2-Dithiolan-3-valeriansaeure; (.+-.)-Lipoic acid; 1,2-DITHIOLANE-3-VALERIC ACID, (+-)-; (RS)-.alpha.-Lipoic acid; 5-[3-(1,2-dithiolanyl)]pentanoic acid; CHEMBL33864; (.+-.)-.alpha.-Lipoic acid; NSC90788; NSC-90788; NCGC00016032-06; DSSTox_CID_5508; Protogen A; (+/-)-alpha-Lipoic acid; DL-Thioctic acid, 98+%; DSSTox_RID_77816; DSSTox_GSID_25508; Berlition; Thiogamma; (R)-(+)-alpha-Lipoic acid;R-(+)-Thioctic acid; L-Thioctic acid; Thioktsaeure [German]; biomolipon; duralipon; Alipure; AlphaLipogamma; Thiotacid; biomo lipon; espa lipon; Alpha Lipogamma; Alpha-Lipogamma; Pyruvate oxidation factor; DL-Thiocticacid; Pleomix Alpha; Thioctacide T; Verla Lipon; AlphaLipon Stada; .alpha.-Lipoic acid; Alpha Lippon AL; alpha-Liponsaeure [German]; Alpha Lipon Stada; Alpha-Lipon Stada; 5-(1,2)Dithiolan-3-yl-pentanoic acid; 5-[1,2]Dithiolan-3-yl-pentanoic acid; Liponsaureratiopharm; alpha-lipon 300; SMR000058198; CAS-1077-28-7; Liponsaure-ratiopharm; 1189471-66-6; (+-)-Thioctic acid; alpha Liponsaure von ct; Tioctidasi acetate replacing factor; SR-01000737460; (RS)-alpha-Lipoic acid; EINECS 200-534-6; EINECS 214-071-2; (+-)-alpha-lipoic acid; BRN 0081853; BRN 0122410; Alpha Lipoic; Alphalipoic-acid; a-lipoic acid; DL-1,2-Dithiolan-3-valeriansaeure [German]; Thioctic acid [INN:BAN:JAN]; HSDB 7818; alpha-lipoic-acid; D,L-Lipoic acid; Thiotomin (TN); D,L-Thioctic acid; lipoic acid (LA); LIPOIC-ACID; Thioctic acid (JAN); ()-alpha-Lipoic acid; PubChem14559; Spectrum_001618; 5-(1,2-dithiolan-3-yl)-pentanoate; Thioctic acid, dl-form; R-(+)-alpaLipoic acid; 1,2-Dithiolane-3-pentanoic acid, (+-)-; Spectrum2_001605; Spectrum3_001188; Spectrum4_000217; Spectrum5_001298; (S)-(-)-Thiocticacid; (+/-)-a-Lipoic acid; cid_864; (.+-.)-Thioctic acid; Lipoic acid, alpha [NF]; ACMC-209ug2; bmse000542; Epitope ID:150922; (+/-)-?-Lipoic acid; (.+/-.)-Lipoic acid; ACMC-1BU44; SCHEMBL51065; BSPBio_002835; DL-Thioctic acid (oxidized); KBioGR_000853; KBioSS_002098; 5-19-07-00237 (Beilstein Handbook Reference); MLS000069736; MLS001332379; MLS001332380; MLS002153365; DivK1c_000912; SPECTRUM1503941; (R)-(+)- a-Lipoic acid; SPBio_001609; DTXSID7025508; BDBM10515; HMS502N14; KBio1_000912; KBio2_002098; KBio2_004666; KBio2_007234; KBio3_002335; NINDS_000912; thioctic acid (alpha-lipoic acid); HMS1922M22; HMS3649H08; HMS3885I16; Pharmakon1600-01503941; ACT14091; ALBB-030318; BCP13221; BCP14048; BCP18944; HY-N0492; Tox21_110285; Tox21_201808; Tox21_303092; BBL013878; CCG-39063; dl-1,2-Dithiolane-3-pentanoic acid; NSC628502; NSC758651; s3996; SBB003484; STK801969; ()-1,2-Dithiolane-3-pentanoic acid; AKOS000121582; AKOS016339634; Tox21_110285_1; AM84329; CS-4370; EBD2203019; KS-1322; LS40210; MCULE-1034910084; NSC-628502; NSC-758651; IDI1_000912; DL-THIOCTIC ACID (OXIDIZED) 25G; NCGC00016032-02; NCGC00016032-03; NCGC00016032-04; NCGC00016032-05; NCGC00016032-07; NCGC00016032-08; NCGC00016032-09; NCGC00016032-11; NCGC00090872-01; NCGC00090872-02; NCGC00090872-03; NCGC00090872-04; NCGC00090872-05; NCGC00256970-01; NCGC00259357-01; (+/-)-alpha-Lipoic acid, >=98.0%; AC-22673; AK-68233; AK-72974; BP-31070; NCI60_042014; O217; R)-(+)-; A-Lipoic acid OOEthyAoEthAEa; ST073359; SY010902; (R)-(+)-(c) paragraph sign-Lipoic acid; SBI-0051871.P002; 5-(1,2-Dithiolan-3-yl)pentanoic acid #; AB0010770; DB-050522; 1,2-Dithiolane-3-pentanoic acid, (+/-)-; 1,2-Dithiolane-3-valeric acid, (.+-.)-; FT-0622068; FT-0625429; FT-0670812; FT-0670813; L0058; 1,2-Dithiolane-3-pentanoic acid, (.+-.)-; 1,2-Dithiolane-3-valeric acid, (.+/-.)-; 1,2-Dithiolane-3-pentanoic acid, (.+/-.)-; 3049-EP2316827A1; C00725; D00086; J10446; M-5249; AB00052393_09; (+/-)?-?1,2-?Dithiolane-?3-?Pentanoic Acid; Q312229; 1,2-Dithiolane-3-pentanoic acid, (+-)- (9CI); J-002007; J-520421; SR-01000737460-2; SR-01000737460-6; F2191-0208; Thioctic acid, European Pharmacopoeia (EP) Reference Standard; (+/-)-alpha-Lipoic acid, BioReagent, cell culture tested, >=99%; (+/-)-alpha-Lipoic acid, synthetic, >=99% (titration), powder; 5,5-dideuterio-5-(3,4,4-trideuteriodithiolan-3-yl)pentanoic acid; Alpha Lipoic Acid, United States Pharmacopeia (USP) Reference Standard; (R)-(+)-1,2-Dithiolane-3-pentanoic acid; R-(+)-Thioctic acid; R-(+)-alpha-Lipoic acid; AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade mark?-Lipoic Acid; Thioctic acid containing impurity B, European Pharmacopoeia (EP) Reference Standard; Thioctic acid for system suitability, European Pharmacopoeia (EP) Reference Standard; Thioctic Acid;1,2-Dithiolane-3-pentanoic acid;5-(1,2-Dithiolan-3-yl)valeric acid	Small molecule	1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)	AGBQKNBQESQNJD-UHFFFAOYSA-N	C1CSSC1CCCCC(=O)O	C8H14O2S2	CAS 1077-28-7	CHEBI:16494	.	.	.	D0P6PQ	.	.	.
NP2691	Spectinomycin	CID: 15541	Spectinomycin; actinospectacin; Trobicin; Espectinomicina; Togamycin; 1695-77-8; Antibiotic 2233wp; Spectam; Spectinomycine; Spectinomycinum; Spectinomicina [Italian]; Actinospectacina [Italian]; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]; Espectinomicina [INN-Spanish]; Spectinomycin hydrochloride; UNII-93AKI1U6QF; M-141; 93AKI1U6QF; CHEBI:9215; SCM; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-; Actinospectacina; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; M 141; U 18409; 22189-32-8; Spectinomycin [INN:BAN]; (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one; U 18409 E; XK 43-1; C14H24N2O7; 21736-83-4; U-18409E; EINECS 216-911-3; Spectinomycin HCl/ Sulphate; BRN 2171701; Specitinomycin; SR-05000001868; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-3,5a,6,7,8,9,9a,10a-octahydro-2H-benzo[[?]]pyrano[[?]][1,4]dioxin-4-one; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-; Prospec (TN); Adspec (TN); SPCM; Spectinomycin (INN); NSC132679; Spectrum_000954; Prestwick0_000804; Prestwick1_000804; Prestwick2_000804; Prestwick3_000804; Spectrum2_001315; Spectrum3_000898; Spectrum4_000993; Spectrum5_001407; SCHEMBL3533; CHEMBL1167; BSPBio_000667; KBioGR_001425; KBioSS_001434; DivK1c_000137; SPBio_001409; SPBio_002588; BPBio1_000735; DTXSID9023592; GTPL11127; KBio1_000137; KBio2_001434; KBio2_004002; KBio2_006570; KBio3_001816; NINDS_000137; HMS2089C03; CHX-3101; ZINC53006806; AKOS015961272; CCG-208273; DB00919; IDI1_000137; SMP1_000276; NCGC00017354-02; NCGC00017354-03; NCGC00017354-04; NCGC00142531-01; NCGC00142531-02; AC-13570; NCI60_000023; O212; ST066911; SBI-0051514.P003; C02078; D08526; U18409; AB00642548-10; AB00642548-11; AB00642548_12; AB00642548_13; Q416154; U-18409; ACTINOSPECTACIN; ESPECTINOMICINA; CHX-3101; SR-05000001868-4; ETHYL2-ANILINO-4-CHLORO-5-FORMYL-3-THIOPHENECARBOXYLATE; (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.0^{3,8}]tetradecan-7-one; (8S,11S,13S,14S,3R,6R,10R,12R)-12,14-bis(methylamino)-3,11,13-trihydroxy-6-met hyl-2,7,9-trioxatricyclo[8.4.0.0<3,8>]tetradecan-4-one	Small molecule	1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1	UNFWWIHTNXNPBV-WXKVUWSESA-N	CC1CC(=O)C2(C(O1)OC3C(C(C(C(C3O2)NC)O)NC)O)O	C14H24N2O7	CAS 1695-77-8	CHEBI:9215	.	.	.	D02PCR	.	.	.
NP2704	Dopamine	CID: 681	dopamine; 4-(2-Aminoethyl)benzene-1,2-diol; 3-Hydroxytyramine; 51-61-6; Dopamin; Hydroxytyramin; Oxytyramine; 3,4-dihydroxyphenethylamine; intropin; Dophamine; 2-(3,4-dihydroxyphenyl)ethylamine; 4-(2-Aminoethyl)catechol; hydroxytyramine; Dopaminum; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)-1,2-benzenediol; 3,4-Dihydroxyphenylethylamine; Dopamina; L-DOPAMINE; ASL 279; Pyrocatechol, 4-(2-aminoethyl)-; 1,2-Benzenediol, 4-(2-aminoethyl)-; Dopaminum [INN-Latin]; Dopamina [INN-Spanish]; 3-Hydroxtyramine; alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; KW-3-060; Sinemet; 4-(2-aminoethyl)-pyrocatechol; UNII-VTD58H1Z2X; Dynatra; NSC 173182; a-(3,4-Dihydroxyphenyl)-b-aminoethane; 4-(2-Aminoethyl)-1,2-bezenediol; VTD58H1Z2X; CHEBI:18243; NSC-173182; LDP; NCGC00015519-05; Pyrocatechol, 4-(2-aminoethyl)- (8CI); Dopamine [INN:BAN]; DSSTox_CID_2420; 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI); DSSTox_RID_76584; DSSTox_GSID_22420; .alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane; (3H)-Dopamine; Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; 62-31-7 (HYDROCHLORIDE); CAS-51-61-6; Dopamine (INN); Medopa (TN); NSC169105; HSDB 3068; EINECS 200-110-0; Intropin [*hydrochloride*]; 4-(2-Aminoethyl)-1,2-benzenediol hydrochloride; SR-01000075366; .beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; m-Hydroxytyramine-; Dopamine (USAN)(*hydrochloride*); IP 498; Intropin (Salt/Mix); Spectrum_001012; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; CHEMBL59; Spectrum2_001023; Spectrum3_000406; Spectrum4_000525; Spectrum5_000945; Lopac-H-8502; Biomol-NT_000001; bmse000909; bmse000933; SCHEMBL8505; 1, 4-(2-aminoethyl)-; Lopac0_000586; Oprea1_088821; BSPBio_001932; GTPL940; KBioGR_001129; KBioGR_002388; KBioGR_002484; KBioSS_001492; KBioSS_002393; KBioSS_002491; cid_65340; BIDD:ER0506; DivK1c_000780; SPECTRUM1505155; SPBio_001205; BPBio1_001123; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; DTXSID6022420; BDBM55121; KBio1_000780; KBio2_001492; KBio2_002388; KBio2_002484; KBio2_004060; KBio2_004956; KBio2_005052; KBio2_006628; KBio2_007524; KBio2_007620; KBio3_001152; KBio3_002867; KBio3_002962; ZINC33882; cMAP_000036; cMAP_000065; NINDS_000780; DOPAMINE, [7-3H(N)]; HMS3743I03; AMY40803; BCP34189; Tox21_110167; 2-(3, 4-Dihydroxyphenyl)ethylamine; 2-(3,4-dihydroxyphenyl) ethylamine; ANW-54385; BBL013043; MFCD00130258; NSC173182; SBB004044; STK301601; 3,4-DihydroxyphenylA currencythylamin; AKOS003790978; Tox21_110167_1; CCG-204675; DB00988; FS-5341; MCULE-7558764100; SDCCGSBI-0050568.P005; 2-(3,4-Dihydroxyphenyl)-1-ethanamine; 4-(2-Amino-ethyl)-benzene-1,2-diol; 4-(2-Aminoethyl)-1,2-benzenediol #; IDI1_000780; UPCMLD0ENAT5885989:001; NCGC00015519-01; NCGC00015519-02; NCGC00015519-03; NCGC00015519-04; NCGC00015519-07; NCGC00015519-08; NCGC00015519-09; NCGC00015519-10; NCGC00015519-11; NCGC00015519-25; NCGC00096050-01; NCGC00096050-02; NCGC00096050-03; NCGC00096050-04; NCGC00096050-05; 50444-17-2; AK100905; BP-23276; ST048774; 4-(2-aminoethyl)pyrocatechol;hydrochloride; SBI-0050568.P004; FT-0698513; T7923; 2-(4-Hydroxy-5-oxylatophenyl)-1-ethanaminium; C03758; D07870; 13510-EP2269989A1; 13510-EP2270011A1; 13510-EP2272537A2; 13510-EP2272825A2; 13510-EP2272847A1; 13510-EP2275420A1; 13510-EP2277882A1; 13510-EP2280010A2; 13510-EP2281559A1; 13510-EP2281815A1; 13510-EP2281819A1; 13510-EP2284169A1; 13510-EP2284170A1; 13510-EP2284171A1; 13510-EP2286811A1; 13510-EP2287161A1; 13510-EP2287162A1; 13510-EP2287165A2; 13510-EP2287166A2; 13510-EP2292620A2; 13510-EP2295437A1; 13510-EP2295439A1; 13510-EP2298312A1; 13510-EP2298313A1; 13510-EP2298731A1; 13510-EP2298734A2; 13510-EP2298758A1; 13510-EP2298759A1; 13510-EP2298775A1; 13510-EP2298776A1; 13510-EP2301540A1; 13510-EP2301933A1; 13510-EP2305260A1; 13510-EP2305633A1; 13510-EP2305640A2; 13510-EP2305644A1; 13510-EP2305648A1; 13510-EP2305650A1; 13510-EP2305652A2; 13510-EP2305656A1; 13510-EP2305659A1; 13510-EP2305664A1; 13510-EP2305675A1; 13510-EP2305689A1; 13510-EP2308828A2; 13510-EP2308867A2; 13510-EP2308870A2; 13510-EP2308875A1; 13510-EP2311494A1; 13510-EP2311801A1; 13510-EP2311802A1; 13510-EP2311803A1; 13510-EP2311818A1; 13510-EP2311827A1; 13510-EP2311828A1; 13510-EP2311835A1; 13510-EP2314571A2; 13510-EP2316470A2; 13510-EP2316836A1; 13510-EP2371814A1; 4-(2-azanylethyl)benzene-1,2-diol;hydrochloride; AB00053463-12; AB00053463_13; AB00053463_14; L000232; Q170304; SR-01000075366-7; Oseltamivir-d3;Hydroxytyramin;4-(2-Aminoethyl)benzene-1,2-diol; 70097-41-5	Small molecule	1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2	VYFYYTLLBUKUHU-UHFFFAOYSA-N	C1=CC(=C(C=C1CCN)O)O	C8H11NO2	CAS 51-61-6	CHEBI:18243	.	.	.	D0T7OW	.	.	.
NP2717	Tangeretin	CID: 68077	Tangeritin; Ponkanetin; Pentamethoxyflavone; 4',5,6,7,8-Pentamethoxyflavone; 5,6,7,8,4'-Pentamethoxyflavone; Tangeretin (6CI); 4H-1-Benzopyran-4-one, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)-; 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)chromen-4-one; UNII-I4TLA1DLX6; NSC 53909; 5,6,7,8-Tetramethoxy-2-(4-methoxyphenyl)-4-benzopyrone; 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)-4H-chromen-4-one; I4TLA1DLX6; CHEMBL73930; MLS002667634; CHEBI:9400; 4H-1-Benzopyran-4-one, 5,6,7,8-tetramethoxy-2-(p-methoxyphenyl)-; NSC53909; Flavone, 4',5,6,7,8-pentamethoxy- (7CI,8CI); MFCD00017438; NSC-53909; Flavone, 5,6,7,8,4'-pentamethoxy; Tangeritin; NSC53909; NSC618905; 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one; EINECS 207-570-1; BRN 0351695; AI3-23869; 4',5,6,7,8-pentamethoxy-flavone; Tangeretin (Tangeritin); 2-(4-Methoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; Spectrum2_001698; Spectrum3_000920; Spectrum4_001019; SCHEMBL19740; KBioGR_001517; 5-18-05-00491 (Beilstein Handbook Reference); SPECTRUM1505269; SPBio_001656; Tangeretin, analytical standard; MEGxp0_001011; Tangeretin, >=95% (HPLC); ACon1_001263; KBio3_001900; DTXSID30197417; Flavone,5,6,7,8-pentamethoxy-; HMS3651A22; HY-N0133; ZINC1531699; 4'',5,6,7,8-pentamethoxyflavone; 4H-1-Benzopyran-4-one, 2-(4-methoxyphenyl)-5,6,7,8-tetramethoxy-; 5,6,7,8,4''-Pentamethoxyflavone; BDBM50209218; CCG-38782; CT0015; LMPK12111443; NSC618905; s2363; AKOS015895209; AC-1699; CS-5484; MCULE-1727108016; NSC 618905; NSC-618905; SDCCGMLS-0066766.P001; Flavone, 4',5,6,7,8-pentamethoxy-; NCGC00095850-01; NCGC00095850-02; NCGC00169520-01; AK168079; AS-11637; NCI60_004330; SMR001557394; ST097546; AB0010469; FT-0632194; N2077; SW219232-1; C10190; K-9174; 481T538; SR-05000002625; CU-01000013437-2; Q-100525; Q1748737; SR-05000002625-1; BRD-K25186396-001-02-1; BRD-K25186396-001-04-7; 4H-1-Benzopyran-4-one,6,7,8-tetramethoxy-2-(4-methoxyphenyl)-; 4H-1-Benzopyran-4-one,6,7,8-tetramethoxy-2-(p-methoxyphenyl)-; 4H-1-Benzopyran-4-one, 5,6,7,8-tetra-methoxy-2-(4-methoxyphenyl)-; 5,6,7,8-Tetramethoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one, 9CI	.	1S/C20H20O7/c1-22-12-8-6-11(7-9-12)14-10-13(21)15-16(23-2)18(24-3)20(26-5)19(25-4)17(15)27-14/h6-10H,1-5H3	ULSUXBXHSYSGDT-UHFFFAOYSA-N	COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC	C20H20O7	CAS 481-53-8	.	HBIN045469	SMIT00621	MOL005814	.	.	1349	.
NP2740	Borneol	CID: 64685	isoborneol; (+)-borneol	.	1S/C10H18O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7-8,11H,4-6H2,1-3H3	DTGKSKDOIYIVQL-UHFFFAOYSA-N	CC1(C2CCC1(C(C2)O)C)C	C10H18O	CAS 507-70-0	.	HBIN018727	SMIT01299	.	D0P8RH	DB11288	985	.
NP2741	Epsilon-viniferin	CID: 5281728	Epsilon-viniferin; 62218-08-0; epsilon-?Viniferin; CHEBI:10556; trans-epsilon-Viniferin; UNII-0K8Z2K6Y7O; 0K8Z2K6Y7O; CHEMBL1224875; C28H22O6; W2075; epsilon-viniferine; 5-[(2R,3R)-2,3-dihydro-6-hydroxy-2-(4-hydroxyphenyl)-4-[(1E)-2-(4-hydroxyphenyl)ethenyl]-3-benzofuranyl]-1,3-benzenediol; 5-[(2R,3R)-6-hydroxy-2-(4-hydroxyphenyl)-4-[(E)-2-(4-hydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-3-yl]benzene-1,3-diol; AC1NQYZ4; Resveratrol dimer; 5-{(2R,3R)-6-hydroxy-2-(4-hydroxyphenyl)-4-[(E)-2-(4-hydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-3-yl}benzene-1,3-diol; (-)-epsilon-Viniferin; (-)-trans-  -viniferin; SureCN3041632; (-)-Trans-epsilon-viniferin; SCHEMBL3041632; epsilon-Viniferin , HPLC Grade; 253435-07-3; HY-N3841; ZINC4098643; BDBM50531887; MFCD12964987; 5-(2,3-Dihydro-6-hydroxy-2(4-hydroxyphenyl)4-(2-(4-hydroxyphenyl)ethenyl)-3-benzofuranyl)-1,3-benzenediol; CS-0024314; C10289; Q5383943; (2R)-2beta-(4-Hydroxyphenyl)-3alpha-(3,5-dihydroxyphenyl)-4-(4-hydroxystyryl)-2,3-dihydrobenzofuran-6-ol; 1,3-Benzenediol, 5-(2,3-dihydro-6-hydroxy-2(4-hydroxyphenyl)4-(2-(4-hydroxyphenyl)ethenyl)-3-benzofuranyl)-; 5-[(2R,3R)-6-hydroxy-2-(4-hydroxyphenyl)-4-[(E)-2-(4-hydroxyphenyl)vinyl]-2,3-dihydrobenzofuran-3-yl]benzene-1,3-diol	Small molecule	1S/C28H22O6/c29-20-7-2-16(3-8-20)1-4-18-11-24(33)15-25-26(18)27(19-12-22(31)14-23(32)13-19)28(34-25)17-5-9-21(30)10-6-17/h1-15,27-33H/b4-1+/t27-,28+/m1/s1	FQWLMRXWKZGLFI-YVYUXZJTSA-N	C1=CC(=CC=C1C=CC2=C3C(C(OC3=CC(=C2)O)C4=CC=C(C=C4)O)C5=CC(=CC(=C5)O)O)O	C28H22O6	CAS 62218-08-0	CHEBI:10556	.	.	.	.	.	.	.
NP2756	Camellia sinensis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP2784	Voacamine	CID: 11953931	VOACAMINE; Voacanginine; Vocamine; 3371-85-5; Methyl 12-methoxy-13-(17-methoxy-17-oxovobasan-3alpha-yl)ibogamine-18-carboxylate; CHEBI:10014; DB04877; C09252; Methyl-12-methoxy-13-(17-methoxy-17-oxovobasan-3alpha-yl)ibogamine-18-carboxylate; methyl (1S,15S,17S,18S)-17-ethyl-6-[(1R,12R,14R,15E)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3(11),4,6,8-tetraen-12-yl]-7-methoxy-3,13-diazapentacyclo[13.3.1.0^{2,10}.0^{4,9}.0^{13,18}]nonadeca-2(10),4,6,8-tetraene-1-carboxylate; methyl (1S,15S,17S,18S)-17-ethyl-6-[(1R,12R,14R,15E)-15-ethylidene-18-methoxycarbonyl-17-methyl-10,17-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate	Small molecule	1S/C43H52N4O5/c1-7-24-15-23-20-43(42(49)52-6)39-27(13-14-47(21-23)40(24)43)29-19-36(50-4)30(17-34(29)45-39)31-16-28-25(8-2)22-46(3)35(37(28)41(48)51-5)18-32-26-11-9-10-12-33(26)44-38(31)32/h8-12,17,19,23-24,28,31,35,37,40,44-45H,7,13-16,18,20-22H2,1-6H3/b25-8-/t23-,24-,28-,31+,35+,37?,40-,43+/m0/s1	VCMIRXRRQJNZJT-XRMSBCOFSA-N	CCC1CC2CC3(C1N(C2)CCC4=C3NC5=CC(=C(C=C45)OC)C6CC7C(C(CC8=C6NC9=CC=CC=C89)N(CC7=CC)C)C(=O)OC)C(=O)OC	C43H52N4O5	CAS 3371-85-5	CHEBI:10014	.	.	.	.	.	.	.
NP2797	Reboxetine	CID: 127151	Reboxetine; 71620-89-8; 98769-81-4; Vestra; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-; Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; (R)-2-((R)-(2-ethoxyphenoxy)(phenyl)methyl)morpholine; (R,R)-Reboxetine; Reboxetine [INN:BAN]; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; R,R-reboxetine; Reboxe- tine; HSDB 7701; Reboxetine (INN); Edronax (TN); 2-[(2-ethoxyphenoxy)-phenyl-methyl]morpholine; SCHEMBL34533; CHEMBL383921; DTXSID1048257; CHEBI:135342; BDBM388642; BCP12060; ZINC3996032; AKOS015966368; DB00234; AS-56251; US9944618, Compound ID No. 178; D08472; AB00920697_06; UNII-947S0YZ36I component CBQGYUDMJHNJBX-RTBURBONSA-N; 41X	Small molecule	1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1	CBQGYUDMJHNJBX-RTBURBONSA-N	CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3	C19H23NO3	CAS 71620-89-8	CHEBI:135342	.	.	.	D0N8FQ	.	.	.
NP2806	Lentinan	CID: 37723	LENTINAN; 37339-90-5; Bromoduline; Biomoduline; LC-33; UNII-6751655D1D; DRG-0171; SCHEMBL1517264; DTXSID30190781; 6751655D1D; A823605; (2R,3R,4S,5S,6R)-2-[[(2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]; (2R,3R,4S,5S,6R)-2-[[(2R,3R,4S,5R,6R)-4-[[(2S,3R,4S,5R,6R)-4-[[(2S,3R,4S,5R,6R)-4-[[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxyme; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[[(2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-6-(hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-6-(hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-4-[(2R,3R,4S,5S,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-6-(hydroxy	Small molecule	1S/C42H72O36/c43-1-8-15(48)22(55)25(58)37(69-8)66-6-13-20(53)32(28(61)36(65)68-13)75-40-29(62)33(18(51)11(4-46)72-40)77-41-30(63)34(19(52)12(5-47)73-41)78-42-31(64)35(76-39-27(60)24(57)17(50)10(3-45)71-39)21(54)14(74-42)7-67-38-26(59)23(56)16(49)9(2-44)70-38/h8-65H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+,25-,26-,27-,28-,29-,30-,31-,32+,33+,34+,35+,36-,37-,38-,39+,40+,41+,42+/m1/s1	MAXBMUKIXLNXGX-DMWITZOWSA-N	C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)O)O)OC3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)CO)O)OC5C(C(C(C(O5)COC6C(C(C(C(O6)CO)O)O)O)O)OC7C(C(C(C(O7)CO)O)O)O)O)O)O)O)O)O)O)O	C42H72O36	CAS 37339-90-5	.	.	.	.	D07XBE	.	.	.
NP2892	Juglans regia	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP2927	Platycodin D	CID: 162859	Platycodin D; 58479-68-8; PlatycodinD; UNII-CWJ06TA2GI; CWJ06TA2GI; CHEBI:70436; Platycodin-D; C57H92O28; CHEMBL1641859; HMS3887G11; HY-N1411; MFCD09952590; s9304; AKOS037514784; CCG-270661; BS-14123; CS-0016836; N1498; X0087; C17410; 479P688; Q-100670; Q15425261; Olean-12-en-28-oic acid, 3-(beta-D-glucopyranosyloxy)-2,16,23,24-tetrahydroxy-, O-D-apio-beta-D-furanosyl-(1-3)-O-beta-D-xylopyranosyl-(1-4)-O-6-deoxy-alpha-L-mannopyranosyl-(1-2)-L-arabinopyranosyl ester, (2beta,3beta,16alpha)-	Small molecule	1S/C57H92O28/c1-23-40(81-45-39(72)41(28(64)18-76-45)82-49-43(73)56(75,21-61)22-78-49)36(69)38(71)46(79-23)83-42-33(66)27(63)17-77-48(42)85-50(74)57-12-11-51(2,3)13-25(57)24-7-8-30-52(4)14-26(62)44(84-47-37(70)35(68)34(67)29(16-58)80-47)55(19-59,20-60)31(52)9-10-53(30,5)54(24,6)15-32(57)65/h7,23,25-49,58-73,75H,8-22H2,1-6H3/t23-,25-,26-,27-,28+,29+,30+,31+,32+,33-,34+,35-,36-,37+,38+,39+,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,52+,53+,54+,56+,57+/m0/s1	CYBWUNOAQPMRBA-NDTOZIJESA-N	CC1C(C(C(C(O1)OC2C(C(COC2OC(=O)C34CCC(CC3C5=CCC6C(C5(CC4O)C)(CCC7C6(CC(C(C7(CO)CO)OC8C(C(C(C(O8)CO)O)O)O)O)C)C)(C)C)O)O)O)O)OC9C(C(C(CO9)O)OC1C(C(CO1)(CO)O)O)O	C57H92O28	CAS 58479-68-8	CHEBI:70436	.	.	.	.	.	.	.
NP2960	Epigallocatechin gallate	CID: 65064	(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl;  EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE	.	1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1	WMBWREPUVVBILR-WIYYLYMNSA-N	C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O	C22H18O11	CAS 989-51-5	.	HBIN025354	.	.	D0U2BH	.	.	.
NP2974	Mangiferin	CID: 5281647	Mangiferin; 4773-96-0; Alpizarin; Chinonin; Chinomin; Hedysarid; Aphloiol; Alpizarine; Shamimin; UNII-1M84LD0UMD; 1M84LD0UMD; CHEBI:6682; 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one; 9H-Xanthen-9-one, 2-b-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; (1S)-1,5-anhydro-1-(1,3,6,7-tetrahydroxy-9-oxo-9H-xanthen-2-yl)-D-glucitol; MFCD00075656; 9H-Xanthen-9-one, 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy- (9CI); 1,3,6,7-Tetrahydroxyxanthone-C2-b-D-glucoside; Chedisaride; Euxanthogen; Hedysaride; Mannipherin; Chinoinin; Chinomine; 1,3,6,7-Tetrahydroxy-2-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-9H-xanthen-9-one; 9H-Xanthen-9-one, 2-.beta.-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; cid_5358385; Alpizarine;; Mangiferin;; Aphloiol;; Chinomin;; NSC248870; Mangiferin,(S); Xanthone-c-glucoside; NSC 248870; 1,3,6,7-tetrahydroxyxanthone C2-beta-D-glucoside; 9H-Xanthen-9-one, 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; Mangiferin Mangifera indica; SCHEMBL556844; Mangiferin, analytical standard; CHEMBL464825; BCBcMAP01_000240; DTXSID60197263; HY-N0290; ZINC4098535; BDBM50248691; s3808; STL564509; AKOS015896788; CCG-268909; CS-4663; MCULE-3926908782; SMP1_000290; AS-15337; O907; N1329; A12088; C10077; 773M960; Q-100508; Q1074417; c2-beta-d-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone; Mangiferin, European Pharmacopoeia (EP) Reference Standard; 1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]xanthen-9-one	Small molecule	1S/C19H18O11/c20-4-11-15(25)17(27)18(28)19(30-11)12-8(23)3-10-13(16(12)26)14(24)5-1-6(21)7(22)2-9(5)29-10/h1-3,11,15,17-23,25-28H,4H2/t11-,15-,17+,18-,19+/m1/s1	AEDDIBAIWPIIBD-ZJKJAXBQSA-N	C1=C2C(=CC(=C1O)O)OC3=C(C2=O)C(=C(C(=C3)O)C4C(C(C(C(O4)CO)O)O)O)O	C19H18O11	CAS 4773-96-0	CHEBI:6682	.	.	.	D04UYB	.	.	.
NP3051	Pregabalin	CID: 5486971	Pregabalin; 148553-50-8; Lyrica; (S)-3-(Aminomethyl)-5-methylhexanoic acid; 3-isobutyl GABA; (3S)-3-(aminomethyl)-5-methylhexanoic acid; CI-1008; (S)-Pregabalin; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-; CI 1008; PD 144723; UNII-55JG375S6M; PD-144723; (S)-3-Isobutyl GABA; CHEMBL1059; CHEBI:64356; (3S)-3-(aminomethyl)-5-methyl-hexanoic acid; 55JG375S6M; MFCD00917044; Hexanoic acid, 3-(aminomethyl)-5-ethyl-, (3S)-; (R-)-3-isobutyl GABA; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)-; Nervalin; Pregablin; HSDB 7530; Pregabalin [USAN:INN:BAN:JAN]; NCGC00095186-01; Lyrica (TN); (S)-3-(Aminomethyl)-5-methylhexanoicacid; SCHEMBL8227; DSSTox_CID_25950; DSSTox_RID_81246; DSSTox_GSID_45950; Pregabalin (JAN/USAN/INN); (S)-(+)-4-amino-3-(2-methylpropyl)butanoic acid; GTPL5484; ZINC5152; DEA No. 2782; Pregabalin, >=97% (NMR); DTXSID1045950; HMS3715J16; Pregabalin 1.0 mg/ml in Methanol; YNP-1807; Tox21_111475; BDBM50164279; CP0100; AKOS001476611; AKOS005145504; Lyrica;CI-1008;PD-144723; AC-1158; ACN-038395; CCG-221247; CM14412; CS-1247; DB00230; KS-5378; NSC 759256; (S)-3-aminomethyl-5-methylhexanoic acid; NCGC00346738-01; 121GE001; HY-17414; (S)-3-Aminomethyl-5-methyl-hexanoic acid; AB0074009; AM20080369; CAS-148553-50-8; EN300-92104; (3S)-3-(aminomethyl)-5-methyl hexanoic acid; (S)-(+)-3-Aminomethyl-5-Methylhexanoic Acid; D02716; W-5218; AB01563007_01; 553P508; A808784; Q412174; SR-01000942257; SR-01000942257-2; Pregabalin, EuropePharmacopoeia (EP) Reference Standard; Z2757554242; 1414928-41-8	Small molecule	1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1	AYXYPKUFHZROOJ-ZETCQYMHSA-N	CC(C)CC(CC(=O)O)CN	C8H17NO2	CAS 148553-50-8	CHEBI:64356	.	.	.	D00WUF	.	.	.
NP3067	Paclitaxel	CID: 36314	Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-	.	1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1	RCINICONZNJXQF-MZXODVADSA-N	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C	C47H51NO14	CAS 33069-62-4	.	HBIN045705	.	.	D0C4RB	.	.	.
NP3076	Clavulanate	CID: 5280980	CLAVULANIC ACID; Clavulanate; 58001-44-8; Acido clavulanico; Acide clavulanique; Antibiotic MM 14151; acidum clavulanicum; Clavulansaeure; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; MM 14151; BRL 14151; BRL-14151; Clavulanate acid; CHEBI:48947; CLAVULANATE POTASSIUM; UNII-23521W1S24; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; CHEMBL777; rx-10100; Sodium Clavulanate; Clavulansaeure [INN]; 23521W1S24; CLAVULANATE LITHIUM; Clavulinic Acid; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; Clavulox (TN); BRL-14151K; Clavulanic acid (INN); EINECS 261-069-2; 3008-B; BRN 0787059; Clavulanic acid [INN:BAN]; clavulonic acid; BRL14151; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; Epitope ID:117130; SCHEMBL6093; SCHEMBL34260; BSPBio_002430; DTXSID2022830; GTPL11128; ZINC3830569; BDBM50021959; AKOS016009164; DB00766; NCGC00188985-01; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2-alpha,3Z,5-alpha))-; SBI-0206779.P001; A12384; C06662; D07711; 49700-EP2275102A1; 49700-EP2295432A1; 49700-EP2308874A1; 49700-EP2311825A1; 001C448; Q415709; W-105420; Clavulanic acid, Antibiotic for Culture Media Use Only; (2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2beta-carboxylic acid; 1365254-41-6; 4-Oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,3-(2-hydroxyethylidene)-7-oxo-,(2R,3Z,5R)-	Small molecule	1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1	HZZVJAQRINQKSD-PBFISZAISA-N	C1C2N(C1=O)C(C(=CCO)O2)C(=O)O	C8H9NO5	CAS 58001-44-8	CHEBI:48947	.	.	.	D0X7JN	.	.	.
NP3125	Procyanidin	CID: 107876	2-(3,4-Dihydroxyphenyl)-2-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-3-yl)oxy)chroman-3,4,5,7-tetraol; 2-(3,4-dihydroxyphenyl)-2-[[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl]oxy]-3,4-dihydrochromene-3,4,5,7-tetrol; 2H-1-Benzopyran-3,4,5,7-tetrol, 2-(3,4-dihydroxyphenyl)-2-((2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl)oxy)-3,4-dihydro-; Procyanidins; 2H-1-Benzopyran-3,4,5,7-tetrol, 2-(3,4-dihydroxyphenyl)-2-[[2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl]oxy]-3,4-dihydro-; BRN 1675863; 2-(3,4-Dihydroxyphenyl)-2-((2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl)oxy)-3,4-dihydro-2H-1-benzopyran-3,4,5,7-tetrol; 3,3',4,4',5,7-Flavanhexol, 2-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-chromanyl)oxy)-; Procyanidin, Technical grade; SCHEMBL15091123; DTXSID90858698; CHEBI:166895; BCP25503; HY-N0794; C31H28O12; MFCD01662851; s5105; AKOS025402316; AC-8032; CCG-270176; CCG-270178; 2-(3,4-dihydroxyphenyl)-2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl]oxy-chromane-3,4,5,7-tetrol; AK321485; CS-0009805; FT-0688150; X1211; Y0170; 852P226; 2-(3,4-dihydroxyphenyl)-2-{[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2h-chromen-3-yl]oxy}-3,4,5,7-chromanetetrol	.	1S/C30H26O13/c31-14-7-19(35)16-11-25(28(41-23(16)9-14)12-1-3-17(33)20(36)5-12)43-30(13-2-4-18(34)21(37)6-13)29(40)27(39)26-22(38)8-15(32)10-24(26)42-30/h1-10,25,27-29,31-40H,11H2	HGVVOUNEGQIPMS-UHFFFAOYSA-N	C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC4(C(C(C5=C(C=C(C=C5O4)O)O)O)O)C6=CC(=C(C=C6)O)O	C30H26O13	CAS 20347-71-1	.	HBIN040755	SMIT02315	MOL003352	.	.	.	.
NP3140	Levodopa	CID: 6047	levodopa; L-dopa; 59-92-7; 3-Hydroxy-L-tyrosine; 3,4-dihydroxy-L-phenylalanine; Dopar; Bendopa; Larodopa; Levopa; 3-(3,4-Dihydroxyphenyl)-L-alanine; Brocadopa; Cidandopa; Insulamina; Maipedopa; Dopaidan; Dopalina; Dopasol; Eldopal; Eldopar; Pardopa; Prodopa; Syndopa; 3,4-Dihydroxyphenylalanine; (-)-Dopa; Dihydroxy-L-phenylalanine; Helfo-Dopa; Dopaflex; Deadopa; Dopal-fher; Doparkine; Dopaston; Dopastral; Eldopatec; Eurodopa; Doparl; Doprin; Veldopa; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; L-3,4-Dihydroxyphenylalanine; Levedopa; L-o-Hydroxytyrosine; Dopa; Levodopum; Ledopa; (-)-3-(3,4-Dihydroxyphenyl)-L-alanine; L-Tyrosine, 3-hydroxy-; 3,4-Dihydroxyphenyl-L-alanine; Dopaston SE; beta-(3,4-Dihydroxyphenyl)-L-alanine; L-(o-Dihydroxyphenyl)alanine; L-(-)-Dopa; L-3-Hydroxytyrosine; L-beta-(3,4-Dihydroxyphenyl)alanine; Weldopa; Parda; L-Dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)alanine; C9H11NO4; Ro 4-6316; beta-(3,4-Dihydroxyphenyl)alanine; alanine, 3-(3,4-dihydroxyphenyl)-, L-; (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; Levodopa free base; MFCD00002598; component of Sinemet; Dopar (TN); CHEBI:15765; beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine; L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine; UNII-46627O600J; Alanine, 3-(3,4-dihydroxyphenyl)-, (-)-; L(-)-Dopa; (-)-(3,4-Dihydroxyphenyl)alanine; dihydroxyphenylalanine; L-3,4-Dihydrophenylalanine; L-.beta.-(3,4-Dihydroxyphenyl)alanine; CHEMBL1009; .beta.-(3,4-Dihydroxyphenyl)-L-alanine; 59-92-7 (free base); L-(3,4-Dihydroxyphenyl)alanine; CVT-301; NSC118381; .beta.-(3,4-Dihydroxyphenyl)alanine; NSC-118381; CAS-59-92-7; NCGC00016270-04; Biodopa; Cerepap; Laradopa; Sobiodopa; L-(3,4-Dihydroxyphenyl)-.alpha.-alanine; 46627O600J; Helfo DOPA; beta-(3,4-Dihydroxyphenyl)-alpha-alanine; Tyrosine, 3-hydroxy-; Atamet; Levodopum [INN-Latin]; BDBM50130192; L-O-Dihydroxyphenylalanine; L Dopa; 3-(3,4-Dihydroxyphenyl)-L-alanine, 99%; CCRIS 3766; HSDB 3348; WLN: QVYZ1R CQ DQ; 3,4-Dihydroxyphenylalanine (VAN); SR-01000075384; 587-45-1; EINECS 200-445-2; NSC 118381; Dopastone; Dopicar; Inbrija; Prolopa; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; Prestwick_185; Levodopa (Sinemet); L-DOPA; Levodopa; Madopa (Salt/Mix); Levodopa [USAN:USP:INN:BAN:JAN]; Spectrum_000454; Carbidopa EP Impurity A; Prestwick0_000017; Prestwick1_000017; Prestwick2_000017; Prestwick3_000017; Spectrum2_000496; Spectrum4_000539; Spectrum5_001899; Lopac-D-9628; Levodopa (JP15/USP); DSSTox_CID_3209; bmse000322; Epitope ID:150927; 3, 4-Dihydroxyphenylalanine; Alanine,4-dihydroxyphenyl)-; DSSTox_RID_76926; DSSTox_GSID_23209; Lopac0_000454; SCHEMBL22655; BSPBio_000053; BSPBio_002354; KBioGR_001177; KBioSS_000934; L-4-5-Dihydroxyphenylalanine; MLS000028514; BIDD:GT0158; DivK1c_000452; SPECTRUM2300205; Levodopa (JP17/USP/INN); SPBio_000391; SPBio_001974; BPBio1_000059; GTPL3639; b-(3,4-Dihydroxyphenyl)alanine; DTXSID9023209; WLN: QVYZ1R CQ DQ -L; 3, 4-Dihydroxy-L-phenylalanine; BDBM60928; HMS501G14; KBio1_000452; KBio2_000934; KBio2_003502; KBio2_006070; Alanine,4-dihydroxyphenyl)-, L-; L-(3, 4-Dihydroxyphenyl)alanine; NINDS_000452; 3-Ethoxy-4-fluorophenylboronicacid; HMS1568C15; HMS1922J14; HMS2090O08; HMS2093N04; HMS2095C15; HMS2230B04; HMS3261K10; HMS3712C15; Pharmakon1600-02300205; ZINC895199; H-Phe{3,4-(OH)2}-OH; HY-N0304; Levodopa;3,4-Dihydroxyphenylalanine; b-(3,4-Dihydroxyphenyl)-L-alanine; Inbrija (levodopa inhalation powder); Tox21_110338; Tox21_500454; ANW-33396; CCG-39571; KM0355; L-3-(3,4-dihydroxy-phenyl)alanine; L-3-(3,4-dihydroxyphenyl)-Alanine; NSC759573; PDSP1_001541; PDSP2_001525; s1726; SBB017533; Alanine, 3-(3,4-dihydroxyphenyl)-; Alanine,4-dihydroxyphenyl)-, (-)-; AKOS010396267; b-(3,4-Dihydroxyphenyl)-a-L-alanine; L-b-(3,4-Dihydroxyphenyl)-a-alanine; .beta.-(3, 4-Dihydroxyphenyl)alanine; AC-8432; AM82124; CS-1945; DB01235; LP00454; MCULE-4743781842; NSC-759573; SDCCGMLS-0066924.P001; SDCCGSBI-0050439.P004; VA11170; IDI1_000452; NCGC00015384-01; NCGC00016270-01; NCGC00016270-06; NCGC00016270-07; NCGC00016270-09; NCGC00016270-10; NCGC00016270-22; NCGC00093869-04; NCGC00261139-01; AK187821; AS-13287; BP-12850; H813; SMR000058312; ST086623; SBI-0050439.P003; AB0013279; L-(3, 4-Dihydroxyphenyl)-.alpha.-alanine; D0600; D9628; EU-0100454; N1648; 59L927; Alanine, 3-(3, 4-dihydroxyphenyl)-, (-)-; C00355; D 9628; D00059; J10404; V-1512; 13173-EP2269989A1; 13173-EP2277876A1; 13173-EP2277882A1; 13173-EP2281559A1; 13173-EP2281815A1; 13173-EP2292614A1; 13173-EP2295412A1; 13173-EP2295413A1; 13173-EP2295439A1; 13173-EP2298731A1; 13173-EP2301933A1; 13173-EP2301934A1; 13173-EP2305633A1; 13173-EP2305640A2; 13173-EP2308867A2; 13173-EP2308870A2; 13173-EP2311827A1; 13173-EP2311837A1; 13173-EP2314571A2; 13173-EP2316470A2; 13173-EP2316834A1; 21660-EP2272832A1; 21660-EP2275420A1; 21660-EP2281559A1; 21660-EP2301934A1; 21660-EP2314571A2; 21920-EP2295410A1; 21920-EP2301939A1; 21920-EP2314571A2; 3,4-Dihydroxy-L-phenylalanine, >=98% (TLC); AB00052418-06; AB00052418-07; AB00052418_08; AB00052418_09; Q300989; Q-201294; SR-01000075384-1; SR-01000075384-4; SR-01000075384-6; SR-01000075384-7; (S)-2-Amino-3-(3,4-dihydroxy-phenyl)-propionic acid; F0347-4695; Levodopa, British Pharmacopoeia (BP) Reference Standard; Levodopa, European Pharmacopoeia (EP) Reference Standard; Z1762772338; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acidL-dopa; UNII-QI9C343R60 component WTDRDQBEARUVNC-LURJTMIESA-N; 1E83F927-C221-46AA-B90A-81B33C5F3868; 3,4-Dihydroxy-L-phenylalanine, Vetec(TM) reagent grade, 98%; Levodopa, United States Pharmacopeia (USP) Reference Standard; 3,4-Dihydroxy-L-phenylalanine, certified reference material, TraceCERT(R); Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material; 122769-74-8; L-Methyldopa ; (2S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; 3-(3,4-Dihydroxyphenyl)-?-methyl-L-alanine; 3-Hydroxy-a-methyl-L-tyrosine	Small molecule	1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1	WTDRDQBEARUVNC-LURJTMIESA-N	C1=CC(=C(C=C1CC(C(=O)O)N)O)O	C9H11NO4	CAS 59-92-7	CHEBI:15765	.	.	.	D08HVR	.	.	.
NP3147	Methylglyoxal	CID: 880	methylglyoxal; pyruvaldehyde; pyruvic aldehyde; 2-Oxopropanal; 78-98-8; acetylformaldehyde; Propanal, 2-oxo-; Acetylformyl; 2-Ketopropionaldehyde; METHYL GLYOXAL; Propanedione; Propanolone; Pyroracemic aldehyde; 2-Oxopropionaldehyde; Glyoxal, methyl; alpha-Ketopropionaldehyde; 1-Ketopropionaldehyde; Propionaldehyde, 2-keto; Propionaldehyde, 2-oxo-; 1,2-Propanedione; alpha-Ketopropionic aldehyde; Methylglyoxal solution; 2-oxo-Propionaldehyde; CH3COCHO; FEMA No. 2969; CCRIS 1741; methyl-glyoxal; 2-oxo-propanal; NSC 79019; NSC 626580; UNII-722KLD7415; CHEBI:17158; MFCD00006960; .alpha.-Ketopropionaldehyde; Pyruvaldehyde polymer; NSC626580; 722KLD7415; Acetalformaldehyde; oxopropanal; Pyruvic aldehyde, 35-45 wt% solution in water; EINECS 201-164-8; NSC 337790; BRN 0906750; Ethanol Ketone; HSDB 7510; Ketopropionaldehyde; acetyl formaldehyde; 51252-84-7; propane-1,2-dione; Pyruvaldehyde solution; Pyruvaldehyde (8CI); 2-keto Propionaldehyde; DSSTox_CID_1628; Epitope ID:143620; WLN: VHV1; EC 201-164-8; DSSTox_GSID_21628; 4-01-00-03631 (Beilstein Handbook Reference); CC(O)=C=O; Propanal, 2-oxo- (9CI); Pyruvic aldehyde Methylglyoxal; Pyruvaldehyde, 40% in water; CHEMBL170721; GTPL6303; DTXSID0021628; [C]C(=O)C=O; Pyruvic Aldehyde (40% solution); NSC79019; STR03080; ZINC1532681; Tox21_303931; ANW-37250; KM1949; Methylglyoxal solution 40% in water; NSC-79019; NSC133492; NSC133493; AKOS000119318; AB00820; DB03587; HY-W020014; MCULE-2718961814; Methylglyoxal solution, ~40% in H2O; NSC-133492; NSC-133493; NSC-626580; CAS-78-98-8; NCGC00356972-01; BP-20618; H451; Pyruvaldehyde solution, 40 wt. % in H2O; CS-0031856; FT-0646558; C00546; Methylglyoxal solution, technical, ~40% in H2O; Q903881; 194597AC-5BFC-42EA-B6C8-DA2E5FAA13AF; J-510228; F0001-2060	Small molecule	1S/C3H4O2/c1-3(5)2-4/h2H,1H3	AIJULSRZWUXGPQ-UHFFFAOYSA-N	CC(=O)C=O	C3H4O2	CAS 78-98-8	CHEBI:17158	.	.	.	D0G4CI	.	.	.
NP3152	Milrinone	CID: 4197	milrinone; 78415-72-2; Primacor; Milrinona; Milrinonum; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile; WIN 47203; 2-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carbonitrile; UNII-JU9YAX04C7; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; MFCD00133539; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 6-methyl-2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile; Win-47203-2; Corotrope; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; CHEMBL189; JU9YAX04C7; CHEBI:50693; Milrinone, 97%; Milrinonum [Latin]; NCGC00015675-08; NCGC00164390-01; Milrinona [Spanish]; WIN 47,203-2; [3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo-; CAS-78415-72-2; (3,4'-BIPYRIDINE)-5-CARBONITRILE, 1,6-DIHYDRO-2-METHYL-6-OXO-; DSSTox_CID_3324; DSSTox_RID_76978; DSSTox_GSID_23324; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 2-Methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile (Milrinone); YM 018; SMR000058475; Milrila (TN); Milrinone(Primacor); WIN 47203-2; CCRIS 3795; SR-01000075524; EINECS 278-903-6; BRN 3546821; Milrinone [USAN:USP:INN:BAN]; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; Milrinone (Primacor); Tocris-1504; 111GE027; (3,4'-Bipyridine)-5-carbonitrile, 6-dihydro-2-methyl-6-oxo-; 1,2-DIHYDRO-6-METHYL-2-OXO-5-(4-PYRIDINYL)NICOTINONITRILE; Prestwick0_001065; Prestwick1_001065; Prestwick2_001065; Prestwick3_001065; Lopac-M-4659; M1663; M 4659; (non-labelled)Milrinone-d3; Milrinone (JAN/USP/INN); Lopac0_000737; SCHEMBL36947; BSPBio_001050; MLS000028818; MLS001424052; MLS006011946; BIDD:GT0197; SPBio_002965; BPBio1_001156; GTPL5225; SCHEMBL8309385; DTXSID5023324; BDBM15296; AOB5617; HMS1571E12; HMS2051L10; HMS2090J14; HMS2098E12; HMS2234A23; HMS3262C16; HMS3267P12; HMS3370H18; HMS3393L10; HMS3656G06; HMS3715E12; HMS3742G09; Pharmakon1600-01505489; AMY40564; BCP02956; ZINC9224016; Tox21_112113; Tox21_400069; Tox21_500737; ANW-42920; CM0151; Milrinone, >=97% (TLC), powder; NSC760072; s2484; SBB055743; Milrinone - CAS 78415-72-2; AKOS015836135; Tox21_112113_1; AC-4730; BCP9000926; CCG-101020; CCG-204822; CS-1367; DB00235; KS-1440; LP00737; MCULE-8377851655; NC00270; NSC 760072; NSC-760072; SDCCGSBI-0050715.P002; NCGC00015675-01; NCGC00015675-02; NCGC00015675-03; NCGC00015675-04; NCGC00015675-05; NCGC00015675-06; NCGC00015675-07; NCGC00015675-09; NCGC00015675-11; NCGC00015675-24; NCGC00025189-01; NCGC00025189-02; NCGC00025189-03; NCGC00261422-01; HY-14252; SMR004703527; SY028050; BCP0726000256; AB0010910; AB00514027; EU-0100737; FT-0630859; SW197308-3; C07224; D00417; AB00514027-02; AB00514027-03; AB00514027_04; AB00514027_05; AB00597139-08; 415M722; A839417; Q847399; SR-01000075524-1; SR-01000075524-3; SR-01000075524-4; SR-01000075524-6; W-104284; BRD-K67080878-001-05-5; Z1522568219; 6-methyl-2-oxo-5-(4-pyridyl)hydropyridine-3-carbonitrile; 1,2-dihydro-6-methyl-2-oxo-5-(4 -pyridinyl)nicotinonitrile; 2-Methyl-6-oxo-1,6-dihydro-[3,4']bipyridinyl-5-carbonitrile; Milrinone, United States Pharmacopeia (USP) Reference Standard; 1,2-DIHYDRO-6-METHYL-2-OXO-5-(4-PYRIDINYL)-NICOTINONITRILE; 6-methyl-2-oxidanylidene-5-pyridin-4-yl-1H-pyridine-3-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4 inverted exclamation mark -bipyridine)-5-carbonitrile	Small molecule	1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)	PZRHRDRVRGEVNW-UHFFFAOYSA-N	CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2	C12H9N3O	CAS 78415-72-2	CHEBI:50693	.	.	.	D0Y9ZE	.	.	.
NP3185	Paeoniflorin	CID: 442534	Paeoniflorin; Peoniflorin; 23180-57-6; Paeonia moutan; Paeony root; NSC 178886; UNII-21AIQ4EV64; 21AIQ4EV64; C23H28O11; ((2S,2aR,2a1S,3aR,4R,5aR)-4-Hydroxy-2-methyl-2a-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-1,5-dioxa-2,4-methanocyclobuta[cd]pentalen-2a1-yl)methyl benzoate; b-D-Glucopyranoside,(1aR,2S,3aR,5R,5aR,5bS)-5b-[(benzoyloxy)methyl]tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta[cd]pentalen-1a(2H)-yl; paeoniflorine; paeoniflorin;; Peoniflorin;; CCRIS 6494; MFCD00869331; NSC178886; EINECS 245-476-2; SCHEMBL549033; CHEBI:7889; CHEMBL4303209; Paeoniflorin, analytical standard; Paeoniflorin, >=98% (HPLC); HMS3884D17; EBD18862; HY-N0293; ZINC8234328; CP0062; s2410; 3-HYDROXY-3-METHYLHEXANOICACID; AKOS025311455; CCG-269549; AS-12193; beta-D-Glucopyranoside, (1aS,2R,3aR,5R,5aR,5bS)-5b-((benzoyloxy)methyl)tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta(cd)pentalen-1a(2H)-yl; AB0011492; C09959; AB01566855_01; 180P576; Q-100296; Q7124104; .beta.-D-Glucopyranoside, (1aR,2S,3aR,5R,5aR,5bS)-5b-[(benzoyloxy)methyl]tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta[cd]pentalen-1a(2H)-yl; [hydroxy-methyl-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-[?]yl]methyl benzoate; 5b-((Benzoyloxy)methyl)tetrahydro-5-hydroxy-2-methyl-2,5-methano-lH-3,4-dioxacyclobuta(cd)pentalen-1a(2H)-yl-beta-D-glucopyranoside; beta-D-Glucopyranoside, 5b-((benzoyloxy)methyl)tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta(cd)pentalen-1a(2H)-yl, (1aR-(1a-alpha,2-beta,3a-alpha,5-alpha,5a-alpha,5b-alpha))-; beta-d-Glucopyranoside, 5b-((benzoyloxy)methyl)tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta(cd)pentalen-1a(2H)-yl, (1aR-(1aalpha,2beta,3aalpha,5alpha,5aalpha,5balpha))-	Small molecule	1S/C23H28O11/c1-20-9-22(29)13-7-23(20,32-18-16(27)15(26)14(25)12(8-24)31-18)21(13,19(33-20)34-22)10-30-17(28)11-5-3-2-4-6-11/h2-6,12-16,18-19,24-27,29H,7-10H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1	YKRGDOXKVOZESV-WRJNSLSBSA-N	CC12CC3(C4CC1(C4(C(O2)O3)COC(=O)C5=CC=CC=C5)OC6C(C(C(C(O6)CO)O)O)O)O	C23H28O11	CAS 23180-57-6	CHEBI:7889	.	.	.	D0PD0F	.	.	.
NP3247	Artemisinin	CID: 68827	Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one	.	1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1	BLUAFEHZUWYNDE-NNWCWBAJSA-N	CC1CCC2C(C(=O)OC3C24C1CCC(O3)(OO4)C)C	C15H22O5	CAS 63968-64-9	.	HBIN016960	SMIT08863	MOL007424	D0S3WH	DB13132	.	.
NP3275	Vitamin D	CID: 5280795	cholecalciferol; Vitamin D3; 67-97-0; Calciol; Colecalciferol; VITAMIN D; Oleovitamin D3; Arachitol; Ricketon; Trivitan; Deparal; Vigorsan; Activated 7-dehydrocholesterol; Colecalcipherol; Delsterol; Ebivit; Quintox; Cholecalciferolum; (+)-Vitamin D3; D3-Vicotrat; D3-Vigantol; vitamin d-3; Vi-de-3-hydrosol; NEO Dohyfral D3; Vitinc Dan-Dee-3; Colecalciferolum; Cholecalciferol, D3; Vi-De3; 1406-16-2; Duphafral D3 1000; FeraCol; MFCD00078131; CC; CHEBI:28940; NSC 375571; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol; Provitina; 7-Dehydrocholesterol activated; Micro-dee; 7-Dehydrocholesterol, Activated; VidDe-3-hydrosol; Vitamin D3 solution; NSC-375571; Colecalciferol (INN); Colecalciferol [INN]; NCGC00159331-02; Rampage; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; DSSTox_CID_6294; DSSTox_RID_78090; DSSTox_GSID_26294; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; Vitamin D3 (Cholecalciferol); UNII-1C6V77QF41; Vitamin D3, 99%, crystalline; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; Colecalciferolo; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; Colecalciferolo [DCIT]; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol; Vigantol Oil; (5e)-cholecalciferol; 22350-41-0; Colecalciferol D3; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol; (S,Z)-3-(2-((1R,3aS,7aR,E)-7a-methyl-1-((R)-6-methylheptan-2-yl)octahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexan-1-ol; Cyclohexanol, 3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1S,3Z)-; Colecalciferolum [INN-Latin]; Vitamin D 3; 7-Dehydrocholestrol, activated; Irradiated 7-dehydrocholesterol; CCRIS 5813; CCRIS 6286; HSDB 820; 7-Dehydrocholesterol, irradiated; Vitamin D3 emulsifiable; EINECS 200-673-2; EINECS 215-797-2; EPA Pesticide Chemical Code 202901; Vitamin D3; Cholecalciferol; 1C6V77QF41; Devaron; Videkhol; NSC375571; Granuvit D3; Delta-D; DP-R206; CAS-67-97-0; Prestwick_63; Cholecalciferol D3; Cyclohexanol, 3-((2E)-2-((1R,3aS,7aR)-1-((1R)-1,5-dimethylhexyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, (1S,3Z)-; cholecalciferol group; Cholecalciferol [USP:BAN:JAN:ISO]; ()-Vitamin D3; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; Delta-D (TN); 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-; Prestwick3_000429; Cholecalciferol Impurity A; bmse000507; UPCMLD-DP152; SCHEMBL3126; CHEMBL1042; BSPBio_000418; 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3b,5Z,7E)-; Cholecalciferol; 67-97-0; Cholecalciferol (JP17/USP); BPBio1_000460; MEGxm0_000458; DTXSID6026294; UPCMLD-DP152:001; ACon1_001997; HMS2096E20; Vitamin d assay system suitability; Cholecalciferol, >=98% (HPLC); (1S,3E)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; 9,10-Secocholestra-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-; Cholecalciferol, analytical standard; ZINC4474460; Tox21_111578; Tox21_202546; BDBM50030475; LMST03020001; s4063; AKOS015950641; AC-8884; CCG-268466; CS-1179; DB00169; SMP1_000068; AK R215 COMPONENT COLECALCIFEROL; AK-R215 COMPONENT COLECALCIFEROL; NCGC00091072-01; NCGC00159331-04; NCGC00260095-01; HY-15398; K119; Vitamin D3 10 microg/mL in Acetonitrile; 9,10-secocholesta-5,7,10-trien-3-ol; Cholecalciferol (D3), analytical standard; 3412-EP2314590A1; 3412-EP2316832A1; 3412-EP2316833A1; 7058-EP2305662A1; C05443; D00188; W-5072; 86554-EP2270000A1; 86554-EP2272827A1; 86554-EP2289483A1; 86554-EP2305640A2; 86554-EP2305684A1; 9,10-Secocholesta-5,7,10(19)-trien-3-ol; Cholecalciferol, meets USP testing specifications; 078V131; 9,10-Secocholesta-5,7,10(19)-trien-3?-ol; Q139347; (5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol; Q-201931; 3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol; Vitamin D3 solution, 100 mug/mL in ethanol, 97% (CP); (3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol; Cholecalciferol, European Pharmacopoeia (EP) Reference Standard; Colecalciferol, British Pharmacopoeia (BP) Reference Standard; Cholecalciferol, United States Pharmacopeia (USP) Reference Standard; Cholecalciferol for system suitability, European Pharmacopoeia (EP) Reference Standard; Vitamin D3 solution, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material; Cholecalciferol (Vitamin D3), Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1	QYSXJUFSXHHAJI-YRZJJWOYSA-N	CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C	C27H44O	CAS 67-97-0	CHEBI:28940	.	.	.	D0K5WS	.	.	.
NP3286	Lactoferrin	CID: 126456119	Lactoferrin; Lactoferrin (Bovine); 151186-19-5; J-008279	Small molecule	1S/C141H226N46O29S3/c1-11-77(6)111(133(212)186-112(80(9)189)134(213)183-106(74-218)130(209)184-110(76(4)5)132(211)176-97(49-32-61-161-141(155)156)120(199)170-93(45-28-57-157-137(147)148)116(195)166-78(7)113(192)180-103(136(215)216)66-82-36-16-13-17-37-82)185-128(207)104(72-188)181-131(210)107-50-33-62-187(107)135(214)79(8)165-109(191)71-164-115(194)100(64-75(2)3)177-121(200)92(44-24-27-56-144)168-117(196)91(43-23-26-55-143)169-125(204)99(53-63-219-10)175-119(198)94(46-29-58-158-138(149)150)172-126(205)101(67-83-69-162-88-40-20-18-38-85(83)88)179-124(203)98(51-52-108(146)190)174-127(206)102(68-84-70-163-89-41-21-19-39-86(84)89)178-122(201)96(48-31-60-160-140(153)154)171-118(197)95(47-30-59-159-139(151)152)173-129(208)105(73-217)182-123(202)90(42-22-25-54-142)167-114(193)87(145)65-81-34-14-12-15-35-81/h12-21,34-41,69-70,75-80,87,90-107,110-112,162-163,188-189,217-218H,11,22-33,42-68,71-74,142-145H2,1-10H3,(H2,146,190)(H,164,194)(H,165,191)(H,166,195)(H,167,193)(H,168,196)(H,169,204)(H,170,199)(H,171,197)(H,172,205)(H,173,208)(H,174,206)(H,175,198)(H,176,211)(H,177,200)(H,178,201)(H,179,203)(H,180,192)(H,181,210)(H,182,202)(H,183,213)(H,184,209)(H,185,207)(H,186,212)(H,215,216)(H4,147,148,157)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t77-,78-,79-,80+,87-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,110-,111-,112-/m0/s1	CSSYQJWUGATIHM-IKGCZBKSSA-N	CCC(C)C(C(=NC(C(C)O)C(=NC(CS)C(=NC(C(C)C)C(=NC(CCCNC(=N)N)C(=NC(CCCNC(=N)N)C(=NC(C)C(=NC(CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C(C(CO)N=C(C2CCCN2C(=O)C(C)N=C(CN=C(C(CC(C)C)N=C(C(CCCCN)N=C(C(CCCCN)N=C(C(CCSC)N=C(C(CCCNC(=N)N)N=C(C(CC3=CNC4=CC=CC=C43)N=C(C(CCC(=N)O)N=C(C(CC5=CNC6=CC=CC=C65)N=C(C(CCCNC(=N)N)N=C(C(CCCNC(=N)N)N=C(C(CS)N=C(C(CCCCN)N=C(C(CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O	C141H226N46O29S3	CAS 151186-19-5	.	.	.	.	D0O5WD	.	.	.
NP3327	Vicenin-2	CID: 442664	23666-13-9; Vicenin 2; Vicenin II; Violantin; Vicenin-2; Vicenin -2; CHEBI:69814; Apigenin-6,8-di-C-glycoside; MLS000575019; Vicenin; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8-bis[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; 5,7,4'-Trihydroxyflavone-6,8-di-C-glucoside; isovitexin 8-C-beta-glucoside; Apigenin 6,8-di-C-glucoside; AC1L9D6K; isovitexin 8-C-glucoside; SureCN5826175; isovitexin 8-C-  -glucoside; SCHEMBL5826175; CHEMBL1442950; DTXSID80904219; HMS2210F06; apigenin-6,8-di-C-glycopyranoside; HY-N2165; ZINC4098604; 9348AF; MFCD08458851; AKOS015896841; NCGC00247567-01; SMR000232371; CS-0019465; C10195; 666V139; Vicenin 2, primary pharmaceutical reference standard; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8-bis[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one	Small molecule	1S/C27H30O15/c28-6-12-17(32)21(36)23(38)26(41-12)15-19(34)14-10(31)5-11(8-1-3-9(30)4-2-8)40-25(14)16(20(15)35)27-24(39)22(37)18(33)13(7-29)42-27/h1-5,12-13,17-18,21-24,26-30,32-39H,6-7H2/t12-,13-,17-,18-,21+,22+,23-,24-,26+,27+/m1/s1	FIAAVMJLAGNUKW-VQVVXJKKSA-N	C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C(=C3O2)C4C(C(C(C(O4)CO)O)O)O)O)C5C(C(C(C(O5)CO)O)O)O)O)O	C27H30O15	CAS 23666-13-9	CHEBI:69814	.	.	.	.	.	.	.
NP3369	Neferine	CID: 159654	Neferine; 2292-16-2; Neferin; 4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-[[(1R)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl]oxy]phenol; BRN 1523459; CHEMBL455560; SCHEMBL12807595; DTXSID40177462; CHEBI:176257; ZINC6017976; AKOS016002114; Phenol, 4-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)-2-((1,2,3,4-tetrahydro-6-methoxy-1-((4-methoxyphenyl)methyl)-2-methyl-7-isoquinolinyl)oxy)-; X1192; A14743; 292N162; Q-100292; 4-{[(1R)-6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl}-2-{[(1R)-6-methoxy-1-(4-methoxybenzyl)-2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl]oxy}phenol	Small molecule	1S/C38H44N2O6/c1-39-15-14-27-21-36(44-5)38(23-30(27)31(39)17-24-7-10-28(42-3)11-8-24)46-34-19-25(9-12-33(34)41)18-32-29-22-37(45-6)35(43-4)20-26(29)13-16-40(32)2/h7-12,19-23,31-32,41H,13-18H2,1-6H3/t31-,32-/m1/s1	MIBATSHDJRIUJK-ROJLCIKYSA-N	CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)OC)OC4=C(C=CC(=C4)CC5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC	C38H44N2O6	CAS 2292-16-2	CHEBI:176257	.	.	.	.	.	.	.
NP3410	Progesterone	CID: 5994	progesterone; 57-83-0; Pregn-4-ene-3,20-dione; Agolutin; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Corpus luteum hormone; Syngesterone; Utrogestan; Luteol; Glanducorpin; Pregnenedione; Progesterol; Syngestrets; Corlutin; Cyclogest; Gesterol; Gestone; Gestormone; Progestin; Progestone; Progestron; Prometrium; Hormoflaveine; Methylpregnone; Progestasert; Progesteronum; Progestronol; Corlutina; Corluvite; Corporin; Flavolutan; Fologenon; Gynlutin; Gynolutone; Hormoluton; Lingusorbs; Lucorteum; Luteodyn; Luteogan; Luteopur; Luteosan; Luteostab; Luteovis; Lutociclina; Lutocyclin; Lutocylin; Lutoform; Lutromone; Membrettes; Nalutron; Piaponon; Primolut; Progekan; Progestosol; Prolidon; Proluton; Protormone; Syntolutan; Gestron; Lutidon; Lutogyl; Lutren; Prolets; Lutex; Luteal hormone; Lucorteum Sol; Bio-luton; Lutocyclin M; Lipo-Lutin; Luteocrin normale; Luteinique; Prochieve; Prolutone; Lutin; 17alpha-Progesterone; Synovex S; Projestaject; Gynoluton; Gesterol 50; Percutacrine Luteinique; Gesterol 100; Cyclogesterin; Akrolutin; Prolutin; Pregnene-3,20-dione; (S)-Progesterone; Colprosterone; Endometrin; Progesteron; Progestogel; Progeston; 3,20-Pregnene-4; Gelbkoerperhormon; Crinone progesterone gel; Gestiron; Lugesteron; Progestol; Luteol (VAN); Lutocuclin M; .beta.-Progesterone; Percutacrine; (S)-4-Pregnene-3,20-dione; Progeffik; Utrogest; Vitarrine; Luteum; Progesteronum [INN-Latin]; Delta(4)-pregnene-3,20-dione; Progesterona [INN-Spanish]; (S)-Pregn-4-en-3,20-dione; NSC-9704; delta(sup 4)-Pregnene-3,20-dione; CCRIS 533; Prontogest; Estima; 17.alpha.-Progesterone; HSDB 3389; Progesterone [Progestins]; AI3-51682; Prometrium (TN); Pregn-4-en-3,20-dione; UNII-4G7DS2Q64Y; Crinone (TN); 6alpha-Methylpregn-4-en-17alpha-ol-3,20-dione; CHEBI:17026; .delta.4-Pregnene-3,20-dione; 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; Pregn-4-ene-3,20-dione, 17alpha-hydroxy-6alpha-methyl-; component of Cyclogesterin; 4-Pregnen-3,20-dione; .delta.(sup4)-Pregnene-3,20-dione; CHEMBL103; D4-Pregnene-3,20-dione; MLS000028517; 4G7DS2Q64Y; NSC9704; NSC64377; MFCD00003658; NSC-64377; Progesterone, 98%; NCGC00015785-04; SMR000058345; DSSTox_CID_2370; (8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; U 3672; DSSTox_RID_76562; DSSTox_GSID_22370; (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; 6.alpha.-Methylpregn-4-en-17.alpha.-ol-3,20-dione; 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; Progesterona; Progestan; Pregn-4-ene-3,20-dione, 17.alpha.-hydroxy-6.alpha.-methyl-; (1S,10S,11S,14S,15S,2R)-14-acetyl-2,15-dimethyl-5-oxotetracyclo[8.7.0.0<2,7>.0 <11,15>]heptadec-6-ene; (8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; SMR000653542; Progesterone (Prometrium); WLN: L E5 B666 OV MUTJ A1 E1 FV1; SR-01000000088; SR-01000076054; NSC 9704; EINECS 200-350-6; NSC 64377; Pregn-4-ene-3, 17.alpha.-hydroxy-6.alpha.-methyl-; BHR-100; Duraprogen; Progestrel; Lipolutin; Lutinus; Lutogynon; delta4-Pregnene-3,20-dione; Progesterone??; beta-Progesterone; progesterone group; 1dbb; 17a-Progesterone; CAS-57-83-0; delta(Sup4)-pregnene-3,20-dione; Progesterone [USP:INN:BAN:JAN]; racemic progesterone; Prestwick_411; CIDR; mpp22; 2aa6; 4bb2; Opera_ID_292; PROG;; Progesterone, >=99%; Prestwick0_000477; Prestwick1_000477; Prestwick2_000477; Prestwick3_000477; Spectrum5_002053; Cyclogesterin (Salt/Mix); bmse000482; Epitope ID:116051; EC 200-350-6; Pregn-4-ne-3,20-ione; SCHEMBL7671; BIDD:PXR0094; Lopac0_000895; BSPBio_000614; MLS000758277; MLS001074187; MLS001423982; MLS002222367; BIDD:ER0547; P0130_SIGMA; SPBio_002553; .delta.-Pregnene-3,20-dione; BDBM8903; BPBio1_000676; GTPL2377; Hydroxyprogesterone Caproic acid; DTXSID3022370; Progesterone (JP17/USP/INN); BHR-310; ETI-411; 1a28; 1h60; HMS1569O16; HMS2051O05; HMS2090J07; HMS2096O16; HMS2230F23; HMS2233P11; HMS3262D12; HMS3713O16; Pregnene, 3,20-dione-delta^4-; BCP22000; HY-N0437; ZINC4428529; Tox21_113157; Tox21_201792; Tox21_300307; Tox21_500895; AC-700; CMC_13406; LMST02030159; s1705; SBB012538; AKOS015894908; Progesterone; 4-Pregnene-3,20-dione; ACN-032010; CCG-100766; CS-1937; DB00396; DR-2011; EBD2157912; LP00895; NC00016; SDCCGSBI-0050870.P002; Progesterone 1.0 mg/ml in Acetonitrile; NCGC00022185-03; NCGC00022185-04; NCGC00022185-05; NCGC00022185-06; NCGC00022185-07; NCGC00022185-08; NCGC00022185-09; NCGC00022185-10; NCGC00022185-11; NCGC00022185-12; NCGC00022185-14; NCGC00022185-21; NCGC00090798-01; NCGC00090798-02; NCGC00254120-01; NCGC00259341-01; NCGC00261580-01; AS-12660; CPD000058345; NCI60_042166; ST069329; FE-999913; EU-0100895; P0478; (14beta,17alpha)-pregn-4-ene-3,20-dione; Progesterone, meets USP testing specifications; Progesterone, Vetec(TM) reagent grade, 98%; 6370-EP1441224A2; 6370-EP2269989A1; 6370-EP2269990A1; 6370-EP2275420A1; 6370-EP2284149A1; 6370-EP2289892A1; 6370-EP2292088A1; 6370-EP2292233A2; 6370-EP2292592A1; 6370-EP2295055A2; 6370-EP2295416A2; 6370-EP2298731A1; 6370-EP2298748A2; 6370-EP2298764A1; 6370-EP2298765A1; 6370-EP2298772A1; 6370-EP2305636A1; 6370-EP2305642A2; 6370-EP2308839A1; 6370-EP2308880A1; 6370-EP2311453A1; C00410; D00066; J10165; P 0130; Q26963; S00293; 10324-EP2295503A1; 10324-EP2301536A1; 10324-EP2301538A1; 10324-EP2311455A1; 10324-EP2316452A1; Progesterone, VETRANAL(TM), analytical standard; Q-201624; SR-01000000088-5; SR-01000000088-6; SR-01000076054-1; SR-01000076054-4; BRD-K64994968-001-03-6; 32104FB6-BF81-4F6E-83C2-024DEEAEB272; Progesterone, British Pharmacopoeia (BP) Reference Standard; Progesterone, powder, BioReagent, suitable for cell culture; Progesterone, European Pharmacopoeia (EP) Reference Standard; Progesterone, gamma-irradiated, BioXtra, suitable for cell culture; Progesterone, United States Pharmacopeia (USP) Reference Standard; Progesterone-Water Soluble, powder, BioReagent, suitable for cell culture; Progesterone for peak identification, European Pharmacopoeia (EP) Reference Standard; Progesterone for system suitability, European Pharmacopoeia (EP) Reference Standard; Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material; (1S,2R,10S,11S,14S,15S)-14-acetyl-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one; 137940-28-4; 753497-20-0; Progesterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material	Small molecule	1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1	RJKFOVLPORLFTN-LEKSSAKUSA-N	CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C	C21H30O2	CAS 57-83-0	CHEBI:17026	.	.	.	D07BSQ	.	.	.
NP3440	Propolis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP3477	Nimbolide	CID: 12313376	25990-37-8; 8(R)-(3-Furanyl)-2aR,5aR,6S,6aR,8R,9,9aR,10aS,10bR,10cR-decahydro-2a,5a,6a,7-tetramethyl-2,5-dioxo-2H,5H-cyclopenta[d']naphtho[1,8-bc:2,3-b']difuran-6-acetic acid, methyl ester; CHEMBL426690; SCHEMBL2146198; ZINC39205816; Nimbolide, from Azadirachta indica, >=98%; (4alpha,5alpha,6alpha,7alpha,15beta,17alpha)-7,15:21,23-diepoxy-6 -hydroxy-4,8-dimethyl-1-oxo-18,24-dinor-11,12-secochola-2,13,20,22-tetraene- 4,11-dicarboxylic acid gamma-lactone methyl ester; Methyl 2-[(1R,2S,4R,6R,9R,10S,11R,15R,18R)-6-(furan-3-yl)-7,9,11,15-tetramethyl-12,16-dioxo-3,17-dioxapentacyclo[9.6.1.02,9.04,8.015,18]octadeca-7,13-dien-10-yl]acetate	.	1S/C27H30O7/c1-13-15(14-7-9-32-12-14)10-16-20(13)27(4)17(11-19(29)31-5)26(3)18(28)6-8-25(2)22(26)21(23(27)33-16)34-24(25)30/h6-9,12,15-17,21-23H,10-11H2,1-5H3/t15-,16-,17-,21-,22+,23-,25-,26+,27-/m1/s1	JZIQWNPPBKFOPT-LSYMHUITSA-N	CC1=C2C(CC1C3=COC=C3)OC4C2(C(C5(C6C4OC(=O)C6(C=CC5=O)C)C)CC(=O)OC)C	C27H30O7	CAS 25990-37-8	.	.	.	.	.	.	.	.
NP3478	Eugenol	CID: 3314	4-Allyl-2-methoxyphenol; 4-Allylguaiacol; Eugenic acid; Allylguaiacol; Caryophyllic acid; p-Allylguaiacol; p-Eugenol; 2-Methoxy-4-prop-2-enylphenol; Engenol; 2-Methoxy-4-allylphenol; Phenol, 2-methoxy-4-(2-propenyl)-; 1,3,4-Eugenol; 4-Allylcatechol-2-methyl ether; Synthetic eugenol; 2-Methoxy-4-(2-propenyl)phenol; 2-Methoxy-1-hydroxy-4-allylbenzene; 4-Allyl-1-hydroxy-2-methoxybenzene; 1-Hydroxy-2-methoxy-4-allylbenzene; 5-Allylguaiacol; 1-Hydroxy-2-methoxy-4-prop-2-enylbenzene	.	1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3	RRAFCDWBNXTKKO-UHFFFAOYSA-N	COC1=C(C=CC(=C1)CC=C)O	C10H12O2	CAS 97-53-0	.	HBIN026067	SMIT00023	MOL000254	D0O4QB	.	4857	.
NP3528	Magnolol	CID: 72300	Magnolol; 528-43-8; 5,5'-Diallyl-[1,1'-biphenyl]-2,2'-diol; 5,5'-Diallyl-2,2'-biphenyldiol; 2,2'-Bichavicol; 5,5'-Diallyl-2,2'-dihydroxybiphenyl; NSC 293099; Dehydrodichavicol; UNII-001E35HGVF; 4-allyl-2-(5-allyl-2-hydroxy-phenyl)phenol; MFCD00016658; MLS001048917; 001E35HGVF; 2-(2-hydroxy-5-prop-2-enylphenyl)-4-prop-2-enylphenol; CHEBI:6643; 5,5'-di(prop-2-en-1-yl)biphenyl-2,2'-diol; 5,5'-Diallylbiphenyl-2,2'-diol; [1,1'-Biphenyl]-2,2'-diol, 5,5'-di-2-propenyl-; SMR000387108; (1,1'-Biphenyl)-2,2'-diol, 5,5'-di-2-propenyl-; 2'-Bichavicol; SR-01000758206; Kopnolia; HSDB 7686; Magnolol,(S); PubChem19035; UPCMLD-DP037; cid_72300; SCHEMBL132477; REGID_for_CID_72300; CHEMBL180920; ZINC1645; DTXSID0044076; UPCMLD-DP037:001; BDBM78304; HMS2269N09; HMS3651O18; AMY40661; BCP28276; HY-N0163; AC-931; BBL027818; CM0085; NSC293099; s2321; STK801955; AKOS005266409; ACN-035415; CCG-208588; CS-5021; DS-1284; MCULE-1351244567; NSC-293099; SMP2_000086; Magnolol, >=95% (HPLC), from plant; NCGC00161609-01; NCGC00161609-02; AK-72952; O906; SY016075; AB0016717; D3971; FT-0628104; N1359; SW219728-1; 5,5`-Diallyl-[1,1`-biphenyl]-2,2`-diol; A10551; C10651; J10186; S-2836; 528M438; 5,5'-Di-2-propenyl-[1,1'-biphenyl]-2,2'-diol; Q-100598; Q6732002; SR-01000758206-3; SR-01000758206-4; BRD-K26168087-001-01-4; Magnolol, European Pharmacopoeia (EP) Reference Standard; [1,1'-Biphenyl]-2,2'-diol, 5,5'-di-2-propen-1-yl-; 2-(2-oxidanyl-5-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol; 5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2,2'-diol; 2-[2-hydroxy-5-(prop-2-en-1-yl)phenyl]-4-(prop-2-en-1-yl)phenol; 5,5 inverted exclamation mark -Diallyl-2,2 inverted exclamation mark -biphenyldiol	Small molecule	1S/C18H18O2/c1-3-5-13-7-9-17(19)15(11-13)16-12-14(6-4-2)8-10-18(16)20/h3-4,7-12,19-20H,1-2,5-6H2	VVOAZFWZEDHOOU-UHFFFAOYSA-N	C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O	C18H18O2	CAS 528-43-8	CHEBI:6643	.	.	.	.	.	.	.
NP3545	Schisandrol B	CID: 634470	Schisandrol B; Gomisin A; 58546-54-6; Schizandrol B; (+)-Gomisin A; Wuweizi alcohol B; Wuweizichun B; Gomisin-A;TJN-101;Wuweizi alcohol-B; Schisantherinol B; NCGC00183134-01; SCHEMBL2109595; TJN 101; MFCD01941645; 3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-9-ol; LS-15009; AB0109732; W1799; 546S546; Q-100673; (+)-(6S,7S, Biar-R)-5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl benzo[3,4]cycloocta[1,2-f][1,3]benzodioxol-6-ol; (6S,7S,13aR)- 5,6,7,8-Tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-benzo[3,4]cycloocta[1,2-f][1,3]benzodioxol-6-ol; 1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxol-6-ol; 1,2,3,13-Tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3,4]cycloocta[1,2-f][1,3]benzodioxol-6-ol, (6S,7S,13aR)-; Benzo[3,4]cycloocta[1,2-f][1,3]benzodioxol-6-ol, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, (6S,7S,13aR)-	Small molecule	1S/C23H28O7/c1-12-7-13-8-16-20(30-11-29-16)22(28-6)17(13)18-14(10-23(12,2)24)9-15(25-3)19(26-4)21(18)27-5/h8-9,12,24H,7,10-11H2,1-6H3	ZWRRJEICIPUPHZ-UHFFFAOYSA-N	CC1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4CC1(C)O)OC)OC)OC)OC)OCO3	C23H28O7	CAS 58546-54-6	.	.	.	.	.	.	.	.
NP3548	Finasteride	CID: 57363	finasteride; 98319-26-7; Proscar; Propecia; Finastid; Prostide; Chibro-Proscar; MK-906; Finpecia; Finasterida; Finasteridum; MK 906; UNII-57GNO57U7G; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; CHEMBL710; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; 57GNO57U7G; CHEBI:5062; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; Finasteride, 98%; MFCD00869737; Finasteridum [INN-Latin]; C23H36N2O2; Finasterida [INN-Spanish]; DSSTox_CID_625; DSSTox_RID_75699; DSSTox_GSID_20625; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; Andozac; Propecia (TN); SMR000466304; Proscar (TN); MK 0906; MK-0906; CCRIS 7438; HSDB 6793; MK906; SR-01000759414; BRN 4269024; L-652,931; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one; NCGC00016965-01; Finasteride [USAN:USP:INN:BAN]; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; CAS-98319-26-7; YM-152; 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-; KS-1058; Finasteride (Proscar); Prestwick0_000717; Prestwick1_000717; Prestwick2_000717; Prestwick3_000717; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; SCHEMBL5509; BSPBio_000933; MLS000759404; MLS001165768; MLS001424046; Finasteride (JAN/USP/INN); SPBio_002854; BPBio1_001027; GTPL6818; DTXSID3020625; BCPP000229; HMS1570O15; HMS2051F09; HMS2090G22; HMS2097O15; HMS2235L23; HMS3714O15; 4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide; ACT02599; EX-A1951; ZINC3782599; Tox21_110717; Tox21_201506; Tox21_302744; BDBM50334788; NSC741485; NSC757443; s1197; AKOS015894916; Tox21_110717_1; AB07586; BCP9000685; CCG-100937; CS-1767; DB01216; Finasteride, >=98% (HPLC), powder; NC00187; NSC 741485; NSC 759318; NSC-741485; NSC-757443; NCGC00093560-05; NCGC00256334-01; NCGC00259057-01; CPD000466304; HY-13635; BCP0726000222; AB00513901; D00321; J10122; X-2990; 32329-EP2272827A1; 32329-EP2275420A1; 32329-EP2280012A2; 32329-EP2281815A1; 32329-EP2292615A1; 32329-EP2295055A2; 32329-EP2295416A2; 32329-EP2295426A1; 32329-EP2295427A1; 32329-EP2298748A2; 32329-EP2298764A1; 32329-EP2298765A1; 32329-EP2298768A1; 32329-EP2301928A1; 32329-EP2301933A1; 32329-EP2305640A2; 32329-EP2305642A2; 32329-EP2305671A1; 32329-EP2311453A1; 32329-EP2311808A1; 32329-EP2311825A1; 32329-EP2311827A1; 32329-EP2311829A1; 32329-EP2311840A1; AB00513901-07; AB00513901-08; AB00513901_09; Finasteride, VETRANAL(TM), analytical standard; 319F267; Q424167; SR-01000759414-4; SR-01000759414-6; BRD-K01095011-001-03-5; BRD-K01095011-001-15-9; Finasteride, British Pharmacopoeia (BP) Reference Standard; Finasteride, European Pharmacopoeia (EP) Reference Standard; ([1-PHENYL-METH-(E)-YLIDENE]-AMINO)-ACETICACIDETHYLESTER; (17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one; Finasteride, United States Pharmacopeia (USP) Reference Standard; (5?,17?)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5-alpha,17-beta)-; 4-Azaandrost-1-ene-17-carboxamide,1-dimethylethyl)-3-oxo-, (5.alpha., 17.beta.)-; Finasteride for peak identification, European Pharmacopoeia (EP) Reference Standard; (1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-isobutyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4AR,4BS,6AS,7S,9AS,9BS,11AR)-4A,6A-DIMETHYL-2-OXO-2,4A,4B,5,6,6A,7,8,9,9A,9B,10,11,11A-TETRADECAHYDRO-1H-INDENO[5,4-F]QUINOLINE-7-CARBOXYLIC ACID TERT-BUTYLAMIDE; (4aR,4bS,6aS,9aS,9bS,11aR)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide; (4aR,6aS)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide; (4aR,6aS,11aR)-4a,6a-Dimethyl-2-oxo-hexadecahydro-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide; (4aR,6aS,7S)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide; (4aR,6aS,7S,11aR)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide; (R)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide; 140375-21-9; 4a,6a,9a-Trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid (Finasteride); 4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide(Finasteride)	Small molecule	1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1	DBEPLOCGEIEOCV-WSBQPABSSA-N	CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C	C23H36N2O2	CAS 98319-26-7	CHEBI:5062	.	.	.	D08IWD	.	.	.
NP3552	Spiramycin	CID: 6419898	spiramycin; 8025-81-8; ST075006; C43H74N2O14; Prestwick_121; Prestwick2_000745; Prestwick3_000745; BPBio1_000804; SCHEMBL5032756; AKOS015896378; 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde; K430; SR-01000872632; SR-01000872632-1; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard; Certified Reference Material; 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acet; 2-{(2S,3S,14S,1R,4R,8R,15R)-2-[5-(4,5-dihydroxy-4,6-dimethyl(2H-3,4,5,6-tetrah ydropyran-2-yl)oxy)-4-(dimethylamino)-3-hydroxy-6-methyl(2H-3,4,5,6-tetrahydro pyran-2-yl)oxy]-14-[5-(dimethylamino)-6-me; 2-{(2S,3S,14S,1R,4R,8R,15R)-2-[5-(4,5-dihydroxy-4,6-dimethyl(2H-3,4,5,6-tetrah ydropyran-2-yl)oxy)-4-(dimethylamino)-3-hydroxy-6-methyl(2H-3,4,5,6-tetrahydro pyran-2-yl)oxy]-14-[5-(dimethylamino)-6-methyl(2H-3,4,5,6-tetrahydropyran-2-yl )oxy]-4-hydroxy-3-; thyl(2H-3,4,5,6-tetrahydropyran-2-yl )oxy]-4-hydroxy-3-methoxy-8,15-dimethyl-6-oxo-7-oxacyclohexadeca-10,12-dienyl} ethanal	Small molecule	1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26?,27?,28?,29+,30?,31-,32+,34?,35?,36?,37?,38?,39+,40+,41?,42?,43?/m1/s1	ACTOXUHEUCPTEW-JMRHEKERSA-N	CC1CC=CC=CC(C(CC(C(C(C(CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C	C43H74N2O14	CAS 8025-81-8	.	.	.	.	D0F5OR	.	.	.
NP3553	Serotonin	CID: 5202	serotonin; 5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Thrombocytin; Thrombotonin; Antemovis; Serotonine; Ds substance; 1H-Indol-5-ol, 3-(2-aminoethyl)-; Hippophain; Antemoqua; Substance DS; Substanz DS; 3-(2-Aminoethyl)indol-5-ol; 5-Hta; Tryptamine, 5-hydroxy-; Indol-5-ol, 3-(2-aminoethyl)-; Enteramin; UNII-333DO1RDJY; 3-(beta-Aminoethyl)-5-hydroxyindole; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(2-Amino-ethyl)-1H-indol-5-ol; 333DO1RDJY; CHEBI:28790; Hippophaine; [3H]-5-HT; EINECS 200-058-9; BRN 0143524; 5-hydroxytryptamin; 5-Hydroxytriptamine; 5-Hydroxyltryptamine; 5-hydroxy-tryptamine; 1H-Indol-5-ol,3-(2-aminoethyl)-; 5-hydroxyl tryptamine; GTPL5; CHEMBL39; Prestwick0_000481; Prestwick1_000481; Prestwick2_000481; Prestwick3_000481; Lopac-H-9523; Biomol-NT_000083; bmse000757; SCHEMBL1495; Lopac0_000607; Oprea1_712368; BSPBio_000341; BSPBio_001112; KBioGR_000452; KBioGR_002472; KBioSS_000452; KBioSS_002479; 5-22-12-00016 (Beilstein Handbook Reference); Serotonin, analytical standard; SPBio_002262; 5-Hydroxytryptamine, free base; BPBio1_000377; BPBio1_001079; DTXSID8075330; BCBcMAP01_000198; BDBM10755; KBio2_000452; KBio2_002472; KBio2_003020; KBio2_005040; KBio2_005588; KBio2_007608; KBio3_000843; KBio3_000844; KBio3_002950; ZINC57058; cMAP_000059; 3-(b-Aminoethyl)-5-hydroxyindole; 5-Hydroxy-3-(b-aminoethyl)indole; Bio1_000450; Bio1_000939; Bio1_001428; Bio2_000396; Bio2_000876; HMS1362H13; HMS1792H13; HMS1990H13; HMS3403H13; 3-(2-Aminoethyl)-1H-indol-5-o; ALBB-006183; 6996AB; MFCD00055054; PDSP1_001512; PDSP2_001496; STK503758; AKOS001484724; 3-(2-Aminoethyl)-1H-indol-5-ol #; CCG-204696; DB08839; MCULE-8788459983; SDCCGSBI-0050589.P002; 3-(.beta.-Aminoethyl)-5-hydroxyindole; 5-Hydroxy-3-(.beta.-aminoethyl)indole; IDI1_002151; SMP1_000272; 5-hydroxy tryptamine creatinine disulfate; NCGC00015525-01; NCGC00015525-02; NCGC00015525-03; NCGC00015525-04; NCGC00015525-05; NCGC00015525-06; NCGC00015525-07; NCGC00015525-08; NCGC00015525-09; NCGC00015525-19; NCGC00142449-01; NCGC00142449-02; NCGC00142449-03; NCGC00142449-04; NCGC00142449-05; CAS-153-98-0; DB-051820; FT-0631212; 14C-5-hydroxy tryptamine creatinine disulfate; C00780; H-8000; K-9367; L000078; Q167934; 6F7FD5B4-A558-45F0-A20A-2D068A3EFE6A; 2-imino-1-methylimidazolidin-4-one; 3-(2-aminoethyl)-1H-indol-5-ol; bis(sulfuric acid); 1094000-36-8	Small molecule	1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2	QZAYGJVTTNCVMB-UHFFFAOYSA-N	C1=CC2=C(C=C1O)C(=CN2)CCN	C10H12N2O	CAS 50-67-9	CHEBI:28790	.	.	.	D0F6CD	.	.	.
NP3555	Evodiamine	CID: 442088	Evodiamine; 518-17-2; d-Evodiamine; (+)-Evodiamine; UNII-C01825BVNL; C01825BVNL; CHEBI:4948; Evodiamine, 98%; (S)-14-methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one; Evodiamine, Evodia rutaecarpa; PubChem18244; Evodiamine, (+)-; Evodiamine,(S); (13bS)-14-methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one; Evodiamine(Isoevodiamine)/; MLS006011787; SCHEMBL682158; CHEMBL463165; DTXSID10966123; ZINC898159; BCP02282; HY-N0114; ABP000693; BBL033833; STK801981; AKOS005622478; CS-6161; MCULE-2788564607; (S)-14-methyl-7,8,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(13H)-one; SMR001934404; VS-12304; N1600; C09187; 518E172; Q-100579; Q27894193; Evodiamine, European Pharmacopoeia (EP) Reference Standard; 14-Methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one; (1S)-21-METHYL-3,13,21-TRIAZAPENTACYCLO[11.8.0.0(2),(1)?.0?,?.0(1)?,(2)?]HENICOSA-2(10),4,6,8,15,17,19-HEPTAEN-14-ONE; (1S)-21-methyl-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,15,17,19-heptaen-14-one; Indol(2',3':3,4)pyrido(2,1-b)quinazolin-5(7H)-one, 8,13,13b,14-tetrahydro-14-methyl-, (13bS)-; Indol(2',3':3,4)pyrido(2,1-b)quinazolin-5(7H)-one, 8,13,13b,14-tetrahydro-14-methyl-, (S)-	Small molecule	1S/C19H17N3O/c1-21-16-9-5-3-7-14(16)19(23)22-11-10-13-12-6-2-4-8-15(12)20-17(13)18(21)22/h2-9,18,20H,10-11H2,1H3/t18-/m0/s1	TXDUTHBFYKGSAH-SFHVURJKSA-N	CN1C2C3=C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5N3	C19H17N3O	CAS 518-17-2	CHEBI:4948	.	.	.	.	.	.	.
NP3615	Piceatannol	CID: 667639	piceatannol; 10083-24-6; 3-Hydroxyresveratol; piceatanol; astringinin; 3,5,3',4'-Tetrahydroxystilbene; (E)-4-(3,5-dihydroxystyryl)benzene-1,2-diol; 3,3',4'5-Tetrahydroxystilbene; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; 3,3',4,5'-Tetrahydroxystilbene; UNII-6KS3LS0D4F; NSC 365798; NSC-365798; NSC 622471; 6KS3LS0D4F; CHEMBL69863; 3,3',4,5'-Stilbenetetrol; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; 4339-71-3; CHEBI:28814; C14H12O4; NSC365798; NSC622471; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-	.	1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+	CDRPUGZCRXZLFL-OWOJBTEDSA-N	C1=CC(=C(C=C1C=CC2=CC(=CC(=C2)O)O)O)O	C14H12O4	CAS 10083-24-6	CHEBI:28814	HBIN039816	.	.	D0O0VZ	.	1583	.
NP3651	Crocin	CID: 5281233	Crocin; alpha-Crocin; Gardenia Yellow; Crocin 1; 42553-65-1; Crocine; Crocin I; crocin-1; Crocetin digentiobiose ester; 94238-00-3; Crocetin bis(gentiobiosyl) ester; UNII-877GWI46C2; all-trans-Crocetin di-beta-D-gentiobiosyl ester; crocetin di-gentiobiose ester; CHEMBL446785; CHEBI:79068; 877GWI46C2; 39465-00-4; NCGC00160471-01; bis[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl] (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate; Crocin A; CCRIS 678; CCRIS 7705; crocetin digentiobiosyl ester; EINECS 255-881-6; BRN 6473367; Crocin-I; HSDB 8211; Natural red 1; EINECS 254-465-1; Natural yellow 19; Saffron (JP15); crocetin digentiobioside; trans-Crocetin di(beta-D-gentiobiosyl) ester; DSSTox_CID_1457; DSSTox_RID_81403; DSSTox_GSID_46172; SCHEMBL1463936; DTXSID7046172; bis(beta-D-gentiobiosyl) crocetin; HMS3887O07; Crocetin Di(Beta-Gentiobiosyl)Ester; HY-N0697; crocetin di-beta-D-gentiobiose ester; Tox21_111837; BDBM50260195; s9511; AKOS015896765; ZINC245224178; DB11874; Bis(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl) 8,8'-diapo-psi,psi-carotenedioate; NCGC00160471-02; 8,8'-Diapo-psi,psi-carotenedioic acid, bis(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl) ester; beta-D-Glucopyranose, 6-O-beta-D-glucopyranosyl-, 1,1'-((2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethyl-2,4,6,8,10,12,14-hexadecaheptaenedioate); CAS-42553-65-1; C.I. 75100; CS-0009714; N1653; N1661; N1889; trans-crocetin bis(beta-D-gentiobiosyl) ester; C08589; Q424767; All-trans-crocetin di-beta-delta-gentiobiosyl ester; UNII-F32BA2H92Z component SEBIKDIMAPSUBY-RTJKDTQDSA-N; (2E,4E,6E,8E,10E,12E,14E)-Bis((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl) 2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate; bis(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate; bis[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)tetrahydro-2H-pyran-2-yl] (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate	Small molecule	1S/C44H64O24/c1-19(11-7-13-21(3)39(59)67-43-37(57)33(53)29(49)25(65-43)17-61-41-35(55)31(51)27(47)23(15-45)63-41)9-5-6-10-20(2)12-8-14-22(4)40(60)68-44-38(58)34(54)30(50)26(66-44)18-62-42-36(56)32(52)28(48)24(16-46)64-42/h5-14,23-38,41-58H,15-18H2,1-4H3/b6-5+,11-7+,12-8+,19-9+,20-10+,21-13+,22-14+/t23-,24-,25-,26-,27-,28-,29-,30-,31+,32+,33+,34+,35-,36-,37-,38-,41-,42-,43+,44+/m1/s1	SEBIKDIMAPSUBY-RTJKDTQDSA-N	CC(=CC=CC=C(C)C=CC=C(C)C(=O)OC1C(C(C(C(O1)COC2C(C(C(C(O2)CO)O)O)O)O)O)O)C=CC=C(C)C(=O)OC3C(C(C(C(O3)COC4C(C(C(C(O4)CO)O)O)O)O)O)O	C44H64O24	CAS 42553-65-1	CHEBI:79068	.	.	.	.	.	.	.
NP3653	Vanadium	CID: 23990	7440-62-2; V; Vanadium; Vanadium(3+); vanadium(5+); Vanadium, elemental; Vanadium(1+); Vanadium dust; VANADIUM ION; vanadium cation; Vanadium(III); Vanadium metallicum; Vanadium 5+; Vanadium(1+), ion; Vanadium, ion(3+); vanadium atom; Vanadium, ion (V5+); UNII-00J9J9XKDE; vanadium(0); 00J9J9XKDE; 22537-31-1; MFCD00011453; Vanadium Nanoparticles; 22541-77-1; V(3+); vanadio; Vanadium (fume or dust); Vanadium ion(5+); HSDB 1022; Vanadium, ion(V1+); EINECS 231-171-1; Vanadium powder; Vanadium foil; Vanadium slugs; Vanadium rod; Vanadium standard solution, for AAS, 1 mg-ml V(3+) in 2% HNO3; Vanadium turnings; Vanadium, foil, thickness 0.01 mm, size 25 x 25 mm, purity 99.8%; Vanadium, foil, thickness 0.0125 mm, size 25 x 25 mm, purity 99.8%; Vanadium, foil, thickness 0.0125 mm, size 50 x 50 mm, purity 99.8%; Vanadium, foil, thickness 0.015 mm, size 100 x 100 mm, purity 99.8%; Vanadium, foil, thickness 0.015 mm, size 150 x 150 mm, purity 99.8%; Vanadium, foil, thickness 0.015 mm, size 50 x 50 mm, purity 99.8%; Vanadium, foil, thickness 0.02 mm, size 100 x 100 mm, purity 99.8%; Vanadium, foil, thickness 0.02 mm, size 150 x 150 mm, purity 99.8%; Vanadium, foil, thickness 0.02 mm, size 50 x 50 mm, purity 99.8%; Vanadium Nanorods; vanadium (III); vanadium (V); Vanadium Nanoprisms; vanadium(I) cation; vanadium(V) cation; vanadium(1+) ion; vanadium(3+) ion; vanadium(5+) ion; vanadium (5+); Vanadium ion(3+); Vanadium (III) ion; vanadium(III) cation; vanadium ion (V5+); Chromium Nano Dispersion; Vanadium Nano Dispersion; EC 231-171-1; Ultra Thin Vanadium Nanofoil; Vanadium,isotope of mass 47; Vanadium powder, -325 mesh; DTXSID2040282; CHEBI:27698; CHEBI:33003; CHEBI:33005; CHEBI:35170; CHEBI:49948; DTXSID50896834; Vanadium Metal Organic Frameworks; Vanadium Turnings, 2.5cm (1.0in) & Down (Metals Basis); AMY22281; 9010AF; AKOS024438066; DB13971; Vanadium rod, 12.7mm (0.5in) dia; Vanadium wire, 1.0mm (0.04in) dia; Vanadium wire, 1.5mm (0.06in) dia; Vanadium wire, 2.0mm (0.08in) dia; Vanadium foil, 1.0mm (0.04in) thick; Vanadium rod, 6.35mm (0.25in) dia; Vanadium wire, 0.25mm (0.01in) dia; Vanadium, granular, 2-5 mm, >=99%; Q722; V(+); V(0); Vanadium foil, 0.25mm (0.01in) thick; Vanadium wire, 0.075mm (0.003in) dia; Vanadium wire, 0.127mm (0.005in) dia; [V+6]; [V+8]; V(5+); Vanadium foil, 0.075mm (0.003in) thick; Vanadium foil, 0.127mm (0.005in) thick; Vanadium pieces, 1.27cm (0.5in) & down; Vanadium, foil, thickness 1.0 mm, 99.7%; Bismuth Selenide (Bi2Se3) Sputtering Targets; Vanadium, turnings, 99.7% trace metals basis; Vanadium arc-cast pellet, 15.9mm (0.63in) dia; Vanadium plate, 3.2mm (0.13in) thick, annealed; Q27104738; Q27115176; Q27115179; Vanadium wire, 1.0mm (0.04in) dia, stress relieved; Vanadium, pieces, 1-3 mm, 99.9% trace metals basis; Vanadium slug, 11mm (0.43in) dia x 4mm (0.16in) thick; Vanadium, powder, -100 mesh, 99.9% trace metals basis; Vanadium, powder, -325 mesh, 99.5% trace metals basis; Vanadium, rod, diam. 6.2 mm, 99.7% trace metals basis; Vanadium, wire reel, 1m, diameter 0.25mm, hard, 99.8%; Vanadium, wire reel, 2m, diameter 0.25mm, hard, 99.8%; Vanadium, wire reel, 5m, diameter 0.25mm, hard, 99.8%; Vanadium, foil, thickness 0.25 mm, 99.7% trace metals basis; Vanadium, foil, thickness 0.5 mm, 99.7% trace metals basis; Vanadium, rod, 11 mm diameter, length 25 mm, purity 99.8%; Vanadium, rod, 11 mm diameter, length 50 mm, purity 99.8%; Vanadium, rod, 11 mm diameter, purity 99.8%, length 100 mm; Vanadium, rod, 5.0 mm diameter, length 50 mm, purity 99.8%; Vanadium, rod, 8.0 mm diameter, length 50 mm, purity 99.8%; Vanadium, wire reel, 0.2m, diameter 0.1mm, as drawn, 99.8%; Vanadium, wire reel, 0.2m, diameter 0.25mm, hard, 99.8%; Vanadium, wire reel, 0.2m, diameter 0.5mm, as drawn, 99.8%; Vanadium, wire reel, 0.5m, diameter 0.1mm, as drawn, 99.8%; Vanadium, wire reel, 0.5m, diameter 0.25mm, hard, 99.8%; Vanadium, wire reel, 0.5m, diameter 0.5mm, as drawn, 99.8%; Vanadium, wire reel, 1m, diameter 0.1mm, as drawn, 99.8%; Vanadium, wire reel, 1m, diameter 0.5mm, as drawn, 99.8%; Vanadium, wire reel, 2m, diameter 0.1mm, as drawn, 99.8%; Vanadium, wire reel, 2m, diameter 0.5mm, as drawn, 99.8%; Vanadium, wire reel, 5m, diameter 0.1mm, as drawn, 99.8%; Vanadium, wire reel, 5m, diameter 0.5mm, as drawn, 99.8%; Vanadium granules, 1-3mm (0.04-0.12in), Vacuum Deposition Grade; Vanadium slug, 6.35mm (0.25in) dia x 12.7mm (0.50in) length; Vanadium slug, 6.35mm (0.25in) dia x 6.35mm (0.25in) length; Vanadium, foil, diameter 6 mm, thickness 0.5 mm, purity 99.8%; Vanadium, foil, thickness 0.006 mm, 4 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.006 mm, 6 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.006 mm, diameter 8 mm, purity 99.8%; Vanadium, foil, thickness 0.007 mm, 4 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.007 mm, 6 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.007 mm, diameter 8 mm, purity 99.8%; Vanadium, foil, thickness 0.008 mm, 4 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.008 mm, 6 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.008 mm, diameter 8 mm, purity 99.8%; Vanadium, foil, thickness 0.01 mm, 10 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.01 mm, 15 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.01 mm, 6 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.01 mm, 8 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.01 mm, diameter 4 mm, purity 99.8%; Vanadium, foil, thickness 0.015 mm, 8 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.015 mm, diameter 4 mm, purity 99.8%; Vanadium, foil, thickness 0.015 mm, diameter 6 mm, purity 99.8%; Vanadium, foil, thickness 0.02 mm, 10 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.02 mm, 6 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.02 mm, diameter 15 mm, purity 99.8%; Vanadium, foil, thickness 0.02 mm, diameter 25 mm, purity 99.8%; Vanadium, foil, thickness 0.02 mm, diameter 4 mm, purity 99.8%; Vanadium, foil, thickness 0.02 mm, diameter 8 mm, purity 99.8%; Vanadium, foil, thickness 0.025 mm, 8 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.025 mm, diameter 4 mm, purity 99.8%; Vanadium, foil, thickness 0.025 mm, diameter 6 mm, purity 99.8%; Vanadium, foil, thickness 0.040 mm, 6 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.040 mm, 8 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.040 mm, diameter 4 mm, purity 99.8%; Vanadium, foil, thickness 0.127 mm, 99.7% trace metals basis; Vanadium, foil, thickness 0.25 mm, 10 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.25 mm, 15 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.25 mm, 6 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.25 mm, 8 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.25 mm, diameter 25 mm, purity 99.8%; Vanadium, foil, thickness 0.25 mm, diameter 4 mm, purity 99.8%; Vanadium, foil, thickness 0.5 mm, 10 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.5 mm, 15 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.5 mm, 25 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.5 mm, 50 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.5 mm, 8 mm diameter, purity 99.8%; Vanadium, foil, thickness 0.5 mm, purity 99.8%, diameter 4 mm; Vanadium, foil, thickness 1.0 mm, 15 mm diameter, purity 99.8%; Vanadium, foil, thickness 1.0 mm, 25 mm diameter, purity 99.8%; Vanadium, foil, thickness 1.0 mm, 4 mm diameter, purity 99.8%; Vanadium, foil, thickness 1.0 mm, 6 mm diameter, purity 99.8%; Vanadium, foil, thickness 1.0 mm, diameter 10 mm, purity 99.8%; Vanadium, foil, thickness 1.0 mm, diameter 50 mm, purity 99.8%; Vanadium, foil, thickness 1.0 mm, diameter 8 mm, purity 99.8%; Vanadium, lump, 10 mm max. lump size, weight 20 g, purity 99.6%; Vanadium, lump, 10 mm max. lump size, weight 50 g, purity 99.6%; Vanadium, lump, 4 mm max. lump size, weight 20 g, purity 99.6%; Vanadium, lump, 4 mm max. lump size, weight 50 g, purity 99.6%; Vanadium, lump, 50 mm max. lump size, weight 20 g, purity 99.6%; Vanadium, lump, 50 mm max. lump size, weight 50 g, purity 99.6%; Vanadium, rod, 1.2 mm diameter, length 100 mm, purity 99.8%; Vanadium, rod, 1.2 mm diameter, length 1000 mm, purity 99.8%; Vanadium, rod, 1.2 mm diameter, length 200 mm, purity 99.8%; Vanadium, rod, 1.2 mm diameter, length 500 mm, purity 99.8%; Vanadium, rod, 1.4 mm diameter, length 100 mm, purity 99.8%; Vanadium, rod, 1.4 mm diameter, length 200 mm, purity 99.8%; Vanadium, rod, 1.4 mm diameter, length 500 mm, purity 99.8%; Vanadium, rod, 2.0 mm diameter, length 100 mm, purity 99.8%; Vanadium, rod, 2.0 mm diameter, length 200 mm, purity 99.8%; Vanadium, rod, 2.0 mm diameter, length 500 mm, purity 99.8%; Vanadium, rod, 20.0 mm diameter, length 100 mm, purity 99.8%; Vanadium, rod, 20.0 mm diameter, length 25 mm, purity 99.8%; Vanadium, rod, 25.0 mm diameter, length 25 mm, purity 99.8%; Vanadium, rod, 25.0 mm diameter, length 50 mm, purity 99.8%; Vanadium, rod, 3.5 mm diameter, length 100 mm, purity 99.8%; Vanadium, rod, 3.5 mm diameter, length 200 mm, purity 99.8%; Vanadium, rod, 3.5 mm diameter, length 500 mm, purity 99.8%; Vanadium, rod, 5.0 mm diameter, length 100 mm, purity 99.8%; Vanadium, rod, 5.0 mm diameter, length 500 mm, purity 99.8%; Vanadium, rod, 8.0 mm diameter, length 100 mm, purity 99.8%; Vanadium, rod, 8.0 mm diameter, length 200 mm, purity 99.8%; Vanadium, rod, length 200 mm, 5.0 mm diameter, purity 99.8%; Vanadium, rod, length 50 mm, 20.0 mm diameter, purity 99.8%; Vanadium, wire reel, 1m, diameter 1.0mm, Stress relieved, 99.8%; Vanadium, wire reel, 2m, diameter 1.0mm, Stress relieved, 99.8%; Vanadium slug, 3.175mm (0.125in) dia x 3.175mm (0.125in) length; Vanadium slug, 3.175mm (0.125in) dia x 6.35mm (0.25in) length; Vanadium, foil, size 100 x 100 mm, thickness 0.007 mm, purity 99.8%; Vanadium, foil, thickness 0.001 mm, size 25 x 25 mm, purity 99.8%; Vanadium, foil, thickness 0.001 mm, size 50 x 50 mm, purity 99.8%; Vanadium, foil, thickness 0.002 mm, size 25 x 25 mm, purity 99.8%; Vanadium, foil, thickness 0.002 mm, size 50 x 50 mm, purity 99.8%; Vanadium, foil, thickness 0.003 mm, size 25 x 25 mm, purity 99.8%; Vanadium, foil, thickness 0.003 mm, size 50 x 50 mm, purity 99.8%; Vanadium, foi	Small molecule	1S/V	LEONUFNNVUYDNQ-UHFFFAOYSA-N	[V]	V	CAS 7440-62-2	CHEBI:27698	.	.	.	.	.	.	.
NP3683	Tricin	CID: 5281702	Tricin; 520-32-1; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)chromen-4-one; 3',5'-DIMETHOXY-4',5,7-TRIHYDROXYFLAVONE; CHEBI:59979; 5,7,4'-trihydroxy-3',5'-dimethoxyflavone; UNII-D51JZL38TQ; D51JZL38TQ; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxy-phenyl)chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4H-1-benzopyran-4-one; 3',5'-O-dimethyltricetin; 3',5'-di-O-methyltricetin; SCHEMBL44475; CHEMBL454320; 3\\',5\\'-di-O-methyltricetin; DTXSID20199965; Tricetin 3',5'-di-methyl ether; LE023; AMY33321; HY-N1127; ZINC5998961; BDBM50487758; LMPK12110873; MFCD00210580; NSC294579; STK694538; AKOS005606119; MCULE-9557900866; NSC 294579; NSC-294579; CS-0016415; FT-0775707; W1630; C10193; 520D321; Q3055452; F0001-1352	Small molecule	1S/C17H14O7/c1-22-14-3-8(4-15(23-2)17(14)21)12-7-11(20)16-10(19)5-9(18)6-13(16)24-12/h3-7,18-19,21H,1-2H3	HRGUSFBJBOKSML-UHFFFAOYSA-N	COC1=CC(=CC(=C1O)OC)C2=CC(=O)C3=C(C=C(C=C3O2)O)O	C17H14O7	CAS 520-32-1	CHEBI:59979	.	.	.	.	.	.	.
NP3689	Carnosine	CID: 439224	L-Carnosine; Carnosine; 305-84-0; beta-Alanyl-L-histidine; Ignotine; Karnozin; Karnozzn; L-Histidine, beta-alanyl-; L-Ignotine; N-2-M; UNII-8HO6PVN24W; Polaprezinc; CHEBI:15727; Nalpha-(beta-alanyl)-L-histidine; L-HISTIDINE, N-beta-ALANYL-; MFCD00005207; NSC 524045; BRN 0087671; 8HO6PVN24W; (3-aminopropanoyl)-L-histidine; L-Histidine, N-.beta.-alanyl-; beta-Alanylhistidine; L-Carnosine, 98%; carnosine zwitterion; Z-103; Z 103; N-beta-alanyl-L-histidine; (2S)-2-(3-aminopropanamido)-3-(1H-imidazol-4-yl)propanoic acid; (2S)-2-(3-aminopropanoylamino)-3-imidazol-4-ylpropanoic acid; (2~{S})-2-(3-azanylpropanoylamino)-3-(1~{H}-imidazol-4-yl)propanoic acid; .beta.-Alanyl-L-histidine; Sevitin; betaAla-His; b-Alanylhistidine; beta-Ala-His-OH; EINECS 206-169-9; 3-Chloromandelicacid; b-Alanyl-L-histidine; PubChem6017; beta-alanyl-l-histidin; .beta.-Alanylhistidine; Spectrum_001178; N-b-alanyl-L-Histidine; SpecPlus_000374; Spectrum2_000454; Spectrum3_001212; Spectrum4_001673; Spectrum5_000605; 3-aminopropionyl-histidine; bmse000246; bmse001002; C00386; N-(b-Alanyl)-L-histidine; SCHEMBL33769; BSPBio_002624; KBioGR_002225; KBioSS_001658; 4-25-00-04381 (Beilstein Handbook Reference); DivK1c_006470; SPECTRUM1500944; N-(3-Aminopropanoyl)histidine; SPBio_000528; CHEMBL242948; GTPL4559; KBio1_001414; KBio2_001658; KBio2_004226; KBio2_006794; KBio3_002124; DTXSID80879594; L-Carnosine, ~99%, crystalline; TNP00340; ZINC2040854; N(alpha)-(beta-alanyl)-L-histidine; ANW-26923; BDBM50485554; CCG-38696; SBB003316; STL466172; AKOS010421481; AKOS015963345; CS-W014210; DB11695; HY-W013494; MCULE-5739145561; SDCCGMLS-0066726.P001; NCGC00017390-01; NCGC00017390-02; NCGC00142487-01; AC-17084; AC-19690; AC-31940; AS-12570; ST057076; A0222; L-Carnosine, Vetec(TM) reagent grade, 98%; S5226; 305C840; Q413822; SR-05000002473; SR-05000002473-1; (2S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl)propanoic acid; (S)-2-(3-aminopropanamido)-3-(1H-imidazol-4-yl)propanoic acid; 8V0	Small molecule	1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/t7-/m0/s1	CQOVPNPJLQNMDC-ZETCQYMHSA-N	C1=C(NC=N1)CC(C(=O)O)NC(=O)CCN	C9H14N4O3	CAS 305-84-0	CHEBI:15727	.	.	.	D0M9BA	.	.	.
NP3710	Gamma linolenic acid	CID: 5280933	gamma-Linolenic acid; GAMOLENIC ACID; 506-26-3; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; (6,9,12)-linolenic acid; CCRIS 7668; all-cis-6,9,12-Octadecatrienoic acid; gamoleic acid; Ligla; UNII-78YC2MAX4O; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; GLA; (6Z,9Z,12Z)-Octadecatrienoic acid; Gamma-?Linolenic acid; .gamma.-Linolenic Acid; 6Z,9Z,12Z-octadecatrienoic acid; (6Z,9Z,12Z)-6,9,12-Octadecatrienoic acid; 78YC2MAX4O; cis-Delta(6,9,12)-octadecatrienoic acid; 6(Z),9(Z),12(Z)-Octadecatrienoic acid; 6-cis,9-cis,12-cis-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; CHEMBL464982; CHEBI:28661; MFCD00065718; 6,9,12-Octadecatrienoic acid; 6,9,12-all-cis-Octadecatrienoic acid; NCGC00160469-01; GAMMA-LINOLENIC ACID (18:3 n-6); C18:3n-6,9,12; cis-6, cis-9, cis-12-octadecatrienoic acid; 18:3 (n-6); Efamast; Epogam; Acido gamolenico; 6Z,9Z,12Z-octadecatrienoate; Acide gamolenique; Acide gamolenique [French]; Acido gamolenico [Spanish]; Acidum gamolenicum; Acidum gamolenicum [Latin]; Gamolenic acid [INN:BAN]; (6Z,9Z,12Z)-Octadecatrienoate; SMR000058609; all-cis-6,9,12-octadecatrienoate; cis-Delta(6,9,12)-octadecatrienoate; Viacutan; Gammolenic acid; gamma-Linolensaeure; Gamma-linoleic acid; gamma-linolenic-acid; gamma-Llnolenic acid; C18:3,n-6; Gamolenic acid (INN); cis-6,cis-9,cis-12-Octadecatrienoic acid; 6,9,12-Octadecatrienoate; DSSTox_CID_26170; DSSTox_RID_81401; DSSTox_GSID_46170; SCHEMBL19418; BSPBio_001338; MLS001333661; MLS001333662; Octadeca-6,9,12-triensaeure; BML3-B06; GTPL4710; DTXSID7046170; NDI 609; HMS1361C20; HMS1791C20; HMS1989C20; HMS2230A18; HMS3402C20; HMS3649H09; 6,9,12-all-cis-Octadecatrienoate; HY-N7140; ZINC3777423; Tox21_111835; BDBM50269532; LMFA01030141; s5743; C18:3, n-6,9,12 all-cis; (Z,Z,Z)-6,9,12-Octadecatrienoate; AKOS022175367; z,z,z-6,9,12-Octadecatrienoic acid; CS-W012291; DB13854; gamma-Linolenic acid, >=99%, liquid; z,z,z-octadeca-6,9,12-trienoic acid; 6(Z),9(Z),12(Z)-Octadecatrienoate; IDI1_033808; gamma-Linolenic acid, analytical standard; NCGC00160469-02; NCGC00160469-03; NCGC00160469-04; C18:3 (n-6); CAS-506-26-3; DS-10685; M520; DB-029858; L0152; Octadecatrienoic acid, 6,9,12-(Z,Z,Z)-; C06426; D07213; 506L263; Q415885; SR-01000838334; SR-01000838334-2; 18:3(N-6); BRD-K18059238-001-02-1; D58CCA4A-7FFA-4E8B-A758-EAA7D073B343; C18H30O2 (cis,cis,cis-octadeca-6,9,12-trienoic acid); UNII-116Z6MZN1M component VZCCETWTMQHEPK-QNEBEIHSSA-N; UNII-44NH37HHP9 component VZCCETWTMQHEPK-QNEBEIHSSA-N; UNII-F85N2YHE4E component VZCCETWTMQHEPK-QNEBEIHSSA-N; cis,cis,cis,6,9,12-Octa-decatrienoic acid-18:3 n6 lithium salt	Small molecule	1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-	VZCCETWTMQHEPK-QNEBEIHSSA-N	CCCCCC=CCC=CCC=CCCCCC(=O)O	C18H30O2	CAS 506-26-3	CHEBI:28661	.	.	.	D0UE9X	.	.	.
NP3718	Honokiol	CID: 72303	5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; Honokiol,(S); UNII-11513CCO0N; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; CHEBI:5759; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 11513CCO0N; 3',5-diallyl-2,4'-biphenyldiol; AK-25837; 5,3&amp; -Diallyl-2,4&amp; Q-100425; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; houpa; 35354-74-6	.	1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2	FVYXIJYOAGAUQK-UHFFFAOYSA-N	C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C	C18H18O2	CAS 35354-74-6	.	HBIN029531	SMIT00240	MOL005955	D04DQJ	.	2851	.
NP3742	Saikosaponin B2	CID: 21637642	Saikosaponin B2; 58316-41-9; SaikosaponinB2; Q63395661; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,4R,4aR,6aR,6bS,8R,8aS,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; SCHEMBL7523565; CHEMBL3792981; HY-N0248; s9303; ZINC85643336; AKOS037514824; CCG-270463; P556; CS-0008279; 316S419; Q-100669; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,4R,4aR,6aR,6bS,8R,8aS,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane	Small molecule	1S/C42H68O13/c1-21-29(47)34(55-35-32(50)31(49)30(48)24(18-43)53-35)33(51)36(52-21)54-28-11-12-38(4)25(39(28,5)19-44)10-13-40(6)26(38)9-8-22-23-16-37(2,3)14-15-42(23,20-45)27(46)17-41(22,40)7/h8-9,21,24-36,43-51H,10-20H2,1-7H3/t21-,24-,25-,26-,27-,28+,29+,30-,31+,32-,33-,34+,35+,36+,38+,39+,40-,41-,42-/m1/s1	WRYJYFCCMSVEPQ-ORAXXRKOSA-N	CC1C(C(C(C(O1)OC2CCC3(C(C2(C)CO)CCC4(C3C=CC5=C6CC(CCC6(C(CC54C)O)CO)(C)C)C)C)O)OC7C(C(C(C(O7)CO)O)O)O)O	C42H68O13	CAS 58316-41-9	.	.	.	.	.	.	.	.
NP3744	Alpha tricalcium phosphate	CID: 24456	Calcium phosphate; 7758-87-4; TRICALCIUM PHOSPHATE; Synthos; Calcium phosphate tribasic; Calcium orthophosphate; Tricalcium diphosphate; Calcigenol simple; beta-TCP; Phosphoric acid, calcium salt (2:3); Tricalcium orthophosphate; beta-Tricalcium phosphate; Calcium tertiary phosphate; Tertiary calcium phosphate; tri-calcium phosphate; FEMA No. 3081; Calciresorb;TCP; 10103-46-5; Phosphoric acid, calcium salt; UNII-K4C08XP666; tricalcium;diphosphate; tricalcium bis(phosphate); CHEBI:9679; K4C08XP666; Synthograft; Bonarka; Cerasorb; OSferion; Natural whitlockite; Calcium phosphate, 96%, pure; Caswell No. 148; Ceredex; Multifos; Ostram; Vitoss; TricOs; Calipharm T; Tricafos P; Calcium phosphate (3:2); Tricalcium bis(orthophosphate); CCRIS 3668; HSDB 879; JAX TCP; Calcium phosphate (Ca3(PO4)2); Calcium phosphate, for analysis, 35-40% (Ca); Calcium orthophosphate, tri-(tert); Tricalcium phosphate (Ca3(PO4)2); EINECS 231-840-8; EPA Pesticide Chemical Code 076401; Posture (calcium supplement); bone phosphate; Phosphoric acid calcium(2+) salt (2:3); Ca3(PO4)2; Bone ash; calcium-phosphate; alpha-TCP; Calcium phosphates; tricalciumphosphate; EINECS 233-283-6; Posture (TN); Hydroxyapatite Powder; MFCD00015984; Phosphoric acid, calcium salt (1:?); calcium phosphate basic; beta tricalcium phosphate; AI3-25607; alpha-Tricalcium phosphate; Ca3O8P2; EC 231-840-8; BONE POWDER, PURIFIED; INS NO.341(III); INS-341(III); CHEMBL2106566; DTXSID1049803; E-341(III); AKOS015833108; DB11348; S338; Tricalcium bis(orthophosphate), with a fluorine content of less than 0,005 % by weight on the dry anhydrous product; Calcium phosphate, tribasic (ca.37% Ca); CS-0013475; FT-0645103; C08136; D00938; Q278387; UNII-97Z1WI3NDX component QORWJWZARLRLPR-UHFFFAOYSA-H; UNII-279O8I0433 component QORWJWZARLRLPR-UHFFFAOYSA-H; Calcium phosphate, Reagent for transient & stable DNA transfections; beta-tri-Calcium phosphate, >=95% beta-phase basis (unsintered powder); Calcium phosphate, purum p.a., >=96.0% (calc. as Ca3(PO4)2, KT); Tricalcium phosphate hydrate, nanopowder, <200 nm particle size (BET); alpha-tri-Calcium phosphate, puriss. p.a., >=75% alpha-phase basis (sinterted powder); alpha-tri-Calcium phosphate, Reagent for transient & stable DNA transfections; beta-tri-Calcium phosphate, puriss. p.a., >=95% beta-phase basis (sintered powder); beta-tri-Calcium phosphate, puriss. p.a., >=98% beta-phase basis (sintered Powder); beta-tri-Calcium phosphate, puriss. p.a., >=98% beta-phase basis (unsintered powder); 21063-37-6	Small molecule	1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6	QORWJWZARLRLPR-UHFFFAOYSA-H	[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]	Ca3O8P2	CAS 7758-87-4	CHEBI:9679	.	.	.	.	.	.	.
NP3787	Vancomycin	CID: 14969	VANCOMYCIN; Vancocin; Vancoled; 1404-90-6; Vancomycinum; Vancomicina; Vancomycine; VANCOR; Vancomycin HCL; UNII-6Q205EH1VU; 6Q205EH1VU; CHEMBL262777; CHEBI:28001; Vancomycin (USP); Vancomycine [INN-French]; Vancomycinum [INN-Latin]; Vancomicina [INN-Spanish]; HSDB 3262; EINECS 215-772-6; vancomicin; vanomycin; Vancomycin [USP:INN:BAN]; Vancomycin hydrochloride from Streptomyces orientalis; Viomycin derivative; [(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-(2-amino-2-oxo-ethyl)-dichloro-pentahydroxy-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-pentaoxo-[?]carboxylic acid; Glycopeptide Antibiotic; C06689; D00212; Tuberactinomycin Analogue; Prestwick0_000497; Prestwick1_000497; Prestwick2_000497; Mannopeptimycin Glycopeptide; SCHEMBL3177; Chloroorienticin B derivative; Lopac0_001267; N-demethylvancomycin derivative; SPBio_002314; Poly ethylene glycol derivative; CHEMBL3735877; DTXSID0042664; GTPL10932; ACT02696; HY-B0671; Mannopeptimycin glycopeptide analogue; BDBM50335519; s5784; AKOS030526092; CCG-205340; CS-3242; DB00512; SDCCGSBI-0051233.P002; NCGC00162383-04; NCGC00162383-11; 6465-EP1441224A2; 6465-EP2277898A2; 6465-EP2295402A2; 6465-EP2298762A2; 6465-EP2305657A2; 6465-EP2305662A1; 6465-EP2308479A2; 4-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole; 404V906; Q424027; SR-01000076194-5; BRD-K91065602-003-05-5; (2.2Sp,3.5Sa,2.6Sp)-O4.2,C3.4:C5.4,O4.6:C3.5,C2.7-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]; (S)-3,6-Diamino-hexanoic acid {(3S,9S,12S,15S)-3-((S)-6-hydroxy-2-imino-hexahydro-pyrimidin-4-yl)-9,12-bis-hydroxymethyl-2,5,8,11,14-pentaoxo-6-[1-ureido-meth-(Z)-ylidene]-1,4,7,10,13pentaaza-cyclohexadec-15-yl}-amide	Small molecule	1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1	MYPYJXKWCTUITO-LYRMYLQWSA-N	CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O	C66H75Cl2N9O24	CAS 1404-90-6	CHEBI:28001	.	.	.	D0B1IV	.	.	.
NP3788	Rosmarinic acid	CID: 5281792	Rosemary acid; (R)-rosmarinic acid; UNII-MQE6XG29YI; Rosmarinate; MQE6XG29YI; CHEMBL324842; CHEBI:50371; Labiatenic acid; C18H16O8; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; 537-15-5; Rosemaric acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid	.	1S/C18H16O8/c19-12-4-1-10(7-14(12)21)3-6-17(23)26-16(18(24)25)9-11-2-5-13(20)15(22)8-11/h1-8,16,19-22H,9H2,(H,24,25)/b6-3+/t16-/m1/s1	DOUMFZQKYFQNTF-WUTVXBCWSA-N	C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O	C18H16O8	CAS 20283-92-5	.	HBIN042438	SMIT00316	MOL011865	D05PTT	.	814	.
NP3806	Ginsenoside compound K	CID: 9852086	ginsenoside C-K; 39262-14-1; ginsenoside CK; ginsenoside compound K; Ginsenoside K; 20(S)-Ginsenoside C-K; 20(S)-GINSENOSIDE CK; CHEBI:77146; CHEMBL3355096; (2s,3r,4s,5s,6r)-2-[(2s)-2-[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; ginsenoside M1; GM1 saponin; IH901 cpd; Compound-K; ginsenoside-C-K; Sg(S)-ginsenoside c-k; Ginsenoside metabolite M1; (20S)-ginsenoside C-K; 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol; 3-O-Deglucosylginsenoside F2; 20-O-(beta-D-glucopyranosyl)-20(S)-protopanaxadiol; Protopanaxadiol 20-O-glucoside; SCHEMBL18179307; DTXSID60431770; HY-N0904; BDBM50023446; IH 901; MFCD07772261; s9105; ZINC96095535; AKOS037514664; CCG-270260; CS-3840; AB0029014; N1890; X1141; C22127; 262S141; Q-100455; Q27146701; 20-(beta-D-glucopyranosyloxy)dammar-24-ene-3beta,12-diol; 20beta-(beta-D-glucopyranosyloxy)dammar-24-ene-3beta,12beta-diol; (20S)-20-(beta-D-Glucopyranosyloxy)dammara-24-ene-3beta,12beta-diol; (3beta,12beta)-3,12-dihydroxydammar-24-en-20-yl beta-D-glucopyranoside	.	1S/C36H62O8/c1-20(2)10-9-14-36(8,44-31-30(42)29(41)28(40)23(19-37)43-31)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(39)32(3,4)24(33)12-17-34(25,35)6/h10,21-31,37-42H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26-,27-,28+,29-,30+,31-,33-,34+,35+,36-/m0/s1	FVIZARNDLVOMSU-IRFFNABBSA-N	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)O)C)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C	C36H62O8	CAS 39262-14-1	.	.	.	.	.	.	.	.
NP3812	Oxymatrine	CID: 114850	Oxymatrine; Ammothamnine; Matrine N-oxide; 16837-52-8; Oxysophoridine; Matrine oxide; Oxymatrine,(S); Matrine 1beta-oxide; 54809-74-4; CHEBI:2672; (7aS,13aR,13bR,13cS)dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one 4-oxide; MFCD00210339; SMR000543093; Pachycarpidine; Matrine 1-oxide; MLS001215101; MLS006011817; Oxymatrine (Matrine N-oxide); CHEMBL458337; SCHEMBL13394285; DTXSID40937482; HMS2854E03; AMY25589; ZINC3881804; 7967AB; BBL030371; s2338; STK801916; AKOS004120031; AKOS022168212; AC-6063; CCG-267091; NCGC00346596-01; NCGC00346596-02; SOPHORIDINE N-OXIDE/OXYSOPHORIDINE; AS-15173; O357; AB0016411; C10749; W-2361; Q-100202; Q15425294; (4(1)S,7aS,13aR,13bR)-10-oxohexadecahydrodipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine 4-oxide; 1212383-03-3; 4-Oxotetradecahydro-1H,10H-4lambda~5~-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one; rel-(41S,7aS,13aR,13bR)-10-Oxohexadecahydrodipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine 4-oxide	Small molecule	1S/C15H24N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-,17?/m0/s1	XVPBINOPNYFXID-LHDUFFHYSA-N	C1CC2C3CCC[N+]4(C3C(CCC4)CN2C(=O)C1)[O-]	C15H24N2O2	CAS 16837-52-8	CHEBI:2672	.	.	.	.	.	.	.
NP3833	Anisodine	CID: 4105431	anisodine; 52646-92-1; SCHEMBL474045; Q2033359; 2,3-Dihydroxy-2-phenylpropanoic acid 9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonane-7alpha-yl ester	Small molecule	1S/C17H21NO5/c1-18-12-7-11(8-13(18)15-14(12)23-15)22-16(20)17(21,9-19)10-5-3-2-4-6-10/h2-6,11-15,19,21H,7-9H2,1H3	JEJREKXHLFEVHN-UHFFFAOYSA-N	CN1C2CC(CC1C3C2O3)OC(=O)C(CO)(C4=CC=CC=C4)O	C17H21NO5	.	.	.	.	.	.	.	.	.
NP3850	Black tea polyphenol	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP3872	Paeonol	CID: 11092	PAEONOL; 552-41-0; 2'-Hydroxy-4'-methoxyacetophenone; 1-(2-Hydroxy-4-methoxyphenyl)ethanone; Peonol; 2-Hydroxy-4-methoxyacetophenone; Ethanone, 1-(2-hydroxy-4-methoxyphenyl)-; Resacetophenone-4-methyl ether; 1-(2-hydroxy-4-methoxyphenyl)ethan-1-one; MFCD00008730; Paeonal; Paeonolum; UNII-3R834EPI82; 4-Methoxy-2-hydroxyacetophenone; 4'-Methoxy-2'-hydroxyacetophenone; Acetophenone, 2'-hydroxy-4'-methoxy-; 1-(2-hydroxy-4-methoxy-phenyl)ethanone; CHEMBL1079227; CHEBI:69581; 3R834EPI82; 1-(2-hydroxy-4-methoxy-phenyl)-ethanone; 2'-Hydroxy-4'-methoxyacetophenone, 99%; 4-O-Methylresacetophenone; 1-acetyl-2-hydroxy-4-methoxybenzene; Resacetophenone, 4-O-methyl ester; EINECS 209-012-2; NSC 401442; BRN 1282794; 2-HYDROXY-4-METHOXYACETOPHENONE (4,4,4-D3); AI3-10581; Paeonol (Peonol); PubChem3271; ACMC-209lls; 1-[2-hydroxy-4-(methyloxy)phenyl]ethanone; Spectrum2_001981; Spectrum3_001686; 2-acetyl-5-methoxyphenol; 2-Acetyl-5-methoxy-phenol; CBiol_000986; BSPBio_003212; 4-08-00-01793 (Beilstein Handbook Reference); Acetophenone, 2'-hydroxy-4'-methoxy- (7CI,8CI); MLS006011902; SPECTRUM1601021; SPBio_002161; SCHEMBL1449478; ZINC1906; DTXSID1022059; KBio3_002432; 4-methoxy 2-hydroxy acetophenone; HMS3656E07; HMS3884J13; 2`-Hydroxy-4`-methoxyacetophenone; ACN-S003528; ACT07801; HY-N0159; ANW-32270; BBL012127; BDBM50310718; CCG-39471; CP0063; ICCB4_000282; NSC401442; s2339; SBB066134; STK078097; AKOS000119646; AC-7982; ACN-027221; AS05193; MCULE-2846207321; NSC-401442; SDCCGMLS-0066845.P001; 1-(2-hydroxy-4-methoxyphenyl)-ethanone; NCGC00095977-01; NCGC00095977-02; NCGC00095977-03; AK-79421; AS-15489; P565; SMR000112386; SY013508; 1-(2-Hydroxy-4-methoxyphenyl)ethanone #; 1-(4-Methoxy-2-hydroxy-phenyl)-ethanone; AB0044007; 1-(2-hydroxy-4-methoxyphenyl)ethane-1-one; AM20040702; FT-0602529; FT-0618875; N1847; ST45027685; SW219250-1; C10712; M-2917; 552H410; Ethanone, 1-(2-hydroxy-4-methoxyphenyl)- (9CI); SR-05000002397; Q-100626; Q7124105; SR-05000002397-1; BRD-K94239562-001-02-2; BRD-K94239562-001-03-0; 2 inverted exclamation mark -Hydroxy-4 inverted exclamation mark -methoxyacetophenone; 2 inverted exclamation marka-Hydroxy-4 inverted exclamation marka-methoxyacetophenone	Small molecule	1S/C9H10O3/c1-6(10)8-4-3-7(12-2)5-9(8)11/h3-5,11H,1-2H3	UILPJVPSNHJFIK-UHFFFAOYSA-N	CC(=O)C1=C(C=C(C=C1)OC)O	C9H10O3	CAS 552-41-0	CHEBI:69581	.	.	.	.	.	.	.
NP3874	Physostigmine	CID: 5983	physostigmine; Eserine; 57-47-6; Antilirium; Physostol; Esromiotin; Ezerin; Calabarine; Erserine; Fysostigmin; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate; (-)-physostigmine; Eserolein, methylcarbamate (ester); UNII-9U1VM840SP; CHEMBL94; 57-47-6 (free base); [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate; 9U1VM840SP; CHEBI:27953; NSC30782; NSC-30782; NCGC00093889-03; DSSTox_CID_3471; DSSTox_RID_77040; DSSTox_GSID_23471; Fysostigmin [Czech]; CHEMBL537674; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-; CAS-57-47-6; CCRIS 3422; HSDB 3161; MCV 4484; EINECS 200-332-8; Eserolein, methylcarbamate; NIH 10421; NSC 30782; Physostigmine [USP:BAN]; RCRA waste no. P204; physostigmin; CS 58525; Methyl-carbamic acid, ester with eseroline; Carbamic acid, methyl-, ester with eseroline; (-) physostigmine; Eserine (TN); Physostigmine (USP); Physostigmine free base; Spectrum_000916; Spectrum_001789; SpecPlus_000381; Prestwick0_000566; Prestwick1_000566; Prestwick2_000566; Prestwick3_000566; Spectrum2_000330; Spectrum2_000757; Spectrum2_001283; Spectrum3_000545; Spectrum3_000901; Spectrum4_000997; Spectrum4_001631; Spectrum4_001913; Spectrum5_000441; Spectrum5_000626; Spectrum5_001672; physostigmine.salicylic acid; 1,2,3,3abeta,8abeta-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)-indol-5-yl methylcarbamate; Lopac0_000483; SCHEMBL24044; BSPBio_000352; BSPBio_002189; KBioGR_001433; KBioGR_002061; KBioGR_002533; KBioSS_001396; KBioSS_002279; (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol methylcarbamate (ester); MLS001304022; DivK1c_006477; SPECTRUM1500753; SPBio_000339; SPBio_000774; SPBio_001285; SPBio_002571; BPBio1_000388; cid_657348; GTPL6598; MEGxp0_001872; DTXSID3023471; ACon1_000097; BDBM11023; KBio1_001421; KBio2_001396; KBio2_002278; KBio2_003964; KBio2_004846; KBio2_006532; KBio2_007414; KBio3_001689; KBio3_001842; Eserine, >=98.0% (N); HMS1921G06; HMS2089M11; HMS2236L08; HMS3261B07; BCP19735; Carbamic acid, ester with eseroline; HY-N6608; MCV-4484; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)-; Tox21_111228; Tox21_301591; Tox21_500483; BDBM50004000; BDBM50222010; CCG-38605; MFCD00151090; ZINC91689892; AKOS016843649; Tox21_111228_1; DB00981; LP00483; MCULE-2638001883; MCULE-9310809074; SDCCGMLS-0066585.P001; SDCCGSBI-0050467.P005; NCGC00093889-01; NCGC00093889-02; NCGC00093889-04; NCGC00093889-05; NCGC00093889-06; NCGC00093889-07; NCGC00093889-08; NCGC00093889-09; NCGC00093889-10; NCGC00093889-12; NCGC00093889-13; NCGC00093889-20; NCGC00255345-01; NCGC00261168-01; AC-15983; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis); SMR000718753; SBI-0050467.P004; CS-0034353; EU-0100483; P0406; Physostigmine 100 microg/mL in Acetonitrile; C06535; D00196; E 8375; Q410595; Eserine; Antilirium; Physostol; Esromiotin; Ezerin; SR-01000075341-1; WLN: T B556 EN GNTT&J B1 E1 G1 KOVM1; BRD-K25650355-001-02-5; BRD-K25650355-059-02-3; BRD-K25650355-059-12-2; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate hydrochloride; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate; 2-hydroxybenzoic acid; Pyrrolo[2, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-	Small molecule	1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1	PIJVFDBKTWXHHD-HIFRSBDPSA-N	CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C	C15H21N3O2	CAS 57-47-6	CHEBI:27953	.	.	.	D09JVV	.	.	.
NP3875	Cryptoxanthin	CID: 5281235	beta-Cryptoxanthin; Cryptoxanthin; 472-70-8; (3R)-beta,beta-caroten-3-ol; UNII-6ZIB13GI33; 6ZIB13GI33; (1R)-3,5,5-trimethyl-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol; Cryptoxanthins; beta,beta-carotene-3-ol; Neo-beta-cryptoxanthin; 3-Hydroxy-beta-carotene; beta-cryptoxanthins; beta,beta-Caroten-3-ol, (3R)-; SCHEMBL24469; CHEBI:10362; DTXSID30912309; ZINC4097702; beta-Cryptoxanthin, >=97% (TLC); LMPR01070269; HY-108059; CS-0027251; C08591; Q392062; 5-AMINOMETHYL-2-HYDROXY-BENZOICACIDMETHYLESTER; UNII-177RP9H0XI component DMASLKHVQRHNES-FKKUPVFPSA-N	Small molecule	1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,36,41H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-/m1/s1	DMASLKHVQRHNES-FKKUPVFPSA-N	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CC(CC2(C)C)O)C)C)C	C40H56O	CAS 472-70-8	CHEBI:10362	.	.	.	.	.	.	.
NP3882	L-canavanine	CID: 439202	canavanine; L-canavanine; Canavanin; 543-38-4; 2-Amino-4-(guanidinooxy)butyric acid; UNII-3HZV514J4B; O-((Aminoiminomethyl)amino)-L-homoserine; O-((Aminoiminomethyl)amino)homoserine; 3HZV514J4B; CHEMBL443732; CHEBI:609827; GGB; L-2-AMINO-4-(GUANIDINOOXY)BUTYRIC ACID; C5H12N4O3; HSDB 3471; L(+)-Canavanine; Spectrum_001137; Tocris-0673; AI3-52153; L-Homoserine, O-((aminoiminomethyl)amino)-; Prestwick3_000609; Spectrum2_000800; Spectrum3_001206; Spectrum4_000783; Spectrum5_001884; Lopac-C-9758; bmse000073; Lopac0_000320; BSPBio_000518; BSPBio_002592; KBioGR_001226; KBioSS_001617; DivK1c_000360; O-carbamimidamido-L-homoserine; SCHEMBL151097; SPECTRUM1500833; SPBio_000940; BPBio1_000570; DTXSID5045041; HMS501B22; KBio1_000360; KBio2_001617; KBio2_004185; KBio2_006753; KBio3_002092; NINDS_000360; HMS1921K08; ZINC3869452; BDBM50271982; BDBM50370459; CCG-40178; AKOS006240676; DB01833; SDCCGMLS-0066683.P001; SDCCGSBI-0050308.P003; IDI1_000360; SMP1_000062; NCGC00015287-01; NCGC00015287-18; NCGC00015287-19; NCGC00024722-01; NCGC00024722-02; NCGC00024722-03; NCGC00024722-04; (2S)-2-amino-4-guanidinooxy-butanoic acid; (S)-2-Amino-4-(guanidinooxy)butanoic acid; O-{[Amino(imino)methyl]amino}-L-homoserine; X6876; Butyric acid, 2-amino-4-(guanidinooxy)-, L; C00308; (2S)-2-amino-4-(carbamimidamidooxy)butanoic acid; L-Alpha-amino-gamma-[guanidinooxy]-N-butyric acid; Q418408; L-Homoserine, O-((aminoiminomethyl)amino)- (9CI); [Eur.J.Pharmacol. 269:269; 271:87 (1994)]; UNII-QXB6XSA047 component FSBIGDSBMBYOPN-VKHMYHEASA-N; (2s)-2-amino-4-(((diaminomethylidene)amino)oxy)butanoic acid; 56C22C33-8657-4884-BE16-CAF24BF61D77; L-Canavanine, >=98% (TLC), powder, from Canavalia ensiformis	Small molecule	1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/t3-/m0/s1	FSBIGDSBMBYOPN-VKHMYHEASA-N	C(CON=C(N)N)C(C(=O)O)N	C5H12N4O3	CAS 543-38-4	CHEBI:609827	.	.	.	D0V9FZ	.	.	.
NP3889	Rutin	CID: 5280805	rutoside; Phytomelin; Quercetin 3-rutinoside; Birutan; Eldrin; Rutin trihydrate; Myrticolorin; Venoruton; Bioflavonoid; Paliuroside; Tanrutin; Osyritrin; Rutine; Rutozyd; 3-Rutinosyl quercetin; 3-Rhamnoglucosylquercetin; Quercetin 3-O-rutinoside; Rutosido; Rutosidum; Rutinum; Globularicitrin; Quercetin-3-rutinoside; Rutabion; Violaquercitrin; Globulariacitrin; Melin; Rutinic acid; Birutan Forte; Birutin; Quercetin rhamnoglucosine; Quercetin-3beta-rutinoside; UNII-5G06TVY3R7; Oxyritin; Rutosid; Ilixanthin; Rutinion acid	.	1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1	IKGXIBQEEMLURG-NVPNHPEKSA-N	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O	C27H30O16	CAS 153-18-4	.	HBIN042670	SMIT00039	MOL000415	D09ALJ	.	143	.
NP3890	Yomogin	CID: 174865	Yomogin; 10067-18-2; 2-Naphthaleneacetic acid, 1,2beta,3,4,4a,7-hexahydro-3alpha-hydroxy-4aalpha,8-dimethyl-alpha-methylene-7-oxo-, gamma-lactone; CHEMBL4547184; DTXSID50143436; 1,2beta,3,4,4a,7-hexahydro-3alpha-hydroxy-4aalpha,8-dimethyl-alpha-methylene-7-oxo-2-naphthaleneacetic acid gamma-lactone; Naphtho(2,3-b)furan-2,6(3H,4H)-dione, 3a,8a,9,9a-tetrahydro-5,8a-dimethyl-3-methylene-, (3aR-(3aalpha,8abeta,9aalpha))-	Small molecule	1S/C15H16O3/c1-8-10-6-11-9(2)12(16)4-5-15(11,3)7-13(10)18-14(8)17/h4-5,10,13H,1,6-7H2,2-3H3/t10-,13-,15-/m1/s1	ONPJVBQNWRHOKG-WDBKCZKBSA-N	CC1=C2CC3C(CC2(C=CC1=O)C)OC(=O)C3=C	C15H16O3	CAS 10067-18-2	.	.	.	.	.	.	.	.
NP3902	Quinapril	CID: 54892	quinapril; 85441-61-8; Quinaprilum [Latin]; Quinaprilum; Accupril; UNII-RJ84Y44811; CHEBI:8713; CI-906; Accuretic; RJ84Y44811; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; Quinapril [USP:INN:BAN]; C09AA06; Quinapril (INN); Spectrum_001597; Spectrum2_000825; Spectrum3_001551; Spectrum4_000727; Spectrum5_001075; CHEMBL1592; SCHEMBL15813; BSPBio_003022; KBioGR_000994; KBioSS_002077; (3S)-2-{N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; BIDD:GT0797; DivK1c_000710; SPBio_000749; GTPL6350; DTXSID4023547; HMS502D12; KBio1_000710; KBio2_002077; KBio2_004645; KBio2_007213; KBio3_002522; NINDS_000710; HMS2090L05; ZINC3801163; BDBM50368166; AKOS015950821; DB00881; MCULE-5721366729; IDI1_000710; NCGC00167962-01; NCGC00167962-02; NCGC00167962-03; NCGC00167962-05; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{(2S)-2-[(1S)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; 3-Isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, (3S-(2(R*(R*)),3R*))-; SBI-0051931.P002; C07398; D03752; 88093-EP2270011A1; 88093-EP2272841A1; 88093-EP2277879A1; 88093-EP2287165A2; 88093-EP2287166A2; 88093-EP2292620A2; 88093-EP2298742A1; 88093-EP2298776A1; 88093-EP2298779A1; 88093-EP2301923A1; 88093-EP2301931A1; 88093-EP2301936A1; 88093-EP2305648A1; AB00053714-07; AB00053714_08; AB00053714_09; 441Q618; A841331; Q596022; BRD-K72222507-003-03-6; BRD-K72222507-003-07-7; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxidanylidene-4-phenyl-butan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-[(2S)-1-ethoxycarbonyl-4-phenylbutan-2-yl]-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (S)-2-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid	Small molecule	1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1	JSDRRTOADPPCHY-HSQYWUDLSA-N	CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC=CC=C3CC2C(=O)O	C25H30N2O5	CAS 85441-61-8	CHEBI:8713	.	.	.	D0I7SZ	.	.	.
NP3947	Toosendanin	CID: 9851101	Toosendanin; Chuanliansu; 58812-37-6; 12-Acetoxyamoorastatin; CHEMBL503044; HY-N0263; ZINC8214370; MFCD00210564; AKOS025311566; AS-56295; CS-0008285; Y0207; 812T376; Q-100679; [(1S,2R,4R,5R,6S,8R,10S,11S,12R,14R,15R,16R,19S,21R)-4-Acetyloxy-6-(furan-3-yl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.01,14.02,11.05,10.08,10]henicosan-21-yl] acetate	Small molecule	1S/C30H38O11/c1-13(31)39-20-10-19(34)29-12-38-25(36)26(20,3)17(29)9-18(33)28(5)23(29)22(35)24(40-14(2)32)27(4)16(15-6-7-37-11-15)8-21-30(27,28)41-21/h6-7,11,16-21,23-25,33-34,36H,8-10,12H2,1-5H3/t16-,17-,18+,19-,20+,21+,23-,24-,25+,26+,27+,28+,29+,30+/m0/s1	NAHTXVIXCMUDLF-RFNFAWMESA-N	CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C46C(O6)CC5C7=COC=C7)C)OC(=O)C)C)O)C)O)O	C30H38O11	CAS 58812-37-6	.	.	.	.	.	.	.	.
NP3975	Cilostazol	CID: 2754	cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; OPC-13013; Cilostazolum; Cilostazolum [INN-Latin]; OPC 13013; OPC 21; OPC-21; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; UNII-N7Z035406B; CHEBI:31401; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one; MLS000028470; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone; MFCD00866780; N7Z035406B; NCGC00015207-07; SMR000058428; 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one; DSSTox_CID_25132; DSSTox_RID_80693; DSSTox_GSID_45132; CAS-73963-72-1; Pletal (TN); SR-01000003107; BRN 3632107; Cilostazol,(S); Cilostazol [USAN:USP:INN:BAN:JAN]; Tocris-1692; Opera_ID_488; Spectrum2_001118; Spectrum3_001170; Spectrum4_000772; Spectrum5_001762; Lopac-C-0737; CHEMBL799; C 0737; Lopac0_000218; REGID_for_CID_2754; SCHEMBL16128; BSPBio_002759; KBioGR_001184; MLS000758281; MLS000759507; MLS001076067; MLS002153891; SPECTRUM1505230; SPBio_001256; Cilostazol (JP17/USP/INN); GTPL7148; DTXSID9045132; HSDB 8312; KBio3_002259; BCPP000279; HMS1922N15; HMS2093M14; HMS2096F16; HMS2234C06; HMS3260L17; HMS3268O09; HMS3412B18; HMS3654J13; HMS3676B18; HMS3713F16; Pharmakon1600-01505230; ACT02663; BCP03724; ZINC1552174; Tox21_110098; Tox21_500218; BDBM50225508; CCG-39646; KM1582; NSC758936; s1294; AKOS015855512; Cilostazol, >=98% (HPLC), powder; OPC 13013; OPC 21; Pletaal; Tox21_110098_1; AC-4334; AM90304; BCP9000530; CS-1759; DB01166; KS-5154; LP00218; MCULE-8893820969; NSC 758936; NSC-758936; SDCCGSBI-0050206.P003; 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-; 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; NCGC00015207-01; NCGC00015207-02; NCGC00015207-03; NCGC00015207-04; NCGC00015207-05; NCGC00015207-06; NCGC00015207-08; NCGC00015207-09; NCGC00015207-10; NCGC00015207-11; NCGC00015207-12; NCGC00015207-25; NCGC00022153-02; NCGC00022153-04; NCGC00022153-05; NCGC00022153-06; NCGC00022153-07; NCGC00260903-01; AK111532; HY-17464; BCP0726000145; RETAL;PLETAL;OPC 21;PLETAAL;Cilostal; SBI-0050206.P002; AB0012441; EU-0100218; FT-0602474; FT-0645036; FT-0665038; SW199053-2; D01896; J90029; AB00382988-14; AB00382988_15; AB00382988_16; 963C721; A837982; Q258591; Q-200854; SR-01000003107-2; SR-01000003107-4; SR-01000003107-7; BRD-K67017579-001-04-2; BRD-K67017579-001-05-9; BRD-K67017579-001-07-5; BRD-K67017579-001-13-3; BRD-K67017579-001-17-4; SR-01000003107-10; Cilastatin sodium, Antibiotic for Culture Media Use Only; Cilostazol, United States Pharmacopeia (USP) Reference Standard; 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril; 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril; Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material; 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-; 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one; 89332-50-3	Small molecule	1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)	RRGUKTPIGVIEKM-UHFFFAOYSA-N	C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4	C20H27N5O2	CAS 73963-72-1	CHEBI:31401	.	.	.	D03VPC	.	.	.
NP3982	Topiramate	CID: 5284627	topiramate; 97240-79-4; Topamax; Epitomax; Topamax Sprinkle; Tipiramate; Topiramatum; McN-4853; Tipiramato; Topiramato; McN 4853; C12H21NO8S; RWJ-17021-000; RWJ-17021; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; UNII-0H73WJJ391; USL255; USL-255; MFCD00865320; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; CHEBI:63631; Tipiramate [French]; Tipiramato [Spanish]; 0H73WJJ391; Topiramate, 98%; ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl sulfamate; Topiramatum [INN-Latin]; topiramatum [Latin]; Topiramato [INN-Spanish]; Topimax; Topomax; Topina; Topiramic acid; DSSTox_CID_3688; DSSTox_RID_77148; DSSTox_GSID_23688; ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl)methyl sulfamate; [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^{2,6}]dodecan-6-yl]methyl sulfamate; Topiragen; Topax; Trokendi XR; Qudexy XR; SMR000466325; Topiramate (TPM); TOR; TPM; Topamax (TN); CAS-97240-79-4; RWJ 17021; BRN 5988957; HSDB 7531; Sulfamate 7; 3hku; 3lxe; USL 255; Topiramate [USAN:USP:INN:BAN]; Topiramate solution; NCGC00095181-01; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[5,4-b:5',3'-d]pyran-3a-yl]methyl sulfamate; Trokendi xr (TN); KS-1122; Spectrum2_001128; beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; CBChromo1_000352; BIDD:PXR0127; SCHEMBL34631; BSPBio_002306; Topiramate (JAN/USP/INN); MLS000759431; MLS001424070; BIDD:GT0854; SPECTRUM1505801; SPBio_000995; CHEMBL220492; FRU009; GTPL6849; DTXSID8023688; BDBM10887; HMS1922H06; HMS2051L09; HMS2093D20; HMS2232H21; HMS3414C15; HMS3678C15; HMS3715I12; HMS3884C17; Pharmakon1600-01505801; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate (non-preferred name); ACT09031; ALBB-022457; HY-B0122; Tox21_111472; Tox21_302401; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; KM3440; NSC759251; s1438; ZINC95616603; AKOS000424547; Topiramate 1.0 mg/ml in Acetonitrile; Topiramate, >=98% (HPLC), solid; Tox21_111472_1; CCG-100940; CS-1885; DB00273; MCULE-9403222429; NC00190; NSC 759251; NSC-759251; NCGC00178714-01; NCGC00178714-04; NCGC00255221-01; SBI-0206907.P001; AB0007831; SW197570-3; C07502; D00537; AB00639961-06; AB00639961-08; AB00639961_09; AB00639961_10; 240T794; Q221174; SR-01000759409; W-60376; Q-201845; SR-01000759409-4; Z1522553470; 2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamate; Topiramate, United States Pharmacopeia (USP) Reference Standard; 2,3:4,5-Bis-O-(1-methylethylidene)-?-D-fructopyranose sulfamate; Topiramate, Pharmaceutical Secondary Standard; Certified Reference Material; Topiramate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5',3'-d]pyran-3a-yl]methyl sulfamate	Small molecule	1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1	KJADKKWYZYXHBB-XBWDGYHZSA-N	CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C	C12H21NO8S	CAS 97240-79-4	CHEBI:63631	.	.	.	D07VDZ	.	.	.
NP4023	Citicoline	CID: 13804	citicoline; cytidine 5'-diphosphocholine; CDP-choline; citicholine; 987-78-0; Citidoline; Cytidoline; Difosfocin; Cyscholin; Haocolin; Nicholin; Niticolin; Recofnan; Recognan; Somazina; Suncholin; Colite; Ensign; cytidine diphosphate choline; Cytidine diphosphocholine; Citicolinum; Citicolina; Cytidine diphosphorylcholine; Choline cytidine diphosphate; Cytidine choline diphosphate; Cytidine 5'-(choline diphosphate); CDP-colina; Cytidine 5'-(cholinyl pyrophosphate); Choline 5'-cytidine diphosphate; cyticholine; Cytidine 5'-diphosphoric choline; Cytidindiphosphocholin; Cereb; Cytidine 5'-diphosphate choline; Cytidine diphosphate choline ester; citidin difosfato de colina; Emicholin; Nicolin; Meibis; CDP-cholin; CDP-choline (neutral charge); Cytidinediphosphoric choline; UNII-536BQ2JVC7; Cytidine 5'-(trihydrogen diphosphate), P'-(2-(trimethylammonio)ethyl) ester, inner salt; IP 302; IP-302; Choline cytidine 5'-pyrophosphate ester; Choline, ester with cytidine 5'-pyrophosphate; CDP-cholin [German]; [2-CYTIDYLATE-O'-PHOSPHONYLOXYL]-ETHYL-TRIMETHYL-AMMONIUM; CDP-colina [Spanish]; Corenalin; Startonyl; Ubelin; Citicoline [INN:JAN]; CYTIDINE-5'-DIPHOSPHOCHOLINE; Citicolinum [INN-Latin]; Citicolina [INN-Spanish]; 536BQ2JVC7; CHEBI:16436; 2-(((((((2R,3S,4R,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)-N,N,N-trimethylethanaminium; Cytidindiphosphocholin [German]; Cytidine diphosphate cholin ester; C14H26N4O11P2; EINECS 213-580-7; Citidin difosfato de colina [Spanish]; Cytidine 5-diphosphocholine; NSC 122002; BRN 4170138; Citifar; Hornbest; Neucolis; Sintoclar; Somazine; Reagin; Rexort; Audes; Emicholine F; Cytidine, 5'-pyrophosphate, ester with choline; Cytidine 5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl] ester, inner salt; Nicholin (TN); Citicoline (JP17/INN); cytidine-5' diphosphocholine; SCHEMBL221081; AOB5033; Cytidine 5-diphosphate-trihydrogen; MFCD00868097; AKOS025312525; CCG-269597; DB04290; DB12153; Choline, hydroxide, 5'-ester with cytidine 5'-(trihydrogen pyrophosphate), inner salt; cytidine-5'-pyrophosphate-hydroxycholine; [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate; Cytidine 5'-(trihydrogen diphosphate), mono(2-(trimethylammonio)ethyl) ester, hydroxide, inner salt; K771; P-hydroxide[2-(trimethylammonio)ethyl] ester; C00307; D00057; W-100063; Q28529682; 5'-O-[(S)-hydroxy({[2-(trimethylammonio)ethoxy]phosphinato}oxy)phosphoryl]cytidine; 5'-O-[hydroxy({[2-(trimethylammonio)ethoxy]phosphinato}oxy)phosphoryl]cytidine; {2-[({[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)oxy]ethyl}trimethylazanium	Small molecule	1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1	RZZPDXZPRHQOCG-OJAKKHQRSA-N	C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O	C14H26N4O11P2	CAS 987-78-0	CHEBI:16436	.	.	.	D02CFP	.	.	.
NP4040	Chitosan	CID: 71853	Chitosan; Deacetylchitin; Poliglusam; Chicol; Flonac C; Flonac N; Sea Cure Plus; 9012-76-4; Kytex H; Kytex M; Kimitsu Chitosan F; Kimitsu Chitosan H; Kimitsu Chitosan L; Kimitsu Chitosan M; Sea Cure F; Chitopearl 3510; Kimitsu Chitosan F 2; Chitopearl BC 3000; Chitopearl BCW 2500; Chitopearl BCW 3000; Chitopearl BCW 3500; Chitopearl BCW 3505; Chitopearl BCW 3507; CTA 4; YEA; Celox; Poliglusam [USAN:INN]; Dac 70; CCRIS 9144; Chitosan, molecular weight: 100,000-300,000; Chitosan, molecular weight: 600,000-800,000; UNII-82LKS4QV2Y; UNII-SBD1A2I75N; EPA Pesticide Chemical Code 128930; UNII-5GV09YMO52; UNII-7SRJ3W89J8; UNII-23R93M6Y64; Poly (D-glucosamine); 82LKS4QV2Y; SBD1A2I75N; SCHEMBL972215; 5GV09YMO52; 7SRJ3W89J8; SCHEMBL21304990; beta-1,4-Poly-delta-glucosamine; AKOS015918343; 23R93M6Y64; FS-4075; A845562; Q408510; methyl N-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-azanyl-5-[(2S,3R,4R,5S,6R)-3-azanyl-5-[(2S,3R,4R,5S,6R)-3-azanyl-5-[(2S,3R,4R,5S,6R)-3-azanyl-5-[(2S,3R,4R,5S,6R)-3-azanyl-5-[(2S,3R,4R,5S,6R)-3-azanyl-6-(hydroxymethyl)-4,5-bis(oxidanyl)oxan-2-yl]oxy-6-(hy; N-[(2S,3R,4R,5S,6R)-5-[[(2S,3R,4R,5S,6R)-3-amino-5-[[(2S,3R,4R,5S,6R)-3-amino-5-[[(2S,3R,4R,5S,6R)-3-amino-5-[[(2S,3R,4R,5S,6R)-3-amino-5-[[(2S,3R,4R,5S,6R)-3-amino-5-[[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-4-hydroxy-6-(hy	Small molecule	1S/C56H103N9O39/c1-87-56(86)65-28-38(84)46(19(10-74)96-55(28)104-45-18(9-73)95-49(27(64)37(45)83)97-39-12(3-67)88-47(85)20(57)31(39)77)103-54-26(63)36(82)44(17(8-72)94-54)102-53-25(62)35(81)43(16(7-71)93-53)101-52-24(61)34(80)42(15(6-70)92-52)100-51-23(60)33(79)41(14(5-69)91-51)99-50-22(59)32(78)40(13(4-68)90-50)98-48-21(58)30(76)29(75)11(2-66)89-48/h11-55,66-85H,2-10,57-64H2,1H3,(H,65,86)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48+,49+,50+,51+,52+,53+,54+,55+/m1/s1	FLASNYPZGWUPSU-SICDJOISSA-N	COC(=O)NC1C(C(C(OC1OC2C(OC(C(C2O)N)OC3C(OC(C(C3O)N)O)CO)CO)CO)OC4C(C(C(C(O4)CO)OC5C(C(C(C(O5)CO)OC6C(C(C(C(O6)CO)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)CO)OC9C(C(C(C(O9)CO)O)O)N)O)N)O)N)O)N)O)N)O)N)O	C56H103N9O39	CAS 9012-76-4	.	.	.	.	.	.	.	.
NP4127	Daidzein	CID: 5281708	4',7-Dihydroxyisoflavone; Daidzeol; 7,4'-Dihydroxyisoflavone; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; UNII-6287WC5J2L; CCRIS 7600; K 251b; 4,7-Dihydroxyisoflavone; EINECS 207-635-4; BRN 0231523; CHEMBL8145; 4',7-Dihydroxy-iso-flavone; d-(+)-alpha-methylbenzylamine; ,7-Dihydroxyisoflavone; 7,4'-dihydroxyisoflavone; DIADZEIN; 486-66-8	.	1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O	C15H10O4	CAS 486-66-8	.	HBIN022577	SMIT00036	MOL000390	D0SY2M	.	2578	.
NP4149	L-carnitine	CID: 10917	L-carnitine; Levocarnitine; 541-15-1; (R)-Carnitine; vitamin BT; Carnitor; (-)-Carnitine; (-)-L-Carnitine; Karnitin; L-(-)-Carnitine; Carnitene; bicarnesine; Levocarnitina; Metina; L-Carnitine inner salt; Levocarnitinum; Carniking; Carnilean; Carnitine, (-)-; L(-)-Carnitine; Levocarnitinum [Latin]; Levocarnitina [Spanish]; Carniking 50; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; gamma-Trimethyl-beta-hydroxybutyrobetaine; gamma-Trimethyl-ammonium-beta-hydroxybutirate; 1-CARNITINE; (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate; 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt; DRG-0211; UNII-0G389FZZ9M; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide; R-(-)-3-hydroxy-4-trimethylaminobutyrate; 3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium; L-gamma-trimethyl-beta-hydroxybutyrobetaine; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (R)-; (R)-3-hydroxy-4-(trimethylammonio)butanoate; (3-Carboxy-2-hydroxypropyl)trimethyl-ammonium hydroxide, inner salt; (L-3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; CHEMBL1149; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L-; Carnicor; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, (R)-; 0G389FZZ9M; (R)-3-Hydroxy-4-(trimethylammonio)butyrate; Carnitolo; Carnovis; Carrier; CHEBI:16347; Lefcar; (-)-(R)-3-Hydroxy-4-(trimethylammonio)butyrate; L-carnitine Base; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-; 44985-71-9; L(-)-Carnitine, 99+%; Levocarnitine [USAN:INN]; L Carnitine; MFCD00038747; vitamin B T; Carnitor (TN); SMR000112475; carnitine (L-form); gamma-Trimethyl-hydroxybutyrobetaine; (3R)-3-hydroxy-4-(trimethylamino)butanoic acid; 3-hydroxy-4-trimethylammoniobutanoate; EINECS 208-768-0; Carnipass; delta-carnitine; Levocarnitine (JAN/USP/INN); L-Carnitin; Malonyl-Carnitin; HSDB 7588; Carnipass 20; Carnitine, L-; L-Carnitine,(S); Car-OH; Levocarnitine [USAN:USP:INN:BAN]; PubChem5901; (R)-3-Hydroxy-4-trimethylammoniobutyrate; bmse000211; L-carnitine (Levocarnitine); SCHEMBL21970; MLS001332549; MLS001332550; ARONIS24315; BIDD:GT0603; 1-Propanaminium,3-carboxy-2-hydroxy-N,N,N-trimethyl-; GTPL4780; DTXSID4023208; HMS2093J13; HMS2267H24; Pharmakon1600-01505437; HY-B0399; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; ABP000696; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide,inner salt; ANW-31960; BDBM50037268; c0049; CC0198; NSC741806; NSC759132; s2388; SBB058880; AKOS005267245; BCP9000830; CCG-213241; DB00583; KS-1422; NSC 759132; NSC-741806; NSC-759132; 6-CHLORO-3-HYDROXY(1H)INDAZOLE; 3-hydroxy-4-trimethylammoniobutanoic acid; AS-11974; gamma-L-trimethyl-beta-hydroxybutyrobetaine; L-Carnitin 100 microg/mL in Acetonitrile; L-Carnitine inner salt, synthetic, >=98%; N1935; ST50824805; C00318; D02176; (3R)-3-oxidanyl-4-(trimethylazaniumyl)butanoate; (R)-3-Hydroxy-4-(trimethylammonio)butanoic acid; AB00919083_05; AB00919083_06; (R)-(-)-3-Hydroxy-4-(trimethylammonio)butyrate; A829968; (3R)-(-)-3-Hydroxy-4-(trimethylammonio)butanoate; Q20735709; (3R)-(-)-3-Hydroxy-4-(trimethylammonio)butanoate 99+%; L-carnitine(Levocarnitine)/Carnitor, vitamin BT, Karnitin; UNII-S7UI8SM58A component PHIQHXFUZVPYII-ZCFIWIBFSA-N; Levocarnitine, European Pharmacopoeia (EP) Reference Standard; Levocarnitine, United States Pharmacopeia (USP) Reference Standard; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)- (9CI); Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L- (8CI); Levocarnitine, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1	PHIQHXFUZVPYII-ZCFIWIBFSA-N	C[N+](C)(C)CC(CC(=O)[O-])O	C7H15NO3	CAS 541-15-1	CHEBI:16347	.	.	.	D0G8SQ	.	.	.
NP4162	Choline	CID: 305	choline; Choline ion; Bilineurine; Choline cation; 62-49-7; Cholinum; 2-Hydroxy-N,N,N-trimethylethanaminium; (2-Hydroxyethyl)trimethylammonium; trimethylethanolamine; N-trimethylethanolamine; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-; CCRIS 5847; 2-hydroxyethyl(trimethyl)azanium; AI3-24208; UNII-N91BDP6H0X; BRN 1736748; N,N,N-trimethylethanol-ammonium; CHEBI:15354; (beta-hydroxyethyl)trimethylammonium; CHEMBL920; N91BDP6H0X; (2-hydroxyethyl)trimethylazanium; 2-hydroxy-N,N,N-trimethyl-ethanaminium; Bilineurine; Choline cation; Choline ion; Nanoveson C; Vitamin J; vitamin J; CHT; NSC402838; NCGC00015219-03; EINECS 200-535-1; 2-hydroxyethyl(trimethyl)ammonium; 1oba; 2reg; 3ppq; Choline (DCF); Choline (8CI); Spectrum_000258; 2ha3; 3r6u; Spectrum2_001938; Spectrum4_000867; Spectrum5_001579; Lopac-C-1754; bmse000285; bmse000953; bmse001003; Epitope ID:116046; SCHEMBL3142; Lopac0_000180; KBioGR_001533; KBioSS_000738; 3-04-00-00651 (Beilstein Handbook Reference); DivK1c_000107; N,N,N-trimethylethanolammonium; SPBio_001975; C[N+](C)(C)CCO; GTPL4551; DTXSID8043789; KBio1_000107; KBio2_000738; KBio2_003306; KBio2_005874; NSC6393; NINDS_000107; (2-Hydroxyethyl)trimethyl ammonium; mono-2-hydroxyethyltrimethylammonium; NSC-6393; ZINC3079337; BBL005532; BDBM50026220; STL137772; AKOS005721137; CCG-204275; DB00122; MCULE-7712564949; IDI1_000107; NCGC00015219-01; NCGC00015219-02; NCGC00015219-04; NCGC00015219-07; NCGC00015219-10; NCGC00162082-01; SBI-0050168.P003; 2-Hydroxy-N,N,N-trimethylammonium chloride; C00114; D07690; 11069-EP2269610A2; 11069-EP2269992A1; 11069-EP2270002A1; 11069-EP2270010A1; 11069-EP2272516A2; 11069-EP2272517A1; 11069-EP2272847A1; 11069-EP2272848A1; 11069-EP2275105A1; 11069-EP2277848A1; 11069-EP2277867A2; 11069-EP2280003A2; 11069-EP2281815A1; 11069-EP2284160A1; 11069-EP2284170A1; 11069-EP2284172A1; 11069-EP2289510A1; 11069-EP2289883A1; 11069-EP2289891A2; 11069-EP2289893A1; 11069-EP2295055A2; 11069-EP2295407A1; 11069-EP2295409A1; 11069-EP2295418A1; 11069-EP2295433A2; 11069-EP2298312A1; 11069-EP2298736A1; 11069-EP2298742A1; 11069-EP2298743A1; 11069-EP2298744A2; 11069-EP2298755A1; 11069-EP2298758A1; 11069-EP2298759A1; 11069-EP2298768A1; 11069-EP2298770A1; 11069-EP2301933A1; 11069-EP2301937A1; 11069-EP2305250A1; 11069-EP2305640A2; 11069-EP2305642A2; 11069-EP2305664A1; 11069-EP2305671A1; 11069-EP2305675A1; 11069-EP2305677A1; 11069-EP2305682A1; 11069-EP2308840A1; 11069-EP2308841A2; 11069-EP2308848A1; 11069-EP2308879A1; 11069-EP2311453A1; 11069-EP2311827A1; 11069-EP2311835A1; 11069-EP2311842A2; 11069-EP2314295A1; 11069-EP2314583A1; 11069-EP2314584A1; 11069-EP2314585A1; 11069-EP2314588A1; 11069-EP2314590A1; 11069-EP2314593A1; 11069-EP2316457A1; 11069-EP2316458A1; 11069-EP2316825A1; 11069-EP2316826A1; 11069-EP2316827A1; 11069-EP2316828A1; AB00053822_02; Ethanaminium, 2-hydroxy-N,N,N-trimethyl- (9CI); Q193166	Small molecule	1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1	OEYIOHPDSNJKLS-UHFFFAOYSA-N	C[N+](C)(C)CCO	C5H14NO+	CAS 62-49-7	CHEBI:15354	.	.	.	D08DAE	.	.	.
NP4234	Bismuth (III)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP4240	Esculetin	CID: 5281416	aesculetin; 6,7-dihydroxycoumarin; cichorigenin	.	1S/C9H6O4/c10-6-3-5-1-2-9(12)13-8(5)4-7(6)11/h1-4,10-11H	ILEDWLMCKZNDJK-UHFFFAOYSA-N	C1=CC(=O)OC2=CC(=C(C=C21)O)O	C9H6O4	CAS 305-01-1	.	HBIN025796	SMIT00192	MOL003837	D0YZ5G	.	108	.
NP4245	Beta aescin	CID: 6540709	Aescin; Escin; beta-Aescin; beta-Escin; beta Escin; Flogencyl; beta-Aescusan; beta-Aescinu; beta-Reparil; Sapogenins Glycosides; beta-Aescinu [Czech]; 11072-93-8; 6805-41-0; s4690; AKOS037514636; CCG-270645; NSC 758653; (2S,3S,4S,5R,6R)-6-[[(3S,4S,6aR,6bS,8R,8aR,9R,10R,14bR)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(Z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2S,3R,; (2S,3S,4S,5R,6R)-6-[[(3S,4S,6aR,6bS,8R,8aR,9R,10R,14bR)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(Z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxane-2-carboxylic acid	Small molecule	1S/C55H86O24/c1-10-23(2)46(71)79-43-44(72-24(3)60)55(22-59)26(17-50(43,4)5)25-11-12-30-51(6)15-14-32(52(7,21-58)29(51)13-16-53(30,8)54(25,9)18-31(55)61)75-49-41(77-48-38(67)36(65)34(63)28(20-57)74-48)39(68)40(42(78-49)45(69)70)76-47-37(66)35(64)33(62)27(19-56)73-47/h10-11,26-44,47-49,56-59,61-68H,12-22H2,1-9H3,(H,69,70)/b23-10-/t26?,27-,28-,29?,30?,31-,32+,33-,34-,35+,36+,37-,38-,39+,40+,41-,42+,43+,44+,47+,48+,49-,51+,52-,53-,54-,55+/m1/s1	AXNVHPCVMSNXNP-ZELRDNAQSA-N	CC=C(C)C(=O)OC1C(C2(C(CC1(C)C)C3=CCC4C5(CCC(C(C5CCC4(C3(CC2O)C)C)(C)CO)OC6C(C(C(C(O6)C(=O)O)OC7C(C(C(C(O7)CO)O)O)O)O)OC8C(C(C(C(O8)CO)O)O)O)C)CO)OC(=O)C	C55H86O24	CAS 11072-93-8	.	.	.	.	.	.	.	.
NP4339	Aclarubicin	CID: 451415	aclarubicin; Aclacinomycin A; 57576-44-0; Aclarubicine; Aclarubicinum; NSC-208734; UNII-74KXF8I502; MA 144-A1; Aclucinomycin A; 74KXF8I502; Aclacinon; Aclacur; Jaclacin; methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate; Aclarubicino; Aclarubicins; Aclacin; CHEBI:77980; ACLACINOMYCIN A1; methyl (1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-O-{2,6-dideoxy-4-O-[(2R,6S)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl}-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate; Antibiotic MA 144A; Aclarubicine [INN-French]; Aclarubicinum [INN-Latin]; Aclarubicino [INN-Spanish]; aclarubicina; Aclarubicin [USAN:INN:BAN]; CCRIS 2262; EINECS 260-824-3; Spectrum_000467; Spectrum2_001934; Spectrum4_000768; Spectrum5_001041; Aclarubicin (USAN/INN); SCHEMBL4532; KBioGR_001156; KBioSS_000947; SPBio_001967; CHEMBL502620; DTXSID1022554; CHEBI:74619; KBio2_000947; KBio2_003515; KBio2_006083; HMS2089B13; AW8655; BDBM50368351; CCG-39864; MFCD00866250; ZINC85537142; DB11617; 1-Naphthacenecarboxylic acid,(2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-Lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-; Methyl (1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-1-naphthacenecarboxylate; C18638; D02756; AB00052311-02; 576A440; Q4674302; 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-; 2-Ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-.alpha.-L-lyxo-hexopyranosyl]-3-(dimethylamino)-.alpha.-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxo-tetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-6-methyl-tetrahydropyran-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate	Small molecule	1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1	USZYSDMBJDPRIF-SVEJIMAYSA-N	CCC1(CC(C2=C(C3=C(C=C2C1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O	C42H53NO15	CAS 57576-44-0	CHEBI:77980	.	.	.	D01UBX	.	.	.
NP4353	Gamabufotalin	CID: 259803	Gamabufotalin; 465-11-2; Gamabufogenin; Gamabufagin; Gammabufotalin; UNII-5HH3KM165O; 5HH3KM165O; CHEBI:80826; 5-[(3S,5R,8R,9S,10S,11R,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one; Gamabufalin; NSC 90384; SCHEMBL866038; CHEMBL465318; DTXSID40878664; 3-beta,11-alpha,14-Trihydroxy-5-beta-bufa-20,22-dienolide; HY-N0883; NSC90384; ZINC4916495; 3689AH; MFCD01740822; NSC-90384; AKOS030526148; CS-3701; NCGC00485918-01; C16962; 465G112; A827057; Q-100490; Q27149869; 5.beta.-Bufa-20, 3.beta.,11.alpha.,14-trihydroxy-; 5-beta-BUFA-20,22-DIENOLIDE, 3-beta,11-alpha,14-TRIHYDROXY-; 5beta-Bufa-20,22-dienolide, 3beta,11alpha,14-trihydroxy- (8CI); Bufa-20, 3,11,14-trihydroxy-, (3.beta.,5.beta.,11.alpha.)-; Bufa-20,22-dienolide, 3,11,14-trihydroxy-, (3-beta,5-beta,11-alpha)- (9CI); 5-[(3S,5R,8R,9S,10S,11R,13R,14S,17R)-10,13-dimethyl-3,11,14-tris(oxidanyl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one; 5-[(3S,5R,8R,9S,10S,11R,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-pyranone	Small molecule	1S/C24H34O5/c1-22-9-7-16(25)11-15(22)4-5-18-21(22)19(26)12-23(2)17(8-10-24(18,23)28)14-3-6-20(27)29-13-14/h3,6,13,15-19,21,25-26,28H,4-5,7-12H2,1-2H3/t15-,16+,17-,18-,19-,21-,22+,23-,24+/m1/s1	FMTLOAVOGWSPEF-KJRPADTMSA-N	CC12CCC(CC1CCC3C2C(CC4(C3(CCC4C5=COC(=O)C=C5)O)C)O)O	C24H34O5	CAS 465-11-2	CHEBI:80826	.	.	.	.	.	.	.
NP4401	Brusatol	CID: 73432	Brusatol; 14907-98-3; Yatansin; (+)-Brusatol; CHEBI:3197; CHEMBL459546; (11beta,12alpha,15beta)-13,20-Epoxy-3,11,12-trihydroxy-15-((3-methyl-1-oxo-2-butenyl)oxy)-2,16-dioxopicras-3-en-21-oic acid, methyl ester; NSC 172924; BRN 1444847; (1R,2S,3S,3aS,3a1R,4R,6aR,7aR,11aS,11bR)-Methyl 1,2,9-trihydroxy-8,11a-dimethyl-4-((3-methylbut-2-enoyl)oxy)-5,10-dioxo-2,3,3a,4,5,6a,7,7a,10,11,11a,11b-dodecahydro-1H-3,3a1-(epoxymethano)dibenzo[de,g]chromene-3-carboxylate; Methyl 13,20-epoxy-3,11,12-trihydroxy-15-((3-methyl-1-oxo-2-butenyl)oxy)-2,16-dioxopicras-3-en-21-oate (11beta,12alpha,15beta)-; SCHEMBL1276480; Brusatol, >=95% (HPLC); DTXSID70164163; QCR-223; BCP15272; BDBM50535743; MFCD01746220; ZINC30726694; AKOS016013415; CS-W019658; 2H-3,11c-beta-(Epoxymethano)phenanthro(10,1-bc)pyran-3-alpha(3a-beta-H)-carboxylic acid, 1,4,5,6a-beta,7,7a-alpha,10,11,11a,11b-alpha-decahydro-8,11a-beta-dimethyl-5,10-dioxo-1-beta,2-alpha,4-beta,9-tetrahydroxy-, methyl ester, 4-(3-methylcrotonate); AS-55977; HY-19543; Picras-3-en-21-oic acid, 13,20-epoxy-3,11,12-trihydroxy-15-((3-methyl-1-oxo-2-butenyl)oxy)-2,16-dioxo-, methyl ester, (11beta,12alpha,15beta)-; C08754; Q27105985; methyl trihydroxy-dimethyl-(3-methylbut-2-enoyloxy)-dioxo-[?]carboxylate; Picras-3-en-21-oicacid,13,20-epoxy-3,11,12-trihydroxy-15-[(3-methyl-1-oxo-2-buten-1-yl)oxy]-2,16-dioxo-,methyl ester, (11b,12a,15b)-	Small molecule	1S/C26H32O11/c1-10(2)6-15(28)37-18-20-25-9-35-26(20,23(33)34-5)21(31)17(30)19(25)24(4)8-13(27)16(29)11(3)12(24)7-14(25)36-22(18)32/h6,12,14,17-21,29-31H,7-9H2,1-5H3/t12-,14+,17+,18+,19+,20+,21-,24-,25+,26-/m0/s1	ZZZYHIMVKOHVIH-VILODJCFSA-N	CC1=C(C(=O)CC2(C1CC3C45C2C(C(C(C4C(C(=O)O3)OC(=O)C=C(C)C)(OC5)C(=O)OC)O)O)C)O	C26H32O11	CAS 14907-98-3	CHEBI:3197	.	.	.	.	.	.	.
NP4406	Colchicine	CID: 6167	colchicine; 64-86-8; Colchicin; Colchicina; Colchisol; Condylon; Colcin; Colsaloid; Colchicinum; Colchineos; Colcrys; 7alphaH-Colchicine; Kolkicin; Goutnil; (S)-colchicine; Mitigare; spindle poison; NSC 757; UNII-SML2Y3J35T; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-Acetyl trimethylcolchicinic acid methylether; NSC757; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; CHEMBL107; SML2Y3J35T; MFCD00078484; CHEBI:27882; NSC-757; Colchicin [German]; NCGC00025125-07; Colchysat; Colchicina [Italian]; 7-alpha-H-Colchicine; DSSTox_CID_4845; DSSTox_RID_77551; DSSTox_GSID_24845; Colstat; Acetamide, N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-; Acetamide, N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]-; Colchicine (TN); N-[(7s)-1,2,3,10-Tetramethoxy-9-Oxo-6,7-Dihydro-5h-Benzo[d]heptalen-7-Yl]ethanamide; 30512-31-3; LOC; SMR000058323; CCRIS 691; Colchicine, Colchicum autumnale; 7.alpha.H-Colchicine; HSDB 3044; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-, (S)-; Colchicine [USP:JAN]; SR-01000075794; SR-01000597576; EINECS 200-598-5; AI3-31149; (S)-colchicina; 4lzr; (S)-colchicin; Acetamide,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(.alpha.)heptalen-7-yl)-; Acetamide,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-; MPC-004; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)- acetamide; CAS-64-86-8; (-)-colchicine; Prestwick_695; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; Spectrum_000842; Tocris-1364; 4o2b; Prestwick0_000363; Prestwick1_000363; Prestwick2_000363; Prestwick3_000363; Spectrum2_000075; Spectrum3_000362; Spectrum4_000298; Spectrum5_000787; Colchicine (JP17/USP); UPCMLD-DP065; Benzo(a)heptalen-9(5H)-one, 7-acetamido-6,7-dihydro-1,2,3,10-tetramethoxy-; C 9754; EC 200-598-5; SCHEMBL8469; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; Lopac0_000310; methoxylated analogue of XD1; BSPBio_000485; BSPBio_002083; KBioGR_000856; KBioSS_001322; MLS001055448; MLS001304089; MLS002153786; DivK1c_000753; SPECTRUM1500205; SPBio_000289; SPBio_002406; BPBio1_000535; GTPL2367; MEGxp0_001879; DTXSID5024845; UPCMLD-DP065:001; ACon1_000353; HMS502F15; KBio1_000753; KBio2_001322; KBio2_003890; KBio2_006458; KBio3_001303; NINDS_000753; HMS1569I07; HMS1920A08; HMS2091G16; HMS2096I07; HMS2231C05; HMS3260N22; HMS3713I07; Pharmakon1600-01500205; ZINC621853; Colchicine, >=96.0% (HPLC); Tox21_110947; Tox21_201547; Tox21_300582; Tox21_500310; BDBM50014846; CCG-39910; KM0881; NSC756702; s2284; AKOS001582887; Colchicine, >=95% (HPLC), powder; Tox21_110947_1; CS-1141; DB08117; EBD2156734; LP00310; MCULE-1568647156; MCULE-7858118731; NSC-756702; SDCCGMLS-0066633.P001; SDCCGSBI-0050298.P006; IDI1_000753; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; NCGC00025125-01; NCGC00025125-02; NCGC00025125-03; NCGC00025125-04; NCGC00025125-05; NCGC00025125-06; NCGC00025125-08; NCGC00025125-09; NCGC00025125-10; NCGC00025125-11; NCGC00025125-12; NCGC00025125-13; NCGC00025125-14; NCGC00025125-15; NCGC00025125-18; NCGC00025125-20; NCGC00025125-33; NCGC00169157-01; NCGC00169157-02; NCGC00169157-03; NCGC00254359-01; NCGC00259096-01; NCGC00260995-01; AK167930; AS-13686; HY-16569; NCI60_041659; SBI-0050298.P004; A3324; EU-0100310; FT-0603187; MLS001055448-02; N1721; C-7100; C07592; D00570; J10109; M01514; 24218-EP2275412A1; 24218-EP2277865A1; 24218-EP2281815A1; 24218-EP2301933A1; 24218-EP2301940A1; 24218-EP2305219A1; 24218-EP2305640A2; 24218-EP2311827A1; 24218-EP2314590A1; binds to tubulin; inhibits microtubular assembly; 078C484; Colchicine (contains 5% Ethyl Acetate at maximum); SR-01000075794-1; SR-01000075794-3; SR-01000075794-6; SR-01000075794-7; SR-01000597576-1; SR-01000597576-3; BRD-K00259736-001-06-5; BRD-K00259736-001-10-7; WLN: L B677 MV&T&J CO1 DO1 EO1 JMV1 NO1; Benzo[a]heptalen-9(5H)-one,7-dihydro-1,2,3,10-tetramethoxy-; Colchicine, (European Pharmacopoeia (EP) Reference Standard); Colchicine, United States Pharmacopeia (USP) Reference Standard; Colchicine, BioReagent, plant cell culture tested, >=95% (HPLC); Colchicine, Pharmaceutical Secondary Standard; Certified Reference Material; (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl) acetamide; Colchicine for system suitability, European Pharmacopoeia (EP) Reference Standard; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]-heptalen-7-yl)-acetamid; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide;; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[d]heptalen-7-yl]acetamide	Small molecule	1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1	IAKHMKGGTNLKSZ-INIZCTEOSA-N	CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC	C22H25NO6	CAS 64-86-8	CHEBI:27882	.	.	.	D09DHY	.	.	.
NP4435	Glycyrrhizin	CID: 14982	Glycyrrhizic acid; glycyrrhizin; Glycyrrhizinic acid; 1405-86-3; Glycyrrhetinic acid glycoside; glyzyrrhizin; Glizigen; Glycyron; 18-beta-Glycyrrhizic acid; Liquorice; UNII-6FO62043WK; CHEBI:15939; C42H62O16; CHEMBL441687; NSC 2800; beta-Glycyrrhizin; 6FO62043WK; Rizinsan K2 A2 (free acid); NSC-167409; NSC-234419; DSSTox_CID_27006; DSSTox_RID_82047; DSSTox_GSID_47006; Glycyrrhitin; Dermacrin; Glycyram; (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; 30-hydroxy-11,30-dioxoolean-12-en-3beta-yl (2-O-beta-D-glucopyranosyluronic acid)-alpha-D-glucopyranosiduronic acid; 18beta-Glycyrrhizic acid; Neo-Umor; CAS-1405-86-3; HSDB 496; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-; EINECS 215-785-7; NSC 167409; NSC 234419; BRN 0077922; CCRIS 8444; MFCD00065194; NCGC00183128-01; (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxy-tetrahydropyran-3-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; Glycyrrhizin, 93%; ammonium-glycyrrhizinate; Glycyrrhizic acid, 2K; beta-Glycyrrhizinic acid; 132215-36-2; Glycyrrhizia uralensis Fisch; SCHEMBL17684; 20beta-Carboxy-11-oxo-30-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; 4-18-00-05156 (Beilstein Handbook Reference); alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucopyranuron osyl-; BIDD:ER0363; GTPL4688; DTXSID8047006; Glycyrrhizin (Glycyrrhizic Acid); HY-N0184; Tox21_111520; Tox21_113426; Tox21_303493; BDBM50185127; HMDB:0029843; s2302; ZINC96015174; AKOS015893086; AKOS015969345; CCG-270511; CS-7695; DB13751; GM-1292; NCGC00257455-01; NCGC00386162-01; NCGC00386162-02; (3beta,20beta)-20-Carboxy-11-oxo-30-norlean-12-en-3-yl-2-O-beta-1- 7-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norlean-12-en-3-yl-2-O-beta-1- 7-glucopyranuronosyl-; AS-13001; E958; G0150; N1792; J10040; AB01566834_01; 405G863; Q418705; Q-201172; BRD-K83486494-318-01-5; Glycyrrhizic acid, United States Pharmacopeia (USP) Reference Standard; xy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; Glycyrrhizic Acid, Pharmaceutical Secondary Standard; Certified Reference Material; (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carbo; (2S,3S,4S,5R,6S)-6-{[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-5-{[(2R,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3,4-dihydroxyoxane-2-carboxylic acid; (3.beta.,20.beta.)-20-Carboxy-11-oxo-30-norlean-12-en-3-yl-2-O-.beta.-1- 7-glucopyranuronosyl-.alpha.-D-glucopyranosiduronic acid	Small molecule	1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1	LPLVUJXQOOQHMX-QWBHMCJMSA-N	CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C	C42H62O16	CAS 1405-86-3	CHEBI:15939	.	.	.	D0T8QB	.	.	.
NP4440	Kaempferol	CID: 5280863	kaempferol; 520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe	.	1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H	IYRMWMYZSQPJKC-UHFFFAOYSA-N	C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O	C15H10O6	CAS 520-18-3	.	HBIN031753	SMIT00041	MOL000422	D0G3TK	.	207	.
NP4522	Retinol	CID: 445354	retinol; Vitamin A; all-trans-Retinol; 68-26-8; Vitamin A1; Alphalin; Axerophthol; Afaxin; Vitamin A alcohol; Oleovitamin A; Chocola A; Alphasterol; Apostavit; Aquasynth; Biosterol; Epiteliol; Ophthalamin; Agiolan; Agoncal; Anatola; Myvpack; Prepalin; Testavol; Veroftal; Aoral; Apexol; Avibon; Avitol; Axerol; Dofsol; Vaflol; Vitpex; Vogan; Disatabs Tabs; Lard Factor; all-trans-Retinyl alcohol; Bentavit A; Dohyfral A; Alcovit A; Anatola A; Vogan-Neu; A-Mulsal; Plivit A; Vi-Alpha; A-Vitan; All-trans retinol; Atars; trans-retinol; Vafol; all-trans-Vitamin A alcohol; Retrovitamin A; Homagenets Aoral; A-Sol; Hi-A-Vita; Sehkraft A; Vitamin A1 alcohol; all-trans-Vitamin A; A-Vi-Pel; ACON; ATAV; Vi-Dom-A; Super A; Anti-infective vitamin; Solu-A; Nio-A-Let; Vio-A; Antixerophthalmic vitamin; Del-VI-A; Vitavel A; Thalasphere; 11103-57-4; trans-Vitamin A alcohol; Vitamin A alcohol, all-trans-; Vitamin A1, all-trans-; Retinol, all trans-; all-trans-Vitamin A1; Vitamin A Oil; Vi-a; UNII-G2SH0XKK91; .beta.-Retinol; beta-Retinol; Vitamin A1 alcohol, all-trans-; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol; MFCD00001552; CHEMBL986; G2SH0XKK91; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 2,4,6,8-Nonatetraen-1-ol, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; Axerophtholum; CHEBI:17336; Wachstumsvitamin; Vitaminum A; Vitamine A; Vitavel-A; VITAMINA; NSC-122759; Retinolo [DCIT]; NCGC00017343-07; Cylasphere; Retinolo; Retinolum; Retinol [INN:BAN]; all-trans-Retinol, 95%; DSSTox_CID_3556; Hydrovit A; Retinolum [INN-Latin]; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; DSSTox_RID_77080; DSSTox_GSID_23556; Ro-a-vit; tROL; Vitamin A alcohol (VAN); Antixerophthalmisches Vitamin; Aquasol A Parenteral; Vi-alpha; Vi-alpha; Rovimix A 500; Vitamin A1 alcohol, all trans; Retinol solution; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetr aen-1-ol; CAS-68-26-8; SMR000112036; Retinol (Vit A); [11,12-3H]-Retinol; 9-cis,13-cis-Retinol; Vitamin A (USP); CCRIS 5444; HSDB 815; Vitamin A [Natural]; SR-01000763813; Retin-11,12-t2-ol (9CI); EINECS 200-683-7; NSC 122759; BRN 0403040; Tegosphere VitA; .alpha.sterol; .alpha.lin; Retinyl A; trans-Retinol acid (Vitamin A); 1rbp; Vi-.alpha.; EINECS 234-328-2; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol; (9Z)-Retinol; PubChem18446; 1gx8; Retinol-(cellular-retinol-binding-protein); Spectrum5_000993; Spectrum5_001997; Retinol, 95%, synthetic; EC 200-683-7; all-trans vitamin A alcohol; SCHEMBL3112; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-; Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol; all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; BIDD:PXR0102; 4-06-00-04133 (Beilstein Handbook Reference); MLS001066379; MLS001074751; MLS006010008; Retinol, all-trans- (8CI); SPECTRUM1501203; GTPL4053; Vitamin A; ; ; Retinoid analogues; DTXSID3023556; HMS501I08; Zinc-ethylenebis(dithiocarbamate); all-trans-13,14-Dihydro retinol; HMS1921B04; HMS2092L13; HMS2270C05; Pharmakon1600-01501203; BCP06593; HY-B1342; ZINC3831417; Tox21_110818; Tox21_202441; Tox21_300287; BDBM50092056; CCG-38864; LMPR01090001; NSC122759; NSC758150; s5592; AKOS015902578; DB00162; NSC-758150; SDCCGMLS-0066724.P001; IDI1_000486; Retinol solution, >=95.0% (HPLC); SMP2_000102; NCGC00017343-02; NCGC00017343-03; NCGC00017343-04; NCGC00017343-05; NCGC00017343-06; NCGC00017343-08; NCGC00017343-09; NCGC00017343-11; NCGC00091784-01; NCGC00091784-02; NCGC00091784-03; NCGC00091784-04; NCGC00091784-05; NCGC00091784-06; NCGC00254024-01; NCGC00259990-01; AC-11701; BS-17906; ST057232; SBI-0051690.P002; CS-0013091; C00473; C17276; D06543; 33563-EP2272846A1; 33563-EP2277869A1; 33563-EP2277870A1; 33563-EP2281813A1; 33563-EP2284174A1; 33563-EP2292608A1; 33563-EP2301936A1; 33563-EP2311820A1; 33563-EP2374791A1; AB00052248_05; 103V574; A836068; Q424976; Retinol, >=95.0% (HPLC), ~2700 U/mg; Retinol, synthetic, >=95% (HPLC), crystalline; J-014834; J-017515; Q-201926; SR-01000763813-2; SR-01000763813-4; W-104683; BRD-K22429181-001-06-8; BRD-K64634304-001-01-5; WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1; Retinol, BioXtra, >=97.5% (HPLC), ~3100 U/mg; UNII-81G40H8B0T component FPIPGXGPPPQFEQ-OVSJKPMPSA-N; 3,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 2,6,8-Nonatetraen-1-ol, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, all (E)-; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-1-nona-2,4,6,8-tetraenol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraen-1-ol; (2Z,4Z,6Z,8Z)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetren-1-ol; Retinol solution, 100 mug/mL +/- 25% (Refer to COA) (Ethanol with 0.1% (w/v) BHT), ampule of 1 mL, certified reference material	Small molecule	1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C	C20H30O	CAS 11103-57-4	CHEBI:17336	.	.	.	D0S7WX	.	.	.
NP4533	Apigenin-7-o-glucoside	CID: 5280704	Apigetrin; COSMOSIIN; 578-74-5; Apigenin 7-glucoside; Cosmosiine; Cosmosioside; APIGENIN-7-GLUCOSIDE; Cosmetin; Apigenin 7-O-beta-D-glucoside; Apigenin-7-O-glucoside; UNII-7OF2S66PCH; Apigenin 7-O-glucoside; Apigenin 7-O-beta-D-glucopyranoside; 7OF2S66PCH; CHEBI:16778; 7-O-beta-D-Glucosyl-5,7,4'-trihydroxyflavone; NSC-407303; 5-Hydroxy-2-(4-hydroxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; Cosemetin; 5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside; 7-(beta-D-Glucopyranosyloxy)-5-hydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Apigenin 7-beta-D-glucoside; apigenin 7-O-beta-glucoside; Cosmociin; MFCD00016787; 7-O-(beta-D-Glucosyl)apigenin; Apigenin, 7-beta-D-glucopyranoside; Cosmosiin (8CI); EINECS 209-430-5; NSC 407303; Spectrum_000176; SpecPlus_000927; Spectrum2_001752; Spectrum3_001249; Spectrum4_001741; Spectrum5_000562; 4-ethynyl-1,1-biphenyl; apigenin 7-O--D-glucoside; 7-O-beta-D-Glucosylapigenin; BSPBio_002758; KBioGR_002182; KBioSS_000656; SPECTRUM211950; DivK1c_007023; SCHEMBL146404; 7-O-beta-D-glucosyl-apigenin; SPBio_001884; Apigenin 7-beta-glucopyranoside; CHEMBL487017; MEGxp0_001431; KBio1_001967; KBio2_000656; KBio2_003224; KBio2_005792; KBio3_002258; Apigenin 7-O-beta-glucopyranoside; 7-O-beta-D-Glucopyranosylapigenin; HMS1923E03; Apigenin-7-O-; A-D-glucopyranoside; HY-N0578; ZINC3983877; BDBM50378582; CCG-38803; s9125; AKOS025117305; Apigenin-7-O-.beta.-D-glucopyranoside; CS-5931; MCULE-8522272831; APIGENIN-7-O-;  cent-D-GLUCOSIDE; NCGC00178486-01; 5-hydroxy-2-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; Apigenin 7-glucoside, analytical standard; AS-75174; N2287; W1637; 4',5,7-Trihydroxyflavone 7-beta-D-glucoside; C04608; 578A745; Q2858304; BRD-K13642330-001-01-8; Apigenin 7-glucoside, primary pharmaceutical reference standard; Apigenin 7-glucoside, EuropePharmacopoeia (EP) Reference Standard; Apigenin-7-O-glucoside 1000 microg/mL in Acetone:Dimethyl sulfoxide; Apigenin 7-glucoside, United States Pharmacopeia (USP) Reference Standard; 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-5-hydroxy-2-(4-hydroxyphenyl)- (9CI); 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranosyloxy)-5-hydroxy-2-(4-hydroxyphenyl)-, Apigenin 7-O-glucoside; 5-hydroxy-2-(4-hydroxyphenyl)-7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one	Small molecule	1S/C21H20O10/c22-8-16-18(26)19(27)20(28)21(31-16)29-11-5-12(24)17-13(25)7-14(30-15(17)6-11)9-1-3-10(23)4-2-9/h1-7,16,18-24,26-28H,8H2/t16-,18-,19+,20-,21-/m1/s1	KMOUJOKENFFTPU-QNDFHXLGSA-N	C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)OC4C(C(C(C(O4)CO)O)O)O)O)O	C21H20O10	CAS 578-74-5	CHEBI:16778	.	.	.	.	.	.	.
NP4536	Calcipotriol	CID: 5288783	Calcipotriol; calcipotriene; Dovonex; Daivonex; Psorcutan; Sorilux; 112965-21-6; Calcitrene; MC 903; MC-903; Calcipotriol hydrate; UNII-143NQ3779B; CHEBI:50749; Dovonex (TN); 143NQ3779B; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; 112828-00-9; NCGC00167465-01; Calciptriol; DSSTox_CID_26648; DSSTox_RID_81793; DSSTox_GSID_46648; Divonex; (22E)-(24S)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrovitamin D3 / (22E)-(24S)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrocholecalciferol / Calcipotriol; (5Z,7E,22E)-(1S,3R,24S)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol; SMR000466353; CAS-112965-21-6; Calcipotriene [USAN]; SR-01000762910; CCRIS 7700; MFCD10567086; (5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol; PRI 2201; Calcipotriol (JAN); Calcipotriol [INN]; Calcipotriene (USP); BMS-181161; PubChem18810; PubChem19334; Epitope ID:114242; SCHEMBL2853; MLS000759467; MLS001424130; GTPL2778; CHEMBL1200666; DTXSID0046648; AMY2864; 1s19; HMS2051N11; HMS2089J08; HMS3269P03; HMS3413D04; HMS3677D04; HMS3713K08; MC903; EX-A4430; PRI-2201; ZINC3921872; Tox21_112469; BDBM50369964; LMST03020106; s3739; AKOS015855239; Tox21_112469_1; CCG-100949; CS-0387; DB02300; NC00199; STF-115469; NCGC00167465-02; AS-56390; CPD000466353; HY-10001; O763; D01125; U-0267; W-5148; 24207-EP2275420A1; 24207-EP2295055A2; 24207-EP2295416A2; 24207-EP2298748A2; 24207-EP2298764A1; 24207-EP2298765A1; 24207-EP2305640A2; 24207-EP2305642A2; 24207-EP2308861A1; 24207-EP2311453A1; 24207-EP2314590A1; AB00698343-05; 828C009; Q155683; SR-01000762910-3; SR-01000762910-4; (1?,3?,5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol; (1S,3R,5Z,7E,14beta,17alpha,22E,24S)-26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene-1,3,24-triol; (5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol hydrate; (5Z,7E,24S)-26,27-Cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1alpha,3beta,24-triol; 9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1alpha,3beta,5Z,7E,22E,24S)-	Small molecule	1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1	LWQQLNNNIPYSNX-UROSTWAQSA-N	CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C	C27H40O3	CAS 112965-21-6	CHEBI:50749	.	.	.	D01QUS	.	.	.
NP4545	Mirtazapine	CID: 4205	mirtazapine; 85650-52-8; Remeron; 61337-67-5; Mepirzepine; Remergil; Zispin; Remergon; Mirtazepine; Rexer; 6-Azamianserin; Remeron SolTab; Mepirzapin; Mirtazipine; Promyrtil; Norset; ORG 3770; Mirtazapina; Avanza; Mirtazapinum; Mirtazapinum [INN-Latin]; Mirtazapina [INN-Spanish]; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; Org-3770; 2-methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; CHEMBL654; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; Mirtazapine (Remeron, Avanza); CHEBI:6950; Mirtazapine, 98%; MFCD00865427; (R)-Org3770;(R)-6-Azamianserin; (S)-Org3770;(S)-6-Azamianserin; NCGC00025346-02; Pyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; Azamianserin; Mirtazapine [USAN:BAN:INN]; Smilon; 2-methyl-1,2,3,4,9,13b-hexahydro-2,4a,5-triaza-tribenzo[a,c,e]cycloheptene; (14bR)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; Org3770; SMR000466347; Remeron (TN); SR-01000597530; EINECS 288-060-6; Mepirzapine; R-Mirtazapine; S-Mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c](2)benzazepine; Mirtazapine [USAN:USP:INN:BAN]; Mirtazapine solution; Reflex (TN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; Mianserin, 6-Aza-; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; ME-2040; PubChem22104; 207516-99-2; DSSTox_CID_3325; DSSTox_RID_76979; DSSTox_GSID_23325; SCHEMBL35408; MLS000759460; MLS001076676; MLS001424294; MLS006011449; Mirtazapine (JAN/USP/INN); GTPL7241; PYR432; DTXSID0023325; Mirtazapine, >=98% (HPLC); HMS2052H03; HMS2233K03; HMS3268F21; HMS3370B05; HMS3374J01; HMS3394H03; HMS3413C11; HMS3657M13; HMS3677C11; HMS3713P13; HMS3884O18; BCP14560; BCP22244; HY-B0352; Mirtazapine 1.0 mg/ml in Methanol; Tox21_110965; ANW-42478; BBL009962; BDBM50115644; CM0152; PDSP1_001529; PDSP2_001513; s2016; STK711107; AKOS005530681; BCP9000930; CCG-101154; CCG-220556; DB00370; KS-1086; MCULE-1174883554; NC00404; NE42580; VA11306; NCGC00025346-01; NCGC00025346-08; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8(13),9,11,15,17-hexaene; AC-15480; K532; AB0014270; CAS-61337-67-5; FT-0601544; FT-0628951; FT-0672414; M-130; M2151; SW197784-4; EN300-49851; C07570; D00563; J10458; AB00698265_08; 337M675; L001294; Q421930; SR-01000597530-1; SR-01000597530-4; BRD-A64977602-001-01-9; BRD-A64977602-001-04-3; Z2327131613; Mirtazapine, European Pharmacopoeia (EP) Reference Standard; Mirtazapine, United States Pharmacopeia (USP) Reference Standard; (+/-)-12-Methyl-1,2,3,4,9,13b-hexahydro-2,4a,5-triaza-tribenzo[a,c,e]cycloheptene; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine.; 2-Methyl-1,2,3,4,10,14b-hexahydrobenzo-[c]pyrazino[1,2-a]pyrido[3,2-f]azepine; Mirtazapine for system suitability, European Pharmacopoeia (EP) Reference Standard; Mirtazapine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0?,?.0?,??]nonadeca-1(19),8,10,12,15,17-hexaene; Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-   85650-52-8; Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (.+/-.)-	Small molecule	1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3	RONZAEMNMFQXRA-UHFFFAOYSA-N	CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4	C17H19N3	CAS 85650-52-8	CHEBI:6950	.	.	.	D05ZIK	.	.	.
NP4551	Heparin	CID: 772	heparin; enoxaparin; 9005-49-6; Ardeparin; Bemiparin; SEMULOPARIN; Lovenox; LMWH; Nadroparin; Nadroparine; Clivarin; Liquaemin; Reviparin; 6-((5-acetamido-4,6-dihydroxy-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-((5-((6-carboxy-4,5-dihydroxy-3-(sulfooxy)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)-3-(sulfoamino)-4-(sulfooxy)tetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-5-(sulfooxy)tetrahydro-2H-pyran-2-carboxylic acid; Adomiparin; Multiparin; Novoheparin; Parnaparin; Parvoparin; Sandoparin; Sublingula; Tinzaparin; Heparina; Heparine; Heparinum; Hepathrom; Liquemin; Octaparin; Pabyrin; PK-10169; Pularin; Subeparin; Triofiban; Fluxum; Vetren; Hed-heparin; Depo-Heparin; Lipo-hepin; Fragmin A; Fragmin B; Vitrum AB; Eparina [DCIT]; Heparin [BAN]; Adomiparin [USAN]; CY 216; FR 860; Heparin CY 216; Heparine [INN-French]; Heparinum [INN-Latin]; Heparina [INN-Spanish]; Semuloparin [USAN:INN]; UNII-1K5KDI46KZ; UNII-4QW4AN84NQ; UNII-E47C0NF7LV; UNII-VL0L558GCB; 1K5KDI46KZ; 4QW4AN84NQ; E47C0NF7LV; UNII-P776JQ4R2F; UNII-V72OT3K19I; VL0L558GCB; 2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose; SCHEMBL543122; UNII-5R0L1D739E; UNII-7UQ7X4Y489; UNII-M316WT19D8; UNII-S79O08V79F; UNII-T2410KM04A; GTPL6811; M 118REH; P776JQ4R2F; V72OT3K19I; Cy 222; HSDB 3094; DTXSID80872762; 5R0L1D739E; 7UQ7X4Y489; M316WT19D8; S79O08V79F; T2410KM04A; UNII-9816XA9004; AVE-5026; BCP13334; EINECS 232-681-7; KB 101; OP 386; OP 622; RP-54563; 9816XA9004; M 118; Q416516; 6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxyoxan-2-yl)oxy-6-(hydroxymethyl)-3-(sulfoamino)-4-sulfooxyoxan-2-yl]oxy-4-hydroxy-5-sulfooxyoxane-2-carboxylic acid; 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)tetrahydropyran-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxy-tetrahydropyran-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxy-tetrahydropyran-3-yl]oxy-3,4-dihydroxy-5-sulfooxy-tetrahydropyran-2-carboxylic acid	Small molecule	1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)	HTTJABKRGRZYRN-UHFFFAOYSA-N	CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O	C26H42N2O37S5	CAS 9005-49-6	.	.	.	.	D01ZJK	.	.	.
NP4582	Glycyrrhetinic acid	CID: 10114	enoxolone; 471-53-4; Glycyrrhetic acid; GLYCYRRHETINIC ACID; Uralenic acid; 18-beta-Glycyrrhetinic acid; 18beta-Glycyrrhetinic acid; Rhetinic Acid; Glycyrrhetin; Biosone; Arthrodont; alpha-Glycyrrhetinic acid; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; UNII-P540XA09DR; 18beta-Glycyrrhetic acid; MFCD00003706; 3-Glycyrrhetinic acid; MLS000028748; CHEMBL230006; P540XA09DR; Enoxolone (Glycyrrhetinic acid); (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; CHEBI:30853; Jintan; Glycyrrhetinate; NSC-35347; NCGC00017244-03; SMR000058239; DSSTox_CID_669; NSC 35347; Glycyrrhetinic acid (JAN); Glycyrrhetinic acid [JAN]; DSSTox_RID_75722; DSSTox_GSID_20669; Enoxolonum; Enoxolona; (3beta,5beta,14beta)-3-Hydroxy-11-Oxoolean-12-En-29-Oic Acid; Enoxolonum [INN-Latin]; 18-beta-Glycyrrhetinic acid, 98+%; Enoxolona [INN-Spanish]; 18-beta-Glycyrrhetic acid; Enoxolone [INN:BAN:DCF]; (5S,8S,15S,18S,1R,2R,10R,14R,20R)-18-hydroxy-1,2,5,8,15,19,19-heptamethyl-13-o xopentacyclo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-8-carboxylic acid; CAS-471-53-4; CCRIS 3962; SR-01000721867; 1449-05-4; EINECS 207-444-6; BRN 2229654; Enoloxone; NSC-35350; Hidermart (TN); 3-beta-Hydroxy-11-oxoolean-12-en-30-oic acid; Enoxolone (INN); NCGC00181115-01; glycyrrhetinic acids; CBW; (3beta)-3-hydroxy-11-oxoolean-12-en-30-oic acid; Enoxolone (Glycyrrhetin); Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3beta,20beta)-; Opera_ID_1048; SCHEMBL18540; 18 beta-Glycyrrhetintic Acid; 4-10-00-03775 (Beilstein Handbook Reference); MLS001146949; MLS002207101; Enoxolone, Glycyrrhetinic acid; Olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-; BX-1; DTXSID9020669; GTPL11264; STX-352; CHEBI: 30853; (3beta,20beta)-3-Hydroxy-11-oxo-olean-12-en-29-oic acid; 18beta-Glycyrrhetinic acid, 97%; HMS2233P23; HY-N0180; Tox21_110804; Tox21_112726; Tox21_200799; BDBM50233538; s2296; SBB006496; ZINC19203131; AKOS015960428; AKOS016036757; HMDB: 0011628; AC-1925; AC-8906; CCG-208506; CS-W020624; DB13089; GM-1658; KS-1262; LMPR0106150014; MCULE-4676598997; Enoxolone 100 microg/mL in Acetonitrile; NCGC00017244-04; NCGC00017244-06; NCGC00142473-03; NCGC00258353-01; 107420-91-7; ST056310; G0149; 3beta-hydroxy-11-oxoolean-12-en-29-oic acid; C02283; D00156; S00284; Enoxolone (synonym: 18ss--Glycyrrhetinic acid); 130100-EP2269977A2; 130100-EP2295411A1; 471G534; A827163; (3?)-3-Hydroxy-11-oxoolean-12-en-30-oic acid; 18beta-Glycyrrhetinic acid, purum, >=97.0% (T); Q-201057; Q5948038; SR-01000721867-3; SR-01000721867-4; SR-01000721867-5; SR-01000721867-6; BRD-K96137854-001-17-1; 3ss-Hydroxy-11-oxo-18ss,20ss-olean-12-en-29-oic acid; Enoxolone, European Pharmacopoeia (EP) Reference Standard; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo- (8CI); 3??-Hydroxy-11-oxo-18??,20??-olean-12-en-29-oic acid; 3beta-Hydroxy-11-oxo-18beta,20beta-olean-12-en-29-oic acid; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxidanyl-13-oxidanylidene-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; Enoxolone; 18beta-Glycyrrhetinic acid;  3?-Hydroxy-11-oxo-18?,20?-olean-12-en-29-oic acid	Small molecule	1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1	MPDGHEJMBKOTSU-YKLVYJNSSA-N	CC1(C2CCC3(C(C2(CCC1O)C)C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C	C30H46O4	CAS 471-53-4	CHEBI:30853	.	.	.	D0X2OD	.	.	.
NP4592	Mithramycin A	CID: 163659	NCGC00181319-05; NCGC00181319-01; DSSTox_CID_3492; DSSTox_RID_77052; Plicatomycin; DSSTox_GSID_23492; CAS-18378-89-7; AC1NR4RB; SCHEMBL4516; DTXSID6023492; Tox21_112787; Tox21_112751; NCGC00181319-08; NCGC00181319-06; NCGC00181319-03; NCGC00181319-04; NCGC00181319-02; NCGC00181319-07	Small molecule	1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1	CFCUWKMKBJTWLW-BKHRDMLASA-N	CC1C(C(CC(O1)OC2CC(OC(C2O)C)OC3=CC4=CC5=C(C(=O)C(C(C5)C(C(=O)C(C(C)O)O)OC)OC6CC(C(C(O6)C)O)OC7CC(C(C(O7)C)O)OC8CC(C(C(O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O	C52H76O24	CAS 18378-89-7	CHEBI:31856	.	.	.	D0GU4Q	.	.	.
NP4593	Fosfomycin	CID: 446987	FOSFOMYCIN; phosphomycin; Phosphonomycin; 23155-02-4; Fosfonomycin; Fosfocina; Monurol; Veramina; Fosfomicina; Fosfomycine; Fosfomycinum; Antibiotic 833A; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)-; UNII-2N81MY12TE; (2R-cis)-(3-Methyloxiranyl)phosphonic acid; (1R,2S)-epoxypropylphosphonic acid; Phosphonemycin; L-cis-1,2-epoxypropylphosphonic acid; (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid; CHEMBL1757; Fosfomycin disodium salt; 2N81MY12TE; CHEBI:28915; FCM; Phosphonic acid, (1,2-epoxypropyl)-, (1R,2S)-(-)-; cis-(1R,2S)-epoxypropylphosphonic acid; 1R-cis-(1,2-epoxypropyl)phosphonic acid; ((2R,3S)-3-methyloxiran-2-yl)phosphonic acid; Fosfomicin; Infectophos; 1,2-EPOXYPROPYLPHOSPHONIC ACID; Levo-phosphonomycin; Fosfomycin (USAN/INN); Fosfomycine [INN-French]; Fosfomycinum [INN-Latin]; Fosfomicina [INN-Spanish]; Fosfomycin [USAN:INN:BAN]; J01XX01; EINECS 245-463-1; MK-955; BRN 1680831; 883A; Fosfomycin (compound 1); Fosfomycinfor culture media; SCHEMBL50951; BIDD:GT0448; BRN 1680831, Fosfocina; ZTI-01; DTXSID4048480; GTPL10813; BCP24891; ZINC1530427; BDBM50024894; cis-(2-Methyloxiranyl)-phosphonic acid; DB00828; (2R,3S)-3-methyloxiran-2-ylphosphonate; 25030-76-6; (1R, 2S)-1,2-epoxypropyl-phosphonic acid; FT-0774116; (2R,3S)-3-methyloxiran-2-ylphosphonic acid; (3-Methyl-oxiranyl)-phosphonic acid(Na salt); C06454; D04253; Q183554; W-107422; BRD-K81101512-234-01-9; Phosphonic acid, P-[(2R,3S)-3-methyl-2-oxiranyl]-; 6F066DFF-696A-4A94-AF78-A28430EBE5BA	Small molecule	1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1	YMDXZJFXQJVXBF-STHAYSLISA-N	CC1C(O1)P(=O)(O)O	C3H7O4P	CAS 23155-02-4	CHEBI:28915	.	.	.	D01GYT	.	.	.
NP4620	Apigenin	CID: 5280443	5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di	.	1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H	KZNIFHPLKGYRTM-UHFFFAOYSA-N	C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O	C15H10O5	CAS 520-36-5	.	HBIN016408	SMIT00003	MOL000008	D00RIX	.	372	.
NP4621	Triptolide	CID: 107985	Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315	.	1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1	DFBIRQPKNDILPW-CIVMWXNOSA-N	CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C	C20H24O6	CAS 38748-32-2	.	HBIN047173	SMIT00526	MOL003187	D0I6LH	DB12025	7086	.
NP4647	Dimethylthiourea	CID: 2723631	N,N'-DIMETHYLTHIOUREA; 1,3-Dimethylthiourea; 534-13-4; 1,3-Dimethyl-2-thiourea; Thiourea, N,N'-dimethyl-; sym-Dimethylthiourea; Dimethylthiocarbamide; Dimethylthiourea; 1,3-Dimethylisothiourea; Urea, 1,3-dimethyl-2-thio-; UNII-8P30PMD17W; 1,3-dimethyl-thiourea; N,N'-Dimethylthiourea, 99%; 8P30PMD17W; Dimethyl-2-thiourea; bis(methylamino)methane-1-thione; 1,3-dimethylthio urea; NSC 8727; EINECS 208-588-2; Thiourea,N,N'-dimethyl-; BRN 0605454; AI3-16377; 1-3-Dimethylthiourea; 1,3-dimethyl thiourea; Thiourea,N'-dimethyl-; N, N'-Dimethylthiourea; Urea,3-dimethyl-2-thio-; (CH3NH)2CS; ACMC-1B43Y; DSSTox_CID_22191; DSSTox_RID_79951; DSSTox_GSID_42191; SCHEMBL45851; 1,3-Dimethylthiourea-[d6]; 4-04-00-00217 (Beilstein Handbook Reference); 61805-96-7; CHEMBL3189044; DTXSID2042191; SCHEMBL12149464; NSC8727; NSC-8727; UREA,1,3-DIMETHYL,2-THIO; ZINC1648203; Tox21_301391; ANW-31741; MFCD00004923; SBB060411; ZB1375; AKOS008944393; FS-4265; MCULE-7998520647; NE10368; WT81717; (Z)-N,N'-dimethylcarbamimidothioic acid; NCGC00255832-01; CAS-534-13-4; CS-0071975; D0804; FT-0629569; ST51046597; Z6162; EN300-16053; N,N inverted exclamation marka-Dimethylthiourea; 10.14272/VLCDUOXHFNUCKK-UHFFFAOYSA-N.1; doi:10.14272/VLCDUOXHFNUCKK-UHFFFAOYSA-N.1; W-109556; Q26840925; F0001-1384	Small molecule	1S/C3H8N2S/c1-4-3(6)5-2/h1-2H3,(H2,4,5,6)	VLCDUOXHFNUCKK-UHFFFAOYSA-N	CNC(=S)NC	C3H8N2S	CAS 534-13-4	.	.	.	.	.	.	.	.
NP4688	Methyl gallate	CID: 7428	METHYL GALLATE; Methyl 3,4,5-trihydroxybenzoate; 99-24-1; Gallic acid methyl ester; Methylgallate; Benzoic acid, 3,4,5-trihydroxy-, methyl ester; Gallic acid, methyl ester; methyl galloate; MFCD00002194; UNII-623D3XG80C; 3,4,5-Trihydroxybenzoic acid methyl ester; AI3-00861; 3,4,5-Trihydroxy-benzoic acid methyl ester; CHEMBL65675; 623D3XG80C; NSC363001; Methyl 3,4,5-trihydroxybenzoate, 99%; GALLINCIN; CCRIS 5567; EINECS 202-741-7; NSC 363001; BRN 2113180; Methyl gallate;; methyl-3,4,5-trihydroxybenzoate; Gallic acid methyl; ACMC-209sc1; cid_7428; SCHEMBL39513; 4-10-00-01998 (Beilstein Handbook Reference); MLS000574912; DTXSID3059189; ZINC21789; CHEBI:145828; HMS2210A23; HMS3346G16; ACT10740; HY-N2010; ANW-40991; BBL010505; BDBM50187133; CM0133; s3790; SBB064246; STL146151; methyl 3,4,5-tris(oxidanyl)benzoate; AKOS000277450; CCG-266463; EBD1614516; MCULE-4626719858; NSC-363001; Methyl 3,4,5-trihydroxybenzoate, 98%; NCGC00247606-01; AC-11364; AK-94175; AS-14808; M666; SMR000156263; SY011144; AB0007856; DB-057768; CS-0018330; FT-0626596; G0017; H6235; ST50825211; A845986; CS-008/03903045; W-100047; Q15425833	Small molecule	1S/C8H8O5/c1-13-8(12)4-2-5(9)7(11)6(10)3-4/h2-3,9-11H,1H3	FBSFWRHWHYMIOG-UHFFFAOYSA-N	COC(=O)C1=CC(=C(C(=C1)O)O)O	C8H8O5	CAS 99-24-1	CHEBI:145828	.	.	.	.	.	.	.
NP4705	Dicoumarol	CID: 54676038	dicumarol; dicoumarol; 66-76-2; Bishydroxycoumarin; dicoumarin; melitoxin; bis-hydroxycoumarin; Antitrombosin; Baracoumin; Dicoumal; Dicumarine; Acadyl; Acavyl; Dicuman; Dicumol; Trombosan; Dufalone; Kumoran; Temparin; Cumid; Cuma; Dicumaol R; 3,3'-Methylenebis(4-hydroxycoumarin); Bis(4-hydroxycoumarin-3-yl)methane; Dicoumarolum; Bis-3,3'-(4-hydroxycoumarinyl)methane; Di-(4-hydroxy-3-coumarinyl)methane; Di-4-hydroxy-3,3'-methylenedicoumarin; 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); 3,3'-Methylen-bis(4-hydroxy-cumarin); 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); 3,3'-Methylene-bis(4-hydroxycoumarine); 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); NC 034; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-; 3,3'-Metilen-bis(4-idrossi-cumarina); 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); UNII-7QID3E7BG7; C19H12O6; NSC 17860; Dicoumarol (INN); 3,3'-Methylenebis[4-hydroxycoumarin]; NSC 221570; 3,3'-Methylene-bis(4-hydroxycoumarin); Coumarin, 3,3'-methylenebis(4-hydroxy-; 4-hydroxy-3-[(4-hydroxy-2-oxochromen-3-yl)methyl]chromen-2-one; 7QID3E7BG7; CHEMBL1466; CHEBI:4513; Anathrombase; Apekumarol; Dicoumerol; Dicumarinum; Dicumarolum; 4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]-2H-chromen-2-one; Dicoumarol [INN]; NSC17860; NSC41834; 3,2-benzopyrone]; Dicumarol, 99%; MFCD00006857; CAS-66-76-2; Dicumarolo [DCIT]; NCGC00016296-01; Dwukumarol [Polish]; Dicumarolo; Dikumarol; Dwukumarol; DSSTox_CID_1729; 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; DSSTox_RID_76296; Dicumarol [INN-Spanish]; DSSTox_GSID_21729; Dicoumarolum [INN-Latin]; CHEMBL43154; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; 2H-1-Benzopyran-2-one, 3,3'-methylenebis(4-hydroxy-; Coumarin,3'-methylenebis[4-hydroxy-; Dicumarol (TN); Dicumarol (USAN); CCRIS 3713; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; NSC221570; HSDB 3223; WLN: T66 BOVJ EQ D1- DT66 BOVJ EQ; SR-05000001605; 4,4'-Dihydroxy-3,3'-methylene bis coumarin; Dicumarol [USAN:USP]; 2H-1-Benzopyran-2-one,3'-methylenebis[4-hydroxy-; EINECS 200-632-9; NSC 41834; 2H-1-Benzopyran-2-one],3'-methylenebis[4-hydroxy-; 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; BRN 0335444; AI3-14546; 4-hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)-2H-chromen-2-one; symmetric dicoumarol analogue, 1; uncoupler of oxidative respiration; Prestwick_90; 2H-1-Benzopyran-2-one), 3,3'-methylenebis(4-hydroxy-; Spectrum_000165; Prestwick0_000785; Prestwick1_000785; Prestwick2_000785; Prestwick3_000785; Spectrum2_000144; Spectrum3_000387; Spectrum4_000508; Spectrum5_000871; M0216; ChemDiv2_003436; Oprea1_150990; SCHEMBL33891; SCHEMBL33892; BSPBio_000890; BSPBio_002173; CBDivE_003005; KBioGR_001055; KBioSS_000645; 5-19-06-00682 (Beilstein Handbook Reference); DivK1c_000896; SPECTRUM1500239; SPBio_000248; SPBio_002829; BPBio1_000980; GTPL6808; DTXSID8021729; BDBM35525; HMS502M18; KBio1_000896; KBio2_000645; KBio2_003213; KBio2_005781; KBio3_001393; Dicoumarol - CAS 66-76-2; NINDS_000896; HMS1378M04; HMS1570M12; HMS1920E20; HMS2091M10; HMS2097M12; HMS3652P10; HMS3714M12; HMS3744M19; HMS3865F03; Pharmakon1600-01500239; HY-N0645; ZINC3869855; Tox21_110357; 3,3'-Methylenbis(4-hydroxycumarin); BBL008904; CCG-34550; NSC-17860; NSC756733; s4299; STK801287; AKOS000520650; Tox21_110357_1; AM10016; CS-7962; DB00266; ETHYLM-TRIFLUOROMETHYLCARBANILATE; MCULE-8095183287; NSC-756733; VZ31493; IDI1_000896; NCGC00016296-02; NCGC00016296-03; NCGC00016296-04; NCGC00016296-05; NCGC00016296-07; NCGC00094650-01; NCGC00094650-02; AS-19619; SBI-0051343.P003; FT-0624734; H2893; SW196402-3; Y1603; 3,3''''''''-methylenebis[4-hydroxycoumarin; 3,3'-Methylene-bis(4-hydroxycoumarin), 99%; A14241; C00796; D03798; 3,3''''''''-methylenebis(4-hydroxy-coumarin; 3,3''''''''-methylenebis(4-hydroxycoumarin); AB00051966_05; Coumarin, 3,3'-methylenebis[4-hydroxy- (8CI); Q420886; SR-05000001605-1; SR-05000001605-3; SR-05000001605-4; W-203471; BRD-K82236179-001-05-0; BRD-K82236179-001-06-8; Z57170530; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy- (9CI); Dicumarol, United States Pharmacopeia (USP) Reference Standard; 4-hydroxy-3-[(4-hydroxy-2-oxo-chromen-3-yl)methyl]chromen-2-one	Small molecule	1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2	DOBMPNYZJYQDGZ-UHFFFAOYSA-N	C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O	C19H12O6	CAS 66-76-2	CHEBI:4513	.	.	.	D02TJS	.	.	.
NP4778	Medroxyprogesterone acetate	CID: 6279	Medroxyprogesterone acetate; 71-58-9; Medroxyprogesterone 17-acetate; Metigestrona; Provera; Farlutin; Gestapuran; Perlutex; Veramix; Methylacetoxyprogesterone; Medroxyacetate progesterone; Depo-Provera; Depcorlutin; Deporone; Lutopolar; Nadigest; Prodasone; Progestalfa; Progevera; Proverone; Repromix; Sirprogen; Supprestral; Lutoral; Nidaxin; Oragest; Depo-Promone; Promone-E; 6-alpha-Methyl-17-alpha-acetoxyprogesterone; Medroxyprogesteroneacetate; NSC-26386; 6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate; 17alpha-Hydroxy-6alpha-methylprogesterone acetate; 6alpha-Methyl-17alpha-hydroxyprogesterone acetate; Amen; 6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate; Depot medroxyprogesterone acetate; Depot-medroxyprogesterone acetate; UNII-C2QI4IOI2G; DP150; 17-Acetoxy-6alpha-methylprogesterone; Aragest; Clinovir; Ralovera; 6alpha-Methyl-17-acetoxy progesterone; Hysron; Provera dosepak; Depo-clinovir; Depo-Ralovera; (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate; U 8839; C2QI4IOI2G; Medroxyprogesterone-17-acetate; MLS000069442; (6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione; CHEBI:6716; ONCO-Provera; NSC-21171; Medrosterona; Clinofem; Cykrina; Depocon; Indivina; Mepastat; Meprate; Repromap; SMR000059125; Sumiferm; Suprestral; Veraplex; Dugen; Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6a)-; Depo-progestin; Depo-Prodasone; Depo-Progevera; Perlutex Leo; DSSTox_CID_5527; Depo-Map; Aragest 5; Med-Pro; MPA-beta; DSSTox_RID_77819; MPA Hexal; MPA-Noury; DSSTox_GSID_25527; (6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; MAP (steroid); 17alpha-Acetoxy-6alpha-methylprogesterone; Depomedroxyprogesterone acetate; Medroxyprogesterone acetate, 97%; MPA GYM; Depo-Medroxyprogesterone acetate; Depo-subq provera; CAS-71-58-9; CCRIS 371; 17.alpha.-Acetoxy-6.alpha.-methylprogesterone; EINECS 200-757-9; medroxyprogesterone-acetate; 6alpha-Methyl-17-acetoxyprogesterone; NSC 21171; Depo-Provera Contraceptive; 17-Acetoxy-6-alpha-methylprogesterone; (6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-; 17.alpha.-Hydroxy-6-.alpha.-methylprogesterone acetate; Pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-, acetate; 6-alpha-Methyl-17-acetoxy progesterone; BRN 2066112; Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, (6.alpha.)-; Progestins; AI3-60127; Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-; 17-Acetoxy-6.alpha.-methylprogesterone; 6.alpha.-Methyl-17-acetoxyprogesterone; NCGC00094713-01; 17alpha-Hydroxy-6-alpha-methylprogesterone acetate; Progesterone, 17-hydroxy-6alpha-methyl-, acetate; 17-alpha-Hydroxy-6-alpha-methylprogesterone acetate; Provera (TN); Depo-provera (TN); 6alpha-Methyl-17alpha-acetoxypregn-4-ene-3,20-dione; Medroxyprogesterone acetate [USP:JAN]; 17-alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione; 17alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione; 6-alpha-Methyl-17-alpha-acetoxypregn-4-ene-3,20-dione; Progesterone, 17-alpha-hydroxy-6-alpha-methyl-, acetate; Medroxyprogesterone acetate [Progestins]; 6-alpha-Methyl-4-pregnene-3,20-dion-17-alpha-ol acetate; 6.alpha.-Methyl-17.alpha.-acetoxyprogesterone; PubChem13062; (6-alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione; 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate; 6alpha-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-; CPD000653524; 17-alpha-Hydroxy-6-alpha-methylpregn-4-ene-3,20-dione acetate; Opera_ID_1110; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone acetate; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone acetate; Medroxiprogesterone Acetate; CHEMBL717; SCHEMBL4276; 6.alpha.-Methyl-17.alpha.-acetoxypregn-4-ene-3,20-dione; Medroxyprogesterone (acetate); 17.alpha.-Acetoxy-6-.alpha.-methylpregn-4-ene-3,20-dione; 4-08-00-02212 (Beilstein Handbook Reference); 6.alpha.-Methyl-4-pregnene-3,20-dion-17.alpha.-ol acetate; MLS001148217; MLS002207115; 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione acetate; Depo-subq provera 104 (TN); DTXSID0025527; HMS2233O07; HMS2235E05; HMS3259O14; HMS3884B10; (6-alpha)-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-; CBP-1011; HY-B0469; NSC21171; NSC26386; ZINC5029557; Tox21_111319; Tox21_200141; BDBM50067678; CM0089; s2567; AKOS015894870; Tox21_111319_1; AC-2174; CCG-264965; DB00603; NC00574; Medroxyprogesterone acetate (JP17/USP); MRF-0000023; NCGC00022037-03; NCGC00022037-04; NCGC00022037-05; NCGC00022037-07; NCGC00257695-01; NCGC00263480-01; AS-13981; I028; SMR000653524; TV-46046; C08150; D00951; 16534-EP2269990A1; 16534-EP2272517A1; 16534-EP2275102A1; 16534-EP2275413A1; 16534-EP2281563A1; 16534-EP2281815A1; 16534-EP2287156A1; 16534-EP2289893A1; 16534-EP2289894A2; 16534-EP2295550A2; 16534-EP2298731A1; 16534-EP2298743A1; 16534-EP2298768A1; 16534-EP2301933A1; 16534-EP2305640A2; 16534-EP2308861A1; 16534-EP2311807A1; 16534-EP2311827A1; 16534-EP2314574A1; 16534-EP2316459A1; 92480-EP2295416A2; 92480-EP2295426A1; 92480-EP2295427A1; 92480-EP2298748A2; 92480-EP2298768A1; 92480-EP2305642A2; AB00384270-14; AB00384270_15; Medroxyprogesterone 17-acetate, >=97% (HPLC); 010M483; Q2823834; (6?)-6-Methyl-3,20-dioxopregn-4-en-17-yl acetate; 6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-; P097000000; Medroxyprogesterone-17-acetate 100 microg/mL in Acetonitrile; Medroxyprogesterone 17-acetate, VETRANAL(TM), analytical standard; Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard; Pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate (8CI); Medroxyprogesterone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material; Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard; Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Medroxyprogesterone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard; Medroxyprogesterone acetate, for performance test, European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1	PSGAAPLEWMOORI-PEINSRQWSA-N	CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C	C24H34O4	CAS 71-58-9	CHEBI:6716	.	.	.	.	.	.	.
NP4808	Brimonidine	CID: 2435	brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; 5-bromo-6-(imidazolin-2-ylamino)quinoxaline; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; AGN 190342; UNII-E6GNX3HHTE; UK 14304; UK-14304; MLS000069370; E6GNX3HHTE; CHEMBL844; SMR000058355; CHEBI:3175; Brimonidine, 98%; MFCD00153878; NCGC00016069-09; UK 14304;AGN190342; DSSTox_CID_25221; DSSTox_RID_80758; DSSTox_GSID_45221; UK 14304 (tartrate);AGN190342 (tartrate); 5-Bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine; Brimonidine [INN:BAN]; [3H]brimonidine; C11H10BrN5; CAS-59803-98-4; N-(5-bromoquinoxalin-6-yl)imidazolidin-2-imine; SR-01000000023; AGN-190342; brimonidina; brimonidinum; BRN 0751629; Brimonidine-d4; LK 14304-18; Brimonidine (INN); 1184971-51-4; UK14304; Tocris-0425; [3H]-UK14304; Opera_ID_612; Lopac-U-104; cid_2435; Lopac0_001216; SCHEMBL24670; GTPL520; MLS001076349; ARONIS24406; BIDD:GT0649; GTPL5386; DTXSID3045221; BDBM34572; AGN-190342 FREE BASE; HMS3259P09; HMS3263D14; HMS3266O03; HMS3411K05; HMS3675K05; HMS3887K07; AMY22318; BCP12632; HY-B0659; Tox21_110299; Tox21_501216; UK-1430418 FREE BASE; AC-162; ANW-59812; NSC318825; PDSP1_000640; PDSP2_000635; s9508; SBB080815; ZINC21303210; AKOS005267239; Tox21_110299_1; CCG-205290; DB00484; GS-3236; LP01216; MCULE-4542695850; NC00638; NSC 318825; NSC-318825; SDCCGSBI-0051183.P002; MRF-0000657; NCGC00016069-01; NCGC00016069-02; NCGC00016069-03; NCGC00016069-04; NCGC00016069-05; NCGC00016069-06; NCGC00016069-07; NCGC00016069-08; NCGC00016069-10; NCGC00016069-11; NCGC00016069-12; NCGC00016069-13; NCGC00016069-24; NCGC00023468-02; NCGC00023468-04; NCGC00023468-05; NCGC00023468-06; NCGC00023468-07; NCGC00261901-01; AK-35795; UK14,304; Brimonidine 100 microg/mL in Acetonitrile; B4132; EU-0101216; FT-0630717; FT-0650586; EN300-50880; UK 14304-18; C07886; D07540; 5-bromo-6-(2-imidazolidinylidenamino)quinoxaline; 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline; 5-Bromo-6-(2-imidazolin-2-ylamino)-quinoxaline; 6-Quinoxalinamine,5-dihydro-1H-imidazol-2-yl)-; (5-bromoquinoxalin-6-yl)-2-imidazolin-2-ylamine; 803B984; A832477; L000615; Q577377; SR-01000000023-2; SR-01000000023-4; BRD-K68264559-001-10-0; Z802671510; (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine; 5-bromanyl-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI)	Small molecule	1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)	XYLJNLCSTIOKRM-UHFFFAOYSA-N	C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br	C11H10BrN5	CAS 59803-98-4	CHEBI:3175	.	.	.	D0AE3X	.	.	.
NP4809	Cystine	CID: 595	DL-CYSTINE; cystine; 923-32-0; 3,3'-disulfanediylbis(2-aminopropanoic acid); Dicysteine; Cystine acid; Cystin; Cysteine disulfide; (H-Cys-OH); Cystine, L-; NSC13203; 2-amino-3-[(2-amino-2-carboxyethyl)disulfanyl]propanoic acid; MFCD00084652; (-)-Cystine; .beta.,.beta.'-Dithiodialanine; CHEBI:17376; Alanine, 3,3'-dithiobis-; Cystine, DL-; alpha-Diamino-beta-dithiolactic acid; 3,3'-Dithiobis(2-aminopropanoic acid); DL-Cystine-d6; 3,3'-Dithiobis(2-aminopropionic acid); Bis(.beta.-amino-.beta.-carboxyethyl) disulfide; C6H12N2O4S2; NSC 13203; cistina; Zystin; MFCD00064228; D,L-cystine; NCGC00164531-01; Cystine,(S); 352431-53-9; Alanine,3'-dithiodi-; DL-Cystine, 99%; PubChem12373; Alanine,3'-dithiobis-; DL-Cystine, free base; ACMC-209ibx; ACMC-209luu; 90350-38-2; L-3,3'-dithiodialanine; ACMC-1AZ5O; (H-DL-Cys-OH)2; CYSTINE, (L); Cystine_RamanathanGurudeeban; SCHEMBL10224; CHEMBL366563; BDBM86199; .beta.,.beta.'-Dithiobisalanine; CAS_595; DTXSID50859005; NSC_595; Pharmakon1600-01300099; BCP29195; ANW-43036; BBL011587; CAS_67678; NSC-13203; NSC_67678; NSC203781; NSC205366; NSC755897; STL163324; AKOS000121517; AKOS016050601; AM81645; CS-W014656; MCULE-2293704247; NE11203; NSC-203781; NSC-205366; NSC-755897; VA50617; .beta.,.beta.'-dicarboxydiethyldisulfide; 3,7-diamino-5-phenyl-phenaziniuchloride; NCGC00164531-02; NCGC00164531-03; AK-43995; AK-49718; AS-66164; K684; SY033311; SY036878; SY038309; .beta.,.beta.'-dicarboxydiethyl disulfide; SBI-0207067.P001; DB-052986; FT-0624467; FT-0625453; FT-0627753; FT-0770594; ST45022122; 24645-67-8; (+/-)-3,3'-Dithiobis(2-aminopropionicacid); 3055-EP2272972A1; 3055-EP2272973A1; 3055-EP2277872A1; 3055-EP2287152A2; 3055-EP2295410A1; 3055-EP2301939A1; Bis(.beta.-amino-.beta.-carboxyethyl)disulfide; C-9765; C01420; L-Cystine-1,1 inverted exclamation marka-13C2; 923C320; SR-01000872746; SR-01000872746-1; Q27102343; Z56346947; L-Cystin;Acetylcysteine Impurity A;3,3'-Dithiodialanine; Propanoic acid,3'-dithiobis[2-amino-, [R-(R*,R*)]-; .beta.,.beta.'-Diamino-.beta.,.beta.'-dicarboxydiethyl disulfide; 5228F255-51E7-421E-8A05-4687B20118CB; 2-amino-3-(2-amino-3-hydroxy-3-oxopropyl)disulfanylpropansure; 2-amino-3-[(2-amino-3-hydroxy-3-oxo-propyl)disulfanyl]propanoic acid; 4746-38-7	Small molecule	1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)	LEVWYRKDKASIDU-UHFFFAOYSA-N	C(C(C(=O)O)N)SSCC(C(=O)O)N	C6H12N2O4S2	CAS 923-32-0	CHEBI:17376	.	.	.	.	.	.	.
NP4822	Malic acids	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP4837	Costunolide	CID: 5281437	Costunolide; 553-21-9; (+)-costunolide; Costunlide; Costundide; Costunolid; Costus lactone; CHEMBL86416; CHEBI:3900; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2(3H)-one; (E,E)-6-alpha-Hydroxygermacra-1(10),4,11(13)-trien-12-oic acid gamma-lactone; (10S,1R)-3,7-dimethyl-11-methylene-13-oxabicyclo[8.3.0]trideca-2,6-dien-12-one; (E,E)-germacra-1(10),4,11(13)-trien-12-oic acid, 6-alpha-hydroxy-gamma-lactone; (3aS,6E,10E)-3-Methylene-6,10-dimethyl-2,3,3abeta,4,5,8,9,11aalpha-octahydrocyclodeca[b]furan-2-one; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2(3H)-one; melampolide; NSC106404; Costunolide,(S); PubChem6258; SCHEMBL92714; Costunolide, >=97% (HPLC); HMS3269I17; HMS3413B19; HMS3677B19; HY-N0036; BDBM50411242; MFCD00210262; ZINC30726859; AKOS015840065; AKOS015969714; CS-1487; MCULE-2058016705; NCGC00381718-02; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one; AC-28334; AS-17708; V1471; C09382; 553C219; Q5175227; BRD-K26833429-001-01-0; (3aS,6E,10E,11aR)-3a,4,5,8,9,11a-Hexahydro-6,10-dimethyl-3-methylene-cyclodeca[b]furan-2(3H)-one; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylene-3,3a,4,5,8,9-hexahydrocyclodeca[b]furan-2(11aH)-one; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one; Cyclodeca[b]furan-2(3H)-one, 3a,4,5,8,9,11a-hexahydro-6,10-dimethyl-3-methylene-, (3aS,6E,10E,11aR)-; NCGC00381718-02_C15H20O2_Cyclodeca[b]furan-2(3H)-one, 3a,4,5,8,9,11a-hexahydro-6,10-dimethyl-3-methylene-, (3aS,6E,10E,11aR)-	Small molecule	1S/C15H20O2/c1-10-5-4-6-11(2)9-14-13(8-7-10)12(3)15(16)17-14/h5,9,13-14H,3-4,6-8H2,1-2H3/b10-5+,11-9+/t13-,14+/m0/s1	HRYLQFBHBWLLLL-AHNJNIBGSA-N	CC1=CCCC(=CC2C(CC1)C(=C)C(=O)O2)C	C15H20O2	CAS 553-21-9	CHEBI:3900	.	.	.	D07KNG	.	.	.
NP4862	Biochanin A	CID: 5280373	Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether; 4'-methylgenistein; BIOCHANIN; 491-80-5	.	1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3	WUADCCWRTIWANL-UHFFFAOYSA-N	COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O	C16H12O5	CAS 491-80-5	.	HBIN018523	SMIT14476	.	D0S9YX	DB15334	.	.
NP4874	Saponin	CID: 198016	Cyclamine; SAPONIN; 8047-15-2; NSC 104795; BRN 0078682; Cyclamin (saponin) (8CI); Olean-29-al, 13,28-epoxy-3-((O-beta-D-glucopyranosyl-(1-3)-O-(beta-D-xylopyranosyl-(1-2))-O-beta-D-glucopyranosyl-(1-4)-O-(beta-D-glucopyranosyl-(1-2))-alpha-L-arabinopyranosyl)oxy)-16-hydroxy-, (3-beta,16-alpha,20-beta)-; 4-18-00-01515 (Beilstein Handbook Reference); Oleanan-29-al, 13,28-epoxy-3-((O-beta-D-glucopyranosyl-(1-3)-O-(beta-D-xylopyranosyl-(1-2))-O-beta-D-glucopyranosyl-(1-4)-O-(beta-D-glucopyranosyl-(1-2))-alpha-L-arabinopyranosyl)oxy)-16-hydroxy-, (3beta,16alpha,20beta)- (9CI)	Small molecule	1S/C58H94O27/c1-52(2)29-7-11-55(5)30(8-12-58-31-15-53(3,22-62)13-14-57(31,23-77-58)32(64)16-56(55,58)6)54(29,4)10-9-33(52)82-50-46(85-51-45(40(71)37(68)27(19-61)80-51)84-49-43(74)39(70)36(67)26(18-60)79-49)44(83-48-42(73)38(69)35(66)25(17-59)78-48)28(21-76-50)81-47-41(72)34(65)24(63)20-75-47/h22,24-51,59-61,63-74H,7-21,23H2,1-6H3/t24-,25-,26-,27-,28+,29?,30-,31+,32-,33+,34+,35-,36-,37-,38+,39+,40+,41-,42-,43-,44+,45-,46-,47+,48-,49-,50+,51+,53-,54+,55-,56+,57?,58?/m1/s1	MAEBCGDGGATMSC-OSHGGGOQSA-N	CC1(C2CCC3(C(C2(CCC1OC4C(C(C(CO4)OC5C(C(C(CO5)O)O)O)OC6C(C(C(C(O6)CO)O)O)O)OC7C(C(C(C(O7)CO)O)O)OC8C(C(C(C(O8)CO)O)O)O)C)CCC91C3(CC(C2(C9CC(CC2)(C)C=O)CO1)O)C)C)C	C58H94O27	CAS 23643-76-7	.	.	.	.	.	.	.	.
NP4902	Streptozocin	CID: 29327	streptozocin; STREPTOZOTOCIN; streptozosin; Zanosar; 18883-66-4; Estreptozocina; Streptozocine; Streptozocinium; Streptozocinum; alpha-Streptozocin; streptozotocin (stz); N-D-Glucosyl-(2)-N'-nitrosomethylurea; C8H15N3O7; CHEBI:9288; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; 66395-18-4; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Desoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; UNII-8H27GUR065; 8H27GUR065; MFCD00006607; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; alkylating agent; DSSTox_CID_1282; STZ; DSSTox_RID_76055; DSSTox_GSID_21282; binds to DNA; Zanosar (TN); SR-05000001720; 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]-D-glucose; 2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-alpha-D-glucopyranose; NCGC00016738-01; CAS-18883-66-4; Spectrum_000960; Streptozotocin - Zanosar; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose; Prestwick3_000732; Spectrum2_000062; Spectrum3_001087; Spectrum4_001244; Spectrum5_001047; Epitope ID:134282; N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; SCHEMBL4748; Streptozocin; Streptozotocin; 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; CHEMBL1603; BSPBio_000684; BSPBio_002734; KBioGR_001768; KBioSS_001440; MLS004774123; DivK1c_000531; SPECTRUM1500543; SPBio_000243; BPBio1_000754; Streptozocin (JAN/USAN/INN); DTXSID2021282; BCBcMAP01_000142; HMS501K13; KBio1_000531; KBio2_001440; KBio2_004008; KBio2_006576; KBio3_001954; NINDS_000531; HMS1921A07; HMS2092I09; HMS2097C06; HMS3714C06; Pharmakon1600-01500543; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; ACT03364; ZINC3977737; Streptozocin, >=98.0% (HPLC); Tox21_110585; Tox21_201859; Tox21_302974; CCG-39870; NSC757321; s1312; AKOS025310730; Tox21_110585_1; DB00428; NSC-757321; IDI1_000531; SMP1_000282; NCGC00178500-01; NCGC00178500-02; NCGC00178500-03; NCGC00178500-04; NCGC00178500-07; NCGC00256594-01; NCGC00259408-01; 1-Methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-3-yl)urea; 1-methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)urea; SMR001233317; SBI-0051517.P003; AB00513906; SW199198-2; C07313; D05932; 24975-EP2275420A1; 24975-EP2277858A1; 24975-EP2292227A2; 24975-EP2295053A1; 24975-EP2298767A1; 24975-EP2314574A1; 27771-EP2272827A1; 27771-EP2295055A2; 27771-EP2295416A2; 27771-EP2295426A1; 27771-EP2295427A1; 27771-EP2298748A2; 27771-EP2298764A1; 27771-EP2298765A1; 27771-EP2298778A1; 27771-EP2305642A2; 27771-EP2308833A2; 27771-EP2308861A1; 27771-EP2311453A1; 27771-EP2311842A2; 27771-EP2314587A1; 27773-EP2277858A1; 27773-EP2292227A2; 27773-EP2298767A1; 27773-EP2314587A1; AB00052092-03; AB00052092_04; AB00052092_05; 883S664; Q257331; SR-01000939745; SR-01000939745-3; SR-05000001720-1; SR-05000001720-2; W-201687; Streptozocin, Vetec(TM) reagent grade, 98%, powder; Streptozocin, >=75% alpha-anomer basis, >=98% (HPLC), powder; alpha-D-Glucopyranose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-; 3-methyl-3-nitroso-1-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]urea	Small molecule	1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1	ZSJLQEPLLKMAKR-GKHCUFPYSA-N	CN(C(=O)NC1C(C(C(OC1O)CO)O)O)N=O	C8H15N3O7	CAS 18883-66-4	CHEBI:9288	.	.	.	D0I8RR	.	.	.
NP4931	Lycopene	CID: 446925	Psi,psi-carotene; all-trans-Lycopene; y,y-Carotene; trans-Lycopene; Lycopene, all-trans-; (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene; Lycopene 7; UNII-SB0N2N0WV6; NSC 407322; C.I. 75125; SB0N2N0WV6; CHEBI:15948; MFCD00017350; lycored; NCGC00166291-01; .psi.,.psi.-Carotene; Lycopene (VAN); Redivivo; 15-cis-Lycopene; LYC-O-MATO; Mexoryl SAQ; Tomat-O-Red; LYC; CCRIS 7925; TOMATO LYCOPENE; E160d; EINECS 207-949-1; lycopenes; CI 75125; LyocpenePowder; lycopene group; NSC407322; NSC-407322; Lycopene all-trans-; Lycopene, dispersion; DSSTox_CID_26593; DSSTox_RID_81750; DSSTox_GSID_46593; BSPBio_003389; Lycopene, analytical standard; INS-160D(III); INS NO.160D(III); CHEMBL501174; DTXSID2046593; FEMA NO. 4110; E-160D(III); Lycopene, >=90%, from tomato; AOB5502; (all-E)-2,6,10,14,19,23,27,31-Octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene; ACT03296; HY-N0287; ZINC8214943; Tox21_112395; LMPR01070257; s3943; AKOS015961276; CS-6378; DB11231; EBD2157929; NCGC00166291-02; NCGC00166291-03; AC-13571; CAS-502-65-8; LS-15428; Lycopene, >=98% (HPLC), from tomato; AB0012241; N2800; 3048-EP2298768A1; 3048-EP2305825A1; C05432; 502L658; Q208130; Q-100561; UNII-32A47J0H1R component OAIJSZIZWZSQBC-GYZMGTAESA-N; UNII-N53I4V2IA6 component OAIJSZIZWZSQBC-GYZMGTAESA-N; Lycopene, United States Pharmacopeia (USP) Reference Standard; Lycopene, Pharmaceutical Secondary Standard; Certified Reference Material; Lycopene, Redivivo(TM), 10% FS, ~10% in corn oil, >=95.0% (sum of isomers); 2,6,10,14,19,23,27,31-Octamethyl-dotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene; 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-octamethyl-, (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-; 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-Octamethyl-, (all-E)-; LYC,  LYCOPENE,  Lycopene 7,  Lycopene all-trans-,  Lycopene, all-trans-,  Lycopene, all-trans- (8CI),  Lycopene (VAN),  Natural yellow 27,  NCGC00166291-01,  NCGC00166291-02,  NSC407322,  NSC 407322	.	1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+	OAIJSZIZWZSQBC-GYZMGTAESA-N	CC(=CCCC(=CC=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C)C)C)C)C	C40H56	CAS 502-65-8	.	HBIN033972	SMIT16376	.	.	.	4317	.
NP4945	Hypericin	CID: 3663	hypericin; 548-04-9; Hypericum red; hypericine; Cyclosan; hipericina; Hyperizin; Mycoporphyrin; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione; Cyclo-Werol; Hypericum Extract; VIMRxyn; UNII-7V2F1075HD; MFCD00016683; NSC407313; Hypericin & Visible light; 7V2F1075HD; NSC622946; Cyclo werrol; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro(1,10,9,8-opqra)perylene-7,14-dione; hexahydroxy(dimethyl)[?]dione; 1:6:8:10:11:13-hexahydroxy-3:4-dimethyl-meso-naphthodianthrene-7:14-dione; Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-; Phenanthro[1,10,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer; C30H16O8; EINECS 208-941-0; NSC 407313; NSC 622946; CCRIS 8166; (component of) Hypericum spp (st. John's wort); BiomolKI_000032; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethyl-mesonapthtodianthron; BiomolKI2_000040; SCHEMBL3182; BIDD:PXR0084; BMK1-D8; SCHEMBL10262695; DTXSID40203270; Hypericin - CAS 548-04-9; Hypericin from Hypericum perforatum; HY-N0453; ZINC3780340; BDBM50060874; CCG-36081; HSCI1_000202; LMPK13040001; AKOS015895658; AC-6048; CS-5687; EBD2048972; MCULE-7319800130; NSC-622946; NCGC00162454-01; NCGC00163378-01; NCGC00163378-02; AS-74733; NCI60_003879; NCI60_006799; NCGC00163378-03!; FT-0627169; N2739; C07606; 33919-EP2275420A1; 33919-EP2295055A2; 33919-EP2295416A2; 33919-EP2298748A2; 33919-EP2298764A1; 33919-EP2298765A1; 33919-EP2305642A2; 33919-EP2311453A1; 548H049; SR-05000002344; Hypericin from Hypericum perforatum, ~95% (HPLC); Hypericin, primary pharmaceutical reference standard; Q-100618; SR-05000002344-2; BRD-K29673530-001-03-9; 4,4',5,5',7,7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; 3,4,6,7,13,14-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-1,8-dione; 3,4,7,8,13,14-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-1,6-dione; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione, 9CI; 1,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro [1,10,9,8-opqra]perylene-7,14-dione P-conformer; 5,7,11,18,22,24-HEXAHYDROXY-13,16-DIMETHYLOCTACYCLO[13.11.1.1(2),(1)?.0(3),?.0?,(2)?.0(1)?,(2)?.0(2)(1),(2)?.0(1)?,(2)?]OCTACOSA-1,3,5,7,10,12,14(28),15(27),16,18,21,23,25-TRIDECAENE-9,20-DIONE; Phenanthro[1,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer	Small molecule	1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,33-38H,1-2H3	YDOIFHVUBCIUHF-UHFFFAOYSA-N	CC1=CC(=O)C2=C(C3=C(C=C(C4=C3C5=C2C1=C6C(=CC(=O)C7=C(C8=C(C=C(C4=C8C5=C67)O)O)O)C)O)O)O	C30H16O8	CAS 548-04-9	.	.	.	.	.	.	.	.
NP4960	Glycine	CID: 750	glycine; 2-Aminoacetic acid; 56-40-6; aminoacetic acid; Glycocoll; Aminoethanoic acid; Glycolixir; Padil; Glycosthene; Aciport; Glicoamin; L-Glycine; H-Gly-OH; Hampshire glycine; Amitone; Leimzucker; Acetic acid, amino-; Aminoazijnzuur; Glycine, non-medical; Sucre de gelatine; Gyn-hydralin; GLY (IUPAC abbrev); polyglycine; Glycinum; Corilin; Glycinum [INN-Latin]; Glicina [INN-Spanish]; Glycine [INN]; glycyl radical; Glyzin; FEMA No. 3287; gly; Acide aminoacetique [INN-French]; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum [INN-Latin]; MFCD00008131; CCRIS 5915; HSDB 495; AI3-04085; amino-Acetic acid; UNII-TE7660XO1C; NSC 25936; [14C]glycine; CHEMBL773; Glycine iron sulphate (1:1); TE7660XO1C; 25718-94-9; CHEBI:15428; 2-aminoaceticacid; AZD-4282; NSC25936; Athenon; NSC-25936; NCGC00024503-01; Glicina; DSSTox_CID_667; Glycine, free base; Polyglycine II; Acido aminoacetico; Acide aminoacetique; DSSTox_RID_75720; DSSTox_GSID_20667; Acidum aminoaceticum; Glycine, 99%, ACS reagent; Glycine, 99+%, for analysis; Glykokoll; Aminoessigsaeure; Hgly; CAS-56-40-6; Glycine, labeled with carbon-14; Glycine [USP:INN]; GLYCINE 1.5% IN PLASTIC CONTAINER; EINECS 200-272-2; H2N-CH2-COOH; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; Glycine, homopolymer (VAN); Aminoethanoate; amino-Acetate; 2-aminoacetate; Glycine;; glycine USP; Glycine Technical; glycine-13c; [3H]glycine; Glycine, EP/USP; H-Gly; L-Gly; Gly-CO; Gly-OH; L-Glycine,(S); [14C]-glycine; Corilin (Salt/Mix); 112898-03-0; Glycine 1 M solution; PubChem18924; Tocris-0219; Glycine (H-Gly-OH); NH2CH2COOH; Glycine, >=99%; Glycine (JP17/USP); Glycine, 99%, FCC; Glycine-1,2-13C2; Biomol-NT_000195; bmse000089; bmse000977; WLN: Z1VQ; EC 200-272-2; H-[15N]Gly-OH; Gly-253; GTPL727; AB-131/40217813; Glycine [for Electrophoresis]; GLYCINE, [2-3H]; Glycine, Electrophoresis Grade; BPBio1_001222; GTPL4084; GTPL4635; N[C]C(O)=O; DTXSID9020667; BDBM18133; Buffer Concentrate, pH 11.01; AZD4282; Glycine, >=99.0% (NT); Glycine, 98.5-101.5%; Pharmakon1600-01300021; 2-Aminoacetic acid;Aminoacetic acid; BCP25965; CS-B1641; HY-Y0966; ZINC4658552; Glycine, ACS reagent, >=98.5%; Tox21_113575; 2-amino-1-$l^{1}-oxidanylethanone; ANW-32505; Glycine, 99%, natural, FCC, FG; NSC760120; s4821; STL194276; Glycine, purum, >=98.5% (NT); Glycine, tested according to Ph.Eur.; AKOS000119626; Glycine, for electrophoresis, >=99%; Tox21_113575_1; AM81781; CCG-266010; DB00145; MCULE-2415764032; NSC-760120; Glycine, BioUltra, >=99.0% (NT); Glycine, BioXtra, >=99% (titration); Glycine, SAJ special grade, >=99.0%; NCGC00024503-02; NCGC00024503-03; 18875-39-3; AK-77854; BP-31024; Glycine, Vetec(TM) reagent grade, 98%; Glycine, 0.2M buffer solution, pH 2.5; Glycine, 0.2M buffer solution, pH 3.0; Glycine, 0.2M buffer solution, pH 3.5; DB-029870; FT-0600491; FT-0669038; G0099; G0317; Glycine, ReagentPlus(R), >=99% (HPLC); A20662; C00037; D00011; M-6155; M03001; L001246; Q620730; SR-01000597729; Glycine, certified reference material, TraceCERT(R); Q-201300; SR-01000597729-1; Q27115084; B72BA06C-60E9-4A83-A24A-A2D7F465BB65; F2191-0197; Glycine, European Pharmacopoeia (EP) Reference Standard; Z955123660; Glycine, BioUltra, for molecular biology, >=99.0% (NT); UNII-0O72R8RF8A component DHMQDGOQFOQNFH-UHFFFAOYSA-N; Glycine, United States Pharmacopeia (USP) Reference Standard; Glycine, Pharmaceutical Secondary Standard; Certified Reference Material; Tris-tricine buffer; Tris-glycine buffer;Tris glycine buffer concentrate; Glycine, analytical standard, for nitrogen determination according to Kjeldahl method; 21931-03-3; Glycine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, >=98.5%; Glycine, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance); Glycine, PharmaGrade, Ajinomoto, EP, JP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture; Glycine, puriss. p.a., Reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance)	Small molecule	1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)	DHMQDGOQFOQNFH-UHFFFAOYSA-N	C(C(=O)O)N	C2H5NO2	CAS 56-40-6	CHEBI:15428	.	.	.	D0M8AB	.	.	.
NP4998	Acovenoside A	CID: 20055381	Acovenoside A; CHEBI:71022; 663-95-6; 3beta-(6-deoxy-3-O-methyl-alpha-L-talopyranosyloxy)-1beta,14-dihydroxy-5beta-card-20(22)-enolide; SCHEMBL1152589; CHEMBL3391850; ZINC87530439; Q27139260	Small molecule	1S/C30H46O9/c1-15-24(33)26(36-4)25(34)27(38-15)39-18-12-17-5-6-21-20(29(17,3)22(31)13-18)7-9-28(2)19(8-10-30(21,28)35)16-11-23(32)37-14-16/h11,15,17-22,24-27,31,33-35H,5-10,12-14H2,1-4H3/t15-,17+,18+,19+,20-,21+,22+,24+,25+,26+,27-,28+,29-,30-/m0/s1	DKYDBQQIQAPGMH-XGOVAQEESA-N	CC1C(C(C(C(O1)OC2CC3CCC4C(C3(C(C2)O)C)CCC5(C4(CCC5C6=CC(=O)OC6)O)C)O)OC)O	C30H46O9	CAS 663-95-6	CHEBI:71022	.	.	.	.	.	.	.
NP5000	Cladribine	CID: 20279	Cladribine; 2-Chloro-2'-deoxyadenosine; 4291-63-8; Leustatin; 2-Chlorodeoxyadenosine; 2-CdA; Chlorodeoxyadenosine; CldAdo; ADENOSINE, 2-CHLORO-2'-DEOXY-; Litak; 2-Chloro-2'-deoxy-beta-adenosine; Cladaribine; RWJ 26251; 2-chloro-deoxyadenosine; 2ClAdo; UNII-47M74X9YT5; (2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol; MLS000028377; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; Cladarabine; RWJ-26251; Leustat; SMR000058553; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; CHEBI:567361; 47M74X9YT5; MFCD00153939; NSC-105014; 2CdA; Movectro; Mylinax; DSSTox_CID_2828; (2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; DSSTox_RID_76747; DSSTox_GSID_22828; cladribina; cladribinum; mavenclad; Leustatin (TN); CL9; CAS-4291-63-8; 2 Chlorodeoxyadenosine; SR-01000003063; NSC 105014; BRN 0624220; Cladiribine; CCRIS 9374; Adenosine, 2-chloro-2'-deoxy; HSDB 7564; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; Cladribine [USAN:USP:INN:BAN]; Mavenclad (TN); NCGC00018167-03; S1199; RWJ-26251-000; Opera_ID_1191; SCHEMBL3775; CHEMBL1619; Cladribine (JAN/USP/INN); 2-chloro-2'-deoxy-adenosine; cid_20279; MLS000028484; MLS000759397; MLS001077345; MLS001424194; GTPL4799; DTXSID8022828; BDBM38920; HMS2052K13; HMS2232C23; HMS3715F17; ACT02615; AMY22140; BCP02868; ZINC3798064; Tox21_110834; Tox21_300596; CC0168; NSC-05014; NSC-105014-F; AKOS015854898; AKOS015892544; AC-7591; BCP9000538; CCG-101116; CS-2057; DB00242; NC00366; NCGC00022567-05; NCGC00022567-06; NCGC00022567-07; NCGC00022567-08; NCGC00164384-01; NCGC00254518-01; 2-Chloro-2'-deoxyadenosine, antileukemic; AS-12366; BP-25407; HY-13599; AB0011806; SW197746-4; D01370; S-7479; AB00382963-17; AB00382963_19; 291C638; A826062; Q414030; SR-01000003063-7; SR-01000003063-10; Cladribine, European Pharmacopoeia (EP) Reference Standard; 6-amino-2-chloro-9-(2-deoxy-beta-erythropentofuranosyl)purine; Cladribine, United States Pharmacopeia (USP) Reference Standard; 6-amino-2-chloro-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; (2R,3S,5R)-5-(6-amino-2-chloro-9-purinyl)-2-(hydroxymethyl)-3-oxolanol; (2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxalan-3-ol; (2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3S,5R)-5-(6-azanyl-2-chloranyl-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; Cladribine for peak identification, European Pharmacopoeia (EP) Reference Standard; 24757-90-2; Leustatin; ; ; 2-Chloro-2'-deoxyadenosine; ; ; 2-CdA; ; ; NSC-105014-F; ; ; (2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol	Small molecule	1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1	PTOAARAWEBMLNO-KVQBGUIXSA-N	C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O	C10H12ClN5O3	CAS 4291-63-8	CHEBI:567361	.	.	.	D05GJW	.	.	.
NP5019	Allyl isothiocyanate	CID: 5971	ALLYL ISOTHIOCYANATE; 57-06-7; 3-isothiocyanatoprop-1-ene; MUSTARD OIL; ALLYLISOTHIOCYANATE; Redskin; AITC; Oil Of mustard; Allylsenevol; Allylsenfoel; Allyl mustard oil; Oleum sinapis; Allylsevenolum; Senfoel; Volatile mustard oil; Allyl isosulfocyanate; Synthetic mustard oil; 2-Propenyl isothiocyanate; 1-Propene, 3-isothiocyanato-; Allyspol; Carbospol; Volatile oil of mustard; Senf oel; Oleum sinapis volatile; Isothiocyanate d'allyle; 3-Isothiocyanato-1-propene; Allyl sevenolum; Isothiocyanic acid allyl ester; Allyspol 75EC; Allyl thioisocyanate; Oil of mustard, artificial; Allyl isosulphocyanate; Artificial mustard oil; Caswell No. 027; Isothiocyansaeureallylester; Allylisothiokyanat [Czech]; NCI-C50464; Allyl isothiocyanate (natural); FEMA No. 2034; Isothiocyanic acid, allyl ester; NSC 5572; 8007-40-7; UNII-BN34FX42G3; Allyl isothiocyanate, non-perfume grade; MFCD00004822; Propene, 3-isothiocyanato-; Allyl isothiocyanate (USP); 3-iso-Thiocyanatoprop-1-ene; BN34FX42G3; CHEMBL233248; CHEBI:73224; Oils, mustard; Mustard seed oil; NCGC00091743-01; prop-2-enisothiocyanate; DSSTox_CID_47; Brassica seed oil; DSSTox_RID_75336; DSSTox_GSID_20047; Oils, brassica alba; Senf oel [German]; Mustard oil (VAN); Oils, brassica nigra; Mustard essential oils; Mustard oil, volatile; Allylsenfoel [German]; Essential oils, mustard; FEMA Number 2034; Oils, essential, mustard; Artificial oil of mustard; Oil of mustard, expressed; Oils, glyceridic, mustard; Allylisothiokyanat; CAS-57-06-7; CCRIS 20; Oil of mustard BPC 1949; FEMA No. 2760; FEMA No. 2761; HSDB 617; Mustard oil, volatile, synthetic; Mustard, brown (Brassica spp.); Isothiocyanate d'allyle [French]; Mustard, yellow (Brassica spp.); Fats and Glyceridic oils, mustard; EINECS 200-309-2; EINECS 232-358-0; UN1545; EPA Pesticide Chemical Code 004901; BRN 0773748; AI3-15283; Allyl isothiocyanate, 94%, stabilized with 0.01% alpha-tocopherol; UNII-3ZT10W4376; Allyl isothiocyanate [USAN:USP]; allyl-iso-thiocyanate; Mustard Essential oil; 3-isothiocyanato-propene; Mustard Oil (Synthetic); Allyl isothiocyanate, 97%; WLN: SCN2U1; 3-isothiocyanate-prop-1-ene; 3-isothiocyanato-prop-1-ene; Potassium allyl isothiocyanate; GTPL2420; Allyl isothiocyanate, stabilized; DTXSID3020047; NSC5572; HMS3264D06; Pharmakon1600-01506103; NSC-5572; ZINC1687017; Tox21_111165; Tox21_202249; Tox21_302890; 5832AE; Allyl isothiocyanate, >=95%, FCC; BBL027483; BDBM50203072; NSC760137; SBB060631; STL194262; Allyl isothiocyanate non-perfume grade; ISOTHIOCYANIC ACID,ALLYL ESTER; AKOS000119301; 3ZT10W4376; CCG-213613; MCULE-3404572895; NSC-760137; NCGC00091743-02; NCGC00256536-01; NCGC00259798-01; BP-12926; Allyl isothiocyanate, purum, >=98% (GC); DB-022435; Potassium, (1-isothiocyanato-2-propenyl)-; I0185; ST51046777; C19317; D02818; Y-9048; AB01563144_01; Q419406; Allyl isothiocyanate, stabilized (0.1% tocopherols); J-512735; Allyl isothiocyanate, contains BHT as stabilizer, 95%; Allyl isothiocyanate, stabilized [UN1545]  [Poison]; F9995-1653; Allyl isothiocyanate, PESTANAL(R), analytical standard, stabilized; 1058737-73-7; 3-isothiocyanatopropene, 2-propenyl isothiocyanate, mustard oil, allyl isorhodanide, allyl mustard oil, synthetic mustard oil, allylsenevol, redskin, volatile oil of mustard	Small molecule	1S/C4H5NS/c1-2-3-5-4-6/h2H,1,3H2	ZOJBYZNEUISWFT-UHFFFAOYSA-N	C=CCN=C=S	C4H5NS	CAS 57-06-7	CHEBI:73224	.	.	.	D0BQ8Y	.	.	.
NP5023	Gambogic acid	CID: 9852185	(-)-Gambogic Acid; Gambogic-acid; UNII-8N585K83U2; beta-Guttiferin; Cambogic acid; B''-Guttiferin; 8N585K83U2; Guttic acid; (Z)-4-((1S,3aR,5S,11R,14aS)-8-hydroxy-2,2,11-trimethyl-13-(3-methylbut-2-en-1-yl)-11-(4-methylpent-3-en-1-yl)-4,7-dioxo-2,3a,4,5,7,11-hexahydro-1H-1,5-methanofuro[3,2-g]pyrano[3,2-b]xanthen-3a-yl)-2-methylbut-2-enoic acid; CHEBI:67521; R-gambogic acid; Gambogic acid;; alpha-Gambogic acid; C38H44O8; Gambogic acid(R+S);; CHEMBL555017; 3-Iodo-5-nitro (1H)indazole; SCHEMBL16160279; BCP21539; HY-N0087; ZINC3933041; BDBM50366237; MFCD16878985; s2448; CCG-270284; CS-1456; BP-22199; Gambogic acid, >=95% (HPLC), powder; AB0029018; G-250; X1145; Q5519727; (2Z)-2-Methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-2-butenoic acid.; 1,5-Methano-1H,3H,11H-furo(3,4-g)pyrano(3,2-b)xanthene-1-crotonic acid, 3a,4,5,7-tetrahydro-8-hydroxy-alpha,3,3,11-tetramethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-, (Z)-	.	1S/C38H44O8/c1-20(2)10-9-15-36(8)16-14-24-29(39)28-30(40)26-18-23-19-27-35(6,7)46-37(33(23)41,17-13-22(5)34(42)43)38(26,27)45-32(28)25(31(24)44-36)12-11-21(3)4/h10-11,13-14,16,18,23,27,39H,9,12,15,17,19H2,1-8H3,(H,42,43)/b22-13-/t23-,27+,36-,37+,38-/m1/s1	GEZHEQNLKAOMCA-RRZNCOCZSA-N	CC(=CCCC1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)OC45C6CC(C=C4C3=O)C(=O)C5(OC6(C)C)CC=C(C)C(=O)O)O)C)C	C38H44O8	CAS 2752-65-0	.	HBIN027097	.	.	.	.	.	.
NP5027	Atractylodes macrocephala	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP5035	Alprostadil	CID: 5280723	alprostadil; Prostaglandin E1; 745-65-3; PGE1; Edex; Caverject; Muse; Prostin VR; Alprostadilum; Topiglan; Femprox; Befar; Alprox-TD; l-Prostaglandin E1; Liprostin; Prostandin; Vitaros; PGE-1; Alprostadil(Caverject); (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; MR-256; UNII-F5TD010360; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid; CHEMBL495; Vasaprostan; CHEBI:15544; 9-oxo-11R,15S-dihydroxy-13E-prostaenoic acid; U-10136; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; F5TD010360; Minprog; Sugiran; Viridal; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; PGE1 Oligomer; U-10,136; Prostin VR Pediatric; Lipoprost; Promostan; Prostivas; Alista; Prink; FemLife; ProstaglandinE1; RayVa; Caverject Impulse; PGE1alpha; 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid; 7-[(1r,3r)-3-Hydroxy-2-[(1e,3s)-3-Hydroxyoct-1-En-1-Yl]-5-Oxocyclopentyl]heptanoic Acid; SMR000112594; (-)-Prostaglandin E1; Befar (TN); Prink (TN); Edex (TN); Muse (TN); (-)-Protaglandin E1; U 10136; l-PGE1; SR-01000597593; MR 256; Alprostadilum [INN-Latin]; Prostin VR pediatric (TN); Alprostadil Prostoglandin E1; BML1-F06; Alprostadil(usan); NSC-165559; HEI-507; NCGC00016535-01; 119314-69-1; CAS-745-65-3; ONO 1608; EINECS 212-017-2; (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate; NSC 165559; Alprostadil [USAN:USP:INN:BAN:JAN]; 11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid; PGE1;Prostaglandin E1; AI3-62116; Prestwick2_001018; Prestwick3_001018; DSSTox_CID_2578; Prostaglandin E1, 98+%; DSSTox_RID_76640; DSSTox_GSID_22578; SCHEMBL33317; BSPBio_001175; BSPBio_001488; MLS000758964; MLS001424250; BIDD:GT0747; BPBio1_001293; GTPL1882; Alprostadil (JP17/USP/INN); DTXSID9022578; PGE1, Prostaglandin E1, powder; SYN3025; HMS1361K10; HMS1571K17; HMS1791K10; HMS1989K10; HMS2052L11; HMS2090L08; HMS2098K17; HMS3268I09; HMS3402K10; HMS3414N09; HMS3648O17; HMS3678N07; HMS3715K17; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; AMY30076; BCP01740; EX-A1411; HY-B0131; ONO-1608; ZINC3813088; Tox21_110482; 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid; 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid; BDBM50101853; l-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid; LMFA03010134; MFCD00077860; s1508; AKOS015961103; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)-; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-; AC-6095; BCP9000277; CCG-101188; CS-1905; DB00770; NC00438; (1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid; IDI1_033958; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; Prostaglandin E1, >=99.0% (TLC); SMP2_000271; NCGC00025234-02; NCGC00025234-03; NCGC00025234-04; NCGC00025234-05; AS-16360; K274; Alprostadil 100 microg/mL in Acetonitrile; AB0014134; 11,15-Dihydroxy-9-oxoprost-13-en-1-oate; AB00514004; B2154; ST50826271; Alprostadil, meets USP testing specifications; A11820; C04741; D00180; Prostaglandin E1, >=98% (HPLC), synthetic; AB00514004-06; AB00514004-08; AB00514004_09; 745P653; Q579348; SR-01000946253; SR-01000597593-1; SR-01000597593-5; SR-01000597593-6; SR-01000946253-1; W-104416; BRD-K52459643-001-06-0; BRD-K52459643-001-10-2; BRD-K52459643-001-17-7; (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoate; (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoic acid; Alprostadil, European Pharmacopoeia (EP) Reference Standard; (13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid; (11?,13E,15S)-11,15-Dihydroxy-9-oxo-prost-13-en-1-oic acid; (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid; 11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (ACD/Name 4.0); 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate; Alprostadil, United States Pharmacopeia (USP) Reference Standard; (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate; (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid; (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate; (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid; (11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, l-; Prostaglandin E1, synthetic, powder, BioReagent, suitable for cell culture; Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-; Prostaglandin E1, powder, gamma-irradiated, BioXtra, suitable for cell culture; 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]hepta noic acid; XPG	Small molecule	1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1	GMVPRGQOIOIIMI-DWKJAMRDSA-N	CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O	C20H34O5	CAS 745-65-3	CHEBI:15544	.	.	.	D0I4DQ	.	.	.
NP5104	Risperidone	CID: 5073	risperidone; 106266-06-2; Risperidal; Risperdal; Rispolept; Risperdal Consta; Risperin; Rispolin; Sequinan; Apexidone; Risperidonum; Risperidona; Risperdal M-Tab; Belivon; Psychodal; Spiron; R 64 766; C23H27FN4O2; UNII-L6UH7ZF8HC; R 64766; R-64766; R 64,766; CHEMBL85; MFCD00274576; L6UH7ZF8HC; 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; Risperidal M-Tab; CHEBI:8871; Risperidonum [Latin]; Risperidone-d4; Risperidona [Spanish]; R-64-766; 106266-06-2 (free base); Risperidone, 99%; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-FLUORO-BENZO[D]ISOXAZOL-3-YL)-PIPERIDIN-1-YL]-ETHYL}-2-METHYL-6,7,8,9-TETRAHYDRO-PYRIDO[1,2-A]PYRIMIDIN-4-ONE; NCGC00015883-05; CAS-106266-06-2; DSSTox_CID_25193; DSSTox_RID_80740; DSSTox_GSID_45193; 3-[2-[4-(6-fluoranyl-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; Zophrenal; Risperdal (TN); 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl}-6,7,8,9-tetrahydro-2-methylpyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-; 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-; SMR000466323; SR-01000075399; BRN 4891881; Perseris; Relday; Rispen; Risperidone-ISM; HSDB 7580; Risperidone???; N05AX08; R64766; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; Risperidone [USAN:USP:INN:BAN]; R-64,766; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; KS-1106; Risperidone impurity K; Risperidone (Risperdal); Lopac-R-118; Prestwick0_001029; Prestwick1_001029; R-118; GTPL96; Risperidone(R 64 766); SCHEMBL27911; MLS000759429; MLS001165758; MLS001424081; US8802672, Risperidone; BIDD:GT0262; R 62 766; SPBio_003078; PYR332; Risperidone (JP17/USP/INN); DTXSID8045193; RCN3028; HMS1571M19; HMS2051H07; HMS2089C22; HMS2098M19; HMS2233O11; HMS3373M18; HMS3393H07; HMS3657G13; HMS3715M19; HMS3887G15; Pharmakon1600-01506038; ZINC538312; ACT04270; BCP08161; RCN-3028; Risperidone 1.0 mg/ml in Methanol; Tox21_110253; ANW-42874; BDBM50001885; CP-018; CR0023; NSC759895; NSC786035; NSC801188; s1615; STK646402; AKOS005577302; Tox21_110253_1; AC-1306; CCG-100930; CS-1619; DB00734; LY03004; MCULE-4027175053; NC00180; NSC 759895; NSC-759895; NSC-786035; NSC-801188; PB26023; Risperidone, >=98% (HPLC), powder; NCGC00015883-01; NCGC00015883-02; NCGC00015883-03; NCGC00015883-04; NCGC00015883-06; NCGC00015883-07; NCGC00015883-08; NCGC00015883-11; NCGC00094352-01; NCGC00094352-02; NCGC00094352-03; NCGC00179257-01; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 4H-Pyrido(1,2-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2-methyl-; AK172045; HY-11018; LY-03004; AB0004623; AB00514010; EU-0101074; FT-0631037; FT-0674432; R0087; SW197348-4; 4767-EP2269990A1; 4767-EP2272537A2; 4767-EP2272841A1; 4767-EP2275420A1; 4767-EP2275423A1; 4767-EP2280008A2; 4767-EP2280010A2; 4767-EP2298731A1; 4767-EP2298776A1; 4767-EP2301936A1; 4767-EP2308867A2; 4767-EP2308870A2; 4767-EP2308875A1; 4767-EP2316836A1; 66R062; D00426; J10290; Q-4040; AB00514010-09; AB00514010-11; AB00514010-12; AB00514010_13; AB00514010_14; A801409; L000510; Q412443; J-001555; SR-01000075399-2; SR-01000075399-8; BRD-K53857191-001-04-5; BRD-K53857191-001-10-2; Z1522566617; Risperidone, British Pharmacopoeia (BP) Reference Standard; Risperidone, European Pharmacopoeia (EP) Reference Standard; Risperidone, United States Pharmacopeia (USP) Reference Standard; Risperidone, Pharmaceutical Secondary Standard; Certified Reference Material; 3-Ethyl-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one(Risperidone Impurity); Risperidone for system suitability, European Pharmacopoeia (EP) Reference Standard; Risperidone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (risperidone)3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one; 2-(2-(4-(benzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-7,8,9,9a-tetrahydro-1H-pyrido[1,2-a]pyrimidin-4(6H)-one; 2-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-6,7,8,8a-tetrahydro-5H-naphthalen-1-one; 3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-[2-[4(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6 fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro- 1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-me thyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[2,1-b]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl}- 6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimid-in-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one (Resperidone); 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one (risperidone); 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one(risperidone); 3-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benz-isoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-; 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-methyl-1,3-dihydro-indol-2-one(Norastemizole)	Small molecule	1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3	RAPZEAPATHNIPO-UHFFFAOYSA-N	CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	C23H27FN4O2	CAS 106266-06-2	CHEBI:8871	.	.	.	D01AZG	.	.	.
NP5145	Atractylenolide 1	CID: 5321018	Atractylenolide I; 73069-13-3; Atractylenolide-1; Atractylenolide-I; Atractylenolide 1; CHEMBL449520; (4aS,8aS)-3,8a-dimethyl-5-methylidene-4a,6,7,8-tetrahydro-4H-benzo[f][1]benzofuran-2-one; Q63396593; 8,9-dehydroasterolide; SCHEMBL1898423; HMS3886N08; HY-N0201; BDBM50241939; MFCD09037395; s8291; ZINC15207341; Atractylenolide I, >=98% (HPLC); AKOS025119313; CCG-266793; CCG-266794; CS-3669; N2541; X1093; C17885; 069A133; Q-100800; 8,12-EPOXYEUDESMA-4(14),7(11),8-TRIEN-12-ONE	Small molecule	1S/C15H18O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h8,12H,1,4-7H2,2-3H3/t12-,15+/m0/s1	ZTVSGQPHMUYCRS-SWLSCSKDSA-N	CC1=C2CC3C(=C)CCCC3(C=C2OC1=O)C	C15H18O2	CAS 73069-13-3	.	.	.	.	.	.	.	.
NP5160	Mycophenolate mofetil	CID: 5281078	mycophenolate mofetil; 128794-94-5; CellCept; RS 61443; 115007-34-6; RS-61443; TM-MMF; Myfenax; Mycophenolic acid morpholinoethyl ester; Mycophenolatemofetil; UNII-9242ECW6R0; CHEBI:8764; Cellcept (TN); 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate; 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; (E)-2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate; Mycophenolate mofetil (CellCept); 9242ECW6R0; MFCD00867568; C23H31NO7; Munoloc; RS-61443-190; DSSTox_CID_3340; DSSTox_RID_76982; Mycophenolate mofetil, 98%; DSSTox_GSID_23340; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)-; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)-; Mycophenylate mofetil; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; SMR002544686; MMF CellCept(TM); CAS-128794-94-5; HSDB 7436; ME-MPA; SR-05000001485; Mycophenolate mofetil Teva; Arzip; Mycophenolatmofetil; Mycophenolate mofetil [USAN:USP]; NCGC00159459-02; (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester; 2-morpholin-4-ylethyl (E)-6-(6-methoxy-7-methyl-4-oxidanyl-3-oxidanylidene-1H-2-benzofuran-5-yl)-4-methyl-hex-4-enoate; mycophenolate-mofetil; Mofetil mycophenolate; 1132748-21-0; R-99; SCHEMBL4195; CHEMBL1456; MLS003915627; MLS004774133; MLS006011929; SCHEMBL218782; GTPL6831; DTXSID3023340; CHEBI:93612; Mycophenolate mofetil(CellCept)/; AOB5505; Mycophenolate mofetil (JAN/USP); HMS2090A03; Pharmakon1600-01504567; ACT01993; ALBB-027273; HY-B0199; Tox21_111686; ABP000539; BBL029073; BDBM50248299; NSC724229; NSC758905; s1501; STL146382; ZINC21297660; AKOS005720900; Tox21_111686_1; AB07560; AC-1562; BCP9000969; CCG-213315; DB00688; KS-1209; NSC 724229; NSC 758905; NSC-724229; NSC-758905; Mycophenolate mofetil, >=98% (HPLC); NCGC00159459-03; NCGC00159459-04; 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate; 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate; LS-15013; SMR004703518; AB0125583; M2387; R3925; SW219893-1; C07908; D00752; J90063; AB01274794-01; AB01274794-02; AB01274794_03; AB01274794_04; 007M346; A803280; A805863; J-005626; Mycophenolate mofetil 100 microg/mL in Acetonitrile; Q-101316; Q4567614; SR-05000001485-1; SR-05000001485-2; BRD-K92428153-001-01-0; MYCOPHENOLIC ACID 2-(4-MORPHOLINYL)ETHYL ESTER; Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard; Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard; Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard; Mycophenolate Mofetil, Pharmaceutical Secondary Standard; Certified Reference Material; (1s,3r,4s)-2-amino-9-[4-(benzyloxy)-3-(benzyloxymethyl)-2-methylidene-cyclopentyl]-3h-purin-6-one; (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid 2-(4-Morpholinyl)ethyl Ester; 1076198-64-5; 2-(4-Morpholinyl)ethyl (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; 2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate; 4-Hexenoic acid,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E); 6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester; morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate; Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)- 4-methylhex-4-enoate; Morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate; Morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate	Small molecule	1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+	RTGDFNSFWBGLEC-SYZQJQIISA-N	CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O	C23H31NO7	CAS 128794-94-5	CHEBI:8764	.	.	.	D04FBR	.	.	.
NP5166	Acorus calamus	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP5172	Urolithin A	CID: 5488186	urolithin A; 1143-70-0; 3,8-dihydroxy-6H-benzo[c]chromen-6-one; 3,8-dihydroxybenzo[c]chromen-6-one; 3,8-Dihydroxy-6H-dibenzo(b,d)pyran-6-one; 3,8-Dihydroxyurolithin; 6H-Dibenzo[b,d]pyran-6-one, 3,8-dihydroxy-; 3,8-Hydroxydibenzo-alpha-pyrone; ILJ8NEF6DT; UNII-ILJ8NEF6DT; 3,8-dihydroxy-6h-dibenzo[b,d]pyran-6-one; MFCD20275235; 6H-Dibenzo(b,d)pyran-6-one, 3,8-dihydroxy-; urolithin-A; 3,8-dihydroxy-urolithin; SCHEMBL803408; CHEMBL1836264; DTXSID40150694; CHEBI:168442; Urolithin A, >=97% (HPLC); EX-A4345; s5312; ZINC13484727; AKOS028108778; CCG-266776; CS-6305; DB15464; AC-31959; AK544544; DS-19328; SY070232; DB-122496; HY-100599; FT-0778244; J-003086; Q15634120; 2-Biphenylcarboxylic acid, 2',4,4'-trihydroxy-, delta-lactone	Small molecule	1S/C13H8O4/c14-7-1-3-9-10-4-2-8(15)6-12(10)17-13(16)11(9)5-7/h1-6,14-15H	RIUPLDUFZCXCHM-UHFFFAOYSA-N	C1=CC2=C(C=C1O)C(=O)OC3=C2C=CC(=C3)O	C13H8O4	CAS 1143-70-0	CHEBI:168442	.	.	.	.	.	.	.
NP5183	Magnesium	CID: 5462224	7439-95-4; Magnesium; Mg; magnesio; Magnesium powder; Magnesium turnings; Magnesium metallicum; Magnesium ribbon; UNII-I38ZP9992A; MFCD00085308; Magnesium sheet; I38ZP9992A; Magnesium powdered; Magnesio [Italian]; Magnesium metal; Rieke's active magnesium; Magnesium compounds; HSDB 654; Magnesium, 99.9+%, (trace metal basis), turnings; EINECS 231-104-6; UN1418; UN1869; UN2950; 12Mg; magnesium atom; Magnesium rod; Magnesium, foil, thickness 0.0125 mm, size 25 x 25 mm, purity 99.9%; Magnesium, foil, thickness 0.0125 mm, size 50 x 50 mm, purity 99.9%; Magnesium, foil, thickness 0.015 mm, size 100 x 100 mm, purity 99.9%; Magnesium, foil, thickness 0.015 mm, size 25 x 25 mm, purity 99.9%; Magnesium, foil, thickness 0.015 mm, size 50 x 50 mm, purity 99.9%; Magnesium, foil, thickness 0.02 mm, size 100 x 100 mm, purity 99.9%; Magnesium, foil, thickness 0.02 mm, size 25 x 25 mm, purity 99.9%; Magnesium, foil, thickness 0.02 mm, size 50 x 50 mm, purity 99.9%; Magnesium, foil, thickness 0.025 mm, size 100 x 100 mm, purity 99.9%; Magnesium, foil, thickness 0.025 mm, size 50 x 50 mm, purity 99.9%; Magnesium, foil, thickness 1.0 mm, size 100 x 100 mm, purity 99.9%; Magnesium, foil, thickness 1.0 mm, size 25 x 25 mm, purity 99.9%; Magnesium, foil, thickness 1.0 mm, size 50 x 50 mm, purity 99.9%; magnesium(0); Magnesium, turnings; Magnesium (0); Magnesium, elemental; Magnesium, 99.5%; ACMC-209oug; Magnesium powder 50 mesh; EC 231-104-6; Magnesium, >=99.8%; Magnesium powder 325 mesh; Magnesium turnings, -4 mesh; Magnesium, powder, >=99%; Magnesium, plate, 99.95%; Magnesium powder, -325 mesh; Magnesium, puriss., 98.0%; Magnesium, puriss., 99.5%; Magnesium turnings for Grignards; CHEMBL2146125; DTXSID0049658; CHEBI:25107; HSDB 7065; Magnesium granules, -12+50 mesh; Magnesium powder, -20+100 mesh; Magnesium powder,-100+200 mesh; ANW-36470; Magnesium powder, -100+200 mesh; MFCD00011101; UN2010; AKOS015902697; AKOS016017174; AKOS028110047; Magnesium, grit, >=99.0% (KT); DB14513; Magnesium, LR, turnings, >=99.5%; Magnesium hydride, hydrogen-storage grade; Magnesium, ribbon, >=99.5% Mg basis; Magnesium, SAJ first grade, >=98.0%; Magnesium, SAJ first grade, >=99.0%; BP-30179; Magnesium, hydrogen activated, >=99.5%; Magnesium, turnings, reagent grade, 98%; FT-0628088; Magnesium, 99+%, ribbon 3 mm x 0.2 mm; Magnesium, ingot, >=99% trace metals basis; Magnesium, ribbon, =99% trace metals basis; X5847; Magnesium, powder or magnesium alloys, powder; Magnesium foil, 1.0mm (0.04in) thick, hard; Magnesium foil, 0.25mm (0.01in) thick, hard; Magnesium, 20-230 mesh, reagent grade, 98%; Magnesium foil, 0.05mm (0.002in) thick, hard; 2.5 grams of Rieke  Magnesium in 100 mL of THF; 25 grams of Rieke(R) Magnesium in 1000mL of THF; 5.0 grams of Rieke(R) Magnesium in 200mL of THF; Magnesium foil, 0.125mm (0.005in) thick, hard; Magnesium hydride [UN2010]  [Dangerous when wet]; Magnesium matrix modifier, for graphite furnace-AAS; 2.5 grams of Rieke(R) Magnesium in 100 mL of THF; Magnesium turnings, 1cm (0.4in) & down, Puratronic?; Magnesium, NIST(R) SRM(R) 980, isotopic standard; M000000010; Magnesium, ReagentPlus(R), powder, -50 mesh, >=99%; Magnesium granules, coated particle size not <149 microns; Magnesium rod, 3.3cm (1.3in) dia x 30cm (12in) long; Magnesium rod, 7.9mm (0.31in) dia x 25mm (1in) length; Magnesium, chips 6-35 mesh, 99.98% trace metals basis; Magnesium, chips, 6-35 mesh, 99.98% trace metals basis; Magnesium, rod, diam. 6 mm, >=99.9% trace metals basis; Magnesium, in a Sure/Seal(TM) bottle, turnings, 37.5 mmol; Magnesium, purum, for Grignard reactions, >=99.5%, turnings; Magnesium, ReagentPlus(R), ribbon, >=99% trace metals basis; Magnesium, turnings, ~1/8 in., 99.95% trace metals basis; Magnesium, wire reel, 1m, diameter 0.4mm, as drawn, 99.9+%; Magnesium, wire reel, 1m, diameter 0.5mm, as drawn, 99.9+%; Magnesium, wire reel, 1m, diameter 1.0mm, as drawn, 99.9+%; Magnesium, wire reel, 1m, diameter 1.1mm, as drawn, 99.9+%; Magnesium, wire reel, 2m, diameter 0.4mm, as drawn, 99.9+%; Magnesium, wire reel, 2m, diameter 0.5mm, as drawn, 99.9+%; Magnesium, wire reel, 2m, diameter 1.0mm, as drawn, 99.9+%; Magnesium, wire reel, 2m, diameter 1.1mm, as drawn, 99.9+%; Magnesium, wire, 127 mum diameter, 99.9% trace metals basis; Magnesium slug, 6.35mm (0.25in) dia x 12.7mm (0.50in) length; Magnesium slug, 6.35mm (0.25in) dia x 6.35mm (0.25in) length; Magnesium standard solution, for AAS, 1 mg-ml Mg in 0.5N HNO3; Magnesium, foil, diameter 8 mm, thickness 0.025 mm, purity 99.9%; Magnesium, foil, diameter 8 mm, thickness 0.075 mm, purity 99.9%; Magnesium, foil, diameter 8 mm, thickness 0.25 mm, purity 99.9%; Magnesium, foil, thickness 0.002 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.002 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.002 mm, diameter 8 mm, purity 99.9%; Magnesium, foil, thickness 0.003 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.003 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.003 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.005 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.005 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.005 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.01 mm, 15 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.01 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.01 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.01 mm, diameter 10 mm, purity 99.9%; Magnesium, foil, thickness 0.01 mm, diameter 6 mm, purity 99.9%; Magnesium, foil, thickness 0.015 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.015 mm, diameter 4 mm, purity 99.9%; Magnesium, foil, thickness 0.015 mm, diameter 8 mm, purity 99.9%; Magnesium, foil, thickness 0.02 mm, 15 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.02 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.02 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.02 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.02 mm, diameter 25 mm, purity 99.9%; Magnesium, foil, thickness 0.02 mm, purity 99.9%, diameter 10 mm; Magnesium, foil, thickness 0.025 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.025 mm, diameter 6 mm, purity 99.9%; Magnesium, foil, thickness 0.05 mm, 10 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.05 mm, 15 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.05 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.05 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.05 mm, diameter 25 mm, purity 99.9%; Magnesium, foil, thickness 0.05 mm, diameter 6 mm, purity 99.9%; Magnesium, foil, thickness 0.075 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.075 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.1 mm, 10 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.1 mm, 15 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.1 mm, 25 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.1 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.1 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.1 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.125 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.125 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.125 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.15 mm, 10 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.15 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.15 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.15 mm, diameter 15 mm, purity 99.9%; Magnesium, foil, thickness 0.15 mm, diameter 25 mm, purity 99.9%; Magnesium, foil, thickness 0.15 mm, diameter 6 mm, purity 99.9%; Magnesium, foil, thickness 0.25 mm, 10 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.25 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.25 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.25 mm, diameter 15 mm, purity 99.9%; Magnesium, foil, thickness 0.25 mm, diameter 25 mm, purity 99.9%; Magnesium, foil, thickness 0.5 mm, 10 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.5 mm, 15 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.5 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.5 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 0.5 mm, diameter 25 mm, purity 99.9%; Magnesium, foil, thickness 0.5 mm, diameter 8 mm, purity 99.9%; Magnesium, foil, thickness 1.0 mm, 10 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.0 mm, 15 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.0 mm, 25 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.0 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.0 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.0 mm, diameter 4 mm, purity 99.9%; Magnesium, foil, thickness 1.5 mm, 15 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.5 mm, 25 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.5 mm, 4 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.5 mm, 6 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.5 mm, 8 mm diameter, purity 99.9%; Magnesium, foil, thickness 1.5 mm, diameter 10 mm, purity 99.9%; Magnesium, rod, 1.6 mm diameter, length 1000 mm, purity 99.9%; Magnesium, rod, 1.6 mm diameter, length 200 mm, purity 99.9%; Magnesium, rod, 1.6 mm diameter, length 500 mm, purity 99.9%; Magnesium, rod, 1.6 mm diameter, purity 99.9%, length 100 mm; Magnesium, rod, 10 mm diameter, length 100 mm, purity 99.97%; Magnesium, rod, 10 mm diameter, length 200 mm, purity 99.97%; Magnesium, rod, 10 mm diameter, length 50 mm, purity 99.97%; Magnesium, rod, 12.7 mm diameter, length 100 mm, purity 99.9%; Magnesium, rod, 12.7 mm diameter, length 500 mm, purity 99.9%; Magnesium, rod, 12.7 mm diameter, purity 99.9%, length 200 mm; Magnesium, rod, 15 mm diameter, length 50 mm, purity 99.97%; Magnesium, rod, 25.4 mm diameter, length 100 mm, purity 99.9%; Magnesium, rod, 25.4 mm diameter, length 1000 mm, purity 99.9%; Magnesium, rod, 25.4 mm diameter, length 200 mm, purity 99.9%; Magnesium, rod, 25.4 mm diameter, length 500 mm	Small molecule	1S/Mg	FYYHWMGAXLPEAU-UHFFFAOYSA-N	[Mg]	Mg	CAS 7439-95-4	CHEBI:25107	.	.	.	D0B8QB	.	.	.
NP5204	Tanshinone I	CID: 114917	Tanshinone I; 568-73-0; Tanshinone A; Tanshinon I; Tanshinone; 1,6-Dimethylphenanthro[1,2-b]furan-10,11-dione; Tanshinone-I; UNII-03UUH3J385; C18H12O3; 1,6-dimethylnaphtho[1,2-g][1]benzofuran-10,11-dione; MLS000697676; 03UUH3J385; 1,6-Dimethyl-phenanthro[1,2-b]furan-10,11-dione; 1,6-dimethylnaphtho[1,2-g]benzofuran-10,11-dione; MFCD00210563; Phenanthro[1,2-b]furan-10,11-dione, 1,6-dimethyl-; SMR000445578; 1,6-Dimethylphenanthro(1,2-b)furan-10,11-dione; Phenanthro(1,2-b)furan-10,11-dione, 1,6-Dimethyl-; Tanshinquinone I; Tanshinone I,(S); TRISTEARYLORTHOFORMATE; MLS006011773; SCHEMBL244391; CHEMBL363535; cid_114917; AIGAZQPHXLWMOJ-UHFFFAOYSA-; BDBM51317; DTXSID90972247; Tanshinone I, analytical standard; CHEBI:149906; HMS2222J14; HMS3656A11; Tanshinone I, >=98% (HPLC); BCP28292; HY-N0134; ZINC2558154; BBL010133; s2364; STK801472; AKOS005613012; AC-7999; CCG-267206; MCULE-4980744982; NCGC00247624-01; NCGC00247624-02; NCGC00247624-03; NCGC00247624-05; AK168189; AS-68049; DB-052982; FT-0632407; N1845; SW219821-1; V1541; 568T730; A831218; Q-100655; 1,6-dimethylnaphtho[1,2-g]benzofuran-10,11-quinone; 1,6-Dimethylphenanthro[1,2-b]furan-10,11-dione #; Q27247588; 1,6-dimethyl-10H,11H-phenanthro[1,2-b]furan-10,11-dione	Small molecule	1S/C18H12O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-8H,1-2H3	AIGAZQPHXLWMOJ-UHFFFAOYSA-N	CC1=C2C=CC3=C(C2=CC=C1)C(=O)C(=O)C4=C3OC=C4C	C18H12O3	CAS 568-73-0	CHEBI:149906	.	.	.	.	.	.	.
NP5233	Wogonin	CID: 5281703	5,7-Dihydroxy-8-methoxyflavone; Vogonin; Norwogonin 8-methyl ether; UNII-POK93PO28W; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; BRN 0287152; POK93PO28W; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one; CHEMBL16171; FLAVONE, 5,7-DIHYDROXY-8-METHOXY-; CHEBI:10043; XLTFNNCXVBYBSX-UHFFFAOYSA-N; 5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one; ST077088; Q-100730; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one; 632-85-9	.	1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3	XLTFNNCXVBYBSX-UHFFFAOYSA-N	COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)O	C16H12O5	CAS 632-85-9	.	HBIN048372	SMIT00392	MOL000173	D00MXS	.	796	.
NP5254	d-tubocurarine	CID: 6000	tubocurarine; d-Tubocurarine; Tubocurarin; Tubocurarine chloride; (+)-Tubocurarine; Tubocurarinum; Delacurarine; Tubarine; Isoquinoline alkaloid; 57-95-4; D-Tubocurarine chloride; UNII-W9YXS298BM; CHEBI:9774; (+)-Tubocurarine chloride; 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium; W9YXS298BM; 6989-98-6; Jexin; (+) Tubocurarine; (1S,16R)-9,21-dihydroxy-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2^{3,6}.1^{8,12}.1^{18,22}.0^{27,31}.0^{16,34}]hexatriaconta-3,5,8,10,12(34),18(33),19,21,24(32),25,27(31),35-dodecaen-15-ium; 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium; NCGC00163242-01; HSDB 2152; Tubocurarine, (+)-; Spectrum_001966; SpecPlus_000475; Spectrum2_001335; Spectrum3_001095; Spectrum4_001922; Spectrum5_000685; Epitope ID:174836; dimethoxy(trimethyl)[?]diol; BSPBio_002770; KBioGR_002264; KBioSS_002526; MLS003882581; DivK1c_006571; SCHEMBL121375; SPBio_001489; CHEMBL339427; GTPL2294; DTXSID0048393; KBio1_001515; KBio2_002518; KBio2_005086; KBio2_007654; KBio3_001990; HMS2089C06; ZINC3978083; BDBM50366799; PDSP1_001485; PDSP2_001469; Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl-; DB01199; SDCCGMLS-0066631.P001; NCGC00163242-02; NCGC00178480-01; 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-, (13aR-(13aR*,25aS*))-; SMR002533646; SBI-0052455.P002; C07547; AB00053831-03; AB00053831_04; Q421268; SR-05000001878-4; BRD-K99621550-003-03-4; 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-, (13aR,25aS)-	Small molecule	1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1	JFJZZMVDLULRGK-URLMMPGGSA-O	CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC	C37H41N2O6+	CAS 57-95-4	CHEBI:9774	.	.	.	D05HSC	.	.	.
NP5278	Saikosaponin C	CID: 131801344	Saikosaponin-C; (3R,4R,5R,6S)-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,9R,10S)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]oxan-2-yl]methoxy]oxan-3-yl]oxy-6-methyloxane-3,4,5-triol	Small molecule	1S/C48H78O18/c1-22-30(52)32(54)35(57)40(62-22)66-38-23(18-49)63-39(37(59)34(38)56)60-19-24-31(53)33(55)36(58)41(64-24)65-29-10-11-43(4)25(44(29,5)20-50)8-12-45(6)26(43)9-13-48-27-16-42(2,3)14-15-47(27,21-61-48)28(51)17-46(45,48)7/h9,13,22-41,49-59H,8,10-12,14-21H2,1-7H3/t22-,23+,24+,25?,26?,27?,28-,29-,30-,31+,32+,33-,34+,35+,36+,37+,38+,39+,40?,41-,43?,44-,45?,46?,47?,48?/m0/s1	QEJKVPWQUWSLGH-XSAUBNEOSA-N	CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OCC3C(C(C(C(O3)OC4CCC5(C(C4(C)CO)CCC6(C5C=CC78C6(CC(C9(C7CC(CC9)(C)C)CO8)O)C)C)C)O)O)O)CO)O)O)O	C48H78O18	.	.	.	.	.	.	.	.	.
NP5284	Ursodeoxycholic acid	CID: 31401	ursodiol; URSODEOXYCHOLIC ACID; 128-13-2; Actigall; ursodeoxycholate; UDCA; Ursofalk; Ursolvan; Delursan; UrSO; Urso Forte; Ursodesoxycholic acid; Destolit; Ursochol; Cholit-ursan; Litursol; Solutrat; Ursobilin; Ursodamor; Arsacol; Deursil; Lyeton; Ursacol; Urso DS; UDCS; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; Ursosan; Ursodexycholic Acid; Urso 250; 7-beta-Hydroxylithocholic acid; 3-alpha,7-beta-Dioxycholanic acid; Ursocholic acid, deoxy-; 3-alpha,7-beta-Dihydroxycholanic acid; NSC 683769; (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; Ursodeoxycholicacid; MFCD00003680; NSC 657950; UNII-724L30Y2QR; BRN 3219888; 3,7-Dihydroxycholan-24-oic acid; Peptarom; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; CHEMBL1551; Ursodesoxycholic acid (UDCA); MLS000028461; CHEBI:9907; (R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; 128-13-2 (free acid); 724L30Y2QR; Antigall; SMR000058403; Urosiol; Acido ursodeossicolico [Italian]; Acido ursodeoxicolico; Acido ursodeossicolico; Acido ursodeoxicolico [INN-Spanish]; Acidum ursodeoxycholicum [INN-Latin]; Acide ursodesoxycholique; Acide ursodesoxycholique [INN-French]; Acidum ursodeoxycholicum; Cholan-24-oic acid, 3,7-dihydroxy-, (3a,5b,7b)-; 7beta-Hydroxylithocholic acid; Actigall (TN); Ursodiol (USP); (4R)-4-[(1S,2S,5R,7S,9S,10R,11S,14R,15R)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid; CCRIS 5502; Urso (TN); SR-01000737091; Ursodiol [USAN:USP]; EINECS 204-879-3; Ursodexycholate; Paptarom; Udiliv; Desol; Urdes; Urosdesoxycholate; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; NSC-683769; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; Ursodeoxycholoc acid; Urosdesoxycholic acid; 5beta-Cholanic Acid-3alpha,7beta-diol; Ursodesoxy cholic acid; Cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7beta)-; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; Ursodiol (Actigal Urso); Prestwick0_000958; Prestwick1_000958; Prestwick2_000958; Prestwick3_000958; U0030; 7A-Hydroxylithocholic acid; EC 204-879-3; U-9000; Ursodeoxycholic acid [INN]; Ursodeoxycholic acid, 99%; SCHEMBL27200; 5-beta-Cholan-24-oic acid; BSPBio_000956; 4-10-00-01604 (Beilstein Handbook Reference); 7bet.-Hydroxylithocholic acid; cid_31401; MLS001066373; MLS002548885; SPBio_003105; Ursodeoxycholic acid, >=99%; BPBio1_001052; GTPL7104; 7.beta.-Hydroxylithocholic acid; Ursodiol (Ursodeoxycholic Acid); 5-beta-Cholan-24-oic acid, 3-alpha,7-beta-dihydroxy-; DTXSID6023731; BDBM53721; AOB5075; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; HMS1570P18; HMS2097P18; HMS2233L14; HMS3259A13; HMS3714P18; Ursodeoxycholic acid (JP17/INN); 3alpha,7beta-dihydroxycholanic acid; ACT02676; ZINC3914809; 3a,7b-dihydroxy-5b-cholan-24-oate; Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-; LMST04010033; s1643; 5A-Cholan-24-oic acid-3A,7A-diol; AKOS015955898; CCG-220958; CS-1932; DB01586; KS-5243; MCULE-4374611501; NC00487; SMP2_000012; 3.alpha.,7.beta.-Dihydroxycholanic acid; 3A,7A-Dihydroxy-5A-holan-24-oic acid; 3a,7b-dihydroxy-5b-cholan-24-oic acid; NCGC00179363-01; NCGC00179363-12; AC-18919; CAS#128-13-2; CPD000058403; HY-13771; NCI60_028904; AB00513977; (3a,5b,7b)-3,7-dihydroxy-cholan-24-oate; 3alpha, 7beta-dihydroxy-5beta-cholanoic acid; 5bet.-Cholan-24-oic acid-3alp.,7bet.-diol; (3a,5b,7b)-3,7-dihydroxycholan-24-oic acid; A-7799; C07880; D00734; J10139; (3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid; AB00513977-09; AB00513977_10; 3alp.,7bet.-Dihydroxy-5bet.-cholan-24-oic acid; Q241374; 3.alpha.,7.beta.-Dihydroxy-5.beta.-cholanic acid; J-005566; J-650210; SR-01000737091-3; SR-01000737091-4; BRD-K15697815-001-16-2; 3.alpha.,7.beta.-Dihydroxy-5.beta.-cholan-24-oic acid; Z2786051717; 5.beta.-Cholan-24-oic acid, 3.alpha.,7.beta.-dihydroxy-; Ursodiol, United States Pharmacopeia (USP) Reference Standard; Ursodeoxycholic acid, British Pharmacopoeia (BP) Reference Standard; Ursodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard; 17.beta.-(1-Methyl-3-carboxypropyl)etiocholane-3.alpha.,7.beta.-diol; 3,7-Dihydroxycholan-24-oic acid-, (3.alpha.,5.beta.,7.beta.)- #; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI); Ursodeoxycholic acid, 500 mug/mL in methanol, certified reference material; Ursodiol, Pharmaceutical Secondary Standard; Certified Reference Material; Ursodeoxycholic acid for system suitability, European Pharmacopoeia (EP) Reference Standard; (4R)-4-[(1S,2S,5R,7S,9S,10R,11S,14R,15R)-5,9-Dihydroxy-2,15-dimethyltetracyclo[8.7.0.02,1.011,1]heptadecan-14-yl]pentanoic acid; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7-bis(oxidanyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; 108609-27-4	Small molecule	1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1	RUDATBOHQWOJDD-UZVSRGJWSA-N	CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C	C24H40O4	CAS 128-13-2	CHEBI:9907	.	.	.	D0G3SH	.	.	.
NP5296	Exemestane	CID: 60198	EXEMESTANE; 107868-30-4; Aromasin; Aromasine; 6-Methyleneandrosta-1,4-diene-3,17-dione; Fce 24304; Exemestano; Exemestanum; Exemestanum [INN-Latin]; Exemestano [INN-Spanish]; FCE-24304; 6-Methylene-androsta-1,4-diene-3,17-dione; UNII-NY22HMQ4BX; FCE24304; Androsta-1,4-diene-3,17-dione, 6-methylene-; 6-methylideneandrosta-1,4-diene-3,17-dione; NY22HMQ4BX; PNU-155971; CHEBI:4953; (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; Aromasil; NSC713563; (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; EXE; DSSTox_CID_3037; DSSTox_RID_76844; DSSTox_GSID_23037; (8R,9S,10R,13S,14S)-10,13-Dimethyl-6-methylene-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17(10H,14H)-dione; Exemestane [USAN:INN:BAN]; Nikidess; (8alpha,10alpha,13alpha)-6-Methylideneandrosta-1,4-Diene-3,17-Dione; Aromasin (TN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione.; SMR000466314; CAS-107868-30-4; HSDB 7463; Curator_000009; Exemestane (JAN/USP/INN); CCRIS 9351; NCGC00095289-01; Exemestane; aromasin; Exemestane, Aromasin; PNU 155971; PubChem5810; SCHEMBL6215; Aromasin (Pharmacia Upjohn); Exemestane(FCE 24304); MLS000759419; MLS001424062; GTPL7073; 6-Methylenandrosta-1,17-dione; CHEMBL1200374; DTXSID5023037; Exemestane, >=98% (HPLC); AOB5604; SYN3023; BCPP000235; HMS2051J04; HMS3713H12; BCP23353; ZINC3973334; Tox21_111499; ANW-63402; BDBM50398447; MFCD00866994; s1196; AKOS015840113; AKOS015895161; Tox21_111499_1; AC-2171; BCP9000676; CCG-100995; CS-1766; DB00990; KS-5136; NC00245; NSC 758907; NSC-713563; NCGC00271596-03; 6-methylenandrost-1,4-dien-3,17-dione; AS-31053; CPD000466314; HY-13632; BCP0726000226; 6-Methylen-androst-1,4-diene-3,17-dione; AB0063735; E0941; C08162; D00963; Z-4332; AB00639936-06; AB00639936-08; AB00639936-09; AB00639936-10; AB00639936_11; 868E304; Q418819; SR-01000759393; SR-01000759393-4; BRD-K33425534-001-12-5; Exemestane, European Pharmacopoeia (EP) Reference Standard; Exemestane, United States Pharmacopeia (USP) Reference Standard; Exemestane, Pharmaceutical Secondary Standard; Certified Reference Material; Exemestane for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,15S)-2,15-dimethyl-8-methylidenetetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,14-dione; EXM	Small molecule	1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C	C20H24O2	CAS 107868-30-4	CHEBI:4953	.	.	.	D0D2VS	.	.	.
NP5407	Moxonidine	CID: 4810	MOXONIDINE; 75438-57-2; Norcynt; Nucynt; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine; Cynt; Physiotens; BE 5895; BDF5895; UNII-CC6X0L40GW; BDF 5895; Lomox; 4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine; LY 326869; 4-chloro-N-imidazolidin-2-ylidene-6-methoxy-2-methylpyrimidin-5-amine; CC6X0L40GW; CHEMBL19236; CHEBI:7009; BDF5896; 4-Chloro-5-(2-imidazolin-2-ylamino)-6-methoxy-2-methylpyrimidine; BE-5895; 75438-57-2 (free base); BE5895; 5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-; NCGC00015649-02; LY326869; Normoxocin; CAS-75438-57-2; DSSTox_CID_25170; DSSTox_RID_80720; DSSTox_GSID_45170; Moxonidinum [Latin]; Moxonidina [Spanish]; Moxonidina; Moxonidinum; 4-chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine; Moxonidine hydrochloride hydrate; BDF-5895; LY-326869; Moxonidine [USAN:INN:BAN]; N-(4-chloro-6-methoxy-2-methylpyrimidin-5-yl)imidazolidin-2-imine; SR-01000075981; Cynt (TN); Moxonidine (USAN/INN); Prestwick0_001016; Prestwick1_001016; Prestwick2_001016; Prestwick3_001016; Lopac-M-1559; Monoxidine [common misspelling of Moxonidine]; Lopac0_000753; SCHEMBL49143; BSPBio_001171; MLS002222183; SPBio_003042; BPBio1_001289; DTXSID5045170; HMS1571K13; HMS2098K13; HMS2230B15; HMS3373O04; HMS3655B17; HMS3715K13; HMS3747A03; Moxonidine 1.0 mg/ml in Methanol; ALBB-022451; BCP23003; BDF-5896; EX-A3409; HY-B0374; ZINC1854466; Tox21_110190; 2-(6-Chloro-4-methoxy-2-methylpyrimidin-5-ylamino)-2-imidazoline; 4-Chloro-5-(2-imidazolidinyldeneamino)-6-methoxy-2-methylpyrimidine; 4-chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine; AC-637; BDBM50050093; KM1693; MFCD22689455; PDSP1_000177; PDSP2_000176; s2066; STL419983; STL450991; AKOS015895873; AKOS015997932; Tox21_110190_1; AF-0062; CCG-204838; DB09242; SDCCGSBI-0050731.P002; VA11330; NCGC00015649-01; NCGC00015649-04; NCGC00015649-05; NCGC00015649-08; NCGC00015649-17; NCGC00092355-02; AK163649; K289; SMR000857402; AB0014143; AB00514003; FT-0601601; FT-0657360; M2660; SW196502-4; T5483; C07451; D05087; AB00514003-08; AB00514003_10; 102678-EP2272841A1; 102678-EP2301936A1; 438M572; Q419944; SR-01000075981-7; BRD-K77771411-001-04-4; (4-Chloro-6-methoxy-2-methyl-pyrimidin-5-yl)-imidazolidin-2-ylidene-amine; 4-chloro-N-(imidazolin-2-ylidene)-6-methoxy-2-methyl-5-pyrimidinamine; 5-pyrimidinamine, 4-chloro-N-2-imidazolidinylidene-6-methoxy-2-methyl-; BDF5895;BDF-5895;BDF 5895;BE 5895; BE-5895; BE5895; 2-(4-Chloro-6-methoxy-2-methyl-pyrimidin-5-ylamino)-4,5-dihydro-3H-imidazol-1-ium; 5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- (9CI); (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid; 1008754-16-2	Small molecule	1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)	WPNJAUFVNXKLIM-UHFFFAOYSA-N	CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC	C9H12ClN5O	CAS 75438-57-2	CHEBI:7009	.	.	.	D0E9PK	.	.	.
NP5424	Flavopiridol	CID: 5287969	FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one	.	1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1	BIIVYFLTOXDAOV-YVEFUNNKSA-N	CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O	C21H20ClNO5	CAS 146426-40-6	.	HBIN026567	.	.	D0LF1U	.	.	.
NP5470	Hesperidin	CID: 10621	Cirantin; Hesperidoside; Hesper bitabs; Hesperetin-rutinosid; Hesperidine; UNII-E750O06Y6O; CCRIS 3940; (S)-(-)-Hesperidin; EINECS 208-288-1; NSC 44184; BRN 0075140; Hesperidin, (2S)-; Hesperetin 7-rutinoside; MLS001304066; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one; CHEBI:28775; USAF CF-3; Hesperidin, (S)-(-)-; Hesperitin-7-rhamnoglucoside; E750O06Y6O; C28H34O15; HESPERIDINE	.	1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1	QUQPHWDTPGMPEX-QJBIFVCTSA-N	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O	C28H34O15	CAS 520-26-3	CHEBI:28775	HBIN029196	SMIT00275	MOL007930	D0I9HF	.	1370	.
NP5538	Gallic acid	CID: 370	3,4,5-Trihydroxybenzoic acid; 149-91-7; gallate; Benzoic acid, 3,4,5-trihydroxy-; Gallic acid, tech.; GALOP; Pyrogallol-5-carboxylic acid; Kyselina gallova; HSDB 2117; 3,4,5-Trihydroxybenzoate; CCRIS 5523; Kyselina gallova [Czech]; Gallic acid polymer; UNII-632XD903SP; NSC 674319; Gallicum acidum; CHEBI:30778; AI3-16412; Kyselina 3,4,5-trihydroxybenzoova; EINECS 205-749-9; NSC 20103; BRN 2050274; GALLIC ACID ANHYDROUS; Kyselina 3,4,5-trihydroxybenzoova [Czech]; CHEMBL288114; LNTHITQWFMADLM-UHFFFAOYSA-N; 632XD903SP	.	1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)	LNTHITQWFMADLM-UHFFFAOYSA-N	C1=C(C=C(C(=C1O)O)O)C(=O)O	C7H6O5	CAS 149-91-7	.	HBIN027097	.	.	D0Y3TZ	.	.	.
NP5545	Misoprostol	CID: 5282381	misoprostol; 59122-46-2; Cytotec; Isprelor; Misoprostolum [INN-Latin]; SC-29333; Misodel; SC 29333; UNII-0E43V0BB57; CCRIS 6859; HSDB 3573; BRN 4155643; methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate; 0E43V0BB57; NCGC00162445-02; Misoprostolum; Misoprost; Misotol; Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester,(11a,13E)-; Misogon; Misopess; Misotac; GyMiso; methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate; Cytotec (TN); misoprostol (methyl ester); SR-01000695425; XP-16J; MVI 200; 103601-27-0; methyl 7-((1R,2R,3R)-3-hydroxy-2-((E)-4-hydroxy-4-methyloct-1-enyl)-5-oxocyclopentyl)heptanoate; 11; A-Misoprostol; CAS_59122-46-2; Misoprostol [USAN:USP:INN:BAN:JAN]; DSSTox_CID_897; Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; CHEMBL606; SCHEMBL7787; (11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester; DSSTox_RID_75852; DSSTox_GSID_20897; MLS000028863; Misoprostol (JAN/USP/INN); GTPL1936; DTXSID7020897; BDBM85606; CHEBI:94387; Misoprostol, >=99% (HPLC); REGID_for_CID_5282381; HMS2090L10; HMS3648F03; HMS3715K08; EX-A1774; HY-B0610; Tox21_112010; MFCD00274550; (+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester; AKOS015899652; CCG-221093; DB00929; Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11alpha,13E)-; SMP1_000193; NCGC00162445-01; NCGC00162445-03; (+-)-Methyl (1R,2R,3R)-3-hydroxy-2-((E)-(4RS)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentaneheptanoate; SMR000058558; CAS-59122-46-2; D00419; AB00513745-05; 122M462; A832173; Q416025; Q-201409; SR-01000695425-2; SR-01000695425-4; BRD-A50310035-001-01-6; Misoprostol, European Pharmacopoeia (EP) Reference Standard; UNII-0E43V0BB57 component OJLOPKGSLYJEMD-URPKTTJQSA-N; Misoprostol, United States Pharmacopeia (USP) Reference Standard; (+/-) methyl 11alpha, 16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate; (+/-) methyl 11alpha,16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate; (+/-) methyl-11alpha,16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate; (+/-) methyl-11alpha,16-dihydroxy-16-methyl-9-oxoprost13E-en-1-oate; (+/-)-(11a,13E)-11,16-Dihydroxy-16-methyl-9-oxo-prost-13-en-1-oic acid methyl ester; (11alpha,13E)-11,16-Dihydroxy-16-methyl-9-oxoprosta-13-ene-1-oic acid methyl ester; Misoprostol for system suitability, European Pharmacopoeia (EP) Reference Standard; 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoic acid methyl ester; methyl 7-[(1R,2R,3R)-2-[(E)-4-methyl-4-oxidanyl-oct-1-enyl]-3-oxidanyl-5-oxidanylidene-cyclopentyl]heptanoate; Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11alpha,13E)-(+-)-	Small molecule	1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1	OJLOPKGSLYJEMD-URPKTTJQSA-N	CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O	C22H38O5	CAS 59122-46-2	CHEBI:94387	.	.	.	D09ANG	.	.	.
NP5581	1,8-cineole	CID: 2758	Eucalyptol; cineole; 1,8-Cineole; 470-82-6; 1,8-Cineol; Cajeputol; Zineol; 1,8-Epoxy-p-menthane; Eucalyptole; Eucapur; 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane; Terpan; p-Cineole; 1,8-Oxido-p-menthane; Eukalyptol; CINEOL; EUCALYPTUS OIL; Cucalyptol; Soledum; Eukalyptol [Czech]; Eucalyptol (natural); Zedoary oil; 2-Oxabicyclo[2.2.2]octane, 1,3,3-trimethyl-; p-Menthane, 1,8-epoxy-; FEMA No. 2465; Cineole (VAN); NCI-C56575; UNII-RV6J6604TK; 2-Oxabicyclo(2.2.2)octane, 1,3,3-trimethyl-; NSC 6171; MFCD00167977; 1,3,3-Trimethyl-2-oxabicyclo(2.2.2)octane; 2-Oxa-1,3,3-trimethylbicyclo(2.2.2)octane; Cineole (Eucalyptol); 8000-48-4; NSC6171; NSC-6171; 2,2,4-trimethyl-3-oxabicyclo[2.2.2]octane; 2-Oxa-1,3,3-trimethylbicyclo[2.2.2]octane; RV6J6604TK; CNL; 4,7,7-trimethyl-8-oxabicyclo[2.2.2]octane; CHEBI:27961; NCGC00091666-01; NCGC00091666-04; DSSTox_CID_616; 1,8-Cineole, 99%; DSSTox_RID_75692; DSSTox_GSID_20616; (1s,4s)-1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane; Eucalyptol 1000 microg/mL in Methanol; CAS-470-82-6; SMR000471853; CCRIS 3727; HSDB 991; Eucalyptol [USAN:USP]; EINECS 207-431-5; Terpane; Cyneol; BIDD:ER0481; AI3-00578; Eucalyptol,(S); Eucalyptol (USP); 1.8-cineole; Eucalyptol, 99%; Eucalyptol, Ph Helv; p-Menthane,8-epoxy-; cineole (1,8-); 1,8-cineol derivatives; WLN: T66 A B AOTJ B1 B1 F1; 1,8-Cineol-[d3]; Spectrum2_000221; Spectrum3_000683; Spectrum4_001747; Spectrum5_000704; bmse000523; EC 207-431-5; SCHEMBL19622; SCHEMBL41020; BSPBio_002405; KBioGR_002194; MLS001050089; MLS001066338; DivK1c_000333; SPECTRUM1500294; SPBio_000261; Eucalyptol, analytical standard; CHEMBL485259; GTPL2464; CHEMBL1231862; CHEMBL1397305; DTXSID4020616; SCHEMBL13554591; SCHEMBL17836873; HMS501A15; KBio1_000333; KBio3_001625; NINDS_000333; HMS2271P04; Pharmakon1600-01500294; ZINC967566; HY-N0066; Tox21_111161; Tox21_202090; Tox21_302902; 5750AF; BDBM50459887; CCG-36080; NSC760388; SBB057535; Acylated oxime isatin derivative, 19; AKOS015903223; AKOS016034339; AKOS037514637; Tox21_111161_1; CCG-266254; CS-8146; DB03852; LMPR0102090019; NSC-760388; IDI1_000333; Eucalyptol, tested according to Ph.Eur.; NCGC00091666-02; NCGC00091666-03; NCGC00091666-05; NCGC00095774-01; NCGC00178671-01; NCGC00256479-01; NCGC00259639-01; AC-20234; Eucalyptol, natural, >=99%, FCC, FG; LS-13868; NCI60_005108; ST096004; 1,3-Trimethyl-2-oxabicyclo[2.2.2]octane; 2-Oxa-1,3-trimethylbicyclo[2.2.2]octane; DB-070775; 2-Oxabicyclo[2.2.2]octane,3,3-trimethyl-; FT-0607033; FT-0626369; 1,3,3-trimethyl-2-oxabicyclo[2,2,2]octane; A15662; A19469; C09844; D04115; AB01563262_01; Q161572; SR-01000763816; SR-01000763816-2; W-106080; 1,8-Cineole, primary pharmaceutical reference standard; Cineole, European Pharmacopoeia (EP) Reference Standard; Eucalyptol, certified reference material, TraceCERT(R); F0001-1260; Eucalyptol, United States Pharmacopeia (USP) Reference Standard; Eucalyptol (cineole), Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C10H18O/c1-9(2)8-4-6-10(3,11-9)7-5-8/h8H,4-7H2,1-3H3	WEEGYLXZBRQIMU-UHFFFAOYSA-N	CC1(C2CCC(O1)(CC2)C)C	C10H18O	CAS 470-82-6	CHEBI:27961	.	.	.	D05YAR	.	.	.
NP5651	Morusin	CID: 5281671	Morusin; 62596-29-6; Mulberrochromene; TCMDC-124149; UNII-T4VGD5NP9B; NSC649220; T4VGD5NP9B; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one; CHEBI:7005; CHEMBL464006; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)pyrano[2,3-f]chromen-4(8H)-one; 4H,8H-Benzo(1,2-b:3,4-b')dipyran-4-one, 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-; Morusin, 3; NSC 649220; MLS000697591; MEGxp0_001039; SCHEMBL2562778; ACon1_001205; cid_5281671; DTXSID70211641; HMS2271K05; BCP16494; HY-N0622; ZINC5195808; BDBM50242014; LMPK12110912; MFCD09953814; AKOS032962066; CS-6885; NSC-649220; AK169967; LS-15105; SMR000470930; FT-0686661; N2266; W1523; A14647; C10106; BRD-K40169295-001-01-2; Q27107393; 2-(2,4-dihydroxyphenyl)-5-hydroxy-3-(3-methyl-2-butenyl)-4H-6,6-dimethylpyrano- [2,3-h]-1-benzopyran-4-one; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one, 9CI; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one	Small molecule	1S/C25H24O6/c1-13(2)5-7-17-22(29)21-19(28)12-20-16(9-10-25(3,4)31-20)24(21)30-23(17)15-8-6-14(26)11-18(15)27/h5-6,8-12,26-28H,7H2,1-4H3	XFFOMNJIDRDDLQ-UHFFFAOYSA-N	CC(=CCC1=C(OC2=C(C1=O)C(=CC3=C2C=CC(O3)(C)C)O)C4=C(C=C(C=C4)O)O)C	C25H24O6	CAS 62596-29-6	CHEBI:7005	.	.	.	.	.	.	.
NP5692	Carvacrol	CID: 10364	CARVACROL; 5-Isopropyl-2-methylphenol; 499-75-2; Isopropyl-o-cresol; o-Thymol; Karvakrol; Antioxine; 5-Isopropyl-o-cresol; 2-p-Cymenol; Phenol, 2-methyl-5-(1-methylethyl)-; Isothymol; p-Cymen-2-ol; 2-Hydroxy-p-cymene; 2-Methyl-5-isopropylphenol; 2-Methyl-5-(Propan-2-Yl)Phenol; 3-Isopropyl-6-methylphenol; 5-Isopropyl-2-methyl-phenol; p-Cymene, 2-hydroxy-; 2-Methyl-5-(1-methylethyl)phenol; o-Cresol, 5-isopropyl-; 2-methyl-5-propan-2-ylphenol; 1-Hydroxy-2-methyl-5-isopropylbenzene; 6-Methyl-3-isopropylphenol; Phenol, 5-isopropyl-2-methyl-; CYMOPHENOL; Oxycymol; 1-Methyl-2-hydroxy-4-isopropylbenzene; Phenol, 3-isopropyl-6-methyl-; 2-Hydroxycymene; NSC 6188; UNII-9B1J4V995Q; CHEBI:3440; CHEMBL281202; 9B1J4V995Q; 2-Methyl-5-(1-methylethyl)-Phenol; MFCD00002236; 2-methyl-5-(methylethyl)phenol; Cymene-2-ol, p-; Caswell No. 511; Cymenol; FEMA No. 2245; CCRIS 7450; HSDB 906; EINECS 207-889-6; EPA Pesticide Chemical Code 022104; BRN 1860514; AI3-03438; Hydroxy-p-cymene; Carvacrol Natural; Carvacrol,(S); p-Cymene-2-ol; Carvacrol, 98%; PubChem10329; ACMC-1AG8Z; DSSTox_CID_22074; DSSTox_RID_79916; DSSTox_GSID_42074; SCHEMBL24734; 3-Isopropyl-6-methyl phenol; 3-Isopropyl-6-methyl-Phenol; 4-06-00-03331 (Beilstein Handbook Reference); BIDD:ER0492; Carvacrol, analytical standard; GTPL2497; Carvacrol, natural, 99%, FG; DTXSID6042074; Methyl-5-(1-methylethyl)phenol; p-Mentha-1,3,5-trien-2-ol; WLN: QR B1 EY1&1; 2-methyl-5-propan-2-yl-phenol; FEMA 2245; NSC6188; Carvacrol, >=98%, FCC, FG; ZINC967563; HY-N0711; NSC-6188; Tox21_301378; ANW-30877; BDBM50240433; s3788; SBB060790; STL453136; AKOS000120828; AC-2688; CCG-266210; FS-4199; LMPR0102090017; MB00118; NCGC00256001-01; AK-88979; CAS-499-75-2; Isothymol (=2-Isopropyl-4-methyl phenol); Carvacrol Cymenol 5-Isopropyl-2-methylphenol; CS-0009729; FT-0627526; ST51046899; 2-HYDROXY-4-ISOPROPYL-1-METHYLBENZENE; C09840; A827907; Q225543; Carvacrol, primary pharmaceutical reference standard; W-105999; BENZENE,2-HYDROXY,4-ISOPROPYL,1-METHYL CARVACROL; F8889-1978; Z1317839236; BENZENE,2-HYDROXY,4-ISOPROPYL,1-METHYL   CARVACROL	Small molecule	1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3	RECUKUPTGUEGMW-UHFFFAOYSA-N	CC1=C(C=C(C=C1)C(C)C)O	C10H14O	CAS 499-75-2	CHEBI:3440	.	.	.	D07JDC	.	.	.
NP5695	Aminoglutethimide	CID: 2145	aminoglutethimide; 125-84-8; dl-Aminoglutethimide; Cytadren; Orimeten; p-Aminoglutethimide; Elipten; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl-; Aminoglutetimida; Aminoglutethimidum; 2-(p-Aminophenyl)-2-ethylglutarimide; Ba-16038; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine; (+/-)-p-AMINOGLUTETHIMIDE; Glutethimide, para-amino; Glutarimide, 2-(p-aminophenyl)-2-ethyl-; AG-1; 3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione; MFCD00010122; CHEMBL488; CHEBI:2654; alpha-(p-Aminophenyl)-alpha-ethylglutarimide; NSC-330915; DSSTox_CID_2589; DSSTox_RID_76647; .alpha.-(p-Aminophenyl)-.alpha.-ethylglutarimide; DSSTox_GSID_22589; (RS)-2-(4-Amino-phenyl)-2-ethyl-glutarimide;(RS)-3-(4-Amino-phenyl)-3-ethyl-2,6-dioxo-piperidine; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Aminoglutetimide; Ba 16038; Cytadren (TN); SMR000326785; C 16038-BA; CCRIS 7562; aminoglutethimide (AG); SR-01000075596; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; EINECS 204-756-4; BRN 0210656; Aminoglutethimide (USP/INN); HSDB 7494; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; Aminoglutethimide [USP:INN:BAN]; NCGC00016379-01; CAS-125-84-8; Prestwick_243; Spectrum_000040; (y)-p-Aminoglutethimide; Aminoglutethimide AG, 4; (?)-p-Aminoglutethimide; Prestwick0_000244; Prestwick1_000244; Prestwick2_000244; Prestwick3_000244; Spectrum2_000093; Spectrum3_000296; Spectrum4_000144; Spectrum5_000802; A 9657; SCHEMBL4306; Aminoglutethimide (Cytadren); Lopac0_000124; BSPBio_000028; BSPBio_001832; KBioGR_000588; KBioSS_000400; (A+/-)-p-Aminoglutethimide; MLS000859924; MLS001213216; DivK1c_000884; SPECTRUM1500115; SPBio_000046; SPBio_002247; BDBM9460; BPBio1_000032; GTPL7054; DTXSID8022589; HMS502M06; KBio1_000884; KBio2_000400; KBio2_002968; KBio2_005536; KBio3_001332; NINDS_000884; HMS1568B10; HMS1920C09; HMS2090I05; HMS2091I09; HMS2095B10; HMS2231M19; HMS3259H10; HMS3260I10; HMS3372M07; HMS3655O17; HMS3712B10; Pharmakon1600-01500115; 55511-44-9; 57288-03-6; AMY33415; BCP28501; EBD40055; HY-B0237; 2, 3-(4-aminophenyl)-3-ethyl-; Tox21_110406; Tox21_303497; Tox21_500124; BBL010961; CCG-38911; NSC330915; NSC755868; SBB000711; STK802074; 2-(4-aminophenyl)-2-ethylglutarimide; AKOS004120070; AKOS022060651; Tox21_110406_1; AT-2947; DB00357; LP00124; MCULE-9118268281; NC00714; NSC 330915; NSC 755868; NSC-755868; SDCCGSBI-0050112.P005; IDI1_000884; SMP1_000017; NCGC00015110-02; NCGC00015110-03; NCGC00015110-04; NCGC00015110-05; NCGC00015110-06; NCGC00015110-07; NCGC00015110-09; NCGC00015110-12; NCGC00015110-21; NCGC00093615-01; NCGC00093615-02; NCGC00093615-03; NCGC00093615-04; NCGC00093615-05; NCGC00257263-01; NCGC00260809-01; AC-12456; AS-13282; H801; NCI60_002900; SBI-0050112.P004; AB0013271; DB-021640; DB-072002; DB-072275; 3-Carboxy-1,1-dimethyl-, (E)-2-propenyl; AB00051935; EU-0100124; FT-0773944; S1672; SW196550-3; ( inverted question mark)-p-Aminoglutethimide; EN300-53368; VU0243029-3; C07617; D00574; K-1913; AB00051935-09; AB00051935-11; AB00051935_12; AB00051935_13; 125A848; A805433; Q241150; 3-(4-aminophenyl)-3-ethylazaperhydroine-2,6-dione; SR-01000075596-1; SR-01000075596-4; SR-01000075596-6; W-108399; BRD-A25234499-001-05-0; BRD-A25234499-001-09-2; Z1259341083; Aminoglutethimide, European Pharmacopoeia (EP) Reference Standard; Aminoglutethimide, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)	ROBVIMPUHSLWNV-UHFFFAOYSA-N	CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N	C13H16N2O2	CAS 125-84-8	CHEBI:2654	.	.	.	D0M6DO	.	.	.
NP5727	L-methionine	CID: 6137	L-methionine; 63-68-3; methionine; h-Met-oh; (S)-2-Amino-4-(methylthio)butanoic acid; Cymethion; L-(-)-Methionine; Liquimeth; S-Methionine; L-Methioninum; Methilanin; Neo-methidin; (L)-Methionine; Methionine (VAN); Acimethin; Metionina [DCIT]; (S)-methionine; L-alpha-Amino-gamma-methylmercaptobutyric acid; h-Met-h; Methioninum [INN-Latin]; metionina; Methioninum; Polymethionine; L-Homocysteine, S-methyl-; L-Methionin; (2S)-2-amino-4-(methylsulfanyl)butanoic acid; METHIONINE, L-; Poly-L-methionine; L(-)-Amino-gamma-methylthiobutyric acid; L-alpha-Amino-gamma-methylthiobutyric acid; L-gamma-Methylthio-alpha-aminobutyric acid; met; CCRIS 5528; CCRIS 5536; HSDB 4317; 2-Amino-4-methylthiobutanoic acid (S)-; UNII-AE28F7PNPL; (S)-2-amino-4-(methylthio)butyric acid; 2-Amino-4-(methylthio)butyric acid, (S)-; (2S)-2-amino-4-methylsulfanyl-butanoic acid; MFCD00063097; L-Met; Butanoic acid, 2-amino-4-(methylthio)-, (S)-; Toxin WAR (Bacillus thuringiensis strain PS205C); L-a-Amino-g-methylthiobutyric acid; S-Methyl-L-homocysteine; (S)-(+)-Methionine; AE28F7PNPL; gamma-Methylthio-alpha-aminobutyric acid; L-2-Amino-4-(methylthio)butanoic acid; CHEMBL42336; (2S)-2-Amino-4-methylsulfanylbutanoic acid; CHEBI:16643; L-2-Amino-4methylthiobutyric acid; L-Methionine-35S; L-Methionine, 98+%; (S)-2-Amino-4-(methylmercapto)butyric acid; 58576-49-1; Methionine [USAN:INN]; C-11 Methionine; l-2-Amino-4-(methylthio)butyric acid; EINECS 200-562-9; (2S)-2-amino-4-(methylsulfanyl)butanoate; NSC 22946; C-11 Met; NSC-22946; 3h-l-methionine; g-Methylthio-a-aminobutyric acid; racemic methionine; 1wkm; Methionine [USAN:USP:INN:BAN]; Toxin WAR; (35S)Methionine; 2-Amino-4-(methylthio)butyrate; Methionine (USP); a-Amino-g-methylmercaptobutyric acid; L-Methionine,(S); NSC 118113; 3654-96-4; L-S-methylhomocysteine; PubChem14349; 1pg2; 1qq9; L-Methionine Z (TN); L-Methionine (JP17); L-Methionine, homopolymer; Methionine, L- (8CI); bmse000044; bmse000915; SCHEMBL4226; G-methylthio-a-aminobutyrate; L-Methionine (H-Met-OH); H-Met-2-Chlorotrityl Resin; 2-Amino-4-methylthiobutanoate; L-a-amino-g-methylthiobutyrate; GTPL4814; A-amino-g-methylmercaptobutyrate; DTXSID5040548; SCHEMBL15702352; Pharmakon1600-01301006; alpha-amino-alpha-aminobutyric acid; gamma-methylthio-alpha-aminobutyrate; HY-N0326; L-Methionine, Cell Culture Reagent; ZINC1532529; L-2-Amino-4-methylthiobutyric acid; ANW-34703; BDBM50142500; MFCD00801344; NSC760117; s5633; L-alpha-amino-gamma-methylthiobutyrate; L-Methionine, Vetec(TM), 98.5%; (S)-2-Amino-4-(methylthio)butanoate; AKOS000281626; AKOS015852512; L-Methionine, labeled with carbon-11; alpha-amino-gamma-methylmercaptobutyrate; CCG-266196; CS-W020566; DB00134; MCULE-7228063662; NSC-760117; (S)-2-amino-4-(methylthio)-Butanoate; NCGC00160620-01; NCGC00160620-02; AS-10898; (S)-2-amino-4-(methylthio)-Butanoic acid; AB0008395; DB-029971; L-Methionine, BioUltra, >=99.5% (NT); 988-EP0930075A1; 988-EP1441224A2; 988-EP2269610A2; 988-EP2269977A2; 988-EP2269978A2; 988-EP2269979A1; 988-EP2269985A2; 988-EP2269989A1; 988-EP2269990A1; 988-EP2269991A2; 988-EP2269992A1; 988-EP2269993A1; 988-EP2269996A1; 988-EP2270001A1; 988-EP2270003A1; 988-EP2270005A1; 988-EP2270006A1; 988-EP2270008A1; 988-EP2270010A1; 988-EP2270011A1; 988-EP2270014A1; 988-EP2270017A1; 988-EP2270018A1; 988-EP2270114A1; 988-EP2270895A2; 988-EP2272509A1; 988-EP2272516A2; 988-EP2272517A1; 988-EP2272817A1; 988-EP2272825A2; 988-EP2272826A1; 988-EP2272827A1; 988-EP2272828A1; 988-EP2272834A1; 988-EP2272838A1; 988-EP2272841A1; 988-EP2272842A1; 988-EP2272844A1; 988-EP2272845A2; 988-EP2272846A1; 988-EP2272972A1; 988-EP2272973A1; 988-EP2275102A1; 988-EP2275105A1; 988-EP2275401A1; 988-EP2275403A1; 988-EP2275404A1; 988-EP2275412A1; 988-EP2275413A1; 988-EP2275414A1; 988-EP2275420A1; 988-EP2275421A1; 988-EP2275469A1; 988-EP2277565A2; 988-EP2277566A2; 988-EP2277567A1; 988-EP2277568A2; 988-EP2277569A2; 988-EP2277570A2; 988-EP2277848A1; 988-EP2277867A2; 988-EP2277868A1; 988-EP2277869A1; 988-EP2277872A1; 988-EP2277874A1; 988-EP2277875A2; 988-EP2277876A1; 988-EP2277877A1; 988-EP2277880A1; 988-EP2277881A1; 988-EP2277882A1; 988-EP2277898A2; 988-EP2278637A1; 988-EP2279741A2; 988-EP2279750A1; 988-EP2280003A2; 988-EP2280006A1; 988-EP2280008A2; 988-EP2280009A1; 988-EP2280010A2; 988-EP2280012A2; 988-EP2280014A2; 988-EP2280282A1; 988-EP2281559A1; 988-EP2281563A1; 988-EP2281812A1; 988-EP2281815A1; 988-EP2281819A1; 988-EP2281820A2; 988-EP2281822A1; 988-EP2281824A1; 988-EP2283898A1; 988-EP2284149A1; 988-EP2284150A2; 988-EP2284151A2; 988-EP2284152A2; 988-EP2284153A2; 988-EP2284154A1; 988-EP2284155A2; 988-EP2284156A2; 988-EP2284157A1; 988-EP2284158A1; 988-EP2284159A1; 988-EP2284160A1; 988-EP2284164A2; 988-EP2284165A1; 988-EP2284169A1; 988-EP2284171A1; 988-EP2284172A1; 988-EP2284174A1; 988-EP2284178A2; 988-EP2284179A2; 988-EP2284920A1; 988-EP2286811A1; 988-EP2286812A1; 988-EP2286915A2; 988-EP2287140A2; 988-EP2287141A1; 988-EP2287147A2; 988-EP2287148A2; 988-EP2287150A2; 988-EP2287156A1; 988-EP2287159A1; 988-EP2287161A1; 988-EP2287162A1; 988-EP2287163A1; 988-EP2287165A2; 988-EP2287166A2; 988-EP2287167A1; 988-EP2287168A2; 988-EP2287940A1; 988-EP2289510A1; 988-EP2289868A1; 988-EP2289871A1; 988-EP2289876A1; 988-EP2289880A1; 988-EP2289881A1; 988-EP2289882A1; 988-EP2289883A1; 988-EP2289886A1; 988-EP2289887A2; 988-EP2289888A2; 988-EP2289890A1; 988-EP2289891A2; 988-EP2289892A1; 988-EP2289893A1; 988-EP2289894A2; 988-EP2292088A1; 988-EP2292227A2; 988-EP2292228A1; 988-EP2292280A1; 988-EP2292576A2; 988-EP2292589A1; 988-EP2292590A2; 988-EP2292593A2; 988-EP2292597A1; 988-EP2292608A1; 988-EP2292610A1; 988-EP2292614A1; 988-EP2292615A1; 988-EP2292617A1; 988-EP2292620A2; 988-EP2292621A1; 988-EP2292622A1; 988-EP2292625A1; 988-EP2292628A2; 988-EP2292630A1; 988-EP2295399A2; 988-EP2295401A2; 988-EP2295406A1; 988-EP2295407A1; 988-EP2295408A1; 988-EP2295410A1; 988-EP2295411A1; 988-EP2295412A1; 988-EP2295413A1; 988-EP2295415A1; 988-EP2295416A2; 988-EP2295417A1; 988-EP2295418A1; 988-EP2295419A2; 988-EP2295422A2; 988-EP2295423A1; 988-EP2295426A1; 988-EP2295427A1; 988-EP2295428A2; 988-EP2295429A1; 988-EP2295432A1; 988-EP2295433A2; 988-EP2295434A2; 988-EP2295436A1; 988-EP2295437A1; 988-EP2295438A1; 988-EP2295439A1; 988-EP2295441A2; 988-EP2295550A2; 988-EP2298077A1; 988-EP2298305A1; 988-EP2298728A1; 988-EP2298732A1; 988-EP2298734A2; 988-EP2298735A1; 988-EP2298736A1; 988-EP2298738A1; 988-EP2298742A1; 988-EP2298743A1; 988-EP2298744A2; 988-EP2298746A1; 988-EP2298747A1; 988-EP2298748A2; 988-EP2298749A1; 988-EP2298752A1; 988-EP2298754A1; 988-EP2298755A1; 988-EP2298758A1; 988-EP2298759A1; 988-EP2298761A1; 988-EP2298762A2; 988-EP2298763A1; 988-EP2298766A1; 988-EP2298767A1; 988-EP2298768A1; 988-EP2298769A1; 988-EP2298770A1; 988-EP2298773A1; 988-EP2298775A1; 988-EP2298776A1; 988-EP2298778A1; 988-EP2298779A1; 988-EP2298780A1; 988-EP2298783A1; 988-EP2298828A1; 988-EP2299785A1; 988-EP2301533A1; 988-EP2301534A1; 988-EP2301536A1; 988-EP2301538A1; 988-EP2301544A1; 988-EP2301911A1; 988-EP2301913A1; 988-EP2301914A1; 988-EP2301922A1; 988-EP2301923A1; 988-EP2301928A1; 988-EP2301929A1; 988-EP2301931A1; 988-EP2301932A1; 988-EP2301933A1; 988-EP2301935A1; 988-EP2301936A1; 988-EP2301937A1; 988-EP2301939A1; 988-EP2301940A1; 988-EP2301983A1; 988-EP2302132A1; 988-EP2305033A1; 988-EP2305250A1; 988-EP2305260A1; 988-EP2305629A1; 988-EP2305636A1; 988-EP2305637A2; 988-EP2305640A2; 988-EP2305641A1; 988-EP2305642A2; 988-EP2305643A1; 988-EP2305644A1; 988-EP2305648A1; 988-EP2305651A1; 988-EP2305652A2; 988-EP2305660A1; 988-EP2305664A1; 988-EP2305668A1; 988-EP2305669A1; 988-EP2305671A1; 988-EP2305672A1; 988-EP2305674A1; 988-EP2305675A1; 988-EP2305676A1; 988-EP2305678A1; 988-EP2305680A2; 988-EP2305682A1; 988-EP2305684A1; 988-EP2305688A1; 988-EP2305689A1; 988-EP2305695A2; 988-EP2305696A2; 988-EP2305697A2; 988-EP2305698A2; 988-EP2305769A2; 988-EP2305808A1; 988-EP2306788A1; 988-EP2306789A1; 988-EP2308479A2; 988-EP2308562A2; 988-EP2308812A2; 988-EP2308828A2; 988-EP2308832A1; 988-EP2308838A1; 988-EP2308839A1; 988-EP2308840A1; 988-EP2308841A2; 988-EP2308844A2; 988-EP2308845A2; 988-EP2308846A2; 988-EP2308849A1; 988-EP2308850A1; 988-EP2308851A1; 988-EP2308852A1; 988-EP2308854A1; 988-EP2308855A1; 988-EP2308858A1; 988-EP2308861A1; 988-EP2308863A1; 988-EP2308866A1; 988-EP2308867A2; 988-EP2308868A1; 988-EP2308869A1; 988-EP2308870A2; 988-EP2308872A1; 988-EP2308873A1; 988-EP2308874A1; 988-EP2308875A1; 988-EP2308876A1; 988-EP2308877A1; 988-EP2308878A2; 988-EP2308879A1; 988-EP2308880A1; 988-EP2308882A1; 988-EP2308960A1; 988-EP2311451A1; 988-EP2311455A1; 988-EP2311494A1; 988-EP2311796A1; 988-EP2311797A1; 988-EP2311798A1; 988-EP2311799A1; 988-EP2311801A1; 988-EP2311802A1; 988-EP2311803A1; 988-EP2311806A2; 988-EP2311807A1; 988-EP2311808A1; 988-EP2311809A1; 988-EP2311810A1; 988-EP2311811A1; 988-EP2311814A1; 988-EP2311816A1; 988-EP2311817A1; 988-EP2311822A1; 988-EP2311825A1; 988-EP2311826A2; 988-EP2311827A1; 988-EP2311828A1; 988-EP2311829A1; 988-EP2311830A1; 988-EP2311831A1; 988-EP2311836A1; 988-EP2311837A1; 988-EP2311842A2; 988-EP2311850A1; 988-EP2314295A1; 988-EP2314574A1; 988-EP2314576A1; 988-EP2314579A1; 988-EP2314580A1; 988-EP2314581A1; 988-EP2314582A1; 988-EP2314583A1; 988-EP2314587A1; 988-EP2314588A1; 988-EP2314590A1; 988-EP2314591A1; 988-EP2314593A1; 988-EP2315303A1; 988-EP2315502A1; 988-EP2316450A1; 988-EP2316452A1; 988-EP2316457A1; 988-EP2316458A1; 988-EP2316824A1; 988-EP2316825A1; 988-EP2316826A1; 988-EP2316827A1; 988-EP2316828A1; 988-EP2316829A1; 988-EP2316830A2; 988-EP2316831A1; 988-EP2316832A1; 988-EP2316833A1; 988-EP2316836A1; 988-EP2316905A1; 988-EP2316906A2; 988-EP2316937A1; 988-EP2371806A1; 988-EP2371807A1; 988-EP2371808A1; 988-EP2371813A1; 988-EP2371814A1; 988-EP2371823A1; 988-EP2374454A1; 988-EP2374533A1; 988-EP2374787A1; 988-EP2374790A1; 988-EP2374791A1; 988-EP2375479A1; 988-EP2377845A1; 988-EP2377849A2; 988-EP2380871A1; 988-EP2380873A1; A5456; AM20100552; M0099; L-Methionine, SAJ special grade, >=98.5%; 63M683; C00073; D00019; L(-)-amino-alpha-amino-alpha-aminobutyric acid; L-Methionine, reagent grade, >=98% (HPLC); M-6051; M02939; M02945; 88843-EP2289892A1; 88843-EP2305825A1; L-Methionine, Vetec(TM) reagent grade, >=98%; C6CB5837-2B49-4B25-AAB0-D305DAFE26EB; Q22124685; F1905-8241; Z1250208671; L-Methionine, certified reference material, TraceCERT(R); Methionine, European Pharmacopoeia (EP) Reference Standard; UNII-0O72R8RF8A component FFEARJCKVFRZRR-BYPYZUCNSA-N; UNII-73JWT2K6T3 component FFEARJCKVFRZRR-BYPYZUCNSA-N; UNII-N7U7BXP2OI component FFEARJCKVFRZRR-BYPYZUCNSA-N; N-(2CT Resin)-L-Met-OH (200-400 mesh, > 0.3 mmol/g); L-Methionine,	Small molecule	1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1	FFEARJCKVFRZRR-BYPYZUCNSA-N	CSCCC(C(=O)O)N	C5H11NO2S	CAS 63-68-3	CHEBI:16643	.	.	.	D0PO8E	.	.	.
NP5732	Osthole	CID: 10228	Osthol; 484-12-8; Ostol; Ostole; 7-methoxy-8-(3-methylbut-2-en-1-yl)-2H-chromen-2-one; 7-Methoxy-8-isopentenylcoumarin; 2H-1-Benzopyran-2-one, 7-methoxy-8-(3-methyl-2-butenyl)-; 7-methoxy-8-(3-methylbut-2-enyl)chromen-2-one; NSC 31868; 8-(3-Methyl-2-butenyl)herniarin; 7-methoxy-8-(3-methyl-2-buten-1-yl)-2H-chromen-2-one; 7-METHOXY-8-(3-METHYL-2-BUTENYL)-COUMARIN; 7-methoxy-8-(3-methyl-2-butenyl)coumarin; UNII-XH1TI1759C; Coumarin, 7-methoxy-8-(3-methyl-2-butenyl)-; CHEMBL52229; XH1TI1759C; CHEBI:69832; NSC31868; 7-Methoxy-8-(3-methyl-but-2-enyl)-chromen-2-one; MFCD00076049; 7-methoxy-8-(3-methylbut-2-enyl)-2H-chromen-2-one; SMR000156202; Osthole (Osthol); A0O; Osthole,(S); Cnidium Fruit Extract; Spectrum_001542; SpecPlus_000946; Spectrum2_000723; Spectrum3_001645; Spectrum4_001687; Spectrum5_000334; Osthole, analytical standard; Oprea1_642606; Oprea1_873803; SCHEMBL50436; BSPBio_003369; KBioGR_001954; KBioSS_002022; ZINC566; MLS000574904; MLS001048988; MLS006011425; DivK1c_007042; SPECTRUM1504165; SPBio_000646; MEGxp0_000155; ACon1_002155; GTPL10302; HSDB 8479; KBio1_001986; KBio2_002022; KBio2_004590; KBio2_007158; KBio3_002589; DTXSID20197507; HMS2267O21; HMS3656A07; AMY40671; BCP10832; EBD33224; HY-N0054; ANW-50075; BBL013019; BDBM50240512; CCG-40172; CO0040; NSC-31868; s2337; STK396321; AKOS000277663; AC-8041; DS-0881; MCULE-5691054147; SDCCGMLS-0066780.P001; NCGC00095694-01; NCGC00095694-02; NCGC00095694-03; NCGC00095694-05; WLN: T66 BOVJ IO1 J2UY1&1; AK-35300; AB0021820; FT-0601535; N1825; O0426; ST50909221; SW219438-1; W1256; C09280; J10077; S-3211; 484O128; A827530; Osthole, primary pharmaceutical reference standard; SR-01000721624; Q-100535; Q4338679; SR-01000721624-4; BRD-K78294846-001-03-3; 7-Methoxy-8-(3-methyl-2-butenyl)-2H-chromen-2-one #; 7-methoxy-8-(3-methylbut-2-enyl)-1-benzopyran-2-one; Osthole, European Pharmacopoeia (EP) Reference Standard; 2H-1-Benzopyran-2-one, 7-methoxy-8-(3-methyl-2-butenyl)- (9CI); 1440642-68-1	.	1S/C15H16O3/c1-10(2)4-7-12-13(17-3)8-5-11-6-9-14(16)18-15(11)12/h4-6,8-9H,7H2,1-3H3	MBRLOUHOWLUMFF-UHFFFAOYSA-N	CC(=CCC1=C(C=CC2=C1OC(=O)C=C2)OC)C	C15H16O3	CAS 484-12-8	.	HBIN038388	SMIT01674	.	.	.	.	.
NP5733	Daphnetin	CID: 5280569	daphnetin; 7,8-Dihydroxycoumarin; 486-35-1; Daphnetol; 7,8-Dihydroxy-2H-chromen-2-one; 7,8-Dihydroxy-2H-1-benzopyran-2-one; 7,8-dihydroxychromen-2-one; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-; 7,8-DIHYDROXY-2H-BENZOPYRAN-2-ONE; UNII-XC84571RD2; C9H6O4; TCMDC-125839; COUMARIN, 7,8-DIHYDROXY-; CHEMBL244948; CHEBI:17313; XC84571RD2; 7,8-Dihydroxycoumarin (Daphnetin); MFCD00016977; NSC633563; SMR001230713; SR-01000075820; EINECS 207-632-8; NSC 633563; BRN 0009372; 7,8-DIHYDROXY-CHROMEN-2-ONE; 1,8-Dihydroxycoumarin; PubChem13303; 7,8-dihydroxy-coumarin; ACMC-1AKCA; SpecPlus_000864; Spectrum3_000784; Spectrum4_001254; Lopac-D-5564; Lopac0_000330; Oprea1_044324; BSPBio_002488; KBioGR_001808; 5-18-03-00211 (Beilstein Handbook Reference); MLS002153288; MLS006012039; DivK1c_006960; SCHEMBL128212; 7,8-Dihydroxycoumarin, 90%; KBio1_001904; KBio3_001708; ZINC57753; 7,8-bis(oxidanyl)chromen-2-one; DTXSID00197560; HMS3261A21; HMS3656G16; 7,8-dihydroxy-1-benzopyran-2-one; HY-N0281; Tox21_500330; ANW-43482; BBL036425; BDBM50206006; CCG-39736; CD0136; HSCI1_000053; s2554; STL558976; 7,8-Dihydroxy-2H-chromen-2-one #; AKOS000277449; LP00330; MCULE-9549774136; NSC-633563; PB17055; SDCCGSBI-0050318.P003; 7,8-Dihydroxycoumarin, >=97%, powder; NCGC00015349-01; NCGC00015349-02; NCGC00015349-03; NCGC00015349-04; NCGC00015349-05; NCGC00015349-06; NCGC00015349-12; NCGC00093770-01; NCGC00093770-02; NCGC00261015-01; AK170408; AS-63138; DB-051567; CS-0008778; D4001; EU-0000106; EU-0100330; FT-0603132; N1567; ST50308908; SW000346-2; V0328; C03093; D 5564; Q-1224; 2H-1-Benzopyran-2-one, 7,8-dihydroxy- (9CI); 486D351; A827573; AE-641/02519040; Q-100543; SR-01000075820-1; SR-01000075820-2; BRD-K61269089-001-01-4; BRD-K61269089-001-02-2; Q27102315	Small molecule	1S/C9H6O4/c10-6-3-1-5-2-4-7(11)13-9(5)8(6)12/h1-4,10,12H	ATEFPOUAMCWAQS-UHFFFAOYSA-N	C1=CC(=C(C2=C1C=CC(=O)O2)O)O	C9H6O4	CAS 486-35-1	CHEBI:17313	.	.	.	.	.	.	.
NP5738	Alpinia purpurata lectin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP5764	Licochalcone A	CID: 5318998	licochalcone a; 58749-22-7; Licochalcone-A; UNII-JTV5467968; CHEMBL139702; JTV5467968; (E)-3-(4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one; Licochalcone-A, Synthetic; 3-Dimethylallyl-4,4'-dihydroxy-6-methoxychalcone; (E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; (2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one,3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-, (2E)-; LICOAGROCHACONE A; LicochalconeA; Licohalconel A; (E)-3-[5-(1,1-Dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-2-propen-1-one; SCHEMBL114042; DTXSID10904181; CHEBI:125689; CHEBI:174541; 3-(4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one; BCP08941; EBD46703; EX-A1193; HY-N0372; ZINC3873123; BDBM50068270; HSCI1_000078; LMPK12120424; MFCD01417903; s7828; AKOS026673964; CCG-208030; CS-5603; Licochalcone A, >=96.0% (HPLC); (E)-3-[5-(1,1-dimethylallyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (E)-; AS-74730; AB0021119; V2343; 749L227; Q-100677; Q1644097; BRD-K99667445-001-01-4; Chalcone base + 2O, 1MeO, 1Prenyl or Licochalcone A (Not validated); (E)-3-[5-(1,1-Dimethyl-allyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxy-phenyl)-propenone; 3-[5-((E)-1,1-Dimethyl-allyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxy-phenyl)-propenone; 2-Propen-1-one, 3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)- (E)-	Small molecule	1S/C21H22O4/c1-5-21(2,3)17-12-15(20(25-4)13-19(17)24)8-11-18(23)14-6-9-16(22)10-7-14/h5-13,22,24H,1H2,2-4H3/b11-8+	KAZSKMJFUPEHHW-DHZHZOJOSA-N	CC(C)(C=C)C1=C(C=C(C(=C1)C=CC(=O)C2=CC=C(C=C2)O)OC)O	C21H22O4	CAS 58749-22-7	CHEBI:125689	.	.	.	D08GEN	.	.	.
NP5766	Ginsenoside Rh2	CID: 119307	(20S)-ginsenoside Rh2; 20(S)-Ginsenoside Rh2; Ginsenoside-Rh2; 20(S)-Ginsenoside; CHEBI:77147; UNII-0JU44A5KWG; 0JU44A5KWG; (2R,3R,4S,5S,6R)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; C36H62O8; 20S-Ginsenoside Rh2; 20(S)-Ginsenoside-RH2; (S)Ginsenoside-Rh2; (20R)Ginsenoside Rh2; CHEMBL1783834; DTXSID70999457; 112246-15-8; 67400-17-3; HY-N0605; BDBM50023457; Ginsenoside Rh2, analytical standard; MFCD00800712; s9023; s9036; ZINC72129809; AKOS037514675; CCG-270259; CCG-270261; CS-3835; X1143; C22128; 12,20-Dihydroxydammar-24-en-3-yl hexopyranoside; 214G332; Q-100827; Q27146703; 3beta-(beta-D-glucopyranosyloxy)dammar-24-ene-3beta,20beta-diol; beta-D-Glucopyranoside, (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl	.	1S/C36H62O8/c1-20(2)10-9-14-36(8,42)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(32(3,4)24(33)12-17-34(25,35)6)44-31-30(41)29(40)28(39)23(19-37)43-31/h10,21-31,37-42H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26-,27-,28+,29-,30+,31-,33-,34+,35+,36-/m0/s1	CKUVNOCSBYYHIS-IRFFNABBSA-N	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)O)C)C)O)C)O)C	C36H62O8	CAS 78214-33-2	.	HBIN027764	SMIT00601	MOL005344	.	.	4649	.
NP5775	Cyclopamine	CID: 442972	CYCLOPAMINE; 11-Deoxojervine; 4449-51-8; 11-Deoxyjervine; UNII-ZH658AJ192; CHEBI:4021; CHEMBL254129; ZH658AJ192; (2'R,3S,3'R,3a'S,6aS,6bS,6'S,7a'R,11aS,11bR)-3',6',10,11b-tetramethyl-1,2,3,3a',4,4',5',6,6a,6b,6',7,7',7a',8,11,11a,11b-octadecahydro-3'H-spiro[benzo[a]fluorene-9,2'-furo[3,2-b]pyridin]-3-ol; Spiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octadecahydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)- (9CI); (3beta,22S,23R)-17,23-epoxyveratraman-3-ol; HSDB 3505; CY8; [3H]-Cyclopamine; Jervine, 11-deoxo-; DSSTox_CID_23709; DSSTox_RID_80067; DSSTox_GSID_43709; SCHEMBL29153; BSPBio_001032; MLS006010945; Veratraman-3-ol, 17,23-epoxy-, (3beta,23beta)-; Jervine, 11-deoxo- (7CI); DTXSID6043709; GTPL10328; AOB1606; EX-A952; BCPP000271; HMS1792D13; HMS1990D13; HMS3403D13; ZINC4098868; Tox21_300632; BDBM50232973; MFCD01735266; NSC734950; s1146; AKOS024456709; BCP9000568; CCG-208181; CS-0633; NSC 734950; NSC-734950; NCGC00163474-03; NCGC00163474-04; NCGC00163474-07; NCGC00254431-01; HY-17024; SMR001822854; CAS-4449-51-8; (3beta23R)-17,23-Epoxyveratraman-3-ol; AB0007896; 6832-EP2316832A1; 6832-EP2316833A1; C10798; W-5421; SR-05000002357; Veratraman-3-ol,23-epoxy-, (3-beta,23-beta)-; Q-200904; Q3271319; SR-05000002357-2; BRD-K58938839-001-03-8; (3alpha,8alpha,14beta,22S,23R)-17,23-epoxyveratraman-3-ol; Veratraman-3-ol, 17,23-epoxy-, (3-beta,23-beta)- (9CI); (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)-1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-Octadecahydro-3',6',10,11b-tetramethylspiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol; 11051-96-0; Spiro(9H-benzo(a)fluorene-9,2-b)pyridin)-3-o l, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octa deca hydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)-	Small molecule	1S/C27H41NO2/c1-15-11-24-25(28-14-15)17(3)27(30-24)10-8-20-21-6-5-18-12-19(29)7-9-26(18,4)23(21)13-22(20)16(27)2/h5,15,17,19-21,23-25,28-29H,6-14H2,1-4H3/t15-,17+,19-,20-,21-,23-,24+,25-,26-,27-/m0/s1	QASFUMOKHFSJGL-LAFRSMQTSA-N	CC1CC2C(C(C3(O2)CCC4C5CC=C6CC(CCC6(C5CC4=C3C)C)O)C)NC1	C27H41NO2	CAS 4449-51-8	CHEBI:4021	.	.	.	D05UKJ	.	.	.
NP5778	Rimonabant	CID: 104850	Rimonabant; 168273-06-1; Acomplia; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; Zimulti; SR141716; SR 141716; SR141716A; UNII-RML78EN3XE; A 281; Rimonabant free base; SR 141716A; SR-141716A; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; RML78EN3XE; CHEMBL111; Rimonabant (SR141716); SR-141716; Rimoslim; CHEBI:34967; 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-; NCGC00164572-01; [3H]SR141716A; 158681-13-1 (HCl); [3H]RIMONABANT; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidinopyrazole-3-carboxamide; DSSTox_CID_26453; DSSTox_RID_81627; DSSTox_GSID_46453; 5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-1-YLAMIDE; N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; Acomplia (TN); SMR003500713; CAS-168273-06-1; Rimonabant (JAN/USAN/INN); Rimonabant [USAN:INN:JAN]; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide; Rimonabant-d10; SR141,716A; 929221-88-5; Rimonabant - from sample; Rimonabant(SR141716); 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide; SCHEMBL38637; GTPL743; MLS004774043; MLS006011772; PYR405; DTXSID3046453; BDBM21278; EX-A688; HMS3604M05; HMS3657O15; BCP07803; ZINC1540228; Tox21_112200; AC-731; BBL030198; MFCD04034714; NSC791533; s3021; STK642500; AKOS005266728; Tox21_112200_1; AM84578; CCG-269385; CS-0645; DB06155; MCULE-7311256045; NSC-791533; SB19549; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1-piperidyl)pyrazole-3-carboxamide; NCGC00164572-02; AS-37280; HY-14136; SR-14171; AB0056959; AC-163720; DB-011649; B1429; FT-0631194; SW220167-1; 81R131; A11547; C14319; D05731; S-3507; AB01566860_01; 143881-EP2287165A2; 143881-EP2287166A2; 143881-EP2292620A2; A810956; L000572; Q412529; SR-01000884001; J-010440; SR-01000884001-1; (N-(Piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1-piperidinyl)-3-pyrazolecarboxamide; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-yl-pyrazole-3-carboxamide; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidino-1H-pyrazole-3-carboxamide; N-piperidino-5-(4-chlorophenyl)-1(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide; N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide; 1H-Pyrazole-3-carboxamide,5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-; 5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide; AY6	Small molecule	1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)	JZCPYUJPEARBJL-UHFFFAOYSA-N	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl	C22H21Cl3N4O	CAS 168273-06-1	CHEBI:34967	.	.	.	D0O3OS	.	.	.
NP5783	Toremifene	CID: 3005573	toremifene; Farestone; 89778-26-7; Toremifeno; Toremifenum; UNII-7NFE54O27T; GTx-006; Z-Toremifene; {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; 7NFE54O27T; CHEBI:9635; Toremifenum [Latin]; Toremifeno [Spanish]; 89778-26-7 (free base); 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Ethanamine, 2-(4-((1Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-; Toremifene Base; GTx 006; Toremifene [INN:BAN]; Estrimex; Toremifene (INN); C26H28ClNO; CCRIS 8745; (E)-Toremifene; 89778-29-0; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); SCHEMBL7465; CHEMBL1655; BIDD:PXR0202; BIDD:ER0222; BIDD:GT0211; GTPL4325; DTXSID3023689; BDBM58492; cid_3005572; HY-B0005A; HMS2090B22; HMS3714P06; BBL029023; DL-519; MFCD00801070; STK626445; ZINC12404516; AKOS005559276; AC-1751; CCG-220952; CS-1268; DB00539; 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethan-1-amine; Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-; MRF-0000351; NCGC00160530-02; NCGC00160530-13; J33.157K; K600; SBI-0206902.P001; 78T267; C08166; D08620; W-5124; 29515-EP2272827A1; 29515-EP2275420A1; 29515-EP2280012A2; 29515-EP2281815A1; 29515-EP2295055A2; 29515-EP2295416A2; 29515-EP2295426A1; 29515-EP2295427A1; 29515-EP2298748A2; 29515-EP2298764A1; 29515-EP2298765A1; 29515-EP2301933A1; 29515-EP2305640A2; 29515-EP2305642A2; 29515-EP2305671A1; 29515-EP2311453A1; 29515-EP2311808A1; 29515-EP2311825A1; 29515-EP2311827A1; 29515-EP2311829A1; 29515-EP2311840A1; 29515-EP2311842A2; AB00698360-07; AB00698360-09; AB00698360-10; AB00698360_11; AB00698360_12; A843306; Q3993743; SR-01000763502-5; BRD-K51350053-048-06-6; (2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; 2-[4-[(Z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-N,N-dimethyl-ethanamine; 2-[4-[(Z)-4-chloro-1,2-di(phenyl)but-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]ethyl-dimethyl-amine;citric acid; 2-[4-[(Z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-N,N-dimethyl-ethanamine;2-oxidanylpropane-1,2,3-tricarboxylic acid; 275360-73-1; T0R	Small molecule	1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-	XFCLJVABOIYOMF-QPLCGJKRSA-N	CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3	C26H28ClNO	CAS 89778-26-7	CHEBI:9635	.	.	.	D04VFJ	.	.	.
NP5811	Tetrodotoxin	CID: 11174599	TETRODOTOXIN; 4368-28-9; Tarichatoxin; Maculotoxin; Spheroidine; Tetrodontoxin; Fugu poison; CHEMBL507974; UNII-3KUM2721U9; Tetrodotoxine; Tetrodoxin; TTX; (1R,5R,6R,7R,9S,11S,12S,13S,14S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1~7,11~.0~1,6~]tetradec-3-ene-5,9,12,13,14-pentol (non-preferred name); Babylonia japonica toxin 1; tettrodotoxin; BJT 1; 3KUM2721U9; CCRIS 9328; HSDB 3543; 9SR; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; EINECS 224-458-8; BRN 0049176; 4-27-00-08206 (Beilstein Handbook Reference); SCHEMBL6406675; 5,9:7,10a-Dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-, (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-; BDBM50344821; ZINC13780673; (4R-(4alpha,4aalpha,5alpha,7alpha,9alpha,10alpha,10abeta,11S*,12S*))-Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d) pyrimidine-4,7,10,11,12-pentol; 5,9:7,10a-Dimethano-10ah-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-, (4R-(4alpha,4aalpha,5alpha,7alpha,9alpha,10alpha,10abeta,11S*,12S*))-; X5934; Q-100286; (1R,5R,6R,7R,9S,11S,12S,13S,14S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol; 10-hydroxymethyl-5-imino-(2S)-12,13-dioxa-4,6-diazatetracyclo[7.3.1.13,11.03,8]tetradecane-1,2,7,10,14-pentaol; 10-hydroxymethyl-5-imino-(2S)-12,13-dioxa-4,6-diazatetracyclo[7.3.1.13,11.03,8]tetradecane-1,2,7,10,14-pentaolCitrate; 5,9:7,10a-Dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-	Small molecule	1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3-,4-,5+,6-,7+,9+,10-,11+/m1/s1	CFMYXEVWODSLAX-QOZOJKKESA-N	C(C1(C2C3C(N=C(NC34C(C1OC(C4O)(O2)O)O)N)O)O)O	C11H17N3O8	CAS 4368-28-9	.	.	.	.	D0C7ET	.	.	.
NP5827	N-butylphthalide	CID: 61361	Butylphthalide; 6066-49-5; 3-n-Butylphthalide; 3-BUTYLPHTHALIDE; 3-butylisobenzofuran-1(3H)-one; 1(3H)-Isobenzofuranone, 3-butyl-; 3-N-BUTYLPHATHLIDE; Phthalide, 3-butyl-; N-butylphthalide; 3-Butyl-2-benzofuran-1(3H)-one; 3-n-Butylphthalide;3-Butylphthalide; (S)-3-Butyl-1(3H)-isobenzofuranone; 3-butyl-1,3-dihydro-2-benzofuran-1-one; 3-Butyl-1(3H)-isobenzofuranone; FEMA No. 3334; CCRIS 7107; Butylphthalide [INN]; EINECS 228-000-8; 3-butyl-3H-isobenzofuran-1-one; 3-butyl-3H-2-benzofuran-1-one; 3-butyl phthalide; ACMC-20mrif; (+/-)-butylphthalide; Rac-3-n-butylphthalide; Butylphthalide (Natural); dibutyl2,2-thiobisacetate; SCHEMBL716879; CHEMBL248594; DTXSID50863687; HMS3886B22; BCP30933; HY-B0647; MFCD01704513; s9263; AKOS005362658; CCG-266504; CS-3609; DB12749; 3-N-Butylphthalide, >=98% (HPLC); AK114739; AS-56990; 3-Butylphthalide pound>>3-n-Butylphthalide; 1(3H)-Isobenzofuranone, 3-butyl-, (R)-; FT-0698673; Y0018; C17854; 066B495; Q5003180; 93133-67-6	Small molecule	1S/C12H14O2/c1-2-3-8-11-9-6-4-5-7-10(9)12(13)14-11/h4-7,11H,2-3,8H2,1H3	HJXMNVQARNZTEE-UHFFFAOYSA-N	CCCCC1C2=CC=CC=C2C(=O)O1	C12H14O2	CAS 6066-49-5	.	.	.	.	.	.	.	.
NP5833	Dihydroartemisinin	CID: 3000518	Artenimol; Cotecxin; Dihydroartemisinine; Dihydroqinghaosu; Dihydroquinghaosu; Dihydroquinghoasu; VM3352; Artenimol (INN); JAV-110; GNF-PF-5634; (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol; [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin; 1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)	.	1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1	BJDCWCLMFKKGEE-ISOSDAIHSA-N	CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C	C15H24O5	CAS 71939-50-9	.	HBIN023813	SMIT08864	MOL007425	D0N6FH	.	.	.
NP5868	Salicylic acid	CID: 338	salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Rutranex; Salonil; Retarder W; Keralyt; Duoplant; Freezone; Saligel; Ionil; Psoriacid-S-stift; Benzoic acid, 2-hydroxy-; Stri-Dex; Salicylic acid soap; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech.; Kyselina salicylova; Clear away wart remover; Duofil wart remover; Domerine; Sebucare; Duofilm; Sebulex; Salicyclic acid; Ionil plus; Dr. Scholl's corn removers; Kyselina salicylova [Czech]; Dr. Scholl's callus removers; Dr. Scholl's wart remover kit; Kyselina 2-hydroxybenzoova; Occlusal; Acido salicilico [Italian]; Advanced pain relief corn removers; Caswell No. 731; 2-hydroxy-benzoic acid; Kyselina 2-hydroxybenzoova [Czech]; Advanced pain relief callus removers; Acido o-idrossibenzoico [Italian]; NSC 180; Salicylic acid & Sulfur Soap; MFCD00002439; CCRIS 6714; HSDB 672; AI3-02407; UNII-O414PZ4LPZ; EPA Pesticide Chemical Code 076602; BRN 0774890; Salicylic Acid-d4; CHEBI:16914; CHEMBL424; O414PZ4LPZ; MLS000069653; NSC180; Salicylic acid inclusion complex; K 537; NSC-180; ATA fraction 10, ammonium salt; NCGC00159447-05; SMR000059163; Mediplast pads; Salicylic acid, 99+%; Akurza Lotion; Hydrisalic Gel; Akurza Cream; Salex Lotion; Salex Cream; DSSTox_CID_6368; DuoPlant Gel; DHS Sal Shampoo; DSSTox_RID_78106; P&S Shampoo; DSSTox_GSID_26368; Salicylic acid [USAN:JAN]; Acido o-idrossibenzoico; Durasal; salicylic-acid; Salicylic acid, 99+%, ACS reagent; salicylicum acidum; CAS-69-72-7; Propa pH Peel-Off Acne Mask; NSC629474; phenol derivative, 7; Salicylic acid (TN); Benzoic acid, 2-hydroxy-, ion(1-); 2,3,4,5-tetradeuterio-6-hydroxybenzoic acid; EINECS 200-712-3; Salicylic acid [USP:JAN]; Azurechelin; Salicylic acid (6CI,8CI); Anti-blemish; Salicylic acid rs; hydroxy-benzoic acid; ortho-salicylic acid; CMC_13852; Fostex (Salt/Mix); Pernox (Salt/Mix); Duofilm Wart Remover; Phenol-2-carboxylate; Duofilm (Salt/Mix); Salicylic Acid,(S); Sebulex (Salt/Mix); 2-hydroxobenzoic acid; Domerine (Salt/Mix); Sebucare (Salt/Mix); 2-Hydroxybenzoate, I; Natural Salicylic Acid; o-hydroxy benzoic acid; 2-hydroxy benzoic acid; Spectrum_000948; ACMC-1AZIK; Opera_ID_582; Salicylic acid ACS grade; [O]C(=O)c1ccccc1O; WLN: QVR BQ; Benzoic acid, o-hydroxy-; Bazuka Extra Strength Gel; 2-Hydroxybenzenecarboxylate; bmse000252; Epitope ID:124929; Retarder SAX (Salt/Mix); UPCMLD-DP126; EC 200-712-3; SCHEMBL1967; Oprea1_040343; KBioSS_001428; ARONIS27188; BIDD:ER0602; DivK1c_000301; Salicylic acid (JP17/USP); 2-Hydroxybenzoic Acid, Natural; FEMA3985; GTPL4306; SGCUT00012; ZINC1554; Salicylic acid, >=99%, FG; Salicylic acid, LR, >=99%; component of Tinver (Salt/Mix); DTXSID7026368; FEMA NO. 3985; UPCMLD-DP126:001; BDBM26193; component of Keralyt (Salt/Mix); KBio1_000301; KBio2_001428; KBio2_003996; KBio2_006564; Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); E9A559BE-383B-4F83-BC02-3031D03D558A; NINDS_000301; HMS2233A10; HMS3373M19; HMS3885B08; KUC106694N; Salicylic acid, p.a., 99.0%; Benzoic acid, 2-hydroxy- (9CI); BCP09067; HY-B0167; to_000004; Lamivudine impurity, salicylic acid-; Tox21_113453; Tox21_201471; Tox21_303109; ANW-43703; s4539; SBB052826; STK258681; AKOS000118979; Salicylic acid, BioXtra, >=99.0%; CCG-212792; DB00936; MCULE-8407868694; NE10196; IDI1_000301; SMP2_000145; NCGC00159447-02; NCGC00159447-04; NCGC00159447-06; NCGC00257065-01; NCGC00259022-01; AK112186; BP-12826; KSC-11-207-4; Lamivudine related compound salicylic acid; Salicylic acid & Sulfur Soap (Salt/Mix); Salicylic acid, ACS reagent, >=99.0%; Salicylic acid, plant cell culture tested; Salicylic acid, ReagentPlus(R), >=99%; TS-03583; Salicylic Acid 1.0 mg/ml in Acetonitrile; SBI-0051510.P003; FT-0645123; FT-0674502; FT-0674503; Salicylic acid, tested according to Ph.Eur.; ST51046715; Salicylic acid, SAJ first grade, >=99.0%; 3253-EP2269610A2; 3253-EP2269988A2; 3253-EP2270002A1; 3253-EP2270006A1; 3253-EP2270008A1; 3253-EP2270011A1; 3253-EP2270113A1; 3253-EP2272935A1; 3253-EP2275401A1; 3253-EP2275413A1; 3253-EP2275420A1; 3253-EP2277867A2; 3253-EP2280003A2; 3253-EP2280008A2; 3253-EP2280010A2; 3253-EP2281563A1; 3253-EP2281816A1; 3253-EP2284146A2; 3253-EP2284147A2; 3253-EP2284160A1; 3253-EP2284178A2; 3253-EP2284179A2; 3253-EP2287156A1; 3253-EP2289510A1; 3253-EP2289883A1; 3253-EP2289890A1; 3253-EP2292592A1; 3253-EP2292597A1; 3253-EP2292617A1; 3253-EP2295053A1; 3253-EP2295401A2; 3253-EP2295416A2; 3253-EP2295424A1; 3253-EP2295433A2; 3253-EP2298734A2; 3253-EP2298735A1; 3253-EP2298748A2; 3253-EP2298757A2; 3253-EP2298758A1; 3253-EP2298759A1; 3253-EP2298764A1; 3253-EP2298765A1; 3253-EP2301931A1; 3253-EP2301937A1; 3253-EP2301940A1; 3253-EP2305243A1; 3253-EP2305248A1; 3253-EP2305257A1; 3253-EP2305646A1; 3253-EP2305651A1; 3253-EP2305655A2; 3253-EP2305662A1; 3253-EP2305663A1; 3253-EP2305664A1; 3253-EP2305675A1; 3253-EP2308851A1; 3253-EP2308854A1; 3253-EP2308873A1; 3253-EP2308875A1; 3253-EP2311807A1; 3253-EP2311809A1; 3253-EP2311810A1; 3253-EP2311814A1; 3253-EP2311831A1; 3253-EP2311842A2; 3253-EP2314574A1; 3253-EP2314588A1; 3253-EP2316457A1; 3253-EP2316458A1; 3253-EP2316459A1; 3253-EP2316825A1; 3253-EP2316826A1; 3253-EP2316827A1; 3253-EP2316828A1; 3253-EP2316836A1; 3253-EP2372017A1; 3253-EP2380874A2; C00805; D00097; Salicylic acid, Vetec(TM) reagent grade, 98%; 44642-EP2281819A1; 44642-EP2292619A1; 44642-EP2305659A1; 44642-EP2311818A1; AB00489876_15; BENZOIC ACID,2-HYDROXY   SALICYLIC ACID; Salicylic acid, puriss. p.a., >=99.0% (T); 197900-EP2269975A2; 197900-EP2269997A2; 197900-EP2275415A2; Q193572; component of Solarcaine first aid spray (Salt/Mix); J-509667; component of Fostex medicated bar and cream (Salt/Mix); F2191-0216; Salicylic acid, certified reference material, TraceCERT(R); UNII-I3P9R8317T component YGSDEFSMJLZEOE-UHFFFAOYSA-N; Salicylic acid, British Pharmacopoeia (BP) Reference Standard; Salicylic acid, European Pharmacopoeia (EP) Reference Standard; Salicylic acid, United States Pharmacopeia (USP) Reference Standard; Salicylic acid, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; Salicylic acid, Pharmaceutical Secondary Standard; Certified Reference Material; 8052-31-1; Salicylic acid, meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (calc. to the dried substance)	Small molecule	1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)	YGSDEFSMJLZEOE-UHFFFAOYSA-N	C1=CC=C(C(=C1)C(=O)O)O	C7H6O3	CAS 69-72-7	CHEBI:16914	.	.	.	D07HBX	.	.	.
NP5888	Cucurbitacin B	CID: 5281316	Cucurbitacin B; 6199-67-3; Datisca principle B; Datiscn Principle B; 1,2-Dihydro-alpha-elaterin; UNII-0115W5MABF; 0115W5MABF; CHEBI:3941; CUCURBITACIN R - DATISCA PRINCIPLE B; NSC49451; Cucurbitacin-B; Cucurbitacin B hydrate; [(E,6R)-6-[(2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate; Cucurbitacine (B); Cucurbitacine B; (R,E)-6-((2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; MLS002702988; HSDB 3476; 19-nor-9.beta.,23-diene-3,11,22-trione, 9-methyl-2.beta.,16.alpha.,20,25-tetrahydroxy-, 25-acetate; 19-Norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23E)-; C32H46O8; NSC 49451; NSC 144154; cucurbitacin B derivatives; SCHEMBL231815; CHEMBL508185; HY-N0416; ZINC4097797; LMST01010104; MFCD07778083; NSC-49451; NSC144154; s8165; AKOS015897085; CCG-270043; CS-3816; NSC-144154; 25-(Acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-5,23-diene-3,11,22-trione; 19-Nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 2beta,16alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23E)-; Cucurbitacin B hydrate, >=97% (HPLC); N2787; X1115; C08794; 199C673; Q-100715; Q27106259; UNII-W3RWP6CB48 component IXQKXEUSCPEQRD-DKRGWESNSA-N; (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate; (3E,6R)-6-[(1R,2R,4S,10S,11S,13R,14R,15R)-4,13-dihydroxy-1,6,6,11,15-pentamethyl-5,17-dioxotetracyclo[8.7.0.0?,?.0??,??]heptadec-7-en-14-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; 19-Nor-9-beta,10-alpha-lanosta-5,23-diene-3,11,22-trione, 2-beta,16-alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, [2.beta.,.gamma.,.beta.,10.alpha.,16.alpha.]-; 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23E)- (9CI); 2beta,16alpha,20,25-tetrahydroxy-9-methyl-19-nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 25-acetate; 2beta,16alpha,20,25-tetrahydroxy-9-methyl-3,11,22-trioxo-19-nor-9beta,10alpha-lanosta-5,23-dien-25-yl acetate	Small molecule	1S/C32H46O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,12-13,19-22,25,34-35,39H,11,14-16H2,1-9H3/b13-12+/t19-,20+,21-,22+,25+,29+,30-,31+,32+/m1/s1	IXQKXEUSCPEQRD-DKRGWESNSA-N	CC(=O)OC(C)(C)C=CC(=O)C(C)(C1C(CC2(C1(CC(=O)C3(C2CC=C4C3CC(C(=O)C4(C)C)O)C)C)C)O)O	C32H46O8	CAS 6199-67-3	CHEBI:3941	.	.	.	.	.	.	.
NP5891	Pristimerin	CID: 159516	Celastrol-methylether; Pristimerine; GNF-PF-476; UNII-28ZK7PR57S; CHEBI:8416; Celastrol methyl ester; 28ZK7PR57S; MFCD01711331; methyl (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylate; (9b,13a,14b,20a)-3-Hydroxy-9,13-dimethyl-2-oxo-24,25,26 -trinoroleana-1(10),3,5,7-tertraen-29-oic acid methyl ester; C30H40O4; methyl (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate; Spectrum_001558; SpecPlus_000649; Spectrum2_000546; Spectrum3_001651; Spectrum4_001681; Spectrum5_000322; 24-Nor-D:A-friedooleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-2-oxo-, methyl ester; SCHEMBL15020; BSPBio_003401; KBioGR_001942; KBioSS_002038; CHEMBL54804; DivK1c_006745; SPECTRUM1504181; SPBio_000591; MEGxp0_000269; DTXSID5044027; ACon0_000836; KBio1_001689; KBio2_002038; KBio2_004606; KBio2_007174; KBio3_002621; HY-N1937; ZINC4097723; BDBM50481947; CCG-38723; s9404; AKOS032960306; CS-6257; SDCCGMLS-0066814.P001; NCGC00178090-01; NCGC00178090-03; B7488; X1210; C08633; Q-100112; Q27108073; (9?,13?,14?,20?)-3-Hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid methyl ester; D:A-Friedo-24-noroleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-2-oxo-, methyl ester, (20alpha)- (9CI)	.	1S/C30H40O4/c1-18-19-8-9-22-28(4,20(19)16-21(31)24(18)32)13-15-30(6)23-17-27(3,25(33)34-7)11-10-26(23,2)12-14-29(22,30)5/h8-9,16,23,32H,10-15,17H2,1-7H3/t23-,26-,27-,28+,29-,30+/m1/s1	JFACETXYABVHFD-WXPPGMDDSA-N	CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)OC)C)C)C)C)O	C30H40O4	CAS 1258-84-0	.	HBIN040737	SMIT05556	MOL003497	.	.	.	.
NP5948	Breviscapine	CID: 6426802	Breviscapine; Scutellarein 7-beta-D-glucuronide; 116122-36-2; SCHEMBL16519697; 6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; AK111245; DB-047268; FT-0630536; A819175; 6-[[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-1-benzopyran-7-yl]oxy]-3,4,5-trihydroxy-2-oxanecarboxylic acid; 6-[2-(4-hydroxyphenyl)-5,6-bis(oxidanyl)-4-oxidanylidene-chromen-7-yl]oxy-3,4,5-tris(oxidanyl)oxane-2-carboxylic acid; 6-{[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid	Small molecule	1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30)	DJSISFGPUUYILV-UHFFFAOYSA-N	C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O	C21H18O12	.	.	.	.	.	.	.	.	.
NP6047	Metformin	CID: 4091	1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metformine; Metiguanide; Dimethylbiguanide; Haurymelin; Fluamine; Flumamine; Gliguanid; Diabex; Melbin; N,N-Dimethylbiguanide; Glumetza; Imidodicarbonimidic diamide, N,N-dimethyl-; N1,N1-Dimethylbiguanide; DMGG; NNDG; N,N-Dimethyldiguanide; 1,1-Dimethyl biguanide; LA-6023; BIGUANIDE, 1,1-DIMETHYL-; 3-(diaminomethylidene)-1,1-dimethylguanidine; Fortamet; UNII-9100L32L2N; CHEMBL1431; CHEBI:6801; Glifage; Islotin; Siofor; Dimethyldiguanide; Diaformin; 9100L32L2N; Metformina [DCIT]; Metforminum; Metformina; Metformina [Spanish]; Metformine [INN-French]; Metforminum [INN-Latin]; Metformin [USAN:INN:BAN]; MLS000028493; [14C]metformin; [14C]-metformin; C4H11N5; 657M249; Metformin (USAN/INN); NCGC00016564-01; SMR000058277; EINECS 211-517-8; CAS-1115-70-4; Dianben; Obimet; Dimethylbiguanid; Metformin base; CCRIS 9321; N-dimethylbiguanide; DMBG; Glucophage (Salt/Mix); n',n'-dimethylbiguanide; Imidodicarbonimidic diamide-, N,N-dimethyl-; Prestwick0_000004; Prestwick1_000004; Prestwick2_000004; Prestwick3_000004; DSSTox_CID_3270; N,N-Dimethylguanylguanidin; SCHEMBL8944; DSSTox_RID_76950; DSSTox_GSID_23270; BSPBio_000007; BSPBio_002314; KBioGR_002310; KBioSS_002312; cid_14219; LA 6023 (Salt/Mix); BIDD:GT0697; SPBio_001928; BPBio1_000009; GTPL4503; GTPL4779; SCHEMBL9913821; DTXSID2023270; SCHEMBL10276396; BDBM57047; KBio2_002310; KBio2_004878; KBio2_007446; KBio3_002790; cMAP_000016; HMS2089D19; HY-B0627; Tox21_302370; BBL012337; BDBM50229665; HSCI1_000295; s5958; STK011633; STL483693; STL484070; ZINC12859773; AKOS000121065; AKOS005206848; AKOS015966566; CCG-102605; DB00331; MCULE-7393156510; 3-carbamimidoyl-1,1-dimethyl-guanidine; AC-32484; AS-65365; CAS-657-24-9; K070; SBI-0206876.P001; 1-carbamimidamido-N,N-dimethylmethanimidamide; CS-0009563; FT-0628266; A19551; C07151; D04966; Q19484; (E)-3-[Amino(dimethylamino)methylidene]guanidine; 1-[(E)-amino(dimethylamino)methylidene]guanidine; W-109589; 	Small molecule	1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)	XZWYZXLIPXDOLR-UHFFFAOYSA-N	CN(C)C(=N)N=C(N)N	C4H11N5	CAS 657-24-9	.	.	.	.	D0D8RC	.	.	.
NP6054	Selenium	CID: 6326970	7782-49-2; Se; Selenium; SELENIUM ATOM; Selenium and compounds; Elemental selenium; Selenium elemental; Selenium, elemental; Selen; SELENIUM COMPOUNDS; Selenium dihydride; SELENIUM POWDER; Hydrogen selenide (H2Se); UNII-H6241UJ22B; MFCD00134090; UNII-V91P54KPAM; H6241UJ22B; Vandex; Gray selenium; Selenium alloy; Selenium base; Selenium dust; Selenium, 99+%, powder; Colloidal selenium; Selen [Polish]; Selenium, metallic; Selenium homopolymer; Selenium, colloidal; Caswell No. 732; selenio; Selenium anhydride; Electronic E-2; Selenium metallicum; Selenium, 99.5+%, powder, 200 mesh; CCRIS 4250; HSDB 4493; EINECS 231-957-4; UN2658; EPA Pesticide Chemical Code 072001; Selenium compounds, n.o.s.; CI 77805; Selenium standard solution, for AAS, 1 mg-ml Se in 10% HCl; Selenium and selenium compounds; HSDB 548; C.I. 77805; Selenium, powder; EINECS 231-978-9; Selenium shot, 4N; UN2202; UN3283; ACMC-20ajqt; Dihydrogen monoselenide; selenium (iv) hydride; Selenium hydride (SeH2); 34Se; EC 231-957-4; Selenium, powder, 99+%; Selenium compound, n.o.s.; Hydrogen selenide, anhydrous; Selenium powder, -200 mesh; Selenium powder, -325 mesh; Selenium, p.a., 99.5%; CHEMBL1235891; DTXSID9021261; CHEBI:27568; HSDB 6909; DTXSID20872822; Selenium Nanopowder in aq. media; 8988AF; MFCD00011224; DB11135; Selenium, pellets, < 5mm, >=99.999%; FT-0701285; Selenium ingot/button, ~38mm (1.5in) dia; C01529; Selenium powder [UN2658]  [Keep away from food]; Selenium shot, amorphous, 1-5mm (0.04-0.20in); Selenium, foil, 25x25mm, thickness 3mm, 99.95%; Hydrogen selenide, anhydrous [UN2202]  [Poison gas]; S008000000; Selenium, plasma standard solution, Specpure, Se 10g/ml; Selenium, shots, 99.99999% (7N), diameter 2-4 mm; Selenium, AAS standard solution, Specpure?, Se 1000?g/ml; Selenium, ingot, 99.9999% diameter 20 mm, length 55 mm; Selenium, pellets, <5 mm, >=99.99% trace metals basis; Selenium, powder, -100 mesh, >=99.5% trace metals basis; Selenium, powder, -100 mesh, 99.99% trace metals basis; Selenium, plasma standard solution, Specpure?, Se 1000?g/ml; Selenium, ingot, 99.99999% (7N), diameter 20 mm, length 55 mm; Selenium, Oil based standard solution, Specpure?, Se 1000?g/g; Selenium, plasma standard solution, Specpure?, Se 10,000?g/ml; Selenium compound, n.o.s. [UN3283]  [Poison, Keep away from food]; Selenium, lump, 3 mm max. lump size, weight 100 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 20 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 50 g, high purity 99.999%; Selenium, pellets, <5 mm particle size, >=99.999% trace metals basis; Selenium shot, amorphous, 2-6mm (0.08-0.2in), Puratronic(R), 99.999% (metals basis); Selenium, powder, 250 max. part. size (micron), purity 99.95%, weight 100 g; Selenium, powder, 250 max. part. size (micron), weight 50 g, purity 99.95%; Selenium, powder, max. particle size 250 micron, weight 200 g, purity 99.95%; Se0; Selenium atomic spectroscopy standard concentrate 1.00 g Se, 1.00 g/L, for 1L standard solution, analytical standard	Small molecule	1S/Se	BUGBHKTXTAQXES-UHFFFAOYSA-N	[Se]	Se	CAS 7782-49-2	CHEBI:27568	.	.	.	.	.	.	.
NP6084	Resveratrol	CID: 445154	Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime; ,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol	.	1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O	C14H12O3	CAS 501-36-0	.	HBIN042111	SMIT00323	MOL012744	D0U3EP	.	2769	.
NP6128	Gossypol	CID: 3503	(-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate	.	1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3	QBKSWRVVCFFDOT-UHFFFAOYSA-N	CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O	C30H30O8	CAS 20300-26-9	.	HBIN028351	SMIT15675	.	D0Z0HH	.	.	.
NP6132	Betulin	CID: 72326	Betulin; 473-98-3; Betulinol; Betuline; Trochol; Betulol; Lup-20(29)-ene-3beta,28-diol; Lup-20(29)-ene-3b,28-diol; UNII-6W70HN7X7O; NSC 4644; 6W70HN7X7O; CHEBI:3086; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(Hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; Betulinic alcohol; NSC-4644; MFCD00016802; Lup-20(30)-ene-3beta,28-diol; (1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-5-(hydroxymethyl)-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0^{2,10}.0^{5,9}.0^{14,19}]henicosan-17-ol; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol; SR-05000002167; EINECS 207-475-5; NSC4644; AI3-62999; NSC692218; Lup-20(29)-ene-3,28-diol, (3beta)-; (3beta)-lup-20(29)-ene-3,28-diol; Betulin, 23; Betulin, >=98%; Prestwick3_000990; Betulinol (obsol pound(c); Betulin, analytical standard; BSPBio_001059; ARONIS24303; CHEMBL23236; SCHEMBL131739; BPBio1_001165; MEGxp0_001726; ACon1_000091; BDBM23207; DTXSID101019934; HMS2098E21; EX-A3354; HY-N0083; ZINC3978650; s4754; SBB080743; Lup-20(29)-ene-3 ,28-diol; AKOS005267212; ACN-035289; CCG-208619; CS-6156; GS-3254; LMPR0106140005; NSC-692218; NCGC00168803-01; NCGC00168803-02; NCGC00168803-04; AB00513988; B0803; N1290; V0184; (3.beta.)-Lup-20(29)-ene-3,28-diol; C08618; Lup-20(29)-ene-3,28-diol, (3-beta)-; S-1793; 473B983; Q419726; Q-100501; SR-05000002167-2; SR-05000002167-3; BRD-K64874225-001-01-3; NCGC00168803-04_C30H50O2_Lup-20(29)-ene-3,28-diol, (3beta)-; (1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-5-(hydroxymethyl)-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0(2),(1)?.0?,?.0(1)?,(1)?]henicosan-17-ol; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3 a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; (5S,17S,1R,2R,8R,9R,10R,13R,14R,19R)-5-(hydroxymethyl)-1,2,14,18,18-pentamethy l-8-(1-methylvinyl)pentacyclo[11.8.0.0<2,10>.0<5,9>.0<14,19>]henicosan-17-ol	Small molecule	1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3/t20-,21+,22-,23+,24-,25+,27-,28+,29+,30+/m0/s1	FVWJYYTZTCVBKE-ROUWMTJPSA-N	CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)CO	C30H50O2	CAS 473-98-3	CHEBI:3086	.	.	.	D05KJY	.	.	.
NP6152	Apocynin	CID: 2214	Acetovanillone; apocynin; 498-02-2; 4'-Hydroxy-3'-methoxyacetophenone; 1-(4-Hydroxy-3-methoxyphenyl)ethanone; Acetoguaiacone; Apocynine; Acetoguaiacon; 4-Acetyl-2-methoxyphenol; Ethanone, 1-(4-hydroxy-3-methoxyphenyl)-; Acetovanilone; Acetovanyllon; 3-Methoxy-4-hydroxyacetophenone; Acetovanillon; 4-HYDROXY-3-METHOXYACETOPHENONE; 4-Hydroxy-3-methoxyphenyl methyl ketone; 1-(4-hydroxy-3-methoxyphenyl)ethan-1-one; Acetophenone, 4'-hydroxy-3'-methoxy-; NSC 209524; UNII-B6J7B9UDTR; EINECS 207-854-5; BRN 0637373; 3-Metoksy-4-hydroksyacetofenon; 2-methoxy-4-acetylphenol; B6J7B9UDTR; CHEBI:2781; MFCD00008747; NSC-209524; Acetovanillone, 98%; 1-(4-hydroxy-3-methoxy-phenyl)-ethanone; WLN: 1VR DQ CO1; 1-acetyl-4-hydroxy-3-methoxybenzene; CCRIS 7285; 3-Metoksy-4-hydroksyacetofenon [Polish]; AI3-15892; 4-Acetylguaiacol; PubChem3315; Vanilloyl methyl ketone; 1-(4-hydroxy-3-methoxy-phenyl)ethanone; ACMC-1AHLR; apocynin (acetovanillone); bmse000584; bmse010031; AURORA KA-3667; Phenol, 4-acetyl-2-methoxy; 4-08-00-01814 (Beilstein Handbook Reference); MLS001304972; SCHEMBL109514; 4-hydroxy3-methoxyacetophenone; 4hydroxy-3-methoxyacetophenone; Acetovanillone, >=98%, FG; CHEMBL346919; DTXSID7060097; TIMTEC-BB SBB008060; 4-hydroxy -3-methoxyacetophenone; NSC2146; Acetovanillone, analytical standard; HMS3651H03; ZINC162515; 3'-Methoxy-4'-hydroxyacetophenone; HY-N0088; NSC-2146; STR03975; AKOS BBS-00003229; ANW-30844; BBL009710; NSC209524; s2425; SBB008060; STL141075; ZINC00162515; AKOS000120562; 4-Hydroxy-3-methoxyphenyl methyl keton; AS03910; CCG-266327; CM10957; CS-5647; DB12618; FS-3673; MCULE-4549346345; 1-(4-hydroxy-3-methoxyphenyl)-ethanone; NCGC00247065-01; 4'-Hydroxy-3'-methoxyacetophenone, 98%; AC-29981; AK-42915; L911; SMR000752909; 1-(4-Hydroxy-3-methoxyphenyl)-1-ethanone; AM20090774; FT-0618638; ST50213415; SW219526-1; A11989; C11380; M-6166; 21432-EP2311824A1; 21432-EP2314295A1; AA-504/20839006; Q414754; Q-200477; ACETOPHENONE,4-HYDROXY,3-METHOXY   ACETOVANILLON; F2191-0004; 4 inverted exclamation marka-Hydroxy-3 inverted exclamation marka-methoxyacetophenone; 16522-48-8; I75	Small molecule	1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3	DFYRUELUNQRZTB-UHFFFAOYSA-N	CC(=O)C1=CC(=C(C=C1)O)OC	C9H10O3	CAS 498-02-2	CHEBI:2781	.	.	.	.	.	.	.
NP6160	Cyanidin-3-O-glucoside chloride	CID: 197081	Kuromanine; 7084-24-4; Chrysontemin; Glucocyanidin; Cyanidin 3-glucoside; Cyanidin-3-glucoside chloride; Kuromanin chloride; Cyanidol 3-glucoside; Kuromanin (chloride); Cyanidin 3-monoglucoside; UNII-8X15R84UEM; CYANIDIN 3-GLUCOSIDE CHLORIDE; Chrysanthemin; cyanidin-3-glucoside; 8X15R84UEM; 2-(3,4-Dihydroxyphenyl)-3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-1-benzopyrylium chloride; cyanidin-3-O-glucoside; cyanidin-3-o-glucoside chloride; Cyanidine 3-glucoside; KUROMANIN; Cyanidin 3 glucoside; EINECS 230-384-7; Chrysanthemin (6CI,8CI); 47705-70-4; SCHEMBL158216; (2S,3R,4S,5S,6R)-2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride; HY-N0640; MFCD27665410; Cyanidin 3-O-glucopyranoside chloride; cyanidin-3-O-beta-d-galactopyranoside; AKOS022185309; CS-5203; 1-Benzopyrylium, 2-(3,4-dihydroxyphenyl)-3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-, chloride; 1-Benzopyrylium, 5,7-dihydroxy-2-(3,4-dihydroxyphenyl)-3-(beta-D-glucopyranosyloxy)-, chloride; AS-56225; N2562; Q-100788; Q5114535; UNII-F02KPB2508 component YTMNONATNXDQJF-UBNZBFALSA-N; UNII-R911H793SU component YTMNONATNXDQJF-UBNZBFALSA-N; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)chromenylium	Small molecule	1S/C21H20O11.ClH/c22-7-16-17(27)18(28)19(29)21(32-16)31-15-6-10-12(25)4-9(23)5-14(10)30-20(15)8-1-2-11(24)13(26)3-8;/h1-6,16-19,21-22,27-29H,7H2,(H3-,23,24,25,26);1H/t16-,17-,18+,19-,21-;/m1./s1	YTMNONATNXDQJF-UBNZBFALSA-N	C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2OC4C(C(C(C(O4)CO)O)O)O)O)O)O)O.[Cl-]	C21H21ClO11	CAS 7084-24-4	.	.	.	.	.	.	.	.
NP6170	Ceramide	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP6205	Asiatic acid	CID: 119034	Asiatic acid; 464-92-6; Dammarolic acid; UNII-9PA5A687X5; MFCD00238541; NSC 166063; Asiantic acid; CHEBI:2873; CHEMBL404313; 9PA5A687X5; 2,3,23-trihydroxyurs-12-en-28-oic acid; Asiatic-acid; HSDB 7662; NSC-166063; Asiatic acid, 97%; SCHEMBL3285999; 2alpha,23-Dihydroxyursolic acid; Asiatic acid, analytical standard; DTXSID901019207; HY-N0194; ZINC8221271; BDBM50241487; AKOS007930256; Urs-12-en-28-oic acid, 2,3,23-trihydroxy-, (2.alpha.,3.beta.,4.alpha.)-; CCG-208549; DB14054; MCULE-1974040943; NCGC00346584-02; CS-0007893; N1356; V1794; C08617; 464A926; Q-100489; Asiatic acid, >=98% (HPLC), from Centella asiatica; BRD-K35079116-001-03-3; Q15478109; (2alpha,3beta)-2,3,23-trihydroxyurs-12-en-28-oic acid; (4alpha)-2alpha,3beta,23-trihydroxy-urs-12-en-28-oic acid; (2alpha,3beta,5beta,20beta)-2,3,23-trihydroxyurs-12-en-28-oic acid; (4I+/-)-a?I+/-,a?I(2),a?3-atrihydroxy-aurs-a?2-aen-a?8-aoic acid; Urs-12-en-28-oic acid, 2,3,23-trihydroxy-, (2alpha,3beta,4alpha)-; Urs-12en-28-oic acid, 2,3,23-trihydroxy-, (2alpha, 3beta, 4alpha)-; (1S,2R,4aS,6aS,6bR,8aR,9R,10R,11R,12aR,12bR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid; 0AS	Small molecule	1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1	JXSVIVRDWWRQRT-UYDOISQJSA-N	CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)CO)O)O)C)C)C2C1C)C)C(=O)O	C30H48O5	CAS 464-92-6	CHEBI:2873	.	.	.	D0LC7K	.	.	.
NP6258	Nafamostat mesylate	CID: 5311180	Nafamostat mesylate; 82956-11-4; Futhan; nafamostat mesilate; FUT-175; Nafamostat (mesylate); 82956-11-4 (mesylate); 6-amidino-2-naphthyl 4-guanidino-benzoate dimethanesulphonate; 6-Carbamimidoylnaphthalen-2-yl 4-guanidinobenzoate dimethanesulfonate; Nafamstat; Nafamostat Mesylate(FUT-175); UNII-1D2T74921W; 6-Amidino-2-naphthyl 4-guanidinobenzoate dimethanesulfonate; (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate;methanesulfonic acid; 6-[amino(imino)methyl]-2-naphthyl 4-{[amino(imino)methyl]amino}benzoate dimethanesulfonate; Benzoic acid, 4-[(aminoiminomethyl)amino]-, 6-(aminoiminomethyl)-2-naphthalenyl ester, dimethanesulfonate; Nafamostat dimethanesulfonate; Nafamostat mesylate (USAN); Nafamstat Mesilate; 1D2T74921W; Ronastat (TN); MFCD00941430; 6-Amidino-2-naphthyl-4-guanidinobenzoate Dimethanesulfonate; Nafamostat mesilate (JP17); cc-149; SCHEMBL1568755; CHEMBL3989553; HY-B0190A; AMY8859; EBD7026; HMS3654J21; 6-Amidino-2-naphthyl 4-Guanidinobenzoate Bis(methanesulfonate); ACT04728; BCP04841; C19H17N5O2.2CH3SO3H; AC-984; CN0030; KM2146; s1386; 4-Guanidinobenzoic Acid 6-Amidino-2-naphthyl Ester Bis(methanesulfonate); AKOS015852498; Nafamostat mesylate, >=98% (HPLC); CCG-207877; HS-0059; S25N102; AK468861; M731; FT-0601583; N0959; SW219392-1; D01670; J-518196; Q27252259; 4-[(Aminoiminomethyl)amino]benzoic acid 6-(aminoiminomethyl)-2-naphthalenyl ester dimethanesulfonate	Small molecule	1S/C19H17N5O2.2CH4O3S/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23;2*1-5(2,3)4/h1-10H,(H3,20,21)(H4,22,23,24);2*1H3,(H,2,3,4)	SRXKIZXIRHMPFW-UHFFFAOYSA-N	CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N	C21H25N5O8S2	CAS 82956-11-4	.	.	.	.	.	.	.	.
NP6293	Myo-inositol	CID: 892	inositol; myo-inositol; Scyllo-inositol; Muco-Inositol; epi-Inositol; Allo-inositol; i-Inositol; meso-Inositol; 87-89-8; Neo-inositol; 1D-Chiro-inositol; 1L-Chiro-inositol; cis-Inositol; D-chiro-Inositol; Myoinositol; 643-12-9; 488-59-5; Scyllitol; D-(+)-chiro-Inositol; Cyclohexane-1,2,3,4,5,6-hexaol; 6917-35-7; mesoinositol; Meat sugar; cyclohexane-1,2,3,4,5,6-hexol; Myoinosite; Quercinitol; Dambose; 488-58-4; Cocositol; Inositene; Inositina; Phaseomannite; Inosital; Inosite; Iso-inositol; 551-72-4; L-chiro-Inositol; Cyclohexitol; Phaseomannitol; Mesoinosit; Mesoinosite; Scyllite; Mesovit; Nucite; Mesol; chiro-inositol; Cyclohexanehexol; Inositol, meso-; Inositol, myo-; Hexahydroxycyclohexane; L-Inositol; 41546-34-3; D-myo-Inositol; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; 643-10-7; Bios I; Insitolum; Isoinositol; (-)-Inositol; L-myo-Inositol; Inositol, i-; L-(-)-chiro-Inositol; Inositol (VAN); 488-55-1; Inositol, allo-; Inositol, muco-; 1D-myo-Inositol; 1L-myo-Inositol; 488-54-0; 1,2,3,4,5,6-Cyclohexanehexol; Rat antispectacled eye factor; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; MFCD00077932; Levoinositol; CCRIS 6745; AZD 103; Inositol, epi-; 576-63-6; Inositol, scyllo-; UNII-63GQX5QW03; UNII-8LQ63P85IC; UNII-9O6Y5O4P9W; UNII-R1Y9F3N15A; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; ELND005; 1,3,5/2,4,6-Hexahydroxycyclohexane; UNII-4661D3JP8D; UNII-6R79WV4R10; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1-L-chiro-Inositol; (-)-chiro-Inositol; UNII-1VS4X81277; CHEBI:17268; AI3-16111; NSC8101; 1,3,5/2,4,6-cyclohexanehexol; UNII-4L6452S749; UNII-587A93P465; 1,2,3,5/4,6-Cyclohexanehexol; NSC 8101; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; MFCD00065455; NSC404118; Inositol, myo- (8CI); myo-Inositol;meso-Inositol; 1,2,3,4,5,6-Hexahydroxycyclohexane; NSC 404118; 63GQX5QW03; 8LQ63P85IC; 9O6Y5O4P9W; R1Y9F3N15A; (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; MI; CHEBI:10642; CHEBI:23927; CHEBI:27372; CHEBI:27987; 4661D3JP8D; 6R79WV4R10; Inositol (VAN8C; NSC-8101; NSC45517; NSC55551; NSC55552; NSC-25142; NSC-55551; UNII-M94176HJ2F; 1VS4X81277; NSC-404118; INS; Inositol, 98+%; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; NCGC00159409-02; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexaol; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 4L6452S749; 587A93P465; DSSTox_CID_3146; D-chiro Inositol; DSSTox_RID_76890; DSSTox_GSID_23146; 1,3,4,5,6-Cyclohexanehexol; 1,3,5/4,6-Cyclohexanehexol; alloinositol; neoinositol; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1,2,4/3,5,6-cyclohexanehexol; rel-(1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-hexaol; rel-(1R,2r,3S,4R,5s,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; Mouse antialopecia factor; 1,2,3,4,5,6-Cyclohexanehexol #; cis-1,2,3,4,5,6-cyclohexanehexol; Inositol, cis-; Inositol, neo-; CAS-87-89-8; cis-1,3,5-trans-4,6-Cyclohexanehexol; SMR000857145; SMR000857319; SMR000857320; M94176HJ2F; (+)-Inositol; Inositol NF 12; SR-05000001655; Chiro-inositol, (-)-; EINECS 201-781-2; inositols; Matezodambose; an inositol; Inositol [Nonspecific isomer]; Muscle sugar; ELND 005; inositol myo-; D-muco-Inositol; Inositol FCC; 4irx; Inositol, chiro-; rac-chiro-inositol; Inosital (TN); Inositol (NF); CBU; EINECS 207-681-5; EINECS 207-682-0; EINECS 209-000-7; EINECS 211-393-5; EINECS 211-394-0; EINECS 230-024-9; NSC 25142; EPIINOSITOL; (+)-Epi-Inositol; (+)-Chiro-Inositol; Epi-inositol, 98%; allo-Inositol, 97%; Inositol [USAN:NF]; INOSITOL, MESO; Spectrum_001595; 2os9; myo-Inositol-C-[d6]; orthorhombic myo-inositol; D-(+)-Chiro Inositol; J101.890F; J101.891D; Chiro-inositol, (+)-; INOSITOL (D); INOSITOL (L); Spectrum3_001053; Spectrum4_001193; Spectrum5_000961; myo-Inositol, >=99%; bmse000102; bmse000103; bmse000113; bmse000901; bmse000922; Epitope ID:144993; scyllo-Inositol, >=98%; SCHEMBL5831; SCHEMBL5832; SCHEMBL5969; NCIOpen2_008191; BSPBio_002606; KBioGR_001885; KBioSS_002075; 38876-99-2; MLS001332377; MLS001332378; MLS001335965; MLS001335966; MLS001335967; MLS001335968; SCHEMBL187278; SCHEMBL187397; SCHEMBL187796; SCHEMBL188106; SCHEMBL188237; SCHEMBL491333; SCHEMBL959404; SCHEMBL959405; AZD103; CHEMBL278373; CHEMBL468154; ELND-005; GTPL4495; GTPL4645; GTPL4648; GTPL4649; MEGxp0_001817; SCHEMBL1055883; SCHEMBL4748543; SCHEMBL6378921; SCHEMBL6468882; SCHEMBL6791918; CHEMBL1222251; CHEMBL1231671; CHEMBL1950780; CHEMBL3976780; DTXSID7023146; SCHEMBL12371461; SCHEMBL12377889; SCHEMBL12411898; SCHEMBL12711208; SCHEMBL12735687; SCHEMBL13058696; SCHEMBL13114115; SCHEMBL13114116; SCHEMBL13114128; SCHEMBL13207905; SCHEMBL13580047; SCHEMBL14542470; SCHEMBL21388397; ACon1_002457; CHEBI:22357; CHEBI:23311; CHEBI:24848; CHEBI:25492; CHEBI:27374; D-(+)-chiro-Inositol, 95%; KBio2_002075; KBio2_004643; KBio2_007211; KBio3_001826; L-(-)-chiro-Inositol, 95%; AZD-103; DTXSID30110000; DTXSID50905091; DTXSID60903982; myo-Inositol, p.a., 98.0%; 1,2,3,4,5/6-cyclohexanehexol; 1,2,3,4/5,6-cyclohexanehexol; 1,2,3/4,5,6-cyclohexanehexol; 1,2,4,5/3,6-cyclohexanehexol; HMS2091N13; HMS2230N03; HMS2235H05; HMS2235M23; HMS3369B06; HMS3369F20; HMS3373E05; Pharmakon1600-01500352; 1,2,3,4,5,6-Cyclohexanehexaol; BCP25172; HY-B1411; HY-N3021; NSC25142; NSC55558; ZINC1530357; D-myo-Inositol, Cell Culture Grade; Tox21_111642; Tox21_302035; 6643AB; ANW-43204; CCG-36096; cis-Inositol, >=98.0% (TLC); KM0846; MFCD00003863; MFCD00272608; MFCD00799555; MFCD00799556; MFCD01321249; NSC 55552; NSC 55558; NSC-45517; NSC-55552; NSC-55558; NSC103959; NSC127230; NSC757076; s4530; STL453612; epi-Inositol, >=98.0% (HPLC); 1,2,3,4,5,6/0-cyclohexanetetrol; AKOS006240678; AKOS006332036; AKOS015895894; AKOS015912905; AKOS015912934; AKOS015960429; AKOS015960633; AKOS015994742; AKOS024318869; Tox21_111642_1; ZINC100018867; ZINC100019018; ZINC100024490; ZINC100032893; ZINC100035580; ZINC100037751; ZINC100055570; ZINC100073149; ZINC100513675; ZINC101185827; ZINC102201844; ZINC103574430; ZINC103574467; ZINC103574475; ZINC250615063; ZINC253837650; ZINC306121118; CS-4782; CS-W010757; DB03106; DB13178; DB15350; HY-W010041; KS-1284; KS-1420; MCULE-2727773046; NSC 103959; NSC 127230; NSC-103959; NSC-127230; NSC-757076; VC30505; D-chiro-Inositol, >=98.0% (HPLC); NCGC00159409-03; NCGC00159409-04; NCGC00169828-01; NCGC00178580-01; NCGC00178580-03; NCGC00255362-01; AC-11070; AK546883; AS-10616; AS-68396; AS-68424; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; K572; LS-13189; NCI60_041778; SY060836; myo-Inositol, purum, >=98.0% (HPLC); rac-chiro-1,2,3,4,5,6-cyclohexanehexol; SBI-0051369.P003; AB0014290; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; DB-051583; DB-051584; DB-054642; HY-121962; myo-Inositol, for microbiology, >=99.0%; CS-0023004; CS-0083766; FT-0627237; FT-0632208; FT-0632209; FT-0632730; FT-0652045; FT-0670351; FT-0670357; FT-0693444; FT-0693614; I0040; I0628; I0629; I0630; I0631; I0632; I0633; S6176; ST50406013; myo-Inositol, BioUltra, >=99.5% (HPLC); myo-Inositol, SAJ special grade, >=99.0%; myo-Inositol, Vetec(TM) reagent grade, 99%; 3635-EP2275412A1; 3635-EP2280282A1; 3635-EP2289886A1; 3635-EP2292088A1; 3635-EP2295417A1; 3635-EP2295437A1; 3635-EP2298312A1; 3635-EP2298775A1; 3635-EP2305636A1; 3635-EP2305677A1; 3635-EP2305682A1; 3635-EP2308879A1; C00137; C06151; C06152; C06153; C19891; D08079; I-6500; K-9876; M01914; 12513-EP2277880A1; 12513-EP2277881A1; 12513-EP2292597A1; 12513-EP2292610A1; 12513-EP2298744A2; 12513-EP2298768A1; 12513-EP2305825A1; 12513-EP2316831A1; 12513-EP2374790A1; 13719-EP2269977A2; 13719-EP2280010A2; 13719-EP2289891A2; 13719-EP2295437A1; 13719-EP2298734A2; 13719-EP2298775A1; 13719-EP2308875A1; 13719-EP2311831A1; 13719-EP2316836A1; 2-Cyano-N-(2,4,6-trimethyl-phenyl)-acetamide; 40032-EP2298312A1; 40032-EP2311830A1; AB00051982_13; 643C129; A834712; A836375; Q407997; Q743661; Q-201583; Q2838375; Q2974313; Q3011024; Q3023527; Q3205874; Q3331426; Q3347078; Q3589114; SR-05000001655-1; SR-05000001655-5; W-202861; W-202862; W-203081; W-203168; W-203392; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol; D-MYO-INOSITOL-1,2,5,6-TETRAPHOSPHATE SODIUM SALT; UNII-M94176HJ2F component CDAISMWEOUEBRE-LKPKBOIGSA-N; UNII-M94176HJ2F component CDAISMWEOUEBRE-SHFUYGGZSA-N; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inositol, United States Pharmacopeia (USP) Reference Standard; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; 2H3; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture; myo-Inositol, PharmaGrade, meets FCC testing specifications, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.	Small molecule	1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H	CDAISMWEOUEBRE-UHFFFAOYSA-N	C1(C(C(C(C(C1O)O)O)O)O)O	C6H12O6	CAS 551-72-4	CHEBI:17268	.	.	.	D03SHD	.	.	.
NP6300	Sinomenine	CID: 5459308	Sinomenine; 115-53-7; Cucoline; Kukoline; Coculine; Sabianine A; CCRIS 1550; UNII-63LT81K70N; CHEBI:9163; CHEMBL248095; 63LT81K70N; morphinan-6-one, 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-, (9alpha,13alpha,14alpha)-; SR-05000002170; EINECS 204-094-6; BRN 0095280; Sinomenine,(S); Sinomenine (Cucoline); (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one hydrochloride; Spectrum2_001242; Spectrum3_001134; Spectrum4_001981; Spectrum5_001621; UPCMLD-DP085; 7,8-Didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-9-alpha,13-alpha,14-alpha-morphinan-6-one; BSPBio_002627; KBioGR_002508; 5-21-13-00516 (Beilstein Handbook Reference); SCHEMBL363812; SPECTRUM1505253; SPBio_001144; 4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one; NP51; UPCMLD-DP085:001; BCBcMAP01_000195; KBio3_002127; DTXSID00871595; BDBM224031; ALBB-020908; BCP20032; ZINC1280591; BDBM50241298; CCG-39100; NSC785175; s2359; AKOS000265568; AKOS015960539; AKOS016023715; AC-8025; NSC-785175; 9-alpha,13-alpha,14-alpha-Morphinan-6-one, 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-; SMP1_000273; NCGC00161641-01; NCGC00161641-02; NCGC00161641-04; NCGC00161641-05; HY-15122; O600; Sinomenine 100 microg/mL in Acetonitrile; CS-0003778; SW219295-1; C09643; 115S537; Sinomenine, 0.3 mol chloroform of crystallization; Q7524904; SR-05000002170-2; SR-05000002170-3; BRD-K83459933-001-02-1; 3-(4-Fluorophenyl)-3-(toluene-4-sulfonylamino)-propionicacid; 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one; morphinan-6-one, 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-, (9alpha,13alpha,14alpha)-, hydrochloride	Small molecule	1S/C19H23NO4/c1-20-7-6-19-10-14(21)16(24-3)9-12(19)13(20)8-11-4-5-15(23-2)18(22)17(11)19/h4-5,9,12-13,22H,6-8,10H2,1-3H3/t12-,13+,19-/m1/s1	INYYVPJSBIVGPH-QHRIQVFBSA-N	CN1CCC23CC(=O)C(=CC2C1CC4=C3C(=C(C=C4)OC)O)OC	C19H23NO4	CAS 115-53-7	CHEBI:9163	.	.	.	D0F9WF	.	.	.
NP6308	Thymoquinone	CID: 10281	Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI	.	1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3	KEQHJBNSCLWCAE-UHFFFAOYSA-N	CC1=CC(=O)C(=CC1=O)C(C)C	C10H12O2	CAS 490-91-5	.	.	.	.	.	.	.	.
NP6356	Vanillic acid	CID: 8468	Vanillic acid; 4-HYDROXY-3-METHOXYBENZOIC ACID; 121-34-6; Acide vanillique; Benzoic acid, 4-hydroxy-3-methoxy-; p-Vanillic acid; 3-Methoxy-4-hydroxybenzoic acid; Vanillate; m-Anisic acid, 4-hydroxy-; Protocatechuic acid, 3-methyl ester; 4-hydroxy-3-methoxy-Benzoic acid; UNII-GM8Q3JM2Y8; 4-Hydroxy-3-methoxybenzoate; NSC 3987; MFCD00002551; NSC 674322; GM8Q3JM2Y8; CHEMBL120568; CHEBI:30816; 4-hydroxy-3-methoxy benzoic acid; NSC674322; VA; VA (VAN); 4-Hydroxy-3-methoxybenzoic acid, 97+%; VNL; 4-hydroxy-m-Anisic acid; EINECS 204-466-8; BRN 2208364; Vanillinsaure; p-Vanillate; Vanilic acid; AI3-19542; Vanillic Acid,(S); 4-hydroxy-m-Anisate; Vanillic acid (M2); Vanillic acid, 97%; PubChem19485; ACMC-1BPT2; bmse000486; bmse000614; bmse010205; WLN: QVR DQ CO1; 3-Methoxy-4-hydroxybenzoate; SCHEMBL26179; MLS000574833; 4-hydroxy-3-methoxy-Benzoate; 4-Hydroxy-3-methoxybenzoicacid; Vanillic acid, >=97%, FG; 4-hydroxy-3methoxy benzoic acid; DTXSID6059522; 4-hydroxyl-3-methoxybenzoic acid; NSC3987; 4- hydroxy-3-methoxybenzoic acid; HMS2197E16; Protocatechuic acid 3-methyl ester; ZINC338275; HY-N0708; NSC-3987; STR02334; ANW-17590; BBL011982; BDBM50337364; s5343; SBB008280; STL163472; AKOS000113195; CCG-266343; MCULE-2667517874; MP-2220; NSC-674322; NCGC00247610-01; AC-11841; AK-32998; BP-13246; SMR000156289; ST086485; SY001450; DB-003804; Vanillic acid, purum, >=97.0% (HPLC); AM20050239; CS-0009728; FT-0650155; C06672; Vanillic acid, Vetec(TM) reagent grade, 97%; 198598-EP2277877A1; Q419672; Q-201921; Z1741973874; Vanillic acid, certified reference material, TraceCERT(R); 3E9555E5-85F5-4FCE-A429-5182E959C6A3	Small molecule	1S/C8H8O4/c1-12-7-4-5(8(10)11)2-3-6(7)9/h2-4,9H,1H3,(H,10,11)	WKOLLVMJNQIZCI-UHFFFAOYSA-N	COC1=C(C=CC(=C1)C(=O)O)O	C8H8O4	CAS 121-34-6	CHEBI:30816	.	.	.	.	.	.	.
NP6365	Phloretin	CID: 4788	phloretin; 60-82-2; Dihydronaringenin; Phloretol; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone; MFCD00002288; 1-Propanone, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-; NSC 407292; UNII-S5J5OE47MK; beta-(p-Hydroxyphenyl)phloropropiophenone; 2',4',6'-Trihydroxy-3-(p-hydroxyphenyl)propiophenone; 2',4',6'-Trihydroxy-3-(4-Hydroxyphenyl)propiophenone; C15H14O5; NSC407292; S5J5OE47MK; beta-(p-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; CHEMBL45068; CHEBI:17276; Phloretin, 98%; beta-(4-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; 2',4',6'-Trihydroxy-3-(4-hydroxyphenyl)-propiophenone; Propiophenone, 2',4',6'-trihydroxy-3-(p-hydroxyphenyl)-; 2',4,4',6'-Tetrahydroxydihydrochalcone; .beta.-(p-Hydroxyphenyl)phloropropiophenone; 2',4,4',6'-Tetrahydroxy-Dihydrochalcone; NSC 407292;RJC 02792; SMR000326783; CCRIS 7459; SR-01000076081; EINECS 200-488-7; Asebogenol; 2uxi; G50; Spectrum_001295; 4,2',4',6'-Tetrahydroxydihydrochalcone; Phloretin, >=99%; ACMC-209mmd; SpecPlus_000333; Spectrum2_000681; Spectrum3_001036; Spectrum4_001172; Spectrum5_001698; Lopac-P-7912; DSSTox_CID_2393; cid_4788; DSSTox_RID_76569; DSSTox_GSID_22393; Lopac0_001012; Oprea1_824722; REGID_for_CID_4788; SCHEMBL38131; BSPBio_002851; KBioGR_001803; KBioSS_001775; SPECTRUM300554; MLS000728507; MLS000859922; MLS006012024; BIDD:ER0174; DivK1c_006429; SPBio_000801; GTPL4285; DTXSID6022393; BCBcMAP01_000040; BDBM23446; KBio1_001373; KBio2_001775; KBio2_004343; KBio2_006911; KBio3_002071; Phloretin - CAS 60-82-2; ZINC47553; HMS2224N17; HMS3263K05; HMS3332J03; HMS3656I07; ACN-S003569; BCP28296; HY-N0142; TNP00255; Tox21_202854; Tox21_501012; ANW-33587; BBL027375; CCG-38573; CP0082; KM0437; LMPK12120525; O1P165; s2342; SBB066137; STL372996; AKOS015856338; AC-7995; ACN-035397; CS-1477; DB07810; LP01012; MCULE-3672992389; NSC-407292; SDCCGMLS-0066637.P001; SDCCGSBI-0050985.P003; CAS-60-82-2; Phloretin, analytical reference material; SMP1_000238; NCGC00015840-01; NCGC00015840-02; NCGC00015840-03; NCGC00015840-04; NCGC00015840-05; NCGC00015840-06; NCGC00015840-07; NCGC00015840-08; NCGC00015840-09; NCGC00015840-18; NCGC00094304-01; NCGC00094304-02; NCGC00094304-03; NCGC00094304-04; NCGC00260400-01; NCGC00261697-01; AK162403; AS-14100; ST057164; SY017103; AB0016775; DB-053714; EU-0101012; FT-0603256; N1316; P1966; SW219308-1; C00774; P 7912; 2',6'-Trihydroxy-3-(p-hydroxyphenyl)propiophenone; Q-100701; Q2268463; SR-01000076081-1; SR-01000076081-7; SR-01000076081-8; .beta.-(p-Hydroxyphenyl)-2,6-trihydroxypropiophenone; BRD-K15563106-001-02-4; BRD-K15563106-001-10-7; Propiophenone,4',6'-trihydroxy-3-(p-hydroxyphenyl)-; .beta.-(p-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; 1-(2,4,6-trihydroxyphenyl)-3-(4-hydroxyphenyl)-1-propanone; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanon; 3-(4-Hydroxy-phenyl)-1-(2,4,6-trihydroxy-phenyl)-propan-1-one; Propiophenone, 2',4',6'-trihydroxy-3-(p-hydroxyphenyl)- (8CI)	Small molecule	1S/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H2	VGEREEWJJVICBM-UHFFFAOYSA-N	C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O	C15H14O5	CAS 60-82-2	CHEBI:17276	.	.	.	D0HD2G	.	.	.
NP6396	Ulinastatin	CID: 105102	Urinastatin; Urinary trypsin inhibitor; Trypsin inhibitor MR-20; MR-20 (Magnetic powder); Uti(68); Acid-stable protease inhibitor; Urinary trypsin inhibitor (68); 2,4-Dioxaspiro[5.5]undec-8-ene, 3-(2-furanyl)-; 80449-31-6; Urinary trypsin inhibitor-like inhibitor (43); Trypsin inhibitor (human urine urinastatin protein moiety); 80449-32-7; 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-; Miraclid; AC1L2Y1N; UTI68; 3-(2-Furanyl)-2,4-dioxaspiro(5.5)undec-8-ene; AC1Q70L4; AKOS025401879; CS-7119; MR 20 (magnetic p	Small molecule	1S/C13H16O3/c1-2-6-13(7-3-1)9-15-12(16-10-13)11-5-4-8-14-11/h1-2,4-5,8,12H,3,6-7,9-10H2	ODVKSTFPQDVPJZ-UHFFFAOYSA-N	C1CC2(CC=C1)COC(OC2)C3=CC=CO3	C13H16O3	CAS 80449-31-6	.	.	.	.	D0DF1R	.	.	.
NP6452	Beta lapachone	CID: 3885	ARQ 501; SL 11001; A-lapachone; LAPACHONE, BETA; AK-693/21096016; 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-B]pyran-5,6-dione	Small molecule	1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3	QZPQTZZNNJUOLS-UHFFFAOYSA-N	CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C	C15H14O3	CAS 4707-32-8	.	.	.	.	D0W0VD	.	.	.
NP6459	Vinblastine	CID: 13342	vinblastine; Vinblastin; Vincaleucoblastin; Vincaleukoblastine; 865-21-4; Velban; Velbe; UNII-5V9KLZ54CY; CHEMBL159; 29060-LE; 5V9KLZ54CY; Vincoblastine; Rozevin; Nincaluicolflastine; Vinblastina; Vinblastinum; Vinblastina [DCIT]; Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; VR-8; VLB; methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate; CCRIS 9002; HSDB 3263; C46H58N4O9; NCI-C04842; NDC 0002-1452-01; EINECS 212-734-0; NSC 47842; cid_5388983; 2'-Epivinblastine; [3H]-Vinblastine; 1z2b; (2'R)-Vincaleukoblastine; SCHEMBL3628; BIDD:PXR0201; BSPBio_001228; (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, methyl ester, (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-; GTPL6851; 132142-72-4; BDBM50012278; NSC-47842; ZINC85432544; AKOS015965500; CS-1336; DB00570; MCULE-9967454324; NCGC00022585-04; NCGC00022585-05; NCGC00485975-02; 72401-36-6; AC-24191; AS-15821; HY-17418; Q943; W-5281; 139299-EP2270008A1; 139299-EP2292617A1; BRD-K01188359-001-02-0; BRD-K01188359-065-02-5; (2alpha,2'beta,3alpha,5beta,19beta)-vincaleukoblastine; (2ALPHA,2''''BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((5S,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate	Small molecule	1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1	JXLYSJRDGCGARV-CFWMRBGOSA-N	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	C46H58N4O9	CAS 865-21-4	.	.	.	.	D0W9MM	.	.	.
NP6465	Ampelopsin	CID: 161557	Dihydromyricetin; Ampelopsin; 27200-12-0; Ampeloptin; (+)-Dihydromyricetin; (+)-Ampelopsin; (2r,3r)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-4-one; UNII-KD8QND6427; 4H-1-Benzopyran-4-one, 2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, (2R-trans)-; KD8QND6427; CHEBI:28429; (2R,3R)-2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydrochromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, (2R,3R)-; (2R,3R)-3,5,7,3',4',5'-hexahydroxyflavanone; Ampelopsin (flavanol); (2R,3R)-3,3',4',5,5',7-hexahydroxy-2,3-dihydroflavanonol; dihydro-myricetin; (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; Flavanone, 3,3',4',5,5',7-hexahydroxy-; 3,3',4',5,5',7-Hexahydroxy-2,3-dihydroflavanonol; (2r,3r)-dihydromyricetin; Dihydromyricetin (diH-Myr); (2R-trans)-2,3-Dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; Dihydromyricetin (Ampeloptin); Dihydromyricetin - Ampeloptin; SCHEMBL723736; CHEMBL3348861; DTXSID50181676; BDBM212434; HMS3884B17; Dihydromyricetin, >=98% (HPLC); HY-N0112; Dihydromyricetin, analytical standard; CD0156; MFCD00189451; s2399; AKOS022168215; ZINC100037633; AC-8004; CCG-267699; CS-3809; NCGC00346604-01; AS-71702; AB0020621; SW219328-1; V1568; C02906; M-1204; Q422305; 2B89FBAC-4DD1-44C9-BE2A-9D0C173BDFD8; Q-100341; (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one	Small molecule	1S/C15H12O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,14-20,22H/t14-,15+/m0/s1	KJXSIXMJHKAJOD-LSDHHAIUSA-N	C1=C(C=C(C(=C1O)O)O)C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O	C15H12O8	CAS 27200-12-0	CHEBI:28429	.	.	.	.	.	.	.
NP6495	Fluoroorotic acid	CID: 69711	5-Fluoroorotic acid; 703-95-7; 5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid; 5-Fluoroorotate; Fluoroorotic acid; Orotic acid, 5-fluoro-; 5-Fluorouracil-4-carboxylic acid; 5-FOA; ENT-26398; NSC 31712; Ro 2-9945; UNII-7IA9OUC93E; WR 152520; MLS000737636; 5-fluoro-2,4-dioxo-1H-pyrimidine-6-carboxylic acid; 4-Pyrimidinecarboxylic acid, 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-; 7IA9OUC93E; Fluoroorotic Acid, Ultra Pure; FOA; 5-Fluorouracil-6-carboxylic Acid; 1,2,3,6-Tetrahydro-2,6-dioxo-5-fluoro-4-pyrimidinecarboxylic acid; MFCD00042526; SMR000393806; 4-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-5-fluoro-; 5-Fluoro orotic acid; 5-Fluoroorotic acid (VAN); EINECS 211-876-0; 5-fluoro-2,6-dioxo-1,3-dihydropyrimidine-4-carboxylic acid; AI3-26398; 5-Fluoroortic acid; FOT; 174.09 (anhydrous); C5H3FN2O4.xH2O; 5-Fluoroorotic acid;5-FOA; SCHEMBL44527; WLN: T6VMVMJ EVQ FF; cid_69711; CHEMBL1232805; BDBM47470; 5-Fluoroorotic acid, 98.0%+; DTXSID90220573; 5-fluorouracil-4-carboxylic acid;; HMS2759G19; ACT03077; EBD39533; NSC31712; ZINC1663959; 5-Fluoro-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinecarboxylic acid; ANW-46244; NSC-31712; SBB066881; AKOS005207200; CS-W017535; 4-Pyrimidinecarboxylic acid, 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-, monohydrate; 5-Fluorouracil-4-carboxylic acid hydrate; NCGC00246927-01; Orotic acid, 5-fluoro- (VAN) (8CI); AC-10068; AS-14168; K187; SY001827; AB0014081; F0382; FT-0620427; ST50405211; F-6300; M-2738; 45988-EP2298735A1; 45988-EP2311807A1; 703F957; 2,6-Dihydroxy-5-fluoropyrimidine-4-carboxylic acid; 5-fluoro-2,4-diketo-1H-pyrimidine-6-carboxylic acid; Q18207160; 1,3,6-Tetrahydro-2,6-dioxo-5-fluoro-4-pyrimidinecarboxylic acid; 4-Pyrimidinecarboxylic acid,2,3,6-tetrahydro-2,6-dioxo-5-fluoro-; 5-fluoranyl-2,4-bis(oxidanylidene)-1H-pyrimidine-6-carboxylic acid; 5-Fluoro-2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid; 5-Fluoro-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid; 4-Pyrimidinecarboxylic acid, 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo- (9CI)	Small molecule	1S/C5H3FN2O4/c6-1-2(4(10)11)7-5(12)8-3(1)9/h(H,10,11)(H2,7,8,9,12)	SEHFUALWMUWDKS-UHFFFAOYSA-N	C1(=C(NC(=O)NC1=O)C(=O)O)F	C5H3FN2O4	CAS 703-95-7	.	.	.	.	D0E2WX	.	.	.
NP6514	Demethoxycurcumin	CID: 5469424	Demethoxycurcumin; 22608-11-3; monodemethoxycurcumin; BHCFM; 24939-17-1; 4-Hydroxycinnamoyl(feroyl)methane; desmethoxycurcumin; Feruloyl-P-hydroxycinnnamoylmethane; curcuminII; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; UNII-W2F8059T80; 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-; 33171-16-3; p-Hydroxycinnamoylferuloylmethane; CHEBI:65737; 4-hydroxycinnamoyl(feruloyl)methane; MFCD03427310; NSC687841; W2F8059T80; (E/Z)-Demethoxycurcumin; 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; demethoxy-curcumin; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-hepta-1,6-diene-3,5-dione; (2E)-Demethoxy Curcumin; feruloyl-p-coumaroylmethane; (1E,6E)-Demethoxycurcumin; SCHEMBL431246; CHEMBL105360; SCHEMBL2553051; SCHEMBL13521973; cid_5324476; HY-N0006A; DTXSID00873751; (1E,6E)-1-(4-HYDROXY-3-METHOXY-PHENYL)-7-(4-HYDROXYPHENYL)HEPTA-1,6-DI ENE-3,5-DIONE; ZINC5115722; Demethoxycurcumin, >=98% (HPLC); 9331AF; BDBM50163744; s9280; Demethoxycurcumin, analytical standard; AKOS015903509; CCG-267896; NSC-687841; (E,E)-1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; LS-14764; CS-0009120; N1720; X1121; A14545; 6-Bromo-2-pyridin-4-yl-quinoline-4-carboxylicacid; Q-100287; Q5264607; 1-(4-Hydroxystyryl)-3-(3-methoxy-4-hydroxystyryl)propanedial; (1E,6E)-1-(4-Hydroxy-3-methoxy-phenyl)-7-(4-hydroxy-phenyl)-hepta-1,6-diene-3,5-dione; 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)- (VAN); 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-, (1E,6E)-; 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione, 9CI; 5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one; (1E,4Z,6E)-5-Hydroxy-1-(4-hydroxy-3-methoxy-phenyl)-7-(4-hydroxy-phenyl)-hepta-1,4,6-trien-3-one; (1E,6E)-1-(4-HYDROXY-3-METHOXY-PHENYL)-7-(4-HYDROXYPHENYL)HEPTA-1,6-DIENE-3,5-DIONE; 297160-27-1	Small molecule	1S/C20H18O5/c1-25-20-12-15(6-11-19(20)24)5-10-18(23)13-17(22)9-4-14-2-7-16(21)8-3-14/h2-12,21,24H,13H2,1H3/b9-4+,10-5+	HJTVQHVGMGKONQ-LUZURFALSA-N	COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC=C(C=C2)O)O	C20H18O5	CAS 22608-11-3	CHEBI:65737	.	.	.	D03EDF	.	.	.
NP6530	Farnesol	CID: 445070	farnesol; trans,trans-Farnesol; 106-28-5; (E,E)-Farnesol; (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol; trans-Farnesol; (2E,6E)-Farnesol; 4602-84-0; 2-trans,6-trans-Farnesol; All-trans-Farnesol; Farnesyl alcohol; 3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; FCI 119a; Inhibitor A2; (E)-farnesol; HSDB 445; 2,6-Di-trans-Farnesol; 2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl-, (2E,6E)-; (2-trans,6-trans)-farnesol; 2E,6E-farnesol; Farnesol (mixture of isomers); UNII-X23PI60R17; 3,7,11-Trimethyl-2,6,10-dodecatrienol; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-; Farnesol, mixture of isomers; Floral Green; CHEBI:16619; 3,7,11-trimethyldodeca-2,6,10-trien-1-ol; X23PI60R17; (2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; trans,trans-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, (E,E)-; ST072172; Farnesol 97+% FCC; MFCD00002918; (E,E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; FEMA No. 2478; Trimethyl dodecatrienol; EINECS 225-004-1; NSC 60597; EPA Pesticide Chemical Code 128911; polyprenols; transfarnesol; Nikkosome; trans- farnesol; AI3-44561; .beta.-Farnesol; E,E-farnesol; all-trans farnesol; (E,E)farnesol; FOF; trans,trans farnesol; Farnesol (6CI); (E,E,)-farnesol; Farnesol, 95%; (2Z,6Z)-Farnesol; Farnesol (2E,6E); Farnesol, (E,E)-; Farnesol, trans, trans; 2E,6E-Farnesyl alcohol; Spectrum5_002027; trans,trans-alpha-farnesol; DSSTox_CID_12389; DSSTox_RID_78934; trans,trans-Farnesol, 96%; trans,trans-Farnesol, 97%; DSSTox_GSID_32389; SCHEMBL58068; 2-trans-S-6-trans-farnesol; BSPBio_002660; Farnesol, analytical standard; CHEMBL25308; SPECTRUM1501022; (e,e)-FARNESOL 97+%; DTXSID2040789; BDBM11021; CHEBI:26199; CHEBI:28600; HY-Y0248A; AMY33538; BCP22704; ZINC1532860; Tox21_302034; AC-422; BBL027412; CCG-38862; s4941; SBB012426; STL372743; AKOS004907430; LMPR0103010001; MB00132; NCGC00095654-01; NCGC00095654-02; NCGC00095654-03; NCGC00095654-04; NCGC00095654-05; NCGC00255293-01; trans,trans-Farnesol, analytical standard; AS-16107; LS-14447; S409; CAS-4602-84-0; CS-0031456; 06F285; C01126; Farnesol, mixture of isomers, analytical standard; A801411; Q420449; Q-201851; W-109985; BRD-K24656285-001-01-0; Farnesol, mixture of isomers, >=95%, stabilized, FG; (2E, 6E)-3,7,11-trimethyl2,6,10-dodecatrien-1-ol; (2E,6E)-3,7,11-trimethyl-1-dodeca-2,6,10-trienol; (E,E,)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; F1905-7040; (2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trien-1-ol; Farnesol mixture of isomers stabilized with alpha tocopherol; UNII-EB41QIU6JL component CRDAMVZIKSXKFV-YFVJMOTDSA-N; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl- (8CI,9CI); A2865747-EC66-4B9C-A593-0A066A438904; (2-trans,6-trans)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol	Small molecule	1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3/b14-9+,15-11+	CRDAMVZIKSXKFV-YFVJMOTDSA-N	CC(=CCCC(=CCCC(=CCO)C)C)C	C15H26O	CAS 4602-84-0	CHEBI:16619	.	.	.	D0M0CF	.	.	.
NP6554	Pentagalloylglucose	CID: 65238	Pentagalloylglucose; 14937-32-7; 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose; 1,2,3,4,6-Pentagalloylglucose; Pentagalloyl glucose; 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose; 1,2,3,4,6-Pgg; 1,2,3,4,6-o-Pentagalloylglucose; UNII-3UI3K8W93I; 1,2,3,4,6-Pentakis-O-galloyl-beta-D-glucose; beta-D-Glucopyranose pentakis(3,4,5-trihydroxybenzoate); 3UI3K8W93I; CHEMBL382408; CHEBI:18082; DB03208; 1,2,3,4,6-pentakis-O-(3,4,5-trihydroxybenzoyl)-beta-D-glucopyranose; beta-Penta-O-galloyl-glucose; 1,2,3,4,6-Penta-O-galloyl-b-D-glucose; penta-O-galloyl-beta-d-glucose hydrate; beta-D-pentagalloylglucose; 1,2,3,4,6-Penta-O-galloylglucose; BETA-1,2,3,4,6-PENTA-O-GALLOYL-D-GLUCOPYRANOSE; 1,2,3,4,6-Penta-O-galloyl beta-glucopyranose; [(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate; [(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy]tetrahydropyran-2-yl]methyl 3,4,5-trihydroxybenzoate; Pentagalloyl-beta-D-glucose; SCHEMBL640108; MEGxp0_001051; ACon1_000145; HY-N0527; BDBM50241052; s9399; AKOS015896803; Beta-1,2,3,4,6-Pentagalloylglucose; ZINC169292785; CCG-270584; CS-5018; NCGC00180839-01; 1,2,3,4,6-Pentagalloyl beta-D-glucose; BS-15460; N2156; 1,2,3,4,6-pentakis-O-galloyl-  -D-glucose; C04576; W-2305; Q4545645; 5GG	Small molecule	1S/C41H32O26/c42-17-1-12(2-18(43)28(17)52)36(57)62-11-27-33(64-37(58)13-3-19(44)29(53)20(45)4-13)34(65-38(59)14-5-21(46)30(54)22(47)6-14)35(66-39(60)15-7-23(48)31(55)24(49)8-15)41(63-27)67-40(61)16-9-25(50)32(56)26(51)10-16/h1-10,27,33-35,41-56H,11H2/t27-,33-,34+,35-,41+/m1/s1	QJYNZEYHSMRWBK-NIKIMHBISA-N	C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C(C(C(C(O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C(=C6)O)O)O	C41H32O26	CAS 14937-32-7	CHEBI:18082	.	.	.	D00QDR	.	.	.
NP6573	Human plasma cholinesterase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP6628	Aloin	CID: 12305761	Barbaloin; aloin; 1415-73-2; Aloin A; Barbaloin A; Aloinum; UNII-648RW354S9; Aloin (Mixture of A and B); CHEBI:2991; MFCD00151160; 1,8-Dihydroxy-3-hydroxymethyl-10-(6-hydroxymethyl-3,4,5-trihydroxy-2-pyranyl)anthrone; Aloin [BAN]; 648RW354S9; DSSTox_CID_25967; (10S)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-10H-anthracen-9-one; (1S)-1,5-anhydro-1-[(9S)-4,5-dihydroxy-2-(hydroxymethyl)-10-oxo-9,10-dihydroanthracen-9-yl]-D-glucitol; (S)-1,8-dihydroxy-3-(hydroxymethyl)-10-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)anthracen-9(10H)-one; 10-(1',5'-Anhydroglucosyl)aloe-emodin-9-anthrone; NSC631263; 10-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9(10H)-anthracenone; Barbaloin,(S); NCGC00183867-01; Aloin (Barbaloin); 8015-61-0; EINECS 215-808-0; NSC 227189; NSC 631263; Aloin, analytical standard; DSSTox_RID_81262; DSSTox_RID_82951; DSSTox_GSID_45967; DSSTox_GSID_48755; CHEMBL2103763; DTXSID0045967; SCHEMBL14837254; 10-beta-D-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9(10H)-anthracenone; 9(10H)-Anthracenone, 10-beta-D-glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-, (10S)-; Aloin, from Curacao aloe, ~50%; HY-N0123; Tox21_111495; Tox21_113216; s2375; AKOS022168218; ZINC100018557; CCG-268870; CS-3707; NSC 407305; NSC 758464; (R)-10-beta-D-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)anthracen-9(10H)-one; 9(10H)-Anthracenone, 10-.beta.-D-glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-, (S)-; CAS-1415-73-2; CAS-8015-61-0; FT-0772660; N2491; C10305; 415B732; A807778; Q413888; Aloin, from Aloe barbadensis Miller leaves, >=97%; Aloin, United States Pharmacopeia (USP) Reference Standard; UNII-W41H6S09F4 component AFHJQYHRLPMKHU-OSYMLPPYSA-N; 10-Glucopyranosyl-1,8-dihydro-3-(hydroxymethyl)-9-anthracenone; 1,8-Dihydroxy-10-(bet.-D-glucopyranosyl)-3-(hydroxymethyl)-9(10H)-anthracenone; 1,8-Dihydroxy-10-(beta-D-glucopyranosyl)-3-(hydroxymethyl)-9(10H)-anthracenone; 10-.BETA.-D-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9(10H)-anthracenone-, 10(S)-; 10-beta-D-Glucopyranosyl-1,8-dihydroxy-3-hydroxymethyl-9(10H)-anthrone,(R)-; (10S)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-10H-anthracen-9-one; (10S)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]-10H-anthracen-9-one; (10S)-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-1,8-bis(oxidanyl)-10H-anthracen-9-one	Small molecule	1S/C21H22O9/c22-6-8-4-10-14(21-20(29)19(28)17(26)13(7-23)30-21)9-2-1-3-11(24)15(9)18(27)16(10)12(25)5-8/h1-5,13-14,17,19-26,28-29H,6-7H2/t13-,14+,17-,19+,20-,21+/m1/s1	AFHJQYHRLPMKHU-OSYMLPPYSA-N	C1=CC2=C(C(=C1)O)C(=O)C3=C(C2C4C(C(C(C(O4)CO)O)O)O)C=C(C=C3O)CO	C21H22O9	CAS 1415-73-2	CHEBI:2991	.	.	.	.	.	.	.
NP6629	Chlorphenamine	CID: 2725	chlorpheniramine; Chlorphenamine; Teldrin; Chlor-trimeton; Chlorophenylpyridamine; 132-22-9; Clorfeniramina; Phenetron; Haynon; Clorfenamina; Chlorpheniraminum; Kloromin; Polaronil; Chlorphenaminum; Chlorpheniramine polistirex; Antagonate; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; Chlo-amine; D-Chlorpheniramine; 2-Pyridinepropanamine, gamma-(4-chlorophenyl)-N,N-dimethyl-; CHEMBL505; Chloropheniramine; Chlorprophenpyridamine; Dexchlorpheniramine free base; Allergican; Allergisan; Chloropiril; Cloropiril; Histadur; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; CHEBI:52010; Chloroprophenpyridamine; 25523-97-1 (free base); 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 2-Pyridinepropanamine, .gamma.-(4-chlorophenyl)-N,N-dimethyl-; 3-(4-chlorophenyl)-N,N-dimethyl-3-(2-pyridyl)propan-1-amine; Aller-Chlor; Chlorphenamine Maleate; 4-Chloropheniramine; Chloropheniramine maleate; 2-[p-chloro-alpha-[2-(dimethylamino)ethyl]benzyl]pyridine; Chlorphenamin; Telachlor; Chlorprophenpyridamine maleate; Clorfeniramina [Italian]; Clorfenamina [INN-Spanish]; Chlorphenaminum [INN-Latin]; Pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethyl)benzyl)-; HSDB 3032; 113-92-8; EINECS 205-054-0; Chlorphenamine [INN:BAN]; [3-(4-Chlorophenyl)-3-(2-pyridyl)propyl]dimethylamine; Clofeniramina; PiriIton; Chlor-Pro; [3H]Chlorphenamine; Clofeniramina (TN); [3H]Chlorpheniramine; Chlorphenamine (INN); Chlorpheniramine-[d6]; chlorpheniaramine maleate; S-(+)-Chlorpheniramine; Prestwick0_000117; Prestwick1_000117; Prestwick2_000117; Prestwick3_000117; NCGC00015227-04; 5-HT,N-ACETYL; SCHEMBL4219; Lopac0_000261; Oprea1_779072; BSPBio_000134; DivK1c_000596; Chlorpheniramine Maleate B.P.; SPBio_002073; BPBio1_000148; GTPL6976; DTXSID0022804; BDBM35938; KBio1_000596; Chlorpheniramine-d6see c424303; NINDS_000596; HMS2090M21; HMS3428J07; Chlorpheniramine polistirex [USAN]; BBL012285; SBB017260; STK736174; AKOS001650136; CCG-108982; DB01114; MCULE-2363896855; SB19135; SDCCGSBI-0050249.P002; IDI1_000596; NCGC00015227-03; NCGC00015227-05; NCGC00015227-06; NCGC00015227-09; NCGC00015227-19; NCGC00162108-01; NCGC00162108-02; ST076791; FT-0665002; FT-0772034; T7375; C06905; D07398; L000003; Q420133; W-108317; BRD-A04553218-050-03-0; BRD-A04553218-050-08-9; .gamma.-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; N-[3-(4-Chlorophenyl)-3-(2-pyridinyl)propyl]-N,N-dimethylamine #; n.-Propanamine, 3-(4-chlorophenyl)-3-(2-pyridyl)-N,N-dimethyl-; (?)-3-(4-Chlorophenyl)-N,N-dimethyl-3-(2-pyridinyl)propan-1-amine; 2-Pyridinepropanamine, .gamma.-(4-chlorophenyl)-N,N-dimethyl-, (S)-; Pyridine, 2-[p-chloro-.alpha.-[2-(dimethylamino)ethyl]benzyl]-, (S)-(+)-	Small molecule	1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3	SOYKEARSMXGVTM-UHFFFAOYSA-N	CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2	C16H19ClN2	CAS 113-92-8	CHEBI:52010	.	.	.	D0B7NG	.	.	.
NP6632	Panax ginseng total saponins	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP6636	Daunorubicin	CID: 30323	daunorubicin; Daunomycin; 20830-81-3; Cerubidine; Acetyladriamycin; Leukaemomycin C; Rubidomycin; (+)-Daunomycin; DaunoXome; Daunorubicinum; Daunorubicine; Cerubidin; Rubomycin C; RP 13057; C27H29NO10; NSC-82151; Daunarubicinum; Daunorrubicina; DaunoXome (TN); Daunamycin; FI 6339; UNII-ZS7284E0ZP; ZS7284E0ZP; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; CHEBI:41977; FI6339; FI-6339; NCGC00024246-05; Anthracyline; NDC-0082-4155; DSSTox_CID_2883; DSSTox_RID_76773; DSSTox_GSID_22883; RP-13057; Daunorubicinum [INN-Latin]; MLS000069508; Daunorubicin [INN:BAN]; RCRA waste no. U059; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; CAS-20830-81-3; Daunorubicin (INN); NSC82151; SMR000058559; NDC 0082-4155; CCRIS 914; SR-01000000033; SR-05000001600; NSC-83142; HSDB 5095; NCI-C04693; EINECS 244-069-7; NSC 83142; VS-103; BRN 1445583; Tocris-1467; Daunorubicin(Daunomycin); AI3-52942; Prestwick3_000487; CHEMBL178; SCHEMBL3041; BSPBio_000353; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-; cid_62770; BPBio1_000389; GTPL7063; DTXSID7022883; BDBM32017; Valrubicin impurity, daunorubicin; HMS2089H04; HMS2091K06; Pharmakon1600-01500223; ZINC3917708; Tox21_110896; BDBM50368352; GR-318; HY-13062A; LMPK13050002; MFCD00866340; NSC756717; Tox21_110896_1; CCG-212559; CS-2004; DB00694; NSC-756717; NCGC00024246-06; NCGC00024246-07; NCGC00024246-09; NCGC00024246-10; NCGC00024246-15; NCGC00025173-01; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-; SBI-0206677.P002; AB00514669; 30D813; C01907; D07776; Epirubicin hydrochloride impurity, daunorubicin-; 15159-EP2270008A1; 15159-EP2272827A1; 15159-EP2277565A2; 15159-EP2277566A2; 15159-EP2277567A1; 15159-EP2277568A2; 15159-EP2277569A2; 15159-EP2277570A2; 15159-EP2289892A1; 15159-EP2292280A1; 15159-EP2292617A1; 15159-EP2295416A2; 15159-EP2295426A1; 15159-EP2295427A1; 15159-EP2298748A2; 15159-EP2298778A1; 15159-EP2301928A1; 15159-EP2305642A2; 15159-EP2305679A1; 15159-EP2308833A2; 15159-EP2308861A1; 15159-EP2311808A1; 15159-EP2311829A1; 15159-EP2311842A2; 15159-EP2316832A1; 15159-EP2316833A1; 16803-EP2272832A1; 16803-EP2277565A2; 16803-EP2277566A2; 16803-EP2277567A1; 16803-EP2277568A2; 16803-EP2277569A2; 16803-EP2277570A2; 16803-EP2280012A2; 16803-EP2281815A1; 16803-EP2286812A1; 16803-EP2292280A1; 16803-EP2292615A1; 16803-EP2298768A1; 16803-EP2301928A1; 16803-EP2301933A1; 16803-EP2305640A2; 16803-EP2305671A1; 16803-EP2311825A1; 16803-EP2311827A1; 16803-EP2311840A1; 16803-EP2316937A1; AB00514669-09; AB01644616_09; AB01644616_10; Q411659; SR-01000000033-4; SR-05000001600-1; SR-05000001600-2; BRD-K43389675-001-01-3; BRD-K43389675-003-02-7; BRD-K43389675-003-03-5; BRD-K43389675-003-20-9; 2-HYDROXY-5-(4-NITRO-PHENYLSULFAMOYL)-BENZOICACID; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-4-methoxy-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (8S,10S)-8-acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 5,12-Naphthacenedione,8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-	Small molecule	1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1	STQGQHZAVUOBTE-VGBVRHCVSA-N	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O	C27H29NO10	CAS 20830-81-3	CHEBI:41977	.	.	.	D01XWG	.	.	.
NP6651	Caspofungin acetate	CID: 6850808	Caspofungin acetate; Cancidas; caspofungin diacetate; 179463-17-3; Cancidas (TN); Caspofungin (Acetate); acetic acid;N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide; SCHEMBL149293; CHEMBL4297142; Caspofungin acetate (JAN/USAN); C56H96N10O19; MFCD08141839; AKOS025401982; AC-27763; Y1176; D02501; W-5367; 463C173	Small molecule	1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+;;/m1../s1	OGUJBRYAAJYXQP-LLXMLGLCSA-N	CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O	C56H96N10O19	CAS 179463-17-3	.	.	.	.	.	.	.	.
NP6711	Glucocorticoids	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP6740	Capsaicin	CID: 1548943	Capsaicin (transdermal patch formulation, neuropathic pain)	.	1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+	YKPUWZUDDOIDPM-SOFGYWHQSA-N	CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC	C18H27NO3	CAS 404-86-4	.	HBIN019690	SMIT00161	MOL002579	D0U5CE	.	3734	.
NP6764	Beta asarone	CID: 5281758	beta-Asarone; 5273-86-9; cis-Isoelemicin; cis-Isoasarone; (Z)-Asarone; cis-Asarone; UNII-IGA3MH6IUW; Cis-Asaron; 1,2,4-trimethoxy-5-[(Z)-prop-1-enyl]benzene; IGA3MH6IUW; (Z)-5-Propenyl-1,2,4-trimethoxybenzene; CHEBI:10353; (Z)-1,2,4-Trimethoxy-5-(1-propenyl)benzene; BENZENE, 1,2,4-TRIMETHOXY-5-PROPENYL-, (Z)-; cis-2,4,5-Trimethoxy-1-propenylbenzene; beta-asaron; CCRIS 1592; .beta.-Asarone; EINECS 226-096-6; 2,4,5-Trimethoxypropen-1-ylbenzene; cis-.beta.-Asarone; I(2)-Asarone; BRN 1910605; 1,2,4-Trimethoxy-5-((Z)-1-propenyl)benzene; (Z)-.beta.-Asarone; AI3-36897; Benzene, 1,2,4-trimethoxy-5-(1-propenyl)-, (Z)-; 3-06-00-06440 (Beilstein Handbook Reference); SCHEMBL528747; CHEMBL477752; CHEBI:68146; CHEBI:78308; cis-2,4,5-trimethoxyphenylpropene; DTXSID601020057; HMS3886B18; BCP23722; HY-N1501; MFCD00009281; s9118; ZINC13424754; AKOS030524038; CCG-266642; CS-W009103; DS-9662; L986; (Z)-1-(2,4,5-Trimethoxyphenyl)-1-propene; 1,2,4-trimethoxy-5-(prop-1-en-1-yl)benzene; C10430; cis-2,4,5-Trimethoxy-1-propenylbenzene, 70%; 1,2,4-Trimethoxy-5-[(1Z)-1-propenyl]benzene; W-105801; 1,2,4-trimethoxy-5-[(1Z)-prop-1-en-1-yl]benzene; beta-Asarone, primary pharmaceutical reference standard; Q27089385; 1,2,4-Trimethoxy-5-((z)-1-propenyl)benzene, ?-asarone; (z)-1 pound not2 pound not4-trimethoxy-5-(1-propenyl)benzene; Benzene, 1,2,4-trimethoxy-5-(1-propenyl)-, (Z)- (9CI)	Small molecule	1S/C12H16O3/c1-5-6-9-7-11(14-3)12(15-4)8-10(9)13-2/h5-8H,1-4H3/b6-5-	RKFAZBXYICVSKP-WAYWQWQTSA-N	CC=CC1=CC(=C(C=C1OC)OC)OC	C12H16O3	CAS 5273-86-9	CHEBI:10353	.	.	.	.	.	.	.
NP6778	Abrin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP6785	Brucine	CID: 442021	BRUCINE; 357-57-3; 10,11-Dimethoxystrychnine; Brucinum; (-)-Brucine; l-Brucine; 2,3-Dimethoxystrychnine; 2,3-Dimethoxystrychnidin-10-one; 10,11-Dimethystrychnine; UNII-6NG17YCK6H; Brucina; Brucin; 6NG17YCK6H; Brucine alkaloid; CHEBI:3193; Dimethoxy strychnine; Bruzin; 2,3-Dimethoxy-strychnine; RCRA waste number P018; DSSTox_RID_77490; DSSTox_GSID_24662; Strychnine, 2,3-dimethoxy-; 145428-94-0; Brucin [German]; Brucina [Italian]; (4aR,4a1R,5aS,8aR,8a1S,15aS)-10,11-dimethoxy-2,4a,4a1,5,5a,7,8,8a1,15,15a-decahydro-14H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one; CAS-357-57-3; SMR000112281; DSSTox_CID_4662; 10,11-dimethoxy strychnine; CCRIS 4754; HSDB 307; anhydrous brucine; Bisdesmethylbrucin; Brucine Anhydrous; UN 1570; NCGC00094861-01; (4aR,5aS,8aR,13aS,15aS,15bR)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-14-one; EINECS 206-614-7; UN1570; PubChem7945; RCRA waste no. P018; Brucine, anhydrous, 98%; GTPL342; MLS000515808; MLS001424166; SCHEMBL113229; CHEMBL501756; MEGxp0_001865; DTXSID2024662; ACon1_001990; Brucine [UN1570]  [Poison]; HMS2052O03; HMS2268L16; ZINC1069090; Tox21_111349; Tox21_302174; BDBM50401037; MFCD00005942; AKOS015955678; AKOS024282466; CCG-101078; MCULE-9524496694; NC00328; NSC 757797; NCGC00255253-01; NCGC00263445-02; NCGC00384497-01; M127; B0670; B0946; C09084; Brucine - CASMI2016 Category 1 - Challenge 9; Q411022; SR-01000712407; Q-100426; SR-01000712407-5; BRD-K68077509-001-01-6; Brucine, European Pharmacopoeia (EP) Reference Standard; (1R,11S,18S,20R,21R,22S)-4,5-dimethoxy-12-oxa-8,17-diazaheptacyclo[15.5.2.0^{1,18}.0^{2,7}.0^{8,22}.0^{11,21}.0^{15,20}]tetracosa-2(7),3,5,14-tetraen-9-one	Small molecule	1S/C23H26N2O4/c1-27-16-8-14-15(9-17(16)28-2)25-20(26)10-18-21-13-7-19-23(14,22(21)25)4-5-24(19)11-12(13)3-6-29-18/h3,8-9,13,18-19,21-22H,4-7,10-11H2,1-2H3/t13-,18-,19-,21-,22-,23+/m0/s1	RRKTZKIUPZVBMF-IBTVXLQLSA-N	COC1=C(C=C2C(=C1)C34CCN5C3CC6C7C4N2C(=O)CC7OCC=C6C5)OC	C23H26N2O4	CAS 357-57-3	CHEBI:3193	.	.	.	D0H2UT	.	.	.
NP6815	Acacetin	CID: 5280442	acacetin; 480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; 4'-Methoxyapigenin; Buddleoflavonol; Acacetine; Linarisenin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; Akatsetin; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; 4H-1-BENZOPYRAN-4-ONE, 5,7-DIHYDROXY-2-(4-METHOXYPHENYL)-; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; ACAETIN; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; NSC76061; KWI7J0A2CC; 4'-Methoxy-5,7-dihydroxyflavone; MLS002693970; CHEMBL243664; CHEBI:15335; MFCD00016936; NSC-76061; SMR001233299; SR-01000841189; EINECS 207-552-3; BRN 0277879; Acaceztin; 4-Methylapigenin; 4'-Methylapigenin; Prestwick_49; 4'-O-Methylapigenin; 5,7-Dihydroxy-4; Kinome_3212; Spectrum_000135; Prestwick0_000695; Prestwick1_000695; Prestwick2_000695; Prestwick3_000695; Spectrum5_000930; Acacetin, analytical standard; BSPBio_000849; KBioSS_000595; SPECTRUM200499; 5-18-04-00575 (Beilstein Handbook Reference); MLS002153960; DivK1c_000878; SCHEMBL107712; SPBio_002770; BPBio1_000935; 00017_FLUKA; BCBcMAP01_000082; BDBM23415; HMS502L20; KBio1_000878; KBio2_000595; KBio2_003163; KBio2_005731; DTXSID00197383; Flavone,7-dihydroxy-4'-methoxy-; NINDS_000878; HMS1570K11; HMS1922P12; HMS2097K11; HMS2234J17; HMS3374F03; Acacetin, >=97.0% (HPLC); BCP15815; HY-N0451; ZINC3871358; LMPK12110468; s5318; AKOS015903365; CCG-208517; CS-5336; MCULE-8773156096; IDI1_000878; SMP1_000001; NCGC00016458-01; NCGC00016458-02; NCGC00016458-03; NCGC00016458-04; NCGC00016458-05; NCGC00095213-01; NCGC00095213-02; NCGC00095213-03; NCGC00179402-01; AK114502; AS-70345; CAS-480-44-4; ST066889; WLN: T66 BO EVJ CR DO1& GQ IQ; AB0021899; DB-051509; FT-0645060; N2109; W1621; Flavone, 5,7-dihydroxy-4'-methoxy- (8CI); A14741; C01470; 480A444; Q2822213; SR-01000841189-3; SR-01000841189-4; BRD-K77685744-001-03-6; BRD-K77685744-001-07-7; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one #; 4H-1-Benzopyran-4-one,7-dihydroxy-2-(4-methoxyphenyl)-; BE7185D3-6331-4E84-8C8E-5D10E505E37A	Small molecule	1S/C16H12O5/c1-20-11-4-2-9(3-5-11)14-8-13(19)16-12(18)6-10(17)7-15(16)21-14/h2-8,17-18H,1H3	DANYIYRPLHHOCZ-UHFFFAOYSA-N	COC1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O	C16H12O5	CAS 480-44-4	CHEBI:15335	.	.	.	D0NS1S	.	.	.
NP6854	Vitamin K2	CID: 5282367	menatetrenone; vitamin K2; Menaquinone-4; 863-61-6; Menaquinone 4; Kefton-2; Vitamin MK 4; Kaytwo; Menaquinone K4; Menatetrenona; Menatetrenonum; 11032-49-8; 2-Methyl-3-trans-tetraprenyl-1,4-naphthoquinone; MK-4; UNII-27Y876D139; 2-Methyl-3-geranylgeranyl-1,4-naphthoquinone; C31H40O2; MLS000028742; 6041-00-5; CHEBI:78277; MFCD00079646; 2-Methyl-3-((2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)naphthalene-1,4-dione; 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]naphthalene-1,4-dione; MK4; SMR000058955; 27Y876D139; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-; 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthoquinone; DSSTox_CID_28895; Vitamin K2(sub 20); Menatetrenone [INN:JAN]; Menatetrenonum [INN-Latin]; K2(sub 20); Menatetrenona [INN-Spanish]; Glakay; E3100; menaquinone(4); NCGC00183125-01; 2-methyl-3-((2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)naphthalene-1,4-dione; Vitamin K2 (TN); Opera_ID_148; 2-Methyl-3-tetraprenyl-1,4-naphthoquinone; 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthochinon; DSSTox_RID_80857; DSSTox_RID_83163; Menatetrenone (JP17/INN); DSSTox_GSID_45406; DSSTox_GSID_48969; 1,4-Naphthalenedione, 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-, (E,E,E)-; MENAQUINONE;VITAMIN K2; SCHEMBL434553; SCHEMBL571912; Menaquinone 4; ; ; Menatetrenone; Vitamin K2 (MK-4) solution; CHEMBL259223; MQ-4; DTXSID6048969; HMS2230J06; Ea-0167; AMY22672; HY-B2156; ZINC3874199; Tox21_110567; Tox21_113413; BDBM50423776; s5082; AKOS025311021; Menaquinone (K2), analytical standard; CCG-269176; DB12148; 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthalenedione; NCGC00181325-01; NCGC00181325-03; 1,4-Naphthalenedione, 2-methyl-3-((2E,6E,10E)3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-; AS-17910; AS-56161; CAS-863-61-6; K541; CS-0020307; V2671; A17083; D00100; E-0167; 863V616; Q192354; 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetrenyl)-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl]-; 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-1,4-naphthoquinone; Vitamin K2 (MK-4) solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material	Small molecule	1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+	DKHGMERMDICWDU-GHDNBGIDSA-N	CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C	C31H40O2	CAS 863-61-6	CHEBI:78277	.	.	.	D05VOH	.	.	.
NP6882	Arctigenin	CID: 64981	Arctigenin; (-)-Arctigenin; 7770-78-7; UNII-U76MR9VS6M; C21H24O6; CHEBI:79; U76MR9VS6M; (3R,4R)-4-(3,4-dimethoxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)dihydrofuran-2(3H)-one; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R-trans)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2(3H)-furanone; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R,4R)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3- [(4-hydroxy-3-methoxyphenyl)methyl]-2-tetrahydrofuranone; (+/-)-Arctigenin; Arctigenin, (+/-)-; Arctigenen; Arctigenin, trans-((+/-)-; 2(3H)-Furanone, 4-[(3,4-dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-, (3R,4R)-; Tocris-1777; SCHEMBL381820; CHEMBL435734; MEGxp0_001799; ACon1_000416; DTXSID60998919; HMS3268E18; HMS3412H04; HMS3676H04; HY-N0035; ZINC1615344; BDBM50375656; MFCD00870597; s3897; STL565840; AKOS015897121; CCG-268327; MCULE-1275881531; MCULE-5621583813; NCGC00025291-01; NCGC00025291-02; NCGC00025291-04; 144901-91-7; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R,4R)-rel-; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, trans-; AS-56162; AB0019692; (-)-Arctigenin, >=95% (LC/MS-ELSD); N2399; C10545; 770A787; SR-01000597504; Q-100825; Q4787603; SR-01000597504-1; BRD-K53523901-001-01-0; UNII-2FD8L150E7 component NQWVSMVXKMHKTF-JKSUJKDBSA-N; 4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(3-methoxy-4-oxidanyl-phenyl)methyl]oxolan-2-one; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxy-phenyl)methyl]tetrahydrofuran-2-one; (3R-trans)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy- 3-methoxyphenyl)methyl]-4,5-dihydrofuran-2(3H)-one; 4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-(3R,4R)-2(3H)-Furanone; 4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-(3R-trans)-2(3H)-Furanone; EQC	Small molecule	1S/C21H24O6/c1-24-18-7-5-13(11-20(18)26-3)8-15-12-27-21(23)16(15)9-14-4-6-17(22)19(10-14)25-2/h4-7,10-11,15-16,22H,8-9,12H2,1-3H3/t15-,16+/m0/s1	NQWVSMVXKMHKTF-JKSUJKDBSA-N	COC1=C(C=C(C=C1)CC2COC(=O)C2CC3=CC(=C(C=C3)O)OC)OC	C21H24O6	CAS 7770-78-7	CHEBI:79	.	.	.	.	.	.	.
NP6905	Curcumin	CID: 969516	Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil	.	1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+	VFLDPWHFBUODDF-FCXRPNKRSA-N	COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O	C21H20O6	CAS 458-37-7	.	HBIN021985	SMIT01361	MOL000090	D07SDQ	.	3258	.
NP6920	Guggulsterone	CID: 6450278	(Z)-Guggulsterone; Guggulsterone; Z-Guggulsterone; 39025-23-5; 95975-55-6; Guggulsterone E&Z; Guggulsterones Z; GUGGULSTERONE Z; Cis-Guggulsterone; UNII-6CST3U34GN; 6CST3U34GN; (Z)-Pregna-4,17(20)-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; Gugulsterone; Pregna-4,17(20)-diene-3,16-dione; (8R,9S,10R,13S,14S,Z)-17-ethylidene-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,16(2H)-dione; Guggulsterone, (Z)-; Pregna-4,17(20)-diene-3,16-dione, (17Z)-; GS; (E&Z)-Guggulsterone; DSSTox_CID_13539; DSSTox_RID_79083; DSSTox_GSID_33539; SCHEMBL141657; CHEMBL410683; DTXSID1033539; BDBM21725; CHEBI:135338; BCP18087; Tox21_202518; MFCD01310757; AKOS015963432; ZINC118912814; (Z)-Guggulsterone, analytical standard; AC-6215; CCG-267610; NCGC00091910-01; NCGC00260067-01; AC-28813; (17Z)-pregna-4,17-diene-3,16-dione; 4,17(20)-trans-Pregnadiene-3,16-dione; CAS-39025-23-5; HY-107738; CS-0029421; S3792; V2228; (Z)-Guggulsterone, >=89% (HPLC), powder; 2-(2-Aminothiazol-3(2H)-yl)-1-phenylethanone; 975G556; BRD-K26674531-001-01-3; Q27264514; UNII-A4PW148END component WDXRGPWQVHZTQJ-OSJVMJFVSA-N; Guggulsterone Z, United States Pharmacopeia (USP) Reference Standard; (1S,2R,10R,11S,14Z,15S)-14-ethylidene-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,13-dione	Small molecule	1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4,11,15,17-18H,5-10,12H2,1-3H3/b16-4+/t15-,17+,18+,20+,21-/m1/s1	WDXRGPWQVHZTQJ-OSJVMJFVSA-N	CC=C1C(=O)CC2C1(CCC3C2CCC4=CC(=O)CCC34C)C	C21H28O2	CAS 39025-23-5	CHEBI:135338	.	.	.	D0G8BV	.	.	.
NP6934	Chlorogenic acid	CID: 1794427	CHLOROGENIC ACID; 327-97-9; 3-Caffeoylquinic acid; 3-O-Caffeoylquinic acid; 3-(3,4-Dihydroxycinnamoyl)quinic acid; Chlorogenate; Heriguard; Hlorogenic acid; Caffeoyl quinic acid; NSC-407296; 3-Caffeoylquinate; UNII-318ADP12RI; 5-O-(3,4-Dihydroxycinnamoyl)-L-quinic acid; CCRIS 1400; Chlorogenic acid (8CI); EINECS 206-325-6; NSC 70861; NSC 407296; 3-trans-Caffeoylquinic acid; CHEMBL284616; 318ADP12RI; CHEBI:16112; 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate); 3-(3,4-Dihydroxycinnamoyl)quinate	.	1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14-,16+/m1/s1	CWVRJTMFETXNAD-JUHZACGLSA-N	C1C(C(C(CC1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O	C16H18O9	CAS 202650-88-2	CHEBI:16112	HBIN020363	SMIT01671	MOL003871	D02HCQ	.	1550	.
NP6954	Artesunate	CID: 6917864	Artesunate; Artesunic acid; Arsumax; Dihydroqinghasu hemsuccinate; 88495-63-0; Arinate; Artesunatum; Artesunato; Plasmotrin; Qinghaozhi; Saphnate; Asumax; Gsunate Forte; Plasmotrim; UNII-60W3249T9M; CHEBI:63918; Succinyl dihydroartemisinin; 60W3249T9M; Arsuamoon; Butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester; cosunate; Artesunata; SM 804; Cosinate; Zysunate; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)butanoic acid; 4-oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)butanoic acid; 4-oxo-4-{[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-yl]oxy}butanoic acid; Armax 200; Artesunatum [INN-Latin]; Artesunato [INN-Spanish]; Artsuna; Nuartez; Artesunate [USAN:INN:BAN]; HSDB 7458; NSC-712571; Quinghaosu reduced succinate ester; D95; Dihydroartemisinine-12alpha-succinate; WR 256283; WR-256283; MLS006011590; CHEMBL361497; GTPL9956; SCHEMBL14552891; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; ACT02643; HY-N0193; STR09744; BDBM50248021; ZINC14096305; CS-8151; DB09274; NCGC00164600-10; SMR002499399; Q707939; BRD-K54634444-001-05-9; WR-256283;ART;Armax 200;SM-804;HSDB-7458; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0?,(1)(3).0?,(1)(3)]hexadecan-10-yl]oxy}butanoic acid; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester	Small molecule	1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1	FIHJKUPKCHIPAT-AHIGJZGOSA-N	CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C	C19H28O8	CAS 88495-63-0	CHEBI:63918	.	.	.	D0D4JO	.	.	.
NP6984	Isoliquiritigenin	CID: 638278	2',4,4'-Trihydroxychalcone; 4,2',4'-Trihydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 6'-deoxychalcone; 2',4',4-Trihydroxychalcone; isoliquirtigenin; UNII-B9CTI9GB8F; C15H12O4; Chalcone, 2',4,4'-trihydroxy-; MFCD00075907; B9CTI9GB8F; 42'4'-trihydroxychalcone; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-; Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxyphenyl)-; CHEMBL129795; 13745-20-5; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; CHEBI:310312; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; trans-2',4,4'-trihydroxychalcone; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-HYDROXYPHENYL)-; (E)-1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propene-1-one; GU 17; GU-17; SMR000112969; CCRIS 7676; SR-01000075499; EINECS 237-316-5; BRN 1914295; GU17; iso-Liquiritigenin; Isoliquiritigenin/; ILTG; ISLQ; PubChem21917; Isoliquiritigenin, powder; Spectrum5_000612; (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (E)-; Lopac0_000681; BSPBio_003411; 1-08-00-00707 (Beilstein Handbook Reference); MLS000438943; MLS002207240; MLS006010045; BIDD:ER0235; SCHEMBL161168; SPECTRUM1504200; cid_638278; MEGxp0_001326; 2',4,4'-Trihydroxy-Chalcone; DTXSID2022466; 2'',4'',4-trihydroxychalcone; 2'',4,4''-trihydroxychalcone; ACon1_000047; CHEBI:94010; BCPP000201; HMS2233H18; HMS3262I03; 2,4''-dihydroxy-4-hydroxychalcone; BCP02312; HY-N0102; ZINC3869608; Tox21_500681; ABP000708; BDBM50042944; CCG-40334; CI0036; CMLD3_000056; LMPK12120096; s2404; SBB066136; 2',4,4'-Trihydroxychalcone, 97%; Isoliquiritigenin, analytical standard; AKOS001590146; BCP9000795; CS-1745; DB03285; KS-5256; LP00681; MCULE-1557671934; SDCCGMLS-0066751.P001; SDCCGSBI-0050660.P004; NCGC00090504-01; NCGC00090504-02; NCGC00090504-03; NCGC00090504-04; NCGC00090504-05; NCGC00090504-06; NCGC00090504-07; NCGC00090504-08; NCGC00090504-24; NCGC00261366-01; O271; ST081356; AB0000350; EU-0100681; I0822; N1288; SW219658-1; C08650; I 3766; M-1539; 961I295; A845551; NCGC00090504-04!2',4,4'-Trihydroxychalcone; 2',4'-Dihydroxy-3-(p-hydroxyphenyl)-Acrylophenone; Q-100904; Q3155537; SR-01000075499-1; SR-01000075499-5; BRD-K33583600-001-03-9; BRD-K33583600-001-04-7; 1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-prop-2-en-1-one; (E)-1-[2,4-bis(oxidanyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one	.	1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3+	DXDRHHKMWQZJHT-FPYGCLRLSA-N	C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O	C15H12O4	CAS 961-29-5	.	HBIN030896	SMIT00122	MOL001789	.	.	2368	.
NP6993	Arsenic trioxide	CID: 14888	Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)	.	1S/2As.3O/q2*+3;3*-2	QTLQKAJBUDWPIB-UHFFFAOYSA-N	[O-2].[O-2].[O-2].[As+3].[As+3]	As2O3	CAS 1327-53-3	CHEBI:30621	.	.	.	D07VIK	.	.	.
NP7079	Miltefosine	CID: 3599	Miltefosine; 58066-85-6; Hexadecylphosphocholine; Miltex; Impavido; Hexadecylphosphorylcholine; HDPC; n-Hexadecylphosphorylcholine; Miltefosinum; Miltefosina; hexadecyl 2-(trimethylammonio)ethyl phosphate; 1-Hexadecylphosphorylcholine; Miltefosin C; n-hexadecylphosphocholine; D-18506; miltefosin; C21H46NO4P; UNII-53EY29W7EC; NSC605583; hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; hexadecyl (2-(trimethylAmmonio)ethyl) phosphate; monohexadecylphosphocholine; CHEMBL125; monohexadecylphosphorylcholine; HePC;Hexadecyl phosphocholine; 53EY29W7EC; CHEBI:75283; MFCD00133396; MMV688990; NSC-605583; NCGC00095169-01; Miltefos; DSSTox_CID_25942; DSSTox_RID_81240; DSSTox_GSID_45942; Miltefosinum [INN-Latin]; Miltefosina [INN-Spanish]; Miltefosine [INN:BAN]; Fos-choline 16; Miltefosine (INN); CAS-58066-85-6; D 18506; Choline hexadecyl phosphate; BRN 3690495; Miltextrade mark; HePC Hydrate; Impavidotrade mark; D18506; Impavido (TN); Choline, inner salt; Miltefosine, 98%; TF-002; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; NSC 605583; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl Phosphorylcholine; H-1850; M-7200; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; SCHEMBL26215; 4-04-00-01460 (Beilstein Handbook Reference); SPECTRUM1505329; ETH098; DTXSID7045942; GTPL11355; Hexadecyl Phosphorylcholine Hydrate; HMS1922D16; HMS2089J15; HMS3649I09; Pharmakon1600-01505329; hexadecylphosphocholine, miltefosine; BCP04506; miltefosine (hexadecylphosphocholine); Tox21_111466; BDBM50034220; CCG-35584; CCG-36097; CCG-40025; DL-131; Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; NSC758968; s3056; 1-N-HEXADECYLPHOSPHORYLCHOLINE; AKOS015914886; Tox21_111466_1; BCP9000927; DB09031; NSC-758968; NCGC00095169-02; NCGC00095169-03; NCGC00095169-05; AK163678; HY-13685; BCP0726000071; FT-0608148; M2445; hexadecyloxy-2-trimethylammonioethylphosphorate; D02494; AB00642217-03; AB00642217_04; Miltefosine, >=98% (perchloric acid titration); A831718; Q411787; Hexadecyl 2-(Trimethylammonio)ethyl Phosphate Hydrate; 2-[hexadecoxy(hydroxy)phosphoryl]oxyethyl-trimethyl-ammonium; Phosphoric Acid Hexadecyl 2-(Trimethylammonio)ethyl Ester; [2-(Hexadecyloxy-hydroxy-phosphoryloxy)-ethyl]-trimethyl-ammonium; 3, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide; hexadecyl 2-(trimethyl-lambda~5~-azanyl)ethyl hydrogen phosphate; Phosphoric Acid Hexadecyl 2-(Trimethylammonio)ethyl Ester Hydrate; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide; Ethanaminium, 2-[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt	Small molecule	1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3	PQLXHQMOHUQAKB-UHFFFAOYSA-N	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C	C21H46NO4P	CAS 58066-85-6	CHEBI:75283	.	.	.	D00FGR	.	.	.
NP7092	Green tea catechins	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP7094	Noscapine	CID: 275196	noscapine; 128-62-1; NARCOTINE; Tusscapine; Terbenol; Capval; Coscopin; Narcompren; Narcosine; Noscapin; Vadebex; Methoxyhydrastine; Narcotin; Narkotin; Noscapalin; Opianine; Opianin; Narcotussin; Longatin; Nectadon; Nicolane; Nipaxon; Lyobex; Opian; (-)-Narcotine; alpha-Narcotine; O-Methylnarcotoline; Coscotabs; Key-tusscapine; Longactin; Noscapal; Noscapina; Noscapinum; Hederix (free base); (-)-alpha-narcotine; L-alpha-Narcotine; Noscopine; UNII-8V32U4AOQU; NSC 5366; NSC-5366; .alpha.-Narcotine; Gnoscopine; L-.alpha.-Narcotine; 8V32U4AOQU; dl-Narcotine; alpha-Gnoscopine; (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-2-benzofuran-1(3H)-one; (S)-6,7-dimethoxy-3-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one; CHEBI:73237; NSC5366; (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; DSSTox_CID_3385; DSSTox_RID_77007; DSSTox_GSID_23385; Q60998699; Narcotine alkaloid; Noskapin; Noscapine dl-form; L-alpha-Noscapine; 8-Methoxyhydrastin; Coscopin (VAN); (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-2H,5H,6H,7H,8H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-1,3-dihydro-2-benzofuran-1-one; (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)-isoquinolin-5-yl), (S-(R*,S*))-; SMR000059119; (+-)-Noscapine; (-)-.alpha.-Norcotine; (-)-alpha-Norcotine; (+-)-alpha-Narcotine; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (S-(R*,S*))-; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-, [S-(R*,S*)]-; 6035-40-1; Noscapinum [INN-Latin]; Noscapina [INN-Spanish]; CCRIS 9304; HSDB 3372; Noscapine [USP:INN:BAN:JAN]; .beta.-Narcotine; Noscapine (TN); (-)-noscapine; NCGC00016388-01; [S-(R*,S*)]-6,7-Dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-1(3H)-Isobenzofuranone; CAS-128-62-1; Narcotine (8CI); Prestwick_959; (-)-a-Narcotine; EINECS 204-899-2; NSC 96350; 1-.alpha.-Narcotine; BRN 0099933; Tocris-1697; Narcotine, (+-)-; Prestwick0_000563; Prestwick1_000563; Prestwick2_000563; Prestwick3_000563; (-)-.alpha.-Narcotine; CBMicro_048259; SCHEMBL4559; (S,R)-Noscapine, 97%; Lopac0_000840; BSPBio_000346; 4-27-00-06838 (Beilstein Handbook Reference); MLS000069475; MLS001060855; ARONIS24067; SPBio_002565; Noscapine (JP15/USP/INN); Noscapine (JP17/USP/INN); BPBio1_000382; CHEMBL364713; DTXSID4023385; GTPL10212; HMS1569B08; HMS2096B08; HMS2269P05; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-((5R)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (3S)-; 6,7-Dimethoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-2-benzofuran-1(3H)-one, (S-(R*,S*))- #; Phthalide, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-; Tox21_110413; BBL012344; BDBM50424716; MFCD00069316; NSC121869; STK054401; ZINC19418974; Noscapine 1.0 mg/ml in Acetonitrile; AKOS000278036; Tox21_110413_1; CCG-204096; CS-5115; DB06174; MCULE-5334942206; NSC-121869; SDCCGSBI-0048054.P004; (-)-3-(2-Methyl-6,7-methylendioxy-8-methoxy-1-isochinolyl)-6,7-dimethoxyphthalid; NCGC00023230-02; NCGC00023230-04; NCGC00023230-05; NCGC00023230-07; NCGC00023230-08; NCGC00023230-10; NCGC00023230-14; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-((5R)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (3S)-rel-; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R*,S*)-; 5-(6,7-Dimethoxyphthalidyl)-5,6,7,8-tetrahydro-4-methoxy-8-methyl-1,3-dioxolo(4,5-g)isoquinoline; AC-20272; AC-33191; HY-13716; L-alpha-2-Methyl-8-methoxy-6,7-methylenedioxy-1-(6,7-dimethoxy-3-phthalidyl)-1,2,3,4-tetrahydroisoquinaline; NCI60_004322; VS-03291; BIM-0048054.P001; H2069; C09592; D01036; A805851; SR-01000075529-6; W-201012; BRD-K89237706-001-03-8; Noscapine, European Pharmacopoeia (EP) Reference Standard; UNII-A4C6WE7BZN component AKNNEGZIBPJZJG-MSOLQXFVSA-N; Noscapine, United States Pharmacopeia (USP) Reference Standard; WLN: T C566 DO FO KN EH & & TJ HO1 K1 J-DT56 BVO DHJ HO1 IO1; (3S)-3-[(5R)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3H)-one; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R*,S*)-(+-)-; 1(3H)-Isobenzofuranone,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-, [S-(R*,S*)]-; Phthalide,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-	Small molecule	1S/C22H23NO7/c1-23-8-7-11-9-14-20(29-10-28-14)21(27-4)15(11)17(23)18-12-5-6-13(25-2)19(26-3)16(12)22(24)30-18/h5-6,9,17-18H,7-8,10H2,1-4H3/t17-,18+/m1/s1	AKNNEGZIBPJZJG-MSOLQXFVSA-N	CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3	C22H23NO7	CAS 6035-40-1	CHEBI:73237	.	.	.	D0Y8AW	.	.	.
NP7102	Elemene	CID: 6918391	Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1R,2R,4S)-rel-; 33880-83-0; beta-Elemene, (-)-; (- )-bete-elemene; EINECS 251-713-0; AC1L1VID; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-; OPFTUNCRGUEPRZ-UHFFFAOYSA-N; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; (1alpha,2beta,4beta)-1-Methyl-2,4-bis(methylvinyl)-1-vinylcyclohexane; LS-56795; EN300-296339; 1-Methyl-1-vinyl-2,4-diisopropenylcyclohexane	.	1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3/t13-,14+,15-/m1/s1	OPFTUNCRGUEPRZ-QLFBSQMISA-N	CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C	C15H24	CAS 33880-83-0	.	HBIN024973	SMIT18326	.	D04VMG	.	991	.
NP7106	Rofecoxib	CID: 5090	rofecoxib; 162011-90-7; Vioxx; Ceoxx; MK 966; 4-(4-(Methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one; MK-966; MK 0966; MK-0966; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; MK0966; UNII-0QTW8Z7MCR; 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; Rofecoxib (Vioxx); C17H14O4S; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 0QTW8Z7MCR; CHEMBL122; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-; CHEBI:8887; TRM-201; refecoxib; NCGC00095118-01; Vioxx Dolor; 2(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-; Vioxx (trademark); SMR000466331; CCRIS 8967; Vioxx (TN); HSDB 7262; SR-01000762904; rofecoxibum; Rofecoxib (JAN/USAN/INN); Rofecoxib [USAN:INN:BAN]; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; MK966; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; KS-1107; MK 0996; PubChem15028; Spectrum_000119; SpecPlus_000669; Spectrum2_000446; Spectrum3_001153; Spectrum4_000631; Spectrum5_001598; DSSTox_CID_3567; SCHEMBL3050; DSSTox_RID_77084; DSSTox_GSID_23567; BSPBio_002705; KBioGR_001242; KBioGR_002345; KBioSS_000559; KBioSS_002348; MLS000759440; MLS001165770; MLS001195623; MLS001424113; MLS006010091; BIDD:GT0399; DivK1c_006765; SPECTRUM1504235; SPBio_000492; 3-(4-methanesulfonylphenyl)-2-phenyl-2-buten-4-olide; GTPL2893; ZINC7455; DTXSID2023567; BDBM22369; KBio1_001709; KBio2_000559; KBio2_002345; KBio2_003127; KBio2_004913; KBio2_005695; KBio2_007481; KBio3_002205; KBio3_002825; AOB6956; EX-A708; M01AH02; cMAP_000024; HMS1922H11; HMS2051G16; HMS2089H20; HMS2093E04; HMS2232G21; HMS3371P11; HMS3393G16; HMS3651F16; HMS3713B07; HMS3750I17; HMS3885E05; Pharmakon1600-01504235; BCP03619; EBD34785; Tox21_111430; ANW-71936; CCG-40253; MFCD00935806; NSC720256; NSC758705; s3043; STK635144; AKOS000280931; AB07701; CS-0997; DB00533; MCULE-4806636118; NC00132; NSC 720256; NSC 758705; NSC-720256; NSC-758705; SB19518; VA11689; NCGC00095118-02; NCGC00095118-03; NCGC00095118-04; NCGC00095118-05; NCGC00095118-08; NCGC00095118-17; NCGC00095118-18; AC-28318; AK-60971; HY-17372; NCI60_041175; SBI-0206774.P001; AB0012045; CAS-162011-90-7; FT-0631192; R0206; SW219668-1; C07590; D00568; J10420; K-5064; AB00052090-06; AB00052090-08; AB00052090_09; AB00052090_10; 011R907; A810324; L000912; Q411412; Q-201676; SR-01000762904-3; SR-01000762904-5; BRD-K21733600-001-02-6; BRD-K21733600-001-06-7; 3-(4-methanesulfonyl-phenyl)-2-phenyl-2-buten-4-olide; 2(5H)-Furanone, 4-[4-(methyl-sulfonyl)phenyl]-3-phenyl-; 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 3-Phenyl-4-(4-(Methylsulfonyl)Phenyl)-2-(5H)-Furanone; 4-(4-METHANESULFONYL-PHENYL)-3-PHENYL-5H-FURAN-2-ONE; 4-(4-methanesulfonylphenyl)-3-phenyl-2,5-dihydrofuran-2-one; 4-(4-methylsulfonylphenyl)-3-phenyl-2,5-dihydro-2-furanone; Vioxx; 4-[4-(Methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one	Small molecule	1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3	RZJQGNCSTQAWON-UHFFFAOYSA-N	CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3	C17H14O4S	CAS 162011-90-7	CHEBI:8887	.	.	.	D05VLS	.	.	.
NP7145	Levosimendan	CID: 3033825	LEVOSIMENDAN; 141505-33-1; Simdax; (-)-OR-1259; UNII-C6T4514L4E; OR-1259; CHEBI:50567; C6T4514L4E; (R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide; Levosimedan; DSSTox_CID_26445; DSSTox_RID_81620; DSSTox_GSID_46445; (R)-Simendan; levosimendanum; SMR002529692; Simdax (TN); CAS-141505-33-1; Levosimendan (USAN/INN); Levosimendan [USAN:INN]; OR 1259; OR1259; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; SCHEMBL83243; MLS003899227; MLS006010741; CHEMBL2051955; DTXSID9046445; Levosimendan, >=98% (HPLC); HMS3264G03; HMS3884N17; KUC109648N; Pharmakon1600-01502356; ACT02710; BCP07048; ZINC3915645; Tox21_112191; Tox21_113768; BDBM50469700; MFCD00867135; NSC759644; s2446; AKOS015895214; Tox21_112191_1; AC-1752; AM84381; CCG-213048; DB00922; DS-8918; NSC 759644; NSC-759644; SB17415; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; KSC-210-010; Mesoxalonitrile (p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; NCGC00253641-01; NCGC00263564-01; NCGC00263564-02; HY-14286; SW219172-1; A11874; D04720; AB01562970_01; AB01562970_02; 741L087; A807767; Q162541; SR-01000931342; SR-01000931342-2; 1-beta-D-Ribofuranose-1H-1,2,4-triazole-3-methylcarbonate; UNII-349552KRHK component WHXMKTBCFHIYNQ-SECBINFHSA-N; (R)-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide; 1-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}methanecarbohydrazonoyl cyanide; 2-[[4-[(4R)-4-methyl-6-oxidanylidene-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile	Small molecule	1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1	WHXMKTBCFHIYNQ-SECBINFHSA-N	CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N	C14H12N6O	CAS 141505-33-1	CHEBI:50567	.	.	.	D0C4HG	.	.	.
NP7186	Genistin	CID: 5281377	Genistin; 529-59-9; Genistine; Genistein 7-glucoside; Genistoside; Genisteol 7-monoglucoside; Genistein 7-O-beta-D-glucoside; UNII-1POG3SCN5T; NSC 5112; Glucosyl-7-genistein; CHEBI:27514; 1POG3SCN5T; MFCD00016883; Genistein, 7-O-beta-D-glucoside; 4',5,7-Trihydroxyisoflavone 7-glucoside; genistein 7-O-glucoside; 4',5,7-trihydroxyisoflavone 7-D-glucoside; Genistein, 7-beta-D-glucopyranoside; Isoflavone, 4',5,7-trihydroxy-, 7-D-glucoside; 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-3-(4-hydroxyphenyl)-; 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside; 5-hydroxy-3-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; Genistin (8CI); 5-hydroxy-3-(4-hydroxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; Glucopyranoside, genistein-7, beta-D-; BRN 0064479; Genistein-7-O-beta-D-glucopyranoside; 7-O-.beta.-D-glucopyranosyl genistein; Genistein glycoside; Genistin,(S); 5-hydroxy-3-(4-hydroxyphenyl)-7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one; Prevention 10 (soy isoflavone concentrate); 4',5,7-Trihydroxyisoflavone 7-.beta.-D-glucopyranoside; SCHEMBL62148; Genistin, analytical standard; 4-18-00-02732 (Beilstein Handbook Reference); MLS006010735; BIDD:ER0520; CHEMBL486625; MEGxp0_000436; DTXSID3022324; ACon1_001495; AOB5041; Genistin - CAS 529-59-9; Genistin, >=97.5% (TLC); HY-N0595; ZINC4097913; BDBM50025609; AKOS025146960; CCG-208377; CS-4240; MCULE-3462482152; NCGC00163559-01; NCGC00163559-02; NCGC00180447-01; AS-11684; SMR003929926; N1860; C09126; S-7711; S-7758; 529G599; Genistin, primary pharmaceutical reference standard; Q-100603; Q5533221; BRD-K51391729-001-01-4; Genistin, from Glycine max (soybean), >=95% (HPLC); UNII-71B37NR06D component ZCOLJUOHXJRHDI-CMWLGVBASA-N; Genistin, United States Pharmacopeia (USP) Reference Standard; 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)- (9CI)	Small molecule	1S/C21H20O10/c22-7-15-18(26)19(27)20(28)21(31-15)30-11-5-13(24)16-14(6-11)29-8-12(17(16)25)9-1-3-10(23)4-2-9/h1-6,8,15,18-24,26-28H,7H2/t15-,18-,19+,20-,21-/m1/s1	ZCOLJUOHXJRHDI-CMWLGVBASA-N	C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)OC4C(C(C(C(O4)CO)O)O)O)O	C21H20O10	CAS 529-59-9	CHEBI:27514	.	.	.	.	.	.	.
NP7199	Cefixime	CID: 5362065	CEFIXIME; 79350-37-1; Cefixima; Cefiximum; Cephoral; Cefspan; Cefiximum [Latin]; Cefixim; (-)-Cefixim; Oroken; FK-027; Cefixima [Spanish]; Suprax; UNII-XZ7BG04GJX; FR-17027; CL-284635; FK 027; FR 17027; Cefixime Anhydrous; XZ7BG04GJX; MLS002222332; Cefixoral; CHEBI:472657; (E)-Cefixime; CFIX; Cefixime, 98%; Cefixime hydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; SMR001307271; Unixime; CL 284,635; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Necopen; Denvar; Tricef; (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-((carboxymethoxy)imino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefixime (INN); Cefixime [USAN:USP:INN:BAN:JAN]; BRN 6025058; PubChem13762; CL 284635; Prestwick3_000462; CHEMBL1541; SCHEMBL24945; BSPBio_000564; BPBio1_000622; BDBM84007; cid_5362065; HMS2096M06; HMS2234J21; HMS3713M06; HY-B1381; MFCD00865020; s4596; ZINC12503147; AKOS015854940; AKOS015961135; AC-4350; AT-7061; CCG-220462; CS-4820; DB00671; NCGC00179521-01; NCGC00179521-03; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-(carboxymethyl)oxime) trihydrate; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid; AB0073052; AB00513842; 50C371; A13697; C06881; D00258; X-2622; Cefixime, Antibiotic for Culture Media Use Only; SR-01000760706; SR-01000760706-4; BRD-K71059170-001-02-5; BRD-K71059170-001-08-2; Q27290799; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-(carboxymethyl)oxime)trihydrate; (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2z)-2-(2-amino-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]Oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, trihydrate, (6R-(6alpha,7beta(Z)))-; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, (6R,7R)-; C04	Small molecule	1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1	OKBVVJOGVLARMR-QSWIMTSFSA-N	C=CC1=C(N2C(C(C2=O)NC(=O)C(=NOCC(=O)O)C3=CSC(=N3)N)SC1)C(=O)O	C16H15N5O7S2	CAS 79350-37-1	CHEBI:472657	.	.	.	D06OVY	.	.	.
NP7288	Plaunotol	CID: 5282197	plaunotol; Kelnac; 64218-02-6; Plaunotolum; CS-684; 18-hydroxygeranylgeraniol; (E,Z,E)-7-Hydroxymethyl-3,11,15-trimethyl-2,6,10,14-hexadecatetraen-1-ol; UNII-MV715X4634; CHEBI:32023; MV715X4634; (2Z,6E)-2-[(3E)-4,8-dimethylnona-3,7-dien-1-yl]-6-methylocta-2,6-diene-1,8-diol; (2Z,6E)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-6-methylocta-2,6-diene-1,8-diol; Plaunotolum [Latin]; Plaunotol [INN:JAN]; Kelnac (TN); (2Z,6E)-2-((E)-4,8-Dimethylnona-3,7-dien-1-yl)-6-methylocta-2,6-diene-1,8-diol; Plaunotol (JAN/INN); SCHEMBL440334; CHEMBL285815; 2,6-Octadiene-1,8-diol, 2-[(3e)-4,8-dimethyl-3,7-nonadienyl]-6-methyl-, (2Z,6E)-; ZINC13907151; LMPR0104010010; (2Z,6E)-2-((3E)-4,8-Dimethyl-3,7-nonadienyl)-6-methyl-2,6-octadiene-1,8-diol; 2,6,10,14-HEXADECATETRAEN-1-OL, 7-(HYDROXYMETHYL)-3,11,15-TRIMETHYL-, (E,Z,E)-; C13273; D01803; Q27114751; 2,6-Octadiene-1,8-diol, 2-(4,8-dimethyl-3,7-nonadienyl)-6-methyl-, (Z,E,E)- (9CI)	Small molecule	1S/C20H34O2/c1-17(2)8-5-9-18(3)10-6-12-20(16-22)13-7-11-19(4)14-15-21/h8,10,13-14,21-22H,5-7,9,11-12,15-16H2,1-4H3/b18-10+,19-14+,20-13-	SUWYPNNPLSRNPS-UNTSEYQFSA-N	CC(=CCCC(=CCCC(=CCCC(=CCO)C)CO)C)C	C20H34O2	CAS 64218-02-6	CHEBI:32023	.	.	.	D05XQE	.	.	.
NP7293	Glucosamine	CID: 439213	2-Amino-2-Deoxy-D-Glucopyranose; 2-Amino-2-Deoxy-D-Glucopyranoside; 2-Amino-2-Deoxy-D-Glucose; 2-Amino-2-Deoxy-Glucopyranose; 2-Amino-2-Deoxy-Glucopyranoside; 2-Amino-2-Deoxy-Glucose; 2-Deoxy-2-Amino-D-Glucopyranose; 2-Deoxy-2-Amino-D-Glucopyranoside; 2-Deoxy-2-Amino-D-Glucose; 2-Deoxy-2-Amino-Glucopyranose; 2-Deoxy-2-Amino-Glucopyranoside; 2-Deoxy-2-Amino-Glucose; D-GlcN; D-Glucosamine; GlcN; Glucosamine; chitosamine; D-(+)-Glucosamine; 2-amino-2-deoxyglucose; Glucosamine free base; CHEBI:47977; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 3416-24-8 (free base); 2-Aminoglucose; D-Glucose, 2-amino-2-deoxy-; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)tetrahydro-2H-pyran-2,4,5-triol; Glucosaminum [INN-Latin]; Glucosamina [INN-Spanish]; glucosamine group; GlcNH2; 2-Deoxy-2-aminoglucose; Glucosamine (USAN/INN); Glucosamine [USAN:INN]; bmse000247; Epitope ID:151531; SCHEMBL167831; 2-Amino-2-deoxyhexopyranose #; CHEMBL493287; BBL009288; STK801823; AKOS005622471; (+)-2-amino-2-deoxy-D-glucopyranose; DB01296; DB-017621; C00329; D04334; Q327506; J-019472	Small molecule	1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6?/m1/s1	MSWZFWKMSRAUBD-IVMDWMLBSA-N	C(C1C(C(C(C(O1)O)N)O)O)O	C6H13NO5	CAS 3416-24-8	CHEBI:47977	.	.	.	D07NSU	.	.	.
NP7303	Silymarin	CID: 5213	Milk thistle extract; Sabal serrulata extract; 84604-20-6; AN-35849; FT-0656490; A835184; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chroman-4-one	.	1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3	SEBFKMXJBCUCAI-UHFFFAOYSA-N	COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O	C25H22O10	CAS 65666-07-1	.	HBIN044040	SMIT18310	.	D0AZ8C	.	.	.
NP7330	Citral	CID: 638011	Citral; GERANIAL; 5392-40-5; trans-Citral; (2E)-3,7-dimethylocta-2,6-dienal; geranialdehyde; 3,7-dimethylocta-2,6-dienal; (E)-Citral; Citral a; Geranaldehyde; alpha-Citral; (E)-Geranial; geranal; Genanial; beta-Geranial; 141-27-5; (E)-3,7-Dimethylocta-2,6-dienal; 3,7-Dimethyl-2,6-octadienal; (E)-Neral; 2,6-Octadienal, 3,7-dimethyl-; Lemsyn GB; CITRAL NATURAL; trans-3,7-Dimethyl-2,6-octadienal; 2,6-Octadienal, 3,7-dimethyl-, (2E)-; lemonal; cis-Citral; NCI-C56348; 2,6-Octadienal, 3,7-dimethyl-, (E)-; (E)-3,7-Dimethyl-2,6-octadienal; 3,7-Dimethyl-trans-2,6-octadienal; UNII-758ZMW724E; FEMA No. 2303; 147060-73-9; cis/trans-3,7-Dimethyl-2,6-octadienal; Lemarome n; CHEBI:16980; NSC6170; 758ZMW724E; MFCD00006997; cis-3,7-Dimethyl-2,6-octadienal; NSC 6170; Citral alpha; Citral, analytical standard; Citral (natural); Z-Citral; Citral, mixture of cis and trans; Caswell No. 221B; citral-b; FEMA Number 2303; Citral, 95%, mixture of cis and trans; CCRIS 1043; HSDB 993; CITRAL SINTETICO; 2,6-Dimethyloctadien-2,6-al-8; 3,7-Dimethyl-1,2,6-octadienal; EINECS 205-476-5; EINECS 226-394-6; EPA Pesticide Chemical Code 040510; BRN 1721871; BRN 1721873; polyprenal; polyprenals; Natural Citral; AI3-01011; AI3-28519; alpha -Citral; (2Z)-3,7-Dimethyl-2,6-octadienal; Citral N; Citral-A; .alpha.-Citral; 3,6-octadienal; cis/trans Citral;; (2e)-geranial; LEMAROME; 3,2,6-octadienal; (2E)-3,7-Dimethyl-2,6-octadienal; Citral, cis + trans; Citral, 95%; EC 205-476-5; EC 226-394-6; Citral Ex Litsea(Citral ); litsea cubeba oil terpeneless; SCHEMBL23073; 3-01-00-03053 (Beilstein Handbook Reference); 4-01-00-03569 (Beilstein Handbook Reference); GTPL6327; CHEMBL1080997; 3,7- dimethylocta-2,6-dienal; FEMA 2303; DTXSID20881217; CHEBI:137934; WLN: VH1UY1&3Y1&U1; HY-N7083; NSC-6170; ZINC1529208; 3,7-dimethyl-(e)-2,6-octadienal; BBL011666; SBB060834; STK802499; 3,7-dimethyl-(2e)-2,6-octadienal; trans-3,7-dimethyl-octa-2,6-dienal; AKOS000119519; CCG-266236; Citral, natural, >=96%, FCC, FG; CS-W010948; EBD2204555; LMPR0102010003; LS41486; (2E)-3,7-dimethyl-octa-2,6-dienal; Citral, Vetec(TM) reagent grade, 94%; NCGC00091550-01; NCGC00091550-02; NCGC00091550-03; NCGC00091550-04; AS-35309; (2E)-3,7-dimethyl-2,6-octadien-1-al; 2,6- OCTADIENAL, 3,7-DIMETHYL-; S5138; ST50308094; 3,7-DIMETHYL-2,6-OCTADIENAL(TRANS); C01499; C15604; Citral, mixture of cis and trans, >=96%, FG; A829835; Q410888; Q-200867; F0001-1403; UNII-T7EU0O9VPP component WTEVQBCEXWBHNA-JXMROGBWSA-N; 2,6-Octadienal,3,7-dimethyl-, reaction products with Et alc.; GRQ	Small molecule	1S/C10H16O/c1-9(2)5-4-6-10(3)7-8-11/h5,7-8H,4,6H2,1-3H3/b10-7+	WTEVQBCEXWBHNA-JXMROGBWSA-N	CC(=CCCC(=CC=O)C)C	C10H16O	CAS 5392-40-5	CHEBI:16980	.	.	.	D00VWN	.	.	.
NP7376	Visnagin	CID: 6716	Visnagin; 82-57-5; Desmethoxykhellin; Visnagidin; Visnagine; 4-Methoxy-7-methyl-5H-furo[3,2-g]chromen-5-one; 5-Methoxy-2-methylfuranochromone; 4-methoxy-7-methylfuro[3,2-g]chromen-5-one; UNII-P64438MLBW; 4-Methoxy-7-methyl-furo[3,2-g]chromen-5-one; CHEMBL45176; P64438MLBW; CHEBI:10002; 5H-Furo[3,2-g][1]benzopyran-5-one, 4-methoxy-7-methyl-; 5H-FURO(3,2-g)(1)BENZOPYRAN-5-ONE, 4-METHOXY-7-METHYL-; 4-Methoxy-7-methylfuro(3,2-g)chromen-5-one; Desmethoxykhellin; NSC 100593; Visnagidin; Visnagine; 4-Methoxy-7-methyl-5H-furo[3,2-g][1]benzopyran-5-one, 97%; 5-methoxy-2-methylfurano[3,2-g]chromen-4-one; SR-01000765669; EINECS 201-430-3; NSC 100593; BRN 0234955; 4-Methoxy-7-methyl-5H-furo(3,2-g)(1)-benzopyran-5-one; 5H-Furo[3,2-g][1]benzopyran-5-one,4-methoxy-7-methyl-; Spectrum_001227; SpecPlus_000453; Spectrum2_001796; Spectrum3_001340; Spectrum4_001766; Spectrum5_000351; Oprea1_854963; BSPBio_003099; GTPL433; KBioGR_002251; KBioSS_001707; SPECTRUM310041; 5-19-06-00030 (Beilstein Handbook Reference); MLS000697721; DivK1c_006549; SCHEMBL498450; SPBio_001751; MEGxp0_000332; KBio1_001493; KBio2_001707; KBio2_004275; KBio2_006843; KBio3_002319; NZVQLVGOZRELTG-UHFFFAOYSA-; DTXSID50231509; FUK-724; HMS2268P15; ZINC120179; 5H-Furo[3, 4-methoxy-7-methyl-; BBL027492; BDBM50051349; CCG-38444; LMPK13110003; NSC100593; SBB057568; STL372894; AKOS015955735; MCULE-6909437128; NSC-100593; SDCCGMLS-0066603.P001; NCGC00095626-01; NCGC00095626-02; NCGC00178297-01; SMR000112234; VS-08551; DB-056633; FT-0603293; ST50307139; W2039; C09049; L000822; 4-methoxy-7-methylpyrano[3,2-f][1]benzoxol-5-one; Q7936365; SR-01000765669-3; SR-01000765669-4; 4-Methoxy-7-methyl-5H-furo[3,2-g]chromen-5-one #; BRD-K68995359-001-02-8; BRD-K68995359-001-06-9; 4-Methoxy-7-methyl-5H-furo[3,2-g]-1-benzopyran-5-one; NCGC00095626-04!4-methoxy-7-methylfuro[3,2-g]chromen-5-one	Small molecule	1S/C13H10O4/c1-7-5-9(14)12-11(17-7)6-10-8(3-4-16-10)13(12)15-2/h3-6H,1-2H3	NZVQLVGOZRELTG-UHFFFAOYSA-N	CC1=CC(=O)C2=C(O1)C=C3C(=C2OC)C=CO3	C13H10O4	CAS 82-57-5	CHEBI:10002	.	.	.	D0MH4R	.	.	.
NP7415	Melatonin	CID: 896	Melatonine; Circadin; 5-Methoxy-N-acetyltryptamine; BRN 0205542; Melatonex	Small molecule	1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)	DRLFMBDRBRZALE-UHFFFAOYSA-N	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC	C13H16N2O2	CAS 73-31-4	.	.	.	.	D0AN7B	.	.	.
NP7418	Khellin	CID: 3828	khellin; 82-02-0; Visammin; Amicardine; Methafrone; Coronin; Amikellin; Ammipuran; Ammivisnagen; Benecardin; Corafurone; Gynokhellan; Medekellin; Viscardan; Kelourin; Rykellin; Interkhellin; Ammispasmin; Interkellin; Kalangin; Kelicorin; Kelincor; Khelangin; Khellamine; Khellanals; Khellinorm; Khelloyd; Visammimix; Visnagalin; Ammivin; Kelamin; Norkel; Kellosal; Khelfren; Khelisem; Lynamine; Mefurina; Simeskellina; Vasokellina; Visnagen; Amiptan; Chellin; Kelicor; Kellin; Kellina; Keloid; Eskel; Cardio-khellin; Ammi-khellin; Bi-Kellina; Benekardin; Khelline I; Chellina; Khelline; Ammicardine; Khellinum; Quelina; 4,9-Dimethoxy-7-methyl-5H-furo[3,2-g]chromen-5-one; 5,8-Dimethoxy-2-methyl-6,7-furanochromone; 5H-Furo[3,2-g][1]benzopyran-5-one, 4,9-dimethoxy-7-methyl-; Viscardin; 4,9-Dimethoxy-7-methyl-5H-furo(3,2-g)(1)benzopyran-5-one; 5,8-Dimethoxy-2-methyl-4',5'-furo-6,7-chromone; UNII-5G117T0TJZ; IT-033; CHEBI:6133; 5,8-Dimethoxy-2-methyl-4',5'-furano-6,7-chromone; 4,9-Dimethoxy-7-methyl-5-oxo-1,8-dioxabenz-(f)indene; 4,9-Dimethoxy-7-methyl-5-oxofuro(3,2-g)(1)benzopyran; 4,9-Dimethoxy-7-methyl-5-oxofuro(3,2-g)-1,2-chromene; NSC37744; 5H-Furo(3,2-g)(1)benzopyran-5-one, 4,9-dimethoxy-7-methyl-; Chorafurone; Vismagen; Khell; MLS000028448; 5G117T0TJZ; 4,9-Dimethoxy-7-methyl-5H-furo[3,2-g][1]benzopyran-5-one; NSC8519; 5,7-furanochromone; MFCD00005007; CAS-82-02-0; NCGC00016327-01; SMR000058278; 4,2-g][1]benzopyran; 4,8-dioxabenz-[f]indene; 4,2-g]-1,2-chromene; DSSTox_CID_25267; DSSTox_RID_80779; DSSTox_GSID_45267; 5,5'-furo-6,7-chromone; 5,5'-furano-6,7-chromone; Chellina [Italian]; 5,9-dimethoxy-2-methylfurano[3,2-g]chromen-4-one; 4,2-g][1]benzopyran-5-one; Khellin [INN:DCF]; Khelline [INN-French]; Khellinum [INN-Latin]; Quelina [INN-Spanish]; 5H-Furo[3, 4,9-dimethoxy-7-methyl-; WLN: T C566 DO JV MOJ BO1 HO1 L1; SR-01000000072; EINECS 201-392-8; NSC 25509; NSC 37744; BRN 0263185; Gynokhellin; Intercellin; Hkelfren; AI3-52114; Prestwick_287; Spectrum_000079; Khellin, for microscopy; Opera_ID_372; 4,9-Dimethoxy-7-methyl-5H-furo[3,2-g]-[1]benzopyran-5-one; Prestwick0_000091; Prestwick1_000091; Prestwick2_000091; Prestwick3_000091; Spectrum2_000593; Spectrum3_000654; Spectrum4_001557; Spectrum5_000154; bmse000751; SCHEMBL9655; Khellin, analytical standard; BSPBio_000042; BSPBio_002287; KBioGR_002054; KBioSS_000479; SPECTRUM210866; 4,9-dimethoxy-7-methylfuro[3,2-g]chromen-5-one; 5-19-06-00320 (Beilstein Handbook Reference); MLS001076533; CHEMBL44746; DivK1c_000046; SPBio_000466; SPBio_001981; BPBio1_000048; MEGxp0_000331; DTXSID9045267; ACon0_000983; ACon1_000350; HMS500C08; HSMPDPBYAYSOBC-UHFFFAOYSA-; KBio1_000046; KBio2_000479; KBio2_003047; KBio2_005615; KBio3_001507; ZINC56654; NINDS_000046; HMS1568C04; HMS1923M07; HMS2095C04; HMS2230B16; HMS3371C21; HMS3712C04; Pharmakon1600-00210866; ALBB-025052; HY-B1394; NSC-8519; NSC25509; Tox21_110374; BDBM50480260; CCG-36453; LMPK13110001; NSC-25509; NSC-37744; NSC755826; s5887; SBB072185; STL561007; AKOS002281934; Tox21_110374_1; MCULE-6233012340; NSC-755826; SDCCGMLS-0003040.P003; IDI1_000046; NCGC00016327-02; NCGC00016327-03; NCGC00016327-04; NCGC00016327-05; NCGC00016327-06; NCGC00016327-07; NCGC00016327-08; NCGC00016327-09; NCGC00016327-11; NCGC00023424-03; NCGC00023424-04; NCGC00169160-01; NCGC00169160-02; NCGC00169160-03; AS-35307; ST076676; SBI-0051567.P002; CS-0013121; FT-0627578; K0039; R1111; W2041; C09010; AB00052134_16; 4,9-Dimethoxy-7-methyl-furo[3,2-g]chromen-5-one; Q2079998; SR-01000000072-3; SR-01000000072-4; SR-01000000072-5; SR-01000000072-6; BRD-K80353807-001-05-5; BRD-K80353807-001-06-3; BRD-K80353807-001-16-2; 4,9-dimethoxy-7-methylpyrano[3,2-f][1]benzoxol-5-one; 4,9-Dimethoxy-7-methyl-5H-furo[3,2-g]chromen-5-one #; NCGC00016327-13!4,9-dimethoxy-7-methylfuro[3,2-g]chromen-5-one	Small molecule	1S/C14H12O5/c1-7-6-9(15)10-11(16-2)8-4-5-18-12(8)14(17-3)13(10)19-7/h4-6H,1-3H3	HSMPDPBYAYSOBC-UHFFFAOYSA-N	CC1=CC(=O)C2=C(C3=C(C(=C2O1)OC)OC=C3)OC	C14H12O5	CAS 82-02-0	CHEBI:6133	.	.	.	D0G4KG	.	.	.
NP7424	Emodin	CID: 3220	Emodol; Frangula emodin; Schuttgelb; Rheum emodin; Frangulic acid; Persian Berry Lake	.	1S/C15H10O5/c1-6-2-8-12(10(17)3-6)15(20)13-9(14(8)19)4-7(16)5-11(13)18/h2-5,16-18H,1H3	RHMXXJGYXNZAPX-UHFFFAOYSA-N	CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O	C15H10O5	CAS 518-82-1	.	HBIN025041	SMIT00049	MOL000472	D0I0TB	.	708	.
NP7425	Zinc oxide	CID: 14806	ZINC OXIDE; 1314-13-2; oxozinc; Zinc White; Zinc oxide (ZnO); Zinc monoxide; Zinc Oxide Powder; MFCD00011300; Amalox; Chinese White; Snow white; Emanay zinc oxide; Felling zinc oxide; Akro-zinc bar 85; Flowers of zinc; Azo-33; Outmine; Supertah; Zincite; Zincoid; Azodox; Ozide; Ozlo; Zincum Oxydatum; Lassars Paste; Zinc oxide, ACS reagent; Flores de zinci; Lassar Paste; Zinci Oxicum; Zinci Oxydum; Hubbuck's White; Blanc de Zinc; Unichem ZO; Zinc oxide, 99.5+%; Vandem VAC; Vandem VOC; Vandem VPC; Green seal-8; Philosopher's wool; White seal-7; K-Zinc; ZNO; Powder base 900; Protox type 166; Protox type 167; Protox type 168; Protox type 169; Protox type 267; Protox type 268; Akro-zinc bar 90; Azodox-55; Azodox-55TT; Red Seal 9; EMAR; CI Pigment white 4; Electrox 2500; Actox 14; Actox 16; Kadox 15; Kadox 72; Kadox-25; Zinc oxide [USAN]; Zinca 20; Protox 166; Protox 168; Protox 169; Caswell No. 920; Electox 2500; Cadox XX 78; Actox 216; Cynku tlenek [Polish]; Desitin; Nogenol; C-Weiss 8 [German]; zincum oxidatum; Azo-55TT; Azo-66TT; Azo-77TT; Cynku tlenek; Zinc gelatin; C.I. Pigment White 4; oxyde de zinc; Zinc oxide fume; RVPaque; Azo 22; Azo-55; Azo-66; Azo-77; No-Genol; Zinc oxide substrate, 10x10x0.5mm, polished one side, 0001 orientation; Zinc oxide substrate, 10x10x0.5mm, polished two sides, 0001 orientation; Pigment white 4; C.I. 77947; Zinc oxide, 99.99% trace metals basis; GIAP 10; CCRIS 1309; C-Weiss 8; Zinc oxide, 99.999%, (trace metal basis); Zn 0701T; HSDB 5024; A&D Medicated Ointment; XX 78; EINECS 215-222-5; Zinc oxide [USP:JAN]; XX 203; XX 601; EPA Pesticide Chemical Code 088502; CI 77947; Zinkoxid; AI3-00277; oxido de cinc; Leaded zinc oxide; ZN-0401 E 3/16''; ZnO Quantum Dots; Zinc (as oxide); Zinc Oxide Slurry; Zinc oxide, heavy; Zinc oxide (TN); Zinc Oxide Nanowire; Zinc Oxide Nanowires; Zine Oxide ,(S); Zinc Oxide Dispersion; Zinc Oxide Nanopowder; Zinc oxide, Nanotek?; Zinc (as zinc oxide); Zinc Oxide Nanoparticle; Zinc oxide, Puratronic; Zinc Oxide Quantum Dots; EC 215-222-5; Zinc oxide (JP17/USP); Zinc oxide, sintered tablets; Zinc oxide, LR, >=99%; Aluminium Doped ZnO Dispersion; Zinc oxide [USAN:USP:JAN]; Zinc oxide, analytical standard; Zinc Oxide Nanopowder Dispersion; CHEBI:36560; Zinc Oxide Nanopowder (Type I); Zinc oxide, NanoArc ZN-0605; Zinc oxide, p.a., 99.0%; Zinc Oxide Nanopowder (Type II); Zinc Oxide Dispersion Wood Coating; Zinc Oxide Powder, 99.9% Nano; Yttrium Doped Zinc Oxide Dispersion; 9015AF; Europium Doped Zinc Oxide Dispersion; Zinc oxide, USP, 99-100.5%; AKOS015904168; Zinc Oxide Nanoparticles / Nanopowder; DB09321; Zinc oxide, ACS reagent, >=99.0%; Zinc oxide, 99.999% (metals basis); Zinc oxide, 30nm,20 wt.% isopropanol; Zinc oxide, tested according to Ph.Eur.; 8051-03-4; Zinc oxide, 99.999% trace metals basis; Zinc oxide, SAJ first grade, >=99.0%; Zinc oxide, JIS special grade, >=99.0%; FT-0631786; FT-0640838; FT-0645092; Antimony Tin Dioxide (ATO) Sputtering Targets; D01170; Zinc oxide, nanopowder, <100 nm particle size; Q190077; Zinc Oxide Nanodispersion Type A-Nonionic (70nm); Zinc Oxide Nanodispersion Type B-Anionic (70nm); Zinc Oxide Nanodispersion Type C-Cationic (70nm); Zinc oxide, nanowires, diam. x L 90 nm x 1 mum; J-005999; Zinc oxide, nanowires, diam. x L 50 nm x 300 nm; Zinc oxide, nanowires, diam. x L 300 nm x 4-5 mum; Zinc oxide, puriss. p.a., ACS reagent, >=99.0% (KT); AZO Powder / AZO MicroPowder / ZnO Doped with Metal Aluminum; Zinc oxide, nanopowder, <50 nm particle size (BET), >97%; Zinc oxide, ReagentPlus(R), powder, <5 mum particle size, 99.9%; Zinc oxide, United States Pharmacopeia (USP) Reference Standard; 20 wt% Zinc Oxide in water, 20 wt% (ZnO) (pale yellow powder), >99% Nano; Zinc oxide sputtering target, 50.8mm (2.0in) dia x 3.18mm (0.125in) thick; Zinc oxide sputtering target, 50.8mm (2.0in) dia x 6.35mm (0.250in) thick; Zinc oxide sputtering target, 76.2mm (3.0in) dia x 6.35mm (0.250in) thick; Zinc oxide, dispersion, nanoparticles, <110 nm particle size, 40 wt. % in butyl acetate; Zinc oxide, dispersion, nanoparticles, 40 wt. % in ethanol, <130 nm particle size; Zinc oxide, dispersion, nanoparticles, <100 nm particle size (TEM), <=40 nm avg. part. size (APS), 20 wt. % in H2O; Zinc oxide, NanoTek Z1102PMA, 50% in 1,2-propanediol monomethyl ether acetate, colloidal dispersion; Zinc oxide, puriss., meets analytical specification of Ph. Eur., BP, USP, 99-100.5% (calc. for dried substance); Zinc oxide, sputtering target, diam. x thickness 3.00 in. x 0.125 in., 99.99% trace metals basis	Small molecule	1S/O.Zn	XLOMVQKBTHCTTD-UHFFFAOYSA-N	O=[Zn]	OZn	CAS 1314-13-2	CHEBI:36560	.	.	.	.	.	.	.
NP7429	Forskolin	CID: 47936	forskolin; Colforsin; 66575-29-9; Coleonol; colforsina; colforsine; colforsinum; Boforsin; Coleonolk; (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate; UNII-1F7A44V6OU; HL 362; 7beta-Acetoxy-8,13-epoxy-1alpha,6beta,9alpha-trihydroxylabd-14-en-11-one; (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1H-benzo[f]chromen-5-yl acetate; L 75 1362B; C22H34O7; 66428-89-5; CHEMBL52606; 1F7A44V6OU; CHEBI:42471; MFCD00082317; NSC375489; NCGC00024996-02; DSSTox_CID_20484; DSSTox_RID_79500; DSSTox_GSID_40484; [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate; 1H-Naphtho(2,1-b)pyran-1-one, dodecahydro-5-(acetyloxy)-3-ethenyl-3,4a,7,7,10a-pentamethyl-6,10,10b-trihydroxy-, (3R-(3-alpha,4a-beta,5-beta,6-beta,6a-alpha,10-alpha,10a-beta,10b-alpha))-; Colforsine [French]; Colforsinum [Latin]; Colforsina [Spanish]; ForsLean; Colforsin [USAN:INN]; 1H-Naphtho[2,1-b]pyran-1-one, 5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-, (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-; FOK; SMR000471881; CAS-66575-29-9; EINECS 266-410-9; NSC 357088; NSC 375489; Forskolin, Coleus forskohlii; Forsklin; Ocufors; forskolin group; Timsaponin-C; forskolin derivatives; Forskolin 20.0%; Colforsin (USAN/INN); forskolin/ rolipram mixture; MolMap_000021; 7-beta-Acetoxy-8,13-epoxy-1-alpha,6-beta,9-alpha-trihydroxylabd-14-en-11-one; SCHEMBL4928; (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-Dodecahydro-5,6,10,10b-tetrahydroxy-3,4a,7,7,10a-pentamethyl-3-vinyl-1H-naphtho(2,1-b)pyran-1-one 5-acetate; 1H-Naphtho(2,1-b)pyran-1-one, 5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-; cid_47936; MLS001066384; MLS001333255; MLS001333256; MLS002172462; MLS002695942; Forskolin, analytical standard; Forskohlii Root Extract (ForsLean)(20% forskohlin); REGID_for_CID_47936; GTPL5190; DTXSID8040484; BCBcMAP01_000132; OHCQJHSOBUTRHG-KGGHGJDLSA-; AOB6380; Bio1_000443; Bio1_000932; Bio1_001421; HMS2235C17; HMS3267I16; HMS3412G19; HMS3676G19; ZINC3977779; Tox21_110940; Tox21_302399; BDBM50010261; HL-362; s2449; 7beta-Acetoxy-8,13-epoxy-1alpha,6beta,9alpha-trihydroxy-labd-14-en-11-one; AKOS024456384; Tox21_110940_1; ACN-035218; AM81249; CCG-268774; CS-1454; DB02587; LMPR0104030004; SMP1_000128; NCGC00024996-03; NCGC00024996-04; NCGC00024996-05; NCGC00024996-06; NCGC00024996-07; NCGC00024996-34; NCGC00177971-03; NCGC00255526-01; 1H-Naphtho(2,1-b)pyran-1-one, 5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-, (3R-(3alpha,4abeta,5beta,6beta,6aalpha,10alpha,10abeta,10balpha))-; 5-(Acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho(2,1-b)pyran-1-one; AC-33150; AS-17443; HY-15371; L-751362B; F0855; M-410; V0151; Y0448; 7088-EP2280000A1; 7088-EP2284169A1; 7088-EP2287147A2; 7088-EP2287161A1; 7088-EP2287162A1; 7088-EP2287165A2; 7088-EP2287166A2; 7088-EP2292620A2; 7088-EP2295550A2; 7088-EP2301931A1; 7088-EP2301937A1; 7088-EP2308562A2; 7088-EP2311806A2; 7088-EP2371811A2; C09076; D03584; MLS-0318096.0001; S-7769; Q412747; SR-01000597378; Forskolin, For use in molecular biology applications; Q-200888; SR-01000597378-1; BRD-K09602097-001-04-5; Forskolin, from Coleus forskohlii, >=98% (HPLC), powder; Forskolin, United States Pharmacopeia (USP) Reference Standard; (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-dodecahydro-1H-naphtho[2,1-b]pyran-5-yl acetate; [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyl-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate; [3R-(3<alpha,4abeta,5beta,6beta,6aalpha,10alpha,10abeta,10balpha)]-5-(Acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one; [3R-(3?,4a?,5?,6?,6a?,10?,10a?,10b?)]-5-(Acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one; [3R-(3a,4ab,5b,6b,6aa,10a,10ab,10ba)]-5-(Acetyloxy)-3-e thenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one	Small molecule	1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1	OHCQJHSOBUTRHG-KGGHGJDLSA-N	CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O	C22H34O7	CAS 66575-29-9	CHEBI:42471	.	.	.	D0V9BP	.	.	.
NP7459	Caffeic acid	CID: 689043	caffeic acid; 3,4-Dihydroxycinnamic acid; 331-39-5; 501-16-6; 3-(3,4-dihydroxyphenyl)acrylic acid; trans-caffeic acid; 3,4-Dihydroxybenzeneacrylic acid; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; 3,4-Dihydroxy-trans-cinnamate; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; 3-(3,4-Dihydroxyphenyl)propenoic acid; Cinnamic acid, 3,4-dihydroxy-; UNII-U2S3A33KVM; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; 4-(2'-Carboxyvinyl)-1,2-dihydroxybenzene; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene; NSC 57197; (E)-3,4-dihydroxycinnamic acid; 3-(3,4-Dihydroxy phenyl)-2-propenoic acid; MFCD00004392; CHEMBL145; U2S3A33KVM; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (E)-; AI3-63211; MLS000069738; CHEBI:16433; 3,4-Dihydroxycinnamic acid, predominantly trans; NSC57197; (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NSC-57197; NSC-623438; SMR000058214; (2E)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeicacid; 71693-97-5; caffeic-acid; CCRIS 847; HSDB 7088; SR-01000000203; EINECS 206-361-2; Caffeic acid dehydrogenation homopolymer; CHEBI:36281; 3,4-Dihydroxycinnamic acid, 99+%, predominantly trans isomer; Caffeic acid, 1; Caffeic acid polymer; Caffeic Acid,(S); PubChem8262; Caffeic acid, trans-; CAFFEIC ACID natural; Opera_ID_1700; Cinnamic acid,4-dihydroxy-; SCHEMBL23358; MLS001076493; MLS002207132; MLS002222302; MLS006011849; BIDD:ER0456; SPECTRUM1503987; 2-Propenoic acid,3-(3,4-dihydroxyphenyl)-, (2E)-; 3,4-Dihydroxycinnamate, XVII; ARONIS023304; BDBM4375; cid_689043; GTPL5155; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid, homopolymer; ZINC58172; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, homopolymer; AMY3943; HMS2235G09; HMS3260J17; HMS3649O17; ACN-S002765; BCP28271; HY-N0172; Tox21_500208; BBL012113; Caffeic Acid - CAS 331-39-5; CCG-38895; NSC623438; s2277; SBB006475; STK397812; Caffeic acid, >=98.0% (HPLC); 2-Propenoic acid,4-dihydroxyphenyl)-; AKOS000144463; AC-8006; ACN-035473; CS-8205; DB01880; LP00208; SDCCGMLS-0002982.P003; SDCCGSBI-0050196.P004; NCGC00017364-04; NCGC00017364-05; NCGC00017364-06; NCGC00017364-07; NCGC00017364-08; NCGC00017364-09; NCGC00017364-10; NCGC00017364-11; NCGC00017364-12; NCGC00017364-13; NCGC00017364-22; NCGC00022654-03; NCGC00022654-04; NCGC00022654-05; NCGC00022654-06; NCGC00022654-07; NCGC00022654-08; NCGC00022654-09; NCGC00260893-01; AS-10895; BP-30112; SMR004703501; ST057529; Caffeic acid, purum, >=95.0% (HPLC); AB0008394; AB00490047; EU-0100208; N1735; SW197202-3; 2-Morpholin-4-yl-isonicotinicacidhydrochloride; C 0625; C01197; C01481; M-2623; (2E)-3-(3,4-Dihydroxyphenyl)-2-propenoic acid; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid polymer; 331C395; Q414116; SR-01000000203-2; SR-01000000203-6; SR-01000000203-7; SR-01000000203-8; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)- (9CI); BRD-K09900591-001-06-9; SR-01000000203-13; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (2E)-; F3096-1708; 8B3E4DA7-F3B0-4972-A315-2E387071737F; trans-Caffeic acid, certified reference material, TraceCERT(R); Caffeic acid, matrix substance for MALDI-MS, >=99.0% (HPLC); Caffeic acid, United States Pharmacopeia (USP) Reference Standard; Caffeic acid, matrix substance for MALDI-MS, >=99.0% (HPLC), powder, light beige; 331-89-5	Small molecule	1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+	QAIPRVGONGVQAS-DUXPYHPUSA-N	C1=CC(=C(C=C1C=CC(=O)O)O)O	C9H8O4	CAS 331-39-5	CHEBI:16433	.	.	.	D0V9EN	.	.	.
NP7463	Tea Polyphenols	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP7488	Tocotrienols	CID: 9929901	Tocotrienol; 6829-55-6; Tocotrienols; (R)-3,4-Dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2H-1-benzopyran-6-ol; CCRIS 7711; CHEMBL120643; SCHEMBL1081622; SCHEMBL1448780; DB12647; NCGC00186586-01; 42152-EP2298776A1; 42152-EP2311808A1; 42152-EP2311829A1; Q27236375; 2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol; 2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2H-1-benzopyran-6-ol; 3,4-Dihydro-2-methyl-2-[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-2H-1-benzopyran-6-ol	Small molecule	1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+	GJJVAFUKOBZPCB-ZGRPYONQSA-N	CC(=CCCC(=CCCC(=CCCC1(CCC2=C(O1)C=CC(=C2)O)C)C)C)C	C26H38O2	CAS 6829-55-6	.	.	.	.	D03VFL	.	.	.
NP7528	3-O-acetylbetulin	CID: 479957	3-O-Acetylbetulin; Betulin 3-acetate; Betulin monoacetate; SCHEMBL214200; CHEMBL1087415; ZINC33829848; [(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl] acetate; 27570-20-3; (5S,17S,1R,2R,8R,14R)-5-(Hydroxymethyl)-1,2,14,18,18-pentamethyl-8-(1-methylvinyl)pentacyclo[11.8.0.0<2,10>.0<5,9>.0<14,19>]henicos-17-yl acetate; [(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl] acetate	Small molecule	1S/C32H52O3/c1-20(2)22-11-16-32(19-33)18-17-30(7)23(27(22)32)9-10-25-29(6)14-13-26(35-21(3)34)28(4,5)24(29)12-15-31(25,30)8/h22-27,33H,1,9-19H2,2-8H3/t22-,23+,24-,25+,26-,27+,29-,30+,31+,32+/m0/s1	XUDTWJGGQFHXCR-VFUWXHBOSA-N	CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)OC(=O)C)C)CO	C32H52O3	.	.	.	.	.	.	.	.	.
NP7529	Alitretinoin	CID: 449171	Alitretinoin; 9-CIS-RETINOIC ACID; Panretin; 5300-03-8; 9-cis-Tretinoin; Panrexin; 9-cis Retinoic Acid; Panretyn; Panretin Gel; (9cis)-retinoic acid; Toctino; 9(Z)-Retinoic acid; Retinoic acid, 9-cis-; Panretin (TN); Alitretinoin (USAN); Alitretinoin [USAN]; ALRT-1057; AGN 192013; trans-Vitamin a acid; BAL-4079; LGD-1057; CHEMBL705; UNII-1UA8E65KDZ; AGN-192013; NSC-659772; 1UA8E65KDZ; Atragen; Effederm; Retinova; LG-100057; ALRT1057; CHEBI:50648; LGD1057; Aberela [Norway]; Avitoin [Norway]; Tretinoin (TN); Effederm [France]; (7E,9Z,11E,13E)-retinoic acid; MFCD00270072; (2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; A-Acido (Argentina); 9-cis-RA; Retin A (TN); LG100057; trans-Retinoate; beta-Retinoate; 9 Cis Retinoic Acid; alitretinoina; alitretinoine; alitretinoinum; Retinoic acid, cis-9,trans-13-; (2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid; Tretinoine [INN-French]; Tretinoinum [INN-Latin]; all-trans-b-Retinoic acid; Tretinoina [INN-Spanish]; Tretinoino [INN-Spanish]; ALRT 1057; 9-cis RA; 9CRA; Isotretinoin Retinoic acid; [3H]9-cis-retinoic acid; tretinoine (French) (EINECS); [3H]-9-cis-retinoic acid; 9-CRA; 9C-RA; Acide retinoique (French) (DSL); 15-Apo-beta-caroten-15-oic acid; B-retinoate; BML2-E06; CCRIS 7098; 9-Retinoate; 9-Retinoic acid; HSDB 7186; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-; Isotretinoin retinoate; All-trans-b-retinoate; NSC 659772; 9-cis- retinoic acid; Ro-04-4079; 9-(Z)-retinoic Acid; Tretinoin (JAN/USP); alpha-acido (argentina); All-trans-beta-retinoate; Spectrum5_001935; Retinoic acid 9-cis-form; alpha-vitaminsyre [denmark]; DSSTox_CID_20404; DSSTox_RID_79490; all-trans- Vitamin A1 acid; DSSTox_GSID_40404; SCHEMBL18666; BSPBio_001495; Tretinoin/all-trans retinoate; Tretinoin [USAN:BAN:INN]; 15-Apo-beta-caroten-15-oate; Alitretinoin [USAN:INN:BAN]; GTPL2645; GTPL5383; DTXSID6040404; UPCMLD-DP097:001; UPCMLD-DP097:002; BDBM31892; Alitretinoin; ; ; Retinoid analogues; HMS1361K17; HMS1791K17; HMS1989K17; HMS3402K17; (2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid; 124510-04-9; AMY21903; Tox21_302195; LMPR01090022; NSC659772; STK801887; ZINC12661824; AKOS005622553; CCG-208266; DB00523; (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; IDI1_033965; 9-cis-Retinoic acid, >=98% (HPLC); NCGC00161590-01; NCGC00161590-02; NCGC00161590-03; NCGC00161590-04; NCGC00161590-05; NCGC00161590-06; NCGC00161590-07; NCGC00255697-01; HY-15128; CAS-5300-03-8; BB 0261656; CS-0003780; C15493; D02815; 42156-EP2295426A1; 42156-EP2295427A1; 42156-EP2311808A1; 42156-EP2311829A1; 42156-EP2311840A1; 300R038; SR-05000013784; Q3611854; SR-05000013784-1; W-200595; BRD-K35483542-001-02-3	Small molecule	1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+	SHGAZHPCJJPHSC-ZVCIMWCZSA-N	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C	C20H28O2	CAS 5300-03-8	CHEBI:50648	.	.	.	D0G3PI	.	.	.
NP7595	Agmatine	CID: 199	agmatine; 1-(4-Aminobutyl)guanidine; 306-60-5; (4-Aminobutyl)guanidine; Argmatine; 1-Amino-4-guanidobutane; guanidine, (4-aminobutyl)-; N-4-Aminobutylguanidine; N-(4-aminobutyl)guanidine; (4-Aminobutyl) guanidine; 1,4-Butanediamine, N-(aminoiminomethyl)-; 2-(4-aminobutyl)guanidine; UNII-70J407ZL5Q; 4-Guanidino-1-butanamine; CHEMBL58343; CHEBI:17431; 70J407ZL5Q; agmatinium; Guanidine, (4-aminobutyl)- (8CI)(9CI); AGMATINE SULFATE ENDOGENOUS AGONIST AT; AG2; EINECS 206-187-7; NSC 56332; 1-Amino-4-guanidinobutane; .Agmatin; Spectrum_001656; Tocris-0842; SpecPlus_000500; Spectrum2_001608; Spectrum4_001905; Spectrum5_000590; Lopac-A-7127; (4-aminobutyl)-Guanidine; bmse000063; bmse000812; bmse000936; 1, N-(aminoiminomethyl)-; Lopac0_000060; SCHEMBL19647; US8633208, Agmatine; KBioGR_002496; KBioGR_002550; KBioSS_002136; KBioSS_002559; Agmatine sulfate, 90.0%+; DivK1c_006596; SPBio_001615; CS-WAA0304; GTPL4127; DTXSID0040961; BDBM85213; KBio1_001540; KBio2_002136; KBio2_002550; KBio2_004704; KBio2_005118; KBio2_007272; KBio2_007686; KBio3_003028; NSC_199; cMAP_000079; NSC56332; ZINC1532560; NSC-56332; AKOS006230062; AKOS015894488; CCG-204155; DB08838; SDCCGMLS-0066765.P001; SDCCGSBI-0050048.P003; N-(aminoiminomethyl)-1,4-Butanediamine; NCGC00015083-01; NCGC00015083-02; NCGC00015083-03; NCGC00015083-04; NCGC00015083-05; NCGC00015083-06; NCGC00015083-10; NCGC00024820-01; NCGC00024820-02; NCGC00024820-03; NCGC00024820-04; AK608136; CAS_306-60-5; DB-068320; FT-0693017; C00179; 21782-EP2314571A2; Q394317; C4D19DE1-F243-434B-9E72-720B42C5AD40	Small molecule	1S/C5H14N4/c6-3-1-2-4-9-5(7)8/h1-4,6H2,(H4,7,8,9)	QYPPJABKJHAVHS-UHFFFAOYSA-N	C(CCN=C(N)N)CN	C5H14N4	CAS 306-60-5	CHEBI:17431	.	.	.	D0K7CV	.	.	.
NP7608	Piperine	CID: 638024	piperine; 94-62-2; 1-Piperoylpiperidine; Piperin; Bioperine; Piperoylpiperidine; (E,E)-1-piperoylpiperidine; N-[(E,E)-Piperoyl]piperidine; Piperidine, 1-piperoyl-, (E,E)-; UNII-U71XL721QK; FEMA No. 2909; CCRIS 5572; Piperine (aliphatic); 1-Piperoylpiperidine, (E,E)-; 7780-20-3; C17H19NO3; EINECS 202-348-0; NSC 21727; 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoyl]piperidine; N-(E,E)-piperoyl-piperidine; CHEMBL43185; U71XL721QK; CHEBI:28821; MXXWOMGUGJBKIW-YPCIICBESA-N; NSC21727; piperidine, 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)	.	1S/C17H19NO3/c19-17(18-10-4-1-5-11-18)7-3-2-6-14-8-9-15-16(12-14)21-13-20-15/h2-3,6-9,12H,1,4-5,10-11,13H2/b6-2+,7-3+	MXXWOMGUGJBKIW-YPCIICBESA-N	C1CCN(CC1)C(=O)C=CC=CC2=CC3=C(C=C2)OCO3	C17H19NO3	CAS 94-62-2	.	HBIN040071	SMIT00114	MOL001592	D0H7PW	.	906	.
NP7644	Tephrosin	CID: 114909	Tephrosin; hydroxydeguelin; 76-80-2; deguelinol I; UNII-9C081V83CC; CHEBI:9442; 9C081V83CC; (1R,14R)-14-hydroxy-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one; CCRIS 7115; (?)-Tephrosin; (-)-TEPHROSIN; SCHEMBL766277; CHEMBL241806; MEGxp0_001258; DTXSID20878627; HY-N1166; ZINC4098748; BDBM50505206; LMPK12060047; Tephrosin, >=95% (LC/MS-ELSD); MCULE-5773910433; NCGC00347726-02!; CS-0016457; C10535; Q7701343; (7aR,13aR)-13,13a-dihydro-7a-hydroxy-9,10-dimethoxy-3,3-dimethyl-3H-bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one; (7aR,13aR)-7a-hydroxy-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-7a-hydroxy-9,10-dimethoxy-3,3-dimethyl-, (7aR,13aR)-; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-7a-hydroxy-9,10-dimethoxy-3,3-dimethyl-, (7aR-cis)-	Small molecule	1S/C23H22O7/c1-22(2)8-7-12-15(30-22)6-5-13-20(12)29-19-11-28-16-10-18(27-4)17(26-3)9-14(16)23(19,25)21(13)24/h5-10,19,25H,11H2,1-4H3/t19-,23-/m1/s1	AQBZCCQCDWNNJQ-AUSIDOKSSA-N	CC1(C=CC2=C(O1)C=CC3=C2OC4COC5=CC(=C(C=C5C4(C3=O)O)OC)OC)C	C23H22O7	CAS 76-80-2	CHEBI:9442	.	.	.	.	.	.	.
NP7649	Antineoplaston A10	CID: 56260	Antineoplaston A10; Antineoplaston A 10; 91531-30-5; UNII-16VY3TM7ZO; N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide; atengenal; 16VY3TM7ZO; ANTINEOPLASTON A-10; A-10; Antineoplaston-A10; A 10; Cengenal; 3-(N-Phenylacetylamino)-2,6-piperidinedione; N-(2,6-Dioxo-3-piperidinyl)benzeneacetamide; 3-((Phenylacetyl)amino)-2,6-piperidinedione; Antineoplaston A10 capsules; ANP-A10; A10; CHEMBL1980825; SCHEMBL20772654; DTXSID00919683; ZINC1590366; MFCD26961095; NSC619130; N-(6-Hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2-phenylethanimidic acid; DB11702; NSC-619130; SB19788; NCI60_005691; HY-128553; CS-0095862; N-[(3s)-2,6-dioxo-3-piperidyl]-2-phenyl-acetamide; Q27251844; Benzeneacetamide, N-(2,6-dioxo-3-piperidinyl)-, (S)-	Small molecule	1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1	OQGRFQCUGLKSAV-JTQLQIEISA-N	C1CC(=O)NC(=O)C1NC(=O)CC2=CC=CC=C2	C13H14N2O3	CAS 91531-30-5	.	.	.	.	D04QRG	.	.	.
NP7659	Bovine lactoferrin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP7663	Cidofovir	CID: 60613	Cidofovir; 113852-37-2; Vistide; HPMPC; Cidofovir anhydrous; (S)-HPMPC; Cidofovirum; GS-504; Cidofovir (Vistide); Cidofovir hydrate; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; CDV; UNII-768M1V522C; GS-0504; [1-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-propan-2-yl]oxymethylphosphonic acid; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine; (S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic acid; CHEBI:3696; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; 768M1V522C; NCGC00184994-01; 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; Cidofovir (anhydrous); Cidofovir hydrate (1:2); Forvade; GS 0504; (S)-(3-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid; [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid; Cidofovir [INN]; ({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; C8H14N3O6P; HSDB 7115; GS504; Cidofovir gel; Cidofovir,Vistide; Cidofovir(Vistide); Forvade (TM); Cidofovir(anhydrous); Cidofovir, anhydrous; (S)-HPMPC; Cidovir; CHEMBL152; SCHEMBL3948; DSSTox_CID_23734; DSSTox_RID_80069; DSSTox_GSID_43734; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; cc-166; MLS003915629; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; DTXSID3043734; BDBM31915; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate; BCP03734; EBD21562; EX-A4209; ZINC1530600; Tox21_112994; CC0162; MFCD00866936; MFCD17215968; NSC742135; s1516; AKOS005145721; AKOS015854828; AC-1666; BCP9000528; CCG-267235; CS-1669; DB00369; GS-6438; NSC-742135; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; [(1S)-1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphonic acid; NCGC00184994-02; NCGC00184994-03; HY-17438; Phosphonic acid, ((2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (S)-; SMR002544687; BCP0726000147; CAS-113852-37-2; AB01566823_01; 394C661; Q423445; SR-01000931969; J-502695; SR-01000931969-2; [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; L8P; Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-; Phosphonic acid,[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-	Small molecule	1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1	VWFCHDSQECPREK-LURJTMIESA-N	C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O	C8H14N3O6P	CAS 113852-37-2	CHEBI:3696	.	.	.	D04AAW	.	.	.
NP7685	Epinephrine	CID: 5816	epinephrine; l-Adrenaline; L-epinephrine; 51-43-4; Adrenalin; adrenaline; Levoepinephrine; Adnephrine; Chelafrin; Epinefrina; Epinephran; Epirenan; (-)-Adrenaline; Nephridine; Adrenal; Epifrin; Renoform; Epipen; Vasoconstrictine; Hypernephrin; Renostypticin; Supracapsulin; Supranephrane; Suprarenaline; Adrenine; Hemisine; Hemostasin; Hemostatin; Levorenin; Levorenine; Lyophrin; Mucidrina; Nieraline; Paranephrin; Renaglandin; Renaleptine; Renalina; Scurenaline; Simplene; Styptirenal; Takamina; Vasotonin; Bosmin; Exadrin; (R)-Adrenaline; Adrin; l-Epirenamine; Bronkaid Mist; Primatene Mist; Sus-Phrine; Antiasthmatique; Esphygmogenina; Methylarterenol; Supranephrine; Adrenamine; Adrenapax; Adrenasol; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Brevirenin; Bronkaid; Drenamist; Dylephrin; Glaucosan; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hyporenin; Intranefrin; Isoptoepinal; Kidoline; Myosthenine; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Supradin; Supranefran; Supranol; Takamine; Tokamina; Twinject; Vasodrine; (-)-Epinephrine; Corisol; Glaucon; Mytrate; Suprel; Tonogen; Asthma-nefrin; Asmatane Mist; L(-)-Epinephrine; Sympathin I; (-)-(R)-Epinephrine; (R)-Epinephrine; Asthma meter mist; Adrenalinum; Epiglaufrin; Glauposine; Adrenalin-Medihaler; Levorenen; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol; Eppy; Dyspne-Inhal; R-(-)-Epinephrine; Adrenalin in Oil; Epinefrin [Czech]; Epinefrin; Renostyptin; Surrenine; Citanest Forte; 1-Epinephrine; 1-Adrenalin; Epipen Jr.; Vaponefrin; (R)-(-)-Adrenaline; Rcra waste number P042; l-Epinephrine (synthetic); Adrenalina [DCIT]; Adrenatrate; Epinefrina [INN-Spanish]; Epinephrinum; Epinephrinum [INN-Latin]; Metanephrin; Renaglandulin; Renostypricin; Vasoconstrictor; Epirenin; Renagladin; Surenine; Vasoton; l-Adrenalin; R-Adrenaline; Suprarenin; Methylaminoethanolcatechol; Auvi-q; (R)-(-)-Epinephrine; l-Methylaminoethanolcatechol; d-Adrenaline; Medihaler-Epi; C9H13NO3; Lyodrin; (R)-(-)-Adnephrine; L-Epinehphrine; (R)-(-)-Epirenamine; l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; RCRA waste no. P042; UNII-YKH834O4BH; Adrenalin (TN); Epirenamine; Micronefrin; Epitrate; Levo-Methylaminoethanolcatechol; Epinephrine hydrochloride; (-)-R-Epinephrine; 1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (R)-; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; AI3-19015; Adrenalin chloride; Lopac-E-4642; 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]-; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; CHEMBL679; YKH834O4BH; Adrenan; Susphrine; Adrine; D-Epinephrine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; D-Epifrin; CHEBI:28918; Benzyl alcohol, 3,4-dihydroxy-alpha-((methylamino)methyl)-, (-)-; Asthmanefrin; MFCD00002204; NCGC00015417-01; NCGC00142615-03; NCGC00142615-08; Adrenalina; 1,2-Benzenediol, 4-((1R)-1-hydroxy-2-(methylamino)ethyl)-; 1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (theta)-; DSSTox_CID_2986; Adrenaline (L-Adrenaline); DSSTox_RID_76819; L(-)-Epinephrine, 99%; DSSTox_GSID_22986; (-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol; Adrenaclick; Exadri; 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (R)-; EPIPEN E Z PEN; l-Epinephine; Asthmahaler Mist; EPI E Z PEN JR; Ana-Guard; Ana-Kit; (+/-)-Epinephrine; CAS-51-43-4; Epipen EZ Pen; L-Adrenaline Base; Twinject 0.3; Epi EZ Pen Jr; ADROP; Epinephrine [USAN:INN:JAN]; Epipen Auto-Injector; SUS-PHRINE SULFITE-FREE; CCRIS 4812; Twinject 0.15; Auvi-Q auto-injector; EPIPEN JR; HSDB 4289; (+/-)-Adrenalin; Bronkaid Suspension Mist; EINECS 200-098-7; NSC 62786; 4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; Epipen Jr. Auto-Injector; (r)-4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol; Epinephrin; Levoreninum; Primatene; Symjepi; NSC62786; Bupivacaine Hcl and Epinephrine; NSC-62786; Epinephrine [USP:INN:BAN:JAN]; ALE; IOP; (-)-Adrenalin; Epinephrine (USP); Epipen (TN); nchembio747-comp9; Twinject 0.30; Adrenaline/Epinephrine; Adrenaline (JP15); Adrenaline (JP17); Epitrate (Salt/Mix); Auvi-q (TN); Epinephrine (USP/INN); bmse000316; 4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol #; Citanest Forte (Salt/Mix); L-Adrenaline (Epinephrine); SCHEMBL3814; 3,4-Dihydroxy-.alpha.-((methylamino)methyl)benzyl alcohol; GTPL479; BIDD:GT0119; E4250_SIGMA; DTXSID5022986; BDBM44818; cid_6852374; HY-B0447B; ZINC39089; component of E-Pilo (Salt/Mix); HMS3884H06; (R)-(-)-3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol; 104655-05-2; BCP09042; Tox21_111562; BDBM50029050; HSCI1_000215; MFCD00063027; PDSP1_001120; PDSP2_001104; s2522; SBB012384; 51-43-4 (FREE BASE); AKOS024283500; Tox21_111562_1; CCG-204593; D29A657; DB00668; MCULE-9462717294; NE58416; SDCCGSBI-0050486.P002; SMP1_000227; (-)-Epinephrine, >=97.0% (NT); NCGC00142615-01; NCGC00142615-04; NCGC00142615-05; NCGC00142615-06; NCGC00142615-07; NCGC00142615-09; NCGC00142615-18; AC-13188; AC-31211; AS-13813; L926; ST069368; 4,5-beta-trihydroxy-N-methylphenethylamine; A0173; SW219274-1; 1401-EP2270011A1; 1401-EP2298735A1; 1401-EP2301934A1; 1401-EP2305677A1; 1401-EP2308562A2; 1401-EP2308861A1; 1401-EP2311464A1; 1401-EP2311823A1; 1401-EP2314571A2; 6367-EP2272841A1; 6367-EP2277861A1; 6367-EP2301934A1; 6367-EP2301936A1; 6367-EP2314571A2; C00788; D00095; J10365; 91382-EP2284149A1; 91382-EP2305636A1; AB00573227-11; AB00573227-12; AB00573227-13; AB00573227_14; AB00573227_15; 204017-EP2277867A2; 204017-EP2280003A2; Q132621; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; Q-200601; SR-01000075267-8; 3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol; 4-[(1R)-1-hydroxy-2-methylaminoethyl]benzene-1,2-diol; Z2686405805; (-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol; Adrenaline, European Pharmacopoeia (EP) Reference Standard; UNII-GR0L9S3J0F component UCTWMZQNUQWSLP-VIFPVBQESA-N; (+/-)-3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol; (-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol; (-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]pyrocatechol;tartaric acid; Adrenaline with impurity F, European Pharmacopoeia (EP) Reference Standard; Benzyl alcohol, 3,4-dihydroxy-.alpha.-[(methylamino)methyl]-, (-)-; 2,3-dihydroxybutanedioic acid;4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol; 2,3-bis(oxidanyl)butanedioic acid;4-[(1R)-2-(methylamino)-1-oxidanyl-ethyl]benzene-1,2-diol	Small molecule	1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1	UCTWMZQNUQWSLP-VIFPVBQESA-N	CNCC(C1=CC(=C(C=C1)O)O)O	C9H13NO3	CAS 51-43-4	CHEBI:28918	.	.	.	D04PHC	.	.	.
NP7687	Pterostilbene	CID: 5281727	4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus; pterostilbene; 537-42-8	.	1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3/b4-3+	VLEUZFDZJKSGMX-ONEGZZNKSA-N	COC1=CC(=CC(=C1)C=CC2=CC=C(C=C2)O)OC	C16H16O3	CAS 537-42-8	.	HBIN041217	SMIT12801	.	D00AII	.	.	.
NP7703	Vincamine	CID: 15376	vincamine; 1617-90-9; Devincan; Pervincamine; Minorine; Vincamidol; Novicet; Angiopac; Equipur; Monorin; (+)-Vincamine; Methyl vincaminate; Arteriovinca; Anasclerol; Vincasaunier; Decincan; Devinkan; Tripervan; Vincadar; Vincafolina; Vincamin; Vincapront; Vincimax; Vinkametrin; Minorin; UNII-996XVD0JHT; Oxygeron; Pervone; Vincachron; Vincafor; Vincagil; Vincapan; Perval; Vinodrel retard; Ocu-vinc; Vinca-Ecobi; Vinca-Minor; Anasclerol (base); 14,15-Dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester; 996XVD0JHT; CHEBI:9985; MFCD00078054; Eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methyl ester, (3alpha,14beta,16alpha)-; DSSTox_CID_20134; DSSTox_RID_79448; Eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methylester, (3a,14b,16a)-; DSSTox_GSID_40134; Vincamina [DCIT]; Vincaminum; Vincamina; Alkaloid obtained from Vinca minor; Vincaminum [INN-Latin]; methyl 14beta-hydroxy-14,15-dihydro-3alpha,16alpha-eburnamenine-14alpha-carboxylate; Vincamine [INN:BAN:DCF]; Methyl (41S,12S,13aS)-13a-ethyl-12-hydroxy-2,3,41,5,6,12,13,13a-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate; HSDB 7150; EINECS 216-576-3; NSC 91998; (3?,14?,16?)-14,15-Dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester; Vincamine (FP); NCGC00094824-01; Vincamine (INN); Prestwick_495; CAS-1617-90-9; Cetal retard (TN); Vincamine, 98%; Prestwick0_000271; Prestwick1_000271; Prestwick2_000271; Prestwick3_000271; Eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methyl ester, (3alpha,14beta,16.); BSPBio_000142; GTPL349; MLS002154249; SCHEMBL147179; SPBio_002361; BPBio1_000158; CHEMBL1165342; DTXSID9040134; BCBcMAP01_000080; HMS1568H04; HMS2095H04; HMS2268C20; HMS3712H04; AMY39091; BCP05837; HY-B1021; ZINC1069082; Tox21_111342; Tox21_301968; s3891; AKOS015896471; Tox21_111342_1; CCG-208544; CS-4536; DB13374; EBD2197880; KS-5179; methyl (3alpha,14beta,16alpha)-14-hydroxy-14,15-dihydroeburnamenine-14-carboxylate; SMP1_000314; Vincamine, analytical reference material; NCGC00184983-01; NCGC00184983-03; NCGC00255542-01; AC-22625; SMR000112509; C09251; D08677; J10447; 617V909; Q416225; Q-100193; BRD-K40902647-001-03-7; Eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-,methyl ester, (3alpha,14beta,16alpha)-; methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.0?,?.0?,??.0??,??]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate; methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.0^{2,7}.0^{8,18}.0^{15,19}]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate	Small molecule	1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1	RXPRRQLKFXBCSJ-GIVPXCGWSA-N	CCC12CCCN3C1C4=C(CC3)C5=CC=CC=C5N4C(C2)(C(=O)OC)O	C21H26N2O3	CAS 1617-90-9	CHEBI:9985	.	.	.	D08UGJ	.	.	.
NP7706	Tazarotene	CID: 5381	tazarotene; 118292-40-3; Tazorac; Zorac; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Avage; AGN-190168; Fabior; AGN 190168; Tazarotene (Avage); UNII-81BDR9Y8PS; C21H21NO2S; 81BDR9Y8PS; CHEMBL1657; ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; CHEBI:32184; NCGC00167525-01; ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; DSSTox_CID_26691; DSSTox_RID_81825; DSSTox_GSID_46691; tazaroteno; tazarotenum; Suretin; Tazoral; Zora; 6-(4,4-Dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester; ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate;6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester; Tazorac (TN); Avage (TN); CAS-118292-40-3; Acnitaz; ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)-ethynyl)nicotinate; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate; Tazarotene (JAN/USAN/INN); Tazarotene [USAN:INN:BAN]; Zorac; ; ; Tazorac; Tazarotene,(S); ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate; Fabior (TN); 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; PubChem24431; SCHEMBL3134; MLS003915630; BIDD:GT0293; GTPL6952; DTXSID5046691; HMS3655K05; HMS3747C19; HMS3747E19; ACT06773; AMY31169; BCP22966; EBD38650; ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate; ZINC1542199; Tox21 112522; Tox21_112522; ABP000994; AC-755; ANW-45265; BDBM50265951; MFCD00867628; s1569; AKOS015902872; Tox21_112522_1; BS-1012; CCG-268046; CS-1029; DB00799; NCGC00167525-02; NCGC00167525-03; 6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; HY-15388; SMR002096194; BCP0726000163; AB0012671; DB-014992; FT-0652578; SW220026-1; AGN190168, AGN-190168; C12531; D01132; S-7551; 15146-EP2275420A1; 15146-EP2295055A2; 15146-EP2295416A2; 15146-EP2298748A2; 15146-EP2298764A1; 15146-EP2298765A1; 15146-EP2298768A1; 15146-EP2305642A2; 15146-EP2308861A1; 15146-EP2311453A1; 15146-EP2311808A1; 15146-EP2311829A1; 15146-EP2314590A1; 15146-EP2316832A1; 15146-EP2316833A1; AB01274801-01; AB01274801_02; 292T403; SR-01000931253; Q-102516; Q3981685; SR-01000931253-2; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate; 6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid ethyl ester; (+/-)OCTAHYDROCYCLOPENTA[B]PYRROLE-2-CARBOXYLICACIDHYDROCHLORIDE; 6-(2-(4,4-dimethyl-thiochroman-6yl)ethynyl)-nicotinic acid ethyl ester; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-pyridinecarboxylic Acid Ethyl Ester; 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; 6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylicacidethylester	Small molecule	1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3	OGQICQVSFDPSEI-UHFFFAOYSA-N	CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C	C21H21NO2S	CAS 118292-40-3	CHEBI:32184	.	.	.	D0BM5G	.	.	.
NP7746	Omega-3 PUFAs	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP7818	Morroniside	CID: 11228693	Morroniside; 25406-64-8; CHEBI:80852; (7Beta-Hydroxy)-Morroniside; methyl (1S,3R,4aS,8S,8aS)-3-hydroxy-1-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,4a,8,8a-hexahydropyrano[3,4-c]pyran-5-carboxylate; CHEMBL1209803; DTXSID60948257; HY-N0532; BDBM50279531; s5465; ZINC56874303; AKOS027250775; CCG-268714; AS-56291; CS-0009065; C17000; Q27151347; (1S)-1alpha-(beta-D-Glucopyranosyloxy)-6alpha-hydroxy-8beta-methyl-4aalpha,5,8,8aalpha-tetrahydro-1H,6H-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester; Methyl 8-(hexopyranosyloxy)-3-hydroxy-1-methyl-4,4a,8,8a-tetrahydro-1H,3H-pyrano[3,4-c]pyran-5-carboxylate	Small molecule	1S/C17H26O11/c1-6-11-7(3-10(19)26-6)8(15(23)24-2)5-25-16(11)28-17-14(22)13(21)12(20)9(4-18)27-17/h5-7,9-14,16-22H,3-4H2,1-2H3/t6-,7+,9+,10+,11+,12+,13-,14+,16-,17-/m0/s1	YTZSBJLNMIQROD-SFBCHFHNSA-N	CC1C2C(CC(O1)O)C(=COC2OC3C(C(C(C(O3)CO)O)O)O)C(=O)OC	C17H26O11	CAS 25406-64-8	CHEBI:80852	.	.	.	.	.	.	.
NP7822	Pancratistatin	CID: 441597	Pancratistatin; 96203-70-2; CHEBI:7906; (+)-Pancratistatin; NSC349156; MLS002701837; (1R,2S,3S,4S,4aR,11bR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-[1,3]dioxolo[4,5-j]phenanthridin-6-one; SCHEMBL93612; CHEMBL419335; ZINC4097654; NSC-349156; SMP1_000217; NCI60_003105; B844009K070; C08535; Q7130395; [1,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,4,7-pentahydroxy-,	Small molecule	1S/C14H15NO8/c16-8-5-3-1-4-13(23-2-22-4)9(17)6(3)14(21)15-7(5)10(18)12(20)11(8)19/h1,5,7-8,10-12,16-20H,2H2,(H,15,21)/t5-,7-,8-,10+,11+,12+/m1/s1	VREZDOWOLGNDPW-ALTGWBOUSA-N	C1OC2=C(O1)C(=C3C(=C2)C4C(C(C(C(C4O)O)O)O)NC3=O)O	C14H15NO8	CAS 96203-70-2	CHEBI:7906	.	.	.	.	.	.	.
NP7824	Ergosterol	.	.	Small molecule	1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3/b8-7+/t19-,20+,22-,24+,25-,26-,27-,28+/m0/s1	DNVPQKQSNYMLRS-APGDWVJJSA-N	CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C	C28H44O	CAS 57-87-4	CHEBI:16933	.	.	.	.	.	.	.
NP7913	Penciclovir	CID: 135398748	penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; BRL 39123; BRL-39123; Pencyclovir; 9-(4-Hydroxy-3-(hydroxymethyl)butyl)guanine; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3H-purin-6-one; Penciceovir; UNII-359HUE8FJC; 9-(4-HYDROXY-3-(HYDROXYMETHYL)BUT-1-YL)GUANINE; PE2; C10H15N5O3; 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine; 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one; 359HUE8FJC; CHEMBL1540; CHEBI:7956; 9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)-; 9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine; NCGC00164630-01; 2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-1H-purin-6(9H)-one; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1,9-dihydro-6H-purin-6-one; DSSTox_CID_26491; DSSTox_RID_81662; DSSTox_GSID_46491; PCV; Penciclovir [USAN:INN:BAN]; Adenovir; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one; 2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-1,9-dihydro-6H-purin-6-one; SMR000466317; Denavir (TN); CAS-39809-25-1; CCRIS 9213; SR-05000001512; 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; Penciclovir (USAN/INN); HSDB 8123; Penciclovir,(S); 2-Amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6H-purin-6-one; MB2488; SCHEMBL3494; Penciclovir-d4 (deuterated); MLS000759422; MLS001424110; ZINC1899; DTXSID9046491; SCHEMBL19236307; HMS2051D06; HMS2090H11; HMS2232A11; HMS3371P04; HMS3393D06; HMS3652H07; HMS3713P14; Pharmakon1600-01502320; BCP13112; Tox21_112248; 2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-3H-purin-6(9H)-one; BDBM50210804; MFCD00866931; NSC759624; s4184; AKOS007930676; AKOS026750166; BRL 39123;VSA 671; Tox21_112248_1; AC-8067; CCG-101000; CCG-213029; CCG-266987; CS-1355; DB00299; KS-5016; NC00250; NSC 759624; NSC-759624; NCGC00263533-01; NCGC00386270-02; AK546699; HY-17424; FT-0601627; FT-0673555; P2164; SW197630-2; C07417; D05407; J90026; W-5154; AB00698242-05; AB01275514-01; AB01275514_02; AB01566918_01; 809P251; A824740; Q420364; SR-01000763121; SR-01000763121-3; SR-05000001512-1; SR-05000001512-2; 2-[2-(2-Amino-6-hydroxy-purin-9-yl)-ethyl]-propane-1,3-diol; 2-azanyl-9-[3-(hydroxymethyl)-4-oxidanyl-butyl]-3H-purin-6-one; 2-Amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6,9-dihydro-3H-purin-6-one; 2-Amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one (PCV); 2-Amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one(PCV, Penciclovir)	Small molecule	1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)	JNTOCHDNEULJHD-UHFFFAOYSA-N	C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N	C10H15N5O3	CAS 39809-25-1	CHEBI:7956	.	.	.	D07BYK	.	.	.
NP7968	Deguelin	CID: 107935	(-)-Deguelin; (-)-cis-deguelin; DEGUELIN(-); UNII-K5Z93K66IE; CHEBI:4357; K5Z93K66IE; MFCD01740600; C23H22O6; (7as,13as)-13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-3h-bis[1]benzopyrano[3,4-b:6',5'-e]pyran-7(7ah)-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one; (7aS,13aS)-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one.; SR-01000597503; CCRIS 8104; Deguelin/; (-)-Deguelin, Mundulea sericea; Spectrum_001044; Tocris-1770; Spectrum2_000298; Spectrum3_001122; Spectrum4_001965; Spectrum5_001852; SCHEMBL73183; BSPBio_002583; KBioGR_002434; KBioSS_001524; SPECTRUM201138; MLS006010295; SPBio_000236; CHEMBL393417; KBio2_001524; KBio2_004092; KBio2_006660; KBio3_002083; DTXSID10200231; HMS1923A05; HMS3268E12; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS-cis)-; EX-A4158; ZINC3978987; 1702AH; ABP000411; BDBM50505204; CCG-39856; LMPK12060019; s8132; AKOS024456769; ACN-053693; BCP9000596; CS-1802; SDCCGMLS-0066380.P001; NCGC00025288-01; NCGC00025288-02; NCGC00025288-03; (-)-Deguelin, >98% (HPLC), powder; AS-56004; HY-13425; SMR004701363; C10417; Q5251862; SR-01000597503-1; SR-01000597503-3; SR-01000597503-4; BRD-K61401890-001-02-0; BRD-K61401890-001-03-8; BRD-K61401890-001-04-6; (1S,14S)-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H,7aH-pyrano[2,3-c;6,5-f']dichromen-7-one; 13,13aS-Dihydro-9,10-dimethoxy-3,3-dimethyl-3H-[1]benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aS)-one; 3H-[1]Benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-	.	1S/C23H22O6/c1-23(2)8-7-12-15(29-23)6-5-13-21(24)20-14-9-17(25-3)18(26-4)10-16(14)27-11-19(20)28-22(12)13/h5-10,19-20H,11H2,1-4H3/t19-,20+/m1/s1	ORDAZKGHSNRHTD-UXHICEINSA-N	CC1(C=CC2=C(O1)C=CC3=C2OC4COC5=CC(=C(C=C5C4C3=O)OC)OC)C	C23H22O6	CAS 522-17-8	.	HBIN022961	.	.	.	.	.	.
NP7978	Salinomycin	CID: 3085092	Procoxacin; Coxistac; 53003-10-4; Bio-cox; UNII-62UXS86T64; CHEBI:80025; 62UXS86T64; (R)-2-((2R,5S,6R)-6-((2S,3S,4S,6R)-6-((2S,5S,7R,9S,10S,12R,15R)-2-((2R,5R,6S)-5-ethyl-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl)-3-hydroxy-4-methyl-5-oxooctan-2-yl)-5-methyltetrahydro-2H-pyran-2-yl)butanoic acid; Salinomicina; Salinomycine; Salinomycinum; (2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(3S,5S,7R,9S,10S,12R,15R)-3-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-3,10,12-trimethyl-4,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid; Salinomycin [INN:BAN]; Salinomycine [INN-French]; Salinomycinum [INN-Latin]; Salinomycin (Procoxacin); Salinomicina [INN-Spanish]; K 364; HSDB 7032; Procoxacin (TN); AHR 3096; EINECS 258-290-1; Salinomycin (INN); SCHEMBL36890; CHEMBL1208572; DTXSID4048486; GTPL11088; NSC757437; s2352; s8129; ZINC85540254; Salinomycin (from Streptomyces albus); CCG-208535; CS-1299; DB11544; NSC-757437; (2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5S,7R,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5?.3?]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid; BS-17023; E716; HY-15597; C15690; D08502; W-6068; Q411909; J-524236; SR-05000002207-3; Salinomycin, from Streptomyces albus, >=98% (HPLC); Salinomycin, Ready Made Solution, from Streptomyces albus, >=98% (HPLC)	.	1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1	KQXDHUJYNAXLNZ-XQSDOZFQSA-N	CCC(C1CCC(C(O1)C(C)C(C(C)C(=O)C(CC)C2C(CC(C3(O2)C=CC(C4(O3)CCC(O4)(C)C5CCC(C(O5)C)(CC)O)O)C)C)O)C)C(=O)O	C42H70O11	CAS 53003-10-4	.	.	.	.	.	.	.	.
NP8057	Parthenolide	CID: 7251185	parthenolide; 20554-84-1; (-)-Parthenolide; MFCD00134592; CHEBI:7939; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; (1aR,4E,7aS,10aS,10bR)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one; (3aS,9aR,10aR,10bS,E)-6,9a-dimethyl-3-methylene-3a,4,5,8,9,9a,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-2(3H)-one; 29552-41-8; partenolide; Parthenolide, Tanacetum parthenium; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_000599; BSPBio_001308; MLS002153872; BPBio1_000659; CHEMBL465158; parthenolide-(alternate-stereo); SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, >=98% (HPLC); HMS1361B10; HMS1569N21; HMS1791B10; HMS1989B10; HMS2096N21; HMS3402B10; HMS3713N21; BCP10404; HY-N0141; ZINC4492886; AKOS016010226; CCG-208244; CS-1919; IDI1_033778; NCGC00163415-01; NCGC00163415-04; AS-17479; SMR001233226; AB0019832; AB00513860; V0355; X-1866; 552P418; Q-100253; (-)-Parthenolide; NSC-157035; NSC 157035; NSC157035; Parthenolide, United States Pharmacopeia (USP) Reference Standard; (1S,2R,4R,7E,11S)-4,8-dimethyl-12-methylidene-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one; (3aS,10R,11R,11aS,6E)-3-Methylene-6,10-dimethyl-10,11-epoxy-1-oxa-2,3,3a,4,5,8,9,10,11,11a-decahydro-1H-cyclopentacyclodecene-2-one	Small molecule	1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1	KTEXNACQROZXEV-PVLRGYAZSA-N	CC1=CCCC2(C(O2)C3C(CC1)C(=C)C(=O)O3)C	C15H20O3	CAS 20554-84-1	CHEBI:7939	.	.	.	D0M4KE	.	.	.
NP8058	Thioguanine	CID: 2723601	thioguanine; 6-Thioguanine; 154-42-7; Tioguanine; 2-Amino-6-mercaptopurine; 6-Mercaptoguanine; Tioguanin; Tabloid; Lanvis; 2-Amino-6-purinethiol; 2-Amino 6MP; 2-Aminopurin-6-thiol; 2-Aminopurine-6-thiol; 2-Aminopurine-6(1H)-thione; Wellcome U3B; 6-Mercapto-2-aminopurine; 2-Amino-9H-purine-6-thiol; 6-TG; 2-Amino-6-merkaptopurin; Tioguaninum; Guanine, thio-; Tioguanina; 6H-Purine-6-thione, 2-amino-1,7-dihydro-; 2-Amino-1,7-dihydro-6H-purine-6-thione; BW 5071; Purine-6-thiol, 2-amino-; Purine-6(1H)-thione, 2-amino-; 2-Amino-1,9-Dihydro-6h-Purine-6-Thione; NSC-752; 2-amino-3,7-dihydropurine-6-thione; TG; C5H5N5S; THG; NSC 752; 2-Amino-1,7-dihydro-6H-purin-6-thion; X 27; UNII-WIX31ZPX66; Tioguanine (INN); 9H-Purine-6-thiol, 2-amino-; 2-amino-1,9-dihydropurine-6-thione; MFCD00233553; CHEMBL727; WIX31ZPX66; 2-amino-6,7-dihydro-3H-purine-6-thione; CHEBI:9555; NSC752; Thioguanine2-Amino-6-purinethiol; 2-Thioguanine; Tioguanine [INN]; 2-amino-1,7-dihydropurine-6-thione; NCGC00094792-01; DSSTox_CID_3652; 2-Amino-6-MP; DSSTox_RID_77129; DSSTox_GSID_23652; Tioguaninum [INN-Latin]; 2-Aminopurin-6-thiol [Czech]; Guanine, thio- (VAN); 2-Amino-6-merkaptopurin [Czech]; 6-Tioguanine; Tioguanina [INN-Spanish]; CAS-154-42-7; DX4; SMR000857244; Lanvis (TN); Thioguanine Anhydrous; CCRIS 8997; NSC-76504; HSDB 2504; SR-05000002077; EINECS 205-827-2; Thioguanine [USAN:USP]; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; Thioquanine; AI3-26078; 7H-Purine-6-thiol, 2-amino-; 6-thioguano-sine; 6-TG/Thioguanine; Tioguanine hemihydrate; PubChem9185; Thioguanine, anhydrous; 6-Thioguanine/6-TG; 1H-Purine-6-thiol, 2-amino- (9CI); Spectrum_000235; ACMC-209dan; Spectrum2_000695; Spectrum3_000577; Spectrum4_000926; Spectrum5_001455; purine antimetabolite: antimetabolite: inhibits nucleic acid replication; 2-Amino-6-mercapto-purin; 6-Thioguanine, >=98%; SCHEMBL3701; SCHEMBL5898; NCIOpen2_004153; BSPBio_001994; KBioGR_001452; KBioGR_002476; KBioSS_000715; KBioSS_002483; MLS001333131; MLS001333132; MLS006010896; DivK1c_000428; SPECTRUM1500573; 6H-Purine-6-thione, 2-amino-3,7-dihydro- (9CI); SPBio_000849; 154-42-7; 6-Thioguanine; 2-amino-6-mercapto-9H-purine; GTPL6845; Thioguanine (TN) (GlaxoSmith); DTXSID6023652; HMS501F10; KBio1_000428; KBio2_000715; KBio2_002476; KBio2_003283; KBio2_005044; KBio2_005851; KBio2_007612; KBio3_001494; KBio3_002954; cMAP_000061; NINDS_000428; BCPE000001; HMS1921E09; HMS2092M11; HMS2235F05; HMS3865G13; Pharmakon1600-01500573; 2-amino-1H-purine-6(9H)-thione; ALBB-023493; BCP27718; ZINC6382803; Tox21_111035; Tox21_113184; Tox21_202401; Tox21_300275; ABP000905; ANW-21501; BDBM50200099; CCG-39890; NSC757348; s1774; SBB067147; AKOS003389499; AKOS015901298; Tox21_111035_1; 2-Amino-1,7-dihydro-purine-6-thione; 2-Amino-1,9-dihydro-purine-6-thione; AC-8421; BCP9000197; CCG-213953; CCG-266338; CS-1497; DB00352; MCULE-5787306636; NSC-757348; PS-5007; VZ33872; WLN: T56 BNM FYM INJ FUS HZ; IDI1_000428; SMP2_000326; NCGC00094792-02; NCGC00094792-03; NCGC00094792-05; NCGC00094792-06; NCGC00188976-01; NCGC00188976-02; NCGC00254082-01; NCGC00259950-01; NCGC00263442-01; NCGC00263442-05; 153981-51-2; 153981-52-3; 154034-61-4; 154034-62-5; AC-23020; H351; HY-13765; NCI60_041643; SMR004701808; SBI-0051533.P003; AB0013003; FT-0611217; R2215; ST45025337; Y7662; 2-Amino-1,7-dihydro-6H-purine-6-thione #; C07648; D08603; J10163; W-5092; 15151-EP2275420A1; 15151-EP2295055A2; 15151-EP2295416A2; 15151-EP2295426A1; 15151-EP2295427A1; 15151-EP2298748A2; 15151-EP2298764A1; 15151-EP2298765A1; 15151-EP2305642A2; 15151-EP2308833A2; 15151-EP2311453A1; 15151-EP2311808A1; 15151-EP2311825A1; 15151-EP2311829A1; 15151-EP2311840A1; 15151-EP2311842A2; 15151-EP2316832A1; 15151-EP2316833A1; AB00174074_06; AB00918694_06; AB01273926-01; AB01273926-02; AB01273926_03; 120118-EP2270008A1; 120118-EP2272827A1; 120118-EP2292617A1; 120118-EP2298778A1; 154T427; Q385347; SR-05000002077-1; SR-05000002077-5; W-108030; W-205813; Z2768769146; 6-Thioguanine;6-TG;2-Amino-6-mercaptopurine;2-Amino-6-purinethiol; Thioguanine, United States Pharmacopeia (USP) Reference Standard; Thioguanine;6-TG; 2-Amino-6-mercaptopurine; 2-Amino-6-purinethiol; 6-Thioguanine, Hybri-Max(TM), 50 x, gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma	Small molecule	1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)	WYWHKKSPHMUBEB-UHFFFAOYSA-N	C1=NC2=C(N1)C(=S)N=C(N2)N	C5H5N5S	CAS 154-42-7	CHEBI:9555	.	.	.	D02ZXM	.	.	.
NP8079	Cantharidin	CID: 5944	cantharidin; 56-25-7; CANTHARIDINE; Cantharone; Kantaridin; Kantharidin; Cantharides camphor; 1,2-Dimethyl-3,6-epoxyperhydrophthalic anhydride; UNII-IGL471WQ8P; NSC61805; exo-1,2-cis-Dimethyl-3,6-epoxyhexahydrophthalic anhydride; BRN 0085302; AI3-04021; (3ar,4s,7r,7as)-3a,7a-dimethylhexahydro-4,7-epoxy-2-benzofuran-1,3-dione; IGL471WQ8P; CHEMBL48449; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3aR,4S,7R,7aS)-rel-; CHEBI:64213; 7a-Dimethylhexahydro-3a,4,7-epoxyisobenzofuran; CAN [Alkaloid]; Hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione; MFCD00134968; NSC-61805; Cantharidin (USAN); Cantharidin [USAN]; 3a,7a-Dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dione; NSC 61805; (3aR,4S,7R,7aS)-3a,7a-dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dione; Kantharidin [German]; Caswell No. 157; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3aalpha,4beta,7beta,7aalpha)-; (3a?,4?,7?,7a?)-Hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione; CCRIS 635; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-; 2,3-Dimethyl-7-oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride; 7-Oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride, 2,3-dimethyl-; HSDB 2181; EINECS 200-263-3; EPA Pesticide Chemical Code 013101; CAS-56-25-7; NCGC00016247-01; PubChem6009; Prestwick3_000885; (1R,2S,3R,6S)-1,2-Dimethyl-3,6-epoxycyclohexane-1,2-dicarboxylic anhydride; 2,3-dicarboxylic anhydride; Hexahydro-3aalpha,7aalpha-dimethyl-4beta,7beta-epoxyisobenzofuran-1,3-dione; NCIMech_000301; BSPBio_000670; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3a-alpha,4-beta,7-beta,7a-alpha); 5-19-05-00051 (Beilstein Handbook Reference); SCHEMBL152262; BPBio1_000738; Cantharides camphor,  Cantharone; cid_6708701; HMS2097B12; HMS3412J13; HMS3676J13; 1,6-epoxyperhydrophthalic anhydride; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3a.alpha.,4.beta.,7.beta.,7a.alpha.)-; ACT03236; AMY33451; BCP09819; HY-N0209; BDBM50090505; CCG-35382; CCG-36082; WHO 11470; ZINC17611186; AKOS015895930; AC-7967; CS-4979; DB12328; 4,3-dione, hexahydro-3a,7a-dimethyl-; exo-1,6-epoxyhexahydrophthalic anhydride; NCGC00025212-02; NCGC00025212-03; NCGC00025212-04; NCGC00025212-05; NCGC00025212-31; AS-18735; NCI60_005413; WLN: T C555 A AO DVOVTJ C1 G1; AB00513946; Hexahydro-3a,7-epoxyisobenzofuran-1,3-dione; X1105; C16778; D11745; 7-Oxabicyclo[2.2.1]heptane-2, 2,3-dimethyl-; 134C968; Q410884; SR-01000597585; SR-01000597585-1; BRD-K80684056-001-01-0; (1R,2S,6R,7S)-2,6-Dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione; (1R,7S)-2,6-Dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione; (1S,2R,6S,7R)-2,6-Dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione; (1S,3S,4R,7R)-2,6-dimethyl-4,10-dioxa-tricyclo[5.2.1.0-2,6]decane-3,5-dione; 4,3-dione, hexahydro-3a,7a-dimethyl-, (3a.alpha.,4.beta.,7.beta.,7a.alpha.)-; Cantharidin:4,7-Epoxyisobenzofuran-1,3-dione,hexahydro-3a,7a- dimethyl-, (3a,4,7,7a)-,	Small molecule	1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10-	DHZBEENLJMYSHQ-XCVPVQRUSA-N	CC12C3CCC(C1(C(=O)OC2=O)C)O3	C10H12O4	CAS 56-25-7	CHEBI:64213	.	.	.	D0Z2RA	.	.	.
NP8116	Anastrozole	CID: 2187	anastrozole; 120511-73-1; Arimidex; anastrazole; Anastrozol; 2,2'-(5-((1H-1,2,4-triazol-1-yl)methyl)-1,3-phenylene)bis(2-methylpropanenitrile); ZD1033; ZD-1033; ICI D1033; UNII-2Z07MYW1AZ; ICI-D1033; 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile; alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 2Z07MYW1AZ; CHEMBL1399; 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); CHEBI:2704; Anastrozole, 98%; NSC719344; NCGC00164619-01; Asiolex; DSSTox_CID_2607; 2-[3-(1-cyano-1-methylethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile; DSSTox_RID_76656; DSSTox_GSID_22607; ZD 1033; 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methyl-propanenitrile; Arimidex (TN); SMR000466301; CAS-120511-73-1; HSDB 7462; ICI-D 1033; SR-01000759390; CCRIS 9352; Anastrozole [USAN:USP:INN:BAN]; tetramethyl-5-(1h-1,2,4-triazol-1ylmethyl) 1,3-benzenediacetionitrile; Arimidex (AstraZeneca); PubChem16625; SCHEMBL9726; ZINC941; 1,3-Benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-; MLS000759396; MLS001424217; MLS006011961; Anastrozole (JAN/USP/INN); GTPL5137; DTXSID9022607; BDBM10015; AOB4816; EBD3898; QCR-114; BCPP000401; HMS2052M11; HMS2089N10; HMS2235M06; HMS3369K05; HMS3394M11; HMS3654I18; HMS3715B05; HMS3742O21; HMS3866K03; Pharmakon1600-01502278; ACT03222; AMY42020; BCP02090; Tox21_112238; Tox21_303568; CA0164; MFCD00866298; NSC759855; s1188; STL451008; AKOS015894980; Tox21_112238_1; AC-4234; BCP9000301; CCG-101109; CS-0716; DB01217; KS-5052; MCULE-3029589501; NC00359; NSC 719344; NSC 759855; NSC-719344; NSC-759855; SB17304; 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 3-Phenylene]bis(2-methyl-propiononitrile; NCGC00164619-02; NCGC00164619-04; NCGC00257356-01; HY-14274; AB0012887; B1382; SW197739-4; 11A731; C08159; D00960; W-5140; AB00639929-06; AB00639929-08; AB00639929-09; AB00639929-10; AB00639929_11; AB00639929_13; A804526; Q419143; 2;2'-[5-(1H-1;2;4-Triazol-1-ylmethyl)-1; SR-01000759390-4; SR-01000759390-5; Z1522566626; 3-AMINO-3-(4-DIETHYLAMINO-2-HYDROXY-PHENYL)-PROPIONICACID; 1,.alpha.,alpha.,alpha.',.alpha.'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-; 2,2'-[5-(1H-1,2,4-triazol-1-yl-methyl)-1,3-phenylene]-di(2-methyl propionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropiononitrile); 2,2'-[5-(1H-1,2,4-triazole-1-yl-methyl)-1,3-phenylene]di(2-methyl propionitrile); a,a,a',a'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile; .alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 2-[3-(1-cyano-1-methylethyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]phenyl]-2-methylpropanenitrile; alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile	Small molecule	1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3	YBBLVLTVTVSKRW-UHFFFAOYSA-N	CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N	C17H19N5	CAS 120511-73-1	CHEBI:2704	.	.	.	D0W0BF	.	.	.
NP8128	Rhein	CID: 10168	Rhein; 478-43-3; Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; Chrysazin-3-carboxylic acid; 1,8-Dihydroxy-3-carboxyanthraquinone; Rheinic acid; NSC 38629; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; MFCD00009618; 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; UNII-YM64C2P6UX; 4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; Rhein (1,8-dihydroxy-3-carboxyl anthraquinone); 9,10-Dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid; YM64C2P6UX; MLS000069639; CHEBI:8825; 2-Anthroic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; 4,5-Dihydroxy-2-anthraquinonecarboxylic acid; 4,5-DiOH-anthraquinone-2-COOH; SMR000058210; ST057726; dipropionyl rhein; 1,8-DIHYDROXY-3-CARBOXYL ANTHRAQUINONE; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthroic acid; Rhein(Monorhein); CCRIS 5129; C15H8O6; EINECS 207-521-4; BRN 2222155; Rhein - Monorhein; RHN; Rhein,(S); Rhein; Rhubarb Yellow; Rhein, technical grade; 4ie7; ACMC-209kan; regid855879; Rhein-[13C6]; DSSTox_CID_6000; Rhein, analytical standard; 1,8-dihydroxy-3-carboxyl-9,10-anthraquinone; DSSTox_RID_77984; DSSTox_GSID_26000; SCHEMBL25253; US9238626, Rhein; 4-10-00-04088 (Beilstein Handbook Reference); cid_10168; MLS006011744; CHEMBL418068; MEGxp0_001866; 4,5-dihydroxy-9,10-dioxo-anthracene-2-carboxylic acid; DTXSID4026000; ACon1_000217; BDBM32021; ACT03257; BCP28202; HY-N0105; NSC38629; ZINC4098704; Tox21_201098; ANW-30573; BBL009695; CR0016; LMPK13040015; NSC-38629; s2400; SBB001152; STL141046; AKOS005259272; AC-7978; ACN-035339; CS-5239; DB13174; MCULE-1248137705; NCGC00018199-01; NCGC00018199-02; NCGC00018199-03; NCGC00018199-04; NCGC00018199-05; NCGC00018199-06; NCGC00018199-07; NCGC00023342-03; NCGC00023342-04; NCGC00258650-01; AK-88490; AM807834; AS-11635; CAS-478-43-3; SY051290; AB0010467; DB-014981; D3986; FT-0645050; FT-0674401; N1810; 4, 5-Dihydroxyanthraquinone-2-carboxylic acid; 2-Anthraquinonecarboxylic acid, 4,5-dihydroxy-; 78R433; C10401; X-4365; Q720356; Q-100512; 4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; BRD-K27335680-001-01-9; 2-Anthroic acid,10-dihydro-4,5-dihydroxy-9,10-dioxo-; 4,5-dihydroxy-9,10-diketo-anthracene-2-carboxylic acid; 2-Anthracenecarboxylic acid,10-dihydro-4,5-dihydroxy-9,10-dioxo-; 2-Anthroic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo- (8CI); 4,5-bis(oxidanyl)-9,10-bis(oxidanylidene)anthracene-2-carboxylic acid; 4,5-Dihydroxy-9,10-dioxo-9,10-dihydro-2-anthracenecarboxylic acid #; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracene carboxylic acid; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid, 9CI	Small molecule	1S/C15H8O6/c16-9-3-1-2-7-11(9)14(19)12-8(13(7)18)4-6(15(20)21)5-10(12)17/h1-5,16-17H,(H,20,21)	FCDLCPWAQCPTKC-UHFFFAOYSA-N	C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)C(=O)O	C15H8O6	CAS CAS 478-43-3	CHEBI:8825	.	.	.	D0M2TY	.	.	.
NP8133	Cucurbitacin I	CID: 5281321	Cucurbitacin I; 2222-07-3; Elatericin B; Cucurbitacine (I); 1,2-Dehydroelatericin A; UNII-SHQ47990PH; CHEBI:3947; SHQ47990PH; (8S,9R,10R,13R,14S,16R,17R)-17-[(E,2R)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,16-dihydroxy-4,4,9,13,14-pentamethyl-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthrene-3,11-dione; JSI-124; NSC521777; NSC 521777; NSC-521777; MLS002702902; 19-nor-9.beta.,5,23-triene-3,11,22-trione, 9-methyl-2,16,20,25-tetrahydroxy-; JSI 124; 19-Norlanosta-1,23-triene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (9.beta.,10.alpha.,16.alpha.)- (VA; EINECS 218-736-8; NSC 112167; CUCURBITACCINE (I); CHEMBL387737; SCHEMBL2523066; SCHEMBL15914446; DTXSID501015546; HY-N1405; ZINC4097803; LMST01010110; NSC112167; AKOS024456675; CS-5431; NCGC00388208-02; 19-Nor-9-beta,10-alpha-lanosta-1,5,23-triene-3,11,22-trione, 9-methyl-2,16,20,25-tetrahydroxy-; 19-Norlanosta-1,5,23-triene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (9beta,10alpha,16alpha)-; 2,16alpha,20,25-Tetrahydroxy-9beta-methyl-10alpha-19-norlanosta-1,5,23(E)-triene-3,11,22-trione; A4512; C08800; 222C073; Q27106265; (4R,9beta,16alpha,23E)-2,16,20,25-tetrahydroxy-9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene-1,11,22-trione; (8S,9R,10R,13R,14S,16R,17R)-17-[(E,1R)-1,5-dihydroxy-1,5-dimethyl-2-oxo-hex-3-enyl]-2,16-dihydroxy-4,4,9,13,14-pentamethyl-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthrene-3,11-dione; (9?,10?,16?,23E)-2,16,20,25-Tetrahydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione; 19-Norlanosta-1,5,23-triene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (9.beta.,10.alpha.,16.alpha.,23E)-; 19-Norlanosta-1,5,23-triene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (9beta,10alpha,16alpha)- (VAN) (9CI)	Small molecule	1S/C30H42O7/c1-25(2,36)12-11-21(33)30(8,37)23-19(32)14-27(5)20-10-9-16-17(13-18(31)24(35)26(16,3)4)29(20,7)22(34)15-28(23,27)6/h9,11-13,17,19-20,23,31-32,36-37H,10,14-15H2,1-8H3/b12-11+/t17-,19-,20+,23+,27+,28-,29+,30+/m1/s1	NISPVUDLMHQFRQ-MKIKIEMVSA-N	CC1(C2=CCC3C4(CC(C(C4(CC(=O)C3(C2C=C(C1=O)O)C)C)C(C)(C(=O)C=CC(C)(C)O)O)O)C)C	C30H42O7	CAS 2222-07-3	CHEBI:3947	.	.	.	.	.	.	.
NP8137	Sclareol	CID: 163263	Sclareol; 515-03-7; (13R)-Labd-14-ene-8,13-diol; labd-14-ene-8,13-diol; UNII-B607NP0Q8Y; SCAREOL; (1R,2R,4aS,8aS)-1-((R)-3-hydroxy-3-methylpent-4-en-1-yl)-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol; B607NP0Q8Y; CHEBI:9053; Q63396017; (1R,2R,4aS,8aS)-1-[(3R)-3-hydroxy-3-methylpent-4-en-1-yl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol labd-14-ene-8,13-diol; Sclareol (natural); Sclareol (6CI); sclareol group; sclareol derivatives; (1R,2R,4aS,8aS)-1-[(3R)-3-hydroxy-3-methylpent-4-enyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-2-ol; EINECS 208-194-0; Sclareol, 98%; BRN 2054148; DSSTox_CID_27111; DSSTox_RID_82121; DSSTox_GSID_47111; Sclareol, analytical standard; 4-06-00-05554 (Beilstein Handbook Reference); SCHEMBL873931; CHEMBL294740; DTXSID0047111; HY-N0128; ZINC3881344; Tox21_302727; MFCD00869558; AKOS025310185; LMPR0104030010; MCULE-9063642375; (13R)-Labd-14-ene-8alpha,13-diol; (1R,2R,8aS)-Decahydro-1-(3-hydroxy-3-methyl-4-pentenyl)-2,5,5,8a-tetramethyl-2-naphthol; NCGC00256908-01; AS-14857; CAS-515-03-7; M896; CS-0007834; N2558; S0916; C09183; Labd-14-ene-8,13-diol, (13R)- (8CI); 515S037; (1R,2R,4aS,8aS)-1-[(3R)-3-hydroxy-3-methyl-pent-4-enyl]-2,5,5,8a-tetramethyl-decalin-2-ol; (1R,2R,4aS,8aS)-1-[(3R)-3-hydroxy-3-methylpent-4-en-1-yl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol; (1R,2R,8aS)-1-((R)-3-hydroxy-3-methylpent-4-enyl)-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol; (1R-(1alpha(R*),2beta,4Abeta,8aalpha))-2-hydroxy-alpha,2,5,5,8a-pentamethyl-alpha-vinyldecahydronaphthalene-1-propan-1-ol; 1-Naphthalenepropanol, alpha-ethenyldecahydro-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (1theta-(1alpha(theta),2beta,4abeta,8aalpha))-; 1-Naphthalenepropanol, alpha-ethenyldecahydro-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (alphaR,1R,2R,4aS,8aS)-; 1-Naphthalenepropanol, alpha-ethenyldecahydro-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (alphaR,1R,2R,4aS,8aS)-: (1R,2R,4aS,8aS)-1-[(3R)-3-hydroxy-3-methylpent-4-en-1-yl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol; 1-Naphthalenepropanol, decahydro-alpha-ethenyl-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (1R-(1-alpha(R*),2-beta,4a-beta,8a-alpha))-; 86023-49-6	Small molecule	1S/C20H36O2/c1-7-18(4,21)13-9-16-19(5)12-8-11-17(2,3)15(19)10-14-20(16,6)22/h7,15-16,21-22H,1,8-14H2,2-6H3/t15-,16+,18-,19-,20+/m0/s1	XVULBTBTFGYVRC-HHUCQEJWSA-N	CC1(CCCC2(C1CCC(C2CCC(C)(C=C)O)(C)O)C)C	C20H36O2	CAS 515-03-7	CHEBI:9053	.	.	.	.	.	.	.
NP8194	Calcitonin	CID: 16220016	Calcitonin-salmon; Thyrocalcitonin (salmon); Cibacalcin; Salmon calcitonin; Calcitonina; Calcitar; Fortical; Bionocalcin; Calcimonta; Calcitoran; Cibacalcine; Eptacalcin; Miracalcic; Osseocalcina; Ostostabil; Porostenina; Prontocalcin; Rulicalcin; Salmocalcin; Salmotonin; Tonocalcin; Astronin; Biocalcin; Calciben; Calcinil; Calcioton; Calogen; Calsynar; Caltine; Catonin; Citonina; Ipocalcin; Kalsimin; Oseototal; Osteobion; Osteovis; Ostosalm; Quosten; Riostin; Salcatyn; Salmofar; Stalcin; Staporos; Steocin; Cadens; Casalm; Ostora; Salcat; Ucecal; Calco; Karil; Sical; Isi-calcin; Calcitonin,salmon; Calsynar Lyo L; Calcitonin(salmon); Calcitonin, salmar; Salmon calcitonin I; Calcitonin vom lachs; Calcitonine de saumon; TZ-CT; Salmon calcitonin-(I-32); Salmon calcitonin-(1-32); CHEBI:3306; Calcitonin, salmon, for bioassay; Calcitonin [USAN:INN:BAN:JAN]; EINECS 256-342-8; NCGC00167232-01; Calcitonin salmon, >=97% (HPLC), powder; Calcitonin salmon, European Pharmacopoeia (EP) Reference Standard; Calcitonin salmon, United States Pharmacopeia (USP) Reference Standard; cyclo-[Cys-Ser-Asn-Leu-Ser-Thr-Cys]-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2; L-Cysteinyl-L-seryl-L-asparaginyl-L-leucyl-L-seryl-L-threonyl-L-cysteinyl-L-valyl-L-leucylglycyl-L-lysyl-L-leucyl-L-seryl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-histidyl-L-lysyl-L-leucyl-L-glutaminyl-L-threonyl-L-tyrosyl-L-prolyl-L-arginyl-L-threonyl-L-asparaginyl-L-threonylglycyl-L-serylglycyl-L-threonyl-L-prolinamide, cyclic(1-7)-disulfide	Small molecule	1S/C145H240N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99-63-239-238-62-79(148)117(210)178-96(59-191)134(227)174-92(52-104(151)202)131(224)172-90(49-69(9)10)129(222)180-98(61-193)135(228)187-114(74(16)197)142(235)181-99)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)/t71-,72-,73-,74-,75-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,110+,111+,112+,113+,114+,115+/m1/s1	BBBFJLBPOGFECG-VJVYQDLKSA-N	CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO	C145H240N44O48S2	CAS 47931-85-1	CHEBI:3306	.	.	.	.	.	.	.
NP8210	Galangin	CID: 5281616	Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one; 548-83-4	.	1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H	VCCRNZQBSJXYJD-UHFFFAOYSA-N	C1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O	C15H10O5	CAS 548-83-4	.	HBIN027003	SMIT04781	MOL002563	D0Y7HG	.	2251	.
NP8223	Febrifugine	CID: 9851692	Febrifugine; 24159-07-7; UNII-89UWD0FH2I; 89UWD0FH2I; Ferbifrugin; Dichroin; beta-Dichroine; 3-(3-(3-Hydroxy-2-piperidinyl)-2-oxopropyl)-4(3H)-quinazolinone; 3-[3-[(2R,3S)-3-Hydroxy-2-piperidinyl]-2-oxopropyl]-4(3H)-quinazolinone; 3-{3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3H)-one; Febrifugine;; NSC 315535; Febrifugine (8CI); 3-[3-[3(S)-Hydroxypiperidin-2(R)-yl]-2-oxopropyl]-3,4-dihydroquinazolin-4-one; CHEMBL322782; SCHEMBL9542831; HY-N2384; ZINC5641945; MFCD11867855; CS-0022587; (E)-3-(3-(3-Hydroxy-2-piperidinyl)acetonyl)-4-(3H)-quinazolinone; (E)-3-(3-(3-Hydroxy-2-piperidinyl)-2-oxopropyl)-4(3H)-quinazolinone; 3-[3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one; trans-3-(beta-Keto-gamma-(3-hydroxy-2-piperidyl)propyl)-4-quinazolone; 4(3H)-Quinazolinone, 3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, (2S-trans)-; 9SF	Small molecule	1S/C16H19N3O3/c20-11(8-14-15(21)6-3-7-17-14)9-19-10-18-13-5-2-1-4-12(13)16(19)22/h1-2,4-5,10,14-15,17,21H,3,6-9H2/t14-,15+/m1/s1	FWVHWDSCPKXMDB-CABCVRRESA-N	C1CC(C(NC1)CC(=O)CN2C=NC3=CC=CC=C3C2=O)O	C16H19N3O3	CAS 24159-07-7	.	.	.	.	.	.	.	.
NP8268	Curcumol	CID: 14240392	(-)-Curcumol; 4871-97-0; UNII-9190RTN07X; 9190RTN07X; MFCD00272163; (3S,3aS,5S,6R,8aS)-Octahydro-3-methyl-8-methylene-5-(1-methylethyl)-6H-3a,6-epoxyazulen-6-ol; 5,8-Epoxy-10(14)-guaien-8-ol; ( -)-Curcumol; CHEMBL4303567; SCHEMBL22404924; HY-N0104; ( -)-Curcumol, analytical standard; s2407; ZINC70466453; AKOS022168205; CCG-266844; NCGC00346607-02; BS-16857; V0174; 871C970; Q-100546; Q27271386; (1S,2S,5S,8R,9S)-2-methyl-6-methylidene-9-propan-2-yl-11-oxatricyclo[6.2.1.01,5]undecan-8-ol; (3S-(3alpha,3aalpha,5alpha,6alpha,8abeta))-Octahydro-3-methyl-8-methylene-5-(1-methylethyl)-6H-3a,6-epoxyazulen-6-ol; 6H-3a,6-Epoxyazulen-6-ol, octahydro-3-methyl-8-methylene-5-(1-methylethyl)-, (3S,3aS,5S,6R,8aS)-	.	1S/C15H24O2/c1-9(2)13-8-14-11(4)5-6-12(14)10(3)7-15(13,16)17-14/h9,11-13,16H,3,5-8H2,1-2,4H3/t11-,12-,13-,14-,15+/m0/s1	QRMPRVXWPCLVNI-YYFQZIEXSA-N	CC1CCC2C13CC(C(O3)(CC2=C)O)C(C)C	C15H24O2	CAS 4871-97-0	.	HBIN021990	SMIT00084	MOL000902	.	.	3259	.
NP8310	Sulforaphane	CID: 5350	Sulforafan; DL-Sulforaphane; 1-Isothiocyanato-4-(methylsulfinyl)butane; D,L-Sulforaphane; L-Sulforaphane; Sulforaphane (unspecified); R,S-Sulforaphane; C6H11NOS2; 1-isothiocyanato-4-methylsulfinylbutane; Sulforaphane Racemate; CCRIS 7221; 1-Isothiocyanato-4-(methylsulfinyl)-butane; Butane, 1-isothiocyanato-4-(methylsulfinyl)-; SUVMJBTUFCVSAD-UHFFFAOYSA-N; 4-(Methylsulfinyl)Butyl Isothiocyanate	.	1S/C6H11NOS2/c1-10(8)5-3-2-4-7-6-9/h2-5H2,1H3	SUVMJBTUFCVSAD-UHFFFAOYSA-N	CS(=O)CCCCN=C=S	C6H11NOS2	CAS 4478-93-7	CHEBI:47807	HBIN045133	.	.	D0X4IO	.	.	.
NP8316	Ivermectin	CID: 6321424	IVERMECTIN; Ivermectin B1a; 70288-86-7; Dihydroavermectin B1a; 22,23-Dihydroavermectin B1a; avermectin H2B1a; 71827-03-7; UNII-91Y2202OUW; Ivermectin Component B1a; CHEBI:63941; 91Y2202OUW; (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-Butan-2-Yl]-20,20b-Dihydroxy-5',6,8,19-Tetramethyl-17-Oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-Tetradecahydro-2h,7h-Spiro[11,15-Methanofuro[4,3,2-Pq][2,6]benzodioxacyclooctadecine-13,2'-Pyran]-7-Yl 2,6-Dideoxy-4-O-(2,6-Dideoxy-3-O-Methyl-Alpha-L-Arabino-Hexopyranosyl)-3-O-Methyl-Alpha-L-Arabino-Hexopyranoside; 5-O-demethyl-22,23-dihydroavermectin A1a; C48H74O14 (B1a form); (1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one; C48H74O14; MK-933; 22,23-Dihydroavermectin B(1)a; Avermectin A1a, 5-O-demethyl-22,23-dihydro-; NCGC00163233-01; Ivermectin (IVM); IVM; EINECS 276-046-2; 70161-11-4; dihydro avermectin Bla; BRN 4643153; 22,23-Dihydro-5-O-demethylavermectin A1a; H2B1a; Prestwick3_000156; DSSTox_CID_3181; Ivermectin (MK-0933); DSSTox_RID_76909; DSSTox_GSID_23181; BSPBio_000292; SCHEMBL312795; BPBio1_000322; CHEMBL263291; DTXSID8023181; CHEBI:94551; HMS2089M09; HMS2095O14; HMS3712O14; Tox21_112034; BDBM50409816; MFCD00869511; s1351; AKOS027470116; ZINC238808778; ZINC252286706; AC-6014; CCG-220156; NCGC00186639-01; NCGC00186639-03; AS-14167; CAS-71827-03-7; HY-126937; AB00513813; CS-0108408; J10179; 22,23-DIHYDROAVERMECTIN B1A; IVERMECTIN; AB00513813-02; AB00513813-03; AB00513813_04; Avermectin A1a, 22,23-dihydro-5-O-demethyl-; 288I867; Ivermectin, Antibiotic for Culture Media Use Only; Q-201262; BRD-K24652731-001-02-7; BRD-K85554912-001-08-9; Q27132923; Ivermectin, British Pharmacopoeia (BP) Reference Standard; Ivermectin, European Pharmacopoeia (EP) Reference Standard; UNII-8883YP2R6D component AZSNMRSAGSSBNP-XPNPUAGNSA-N; Ivermectin, United States Pharmacopeia (USP) Reference Standard; Ivermectin, Pharmaceutical Secondary Standard; Certified Reference Material; (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17; 22,23-Dihydroavermectin B1; ; ; Heartgard 30; ; ; Ivomec; ; ; Ivosint; ; ; Mectizan; ; ; Stromectol; ; ; Uvemec; ; ; Vermic; ; ; Zimecterin; clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside	Small molecule	1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1	AZSNMRSAGSSBNP-XPNPUAGNSA-N	CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C	C48H74O14	CAS 71827-03-7	CHEBI:63941	.	.	.	D09YHJ	.	.	.
NP8371	Monocyte activating polypeptide II	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP8392	Pseudoephedrine	CID: 7028	PSEUDOEPHEDRINE; (+)-Pseudoephedrine; d-Pseudoephedrine; Isoephedrine; Sudafed; trans-Ephedrine; d-Isoephedrine; Psi-ephedrin; Psi-ephedrine; d-psi-Ephedrine; L(+)-psi-Ephedrine; (+)-threo-Ephedrine; L-(+)-Pseudoephedrine; (+)-psi-Ephedrine; 90-82-4; Pseudoefedrina; Pseudoephedrinum; Besan; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; (+)-(1S,2S)-Pseudoephedrine; Pseudoephedrine d-form; (1S,2S)-Pseudoephedrine; (1S,2S)-(+)-Pseudoephedrine; d-psi-2-Methylamino-1-phenyl-1-propanol; UNII-7CUC9DDI9F; 7CUC9DDI9F; 90-82-4 (free base); Pseudoephedrine, (+)-; CHEBI:51209; Pseudoephedrine, L-(+)-; alpha-(1-(Methylamino)ethyl)benzyl alcohol; Pseudoephedrine (D); Pseudoefedrina [INN-Spanish]; Pseudoephedrinum [INN-Latin]; (+) threo-2-(methylamino)-1-phenyl-1-propanol; Pseudoephedrine [INN:BAN]; Pseudoephedrine Ephedrine; psi-Ephedrine, (+)-; 2-(Methylamino)-1-phenyl-1-propanol; Neodurasina (TN); Acunaso (TN); pseudophedrine sulphate; HSDB 3177; Pseudoephedrine (INN); Pseudoephedrine polistirex; EINECS 202-018-6; Benzenemethanol, .alpha.-[(1S)-1-(methylamino)ethyl]-, (.alpha.S)-; (I)-Ephedrin; ephedrine-(racemic); (+) pseudoephedrine; d-Pseudoephedrine base; Spectrum_000878; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))-; Spectrum2_001303; Spectrum3_001771; Spectrum4_001162; Spectrum5_000650; Lopac-E-3250; (1S,2S) pseudoephedrine; (1S,2S)-2-methylamino-1-phenylpropan-1-ol; (1s, 2s) pseudoephedrine; EC 202-018-6; SCHEMBL4368; CHEMBL1590; (1S,2S)-2-(methylamino)-1-phenyl-propan-1-ol; BSPBio_003261; KBioGR_001763; KBioSS_001358; BIDD:GT0817; DivK1c_000451; SPBio_001365; GTPL7286; DTXSID0023537; KBio1_000451; KBio2_001358; KBio2_003926; KBio2_006494; KBio3_002762; ZINC20259; (1s, 2s)-(+)-pseudoephedrine; NINDS_000451; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaS)-; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-; PDSP1_001347; AKOS025401512; DB00852; MCULE-5756045923; IDI1_000451; (1S,2S)-(+)-Pseudoephedrine, 98%; NCGC00015408-01; NCGC00178180-01; NCI60_002955; SBI-0051498.P003; C02765; D08449; 064P256; Q263958; BRD-K84175871-003-02-2; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI); (S,S)-(+)-Pseudoephedrine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material	Small molecule	1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1	KWGRBVOPPLSCSI-WCBMZHEXSA-N	CC(C(C1=CC=CC=C1)O)NC	C10H15NO	CAS 90-82-4	CHEBI:51209	.	.	.	D00HHS	.	.	.
NP8393	Alpha-1 antitrypsin	.	.	.	.	.	.	.	.	.	.	.	.	D04TEF	.	.	.
NP8426	Olanzapine	CID: 135398745	olanzapine; 132539-06-1; Zyprexa; Zyprexa Zydis; Olansek; Zalasta; Zyprexa Intramuscular; Zolafren; Zypadhera; Zyprexa Velotab; LY-170053; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olzapin; Lanzac; Oferta; LY 170053; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; C17H20N4S; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; UNII-N7U69T4SZR; 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; LY170053; CHEMBL715; N7U69T4SZR; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; CHEBI:7735; MFCD00866702; olanzapina; NCGC00096077-03; DSSTox_CID_3388; 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine; DSSTox_RID_77010; DSSTox_GSID_23388; olanzapinum; Olanzapin; Midax; Olanzapine Mylan; 2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine; Olanzapine  Teva; 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; SMR000466345; Olanzapine Neopharma; CAS-132539-06-1; SR-01000759343; Olanzapine-d8; ALKS-7921; HSDB 8155; Olanzapine [USAN:USP:INN:BAN]; Olanzapine solution; Olanzapine (Zyprexa); KS-1090; ACMC-209wx7; GTPL47; BIDD:PXR0138; SCHEMBL28763; Olanzapine (JAN/USP/INN); US8802672, Olanzapine; MLS000759457; MLS001165781; MLS001195646; MLS001424057; BIDD:GT0332; SCHEMBL117695; SPECTRUM1505024; Olanzapine (LY-170053); DTXSID9023388; Olanzapine, >=98% (HPLC); BDBM35254; BDBM82479; CHEBI:94534; AMY7709; HMS2051H05; HMS2089M04; HMS2093I04; HMS2233F24; HMS3374L02; HMS3393H05; HMS3657I15; HMS3714J03; HMS3743A09; HMS3884J21; ACT03231; ALBB-027265; BCP04917; EBD23216; NSC_4585; ZINC3873830; Tox21_111556; AC-665; ANW-46937; CO0033; NSC754829; NSC801187; s2493; STK634338; STL388024; ZINC52957434; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; AKOS000282888; AKOS005566122; Olanzapine 1.0 mg/ml in Acetonitrile; Tox21_111556_1; ACN-029909; BCP9001021; CCG-100922; CS-1114; DB00334; MCULE-1620364835; NC00172; NSC-754829; NSC-801187; NCGC00096077-01; NCGC00096077-04; NCGC00096077-05; NCGC00096077-06; NCGC00096077-18; NCGC00389791-02; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; HY-14541; I960; SBI-0206786.P001; AB0013948; CAS_132539-06-1; FT-0673219; O0393; SW220248-1; A10667; C07322; D00454; J10363; S-4287; AB00639907-06; AB00639907-07; AB00639907_08; AB00639907_09; 539O061; A806453; L000455; L005958; Q201872; J-006186; SR-01000759343-4; SR-01000759343-6; Z1868057799; Olanzapine, European Pharmacopoeia (EP) Reference Standard; Olanzapine, United States Pharmacopeia (USP) Reference Standard; Olanzapine, Pharmaceutical Secondary Standard; Certified Reference Material; (E)-2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene; 2-methyl-4-(4-methyl-1-piperazinyl) -10h-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine #; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H- thieno[2,3-b][1,5]benzodiazepin; Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard; Olanzapine-d8, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Lanzac; Zyprexa; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0(3),?]tetradeca-1(14),3(7),5,8,10,12-hexaene; Olanzapine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material	Small molecule	1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3	KVWDHTXUZHCGIO-UHFFFAOYSA-N	CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C	C17H20N4S	CAS 132539-06-1	CHEBI:7735	.	.	.	D0V4QS	.	.	.
NP8427	Phloroglucinol	CID: 359	phloroglucinol; 108-73-6; Benzene-1,3,5-triol; 1,3,5-trihydroxybenzene; 1,3,5-benzenetriol; Phloroglucin; Phloroglucine; Spasfon-Lyoc; s-Trihydroxybenzene; 5-Hydroxyresorcinol; Benzene-s-triol; 3,5-Dihydroxyphenol; Phloroglucinol anhydrous; Benzene, trihydroxy; sym-Trihydroxybenzene; 5-Oxyresorcinol; Dilospan S; Floroglucinol; Floroglucin; 5-Oxyresorcinolphloroglucin; 1,3,5-THB; 1,3,5-Trihydroxycyclohexatriene; 1,3,5-Triol; MFCD00002286; Benzene, 1,3,5-trihydroxy-; UNII-DHD7FFG6YS; Phloroglucinol, anhydrous; 5-Benzenetriol; 1,2,5-trihydroxybenzene; NSC 1572; Phloroglucinol (JAN); DHD7FFG6YS; CHEMBL473159; CHEBI:16204; NSC-1572; Floroglucin [Czech]; Floroglucinol [Czech]; Phloroglucinol, 99+%, anhydrous; CCRIS 4147; NCGC00166270-01; EINECS 203-611-2; BRN 1341907; AI3-08848; phloroglucinol ts; 1,5-Benzenetriol; 13X; Dilospan S (TN); PubChem2603; Phloroglucinol [BAN]; 1,5-Trihydroxybenzene; 1,5-Triol; Benzene,3,5-trihydroxy-; WLN: QR CQ EQ; 1,3,5-trihydroxylbenzene; 1,3,5-trihydroxy benzene; 1,3,5-trihydroxy-benzene; 1,3, 5-Trihydroxybenzene; SCHEMBL26311; 1,5-Trihydroxycyclohexatriene; 4-06-00-07361 (Beilstein Handbook Reference); Phloroglucinol, p.a., 99%; DTXSID9048354; NSC1572; ZINC391883; ACT13446; ANW-15974; BBL018701; BDBM50249069; STL146346; phloroglucinol (1,3,5-benzenetriol); Phloroglucinol, >=99.0% (HPLC); AKOS000119851; AM84333; AS04650; DB12944; FS-4574; MCULE-5869131240; 1,3,5-Benzenetriol (ACD/Name 4.0); NCGC00166270-02; AC-10081; FT-0606511; FT-0673853; P0249; P1376; ST50214381; A-8565; C02183; D00152; A801919; Q899008; Q-200070; Phloroglucinol, plant cell culture tested, BioReagent; F0001-0177; Phloroglucinol, Used to detect the presence of wood fiber.; Phloroglucinol (anhydrous), European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H	QCDYQQDYXPDABM-UHFFFAOYSA-N	C1=C(C=C(C=C1O)O)O	C6H6O3	CAS 108-73-6	CHEBI:16204	.	.	.	D07EXH	.	.	.
NP8435	Apicidin	CID: 6918328	CHEMBL430060; OSI-2040; Apicidin _120249; Acipidin; SCHEMBL147997; ChEMBL_275631; GTPL7495; DTXSID40274182; BDBM50238632; ZINC17654900; MCULE-8969470747; NCGC00165733-01; (3S,6S,9S,12R)-3-[(2S)-butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone; Q16829635; (6S,9S,12S,14aR)-6-((S)-sec-Butyl)-9-(1-methoxy-1H-indol-3-ylmethyl)-12-(6-oxo-octyl)-decahydro-4a,7,10,13-tetraaza-benzocyclododecene-5,8,11,14-tetraone	Small molecule	1S/C34H49N5O6/c1-5-22(3)30-34(44)38-19-13-12-18-29(38)33(43)35-26(16-9-7-8-14-24(40)6-2)31(41)36-27(32(42)37-30)20-23-21-39(45-4)28-17-11-10-15-25(23)28/h10-11,15,17,21-22,26-27,29-30H,5-9,12-14,16,18-20H2,1-4H3,(H,35,43)(H,36,41)(H,37,42)/t22-,26-,27-,29+,30-/m0/s1	JWOGUUIOCYMBPV-GMFLJSBRSA-N	CCC(C)C1C(=O)N2CCCCC2C(=O)NC(C(=O)NC(C(=O)N1)CC3=CN(C4=CC=CC=C43)OC)CCCCCC(=O)CC	C34H49N5O6	.	.	.	.	.	D0W1PV	.	.	.
NP8440	Cryptolepine	CID: 82143	Cryptolepine; 480-26-2; CCRIS 9019; 5H-Quindoline, 5-methyl-; 5-METHYL-5H-INDOLO[3,2-B]QUINOLINE; 5-methylindolo[3,2-b]quinoline; Cryptolepine hydrate; OF1UIT4RDH; UNII-OF1UIT4RDH; CHEBI:3930; NSC647765; 5-Methylquindoline; C09142; SCHEMBL542771; CHEMBL119096; 5-Methyl-5H-quindoline hydrate; DTXSID6037645; ZINC898100; BDBM50412201; MFCD17215953; Q5190964	Small molecule	1S/C16H12N2/c1-18-15-9-5-2-6-11(15)10-14-16(18)12-7-3-4-8-13(12)17-14/h2-10H,1H3	KURWKDDWCJELSV-UHFFFAOYSA-N	CN1C2=CC=CC=C2C=C3C1=C4C=CC=CC4=N3	C16H12N2	CAS 480-26-2	CHEBI:3930	.	.	.	.	.	.	.
NP8452	Theaflavin-3,3'-digallate	CID: 21146795	Q51617480; Theaflavin-3,3'-digallate; SCHEMBL717489; Q7777226	Small molecule	1S/C43H32O20/c44-17-7-23(46)21-12-29(52)39(60-32(21)9-17)14-1-19-20(40-30(53)13-22-24(47)8-18(45)10-33(22)61-40)11-31(54)41(63-43(59)16-4-27(50)37(56)28(51)5-16)35(19)38(57)34(6-14)62-42(58)15-2-25(48)36(55)26(49)3-15/h1-11,29-30,39-40,44-56H,12-13H2/t29-,30-,39-,40-/m1/s1	FJYGFTHLNNSVPY-BBXLVSEPSA-N	C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC4=C(C(=C(C=C4C5C(CC6=C(C=C(C=C6O5)O)O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O)C(=O)C(=C3)OC(=O)C8=CC(=C(C(=C8)O)O)O)O	C43H32O20	.	.	.	.	.	.	.	.	.
NP8476	Oxyprogesterone caproate	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP8491	Acarbose	CID: 41774	acarbose; 56180-94-0; Glucobay; Precose; Acarbosum; Prandase; CHEBI:2376; MFCD00869592; BAY-g 5421; C25H43NO18; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; SMR000466376; SR-01000759407; Acarbose/; Glucobay;; Prandase;; Precose;; Acarbose,(S); Precose (TN); Acarbose (JAN/USAN/INN); MLS000759506; MLS001424056; MLS006011898; SPECTRUM1505172; CHEMBL404271; SCHEMBL5316305; CHEMBL3734896; BDBM23406; HMS2051F03; HMS2093I22; HMS2236P06; Pharmakon1600-01505172; C25H43NO18;; ABP000588; BBL030515; BDBM50180587; NSC758915; STK801930; AKOS005622515; AB07578; CCG-100913; CCG-213345; MCULE-2053937515; MD-0230; NC00163; NSC-758915; NCGC00160515-01; SBI-0206777.P001; C06802; D00216; J10300; AB00639959-06; AB00639959_08; Abamectin, Antibiotic for Culture Media Use Only; 180A940; Q-200574; SR-01000759407-4; SR-01000759407-5; SR-01000759407-6; xan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol; BRD-A16444946-001-07-1; (3R,4R,5S,6R)-5-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol; (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)o; (3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol; 4',6'-Dideoxy-4'-([1S]-[1,4,6/5]-4,5,6-trihydroxy-3-hydroxymethyl-2-yclohexenylamino)-maltotriose; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; Precose (TN);	Small molecule	1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1	XUFXOAAUWZOOIT-UGEKTDRHSA-N	CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO	C25H43NO18	CAS 56180-94-0	CHEBI:2376	.	.	.	D0AD5C	.	.	.
NP8519	Cepharanthine	CID: 10206	Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); ecaene (non-preferred name); DSSTox_CID_25957; DSSTox_RID_81253; DSSTox_GSID_45957; C37H38N2O6; NSC-623442; CAS-481-49-2; CCRIS 6539; SR-01000779734; NSC 623442; BRN 0075231; Cepharanthin,(S); NCGC00095194-01; (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2~16,19~.1~3,10~.1~21,25~.0~4,8~.0~14,39~.0~31,35~]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dod; Cepharanthine (TN); Spectrum2_000832; Spectrum3_001963; 12-O-Methylcepharanoline; UPCMLD-DP054; BSPBio_003563; 4-27-00-09061 (Beilstein Handbook Reference); MLS000728518; SCHEMBL154545; SPECTRUM1505322; SPBio_000783; CHEMBL449782; DTXSID6045957; UPCMLD-DP054:001; KBio3_002909; Cepharanthine, >=95% (HPLC); Cepharanthine, >=98% (HPLC); HMS1922J12; HMS2232F21; Pharmakon1600-01505322; HY-N6972; Tox21_111483; BBL030154; BDBM50423643; CCG-40294; MFCD00210482; NSC758965; s4238; STK801907; ZINC30726863; AKOS004119865; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; Tox21_111483_1; MCULE-4243165865; NSC-758965; SDCCGMLS-0066893.P001; NCGC00161621-01; NCGC00161621-02; NCGC00161621-03; NCGC00161621-05; NCGC00161621-13; AC-15206; AK168069; AS-17451; SMR000445632; SBI-0207049.P001; CS-0007138; V0178; C09391; D01035; AB00643356_08; AB00643356_09; 481C492; Q-100524; SR-01000779734-3; SR-01000779734-4; BRD-K96194081-001-06-0; Q15410888; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-[methylenebis-(oxy)]oxyacanthan; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))- (9CI); (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2(16,19).1(3,10).1(21,25).0(4,8).0(14,39).0(31,35)]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dodecaene; (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2??,??.1?,??.1??,??.0?,?.0??,??.0??,??]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dodecaene	.	1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1	YVPXVXANRNDGTA-WDYNHAJCSA-N	CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3	C37H38N2O6	CAS 481-49-2	.	HBIN020124	SMIT00671	MOL006973	.	.	.	.
NP8525	Lactobacillus plantarum	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP8547	Roxithromycin	CID: 6915744	roxithromycin; Rulide; Roxithromycine; Roxithromycinum; Roxitromicina; 80214-83-1; RU 965; RU 28965; UNII-21KOF230FA; RU-965; Rulid; CHEBI:48935; 21KOF230FA; RU-28965; 9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin; (9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); (E)-roxithromycin; Roxithromycine [French]; Roxithromycinum [Latin]; Roxitromicina [Spanish]; Rulide (TN); 9-[O-[(2-Methoxyethoxy)methyl]oxime]erythromycin; SR-05000001850; CHEBI:48844; CCRIS 3461; Roxithromycin,(S); (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10; (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R,E)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-10-(((2-methoxyethoxy)methoxy)imino)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one; Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); Roxithromycin [USAN:INN:BAN:JAN]; RC2952; BRN 4286925; Spectrum5_001058; SCHEMBL65985; BSPBio_002717; SPECTRUM1503276; 9-[O-(2-methoxyethoxymethyl)-oxime] of erythromycin; Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime); CHEMBL1214185; HMS501D04; Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime), (9E)-; HMS1922O19; HMS2093C11; HMS3714L09; Pharmakon1600-01503276; Roxithromycin (JP17/USAN/INN); HY-B0435; BDBM50248154; CCG-39329; NSC758443; ZINC96061888; AKOS015969730; DB00778; NSC 758443; NSC-758443; IDI1_000382; NCGC00178510-01; SBI-0051809.P002; Roxithromycin 100 microg/mL in Acetonitrile; C13173; D01710; AB00052342_02; SR-05000001850-1; SR-05000001850-2; BRD-K38684403-001-03-9; BRD-K38684403-001-05-4; Q27895851; 9-[O-[(2-Methoxyethoxy)methyl]oxime]erythromycin, (9E)-; (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-10-{[(2-methoxyethoxy)methoxy]imino}-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one; (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one; (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-10-{[(2-methoxyethoxy)m; (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-10-{[(2-methoxyethoxy)methoxy]imino}-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one; (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione 10-{O-[(2-methoxyethoxy)methyl]oxime} (non-preferred name); (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-10-{[(2-methoxyethoxy)methoxy]imino}-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one; (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-10-(2,4,7-trioxa-1-azaoctan-1-ylidene)-1-oxacyclotetradecan-2-one; (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R,E)-6-(((2S,3R,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-10-(((2-methoxyethoxy)methoxy)imino)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one	Small molecule	1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1	RXZBMPWDPOLZGW-XMRMVWPWSA-N	CCC1C(C(C(C(=NOCOCCOC)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O	C41H76N2O15	CAS 80214-83-1	CHEBI:48935	.	.	.	D0Y4FL	.	.	.
NP8600	Yohimbine	CID: 8969	Yohimbine; Yohimbin; Quebrachin; Quebrachine; 146-48-5; Corynine; APHRODINE; Yohimbic acid methyl ester; Aphrosol; (+)-Yohimbine; Johimbin; Actibine; UNII-2Y49VWD90Q; 17-Hydroxyyohimban-16-carboxylic acid methyl ester; CHEMBL15245; 2Y49VWD90Q; 17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester; CHEBI:10093; (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester; methyl 17alpha-hydroxyyohimban-16alpha-carboxylate; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-; DSSTox_CID_20130; DSSTox_RID_79446; DSSTox_GSID_40130; methyl (1S,15R,18S,19R,20S)-18-hydroxy-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate; YOHIMBINE CHLORIDE; CHEMBL537669; Yohimbine (DCF); CAS-146-48-5; methyl (1R,2S,4aR,13bS,14aS)-2-hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate hydrochloride; methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate; methyl hydroxy[?]carboxylate; EINECS 205-672-0; BRN 0097276; trans-Quinolizidine yohimbine; YOHIMBE HYDROCHLORIDE; CCRIS 9415; SR-01000075297; Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.; Yohimbe bark extract; NSC19509; methyl (2S,13bS,14aS,1R,4aR)-2-hydroxy-1,2,3,4,5,8,14,13b,14a,4a-decahydrobenz o[1,2-g]indolo[2,3-a]quinolizinecarboxylate; Prestwick0_000584; Prestwick1_000584; Prestwick2_000584; Prestwick3_000584; Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester; Yohimbe Extract Yohimbine; cid_6169; cid_8969; Lopac0_001210; SCHEMBL33954; BSPBio_000428; BSPBio_001236; GTPL102; KBioGR_000576; KBioSS_000576; 4-25-00-01237 (Beilstein Handbook Reference); MLS000728591; SPBio_002647; BPBio1_000472; Yohimbol-16alpha-carboxylic acid, methyl ester (6CI); DTXSID9040130; BCBcMAP01_000032; KBio2_000576; KBio2_003144; KBio2_005712; KBio3_001031; KBio3_001032; Bio1_000455; Bio1_000944; Bio1_001433; Bio2_000458; Bio2_000938; HMS1362N17; HMS1792N17; HMS1990N17; HMS2089G19; HMS2234C18; ZINC3860825; Tox21_110019; BDBM50013515; BDBM50203564; MFCD00005093; AKOS015902024; Tox21_110019_1; Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester; Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI); CCG-205284; CS-5173; DB01392; GS-5751; MCULE-1043513122; SDCCGSBI-0051177.P002; IDI1_002213; MRF-0000020; SMP1_000320; NCGC00013260-01; NCGC00025018-05; NCGC00025018-06; NCGC00025018-07; NCGC00025018-10; NCGC00025018-11; NCGC00025018-17; HY-12715; SMR000470778; 17a-hydroxy-16a-methoxycarbonyl-yohimbane; 65Y190; C09256; D08685; Q412226; SR-01000075297-5; BRD-K35586044-001-02-6; BRD-K35586044-003-03-0; BRD-K35586044-003-11-3; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- (9CI); (1R,2S,4aR,13bS,14aS)-2-hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2'',3'':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester hydrochloride; 103834-06-6	Small molecule	1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1	BLGXFZZNTVWLAY-SCYLSFHTSA-N	COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O	C21H26N2O3	CAS 146-48-5	CHEBI:10093	.	.	.	D0H4JM	.	.	.
NP8605	6-dehydrogingerdione	CID: 22321203	6-Dehydrogingerdione; Dehydro-6-gingerdione; CHEMBL555195; SCHEMBL14952275; CHEBI:81311; C17746; 1-(3-Methoxy-4-hydroxyphenyl)-3-hydroxy-1,3-decadiene-5-one; (1E,3Z)-3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)deca-1,3-dien-5-one	Small molecule	1S/C17H22O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-16(20)17(11-13)21-2/h7-12,19-20H,3-6H2,1-2H3/b9-7+,15-12-	FZWNRFAUDBWSKY-QNQPVOBRSA-N	CCCCCC(=O)C=C(C=CC1=CC(=C(C=C1)O)OC)O	C17H22O4	.	CHEBI:81311	.	.	.	.	.	.	.
NP8606	Fisetin	CID: 5281614	2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; 3,7,3',4'-Tetrahydroxyflavone; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1; FISETIN	.	1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H	XHEFDIBZLJXQHF-UHFFFAOYSA-N	C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O	C15H10O6	CAS 528-48-3	.	HBIN026506	SMIT00327	MOL013179	D0MF5Y	.	6437	.
NP8625	Gamma tocotrienol	CID: 5282349	gamma-Tocotrienol; 14101-61-2; Gama-Tocotrienol; Plastochromanol 3; UNII-185QAE24TR; D-gamma-Tocotrienol; 7,8-Dimethyltocotrienol; 185QAE24TR; CHEBI:33277; (2R)-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol; (R-(E,E))-3,4-Dihydro-2,7,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2H-1-benzopyran-6-ol; .gamma.-Tocotrienol; (R)-2,7,8-Trimethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chroman-6-ol; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,7,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-, (R-(E,E))-; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,7,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-, [R-(E,E)]-; 2H-1-benzopyran-6-ol, 3,4-dihydro-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-, (2R)-; 2R,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2H-chromen-6-ol; Plastochromanol; 2R-gamma-tocotrienol; (R)-gamma-Tocotrienol; D-.gamma.-Tocotrienol; (R)-.gamma.-Tocotrienol; BIDD:PXR0016; CHEMBL120697; SCHEMBL3272929; SCHEMBL16430897; DTXSID101019984; HMS3650C14; ZINC3791929; 1715AH; LMPR02020057; gamma-Tocotrienol, analytical standard; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-tr imethyl-3,7,11-tridecatrienyl]-, (2R)- (9CI); HY-108694; CS-0029988; C14155; D-gamma-Tocotrienol, analytical reference material; SR-01000946268; SR-01000946268-1; Q15633932; UNII-KP2MW85SSQ component OTXNTMVVOOBZCV-WAZJVIJMSA-N; (R)-2,7,8-trimethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-ol; 6-Chromanol, 2,7,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-; 6-Chromanol, 2,7,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)- (7CI,8CI); (2R)-2,7,8-trimethyl-2-(4',8',12'-trimethyl-trideca-3',7',11'-trienyl)-6-hydroxychroman; (2R)-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2H-chromen-6-ol; 153831-49-3; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrien-1-yl]-, (2R)-; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-, (2R)- (9CI)	Small molecule	1S/C28H42O2/c1-20(2)11-8-12-21(3)13-9-14-22(4)15-10-17-28(7)18-16-25-19-26(29)23(5)24(6)27(25)30-28/h11,13,15,19,29H,8-10,12,14,16-18H2,1-7H3/b21-13+,22-15+/t28-/m1/s1	OTXNTMVVOOBZCV-WAZJVIJMSA-N	CC1=C(C=C2CCC(OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)O	C28H42O2	CAS 14101-61-2	CHEBI:33277	.	.	.	D09YBF	.	.	.
NP8646	Arabinogalactan	CID: 24847856	Galactoarabinan; 9036-66-2; (+)-Arabinogalactan; ARABINOGALACTAN; 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol; ANW-42610; FT-0604415	Small molecule	1S/C20H36O14/c1-7-11(23)18(12(24)9(4-21)32-7)34-20-15(27)17(29-3)13(25)10(33-20)6-31-19-14(26)16(28-2)8(22)5-30-19/h7-27H,4-6H2,1-3H3	SATHPVQTSSUFFW-UHFFFAOYSA-N	CC1C(C(C(C(O1)CO)O)OC2C(C(C(C(O2)COC3C(C(C(CO3)O)OC)O)O)OC)O)O	C20H36O14	CAS 9036-66-2	.	.	.	.	.	.	.	.
NP8680	Glycyrol	CID: 5320083	Glycyrol; Neoglycyrol; 23013-84-5; CHEBI:80832; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one; MLS000697623; SCHEMBL758197; CHEMBL132695; DTXSID00177569; HMS2270J05; HY-N3961; ZINC13130921; AKOS032949068; SMR000470955; 3,9-Dihydroxy-1-methoxy-2-prenylcoumestan; CS-0024524; FT-0775552; C16968; Q27149874; 3,9-Dihydroxy-1-methoxy-2-(3-methyl-but-2-enyl)-benzofuro[3,2-c][1]benzopyran-6-one; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-enyl)benzofuro[3,2-c]chromen-6-one; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-1-methoxy-2-(3-methyl-2-butenyl)-; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-en-1-yl)-6H-[1]benzofuro[3,2-c][1]benzopyran-6-one	Small molecule	1S/C21H18O6/c1-10(2)4-6-12-14(23)9-16-18(19(12)25-3)20-17(21(24)27-16)13-7-5-11(22)8-15(13)26-20/h4-5,7-9,22-23H,6H2,1-3H3	LWESBHWAOZORCQ-UHFFFAOYSA-N	CC(=CCC1=C(C2=C(C=C1O)OC(=O)C3=C2OC4=C3C=CC(=C4)O)OC)C	C21H18O6	CAS 23013-84-5	CHEBI:80832	.	.	.	.	.	.	.
NP8751	Shikonin	CID: 479503	NSC 252844; Shikonin S; Shikonin,(S); Tokyo Violet	.	1S/C16H16O5/c1-8(2)3-4-10(17)9-7-13(20)14-11(18)5-6-12(19)15(14)16(9)21/h3,5-7,10,17-19H,4H2,1-2H3/t10-/m1/s1	NEZONWMXZKDMKF-SNVBAGLBSA-N	CC(=CCC(C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C	C16H16O5	CAS 517-89-5	.	HBIN043899	SMIT01617	.	D0QM4U	.	6222	.
NP8778	Morphine	CID: 5288826	morphine; Morphia; Morphinum; Morphium; Morphin; (-)-Morphine; Morphina; DepoDur; Duromorph; Meconium; Morphinism; Moscontin; Ospalivina; MS Contin; l-Morphine; 57-27-2; Dulcontin; Morfina; Roxanol; MORPHINE SULFATE; Infumorph; Dreamer; Morpho; Avinza; Hocus; Kadian; Unkie; Cube juice; Hard stuff; Statex SR; Ms Emma; Morphin [German]; Morfina [Italian]; Duramorph; Morphina [Italian]; M-Eslon; Morphine [BAN]; Nepenthe; CCRIS 5762; HSDB 2134; (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; UNII-76I7G6D29C; CHEBI:17303; CHEMBL70; (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; Morphine Anhydrate; 76I7G6D29C; Morphine (BAN); RMS; (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; methyl[?]diol; Aguettant; Dinamorf; Sevredol; Dimorf; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; D-(-)-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; EINECS 200-320-2; Dolcontin; Oramorph; DEA No. 9300; (Morphine); Anhydrous morphine; N02AA01; Substitol (TN); MOR; (-)-(etorphine); (-)Morphine sulfate; Morfina Dosa (TN); NSC11441; Epitope ID:116646; SCHEMBL2997; BIDD:GT0147; GTPL1627; IDS-NM-009; DTXSID9023336; Morphine 0.1 mg/ml in Methanol; Morphine 1.0 mg/ml in Methanol; ZINC3812983; BDBM50000092; AKOS015966554; DB00295; MOI; C01516; D08233; Hydromorphone hydrochloride impurity, morphine-; Q81225; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; UNII-1M5VY6ITRT component BQJCRHHNABKAKU-KBQPJGBKSA-N; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine); (5alpha,6beta)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester; 6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraene-10,14-diol; (morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ; HydroChloride; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ;sulphate salt(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine)); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine sulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine); 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine); 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine); 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; MORPHINE; (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL; MORPHIUM; MORPHIA; DOLCONTIN; DUROMORPH; MORPHINA; NEPENTHE; Morphine;4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol	Small molecule	1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1	BQJCRHHNABKAKU-KBQPJGBKSA-N	CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O	C17H19NO3	CAS 57-27-2	CHEBI:17303	.	.	.	D0WE3O	.	.	.
NP8797	Celastrol	CID: 122724	Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid	.	1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1	KQJSQWZMSAGSHN-JJWQIEBTSA-N	CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C)O	C29H38O4	CAS 34157-83-0	.	HBIN020031	SMIT14614	.	D0I9XH	.	7044	.
NP8829	Oroxylin A	CID: 5320315	Oroxylin; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one; 5,7-dihydroxy-6-methoxy-2-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl-; UNII-53K24Z586G; Baicalein 6-methyl ether;6-Methoxybaicalein; CHEBI:61668; 5,7-dihydroxy-6-methoxy-2-phenyl-4H-chromen-4-one; MFCD02259441; 53K24Z586G; Oroxylin-A; 6-Methoxybaicalein;; baicalein 6-methyl ether; Oroxylin?A; 5,7-dihydroxy-6-methoxyflavone; 5,7-Dihydroxy-6-methoxyflavone;; SCHEMBL431423; CHEMBL183513; DTXSID70197375; Oroxylin A, >=98% (HPLC); BCP31803; EX-A4028; HY-N0560; ZINC5998558; BDBM50430091; LMPK12111096; s9204; AKOS015903364; CCG-267292; CS-4948; AC-31960; AK168138; BS-16891; FT-0688332; O-160; Y0150; A14367; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one.; 5,7-Dihydroxy-6-methoxy-2-phenyl-chromen-4-one; Q3356627	.	1S/C16H12O5/c1-20-16-11(18)8-13-14(15(16)19)10(17)7-12(21-13)9-5-3-2-4-6-9/h2-8,18-19H,1H3	LKOJGSWUMISDOF-UHFFFAOYSA-N	COC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC=CC=C3)O	C16H12O5	CAS 480-11-5	.	HBIN038302	SMIT18852	.	.	.	1498	.
NP8848	Danthron	CID: 2950	danthron; 1,8-Dihydroxyanthraquinone; 117-10-2; Chrysazin; Dantron; Antrapurol; Dorbane; Istizin; Laxanthreen; Diaquone; Laxanorm; Altan; 1,8-Dihydroxyanthracene-9,10-dione; Laxipurin; Zwitsalax; Danivac; Dionone; Duolax; Laxipur; 9,10-Anthracenedione, 1,8-dihydroxy-; danthrone; Modane; Prugol; Roydan; 1,8-Dihydroxy-9,10-anthraquinone; 1,8-Dihydroxyanthrachinon; Usaf nd-59; Dioxyanthrachinonum; Chrysazine; Dantrone; Dorbanex; 1,8-Dihydroxyanthra-9,10-quinone; 1,8-Dihydroxy-9,10-anthracenedione; Criasazin; Dantrona; Dantronum; LTAN; Anthraquinone, 1,8-dihydroxy-; 1,8-Dihydroanthraquinone; UNII-Z4XE6IBF3V; 1,8-dihydroxy-anthraquinone; MFCD00001211; NSC 38626; NSC 646568; NSC7210; Z4XE6IBF3V; CHEMBL53418; CHEBI:3682; Pastomin; Bancon; Istan; component of Doxan; Neokutin S; component of Modane; Scatron D; 1,8-dihydroxy-9,10-dihydroanthracene-9,10-dione; Dantron (INN); Dantron [INN]; component of Doxidan; NSC646568; component of Dorbantyl; NCGC00091367-01; NCGC00091367-05; 9, 1,8-dihydroxy-; DSSTox_CID_328; Anthraquinone,8-dihydroxy-; Dantrone [INN-French]; Dantronum [INN-Latin]; Dantrona [INN-Spanish]; DSSTox_RID_75516; DSSTox_GSID_20328; 1,4,5,8-Tetroxyantraquinone; 1,8-Dihydroxyanthraquinone, 95%; WLN: L C666 BV IVJ DQ NQ; 1,8-Dihydroxyanthrachinon [Czech]; Danthron [USP]; CAS-117-10-2; CCRIS 3529; EINECS 204-173-5; Istizine; Laxapur; AI3-38117; HSDB 7764; 3nsq; Danthron, BAN; Dantron, INN; ACMC-20mzuc; Dorbanex (Salt/Mix); Dorbantyl (Salt/Mix); 1,10-Anthracenedione, 8,9-dihydroxy-; Spectrum_001750; dihyanthraquin_P41_LT; Spectrum2_000603; Spectrum3_000650; Spectrum4_001682; Spectrum5_000324; dihyanthraquin_P21/n_LT; NCIMech_000114; dihyanthraquin_P41212_RT; 1,8 Dihydroxy Anthraquinone; SCHEMBL83688; Anthraquinone-related compound; BSPBio_002259; KBioGR_001944; KBioSS_002230; SPECTRUM211468; MLS000069608; Pilules Vinchy N.F. (TN); ARONIS23892; DivK1c_000284; SPBio_000506; MEGxp0_001693; DTXSID9020328; ACon1_000135; BDBM11316; HMS500O06; KBio1_000284; KBio2_002230; KBio2_004798; KBio2_007366; KBio3_001479; 1,8-Dihydroxyanthraquinone ,(S); 1,8-Dihydroxyanthraquinone-[d6]; dihyanthraquin_P41_LT-Polymorph5; dihyanthraquin_P41_RT-Polymorph1; NINDS_000284; 1,8-Dihydroxyanthraquinone, 96%; HMS2091A09; HMS3715F08; Pharmakon1600-00211468; 8,9-dihydroxy-1,10-anthraquinone; BCP31079; HY-B0923; NSC-7210; NSC38626; ZINC3860369; Tox21_111122; Tox21_200986; ANW-17004; BBL013161; CCG-35470; NSC-38626; NSC755828; s4561; SBB057973; STK238373; AKOS001583216; Tox21_111122_1; 1,8-Dihydroxyanthra-9,10-quinone #; AM10629; CS-4392; DB04816; HS-1003; MCULE-5800615690; NSC-646568; NSC-755828; IDI1_000284; NCGC00091367-02; NCGC00091367-03; NCGC00091367-04; NCGC00091367-06; NCGC00091367-07; NCGC00258539-01; 1,8-bis(oxidanyl)anthracene-9,10-dione; 140861-59-2; AK208660; NCI60_041443; R229; SMR000059018; SY011288; SBI-0051330.P003; 1,8-Dihydroxy-9,10-anthracenedione, 9CI; D0563; EU-0099935; FT-0624445; ST50330603; C10312; D07107; 1,8-Dihydroxyanthracene-9,10-dione (Danthron); AB00051961_09; Danthron (1,8-Dihydroxyanthracene-9,10-dione); A803710; SR-01000721864; Q5221244; SR-01000721864-2; W-108572; BRD-K10065684-001-02-5; BRD-K10065684-001-03-3; BRD-K10065684-001-06-6; 1,8-Dihydroxyanthraquinone, Vetec(TM) reagent grade, 96%; Dantron; Chrysazin;1,8-Dihydroxyanthraquinone;1,4,5,8-tetroxyantraquinone	Small molecule	1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H	QBPFLULOKWLNNW-UHFFFAOYSA-N	C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O	C14H8O4	CAS 117-10-2	CHEBI:3682	.	.	.	D0J0EL	.	.	.
NP8888	Polymyxin B	CID: 49800004	polymyxin b; Polymixin B; POLUMYXIN B; BDBM50410807; DB00781; A807660; N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]; N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-15-(phenylmethyl)-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-y; N-[(2S)-4-azanyl-1-[[(2S,3R)-1-[[(2S)-4-azanyl-1-oxidanylidene-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-azanylethyl)-12-(2-methylpropyl)-3-[(1R)-1-oxidanylethyl]-2,5,8,11,14,17,20-heptakis(oxidanylidene)-15-(phenylmethyl)-1,4,7,10,13,16,19-heptazacycl	Small molecule	1S/C56H98N16O13/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80)/t32?,33-,34-,36+,37+,38-,39+,40+,41+,42+,43-,45+,46+/m1/s1	WQVJHHACXVLGBL-BPJDFBQWSA-N	CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)C(C)O	C56H98N16O13	CAS 1404-26-8	.	.	.	.	.	.	.	.
NP8902	Ursolic acid	CID: 64945	Prunol; Malol; Urson; 77-52-1; 3beta-Hydroxyurs-12-en-28-oic acid; (3beta)-3-Hydroxyurs-12-en-28-oic acid; 3beta-Hydroxy-12-ursen-28-ic acid; UNII-P3M2575F3F; CHEBI:9908; CCRIS 7123; EINECS 201-034-0; CHEMBL169; Merotaine; AI3-03109; NSC4060; P3M2575F3F; NSC-4060; Urs-12-en-28-oic acid, 3-hydroxy-, (3beta)-; HNMR; .beta.-Ursolic acid; NSC 4060; NSC 167406	.	1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1	WCGUUGGRBIKTOS-GPOJBZKASA-N	CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1C)C)C(=O)O	C30H48O3	CAS 77-52-1	.	HBIN047613	SMIT00055	MOL000511	D07LUJ	DB15588	1244	.
NP8905	Astilbin	CID: 119258	Astilbin; 29838-67-3; Isoastilbin; Taxifolin 3-O-rhamnoside; Neoisoastilbin; CHEBI:38200; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)chroman-4-one; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-3,4-dihydro-2H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one,3-[(6-deoxy-a-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R,3R)-; Dihydroquercitrin; 54081-48-0; CHEMBL486017; MEGxp0_000363; ACon1_000616; dihydroquercetin-3-O-alpha-LRhap; DTXSID501019948; AMY22307; HY-N0509; s3932; ZINC31156118; AKOS025402308; AC-8008; CCG-269236; MCULE-6234117773; NCGC00168909-01; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one; BS-16813; CS-0009049; W1551; C17449; Astilbin from Engelhardtia roxburghiana, >=98%; Dihydroquercetin 3-O-.alpha.-L-rhamnopyranoside; Q-100379; Q4810880; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-3,4-dihydro-2H-chromen-3-yl 6-deoxy-alpha-L-mannopyranoside; (2R,3R)-3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-4H-1-benzopyran-4-one; (2R-trans)-3-((6-Deoxy-alpha-L-mannopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R,3R)-; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R-trans)-; 4H-1-Benzopyran-4-one, 3-[(6-deoxy-.alpha.-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R,3R)-; NCGC00168909-02!(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one	Small molecule	1S/C21H22O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-26,28-29H,1H3/t7-,15-,17+,18+,19+,20-,21-/m0/s1	ZROGCCBNZBKLEL-MPRHSVQHSA-N	CC1C(C(C(C(O1)OC2C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O	C21H22O11	CAS 29838-67-3	CHEBI:38200	.	.	.	.	.	.	.
NP8924	Alpha linolenic acid	CID: 5280934	linolenic acid; alpha-Linolenic acid; 463-40-1; linolenate; (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid; a-Linolenic acid; cis,cis,cis-9,12,15-Octadecatrienoic acid; all-cis-9,12,15-Octadecatrienoic acid; 9-cis,12-cis,15-cis-Octadecatrienoic acid; 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-; (Z,Z,Z)-9,12,15-Octadecatrienoic acid; (9,12,15)-linolenic acid; Linolenic acid (8CI); alpha-Lnn; 9Z,12Z,15Z-Octadecatrienoic acid; Industrene 120; 9,12,15-Octadecatrienoic acid; CCRIS 656; (9Z,12Z,15Z)-Octadecatrienoic acid; UNII-0RBV727H71; .alpha.-Linolenic acid; CHEMBL8739; cis-delta9,12,15-Octadecatrienoic acid; AI3-23986; cis-Delta(9,12,15)-octadecatrienoic acid; (Z,Z,Z)-Octadeca-9,12,15-trienoic acid; CHEBI:27432; 0RBV727H71; MFCD00065720; LINOLENIC ACID (18:3 n-3); 9,12,15-all-cis-Octadecatrienoic acid; NCGC00091058-04; Linolenic acid, 99%; DSSTox_CID_5506; cis-9, cis-12, cis-15-octadecatrienoic acid; DSSTox_RID_77815; (9Z,12Z,15Z)octadeca-9,12,15-trienoic acid; DSSTox_GSID_25506; alpha-LA; CAS-463-40-1; SMR000857336; C18:3n-3,6,9; (9Z,12Z,15Z)-Octadecatrienoate; Linolenic acid, crude; cis,cis,cis-9,12,15-octadecatrienoate; a-Linolenate; cis-9,12,15-octadecatrienoic acid; cis,cis-9,12,15-Octadecatrienoic acid; (9Z,12Z,15Z)-9,12,15-Octadecatrienoic acid; NSC 2042; alpha-linolenic-acid; EINECS 207-334-8; C18:3; Linolenic acid, >=99%; SCHEMBL15282; 9,12,15-Octadecatrienoate; BSPBio_001376; 68424-45-3; MLS001336029; MLS001336030; MLS002454413; BML3-B05; GTPL1049; Linolenic acid, ~70% (GC); DTXSID7025506; cid_5280934; cis-9,12,15-octadecatrienoate; NSC2042; FA005; HMS1361E18; HMS1791E18; HMS1989E18; HMS2233C13; HMS3402E18; HMS3649H05; Linolenic acid, analytical standard; CMC_7371; HY-N0728; NSC-2042; ZINC3802189; all-cis-9,15-Octadecatrienoic acid; Tox21_111071; Tox21_201727; Tox21_303322; all-cis-9,12,15-Octadecatrienoate; BDBM50240347; LMFA01030152; SBB069548; AKOS016008598; DB00132; (Z,Z,Z)-9,12,15-Octadecatrienoate; 9-cis,12-cis,15-cis-octadecatrienoate; IDI1_033846; Linolenic acid 10 microg/mL in Methanol; NCGC00091058-01; NCGC00091058-02; NCGC00091058-05; NCGC00091058-06; NCGC00091058-07; NCGC00091058-08; NCGC00091058-09; NCGC00091058-10; NCGC00257192-01; NCGC00259276-01; (all-Z)-9,12,15-Octadecatrienoic acid; 9,15-Octadecatrienoic acid, (Z,Z,Z)-; AS-57338; M621; ST072192; 9(Z),12(Z),15(Z)-Octadecatrienoic acid; cis-9,cis-12,cis-15-Octadecatrienoic acid; CS-0009741; L0050; cis,cis,cis-octadeca-9,12,15-trienoic acid; Octadecatrienoic acid, 9,12,15-(Z,Z,Z)-; A-8311; C06427; Linolenic acid, Vetec(TM) reagent grade, 98%; L000707; Q256502; SR-01000838327; SR-01000838327-2; 2DCD0473-E5CC-47BB-A0A4-95899AFF6C4B; BRD-K33396764-001-02-0; 9,12,15-Octadecatrienoic acid, (9Z,12Z,15Z)- (9CI); UNII-0JXR8F0V1Q component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-5U9XZ261ER component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-71M78END5S component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-96GS7P39SN component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-F85N2YHE4E component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-HBA528N3PW component DTOSIQBPPRVQHS-PDBXOOCHSA-N; alpha-Linolenic acid, 1.0 mg/mL in ethanol, certified reference material	Small molecule	1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-	DTOSIQBPPRVQHS-PDBXOOCHSA-N	CCC=CCC=CCC=CCCCCCCCC(=O)O	C18H30O2	CAS 463-40-1	CHEBI:27432	.	.	.	D0C5SV	.	.	.
NP8937	Pinocembrin	CID: 68071	Pinocembrin; 480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxy-2-phenylchroman-4-one; UNII-8T7C8CH791; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-5,7-dihydroxyflavanone; CHEMBL399910; CHEBI:28157; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); (2S)-5,7-dihydroxy-2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one; SMR000232372; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-; NSC 43318; NSC 279005; NSC 661207; NSC43318; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (S)-; NSC-43318; NSC661207; NSC-279005; Spectrum_001879; SpecPlus_000896; Spectrum2_001670; Spectrum3_001635; Spectrum4_001765; Spectrum5_000349; Oprea1_508274; BSPBio_003329; KBioGR_002249; KBioSS_002406; MLS000697595; MLS000728654; DivK1c_006992; SPBio_001859; DTXSID3075412; SCHEMBL10026578; BDBM26667; KBio1_001936; KBio2_002401; KBio2_004969; KBio2_007537; KBio3_002549; ZINC73693; HMS2205J20; HY-N0575; CCG-39668; LMPK12140214; s3941; STL578139; AKOS004111068; SDCCGMLS-0066749.P001; NCGC00178137-01; AS-56293; ST023293; (2S)-5,7-dihydroxy-2-phenylchroman-4-one; CS-0009111; (2S)-5,7-dihydroxy-2-phenyl-chroman-4-one; C09827; SR-01000762561; SR-01000762561-3; BRD-K94689771-001-02-5; Pinocembrin, analytical standard, 95% (TLC), solid; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (S)-(-)-	Small molecule	1S/C15H12O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-7,13,16-17H,8H2/t13-/m0/s1	URFCJEUYXNAHFI-ZDUSSCGKSA-N	C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=CC=C3	C15H12O4	CAS 480-39-7	CHEBI:28157	.	.	.	D0G5CS	.	.	.
NP8942	Calycosin	CID: 5280448	Calycosin; 20575-57-9; 3'-hydroxyformononetin; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)chromen-4-one; UNII-09N3E8P7TA; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 3',7-dihydroxy-4'-methoxyisoflavone; 09N3E8P7TA; CHEBI:17793; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 7,3'-dihydroxy-4'-methoxyisoflavone; HSDB 8109; 3-Hydroxyformononetin; 3'-hydroxy-formononetin; SCHEMBL73013; MLS000876988; CHEMBL241608; MEGxp0_001325; 7-hydroxy-3-(3-hydroxy-4-methoxy-phenyl)chromen-4-one; ACon1_000650; DTXSID70174580; HMS2268B05; BCP28682; HY-N0519; ZINC6018563; LMPK12050056; MFCD00210598; s9038; AKOS015896719; 3',7-dihydroxy-4'-methoxy-isoflavone; AC-8043; CS-3715; MCULE-7559555984; NCGC00169494-01; AK168211; LS-14468; SMR000440659; DB-045290; FT-0630465; N1412; X1103; C01562; 575C579; A814711; Q-100254; Q5024637; BRD-K05039497-001-01-6; 3-(4-methoxy-3-oxidanyl-phenyl)-7-oxidanyl-chromen-4-one; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-1-benzopyran-4-one	Small molecule	1S/C16H12O5/c1-20-14-5-2-9(6-13(14)18)12-8-21-15-7-10(17)3-4-11(15)16(12)19/h2-8,17-18H,1H3	ZZAJQOPSWWVMBI-UHFFFAOYSA-N	COC1=C(C=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O)O	C16H12O5	CAS 20575-57-9	CHEBI:17793	.	.	.	.	.	.	.
NP9025	Fucoxanthin	CID: 5281239	all-trans-Fucoxanthin; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-beta,beta-carotene; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; CCRIS 4055; BRN 0073179; Fucoxanthol; cis-Fucoxanthin; yl acetate; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-yl acetate; C42H58O6; Beta-sitosterol 45%; SCHEMBL37284; 5-18-04-00673 (Beilstein Handbook Reference); beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; MLS000728353; Fucoxanthin, analytical standard; CHEMBL1575074; SJWWTRQNNRNTPU-ABBNZJFMSA-; Fucoxanthin carotenoid antioxidant; Fucoxanthin, carotenoid antioxidant; HMS2219K22; Fucoxanthin (from Wakame) (Brown Seaweed) (Undaria Pinnatifida); HY-N2302; ZINC8221218; 1772AH; LMPR01070300; MFCD01745140; AKOS037514648; CS-8167; NCGC00247434-01; AS-56344; SMR000453597; C08596; Q96385; 351F868; Fucoxanthin solution, 1 mg/L in ethanol, analytical standard; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaenylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S)-3'-Acetoxy-5alpha,6alpha-epoxy-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6,7,8-tetrahydro-beta,beta-carotene; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-	.	1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1	SJWWTRQNNRNTPU-ABBNZJFMSA-N	CC(=CC=CC=C(C)C=CC=C(C)C(=O)CC12C(CC(CC1(O2)C)O)(C)C)C=CC=C(C)C=C=C3C(CC(CC3(C)O)OC(=O)C)(C)C	C42H58O6	CAS 3351-86-8	.	HBIN026808	.	.	.	.	7214	.
NP9032	Allicin	CID: 65036	Diallyl thiosulfinate; Diallyldisulfid-S-oxid; Thio-2-propene-1-sulfinic acid S-allyl ester; S-Allyl acrylo-1-sulphinothioate; Allylthiosulphinic acid allyl ester; DADSO; S-allyl prop-2-ene-1-sulfinothioate; diallyl disulfide-oxide; S-allyl 2-propene-1-sulfinothioate; C6H10OS2; CCRIS 9053; EINECS 208-727-7; 2-Propene-1-sulfinothioic acid, S-2-propenyl ester; BRN 1752823; 3-prop-2-enylsulfinylsulfanylprop-1-ene; CHEMBL359965; CHEBI:28411; 3-allylsulfinylsulfanylprop-1-ene; 2-Propene-1-sulfinic acid, thio-, S-; 539-86-6	.	1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2	JDLKFOPOAOFWQN-UHFFFAOYSA-N	C=CCSS(=O)CC=C	C6H10OS2	CAS 539-86-6	.	HBIN015200	SMIT00280	MOL008354	D0X9YD	.	1696	.
NP9067	Pitavastatin	CID: 5282452	Pitavastatin; Itavastatin; 147511-69-1; Livalo; Pitavastatin calcium; NK 104; UNII-M5681Q5F9P; NK-104; C25H24FNO4; CHEBI:32020; M5681Q5F9P; Zypitamag; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; Pitavastatin [INN]; Pitavastatin calcium (JAN); (3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; pitavastatia; pitavastatine; pitavastatinum; Itavastin; (3r,5s,6e)-7-[2-cyclopropyl-4-(p-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid; 121659-03-8; P 872441; P-872441; SCHEMBL3369; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; MLS006010096; SCHEMBL464781; GTPL3035; CHEMBL1201753; DTXSID1048384; BDBM86707; HSDB 8367; HY-B0144A; ZINC1534965; 3972AH; AKOS005145916; AM84440; DB08860; NSC 760423; (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (3R,5S,6E)-; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (S-(R*,S*-(E)))-; SMR003965244; CAS_147511-69-1; Q412677; BRD-K75958547-001-01-2; (3R,5S)-3,5-Dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-6-heptenoic acid; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy hept-6-enoic acid; (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; (E)-(3R,5S)-7-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid; (e)-(3r,5s)-7-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6enoic acid; E-(3R,5S)-7-[2-Cyclopropyl-4-(4fluoro-phenyl)quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid; Itavastatin; ; ; Nisvastatin; ; ; NK-104; ; ; P-872441; ; ; (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid	Small molecule	1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1	VGYFMXBACGZSIL-MCBHFWOFSA-N	C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F	C25H24FNO4	CAS 147511-69-1	CHEBI:32020	.	.	.	.	.	.	.
NP9072	Doxercalciferol	CID: 5281107	Doxercalciferol; 54573-75-0; Hectorol; 1alpha-Hydroxyergocalciferol; 1-Hydroxyergocalciferol; 1alpha-hydroxyvitamin D2; 1-alpha-Hydroxyvitamin D2; TSA 840; 1-Hydroxyvitamin D2; UNII-3DIZ9LF5Y9; 1alpha-OH-D2; 3DIZ9LF5Y9; 1-alpha-hydroxyergocalciferol; CHEBI:4712; (1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol; MFCD00871065; 1alpha-hydroxyvitamin D2 / 1alpha-hydroxyergocalciferol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3-diol; Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol; 1alpha-OHD2; BRN 4716774; Doxercalciferol [USAN:INN]; Vitamin D2, 1alpha-Hydroxy-; Doxercalciferolum; NCGC00182058-03; 1alphaOHD2; PubChem18823; 1alpha-hydroxy vitamin D2; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-alpha-hydroxy-vitamin D2; DSSTox_CID_14214; DSSTox_RID_79125; Doxercalciferol (USAN/INN); DSSTox_GSID_34214; (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol; SCHEMBL322422; GTPL2790; CHEMBL1200810; DTXSID1034214; TSA-840; ACT06836; EX-A4428; ZINC4641374; Tox21_112978; HSCI1_000341; LMST03010028; AKOS005146517; CS-0395; DB06410; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1-alpha,3-beta,5Z,7E,22E)-; BS-17040; GZ427397; HY-32348; CAS-54573-75-0; V1826; C08211; D01009; W-5181; 42163-EP2298768A1; 42163-EP2311808A1; 42163-EP2311829A1; 573D750; Q5303688; Doxercalciferol, >=98% (HPLC), solubility: >10 mg/mL in DMSO; Doxercalciferol, United States Pharmacopeia (USP) Reference Standard; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1alpha,3beta,5Z,7E,22E)-; (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7?-methyl-1-[(1R,2E)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7alpha-methyl-1-[(1R,2E)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	Small molecule	1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1	HKXBNHCUPKIYDM-CGMHZMFXSA-N	CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C	C28H44O2	CAS 54573-75-0	CHEBI:4712	.	.	.	D0G5CF	.	.	.
NP9073	Gingerol	CID: 442793	[6]-Gingerol; 6-Gingerol	.	1S/C17H26O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-16(20)17(11-13)21-2/h8,10-11,14,18,20H,3-7,9,12H2,1-2H3/t14-/m0/s1	NLDDIKRKFXEWBK-AWEZNQCLSA-N	CCCCCC(CC(=O)CCC1=CC(=C(C=C1)O)OC)O	C17H26O4	CAS 23513-14-6	.	HBIN027670	SMIT18460	.	D0Y1YR	.	2538	.
NP9078	Cinobufotalin	CID: 259776	Cinobufotalin; 1108-68-5; CINOBUFOTLIN; UNII-L0QBZ37386; L0QBZ37386; NSC-90326; Q63409230; (1R,2R,2aR,3aS,3bR,5aS,7S,9aR,9bS,11aR)-5a,7-dihydroxy-9a,11a-dimethyl-1-(2-oxo-2H-pyran-5-yl)hexadecahydronaphtho[1',2':6,7]indeno[1,7a-b]oxiren-2-yl acetate; NSC 90326; SCHEMBL643121; CHEMBL517341; AMY40640; HY-N0880; NSC90326; ZINC4916381; 3551AH; MFCD28396383; AKOS030526073; CS-3698; 5-beta-Bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta,5,16-beta-trihydroxy-, 16-acetate; 5.beta.-Bufa-20, 14,15.beta.-epoxy-3.beta.,5,16.beta.-trihydroxy-, 16-acetate; 5beta-Bufa-20,22-dienolide, 14,15beta-epoxy-3beta,5,16beta-trihydroxy-, 16-acetate (8CI); Bufa-20, 16-(acetyloxy)-14,15-epoxy-3,5-dihydroxy-, (3.beta.,5.beta.,15.beta.,16.beta.)-; Bufa-20,22-dienolide, 16-(acetyloxy)-14,15-epoxy-3,5-dihydroxy-, (3beta,5beta,15beta,16beta)- (9CI)	Small molecule	1S/C26H34O7/c1-14(27)32-21-20(15-4-5-19(29)31-13-15)24(3)10-7-17-18(26(24)22(21)33-26)8-11-25(30)12-16(28)6-9-23(17,25)2/h4-5,13,16-18,20-22,28,30H,6-12H2,1-3H3/t16-,17-,18+,20-,21+,22+,23+,24+,25-,26+/m0/s1	KBKUJJFDSHBPPA-ZNCGZLKOSA-N	CC(=O)OC1C(C2(CCC3C(C24C1O4)CCC5(C3(CCC(C5)O)C)O)C)C6=COC(=O)C=C6	C26H34O7	CAS 1108-68-5	.	.	.	.	.	.	.	.
NP9092	Diallyl disulfide	CID: 16590	DIALLYL DISULFIDE; Allyl disulfide; 2179-57-9; Diallyldisulfide; Diallyl disulphide; 1,2-Diallyldisulfane; Disulfide, di-2-propenyl; 2-Propenyl disulphide; Allyl disulphide; 4,5-Dithia-1,7-octadiene; 3-(prop-2-enyldisulfanyl)prop-1-ene; 3-Allyldisulfanyl-Propene; MFCD00008656; UNII-5HI47O6OA7; Disulfide, di-2-propen-1-yl; 5HI47O6OA7; CHEBI:4488; CHEMBL366603; 3-(Allyldisulfanyl)-1-propene; Di-2-propenyl disulfide, 9CI; 3-(prop-2-en-1-yldisulfanyl)prop-1-ene; 2-Propenyl disulfide; Di(2-propenyl) disulfide; diallyldisulphide; FEMA No. 2028; 3-(allyldisulfanyl)prop-1-ene; CCRIS 6290; HSDB 595; Garlicin?; diAllS2; EINECS 218-548-6; NSC 29228; di-Propenyl disulfide; BRN 1699241; di-2-propenyldisulfide; diprop-2-enyl disulfide; di-2-Propenyl disulfide; AI3-35128; ACMC-1CDL1; DSSTox_CID_15206; DSSTox_RID_79248; DSSTox_GSID_35206; SCHEMBL93944; SPECTRUM1505174; 3,3'-dithiobis(prop-1-ene); Allyl disulfide, >=80%, FG; DTXSID9035206; FEMA 2028; 3-(Allyldisulfanyl)-1-propene #; NSC29228; ZINC1531082; 3,3'-disulfanediylbis(prop-1-ene); Tox21_302178; 7491AF; ANW-24581; BDBM50318453; Diallyl disulfide, >=98% (HPLC); NSC-29228; NSC797351; Diallyl disulfide, analytical standard; 3-(prop-2-enyldisulfanyl)-1-propene; AKOS015840490; Allyl disulfide, technical grade, 80%; CCG-214421; MCULE-7486690483; NSC-797351; NCGC00095294-01; NCGC00095294-02; NCGC00255533-01; NCI60_002410; CAS-2179-57-9; DB-003623; D0071; FT-0624594; ST51038174; C08369; A815665; Q419633; SR-05000002379; J-014293; SR-05000002379-1; UNII-609MRV3T0J component PFRGXCVKLLPLIP-UHFFFAOYSA-N; Allyl disulfide, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C6H10S2/c1-3-5-7-8-6-4-2/h3-4H,1-2,5-6H2	PFRGXCVKLLPLIP-UHFFFAOYSA-N	C=CCSSCC=C	C6H10S2	CAS 2179-57-9	CHEBI:4488	.	.	.	.	.	.	.
NP9120	Chrysin	CID: 5281607	5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0	.	1S/C15H10O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-8,16-17H	RTIXKCRFFJGDFG-UHFFFAOYSA-N	C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O	C15H10O4	CAS 480-40-0	.	HBIN020447	SMIT00508	MOL002560	D01UYI	.	2248	.
NP9143	1,4-naphthoquinone	CID: 8530	1,4-NAPHTHOQUINONE; 130-15-4; naphthalene-1,4-dione; 1,4-Naphthalenedione; p-Naphthoquinone; NAPHTHOQUINONE; alpha-Naphthoquinone; 1,4-Naphthylquinone; 1,4-Naphthaquinone; USAF CY-10; 1,4-Dihydro-1,4-diketonaphthalene; 1,4-Naftochinon; RCRA waste number U166; 1,4-dihydronaphthalene-1,4-dione; UNII-RBF5ZU7R7K; NSC 9583; .alpha.-Naphthoquinone; MFCD00001676; RBF5ZU7R7K; CHEMBL55934; NQ-1; CHEBI:27418; NSC9583; 1,4-Naftochinon [Czech]; 1,4 naphthoquinone; CCRIS 5424; 1,4-naphtho-quinone; HSDB 2037; 1,4-Naphthoquinone, 99%, contains up to 6% water; EINECS 204-977-6; RCRA waste no. U166; napthoquinone; AI3-24292; naphthalene-1; Naphthoquinone #; Naphthoquinone 1; 1,4naphtaquinone; naphthoquinone group; 1,4-naphtoquinone; 1,4-diketonaphthalene; 1,4-naphthalene-dione; PubChem22093; ACMC-1BTZT; Spectrum2_000481; Spectrum3_000754; Spectrum4_001245; 1,4-naphtho-quinone, 3; DSSTox_CID_20704; WLN: L66 BV EVJ; DSSTox_GSID_40704; SCHEMBL42139; 1,4-Naphthoquinone, 97%; BSPBio_002368; KBioGR_001770; MLS000069814; SPBio_000341; DTXSID5040704; BDBM24776; KBio3_001588; ZINC901405; NSC-9583; Tox21_303967; ANW-19159; BBL025616; CCG-39519; s9342; SBB058659; STL146359; AKOS004907201; AKOS025243281; CS-W016206; FS-2704; HY-W015490; MCULE-4996549760; NE10115; NCGC00164067-01; NCGC00164067-02; NCGC00357275-01; AK-57313; CAS-130-15-4; SMR000059173; DB-005069; FT-0606918; N0040; ST51036980; C02617; 1,4-Naphthoquinone, purum, >=96.5% (HPLC); 1,4-Naphthalenedione-2,3,5,6,7,8-d6(9CI); Q161542; Q-200085; F0001-0400; Z1741972099; 1,4-Naphthoquinone, 97% (dry wt.), cont. up to 5% water; 26473-08-5	Small molecule	1S/C10H6O2/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6H	FRASJONUBLZVQX-UHFFFAOYSA-N	C1=CC=C2C(=O)C=CC(=O)C2=C1	C10H6O2	CAS 130-15-4	CHEBI:27418	.	.	.	D0DQ6Z	.	.	.
NP9147	Dihydroisotanshinone 1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP9189	Pannarin	CID: 162780	Pannarin; Pannarine; NSC646008; 55609-84-2; NSC-646008; CHEMBL285415; 2-Chloro-3-hydroxy-8-methoxy-1,6,9-trimethyl-11-oxo-11H-dibenzo[b,e][1,4]dioxepine-4-carbaldehyde; DTXSID50204157; CHEBI:144185; BDBM50056915; 8-chloro-9-hydroxy-3-methoxy-1,4,7-trimethyl-6-oxobenzo[b][1,4]benzodioxepine-10-carbaldehyde; NCI60_015821; 11H-Dibenzo(b,e)(1,4)dioxepin-4-carboxaldehyde, 2-chloro-3-hydroxy-8-methoxy-1,6,9-trimethyl-11-oxo-; 8-chloro-9-hydroxy-3-methoxy-1,4,7-trimethyl-6-oxo-benzo[b][1,4]benzodioxepine-10-carbaldehyde	Small molecule	1S/C18H15ClO6/c1-7-5-11(23-4)8(2)16-15(7)24-17-10(6-20)14(21)13(19)9(3)12(17)18(22)25-16/h5-6,21H,1-4H3	LVGKNESDSKGROR-UHFFFAOYSA-N	CC1=CC(=C(C2=C1OC3=C(C(=C(C(=C3C(=O)O2)C)Cl)O)C=O)C)OC	C18H15ClO6	CAS 55609-84-2	CHEBI:144185	.	.	.	.	.	.	.
NP9219	Withaferin A	CID: 265237	Withaferin A; 5119-48-2; Withaferine A; NSC 273757; UNII-L6DO3QW4K5; WITHAFERIN DERIV JPR, IOWA U. COMPOUND; NSC101088; L6DO3QW4K5; NSC-101088; Ashwagandha; CHEBI:69120; 4beta,27-dihydroxy-1-oxo-5beta,6beta-epoxywitha-2,24-dienolide; (4beta,5beta,6beta,22R)-4,27-dihydroxy-5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione; BRN 1335150; 5.beta.-Ergosta-2, 5,6.beta.-epoxy-4.beta.,22,27-trihydroxy-1-oxo-, .delta.-lactone, (20S,22R)-; Ergosta-2, 5,6-epoxy-4,22,27-trihydroxy-1-oxo-, .delta.-lactone, (4.beta.,5.beta.,6.beta.,22R)-; 5-19-06-00604 (Beilstein Handbook Reference); MLS006010687; SCHEMBL157208; CHEMBL517080; 5,6-Epoxy-4,27-dihydroxy-1-oxowitha-2,24-dienolide; DTXSID10965459; Withaferin A, analytical standard; Withaferin A, >=95% (HPLC); HY-N2065; ZINC8234189; MFCD10687098; NSC273757; s8587; NSC-273757; NCGC00180796-02; (4beta,5beta,6beta,22R)-5,6-Epoxy-4,22,27-trihydroxy-1-oxoergosta-2,24-dien-26-oic acid, delta-lactone; 5-beta-Ergosta-2,24-dien-26-oic acid, 5,6-beta-epoxy-4-beta,22,27-trihydroxy-1-oxo-, delta-lactone, (20S,22R)-; Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-4,22,27-trihydroxy-1-oxo-, gamma-lactone, (4bta,5beta,6beta,22R)-; NCI60_000031; SMR004701668; B7199; CS-0018562; Withaferin A 100 microg/mL in Acetonitrile; C08841; A1-06845; Q6606395; BRD-K88378636-001-01-0; 4,27-Dihydroxy-5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione; WLN: T3 F5 E666 1A R AXO OV PU CH&TTTTJ J1 N1 RQ IY1&- FT6OV CUTJ C1Q D1; 5beta-Ergosta-2,24-dien-26-oic acid, 5,6beta-epoxy-4beta,22,27-trihydroxy-1-oxo-, delta-lactone, (20S,22R)- (8CI); NCGC00180796-02_C28H38O6_(4beta,5beta,6beta,22R)-4,27-Dihydroxy-5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione	Small molecule	1S/C28H38O6/c1-14-11-21(33-25(32)17(14)13-29)15(2)18-5-6-19-16-12-24-28(34-24)23(31)8-7-22(30)27(28,4)20(16)9-10-26(18,19)3/h7-8,15-16,18-21,23-24,29,31H,5-6,9-13H2,1-4H3/t15-,16-,18+,19-,20-,21+,23-,24+,26+,27-,28+/m0/s1	DBRXOUCRJQVYJQ-CKNDUULBSA-N	CC1=C(C(=O)OC(C1)C(C)C2CCC3C2(CCC4C3CC5C6(C4(C(=O)C=CC6O)C)O5)C)CO	C28H38O6	CAS 5119-48-2	CHEBI:69120	.	.	.	D0V3PN	.	.	.
NP9241	Amentoflavone	CID: 5281600	Amentoflavone; 1617-53-4; Didemethyl-ginkgetin; 3',8''-Biapigenin; Amenthoflavone; UNII-9I1VC79L77; I3,II8-biapigenin; MLS000574827; CHEBI:2631; 9I1VC79L77; MFCD00017470; 8-[5-(5,7-dihydroxy-4-oxo-chromen-2-yl)-2-hydroxy-phenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; SMR000156235; 4H-1-Benzopyran-4-one, 8-[5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-; 8-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 8-(5-(5,7-Dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 8-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Tridemethylsciadopitysin; SR-01000721725; 4H-1-Benzopyran-4-one, 8-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-; NSC 295677; BIDD:PXR0028; SCHEMBL312563; MEGxp0_000924; med.21724, Compound 138; DTXSID20167225; Amentoflavone, analytical standard; BDBM429466; HMS2228B12; HMS3343J17; HMS3885A08; BCP13255; HY-N0662; ZINC3984030; Amentoflavone, >=99.0% (HPLC); LMPK12040009; MFCD20275041; NSC295677; s3833; (4-hydroxyphenyl)-4H-chromen-4-one; AKOS015896819; CCG-269950; CS-4945; NSC-295677; 3',8-Bi[4',5,7-trihydroxyflavone]; NCGC00247542-01; 8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; AK167966; BS-15502; DB-043499; FT-0622262; N2268; W1536; C10018; 617A534; A810291; 8-(5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2; Q-100192; Q4742425; SR-01000721725-2; SR-01000721725-3; 4',5,7-Trihydroxyflavone(3'->8)-4',5,7-trihydroxyflavone; 4',4''',5,5'',7,7''-Hexahydroxy-3''',8-biflavone, 8CI; 5,5',7,7'-Tetrahydroxy-2,2'-bis(4-hydroxyphenyl)-[3,8'-bi-4H-1-benzopyran]-4,4'-dione; 4H-1-Benzopyran-4-one, 8-[5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl); 8-[5-(5,7-dihydroxy-4-oxo-1-benzopyran-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-1-benzopyran-4-one; 8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one.; 8-[5-[5,7-bis(oxidanyl)-4-oxidanylidene-chromen-2-yl]-2-oxidanyl-phenyl]-2-(4-hydroxyphenyl)-5,7-bis(oxidanyl)chromen-4-one	Small molecule	1S/C30H18O10/c31-15-4-1-13(2-5-15)24-12-23(38)29-21(36)10-20(35)27(30(29)40-24)17-7-14(3-6-18(17)33)25-11-22(37)28-19(34)8-16(32)9-26(28)39-25/h1-12,31-36H	YUSWMAULDXZHPY-UHFFFAOYSA-N	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O)O	C30H18O10	CAS 1617-53-4	CHEBI:2631	.	.	.	D06HRX	.	.	.
NP9253	Liquiritin	CID: 503737	Liquiritin; Liquiritoside; 551-15-5; 7-Hydroxyflavanone 4'-O-glucoside; Likviritin; UNII-T0O79T74CD; CHEBI:80845; T0O79T74CD; 4',7-Dihydroxyflavanone 4'-(beta-D-glucopyranoside); (2S)-7-hydroxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxyphenyl]chroman-4-one; 4'-O-beta-D-glucopyranosyl-7-hydroxyflavan-4-one; Likviriton; 4H-1-Benzopyran-4-one,2-[4-(b-D-glucopyranosyloxy)phenyl]-2,3-dihydro-7-hydroxy-, (2S)-; (S)-7-hydroxy-2-(4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)chroman-4-one; 4',7-Dihydroxyflavanone 4'-(beta-D-glucoside); Liquiritigenin-4'-O-glucoside; MLS000575018; CHEMBL511995; Liquiritigenin-4'-beta-glucoside; DTXSID40203619; HMS2214B11; liquiritigenin-4'-beta-D-glucoside; HY-N0376; ZINC8829785; BDBM50479044; MFCD00210526; s3930; AKOS015897117; CCG-268869; (S)-2-(4-(beta-D-Glucopyranosyloxy)phenyl)-2,3-dihydro-7-hydroxy-4H-1-benzopyran-4-one; AS-74201; AT-22713; SMR000232362; 7-hydroxyflavanone 4'-O-beta-D-glucoside; liquiritigenin 4'-O-beta-D-glucopyranoside; CS-0008920; X1173; A12084; C16989; Q-100625; Q3242316; Liquiritin, from Glycyrrhizae root (licorice root), >=98% (HPLC); 4-[(2S)-7-hydroxy-4-oxo-3,4-dihydro-2H-1-benzopyran-2-yl]phenyl beta-D-glucopyranoside; (2S)-7-hydroxy-2-(4-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-3,4-dihydro-2H-1-benzopyran-4-one; (S)-7-hydroxy-2-(4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)phenyl)chroman-4-one; (S)-7-Hydroxy-2-[4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-phenyl]-chroman-4-one; 4H-1-Benzopyran-4-one, 2-(4-(beta-D-glucopyranosyloxy)phenyl)-2,3-dihydro-7-hydroxy-, (S)-	Small molecule	1S/C21H22O9/c22-9-17-18(25)19(26)20(27)21(30-17)28-12-4-1-10(2-5-12)15-8-14(24)13-6-3-11(23)7-16(13)29-15/h1-7,15,17-23,25-27H,8-9H2/t15-,17+,18+,19-,20+,21+/m0/s1	DEMKZLAVQYISIA-ZRWXNEIDSA-N	C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O	C21H22O9	CAS 551-15-5	CHEBI:80845	.	.	.	.	.	.	.
NP9274	Palmitic acid	CID: 985	palmitic acid; Hexadecanoic acid; 57-10-3; Cetylic acid; palmitate; n-Hexadecanoic acid; Hexadecylic acid; Hydrofol; n-Hexadecoic acid; 1-Pentadecanecarboxylic acid; Palmitinic acid; Pentadecanecarboxylic acid; C16 fatty acid; hexaectylic acid; 1-Hexyldecanoic Acid; Industrene 4516; Emersol 140; Emersol 143; Hystrene 8016; Hystrene 9016; hexadecoic acid; Palmitic acid, pure; Palmitinsaeure; Palmitic acid 95%; Palmitic acid (natural); Fatty acids, C14-18; Prifac 2960; FEMA No. 2832; Pristerene 4934; Edenor C16; Kortacid 1698; Lunac P 95KC; C16:0; Loxiol EP 278; Lunac P 95; Lunac P 98; Hydrofol Acid 1690; HSDB 5001; AI3-01594; C16H32O2; NSC 5030; MFCD00002747; UNII-2V16EO95H1; Palmitic acid (NF); Glycon P-45; CHEBI:15756; NSC5030; Hexadecanoic acid (9CI); Palmitic acid (7CI,8CI); CHEMBL82293; 67701-02-4; CH3-[CH2]14-COOH; 2V16EO95H1; n-hexadecoate; LMFA01010001; PA 900; FA 1695; 1-hexyldecanoate; Palmitic acid, 98%; NCGC00164358-01; DSSTox_CID_1602; pentadecanecarboxylate; DSSTox_RID_76229; DSSTox_GSID_21602; Hexadecanoic-9,9-d2 acid; PLM; palmitic-acid; palmic acid; Hexadecanoate (n-C16:0); HEXADECANOIC-12-D1 ACID; Hexadecanoic-16,16,16-d3acid; HEXADECANOIC-3,3-D2 ACID; HEXADECANOIC-4,4-D2 ACID; CAS-57-10-3; HEXADECANOIC-13,13-D2 ACID; CCRIS 5443; SR-01000944716; Hexadecanoic-11,11,12,12-d4acid (9CI); EINECS 200-312-9; Palmitic acid [USAN:NF]; BRN 0607489; palmitoate; Hexadecoate; Palmitinate; palmitoic acid; Aethalic acid; Hexadecanoic acid Palmitic acid; (C14-C18)Alkylcarboxylic acid; 2hmb; 2hnx; (C14-C18) Alkylcarboxylic acid; Fatty acid pathway; palmitic acid group; Palmitic acid_jeyam; EINECS 266-926-4; Palmitic Acid, FCC; Kortacid 1695; Palmitic acid_RaGuSa; Univol U332; 272442-14-5; 285979-77-3; 30719-28-9; 358730-99-1; 62690-28-2; 75736-57-1; 81462-28-4; 83293-32-7; Prifrac 2960; Hexadecanoic acid anion; 3v2q; ACMC-1ASQF; SDA 17-005-00; Palmitic acid, >=99%; bmse000590; Epitope ID:141181; EC 200-312-9; SCHEMBL6177; 4-02-00-01157 (Beilstein Handbook Reference); FAT; WLN: QV15; P5585_SIGMA; Palmitic acid-[9,10-3H]; GTPL1055; QSPL 166; CCCCCCCCCCCCCCCC([O])=O; DTXSID2021602; 1b56; HMS3649N08; Palmitic acid, analytical standard; Palmitic acid, BioXtra, >=99%; Palmitic acid, Grade II, ~95%; HY-N0830; NSC-5030; Palmitic acid, natural, 98%, FG; ZINC6072466; Tox21_112105; Tox21_201671; Tox21_302966; ANW-13574; BBL011563; BDBM50152850; s3794; SBB017229; STL146733; Palmitic acid, >=95%, FCC, FG; AKOS005720983; Light end (C14-C18) saturated fatty acid fraction from tallow fatty acids; Tox21_112105_1; CCG-267027; CR-0047; DB03796; FA 16:0; MCULE-1361949901; Palmitic acid, for synthesis, 98.0%; NCGC00164358-02; NCGC00164358-03; NCGC00256424-01; NCGC00259220-01; AK-48351; I728; Palmitic acid, purum, >=98.0% (GC); ST023798; SY006518; CS-0009861; FT-0626965; FT-0772579; N2456; P0002; P1145; Palmitic acid, SAJ first grade, >=95.0%; Palmitic acid-15,15,16,16,16-[d5]; A14813; C00249; D05341; Hexadecanoic acid 10 microg/mL in Acetonitrile; Palmitic acid, Vetec(TM) reagent grade, 98%; Palmitic acid, >=98% palmitic acid basis (GC); HEXADECANOIC ACID-13C16 (ALGAL SOURCE) (; Q209727; SR-01000944716-1; SR-01000944716-2; BA71C79B-C9B1-451A-A5BE-B480B5CC7D0C; F0001-1488; Z955123552; Palmitic acid, certified reference material, TraceCERT(R); UNII-13FB83DEYU component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-44NH37HHP9 component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-5U9XZ261ER component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-7N137Q0QYJ component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-96GS7P39SN component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-B6G0Y5Z616 component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-D1CZ545P7Z component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-HBA528N3PW component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-J505W0PXX8 component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-MO7HV04S9Y component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-ODL221H4AM component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-Q8Y7S3B85M component IPCSVZSSVZVIGE-UHFFFAOYSA-N; UNII-V1PY73ZXPE component IPCSVZSSVZVIGE-UHFFFAOYSA-N; Palmitic acid, European Pharmacopoeia (EP) Reference Standard; UNII-79P21R4317 component IPCSVZSSVZVIGE-UHFFFAOYSA-N; Palmitic acid, United States Pharmacopeia (USP) Reference Standard; Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material; HEXADECANOIC-9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-D17 ACID; Sodium Palmitate, Palmitic acid sodium salt, Sodium hexadecanoate, Sodium pentadecanecarboxylate, HSDB 759	Small molecule	1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)	IPCSVZSSVZVIGE-UHFFFAOYSA-N	CCCCCCCCCCCCCCCC(=O)O	C16H32O2	CAS 57-10-3	CHEBI:15756	.	.	.	D02TVS	.	.	.
NP9279	Genistein	CID: 5280961	Bonistein; GEN; Genestein; Genisteol; Genisterin; Prunetol; Sophoricol; Differenol A; G 6649; G10000; IN1327; NPI 031L; STO514; TNP00151; GENISTEIN (ENDOCRINE DISRUPTER); Lactoferrin-genistein; PTI G4660 (Genistein); PTI-G4660; SIPI 807-1; C.I. 75610; SIPI-9764-I; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; ,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one	.	1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H	TZBJGXHYKVUXJN-UHFFFAOYSA-N	C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O	C15H10O5	CAS 446-72-0	CHEBI:28088	HBIN027456	SMIT00052	MOL000481	D0L4FS	.	2582	.
NP9303	1-deoxynojirimycin	CID: 29435	1-DEOXYNOJIRIMYCIN; 19130-96-2; DUVOGLUSTAT; Moranoline; deoxynojirimycin; (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Deoxy-1,5-imino-D-mannitol; Moranolin; 1,5-Dideoxy-1,5-imino-D-glucitol; UNII-FZ56898FLE; C6H13NO4; D-1-deoxynojirimycin; (+)-1-DEOXYNOJIRIMYCIN; S-GI; (2R,3R,4R,5S)-2-Hydroxymethyl-piperidine-3,4,5-triol; 1-deoxynojirimycin (DNJ); 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R,3R,4R,5S)-; CHEMBL307429; FZ56898FLE; DNJ; CHEBI:44369; 1-Deoxy-Nojirimycin; MFCD00063474; 5-Amino-1,5-dideoxy-D-glucopyranose; (2R,3R,4R,5S)-2-(Hydroxymethyl)-3,4,5-piperidinetriol; 1 Deoxynojirimycin; 1oim; Antibiotic S-GI; BAY-h-5595; DNM; 70956-02-4; Duvoglustat [USAN:INN]; BAY-h 5595; 1-Deoxynojirimicin; NOJ; PubChem21441; Duvoglustat (USAN/INN); EC 606-239-2; SCHEMBL2969; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-; BSPBio_000993; GTPL4642; BDBM18351; DTXSID70172647; 2j77; Bio1_000415; Bio1_000904; Bio1_001393; HMS1792A15; HMS1990A15; HMS3267J09; HMS3403A15; 1,5-dideoxy-1,5-imino-d-glucito; AMY37043; ZINC3794714; s3839; 1,5-didesoxy-1,5-imino-D-glucitol; 1, 5-dideoxy-1,5-imino-D-glucitol; AKOS006275143; 1-Deoxynojirimycin, analytical standard; AC-1386; CCG-266301; CS-5594; DB03206; SMP2_000333; NCGC00025085-02; NCGC00025085-03; BS-15755; HY-14860; S606; N1659; 30D962; A14383; C16843; D09605; SR-01000597392; Q-100789; SR-01000597392-1; W-201703; Q15274561; (2R,3R,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol, 10	Small molecule	1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1	LXBIFEVIBLOUGU-JGWLITMVSA-N	C1C(C(C(C(N1)CO)O)O)O	C6H13NO4	CAS 19130-96-2	CHEBI:44369	.	.	.	D0S5LT	.	.	.
NP9320	Lithium	CID: 3028194	7439-93-2; Li; Lithium; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis	Small molecule	1S/Li	WHXSMMKQMYFTQS-UHFFFAOYSA-N	[Li]	Li	CAS 7439-93-2	CHEBI:30145	.	.	.	D5MF8Y	.	.	.
NP9331	Plumbagin	CID: 10205	Plumbagin; 481-42-5; Plumbagine; 5-Hydroxy-2-methyl-1,4-naphthoquinone; Plumbaein; 5-hydroxy-2-methylnaphthalene-1,4-dione; Plumbagone; 2-Methyljuglone; 1,4-Naphthalenedione, 5-hydroxy-2-methyl-; 5-Hydroxy-2-methyl-[1,4]naphthoquinone; 5-Hydroxy-2-methyl-1,4-naphthalenedione; 2-Methyl-5-hydroxy-1,4-naphthoquinone; UNII-YAS4TBQ4OQ; NSC 236613; NSC 688284; YAS4TBQ4OQ; CHEBI:8273; CHEMBL295316; 1,4-NAPHTHOQUINONE, 5-HYDROXY-2-METHYL-; MFCD00001682; NSC236613; NSC688284; ST069355; 5-Hydroxy-2-methyl-naphthalene-1,4-dione; 5-hydroxy-2-methyl-1,4-dihydronaphthalene-1,4-dione; plumbapin; CCRIS 6671; SR-05000002263; EINECS 207-569-6; BRN 1870475; Ophioxylin; Pumbagin; AI3-38055; Plumbagin, 99+%; RTK1; 1, 5-hydroxy-2-methyl-; SCHEMBL34186; BSPBio_002546; 4-08-00-02376 (Beilstein Handbook Reference); Plumbagin from Plumbago indica; SPECTRUM1505129; GTPL7003; DTXSID8075413; ACon1_001611; ZINC58187; HMS3870L13; WLN: L66 BV EVJ C1 GQ; HY-N1497; ANW-41868; BDBM50012070; s4777; SBB012388; STL564479; AKOS015969699; CCG-208032; CCG-208410; MCULE-9327502882; NSC-236613; NSC-688284; NCGC00094567-01; NCGC00094567-02; NCGC00094567-03; NCGC00094567-04; NCGC00094567-05; NCGC00094567-06; AK-35295; BP-25404; NCI60_001904; PS-11338; 2-methyl-5-oxidanyl-naphthalene-1,4-dione; DB-051524; CS-0017042; FT-0602795; P1139; 5- HYDROXY,2-METHYL-1,4-NAPHTOQUINONE; C10387; K-9170; A827479; 1,4-Naphthalenedione, 5-hydroxy-2-methyl- (9CI); A1-00788; Q2550553; SR-05000002263-2; SR-05000002263-3; W-202844; BRD-K36137799-001-02-4; BRD-K36137799-001-03-2	Small molecule	1S/C11H8O3/c1-6-5-9(13)10-7(11(6)14)3-2-4-8(10)12/h2-5,12H,1H3	VCMMXZQDRFWYSE-UHFFFAOYSA-N	CC1=CC(=O)C2=C(C1=O)C=CC=C2O	C11H8O3	CAS 481-42-5	CHEBI:8273	.	.	.	D0P0IE	.	.	.
NP9338	Manuka honey	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP9343	Cucurbitacin D	CID: 5281318	Cucurbitacin D; Elatericin A; Cucurbitacine (D); 3877-86-9; Elatericine A; UNII-5I62H4ORC7; 5I62H4ORC7; CHEBI:3943; NSC308606; (2S,8S,9R,10R,13R,14S,16R,17R)-17-[(E,2R)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,16-dihydroxy-4,4,9,13,14-pentamethyl-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthrene-3,11-dione; NSC 308606; NSC 521776; 19-nor-9.beta.,23-diene-3,11,22-trione, 9-methyl-2.beta.,16.alpha.,20,25-tetrahydroxy-; 19-Norlanosta-5,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23E)-; cucurbitacin D derivatives; 19-Norlanosta-5,23-diene-3,11,22-trione,2,16,20,25-tetrahydroxy-9-methyl-, (2b,9b,10a,16a,23E)-; SCHEMBL230654; CHEMBL493646; HY-N1986; ZINC4097799; LMST01010106; NSC521776; AKOS015896755; MCULE-5684742998; NSC-308606; NSC-521776; NCGC00385253-01; 19-Nor-9-beta,10-alpha-lanosta-5,23-diene-3,11,22-trione, 9-methyl-2-beta,16-alpha,20,25-tetrahydroxy-; CS-0018307; C08796; Q15410915; UNII-W3RWP6CB48 component SRPHMISUTWFFKJ-QJNWWGCFSA-N; (23E)-2beta,16alpha,20,25-tetrahydroxy-10alpha-cucurbita-5,23-diene-3,11,22-trione; (23E)-2beta,16alpha,20,25- tetrahydroxy-9beta-methyl-19-nor-10alpha-lanosta-5,23-diene-3,11,22-trione; (2S,4R,23E)-2,16,20,25-tetrahydroxy-9beta,10,14-trimethyl-4,9-cyclo-9,10-seco-16alpha-cholesta-5,23-diene-1,11,22-trione; 19-Norlanosta-5,23-diene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23E)- (9CI); NCGC00385253-01_C30H44O7_(2S,4R,9beta,16alpha,23E)-2,16,20,25-Tetrahydroxy-9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-5,23-diene-1,11,22-trione	Small molecule	1S/C30H44O7/c1-25(2,36)12-11-21(33)30(8,37)23-19(32)14-27(5)20-10-9-16-17(13-18(31)24(35)26(16,3)4)29(20,7)22(34)15-28(23,27)6/h9,11-12,17-20,23,31-32,36-37H,10,13-15H2,1-8H3/b12-11+/t17-,18+,19-,20+,23+,27+,28-,29+,30+/m1/s1	SRPHMISUTWFFKJ-QJNWWGCFSA-N	CC1(C2=CCC3C4(CC(C(C4(CC(=O)C3(C2CC(C1=O)O)C)C)C(C)(C(=O)C=CC(C)(C)O)O)O)C)C	C30H44O7	CAS 3877-86-9	CHEBI:3943	.	.	.	.	.	.	.
NP9386	Naringin	CID: 442428	naringin; 10236-47-2; Naringoside; UNII-N7TD9J649B; Naringenin 7-O-neohesperidoside; Naringenine-7-rhamnosidoglucoside; 4'5-diOH-Flavone-7-rhgluc; CHEMBL451532; N7TD9J649B; CHEBI:28819; Naringenin 7-Rhamnoglucoside; C27H32O14; aurantiin; (2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one; (S)-7-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one; 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one; Naringenin 7-O-[alpha-L-rhamnosyl-(1->2)-beta-D-glucoside]; MFCD00148888; (2S)-Naringin; SR-01000736681; Naringenin,(S); Naringenin-7-beta-neohesperidoside; (S)-7-((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-2-yloxy)-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one; EINECS 233-566-4; yphenyl)chroman-4-one; Naringin (Naringoside); AI3-19008; Prestwick0_000467; Prestwick1_000467; Prestwick2_000467; Prestwick3_000467; 4',5,7-trihydroxyflavanone 7-rhamnoglucoside; SCHEMBL23432; BSPBio_000574; 7-(2-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyloxy)-2,3-dihydro-4',5,7-trihydroxyflavone; cid_25075; MLS000069459; BIDD:ER0262; DivK1c_000247; SPBio_002513; BPBio1_000632; cid_442428; GTPL4738; MEGxp0_001877; 3-Bromo-4-isopropoxybenzoicacid; DTXSID6022478; ACon1_000139; HMS500M09; KBio1_000247; NINDS_000247; HMS2231M18; HY-N0153; ZINC8143604; BDBM50241582; s2329; AKOS016034302; CCG-208591; CS-5632; MCULE-5348711723; IDI1_000247; NCGC00142617-01; NCGC00142617-02; NCGC00142617-03; 5-Hydroxy-2-(4-hydroxyphenyl)-7-(2-O-alpha-L-rhamnopyranosyl-beta-D-glucopyranosyloxy)-4-chromanon; AS-12929; SMR000059108; ST072162; N2371; C09789; J10148; 236N472; Q418469; SR-01000736681-4; SR-01000736681-5; BRD-K02953697-001-09-2; BRD-K02953697-002-03-3; Naringenin 7-O-alpha-L-rhamnosyl-(1->2)-beta-D-glucoside; naringenin 7-O-(alpha-L-rhamnosyl-(1,2)-beta-D-glucoside); (2S)-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside; (2S)-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 2-O-(6-deoxy-alpha-L-mannopyranosyl)-betaD-glucopyranoside; (2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2S)-7-[(2S,4S,5S,3R,6R)-3-((2S,6S,3R,4R,5R)-3,4,5-trihydroxy-6-methyl(2H-3,4, 5,6-tetrahydropyran-2-yloxy))-4,5-dihydroxy-6-(hydroxymethyl)(2H-3,4,5,6-tetra hydropyran-2-yloxy)]-5-hydroxy-2-(4-hydrox; (2S)-7-[(2S,4S,5S,3R,6R)-3-((2S,6S,3R,4R,5R)-3,4,5-trihydroxy-6-methyl(2H-3,4, 5,6-tetrahydropyran-2-yloxy))-4,5-dihydroxy-6-(hydroxymethyl)(2H-3,4,5,6-tetra hydropyran-2-yloxy)]-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2S)-7-{[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-5-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one; (S)-7-((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-yloxy)-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one; 4H-1-Benzopyran-4-one, 7-((2-O-(6-deoxy-alpha-L-mannapyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl), (S)-; 4H-1-Benzopyran-4-one, 7-((2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-, (2S)-; 7-(2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyloxy)-2,3-dihydro-4,5,7-trihydroxyflavone;Naringin; 7-[[2-O-(6-Deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-5-hydroxy-2(S)-(4-hydroxyphenyl)-4H-1-benzopyran-4-one	Small molecule	1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3/t10-,16-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1	DFPMSGMNTNDNHN-ZPHOTFPESA-N	CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O	C27H32O14	CAS 10236-47-2	CHEBI:28819	.	.	.	D09VQM	.	.	.
NP9436	Camptothecin	CID: 24360	camptothecin; Camptothecine; (S)-(+)-Camptothecin; 7689-03-4; Campathecin; (+)-Camptothecine; d-Camptothecin; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; Camptothecine (8CI); Camptothecine (S,+); CHEMBL65; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-4-ethyl-4-hydroxy-1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; UNII-XT3Z54Z28A; MLS000766223; XT3Z54Z28A; CHEBI:27656; MFCD00081076; NSC-94600; (+)-Camptothecin, 98%; (S)-Camptothecin; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 20(S)-Camptothecin; 4-ETHYL-4-HYDROXY-1,12-DIHYDRO-4H-2-OXA-6,12A-DIAZA-DIBENZO[B,H]FLUORENE-3,13-DIONE; SR-01000075798; SR-01000597379; d-camptothecine; (s)-camptothecine; Camptothecin, Camptotheca acuminata; Camptothecin,(S); ( )-Camptothecin; (S)-4-ethyl-4-hydroxy-1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; Prestwick_102; (+)-Camptothecin;; PubChem10183; Spectrum_000299; Tocris-1100; SpecPlus_000712; Prestwick0_000200; Prestwick1_000200; Prestwick2_000200; Prestwick3_000200; Spectrum2_000903; Spectrum3_001203; Spectrum4_000738; Spectrum5_001126; Lopac-C-9911; SCHEMBL6038; Lopac0_000341; BSPBio_000159; BSPBio_002586; KBioGR_001036; KBioSS_000779; KBioSS_002283; cid_24360; DivK1c_000826; DivK1c_006808; SPECTRUM1502232; SPBio_000746; SPBio_002080; BPBio1_000175; CCRIS 8162; DTXSID0030956; HMS502J08; KBio1_000826; KBio1_001752; KBio2_000779; KBio2_003347; KBio2_005915; KBio3_002086; 4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NINDS_000826; Bio1_000400; Bio1_000889; Bio1_001378; HMS1568H21; HMS1921N08; HMS2089F08; HMS2095H21; HMS3261E03; HMS3414J17; HMS3654D13; HMS3678J15; HMS3712H21; ZINC105309; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; ACT02668; BCP02857; Tox21_500341; AC-202; BBL033963; BDBM50008923; CCG-40255; GR-301; NSC 94600; s1288; STK801886; AKOS004119861; CS-1049; DB04690; KS-5235; LP00341; MCULE-1654983682; SDCCGMLS-0066688.P001; SDCCGSBI-0050329.P003; BRN 0631069; CAS-2114454; IDI1_000826; NCGC00015290-01; NCGC00016994-01; NCGC00016994-02; NCGC00016994-03; NCGC00016994-04; NCGC00016994-05; NCGC00016994-06; NCGC00016994-07; NCGC00016994-08; NCGC00016994-09; NCGC00016994-10; NCGC00016994-11; NCGC00016994-12; NCGC00016994-16; NCGC00016994-29; NCGC00024997-01; NCGC00024997-02; NCGC00024997-03; NCGC00024997-04; NCGC00024997-05; NCGC00024997-06; NCGC00178592-01; NCGC00178592-02; NCGC00261026-01; AK-39842; HY-16560; K332; NCI60_042105; SMR000445686; SY010324; AI3-62475; EU-0100341; N1868; SW196414-3; C 9911; C01897; J10012; M01564; S-2515; 32320-EP2270008A1; 32320-EP2272827A1; 32320-EP2275420A1; 32320-EP2277507A1; 32320-EP2277865A1; 32320-EP2280013A1; 32320-EP2281815A1; 32320-EP2286795A1; 32320-EP2286812A1; 32320-EP2289892A1; 32320-EP2292615A1; 32320-EP2292617A1; 32320-EP2295055A2; 32320-EP2295416A2; 32320-EP2298748A2; 32320-EP2298764A1; 32320-EP2298765A1; 32320-EP2298778A1; 32320-EP2301933A1; 32320-EP2305640A2; 32320-EP2305642A2; 32320-EP2305671A1; 32320-EP2308855A1; 32320-EP2311453A1; 32320-EP2311827A1; 32320-EP2311840A1; AB00052452-08; AB00052452-09; AB00052452_10; (S)-(+)-Camptothecin, >=90% (HPLC), powder; 157594-EP2277507A1; 157594-EP2286795A1; 179002-EP2280013A1; 689C034; Q419964; Q-200785; SR-01000075798-1; SR-01000075798-4; SR-01000597379-1; SR-01000597379-3; BRD-K37890730-001-09-4; BRD-K37890730-001-10-2; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]florene-3,13-dione; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 4-Ethyl-4-hydroxy-1H-pyrano-[3[,4[:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Topotecan Related Compound C, United States Pharmacopeia (USP) Reference Standard; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0(2),(1)(1).0?,?.0(1)?,(2)?]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 4(S)-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H)-dione; 4-ethyl-4-hydroxy-(4S)-3,4,12,14-tetrahydro-1H-pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-3,14-dione; 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (camptothecin or CPT); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (Camptothecin); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (CPT, Camptothecin)	Small molecule	1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1	VSJKWCGYPAHWDS-FQEVSTJZSA-N	CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O	C20H16N2O4	CAS 7689-03-4	CHEBI:27656	.	.	.	D09YDM	.	.	.
NP9453	Schisandrol A	CID: 23915	Schisandrin; Schizandrin; Schizandrol A; 7432-28-2; Wuweizichun A; Wuweizi alcohol A; Schisandrol A; (+)-Schizandrin; 3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaen-9-ol; Schisandrine; MFCD00905761; Schisandrin,(S); SCHEMBL2702845; CHEBI:80900; DTXSID20995843; AKOS015918158; 1,2,3,10,11,12-hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulen-6-ol; AS-17718; DB-055861; FT-0630370; N1884; V1514; C17064; 432S282; Q-100805; 1,2,3,10,11,12-Hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cycloocten-6-ol #; Dibenzo(a,c)cycloocten-6-ol, 5,6,7,8-tetrahydro-6,7-dimethyl-1,2 3,10,11,12-hexamethoxy-,stereoisomer	Small molecule	1S/C24H32O7/c1-13-9-14-10-16(26-3)20(28-5)22(30-7)18(14)19-15(12-24(13,2)25)11-17(27-4)21(29-6)23(19)31-8/h10-11,13,25H,9,12H2,1-8H3	YEFOAORQXAOVJQ-UHFFFAOYSA-N	CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3CC1(C)O)OC)OC)OC)OC)OC)OC	C24H32O7	CAS 7432-28-2	CHEBI:80900	.	.	.	.	.	.	.
NP9520	Ginsenoside Rg3	CID: 9918693	(20S)-ginsenoside Rg3	.	1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1	RWXIFXNRCLMQCD-JBVRGBGGSA-N	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)O)C	C42H72O13	CAS 14197-60-5	.	HBIN027751	SMIT04681	MOL002448	D01BKS	.	4645	.
NP9535	Allium sativum	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP9550	Garcinol	CID: 5281560	Camboginol; 78824-30-3; AC1Q1NUM; GTPL7001; QDKLRKZQSOQWJQ-SMDXAGPFSA-N; ZINC4098424; AKOS025142024; (1S,5R,7R)-3-[(3,4-dihydroxyphenyl)(hydroxy)methylidene]-6,6-dimethyl-1-[(2S)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-5,7-bis(3-methylbut-2-en-1-yl)bicyclo[3.3.1]nonane-2,4,9-trione; (1R,5R,7R)-3-(3,4-Dihydroxybenzoyl)-4-hydroxy-8,8-dimethyl-1,7-bis(3-methyl-2-buten-1-yl)-5-[(2S)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-Bicyclo[3.3.1]non-3-ene-2,9-dione	.	1S/C38H50O6/c1-22(2)11-13-27(25(7)8)20-37-21-28(15-12-23(3)4)36(9,10)38(35(37)44,18-17-24(5)6)34(43)31(33(37)42)32(41)26-14-16-29(39)30(40)19-26/h11-12,14,16-17,19,27-28,39-41H,7,13,15,18,20-21H2,1-6,8-10H3/b32-31-/t27-,28+,37+,38-/m0/s1	DTTONLKLWRTCAB-BZSUNBQASA-N	CC(=CCC1CC2(C(=O)C(=C(C3=CC(=C(C=C3)O)O)O)C(=O)C(C2=O)(C1(C)C)CC=C(C)C)CC(CC=C(C)C)C(=C)C)C	C38H50O6	CAS 78824-30-3	.	HBIN027349	.	.	D03JNC	.	.	.
NP9583	Paroxetine	CID: 43815	paroxetine; 61869-08-7; Paxil; Paxil CR; Casbol; Seroxat; Paroxetina; Paroxetinum; Aropax; Paroxetinum [INN-Latin]; Paroxetina [INN-Spanish]; BRL 29060; Paxetil; FG 7051; Pexeva; Frosinor; Motivan; PaxPar; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; BRL-29060; UNII-41VRH5220H; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; [3H]Paroxetine; FG-7051; CHEMBL490; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-; CHEBI:7936; 41VRH5220H; C19H20FNO3; 110429-35-1; DSSTox_CID_3425; (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; Paroxetine (TN); DSSTox_RID_77022; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-; DSSTox_GSID_23425; Paroxetine [USAN:INN:BAN]; CHEMBL1708; Paroxetine Base; piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3S,4R)-; (-)-Paroxetine; PAROXETINE HCL HEMIHYDRATE; CAS-61869-08-7; Paroxetine (USP/INN); 3h-paroxetine; Paroxetine.HCl; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-; NCGC00182968-01; 8PR; NNC-20-7051; Spectrum_001752; SpecPlus_000788; Prestwick3_000851; Spectrum5_001665; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; SCHEMBL27799; BSPBio_000861; KBioSS_002232; BIDD:GT0673; DivK1c_006884; BPBio1_000949; GTPL4790; DTXSID3023425; BDBM22416; HSDB 7175; KBio1_001828; KBio2_002232; KBio2_004800; KBio2_007368; HMS2090H05; ZINC527386; Tox21_113123; BDBM50331515; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; AKOS015888636; Tox21_113123_1; AC-8185; DB00715; SDCCGSBI-0051908.P003; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; NCGC00025355-02; NCGC00025355-03; NCGC00025355-04; NCGC00025355-05; NCGC00025355-06; NCGC00025355-07; NCGC00025355-08; NCGC00025355-09; NCGC00025355-12; NCGC00025355-22; SBI-0051908.P002; AB00514724; C07415; D02362; AB00053704-21; AB00053704_22; AB00053704_23; Paroxetine Hydrochloride Anhydrous EP Impurity E; 869P087; paroxetine hydrochloride (anhydrous or hemihydrate); Q408471; BRD-K37991163-003-02-7; BRD-K37991163-050-05-1; cis-Paroxetine; Paroxetine USP Related Compound D;[(3S,4R)-4-(p-Fluorophenyl)-3-piperidyl](1,3-dioxa-5-indanyloxy)methane	Small molecule	1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1	AHOUBRCZNHFOSL-YOEHRIQHSA-N	C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4	C19H20FNO3	CAS 61869-08-7	CHEBI:7936	.	.	.	D06GDY	.	.	.
NP9635	Matrine	CID: 91466	(+)-Matrine; Matrinium; Matridin-15-one; UNII-N390W430AC; CHEBI:6700; Matrene, (+)-; (7aS,13aR,13bR,13cS)-Dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one; N390W430AC; (41S,7aS,13aR,13bR)-dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one; NSC 146051; BRN 0085851; alpha-Matrine; cis-Neomatrine; trans-Neomatrine; Matrine,(S); Matrine ((+)-Matrine); Matridin-15-one (9CI); 5-24-02-00301 (Beilstein Handbook Reference); SCHEMBL177907; CHEMBL204860; DTXSID00274188; HMS3884F13; AMY25701; BCP08193; HY-N0164; ZINC2083329; ANW-43480; BDBM50249581; CM0087; MFCD00210527; NSC146051; s2322; AKOS007930266; CCG-208589; CS-1601; KS-5203; NSC-146051; NCGC00346593-01; AK164135; O723; M2120; N1836; 19M028; C10774; (7aS,13aR,13bS,13cS)dodecahydro-1H,5H,10H-dipyrido[2,1-f:3,2,1-ij][1,6]naphthyridin-10-one	.	1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-/m0/s1	ZSBXGIUJOOQZMP-JLNYLFASSA-N	C1CC2C3CCCN4C3C(CCC4)CN2C(=O)C1	C15H24N2O	CAS 519-02-8	.	HBIN034558	SMIT00239	MOL005944	.	.	3619	.
NP9650	Peginterferon alpha 2b	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
NP9654	Bufalin	CID: 9547215	3,14-Dihydroxy-bufa-20,22-dienolide; U549S98QLW; 5-((3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one; CHEBI:517248; 3-beta,14-Dihydroxy-5-beta-bufa-20,22-dienolide; 3beta,14beta-dihydroxy-5beta-bufa-20,22-dienolide; 5-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one; Ch'an su; BUF; NSC 89595; BRN 5141601; (3beta,5beta)-3,14-dihydroxybufa-20,22-dienolide; 5beta, 20(22)-Bufadienolide-3beta, 14-diol; SCHEMBL165666; CHEMBL399680; DTXSID90873563; AMY40632; Bufalin: Bufa-20,22-dienolide, 3,14-dihydroxy-, (3b,5b)-,; HY-N0877; ZINC4215121; HSCI1_000110; LMST01130001; s7821; AKOS015965454; CS-3694; SMP2_000290; AC-20197; BS-17080; C16922; BRD-K63606607-001-01-8; BRD-K63606607-001-02-6; Q18379323; 5-beta-BUFA-20,22-DIENOLIDE, 3-beta,14-DIHYDROXY-; 5beta-Bufa-20,22-dienolide, 3beta,14-dihydroxy- (8CI); (3beta,5beta,10alpha,17alpha)-3,14-dihydroxybufa-20,22-dienolide; Bufa-20,22-dienolide, 3,14-dihydroxy-, (3-beta,5-beta)- (9CI); Bufa-20,22-dienolide, 3,14-dihydroxy-, (3beta,5beta)- (9CI)	.	1S/C24H34O4/c1-22-10-7-17(25)13-16(22)4-5-20-19(22)8-11-23(2)18(9-12-24(20,23)27)15-3-6-21(26)28-14-15/h3,6,14,16-20,25,27H,4-5,7-13H2,1-2H3/t16-,17+,18-,19+,20-,22+,23-,24+/m1/s1	QEEBRPGZBVVINN-BMPKRDENSA-N	CC12CCC(CC1CCC3C2CCC4(C3(CCC4C5=COC(=O)C=C5)O)C)O	C24H34O4	CAS 465-21-4	.	HBIN018981	.	.	.	.	.	.
NP9718	Methylselenocysteine	CID: 147004	Se-methylselenocysteine; 26046-90-2; Methylselenocysteine; 3-(Methylseleno)-L-alanine; (R)-2-Amino-3-(methylselanyl)propanoic acid; Se-Methyl-L-selenocysteine; L-Alanine, 3-(methylseleno)-; Selenium-methylselenocystine; Se-Methyl-seleno-L-cysteine; UNII-TWK220499Z; CHEBI:27812; TWK220499Z; Se-methylseleno-L-cysteine; Se-(Methyl)selenocysteine hydrochloride; (2R)-2-amino-3-methylselanylpropanoic acid; Se-methylseleno-L-cysteine, 98%; Selenomethylselenocysteine; CCRIS 5465; Selenomethyl selenocysteine; Methylseleno-L-cysteine; L-Se-methylselenocysteine; C4H9NO2Se; L-methylselenocysteine; methyl-L-selenocysteine; Cysteine, seleno-methyl-; Lopac0_000799; 3-(Methylselanyl)-L-alanine; CHEMBL62382; SCHEMBL420015; Se-(Methyl)seleno-L-cysteine; L-Selenomethylcysteine 0.5% Tr; 2218AB; ANW-64816; MFCD00800565; AKOS016005152; 2-Amino-3-methylselenyl propionic acid; CCG-204883; DB12697; SDCCGSBI-0050776.P002; NCGC00162258-01; NCGC00162258-02; HY-114245; CS-0080570; (2R)-2-amino-3-(methylselanyl)propanoic acid; C05689; 046S902; J-016235; Q21099600; 06E70014-448A-45CD-9AF1-4C0B9CF51C14	Small molecule	1S/C4H9NO2Se/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1	XDSSPSLGNGIIHP-VKHMYHEASA-N	C[Se]CC(C(=O)O)N	C4H9NO2Se	CAS 26046-90-2	CHEBI:27812	.	.	.	D53CMU	.	.	.
NP9745	Picropodophyllin	CID: 72435	BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum	.	1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19+,20-/m0/s1	YJGVMLPVUAXIQN-HAEOHBJNSA-N	COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O	C22H22O8	CAS 477-47-4	.	HBIN039888	SMIT00475	MOL001710	D01SJS	.	6101	.
NP9772	Diosmin	CID: 5281613	D3908	.	1S/C28H32O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-8,10,19,21-30,32-37H,9H2,1-2H3/t10-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1	GZSOSUNBTXMUFQ-YFAPSIMESA-N	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O	C28H32O15	CAS 520-27-4	.	HBIN024193	SMIT01384	MOL005093	D0X9XP	.	2255	.
NP9796	Betulinic Acid	CID: 64971	Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624	.	1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1	QGJZLNKBHJESQX-FZFNOLFKSA-N	CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C(=O)O	C30H48O3	CAS 472-15-1	.	HBIN018379	SMIT02321	.	D0R9YR	DB12480	548	.
NP9807	Pentostatin	CID: 439693	pentostatin; Deoxycoformycin; Nipent; 53910-25-1; 2'-Deoxycoformycin; 2'-DCF; CO-Vidarabine; Covidarabine; Vidarbine; CI-825; NSC-218321; YK-176; Co-V; PD-ADI; UNII-395575MZO7; 2'-Dexoycoformycin; Vira A deaminase inhibitor; PD 81565; PD-81565; 395575MZO7; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol; NCGC00182045-01; Deaminase inhibitor (PD); NSC 218321; (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; Pentostatina; Pentostatine; Pentostatinum; (R)-3-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; (R)-Deoxycoformycin; CL 67310465; 8R-2'-Deoxycoformycin; (R)-2'-Deoxycoformycin; Pentostatine [INN-French]; Pentostatinum [INN-Latin]; Pentostatina [INN-Spanish]; Pentostatn; Pentostatin (JAN/USAN/INN); HSDB 6547; (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; (R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; Pentostatin [USAN:INN:BAN:JAN]; Pentostatin (PTN); BRN 1223097; DSSTox_CID_3436; CL-67310465; Deaminase, inhibitor for adenosine arabinoside; Pentostatin(Deoxycoformycin); SCHEMBL2817; CHEMBL1580; DSSTox_RID_77027; DSSTox_GSID_23436; BIDD:GT0136; GTPL4805; DTXSID2023436; BDBM22925; Pentostatin, >=95% (HPLC); BDBM223291; AMY10324; HY-A0006; ZINC3806262; Tox21_113417; MFCD00078802; s9521; AKOS024456918; AKOS032949742; CS-0374; DB00552; PB12063; NCGC00388420-02; Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)-; AB0010579; CAS-53910-25-1; A3708; C02267; D00155; Q-4464; 910P251; Q425470; SR-01000883935; J-523899; SR-01000883935-1; Adenosine Deaminase Inhibitor, DCF - CAS 53910-25-1; Z2216208604; (8R)-3-(2-Deoxy-?-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,4H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-8-ol; (R,Z)-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)-	Small molecule	1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1	FPVKHBSQESCIEP-JQCXWYLXSA-N	C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O	C11H16N4O4	CAS 53910-25-1	.	.	.	.	D0T3AD	.	.	.
NP9823	Xanthotoxin	CID: 4114	methoxsalen; 8-Methoxypsoralen; 298-81-7; XANTHOTOXIN; Ammoidin; Meladinine; Xanthotoxine; 8-MOP; Meloxine; Oxsoralen; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; Meladinin; Oxypsoralen; Puvalen; Meladoxen; Ammodin; Uvadex; Methoxa-Dome; 8-Methoxypsoralene; Oxsoralen-ultra; New-Meladinin; Geroxalen; Methoxalen; Puvamet; Oxsoralen lotion; Zanthotoxin; Psoralon-MOP; 9-Methoxypsoralen; 8-MP; 8-Methoxyfuranocoumarin; 9-methoxyfuro[3,2-g]chromen-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; O-methylxanthotoxol; 8-Methoxy-2',3',6,7-furocoumarin; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-methoxy-; NCI-C55903; Methoxy-8-psoralen; 8-Methoxy-4',5',6,7-furocoumarin; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; Methoxsalen-d3; UNII-U4VJ29L7BQ; 8-Methoxy-[furano-3'.2':6.7-coumarin]; NSC45923; MFCD00005009; NSC 45923; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-(furano-3'.2':6.7-coumarin); 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; Methoxsalen (Oxsoralen); 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; CHEMBL416; Oxsoralen Ultra; 7H-Furo(3,2-G)(1)benzopyran-7-one, 9-methoxy-; U4VJ29L7BQ; 8-Methoxy-6,7-furanocoumarin; CHEBI:18358; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; Proralone-mop; NSC-45923; 9-methoxyfurano[3,2-g]chromen-2-one; Meladinin (VAN); NCGC00016418-07; CAS-298-81-7; Methoxaten; Oxoralen; ST041029; DSSTox_CID_830; 8-Methoxypsoralen, 99%; Ultra Mop; DSSTox_RID_75816; DSSTox_GSID_20830; 1246819-63-5; Deltapsoralen; Dltasoralen; Methoxsalene; Metoxaleno; Methoxsalen, 8-; SMR000071170; CCRIS 2083; HSDB 2505; 8-Methoxypsoralen with ultraviolet A therapy; OXSORALEN (TN); SR-01000629727; EINECS 206-066-9; Methoxsalen plus ultraviolet radiation; BRN 0196453; Vitpso; Methoxsalen [USP:BAN:JAN]; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; Prestwick_661; Spectrum_001023; 5-Demethoxyisoimpinellin; 8-Methoxy(furano-3'.2':6.7-coumarin); Prestwick0_000479; Prestwick1_000479; Prestwick2_000479; Prestwick3_000479; Spectrum2_001052; Spectrum3_000499; Spectrum4_000052; Spectrum5_001891; UVADEX (TN); Methoxsalen (JP17/USP); 7H-Furo[3, 9-methoxy-; Oprea1_166319; SCHEMBL19168; BSPBio_000618; BSPBio_001997; KBioGR_000543; KBioSS_001503; 5-19-06-00015 (Beilstein Handbook Reference); 8MO; MLS000062633; MLS002303011; DivK1c_000763; SPECTRUM1500400; SPBio_001004; SPBio_002557; BPBio1_000680; MEGxp0_000095; Xanthotoxin, analytical standard; DTXSID8020830; ACon1_000174; HMS502G05; KBio1_000763; KBio2_001503; KBio2_004071; KBio2_006639; KBio3_001497; 8-Methoxy Psoralen-[13C,d3]; 8-Methoxy-2',6,7-furocoumarin; 8-Methoxy-4',6,7-furocoumarin; NINDS_000763; HMS1569O20; HMS1920N05; HMS2091D20; HMS2096O20; HMS2269P03; HMS3259L13; HMS3655B05; HMS3884K16; Pharmakon1600-01500400; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; BCP28212; SM-88 COMPONENT METHOXSALEN; ZINC2548959; Tox21_110432; Tox21_201767; Tox21_302816; 8-Methoxypsoralen;Xanthotoxin;8-MOP; BDBM50041234; CCG-36366; NSC757114; s1952; SBB005950; STK735539; WLN: T C566 DO LVOJ BO1; 8-Methoxypsoralen, analytical standard; AKOS000277012; Tox21_110432_1; 9-Methoxy-furo[3,2-g]chromen-7-one; AC-4259; AM84906; CS-1983; DB00553; DS-5159; MCULE-2500932325; NC00652; NSC-757114; SDCCGMLS-0042377.P002; IDI1_000763; 8-methoxy-2'',3'',6,7-furocoumarin; 8-methoxy-4'',5'':6,7-furocoumarin; NCGC00016418-01; NCGC00016418-02; NCGC00016418-03; NCGC00016418-04; NCGC00016418-05; NCGC00016418-06; NCGC00016418-08; NCGC00016418-09; NCGC00016418-10; NCGC00016418-11; NCGC00016418-12; NCGC00016418-14; NCGC00016418-15; NCGC00060938-02; NCGC00060938-03; NCGC00060938-04; NCGC00060938-05; NCGC00060938-06; NCGC00178871-01; NCGC00178871-02; NCGC00178871-03; NCGC00256435-01; NCGC00259316-01; AK111265; HY-30151; NCI60_004085; Q039; SBI-0051443.P003; FT-0602101; FT-0671145; N1305; SW167762-4; 8-methoxy-[furano-3''.2'':6.7-coumarin]; 9-Methoxy-7H-furo[3,2-g]chromen-7-one #; EN300-52504; C01864; D00139; J10204; 9-(Trideuteriomethoxy)furo[3,2-g]chromen-7-one; AB00052042-14; AB00052042-15; AB00052042_16; AB00052042_17; 298M817; 9-METHOXY-2H-FURO[3,2-G]CHROMEN-2-ONE; 9-Methoxy-7H-furo[3,2- g][1]benzopyran-7-one; Q408570; Q-100381; SR-01000629727-2; SR-01000629727-4; BRD-K63430059-001-03-2; BRD-K63430059-001-06-5; BRD-K63430059-001-09-9; Z1258578369; Methoxsalen, United States Pharmacopeia (USP) Reference Standard; 12692-94-3	Small molecule	1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3	QXKHYNVANLEOEG-UHFFFAOYSA-N	COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2	C12H8O4	CAS 298-81-7	CHEBI:18358	.	.	.	D08SKH	.	.	.
NP9845	Quetiapine fumarate	CID: 5281025	Quetiapine fumarate; 111974-72-2; Quetiapine hemifumarate; Seroquel; Seroquel XR; ICI 204,636; ICI-204636; UNII-2S3PL1B6UJ; ZD5077; ZM 204636; ZM 204,636; 2S3PL1B6UJ; ICI 204636; MFCD03423782; 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol hemifumarate; CHEBI:8708; FK949E; Quetiapine fumarate [USAN]; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol fumarate (2:1) (salt); 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(E)-but-2-enedioic acid; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (2E)-2-butenedioate (2:1); ZM-204636; Seroquel (TN); 2-(2-(4-Dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol; zlchem 12; D00458; Quetiapine fumarate solution; Quetiapine hemifumarate salt; DSSTox_CID_24201; DSSTox_RID_80114; DSSTox_GSID_44201; Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt); SCHEMBL122596; SCHEMBL390694; Quetiapine fumarate (Seroquel); FK947E; CHEMBL3188993; DTXSID3044201; FK-947E; ZLA0014; Quetiapine fumarate (JP17/USP); HMS2089G04; HMS3713M10; HMS3884A10; BCP04154; Tox21_302366; AKOS015855887; AC-4236; CCG-220464; KS-1099; C21H25N3O2S.0.5C4H4O4; NCGC00255945-01; AS-12050; CAS-111974-72-2; SW220283-1; Quetiapine hemifumarate salt, >=98% (HPLC); K-0936; 974Q697; J-002679; Q-201653; Q27108136; Quetiapine Fumarate 1.0 mg/ml in Methanol (as free base); Quetiapine fumarate, European Pharmacopoeia (EP) Reference Standard; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin- 11-yl-1-piperazinyl)ethoxy]ethanol hemifumarate; bis(2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethan-1-ol) fumarate; Quetiapine for system suitability, European Pharmacopoeia (EP) Reference Standard; Quetiapine Fumarate, Pharmaceutical Secondary Standard; Certified Reference Material; Quetiapine fumarate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material; Quetiapine fumarate, United States Pharmacopeia (USP) Reference Standard, monograph mol wt. 883.09 ((C21H25N3O2S)2 ?? C4H4O4)	Small molecule	1S/2C21H25N3O2S.C4H4O4/c2*25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21;5-3(6)1-2-4(7)8/h2*1-8,25H,9-16H2;1-2H,(H,5,6)(H,7,8)/b;;2-1+	ZTHJULTYCAQOIJ-WXXKFALUSA-N	C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=CC(=O)O)C(=O)O	C46H54N6O8S2	CAS 111974-72-2	CHEBI:8708	.	.	.	.	.	.	.
NP9846	Phytosphingosine	CID: 122121	phytosphingosine; 554-62-1; (2S,3S,4R)-2-aminooctadecane-1,3,4-triol; 4-D-Hydroxysphinganine; D-Ribo-phytosphingosine; C18-Phytosphingosine; UNII-GIN46U9Q2Q; 4R-hydroxysphinganine; GIN46U9Q2Q; 1,3,4-Octadecanetriol, 2-amino-, (2S,3S,4R)-; (+)-D-ribo-Phytosphingosine; 4-R-hydroxyoctadecasphinganine; CHEBI:46961; 4-hydroxysphinganine; D-Ribo-1,3,4-trihydroxy-2-aminooctadecane; Phytosphingosin; C18H39NO3; DS-phytosphingosine; phytosphingosine group; 4D-Hydroxysphinganine; 4-D-hydroxy-Sphinganine; EC 439-210-6; SCHEMBL20110; C18-PHS; CHEMBL236036; DTXSID80203951; ZINC8437018; 5544AE; ANW-32318; LMSP01030001; MFCD02259274; AKOS015949172; AKOS016015084; CCG-208251; CS-W012019; DB14119; FS-5977; HY-W011303; D-ribo-2-amino-1,3,4-Octadecanetriol; SMP2_000142; NCGC00163609-01; P1765; (2S,3S,4R)-2-Amino-1,3,4-octadecanetriol; C12144; SR-05000002328; J-501034; Q3746193; SR-05000002328-2; (2S,3S,4R)-2-Amino-1,3,4-octadecanetriol, AldrichCPR; [2S-(2R*,3R*,4S*)]-2-amino-1,3,4-Octadecanetriol; 1,3,4-Octadecanetriol, 2-amino-, (2S-(2R*,3R*,4S*))-; D-ribo-Phytosphingosine, 4-hydroxysphinganine (Saccharomyces Cerevisiae), powder	Small molecule	1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/t16-,17+,18-/m0/s1	AERBNCYCJBRYDG-KSZLIROESA-N	CCCCCCCCCCCCCCC(C(C(CO)N)O)O	C18H39NO3	CAS 554-62-1	CHEBI:46961	.	.	.	.	.	.	.
NP9855	Asiaticoside	CID: 11954171	Asiaticoside; Madecassol; Centelase; 16830-15-2; Asiaticosid; UNII-PKO39VY215; Emdecassol; Dermatologico; Blastoestimulina; PKO39VY215; CHEBI:79928; Blastostimulina; Marticassol; Ba 2742; CCRIS 8995; Madecassol (TN); Asiaticoside, 21; EINECS 240-851-7; NSC 36002; NSC 166062; BRN 0078195; 4-17-00-03627 (Beilstein Handbook Reference); CHEMBL1684590; BDBM23211; HY-N0439; AKOS037514554; ZINC253529453; DB14081; (O-alpha-L-Rhamnopyranoxyl-(1-4)-O-beta-D-glucopyranosyl-(1-6)-O-beta-D-glucopyranosyl)-2alpha,3beta,23-trihydroxy-12-ursen-28-oat; 2alpha,3beta,23-Trihydroxy-urs-12-en-28-saeure(O-alpha-L-rhamnopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-6)-O-beta-D-glucopyranosyl)ester; O-6-Desoxy-alpha-L-mannopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-6)-O-beta-D-glucopyranosyl 2alpha,3beta,23-trihydroxy-12-ursen-28-at; CS-0008960; C15428; D07576; A810959; Q27149094; (1S,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid [(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxyme; [(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-6-methyl-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-3,4-bis(oxidanyl)oxan-2-yl]oxymethyl]-3,4,5-tris(oxidanyl)oxan-2-yl] (1S,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-9-(hydroxymethyl); O-6-Deoxy-alpha-L-mannopyranosyl-(1.4)-O-beta-D-glucopyranosyl-(1.6)-beta-D-glucopyranosyl (2alpha,3beta,4alpha)-2,3,23-trihydroxyurs-12-en-28-oate; Urs-12-en-28-oic acid, 2,3,23-trihydroxy-, O-6-deoxy-alpha-L-mannopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-6)-beta-D-glucopyranosyl ester, (2alpha,3beta,4alpha)-; Urs-12-en-28-oic acid, 2-alpha,3-beta,23-trihydroxy-, O-6-deoxy-alpha-L-mannopyranosyl-(1-4)-o-beta-D-glucopyranosyl-(1-6)-o-beta-D-glucopyranosyl ester	Small molecule	1S/C48H78O19/c1-20-10-13-48(15-14-46(6)23(29(48)21(20)2)8-9-28-44(4)16-24(51)39(60)45(5,19-50)27(44)11-12-47(28,46)7)43(61)67-42-36(58)33(55)31(53)26(65-42)18-62-40-37(59)34(56)38(25(17-49)64-40)66-41-35(57)32(54)30(52)22(3)63-41/h8,20-22,24-42,49-60H,9-19H2,1-7H3/t20-,21+,22+,24-,25-,26-,27-,28-,29+,30+,31-,32-,33+,34-,35-,36-,37-,38-,39+,40-,41+,42+,44+,45+,46-,47-,48+/m1/s1	WYQVAPGDARQUBT-FGWHUCSPSA-N	CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)CO)O)O)C)C)C2C1C)C)C(=O)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)O)O)O)O	C48H78O19	CAS 16830-15-2	CHEBI:79928	.	.	.	D0P2IT	.	.	.
NP9875	Propranolol	CID: 4946	propranolol; Propanolol; 525-66-6; beta-Propranolol; Anapriline; Betalong; Euprovasin; Propanalol; Proprasylyt; Avlocardyl; Dociton; Propanix; Reducor; Inderal; propranololo; Sawatal; Propranololum; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; CHEMBL27; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-; CHEBI:8499; Betadren; Corpendol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-; Sumial; Inderex; Inderol; Pranolol; Racemic propranolol; 13013-17-7; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-; Inderal hydrochloride; D,L-Propranolol; 3-[(methylethyl)amino]-1-naphthyloxypropan-2-ol; (+-)-Propranolol; Propranololo [DCIT]; hemangiol; Propranolol, L-; Propranalol; [2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine; Bedranol; dl-propranolol; (+)-Propranolol hydrochloride; (R)-(+)-Propranolol hydrochloride; Propranolol [INN:BAN]; AY 20694; Propanolol [INN-Spanish]; Propranololum [INN-Latin]; racemic-Propranolol; (R)-Propranolol (hydrochloride); NSC91523; CCRIS 3082; AY-20694; EINECS 208-378-0; EINECS 235-867-6; b-Propranolol; Propranolol (TN); .beta.-Propranolol; rac-Propranolol-d7; Propranolol (INN); 1-(Isopropylamino)-3-(naphthalen-1-yloxy)propan-2-ol; Dociton (Salt/Mix); Inderal (Salt/Mix); Obsidan (Salt/Mix); Propanolol,(+/-); PROPRANOLOL, d; Avlocardyl (Salt/Mix); 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride; beta-Propranolol;Dociton; 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-, (+-)-; PROPANOLOL(-); Prestwick0_000952; Prestwick1_000952; Prestwick2_000952; Prestwick3_000952; PROPRANOLOL,(+); PROPRANOLOL,(-); Spectrum2_001301; Spectrum2_001699; Spectrum3_000883; Spectrum3_001071; Spectrum4_000974; Spectrum4_001222; Spectrum5_000751; (.+/-.)-Propranolol; SCHEMBL3955; Lopac0_000896; Oprea1_304193; BSPBio_000944; BSPBio_002682; CBDivE_006180; GTPL564; KBioGR_001347; KBioGR_001684; KBioGR_002515; KBioSS_002523; ARONIS27011; DivK1c_000023; R(+)-PROPRANOLOL HCL; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; SPBio_001361; SPBio_001658; SPBio_003093; BPBio1_001040; ICI 45520 (Salt/Mix); NSC 91523 (Salt/Mix); DTXSID6023525; SCHEMBL12264958; BDBM25761; HY-B0573B; KBio1_000023; KBio2_002515; KBio2_005083; KBio2_007651; KBio3_001766; KBio3_001902; KBio3_002993; cMAP_000071; NINDS_000023; (A+/-)-Propranolol hydrochloride; Bio1_000367; Bio1_000856; Bio1_001345; HMS2090L21; HMS3428G03; ALBB-023324; BCP26001; BCP31343; BBL023437; PDSP1_000767; PDSP1_001607; PDSP1_001608; PDSP2_000755; PDSP2_001591; PDSP2_001592; STK735510; AKOS000588816; AKOS016050338; CCG-103643; DB00571; FE-0204; MCULE-7804628650; SDCCGSBI-0050871.P004; IDI1_000023; NCGC00015798-04; NCGC00015798-05; NCGC00015798-06; NCGC00015798-07; NCGC00015798-08; NCGC00015798-09; NCGC00015798-19; NCGC00024690-02; NCGC00024690-03; ST024757; SBI-0050871.P003; AB0108847; AY-64043-; AB00053537; CS-0069968; FT-0650563; FT-0674088; T7896; EN300-40731; C07407; D08443; AB00053537-10; AB00053537_11; AB00053537_12; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 525P666; L000679; Q423364; 1(-alpha-naphthoxy)-3-(iso-propylamino)-2-propanol; 1-(alpha-naphthoxy)-3-(iso-propylamino)-2-propanol; 1-(alpha-naphthoxy)-3-(isopropylamino)-2-propanol; W-109550; 1-(isopropylamino)-3-naphthalen-1-yloxy-propan-2-ol; BRD-A10070317-003-06-9; BRD-A10070317-003-17-6; 1-((1-Methylethyl)amino)-3-(1-naphthyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; F0001-3681; 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-  (9CI); 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-methyl-3-(trifluoromethyl)-, ethyl ester; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI); (+/-)-Propranolol-D7 (ring-D7) solution, 100 mug/mL in methanol with 5% 1 M HCl, ampule of 1 mL, certified reference material	Small molecule	1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3	AQHHHDLHHXJYJD-UHFFFAOYSA-N	CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O	C16H21NO2	CAS 525-66-6	CHEBI:8499	.	.	.	D04JEE	.	.	.
NP9882	Anidulafungin	CID: 166548	Anidulafungin; Eraxis; 166663-25-8; Ecalta; UNII-9HLM53094I; Anidulafungin (LY303366); VER-002; CHEBI:55346; LY-303366; 9HLM53094I; LY303366; V-Echinocandin; Anidulafungina; Anidulafungine; Anidulafunginum; Anidulafungin [USAN:INN:BAN]; C58H73N7O17; SCHEMBL38292; (4R,5R)-4,5-Dihydroxy-N(sup 2)-((4'-(pentyloxy)-p-terphenyl-4-yl)carbonyl)-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline cyclic (6-1)-peptide; CHEMBL264241; VER002; BDBM50417554; MFCD00917070; s4286; CCG-270647; DB00362; NCGC00386349-01; AT-36943; SW222238-1; A13436; D70013; Z-3192; 663A258; J-010304; Q4764531; Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-L-ornithine); N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide; N-[[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-tetrahydroxy-bis[(1R)-1-hydroxyethyl]-methyl-hexaoxo-[?]yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide; N-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-4''-(pentyloxy)-1,1':4',1''-terphenyl-4-carboxamide	Small molecule	1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1	JHVAMHSQVVQIOT-MFAJLEFUSA-N	CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O	C58H73N7O17	CAS 166663-25-8	CHEBI:55346	.	.	.	D0F9BY	.	.	.
NP9888	Acitretin	CID: 5284513	Acitretin; 55079-83-9; Etretin; Soriatane; Neotigason; all-trans-Acitretin; Acitretine; Retinoid etretin; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; Acitretina; Acitretinum; TMMP; Ro 10-1670; 13-cis-Acitretin; Ro 10-1670/000; UNII-LCH760E9T7; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; CHEBI:50173; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)-; Ro-101670000; LCH760E9T7; 54757-46-9; NCGC00163127-02; Acitretine [French]; Acitretinum [Latin]; Acitretina [Spanish]; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-, (all-E)-; Soriatane CK; Soriatane (TN); CCRIS 5534; Ro-10-1670; HSDB 7187; EINECS 259-474-4; CHEBI:50172; Acitretin/; U0279; all-trans-Etretin; Acitretin [USAN:USP:INN:BAN]; Acitretin,(S); 69427-46-9; Acitretin (USP/INN); Spectrum5_002065; DSSTox_CID_2553; Ro-10-1670/000; SCHEMBL3759; CHEMBL1131; DSSTox_RID_76624; DSSTox_GSID_22553; MLS001076667; BIDD:GT0617; GTPL7598; DTXSID6022553; BCPP000437; HMS2234L17; HMS3259J12; HMS3714E17; 2-Ethynyl-5-Methylpyridine1-oxide; Acitretin, >=98.0% (HPLC); HY-B0107; ZINC3798734; Tox21_112012; ABP000589; BDBM50088429; MFCD00866632; s1368; STL565770; AKOS015889991; AB07538; AC-4702; BCP9000229; CCG-220668; CS-1855; DB00459; KS-5246; NC00723; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-; NCGC00163127-01; NCGC00163127-03; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; AS-12644; SMR000499573; AB0007949; CAS-55079-83-9; SW199134-2; D02754; AB00698376-08; AB00698376_09; Acitretin 100 microg/mL in Acetonitrile:Acetone; 079A839; A830475; Q341500; SR-01000763200; SR-01000763200-3; BRD-K90699611-001-01-4; Acitretin, British Pharmacopoeia (BP) Reference Standard; Acitretin, European Pharmacopoeia (EP) Reference Standard; Acitretin, United States Pharmacopeia (USP) Reference Standard; Acitretin, Pharmaceutical Secondary Standard; Certified Reference Material; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2E,4E,6E,8E)-	Small molecule	1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+	IHUNBGSDBOWDMA-AQFIFDHZSA-N	CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC	C21H26O3	CAS 55079-83-9	CHEBI:50173	.	.	.	D05QDC	.	.	.
NP9921	Ferutinin	CID: 354654	Ferutinine; Ferutinin; 41743-44-6; Jaeschkeanadiol p-hydroxybenzoate; [(3R,3aS,4S,8aR)-3-hydroxy-6,8a-dimethyl-3-propan-2-yl-1,2,3a,4,5,8-hexahydroazulen-4-yl] 4-hydroxybenzoate; 4-Oxy-6-(4-oxybezoyloxy)dauc-8,9-en; From Ferula tingiatana; 4mg7; Isolated from the plant Ferula tenuisecta; CHEMBL465040; Ferutinin, >=98% (HPLC); SCHEMBL12512403; DTXSID20961947; Jaeschkeanadiol p-hydroxy benzoate; 3-Hydroxy-6,8a-dimethyl-3-(propan-2-yl)-1,2,3,3a,4,5,8,8a-octahydroazulen-4-yl 4-hydroxybenzoate; ZINC2564854; NSC606959; NSC-606959; Q27452770; (3R,3aS,4S,8aR)-3-hydroxy-6,8a-dimethyl-3-(propan-2-yl)-1,2,3,3a,4,5,8,8a-octahydroazulen-4-yl 4-hydroxybenzoate; Benzoic acid, 4-hydroxy-, (3R,3aS,4S,8aR)-1,2,3,3a,4,5,8,8a-octahydro-3-hydroxy-6,8a-dimethyl-3-(1-methylethyl)-4-azulenyl ester; Benzoic acid, 4-hydroxy-, 1,2,3,3a,4,5,8,8a-octahydro-3-hydroxy-6,8a-dimethyl-3-(1-methylethyl)-4-azulenyl ester, (3R-(3alpha,3abeta,4beta,8aalpha))-	Small molecule	1S/C22H30O4/c1-14(2)22(25)12-11-21(4)10-9-15(3)13-18(19(21)22)26-20(24)16-5-7-17(23)8-6-16/h5-9,14,18-19,23,25H,10-13H2,1-4H3/t18-,19+,21-,22+/m0/s1	CYSHNJQMYORNJI-YUVXSKOASA-N	CC1=CCC2(CCC(C2C(C1)OC(=O)C3=CC=C(C=C3)O)(C(C)C)O)C	C22H30O4	CAS 41743-44-6	.	.	.	.	.	.	.	.
NP9981	Beta carotene	CID: 5280489	beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; beta-Karotin; .beta.-Carotene; C.I. Food Orange 5; Food orange 5; Zlut prirodni 26; Lucaratin; BetaVit; beta-Carotin; beta;-Carotene; b,b-Carotene; .beta. Carotene; C.I. 75130; UNII-01YAE03M7J; NSC 62794; C40H56; (all-E)-1,1'-(3,7,12,16-Tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis(2,6,6-trimethylcyclohexene); all-trans-.beta.-Carotene; MLS001066383; .beta.,.beta.-Carotene; 01YAE03M7J; 2,2'-((1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaene-1,18-diyl)bis(1,3,3-trimethylcyclohex-1-ene); CHEBI:17579; NSC62794; Betacarotene (INN); Betacarotene [INN]; 1,1'-(3,7,12,16-Tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis(2,6,6-trimethylcyclohexene), (all E)-; 1,3,3-trimethyl-2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene; NCGC00096081-01; SMR000112037; Solatene (caps); Karotin [Czech]; Cyclohexene, 1,1'-(3,7,12,16-tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis(2,6,6-trimethyl-, (all-E)-; .beta.-Carotene, all-trans-; Betacarotenum [Latin]; Betacaroteno; Betacaroteno [Spanish]; Betacarotenum; MFCD00001556; beta-Carotene, all-trans-; Betacarotenum [INN-Latin]; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech]; 1,1'-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaene-1,18-diyl]bis(2,6,6-trimethylcyclohexene); trans-beta-Carotene; CCRIS 3245; HSDB 3264; Diet,beta-carotene supplementation; E160A; SR-01000763803; EINECS 230-636-6; Beta carotene [USAN:USP]; CI 40800; CI 75130; beta-carotenes; beta-Carotine; beta -carotene; NSC-62794; Carotene, .beta.; Solatene (TN); Cyclohexene, 1,1'-(3,7,12,16-tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis[2,6,6-trimethyl-, (all-E)-; I(2)-Carotene; Beta Carotene Natural; beta Carotene (USP); trans-.beta.-Carotene; Carotene, Provitamin A; all trans beta-Carotene; all-E-.beta.-Carotene; DSSTox_CID_253; Spectrum5_000505; .beta., .beta.-Carotene; bmse000832; EC 230-636-6; C40H56 (beta-carotene); (9Z,13Z)-beta-Carotene; CHEMBL1293; DSSTox_RID_75466; BIDD:PXR0110; DSSTox_GSID_20253; BSPBio_003404; DTXSID3020253; BDBM54988; cid_5280489; HMS501A12; .beta.,.beta.-Carotene, neo B; HMS2091M17; Pharmakon1600-01500143; HY-N0411; ZINC6845076; beta-Carotene, >=97.0% (UV); Tox21_111557; CC0205; CCG-36062; LMPR01070001; NSC755910; s1767; AKOS015896682; AC-1869; DB06755; NSC-755910; SDCCGMLS-0066579.P001; IDI1_000330; NCGC00096081-02; AS-13354; H982; ST097774; CAS-7235-40-7; SBI-0051295.P003; C.I.-40800; N1547; SW220035-1; 3046-EP2298772A1; 3046-EP2308839A1; C02094; D03101; J10299; AB00051925_06; AB00051925_07; beta-Carotene, Vetec(TM) reagent grade, >=93%; 117179-EP2292227A2; 117179-EP2298776A1; Q306135; Q-200706; SR-01000763803-2; SR-01000763803-3; SR-01000763803-4; beta-Carotene, Type I, synthetic, >=93% (UV), powder; UNII-N53I4V2IA6 component OENHQHLEOONYIE-JLTXGRSLSA-N; 89648336-F9B2-44A0-9BF8-62E73369CB9B; Beta Carotene, United States Pharmacopeia (USP) Reference Standard; beta-Carotene, Type II, synthetic, >=95% (HPLC), crystalline; beta-Carotene, Pharmaceutical Secondary Standard; Certified Reference Material; Cyclohexane,1,1'-(3,7,12,16-tetramethyl-1,18-octadecanediyl)bis[2,2,6-trimethyl-; (1E,3E,5E,7E,9E,11E,13E,15E,17E)-1,18-bis(2,6,6-trimethylcyclohex-1-enyl)-3,7, 12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaene; (all-E)-1,1'-(3,7,12,16-Tetramethyl-1,3,5, 7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis[2,6, 6-trimethylcyclohexene]; 1,18-Bis(2,6,6-trimethyl-1-cyclohexenyl)-3,7,12,16-tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonene	Small molecule	1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+	OENHQHLEOONYIE-JLTXGRSLSA-N	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C)C)C	C40H56	CAS 7235-40-7	CHEBI:17579	.	.	.	D0MY8N	.	.	.